<SEC-DOCUMENT>0001570562-19-000143.txt : 20191104
<SEC-HEADER>0001570562-19-000143.hdr.sgml : 20191104
<ACCEPTANCE-DATETIME>20191104160523
ACCESSION NUMBER:		0001570562-19-000143
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		60
CONFORMED PERIOD OF REPORT:	20190930
FILED AS OF DATE:		20191104
DATE AS OF CHANGE:		20191104

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Evolus, Inc.
		CENTRAL INDEX KEY:			0001570562
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				461385614
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38381
		FILM NUMBER:		191189764

	BUSINESS ADDRESS:	
		STREET 1:		520 NEWPORT CENTER DRIVE
		STREET 2:		SUITE 1200
		CITY:			NEWPORT BEACH
		STATE:			CA
		ZIP:			92660
		BUSINESS PHONE:		(949) 284-4555

	MAIL ADDRESS:	
		STREET 1:		520 NEWPORT CENTER DRIVE
		STREET 2:		SUITE 1200
		CITY:			NEWPORT BEACH
		STATE:			CA
		ZIP:			92660
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>evolus09301910-q.htm
<DESCRIPTION>10-Q
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Document</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sEB46A6B64BA55AC780A4F0B5CFD903FB"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:right;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;text-align:-moz-right;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;margin-left:auto;margin-right:0;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:3px double #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:5px;text-align:center;padding-left:0px;text-indent:0px;font-size:17pt;"><font style="font-family:Times New Roman;font-size:17pt;color:#000000;font-weight:bold;">UNITED STATES</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:17pt;"><font style="font-family:Times New Roman;font-size:17pt;color:#000000;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:11pt;"><font style="font-family:Times New Roman;font-size:11pt;color:#000000;font-weight:bold;">Washington, D.C. 20549</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;padding-left:0px;font-size:7pt;"><font style="font-family:Times New Roman;font-size:7pt;font-weight:bold;">_________________________________________________________________</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:17pt;"><font style="font-family:Times New Roman;font-size:17pt;color:#000000;font-weight:bold;">FORM 10-Q</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;padding-left:0px;font-size:7pt;"><font style="font-family:Times New Roman;font-size:7pt;font-weight:bold;">_________________________________________________________________</font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#000000;font-weight:bold;">(Mark One)</font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:0px;font-size:11pt;"><font style="font-family:Times New Roman;font-size:11pt;">&#9746; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:Times New Roman;font-size:11pt;color:#000000;font-weight:bold;">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;text-align:center;padding-left:0px;text-indent:0px;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">For the quarterly period ended </font><font style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">September&#160;30, 2019</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;padding-left:0px;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;font-weight:bold;">or</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:0px;font-size:11pt;"><font style="font-family:Times New Roman;font-size:11pt;font-weight:bold;">&#9744;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:Times New Roman;font-size:11pt;color:#000000;font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:center;padding-left:0px;text-indent:0px;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">For the transition period from ___________ to ___________</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;padding-left:0px;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;font-weight:bold;">Commission File Number:&#160;001-38381</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;padding-left:0px;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;padding-left:0px;font-size:7pt;"><font style="font-family:Times New Roman;font-size:7pt;font-weight:bold;">_________________________________________________________________</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;padding-left:0px;font-size:23pt;"><font style="font-family:Times New Roman;font-size:23pt;font-weight:bold;">EVOLUS, INC.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;padding-left:0px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">(Exact name of registrant as specified in its charter)</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;padding-left:0px;font-size:7pt;"><font style="font-family:Times New Roman;font-size:7pt;font-weight:bold;">_________________________________________________________________</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;padding-left:0px;font-size:6pt;"><font style="font-family:Times New Roman;font-size:6pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:84.12698412698413%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:15%;"></td><td style="width:23%;"></td><td style="width:3%;"></td><td style="width:17%;"></td><td style="width:3%;"></td><td style="width:23%;"></td><td style="width:16%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Delaware</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">46-1385614</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">(State or other jurisdiction of </font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">incorporation or organization)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">(I.R.S. Employer</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Identification Number)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;font-weight:bold;">520 Newport Center Drive Suite 1200</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;font-weight:bold;">Newport Beach, California</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;font-weight:bold;">92660</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">(Address of Principal Executive Offices)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">(Zip Code)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;font-weight:bold;">(949) 284-4555</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">(Registrant&#8217;s Telephone Number, Including Area Code)<br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:4px;text-align:left;padding-left:0px;text-indent:0px;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#000000;">Securities registered pursuant to Section 12(b) of the Act:</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.8015873015873%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:20%;"></td><td style="width:15%;"></td><td style="width:7%;"></td><td style="width:15%;"></td><td style="width:7%;"></td><td style="width:15%;"></td><td style="width:21%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;text-decoration:underline;">Title of Class</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;text-decoration:underline;">Trading Symbol(s)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;text-decoration:underline;">Name of each exchange on which registered</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Common Stock, par value $0.00001 per share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">EOLS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Nasdaq Global Market</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;padding-left:0px;text-indent:0px;font-size:11pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#000000;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;&#160;Yes&#160;</font><font style="font-family:Times New Roman;font-size:11pt;">&#9746;</font><font style="font-family:Times New Roman;font-size:9pt;color:#000000;">&#160;&#160;&#160;&#160;&#160;No&#160;</font><font style="font-family:Times New Roman;font-size:11pt;font-weight:bold;">&#9744;</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:11pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#000000;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T (&#167;&#160;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;Yes&#160;</font><font style="font-family:Times New Roman;font-size:11pt;">&#9746;</font><font style="font-family:Times New Roman;font-size:9pt;color:#000000;">&#160;&#160;&#160;&#160;No&#160;</font><font style="font-family:Times New Roman;font-size:11pt;font-weight:bold;">&#9744;</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:5px;text-align:justify;padding-left:0px;text-indent:0px;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#000000;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:23%;"></td><td style="width:49%;"></td><td style="width:24%;"></td><td style="width:4%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;">Large&#160;accelerated&#160;filer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Times New Roman;font-size:11pt;font-weight:bold;">&#9744;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;">Accelerated filer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Times New Roman;font-size:11pt;font-weight:bold;">&#9744;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;">Non-accelerated&#160;filer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Times New Roman;font-size:11pt;">&#9746;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;">Smaller&#160;reporting&#160;company</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Times New Roman;font-size:11pt;">&#9746;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;">Emerging growth company</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:Times New Roman;font-size:11pt;">&#9746;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:5px;text-align:justify;padding-left:0px;text-indent:0px;font-size:11pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#000000;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#160;&#160;&#160;</font><font style="font-family:Times New Roman;font-size:11pt;">&#9746;</font></div><div style="line-height:120%;padding-bottom:5px;padding-top:5px;text-align:justify;padding-left:0px;text-indent:0px;font-size:11pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#000000;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Act).&#160;&#160;Yes&#160;</font><font style="font-family:Times New Roman;font-size:11pt;font-weight:bold;">&#9744;</font><font style="font-family:Times New Roman;font-size:9pt;color:#000000;">&#160;No&#160;</font><font style="font-family:Times New Roman;font-size:11pt;">&#9746;</font><font style="font-family:Times New Roman;font-size:9pt;color:#000000;">&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:0px;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;">As of November 1, 2019, </font><font style="font-family:Times New Roman;font-size:9pt;">27,425,230</font><font style="font-family:Times New Roman;font-size:9pt;">&#32;shares of t</font><font style="font-family:Times New Roman;font-size:9pt;background-color:#ffffff;">he registrant&#8217;s common stock, par value $0.00001, were outstanding.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div><br></div><hr style="page-break-after:always"><div><a name="sA9B010344B1252489F229F26AB5A0DDF"></a></div><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sA9B010344B1252489F229F26AB5A0DDF"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:94.44444444444444%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:9%;"></td><td style="width:85%;"></td><td style="width:6%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">TABLE OF CONTENTS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Page</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;font-weight:normal;" href="#s4F98B016778F573EB70411574588A5FC"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;">Special Note Regarding Forward-Looking Statements</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s4F98B016778F573EB70411574588A5FC">3</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">PART I - FINANCIAL INFORMATION</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Item 1.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sDFFDF16D50A15C86B4B5333D789A7751"><font style="font-family:Times New Roman;font-size:10pt;">Financial Statements (unaudited)</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sDFFDF16D50A15C86B4B5333D789A7751">5</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sDFFDF16D50A15C86B4B5333D789A7751"><font style="font-family:Times New Roman;font-size:10pt;">Condensed Balance Sheets</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sDFFDF16D50A15C86B4B5333D789A7751">5</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAAF2EAF3D1695170977F00040EBC23CD"><font style="font-family:Times New Roman;font-size:10pt;">Condensed Statements of Operations and Comprehensive Loss</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAAF2EAF3D1695170977F00040EBC23CD">6</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s22BA7206C76B55C590635CFE1D3AA1DC"><font style="font-family:Times New Roman;font-size:10pt;">Condensed Statements of Stockholders&#8217; Equity</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s22BA7206C76B55C590635CFE1D3AA1DC">7</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s4E28281A3F165F9AB3B1AE1B05BF7DB6"><font style="font-family:Times New Roman;font-size:10pt;">Condensed Statements of Cash Flows</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s4E28281A3F165F9AB3B1AE1B05BF7DB6">9</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s2683E9FD407558CC97097B231850A754"><font style="font-family:Times New Roman;font-size:10pt;">Notes to Condensed Financial Statements</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s2683E9FD407558CC97097B231850A754">11</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Item 2.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s41BD32CC1AC05E968606F550692A64A6"><font style="font-family:Times New Roman;font-size:10pt;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s41BD32CC1AC05E968606F550692A64A6">31</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Item 3.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sC929ADF3F4E254BBBDA8A6BBE596EDD8"><font style="font-family:Times New Roman;font-size:10pt;">Quantitative and Qualitative Disclosures About Market Risk</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sC929ADF3F4E254BBBDA8A6BBE596EDD8">41</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Item 4.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s0DB814D41B8854A08B3ACF86B50C6028"><font style="font-family:Times New Roman;font-size:10pt;">Controls and Procedures</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s0DB814D41B8854A08B3ACF86B50C6028">42</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">PART II - OTHER INFORMATION</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Item 1.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAF90887A1ABB53988FCC4FE8AD5AB400"><font style="font-family:Times New Roman;font-size:10pt;">Legal Proceedings</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAF90887A1ABB53988FCC4FE8AD5AB400">43</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Item 1A.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sD55A2E11664753A58361FFD69480D0C0"><font style="font-family:Times New Roman;font-size:10pt;">Risk Factors</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sD55A2E11664753A58361FFD69480D0C0">44</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Item 2.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sADAF8E2F0EBB5D2C8F88390D3E1F8D45"><font style="font-family:Times New Roman;font-size:10pt;">Unregistered Sales of Equity Securities and Use of Proceeds</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sADAF8E2F0EBB5D2C8F88390D3E1F8D45">82</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Item 3.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s18AE933ADD7A586A85003EC23C2674E0"><font style="font-family:Times New Roman;font-size:10pt;">Defaults Upon Senior Securities</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s18AE933ADD7A586A85003EC23C2674E0">82</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Item 4.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sEDD4A195A83A5A1681E8658D9DE2437C"><font style="font-family:Times New Roman;font-size:10pt;">Mine Safety Disclosures</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sEDD4A195A83A5A1681E8658D9DE2437C">82</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Item 5.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sA9EACFD418205A75BECABB1973B9A48B"><font style="font-family:Times New Roman;font-size:10pt;">Other Information</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sA9EACFD418205A75BECABB1973B9A48B">82</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Item 6.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s0E8D53C33CF25D3EBCB2753D7145F3B0"><font style="font-family:Times New Roman;font-size:10pt;">Exhibits</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s0E8D53C33CF25D3EBCB2753D7145F3B0">83</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sA5837C26E50A59DC9246E4281CA0FF9A"><font style="font-family:Times New Roman;font-size:10pt;">Signatures</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sA5837C26E50A59DC9246E4281CA0FF9A">84</a></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;padding-bottom:13px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="s4F98B016778F573EB70411574588A5FC"></a></div><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sA9B010344B1252489F229F26AB5A0DDF"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Special Note Regarding Forward-Looking Statements</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, that involve risks and uncertainties, including statements based on our current expectations, assumptions, estimates and projections about future events, our business, financial condition, results of operations and prospects, our industry and the regulatory environment in which we operate. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terms such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; &#8220;would&#8221; or the negative of those terms, or other comparable terms intended to identify statements about the future. Forward-looking statements include, but are not limited to, statements about:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">our ability to successfully commercialize our sole product Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;">&#32;including our ability to successfully market and sell Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;">&#32;to our customers;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">our ability to maintain regulatory approval of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174; </sup></font><font style="font-family:Times New Roman;font-size:10pt;">and comply with any related restrictions, limitations and warnings in the label of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;">&#32;and any relevant regulatory requirements;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">the potential market size, opportunity and growth potential for Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;">;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">the attractiveness of the product characteristics of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;">&#32;(including the benefits of a 900 kilodalton, or kDa, botulinum toxin type A complex) and the rate and degree of physician and patient acceptance of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;">;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">the pricing of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;">, and the flexibility of our pricing and marketing strategy compared to our competitors;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">the performance of our third-party licensors, suppliers, manufacturers and distributors;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">our expectations regarding our future development of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;">&#32;for other indications and approval in other jurisdictions;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">the accuracy of our estimates regarding the amount and timing of expenses, revenue, capital requirements and needs for additional financing; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">regulatory and legislative developments in the United States, European Union, or EU, Canada and other countries;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">developments and projections relating to our competitors and our industry, including competing products and procedures;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">the loss of key management personnel;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">our future financial performance and our ability to continue as a going concern; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">the results of current and any future legal proceedings.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The forward-looking statements included herein are not guarantees of future performance or events and are based on current expectations of our management based on available information and involve a number of risks and uncertainties, all of which are difficult or impossible to predict accurately and many of which are beyond our control.&#160;As such, our actual results may differ materially from those expressed in any forward-looking statements.&#160; Factors that may cause or contribute to such differences include, but are not limited to, those discussed in more detail in Item 2 &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; of Part I and Item 1A &#8220;Risk Factors&#8221; of Part&#160;II of this </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Quarterly Report on Form 10-Q.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;Readers should carefully review these risks, as well as the additional risks described in other documents we file from time to time with the Securities and Exchange Commission, or SEC.&#160;In light of the significant risks and uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as a representation by us or any other person that such results will be achieved, and readers are cautioned not to place undue reliance on such forward-looking statements.&#160;Except as required by law, we undertake no obligation to revise the forward-looking statements contained herein to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. You should read this Quarterly Report on Form 10-Q and the documents we file with the SEC, with the understanding that our actual future results, levels of activity, performance and achievements may be materially different from what we expect. We qualify all of our forward-looking statements by these cautionary statements. </font></div><div><br></div><div><div style="line-height:120%;padding-bottom:13px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">3</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sA9B010344B1252489F229F26AB5A0DDF"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Unless the context indicates otherwise, as used in this Quarterly Report on Form 10-Q, the terms &#8220;Evolus,&#8221; &#8220;company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to Evolus, Inc., a Delaware corporation, and our subsidiaries taken as a whole, unless otherwise noted. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:11pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">EVOLUS</font><font style="font-family:Times New Roman;font-size:11pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#8482;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;are two of our trademarks that are used in this Quarterly Report on Form 10-Q. Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;is the trade name in the United States for our approved product with non-proprietary name, prabotulinumtoxinA-xvfs.  The product has different trade names outside of the United States, but is referred to throughout this Quarterly Report on Form 10-Q as Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.  This Quarterly Report on Form 10-Q also includes trademarks, trade names and service marks that are the property of other organizations, such as BOTOX</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and BOTOX</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;Cosmetic, which we refer to throughout this Quarterly Report on Form 10-Q as BOTOX. Solely for convenience, trademarks and trade names referred to in this Quarterly Report on Form 10-Q may appear without the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:11pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#8482;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;symbols, but those references are not intended to indicate that we will not assert, to the fullest extent under applicable law, our rights, or that the applicable owner will not assert its rights, to these trademarks and trade names. We do not intend our use or display of other companies&#8217; trade names or trademarks to imply a relationship with, or endorsement or sponsorship of us by, any other companies.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;padding-bottom:13px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">4</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="s045EF56ED0605076823195CF3D56AE4E"></a></div><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sA9B010344B1252489F229F26AB5A0DDF"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div><a name="sDFFDF16D50A15C86B4B5333D789A7751"></a></div><div style="line-height:120%;padding-bottom:13px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">PART I&#8212;FINANCIAL INFORMATION</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Item 1. &#160;&#160;&#160;&#160;Financial Statements</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Evolus, Inc.</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Condensed Balance Sheets</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands, except share data)</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:67%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;font-weight:bold;">September 30, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;font-weight:bold;">December&#160;31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;font-weight:bold;">(unaudited)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;font-weight:bold;">(Note 2)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;font-weight:bold;">ASSETS</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;font-weight:bold;">Current assets</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">39,116</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">93,162</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">Short-term investments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">34,913</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">Accounts receivable, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">7,206</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">Inventories</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">10,043</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">Prepaid expenses and other current assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">3,906</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">1,177</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;font-weight:bold;">Total current assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">95,184</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">94,339</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">Property and equipment, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">984</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">Operating lease right-of-use assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">4,238</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">Intangible assets, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">59,857</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">56,076</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">Goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">21,208</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">21,208</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">Other assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">1,195</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">221</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;font-weight:bold;">Total assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">182,666</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">171,844</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;font-weight:bold;">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;font-weight:bold;">Current liabilities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">Accounts payable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">6,125</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">1,558</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">Accrued expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">14,378</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">3,718</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">Contingent royalty obligation payable to Evolus Founders</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">4,323</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">Operating lease liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">1,148</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;font-weight:bold;">Total current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">25,974</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">5,276</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">Contingent royalty obligation payable to Evolus Founders</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">44,572</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">50,200</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">Contingent promissory note payable to Evolus Founders</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">17,674</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">16,904</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">Long-term debt, net of discounts and issuance costs</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">73,180</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">Operating lease liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">4,067</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">Deferred tax liability</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">156</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">15,055</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">Deferred rent</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">25</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;font-weight:bold;">Total liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">165,623</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">87,460</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">Commitments and contingencies (Note 8)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;font-weight:bold;">Stockholders&#8217; equity</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">Preferred stock, $0.00001 par value; 10,000,000 shares authorized; no shares issued and outstanding at September 30, 2019 and December 31, 2018, respectively</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">Common stock, $0.00001 par value; 100,000,000 shares authorized; 27,425,230 and 27,274,991 shares issued and outstanding at September 30, 2019 and December 31, 2018, respectively</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">Additional paid-in capital</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">215,574</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">207,408</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">Accumulated other comprehensive gain</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">19</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">Accumulated deficit</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">(198,551</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">(123,025</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;font-weight:bold;">Total stockholders&#8217; equity</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">17,043</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">84,384</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;font-weight:bold;">Total liabilities and stockholders&#8217; equity</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;">182,666</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;">171,844</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#000000;">See accompanying notes to financial statements.</font></div><div><br></div><div><div style="line-height:120%;padding-bottom:13px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">5</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="sAAF2EAF3D1695170977F00040EBC23CD"></a></div><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sA9B010344B1252489F229F26AB5A0DDF"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Evolus, Inc.</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Condensed Statements of Operations and Comprehensive Loss</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands, except share and per share data)</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(Unaudited)</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#231f20;font-weight:bold;">Three Months Ended<br>September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#231f20;font-weight:bold;">Nine Months Ended<br>September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">Net revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;">13,167</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;">15,478</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">Cost of sales (excludes amortization of intangible assets)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;">3,718</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;">4,378</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">Gross profit</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;">9,449</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;">11,100</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">Operating expenses:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">Selling, general and administrative</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">30,897</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">7,209</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">83,308</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">16,924</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">Research and development</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">693</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">1,977</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">3,555</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">5,303</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">Revaluation of contingent royalty obligation payable to Evolus Founders</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">1,795</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">2,300</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">7,977</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">11,400</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">Depreciation and amortization</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">1,202</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">2,664</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">Total operating expenses</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">34,587</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">11,489</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">97,504</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">33,634</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">Loss from operations</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">(25,138</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">(11,489</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">(86,404</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">(33,634</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">Other income (expense):</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">Interest income</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">460</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">1,464</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">Interest expense</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">(2,455</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">(322</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">(5,485</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">(750</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">Loss before income taxes:</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">(27,133</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">(11,811</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">(90,425</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">(34,384</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">Income tax (benefit) expense</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">(149</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">19</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">(14,899</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">41</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">Net loss</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">(26,984</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">(11,830</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">(75,526</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">(34,425</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">Other comprehensive (loss) gain:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">Unrealized (loss) gain on available-for-sale securities, net of tax</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">(24</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">19</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">Comprehensive loss</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">(27,008</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">(11,830</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">(75,507</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">(34,425</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">Net loss per share, basic and diluted</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">(0.98</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">(0.48</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">(2.76</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">(1.47</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">Weighted-average shares outstanding used to compute basic and diluted net loss per share</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">27,470,558</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">24,768,581</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">27,403,683</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">23,417,417</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:13px;text-align:center;padding-left:0px;text-indent:0px;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#000000;">See accompanying notes to financial statements.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">6</font></div></div><hr style="page-break-after:always"><div><a name="s22BA7206C76B55C590635CFE1D3AA1DC"></a></div><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sA9B010344B1252489F229F26AB5A0DDF"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Evolus, Inc.</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Condensed Statements of Stockholders&#8217; Equity</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands, except share data)</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(Unaudited)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="30"></td></tr><tr><td style="width:36%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Series A Preferred Stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;font-weight:bold;">Common Stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;font-weight:bold;">Additional </font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;font-weight:bold;">Paid In </font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;font-weight:bold;">Capital</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;font-weight:bold;">Other Comprehensive (Loss) Gain</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Accumulated Deficit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Total Stockholders&#8217; Equity</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;font-weight:bold;">Balance at December 31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">1,250,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">16,527,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">(75,543</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">(75,543</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Deemed contribution from Parent, increase of related-party receivable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">1,051</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">1,051</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Deemed distribution to Parent, increase of convertible note obligation</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">(1,387</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">(615</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">(2,002</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Capital contribution from Parent, convertible note write-off</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">66,998</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">66,998</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Capital contribution from Parent, forgiveness of related party borrowings</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">13,188</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">13,188</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Preferred stock conversion upon initial public offering</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">(1,250,000</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">2,065,875</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Issuance of common stock upon initial public offering, net of issuance costs</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">5,047,514</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">53,445</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">53,446</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Stock-based compensation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">1,006</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">1,006</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Net loss and comprehensive loss</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">(6,162</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">(6,162</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;font-weight:bold;">Balance at March 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">23,640,389</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">134,301</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">(82,320</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">51,982</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Issuance of common stock in connection with the incentive equity plan</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">34,602</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">(238</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">(238</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Stock-based compensation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">2,623</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">2,623</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Net loss and comprehensive loss</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">(16,433</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">(16,433</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;font-weight:bold;">Balance at June 30, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">23,674,991</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">136,686</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">(98,753</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">37,934</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Issuance of common stock upon follow-on offering, net of issuance costs</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">3,600,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">67,380</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">67,380</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Stock-based compensation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">1,482</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">1,482</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Net loss and comprehensive loss</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">(11,830</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">(11,830</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;font-weight:bold;">Balance at September&#160;30, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">27,274,991</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">205,548</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">(110,583</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">94,966</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">7</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sA9B010344B1252489F229F26AB5A0DDF"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Evolus, Inc.</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Condensed Statements of Stockholders&#8217; Equity</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands, except share data)</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(Unaudited)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="30"></td></tr><tr><td style="width:36%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Series A Preferred Stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;font-weight:bold;">Common Stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;font-weight:bold;">Additional </font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;font-weight:bold;">Paid In </font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;font-weight:bold;">Capital</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;font-weight:bold;">Other Comprehensive (Loss) Gain</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Accumulated Deficit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Total Stockholders&#8217; Equity</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;font-weight:bold;">Balance at December 31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">27,274,991</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">207,408</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">(123,025</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">84,384</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Issuance of common stock in connection with the incentive equity plan</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">10,372</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">(58</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">(58</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Stock-based compensation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">2,015</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">2,015</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Net loss</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">(10,975</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">(10,975</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Other comprehensive loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">(9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">(9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;font-weight:bold;">Balance at March 31, 2019</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">27,285,363</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">209,365</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">(9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">(134,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">75,357</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Issuance of common stock in connection with the incentive equity plan</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">107,641</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">853</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">853</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Stock-based compensation</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">2,486</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">2,486</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Net loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">(37,567</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">(37,567</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Other comprehensive gain</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">52</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">52</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;font-weight:bold;">Balance at June 30, 2019</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">27,393,004</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">212,704</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">43</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">(171,567</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">41,181</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Issuance of common stock in connection with the incentive equity plan</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">32,226</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">314</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">314</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Stock-based compensation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">2,556</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">2,556</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Net loss</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">(26,984</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">(26,984</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Other comprehensive loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">(24</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">(24</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;font-weight:bold;">Balance at September&#160;30, 2019</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">27,425,230</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">215,574</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">19</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">(198,551</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">17,043</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:13px;text-align:center;padding-left:0px;text-indent:0px;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#000000;">See accompanying notes to financial statements.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">8</font></div></div><hr style="page-break-after:always"><div><a name="s4E28281A3F165F9AB3B1AE1B05BF7DB6"></a></div><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sA9B010344B1252489F229F26AB5A0DDF"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Evolus, Inc.</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Condensed Statements of Cash Flows </font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(Unaudited)</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:92.33716475095785%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;font-weight:bold;">Nine Months Ended<br>September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;font-weight:bold;">Cash flows from operating activities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Net loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">(75,526</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">(34,425</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Adjustments to reconcile net loss to net cash used in operating activities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Depreciation and amortization</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">2,664</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Stock-based compensation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">6,981</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">5,111</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Provisions for rebate and coupon programs</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">6,671</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Accretion of discount on short-term investments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">(912</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Amortization of operating lease right-of-use assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">702</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Amortization of debt discount and issuance costs</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">1,513</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">749</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Deferred income taxes</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">(14,899</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">41</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Revaluation of contingent royalty obligation payable to Evolus Founders</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">7,977</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">11,400</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Changes in assets and liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Inventories</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">(6,225</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Accounts receivable, net</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">(7,206</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Prepaid expenses and other current assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">(1,406</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">(739</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Accounts payable</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">736</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">378</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Accrued expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">2,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">3,825</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Operating lease liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">(531</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Deferred rent</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">(8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Net cash used in operating activities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">(77,461</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">(13,661</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;font-weight:bold;">Cash flows from investing activities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Purchases of property and equipment</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">(346</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">(9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Additions to capitalized software</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">(3,080</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Purchases of short-term investments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">(98,982</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Maturities of short-term investments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">65,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Net cash used in investing activities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">(37,408</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">(9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;font-weight:bold;">Cash flows from financing activities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Payment of contingent royalty obligation to Evolus Founders</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">(9,282</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Milestone payment for intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">(2,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Proceeds from issuance of long-term debt, net of discounts</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">73,906</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Payment for debt obligation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">(705</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Payments for debt issuance costs</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">(2,205</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Proceeds from initial public offering, net of underwriters fees</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">56,330</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Proceeds from follow-on offering, net of underwriters fees</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">67,680</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Payments for offering costs</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">(1,060</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Related party borrowings</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">1,127</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Payments on related party borrowings</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">(5,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">Issuance of common stock in connection with incentive equity plan</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">1,109</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">(239</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Net cash provided by financing activities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">60,823</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">118,838</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Change in cash and cash equivalents</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">(54,046</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">105,168</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Cash and cash equivalents, beginning of period</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">93,162</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Cash and cash equivalents, end of period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">39,116</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">105,168</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:4px;text-align:center;padding-left:0px;text-indent:0px;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#000000;">See accompanying notes to financial statements.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">9</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sA9B010344B1252489F229F26AB5A0DDF"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Evolus, Inc.</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">Condensed Statements of Cash Flows (Continued)</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(in thousands)</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#000000;font-weight:bold;">(Unaudited)</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:4px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:85.82375478927203%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:75%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;font-weight:bold;">Nine Months Ended<br>September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;font-weight:bold;">Supplemental disclosure of cash flow information:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">Cash paid for interest</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">3,365</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">Cash paid for operating leases</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">716</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;font-weight:bold;">Non-cash investing and financing information:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">Related party receivable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">73,690</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">Related party borrowings</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">(68,767</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">Note obligation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">(140,688</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">Contingent royalty obligation payable to Evolus Founders</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">39,700</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">Contingent promissory note payable to Evolus Founders</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">16,042</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">Capital contribution from Parent, convertible note write-off</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">66,998</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">Capital contribution from Parent, forgiveness of related party borrowings</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">13,188</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">Deferred offering costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">(2,885</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">Accounts payable, paid by Parent</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">(163</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">Operating lease right-of-use assets obtained in exchange for operating lease liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">5,565</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">Landlord paid tenant improvements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">781</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">Financed D &amp; O insurance payment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">1,561</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">Capitalized software recorded in accounts payable and accrued expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">147</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">Accrued milestone payment for intangible assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">1,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:13px;text-align:center;padding-left:0px;text-indent:0px;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#000000;">See accompanying notes to financial statements.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">10</font></div></div><hr style="page-break-after:always"><div><a name="s2683E9FD407558CC97097B231850A754"></a></div><div><div style="line-height:120%;padding-bottom:4px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sA9B010344B1252489F229F26AB5A0DDF"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Evolus, Inc.</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Notes to Condensed Financial Statements</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">(in thousands, except share and per share data)</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">(Unaudited)</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;text-align:left;font-size:1pt;"><font style="font-family:Times New Roman;font-size:1pt;"><br></font></div><div><a name="s038BFE79E7625F0C941BD6963B8B6B65"></a></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Note 1</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">.&#160;&#160;&#160;&#160;Description of Business and Basis of Presentation</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Description of Business</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Evolus, Inc., (&#8220;Evolus&#8221; or the &#8220;Company&#8221;) is a performance beauty company focused on delivering products in the self-pay aesthetic market. The Company received the approval of its first product Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;(prabotulinumtoxinA-xvfs) from the U.S. Food and Drug Administration (the &#8220;FDA&#8221;) in February 2019.  The product was approved by Health Canada in August 2018 and the European Commission (&#8220;EC&#8221;) in 31 countries in September 2019. Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;is a proprietary 900 kDa purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as &#8220;frown lines,&#8221; in adults. In May 2019, the Company commercially launched Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;in the United States and launched in Canada through a distributor in October 2019. The Company is headquartered in Newport Beach, California.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Liquidity and Financial Condition </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The accompanying unaudited condensed financial statements&#160;have been prepared&#160;on a basis that&#160;assumes that&#160;the Company will continue as a going concern. Since inception</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the Company has incurred recurring net operating losses. T</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">he Company has recorded net losses</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$26,984</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$75,526</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">three and nine months ended September 30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, respectively. Additionally, the Company used cash of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$77,461</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;in operations during the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">nine months ended September 30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">September&#160;30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the Company had </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$74,029</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;in </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">cash and cash equivalents and short-term investments, and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">an accumulated deficit of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$198,551</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company&#8217;s ability to execute on its business strategy, meet its future liquidity requirements, and achieve profitable operations, is dependent on a number of factors, including its ability to gain market acceptance of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and achieve a level of revenues adequate to support its cost structure, and operate its business without infringing third party intellectual property rights.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company believes that its current capital resources, which consist of cash, cash equivalents, and short-term investments, are sufficient to fund operations through at least the next twelve months from the date the accompanying financial statements are issued based on the expected cash burn rate. The Company may be required to raise additional capital to fund future operations through the sale of its equity securities, the incurrence of debt </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">to the extent allowed under existing debt arrangements</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the entry into licensing or collaboration agreements with partners, or other sources of financing. Sufficient funds may not be available to the Company at all or on attractive terms when needed from equity or debt financings. If the Company is unable to obtain additional funding from these or other sources when needed, or to the extent needed, it may be necessary to significantly reduce its controllable and variable expenditures and current rate of spending through reductions in staff and delaying, scaling back, or suspending certain research and development, sales and marketing programs and other operational goals.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Basis of Presentation</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">T</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">he accompanying unaudited condensed financial statements have been prepared </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">on a consistent basis with the annual financial statements and</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) and the requirements of the Securities and Exchange Commission (&#8220;SEC&#8221;) for interim reporting</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. Pursuant to these SEC rules and regulations, the Company has condensed or omitted certain financial information and disclosures normally included in annual financial statements prepared in accordance with GAAP. In the opinion of management, the interim financial statements reflect all adjustments, which include normal recurring adjustments, considered necessary for a fair statement of the interim periods. The interim results presented herein are not necessarily indicative of the results of operations to be expected for the full year ending </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;or for any other interim period.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The accompanying unaudited condensed financial statements and related disclosures should be read in conjunction with the financial statements and notes included in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2018, as filed with the SEC on March 20, 2019. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">11</font></div></div><hr style="page-break-after:always"><div><a name="s01FD1A3B9F005FC1A1A5AB4D740180F3"></a></div><div><div style="line-height:120%;padding-bottom:4px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sA9B010344B1252489F229F26AB5A0DDF"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Evolus, Inc.</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Notes to Condensed Financial Statements</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">(in thousands, except share and per share data)</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">(Unaudited)</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Note 2</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">.&#160;&#160;&#160;&#160;Summary of Significant Accounting Policies</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">There have been no material changes in the Company&#8217;s significant accounting policies during the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">nine months ended September 30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;as compared with those disclosed in the Annual Report other than the adoption of the new lease and revenue recognition accounting standards described below. </font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The preparation of financial statements in conformity with GAAP requires management to make estimates, judgments, and assumptions that affect the amounts reported in the financial statements and disclosures made in the accompanying notes. Actual results could materially differ from those estimates, judgments, and assumptions. Management considers many factors in selecting appropriate financial accounting policies and controls and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes, and management must select an amount that falls within that range of reasonable estimates.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On an ongoing basis, the Company evaluates the most significant estimates, including those related to net revenues, allowance for doubtful accounts, fair value measurements, goodwill and long-lived asset valuations and impairment assessments, inventory valuations, income tax valuations and stock-based compensation expense, among others. Although the Company bases estimates on historical experience, knowledge of current events and actions it may undertake in the future, and on various other assumptions that are believed to be reasonable, this process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Risk and Uncertainties</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In 2013, Evolus and Daewoong Pharmaceuticals Co., Ltd. (&#8220;Daewoong&#8221;) entered into an agreement (the &#8220;Daewoong Agreement&#8221;), pursuant to which, the Company has an exclusive distribution license to Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;from Daewoong for aesthetic indications in the United States, European Union, Canada, Australia, Russia, Commonwealth of Independent States, and South Africa, as well as co-exclusive distribution rights with Daewoong in Japan. Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;is manufactured by Daewoong in a facility in South Korea. The Company also has the option to negotiate first with Daewoong to secure a distribution license for any product that Daewoong directly or indirectly develops or commercializes that is classified as an injectable botulinum toxin (other than Jeuveau&#174;) in a territory covered by the Daewoong Agreement. The Company relies on Daewoong, its exclusive and sole supplier, to manufacture Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. Any termination or loss of significant rights, including exclusivity, under the Daewoong Agreement would materially and adversely affect the Company&#8217;s commercialization of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. The Daewoong Agreement, and Daewoong&#8217;s rights relating to Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, are subject to litigation. See </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Note 8</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Commitments and Contingencies</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for additional information regarding such litigation.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company commercially launched Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;in the United States in May 2019 and, as such, has a limited history of sales. Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;also requires regulatory approval from certain regulatory authorities prior to commercial sales in the related jurisdictions. If any previously granted approval is retracted or the Company is denied approval or approval is delayed by any other regulators, it may have a material adverse impact on the Company&#8217;s business and its financial statements.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company is subject to risks common to early stage companies in the pharmaceutical industry including, but not limited to, dependency on the clinical and commercial success of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and any future product candidates, ability to obtain and maintain regulatory approval of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and any future product candidates in the jurisdictions where approval is sought, the need for additional financing to achieve its goals, uncertainty of broad adoption of its approved products, if any, by physicians and patients, significant competition and untested manufacturing capabilities.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Segment Reporting</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company has determined that it operates in a single </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">operating and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">reportable segment. The Company&#8217;s chief operating decision maker is its Chief Executive Officer who manages operations and reviews the financial information as a single operating segment for purposes of allocating resources and evaluating its financial performance.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">12</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:4px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sA9B010344B1252489F229F26AB5A0DDF"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Evolus, Inc.</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Notes to Condensed Financial Statements</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">(in thousands, except share and per share data)</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">(Unaudited)</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Cash and Cash Equivalents</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Cash and cash equivalents consist of cash and highly liquid investments with remaining maturities at purchase of three months or less that can be liquidated without prior notice or penalty. Cash and cash equivalents may include deposits, money market funds and debt securities. &#160;Amounts receivable from credit card issuers are typically converted to cash within two to four days of the original sales transaction and are considered to be cash equivalents. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company places its cash and cash equivalents with high credit quality financial institutions.&#160;At times, such investments may be in excess of the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;) limit. Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash deposits.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Short-Term Investments</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Short-term investments as of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">September&#160;30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;consisted of available-for-sale U.S. Treasury securities with original maturities greater than three months and remaining maturities of less than twelve months. These investments are recorded at fair value based on quoted prices in active markets, with unrealized gains and losses reported in other comprehensive (loss) gain in the Company&#8217;s condensed statements of operations and comprehensive loss. Purchase premiums and discounts are recognized in interest expense using the effective interest method over the terms of the securities. Realized gains and losses and declines in fair value that are deemed to be other than temporary are reflected in the condensed statements of operations and comprehensive loss using the specific-identification method. The Company periodically reviews all available-for-sale securities for other than temporary declines in fair value below the cost basis whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company also evaluates whether it has plans or is required to sell short-term investments before recovery of their amortized cost bases. To date, the Company has not identified any other than temporary declines in fair value of its short-term investments. </font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Inventories</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Inventories consist of finished goods held for sale and distribution. Cost is determined using the first&#8209;in, first&#8209;out method. However, the Company ships products with the earliest expiration dates.&#160;Inventory valuation reserves are established based on a number of factors including, but not limited to, finished goods not meeting product specifications, product excess and obsolescence, or application of the lower of cost or net realizable value concepts. The determination of events requiring the establishment of inventory valuation reserves, together with the calculation of the amount of such reserves may require judgment. No material inventory valuation reserves have been recorded for the periods presented. Adverse changes in assumptions utilized in the Company&#8217;s inventory reserve calculations could result in an increase to its inventory valuation reserves.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Fair Value of Financial Instruments</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Fair value is defined as the exchange price that would be received for an asset or an exit price paid to transfer a liability in an orderly transaction between market participants in a principal market on the measurement date.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The fair value hierarchy defines a three-tiered valuation hierarchy for disclosure of fair value measurement is classified and disclosed by the Company in one of the three categories as follows:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Level 1&#8212;Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Level 2&#8212;Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities in active markets; quoted prices in markets that are not active; or other inputs that are observable, either directly or indirectly, or can be corroborated by observable market data for substantially the full term of the asset or liability; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Level 3&#8212;Prices or valuation techniques that require inputs that are unobservable that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">13</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:4px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sA9B010344B1252489F229F26AB5A0DDF"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Evolus, Inc.</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Notes to Condensed Financial Statements</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">(in thousands, except share and per share data)</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">(Unaudited)</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Goodwill</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Goodwill represents the excess of the purchase price over the fair value of the net tangible and intangible assets acquired in a business combination. The Company reviews goodwill for impairment annually and whenever events or changes in circumstances indicate the carrying amount of goodwill may not be recoverable. The Company performs an annual qualitative assessment of its goodwill in the fourth quarter of each calendar year to determine if any events or circumstances exist, such as an adverse change in business climate or a decline in the overall industry demand, that would indicate that it would more likely than not reduce the fair value of a reporting unit below its carrying amount, including goodwill. If events or circumstances do not indicate that the fair value of a reporting unit is below its carrying amount, then goodwill is not considered to be impaired and no further testing is required. If further testing is required, the Company performs a two-step process. The first step involves comparing the fair value of the Company&#8217;s reporting unit to its carrying value, including goodwill. If the carrying value of the reporting unit exceeds its fair value, the second step of the test is performed by comparing the carrying value of the goodwill in the reporting unit to its implied fair value. An impairment charge is recognized for the excess of the carrying value of goodwill over its implied fair value. For the purpose of impairment testing, the Company has determined that it has </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">one</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;reporting unit. There was </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">no</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;impairment of goodwill for any of the periods presented.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Intangible Assets</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Upon FDA approval of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;in February 2019, in process research and development (&#8220;IPR&amp;D&#8221;) related to Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;was evaluated as completed and reclassified to a definite-lived distribution right intangible asset, which is amortized over the period the asset is expected to contribute to the future cash flows of the Company. The Company determined the pattern of this intangible asset&#8217;s future cash flows could not be readily determined with a high level of precision. As a result, the distribution right intangible asset is being amortized on a straight-line basis over the estimated useful life of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">20</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;years.  </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company capitalizes certain internal-use software costs associated with the development of its mobile and web-based customer platforms. These costs include personnel expenses and external costs that are directly associated with the software projects. These costs are included as intangible assets in the accompanying condensed balance sheets. The capitalized internal-use software costs are amortized on a straight-line basis over the estimated useful life of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">two years</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;upon being placed in service. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company reviews long-term and identifiable definite-lived intangible assets or asset groups for impairment when events or changes in circumstances indicate that the carrying amount of an asset or asset group may not be recoverable. If the sum of the expected future undiscounted cash flows is less than the carrying amount of the asset or an asset group, further impairment analysis is performed. An impairment loss is measured as the amount by which the carrying amount of the asset or asset groups exceeds the fair value for assets to be held and used or fair value less cost to sell for assets to be disposed of. The Company also reviews the useful lives of its assets periodically to determine whether events and circumstances warrant a revision to the remaining useful life. Changes in the useful life are adjusted prospectively by revising the remaining period over which the asset is amortized. There was </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">no</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;material impairment of long-lived assets for any periods presented.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Leases</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In accordance with Accounting Standards Update (&#8220;ASU&#8221;) No. 2016-02 as adopted on January 1, 2019, at the inception of a contractual arrangement, the Company determines whether the contract contains a lease by assessing whether there is an identified asset and whether the contract conveys the right to control the use of the identified asset in exchange for consideration over a period of time. If both criteria are met, upon lease commencement, the Company records a lease liability which represents the Company&#8217;s obligation to make lease payments arising from the lease, and a corresponding right-of-use (&#8220;ROU&#8221;) asset which represents the Company&#8217;s right to use an underlying asset during the lease term. Operating lease assets and liabilities are included in ROU assets, current portion of operating lease liabilities and noncurrent operating lease liabilities in the accompanying condensed balance sheets. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Operating lease ROU assets and lease liabilities are initially recognized based on the present value of the future minimum lease payments over the lease term at commencement date calculated using the Company&#8217;s incremental borrowing rate applicable to the underlying asset unless the implicit rate is readily determinable. Operating lease ROU assets also include any lease payments made at or before lease commencement and exclude any lease incentives received, if any. The Company determines the lease term as the noncancellable period of the lease and may include options to extend or terminate the lease </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">14</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:4px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sA9B010344B1252489F229F26AB5A0DDF"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Evolus, Inc.</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Notes to Condensed Financial Statements</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">(in thousands, except share and per share data)</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">(Unaudited)</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">when it is reasonably certain that the Company will exercise such options. The Company&#8217;s leases do not contain any residual value guarantees. Leases with a term of 12 months or less are not recognized on the condensed balance sheets. For operating leases, the Company recognized rent expense on a straight-line basis over the lease term. There were no significant finance leases as of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">September&#160;30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Contingent Royalty Obligation Payable to the Evolus Founders</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company determines the fair value of the contingent royalty obligation payable at each reporting period end based on Level 3 inputs using a discounted cash flows method. Changes in the fair value of the contingent royalty obligation payable are determined at each reporting period end and recorded in operating expenses in the accompanying statements of operations and comprehensive loss and as a liability in the condensed balance sheets.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Contingent Promissory Note Payable to Evolus Founders</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On February 12, 2018, the Company recognized a contingent promissory note payable at present value using a discount rate for similar rated debt securities based on an estimated date that the Company believed the contingent promissory note will mature. Discount amortization related to the contingent promissory note is recorded in interest expense in the condensed statements of operations and comprehensive loss with a corresponding increase to the non-current liabilities in the condensed balance sheets. </font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Long-Term Debt</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company recorded borrowings classified as long-term debt in the accompanying condensed balance sheets. Debt issuance costs represent legal, lender and consulting costs or fees associated with debt financing. Debt&#160;discounts and issuance costs are allocated pro rata between the funded and unfunded portions of the debt and are amortized into interest expense over the term of the debt.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Revenue Recognition</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company applies Accounting Standards Codification 606, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Revenue from Contracts with Customers</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;(&#8220;ASC 606&#8221;), to account for revenue generated since the commercial launch of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;in May 2019. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">General</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company currently generates all of its revenue from the sale of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;in the United States.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company recognizes revenue when control of the promised goods under a contract is transferred to a customer, in an amount that reflects the consideration the Company expects to receive in exchange for those goods as specified in the customer contract. The transfer of control occurs upon receipt of the goods by the customer since that is when the customer has obtained control of the goods&#8217; economic benefits. The Company does not provide any service-type warranties and does not accept product returns except under limited circumstances such as damages in transit or ineffective product. The Company also excludes any amounts related to taxes assessed by governmental authorities from revenue measurement. Shipping and handling costs associated with outbound product freight are accounted for as fulfillment costs and are included in selling, general and marketing expenses in the accompanying condensed statements of operations and comprehensive loss.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Disaggregation of Revenue</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company&#8217;s disaggregation of revenue is consistent with its operating segment as disclosed above, and all of the Company&#8217;s net sales are considered revenue from contracts with customers.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Gross-to-Net Revenue Adjustments</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company provides customers with trade and volume discounts and prompt pay discounts that are directly reflected in the invoice price. Revenues are recorded net of sales-related adjustments, wherever applicable, for rebates and coupon programs. Accrued rebate and coupon balances are recorded in accrued expenses on the accompanying condensed balance sheets.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Volume-based Rebates - </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Volume-based rebates are contractually offered to certain customers. The rebates payable to each customer are determined based on the contract and quarterly purchase volumes. </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">15</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:4px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sA9B010344B1252489F229F26AB5A0DDF"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Evolus, Inc.</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Notes to Condensed Financial Statements</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">(in thousands, except share and per share data)</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">(Unaudited)</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Coupons - </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company implemented a program by which customers receive coupons redeemable into gift cards funded by the Company for the benefit of patients. The coupons are accounted for as variable consideration. The Company estimates the coupon redemption rates based on historical data. The coupons are accrued based on estimated redemption rates and the volume of products purchased and are recorded as a reduction to revenues on product delivery. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">September&#160;30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, accrued volume-based rebate and coupon liability was </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$3,932</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.  During the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">three and nine months ended September 30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, provisions for accrued volume-based rebate and coupon liability were </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$5,740</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$6,671</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, respectively, which were offset by related payments of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$2,739</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;in the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">three and nine months ended September 30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Contract balances</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">A contract with a customer states the terms of the sale, including the description, quantity and price of each product purchased. Amounts are recorded as accounts receivable when the Company&#8217;s right to consideration becomes unconditional. As payment terms are short-term, the Company does not have any significant financing components in customer contracts given the expected time between transfer of the promised products and the payment of the associated consideration is less than one year. As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">September&#160;30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, all amounts included in accounts receivable, net on the accompanying condensed balance sheets are related to contracts with customers.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company did not have any contract assets nor unbilled receivables as of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">September&#160;30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. Sales commissions are included in selling, general and administrative expenses when incurred.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Contract liabilities reflect estimated amounts that the Company is obligated to pay to customers or patients under the rebate and coupon programs. The Company&#8217;s contract liabilities are included in accounts payable and accrued expenses in the condensed balance sheets.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">During the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">three and nine months ended September 30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the Company did not recognize any revenue related to changes in transaction prices regarding its contracts with customers and did not recognize any material changes in revenue related to amounts included in contract liabilities at the beginning of the period.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Collectability</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Accounts receivable are recorded at the invoiced amount and do not bear interest. At the time of contract inception or new customer account set-up, the Company performs a collectability assessment of the customer&#8217;s creditworthiness. The Company assesses the probability that the Company will collect the entitled consideration in exchange for the goods sold, by considering the customer&#8217;s ability and intention to pay when consideration is due. On a recurring basis, the Company estimates the amount of receivables considered uncollectable to reflect an allowance for doubtful accounts.&#160;There was no significant provision for allowance or write-off of doubtful accounts during the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">nine months ended September 30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Practical Expedients</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company expenses sales commissions when incurred as the amortization period is one year or less. These costs are recorded within selling, general and administrative expenses in the accompanying condensed statements of operations and comprehensive loss. The Company does not adjust the amount of promised consideration for the effects of the time value of money for contracts in which the anticipated period between when the Company transfers the goods or services to the customer and when the customer pays within one year.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Stock-Based Compensation</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company recognizes stock-based compensation expense for employees, consultants and members of the Board of Directors based on the fair value at the date of grant. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company uses the Black-Scholes option pricing model to value stock option grants. The Black-Scholes option pricing model requires the input of subjective assumptions, including the expected volatility of the Company&#8217;s common stock, expected risk-free interest rate and the option&#8217;s expected life. The fair value of the Company&#8217;s restricted stock units (&#8220;RSUs&#8221;) is based on the fair value on the grant date of the Company&#8217;s common stock. The Company also evaluates the impact of modifications made to the original terms of equity awards when they occur.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">16</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:4px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sA9B010344B1252489F229F26AB5A0DDF"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Evolus, Inc.</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Notes to Condensed Financial Statements</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">(in thousands, except share and per share data)</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">(Unaudited)</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The fair value of equity awards that are expected to vest is amortized on a straight-line basis over the requisite service period. Stock-based compensation expense is recognized net of actual forfeitures when they occur, as an increase to additional paid-in capital in the condensed balance sheets and in the selling, general and administrative or research and development expenses in the condensed statements of operations and comprehensive loss. </font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Income Taxes</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company applies an estimated annual effective tax rate (&#8220;ETR&#8221;) approach for calculating a tax provision or benefit for interim periods, as required under GAAP.&#160; The Company recorded a benefit for income taxes of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$149</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$14,899</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">three and nine months ended September 30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, respectively, and did not record a significant tax provision or benefit for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">three and nine months ended September 30, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.&#160;The Company&#8217;s ETR differs from the U.S. federal statutory tax rate of 21% primarily as a result of the impact of a valuation allowance on its deferred tax assets.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company accounts for income taxes using the asset and liability method. Under this method, deferred tax assets and liabilities are determined on the basis of differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">A valuation allowance is recorded against deferred tax assets to reduce the net carrying value when it is more likely than not that some portion or all of a deferred tax asset will not be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, and ongoing prudent and feasible tax planning strategies in assessing the amount of the valuation allowance. When the Company establishes or reduces the valuation allowance against its deferred tax assets, its provision for income taxes will increase or decrease, respectively, in the period such determination is made.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As of each reporting date, the Company considers evidence, both positive and negative, that could affect its view of the future realization of deferred tax assets.&#160;As of December 31, 2018, the deferred tax assets were primarily the result of U.S. net operating loss and tax credit carryforwards, and a valuation allowance of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$34,500</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;was recorded against the gross deferred tax asset balance.&#160;Upon FDA approval of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;in February 2019, the Company&#8217;s IPR&amp;D intangible asset was reclassified to a definite-lived distribution right intangible asset. As a result, management determined that it was more likely than not that certain deferred tax assets became realizable due to the future reversals of the deferred tax liability associated with such intangible asset.&#160;Accordingly, the Company released </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$14,402</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;of its valuation allowance as a discrete item upon FDA approval in February 2019. For the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">three and nine months ended September 30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the Company released an additional </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$149</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$497</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, respectively, from its valuation allowance.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Additionally, the Company recognizes the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities based on the technical merits of the position. The tax benefit recognized in the financial statements for a particular tax position is based on the largest benefit that is more likely than not to be realized upon settlement. Accordingly, the Company establishes reserves for uncertain tax positions. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In accordance with SEC Staff Accounting Bulletin No. 118, the Company&#8217;s accounting for the elements of the Tax Cuts and Jobs Act was complete as of December 31, 2018 and no adjustments were made to the original provisional estimate recorded in 2017.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Net Loss Per Share</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Basic net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock outstanding during the period including contingently issuable shares. Diluted earnings per share is based on the treasury stock method and includes the effect from potential issuance of ordinary shares, such as shares issuable pursuant to the exercise of stock options and the vesting of restricted stock units. Because the impact of the options and non-vested RSUs are anti-dilutive during periods of net loss, there was no difference between the weighted-average number of shares used to calculate basic and diluted net loss per common share for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">three and nine months ended September 30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. Excluded from the dilutive net loss per share computation were </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">4,052,161</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;stock options and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">182,758</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;non-vested RSUs for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">three and nine months ended September 30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;because their inclusion would have been anti-dilutive. Although these securities were anti-dilutive for these periods, they could be dilutive in future periods.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">17</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:4px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sA9B010344B1252489F229F26AB5A0DDF"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Evolus, Inc.</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Notes to Condensed Financial Statements</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">(in thousands, except share and per share data)</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">(Unaudited)</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Recently Adopted Accounting Pronouncements</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In August 2018, the SEC adopted the final rule under SEC Release No. 33-10532,&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Disclosure Update and Simplification</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, amending certain disclosure requirements that were redundant, duplicative, overlapping, outdated or superseded. In addition, the amendments expanded the disclosure requirements on the analysis of stockholders&#8217; equity for interim financial statements. Under the amendments, an analysis of changes in each caption of stockholders&#8217; equity presented in the balance sheet must be provided in a note or separate statement. The analysis should present a reconciliation of the beginning balance to the ending balance of each period for which a statement of comprehensive income is required to be filed. This final rule was effective on November 5, 2018 and it did not have a material impact on the Company&#8217;s financial statements upon adoption on January 1, 2019.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In July 2018, the Financial Accounting Standards Board (the &#8220;FASB&#8221;) issued&#160;ASU No. 2018-09,&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Codification Improvements</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, which clarifies certain amendments to guidance that may have been incorrectly or inconsistently applied by certain entities and includes Amendments to Subtopic 718-740, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Compensation - Stock Compensation - Income Taxes</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. The guidance in paragraph 718-740-35-2, as amended by the amendments in&#160;ASU 2016-09, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, is unclear on whether an entity should recognize excess tax benefits (or tax deficiencies) for compensation expense that is taken on the entity&#8217;s tax return. The amendment to paragraph 718-740-35-2 in this update clarifies that an entity should recognize excess tax benefits in the period in which the amount of deduction is determined. The Company adopted the guidance on January 1, 2019, and such adoption did not have a material impact on its financial statements.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In June 2018, the FASB issued ASU No. 2018-07,&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Compensation&#8212;Stock Compensation (Topic 718): Improvements to Nonemployee Share-based Payment Accounting,</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;which amends the financial reporting for stock-based payments issued to nonemployees and also expands the scope of ASC 718,&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Compensation - Stock Compensation</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">,&#160;to also include stock-based payments issued to nonemployees for goods and services. The amendment substantially aligns accounting for stock-based payments to employees and nonemployees. The Company early adopted the guidance in the quarter ended December 31, 2018. The adoption did not have a material impact on the Company&#8217;s financial statements.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In February 2016, the FASB issued ASU No. 2016-02 and its related amendments which introduced </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Leases (Topic 842, or </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8220;ASC 842&#8221;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">)</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, a new comprehensive lease accounting model that supersedes the current lease guidance under&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Leases (Topic 840)</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. The new accounting standard requires lessees to recognize ROU assets and corresponding lease liabilities for all leases with lease terms of greater than 12 months. It also changes the definition of a lease and expands the disclosure requirements of lease arrangements. In July 2018, the FASB added a transition option for implementation that allows companies to continue to use the legacy guidance in ASC 840, Leases, including its disclosure requirements, in the comparative periods presented in the year of adoption. The Company adopted the guidance effective January 1, 2019. The Company elected the transition package of three practical expedients and elected the optional transition method that allows for a cumulative-effect adjustment in the period of adoption without a restatement of prior periods. Further, the Company elected a short-term lease exception policy, permitting the Company to not apply the recognition requirements of this standard to short-term leases (i.e. leases with terms of 12 months or less) and an accounting policy to account for lease and non-lease components as a single component for certain classes of assets. As a result of the adoption, the Company adjusted its beginning balance of 2019 by recording operating lease ROU assets and liabilities through a cumulative-effect adjustment. The adoption impacted the accompanying condensed balance sheet, but did not have an impact on the condensed statements of operations and comprehensive loss. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The impact of the adoption of ASC 842 on the accompanying condensed balance sheet as of January 1, 2019 was as follows:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.8015873015873%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:44%;"></td><td style="width:1%;"></td><td style="width:16%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:16%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:16%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">December 31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Adjustments Due to the Adoption of ASC 842</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">January 1, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Operating lease right-of-use assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,029</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,029</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Current portion of operating lease liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">916</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">916</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Operating lease liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">138</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">138</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Deferred rent</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">25</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(25</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">18</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:4px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sA9B010344B1252489F229F26AB5A0DDF"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Evolus, Inc.</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Notes to Condensed Financial Statements</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">(in thousands, except share and per share data)</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">(Unaudited)</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Recent Accounting Pronouncements</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In November 2018, the FASB issued ASU No. 2018-18,&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Clarifying the Interaction between Topic 808 and Topic 606</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, which requires transactions in collaborative arrangements to be accounted for under ASC 606,&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Revenue from Contracts with Customers</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">,&#160;if the counter-party is a customer for a good or service that is a distinct unit of account. The amendments also preclude entities from presenting consideration from transactions with a collaborator that is not a customer together with revenue recognized from contracts with customers. The guidance is effective for interim and annual reporting periods during the year ending December 31, 2020. Early adoption is permitted, including in any interim period.&#160;The Company is currently evaluating the impact that the adoption of this guidance will have on its financial statements and related disclosures.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In August 2018, the FASB issued&#160;ASU No. 2018-15,&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Intangibles-Goodwill and Other-Internal-Use Software: Customer&#8217;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement that is a Service Contract</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.&#160;ASU 2018-15&#160;requires implementation costs incurred by customers in cloud computing arrangements (i.e., hosting arrangements) to be capitalized under the same premises of authoritative guidance for internal-use software, and deferred over the noncancellable term of the cloud computing arrangements plus any option renewal periods that are reasonably certain to be exercised by the customer or for which the exercise is controlled by the service provider. The guidance is effective for interim and annual reporting periods during the year ending December 31, 2020. Early adoption is permitted. The Company is in the process of determining the effects the adoption will have on its financial statements as well as whether to early adopt the new guidance.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In August 2018, the FASB issued&#160;ASU No. 2018-13,&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Fair Value Measurement (Topic 820): Disclosure Framework &#8212; Changes to the Disclosure Requirements for Fair Value Measurement</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.&#160;The update&#160;is part of the disclosure framework project and eliminates certain disclosure requirements for fair value measurements, requires entities to disclose new information, and modifies existing disclosure requirements. Under the new guidance,&#160;entities will no longer be required to disclose the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy, or valuation processes for Level 3 fair value measurements. However, public companies will be required to disclose the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and related changes in unrealized gains and losses included in other comprehensive income. The guidance is effective for interim and annual reporting periods during the year ending December 31, 2020. Early adoption is permitted. The Company is currently evaluating the impact this change will have on its financial statements as well as whether to early adopt the new guidance.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In January 2017, the FASB issued ASU No. 2017-04,&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Intangibles&#8212;Goodwill and Other (Topic 350):&#160;Simplifying the Test for Goodwill Impairment</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. The update simplifies the accounting for goodwill impairment by removing step two of the goodwill impairment test, which requires a hypothetical purchase price allocation. A goodwill impairment will be the amount by which a reporting unit&#8217;s carrying amount, including goodwill, exceeds its fair value. The impairment charge will be limited to the amount of goodwill allocated to that reporting unit. The update is effective for the Company beginning January&#160;1, 2020. The standard requires prospective application. Early adoption is permitted. The Company is evaluating the effect of this standard on its financial statements and related disclosures as well as whether to early adopt the new guidance.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In June 2016, the FASB issued ASU No. 2016-13,&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, which modifies the measurement and recognition of credit losses for most financial assets and certain other instruments. The new standard requires the use of forward-looking expected credit loss models based on historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount, which may result in earlier recognition of credit losses under the new standard. The new guidance also modifies the impairment models for available-for-sale debt securities and for purchased financial assets with credit deterioration since their origination. Subsequent to the issuance of ASU 2016-13, the FASB issued ASU 2018-19,&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Codification Improvements to Topic 326, Financial Instruments - Credit Losses</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. This ASU does not change the core principle of the guidance in ASU 2016-13, instead these amendments are intended to clarify and improve operability of certain topics included within the credit losses standard.&#160;The FASB also subsequently issued ASU 2019-04 which did not change the core principle of the guidance in ASU 2016-13 but clarified that expected recoveries of amounts previously written off and expected to be written off should be included in the valuation account and should not exceed amounts previously written off and expected to be written off. The guidance is effective for interim and annual reporting periods beginning after December 15, 2019 and interim periods within those periods, and early adoption is permitted. The guidance will be effective for the Company during the first quarter of 2020. The Company is in the process of determining the effects the adoption will have on its financial statements and reviewing credit loss models to assess the impact of the adoption of the standard on the financial statements. Based on initial </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">19</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:4px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sA9B010344B1252489F229F26AB5A0DDF"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Evolus, Inc.</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Notes to Condensed Financial Statements</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">(in thousands, except share and per share data)</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">(Unaudited)</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">assessments, the Company believes that while adoption will modify the way it analyzes financial instruments, it does not expect adoption of this guidance will have a material impact to its financial statements.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Other recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the American Institute of Certified Public Accountants, and the SEC did not, or are not believed by management to, have a material impact on the Company&#8217;s present or future financial position, results of operations or cash flows.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div><a name="sDB74DB2859D351CEBE7F5E8860018C20"></a></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Note 3</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">.&#160;&#160;&#160;&#160;</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Related Party Transactions</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#32;</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Services with ALPHAEON</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Prior to the Company&#8217;s initial public offering (&#8220;IPO&#8221;) in February 2018, the Company had funded its operations primarily through contributions and related party borrowings from ALPHAEON Corporation (&#8220;ALPHAEON&#8221;). For the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">three and nine months ended September 30, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$0</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$383</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, respectively, were included in Evolus&#8217; selling, general and administrative expenses that were generated by transactions with ALPHAEON. After completion of the Company&#8217;s IPO on February 12, 2018, ALPHAEON did not incur any administrative or research and development expenses on the Company&#8217;s behalf. As of December 31, 2018 and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">September&#160;30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, there were no related party accounts receivable, payable, or debt with ALPHAEON, respectively. </font><font style="font-family:Times New Roman;font-size:10pt;font-style:normal;font-weight:normal;">&#32;&#32;</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Evolus Founders</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Certain of the Evolus Founders from whom SCH-AEON, LLC (&#8220;SCH&#8221;) purchased its equity interests include individuals who were previously employed by the Company in operational roles, including the Company&#8217;s former Chief Operating Officer. </font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Payment Obligations Related to the Acquisition by ALPHAEON</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company was acquired by SCH in 2013 and subsequently by its subsidiary, ALPHAEON Corporation, by means of a stock purchase agreement (&#8220;Stock Purchase Agreement&#8221;) pursuant to which ALPHAEON assumed certain payment obligations related to the acquisition. On December 14, 2017, the Stock Purchase Agreement was amended (&#8220;Amended Stock Purchase Agreement&#8221;), and, as a result, effective upon the closing of the Company&#8217;s IPO, the Company assumed all of ALPHAEON&#8217;s payment obligations under the Amended Stock Purchase Agreement. Refer to the notes to the financial statements in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2018 for details of the acquisition of the Company.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Under the Amended Stock Purchase Agreement, the payment obligations consisted of (i) a </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$9,200</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;up-front payment upon obtaining FDA approval for Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for the treatment of glabellar lines which was paid in full during the first quarter of 2019, (ii) quarterly royalty payments of a low single digit percentage of net sales of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, and (iii) a </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$20,000</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;promissory note that matures in November 2021. The payment obligations set forth in (ii) above terminates in the quarter following the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">10</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">-year anniversary of the first commercial sale of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;in the United States. Under the Amended Stock Purchase Agreement, the Company recorded the fair value of all revised payment obligations and the promissory note owed to the Evolus Founders of </font><font style="font-family:Times New Roman;font-size:10pt;">$55,742</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;(comprised of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$39,700</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;related to the contingent royalty obligation payable and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$16,042</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;related to the contingent promissory note) as of February 12, 2018. See </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Note 7</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Fair</font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;">&#32;Value Measurements</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;">and Short-Term Investments</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;">&#32;for more information about the Company&#8217;s accounting thereof. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In addition, the outstanding related party borrowings from ALPHAEON as of February 12, 2018 were offset and reduced, on a dollar-for-dollar basis, taking into account the then-fair value of all payment obligations the Company assumed from ALPHAEON, the fair value of which, as of February 12, 2018, was </font><font style="font-family:Times New Roman;font-size:10pt;">$55,742</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.  </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Under the Amended Stock Purchase Agreement, Evolus paid one-time bonuses of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$1,575</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;to certain current and former employees upon FDA approval of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;in February 2019, including a one-time bonus of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$700</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;paid to the Company&#8217;s Chief Medical Officer and Head of Research &amp; Development. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The payment is included in research and development expenses in the accompanying condensed statements of operations and comprehensive loss for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">three and nine months ended September 30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">20</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:4px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sA9B010344B1252489F229F26AB5A0DDF"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Evolus, Inc.</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Notes to Condensed Financial Statements</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">(in thousands, except share and per share data)</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">(Unaudited)</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company has the right to prepay the promissory note, in whole or in part, at any time and from time to time without penalty. Upon an event of default under the promissory note, all unpaid principal becomes immediately due and payable at the option of the holder. An event of default occurs under the terms of the promissory note upon any of the following events: (i) Evolus fails to meet the obligations to make the required payments thereunder, (ii) Evolus makes an assignment for the benefit of creditors, (iii) Evolus commences any bankruptcy proceeding, or (iv) Evolus materially breaches the Amended Stock Purchase Agreement or Tax Indemnity Agreement (which is defined below) and such breach is not cured within </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">30</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;days. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In addition, upon a change-of-control of Evolus, all unpaid principal becomes immediately due and payable. Under the terms of the promissory note, a change-of-control is defined as (i) the sale of all or substantially all of Evolus&#8217; assets, (ii) the exclusive license of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;or the business related to Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;to a third-party (other than a sublicense under the Daewoong Agreement), or (iii) any merger, consolidation, or acquisition of Evolus, except a merger, consolidation, or acquisition of Evolus in which the holders of capital stock of Evolus immediately prior to such merger, consolidation, or acquisition hold at least </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">50%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;of the voting power of the capital stock of Evolus or the surviving entity. Notwithstanding the foregoing, the promissory note expressly provides that neither the IPO or any merger with or acquisition by ALPHAEON or any of its subsidiaries or affiliates constitutes a change-of-control. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In connection with the Amended Stock Purchase Agreement, the Company entered into a tax indemnity agreement with the Evolus Founders (&#8220;Tax Indemnity Agreement&#8221;). Pursuant to the Tax Indemnity Agreement, the Company is obligated to indemnify the Evolus Founders for any tax liability resulting from the Company&#8217;s assumption of the revised payment obligations under the Amended Stock Purchase Agreement from ALPHAEON. Such assumption of the revised payment obligations occurred upon the completion of the IPO. Under the Amended Stock Purchase Agreement, the payment obligations are contingent and thus eligible for installment sale reporting under Section 453 of the Internal Revenue Code of 1986, as amended. Under the Tax Indemnity Agreement, the Company was obligated to indemnify the Evolus Founders for any taxes or penalties required to be paid by the Evolus Founders in the event the U.S. Internal Revenue Service or other taxing authority were to determine that Company&#8217;s assumption of the revised payment obligations under the Amended Stock Purchase Agreement rendered continued installment sale reporting unavailable to the Evolus Founders. Any taxes or penalties paid by us on behalf of the Evolus Founders under the Tax Indemnity Agreement will be offset dollar-for-dollar against the promissory note and future royalties that will be payable to the Evolus Founders under the Amended Stock Purchase Agreement. </font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Exclusive Distribution and Supply Agreement with Clarion Medical Technologies Inc.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On November 30, 2017, the Company entered into an exclusive distribution and supply agreement (the &#8220;Distribution Agreement&#8221;), with Clarion Medical Technologies Inc. (&#8220;Clarion&#8221;). The Distribution Agreement provides terms pursuant to which the Company will exclusively supply </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;to Clarion in Canada.&#160; Clarion was previously a wholly-owned subsidiary of ALPHAEON. However, pursuant to previous agreements among ALPHAEON, Clarion, and previous equity holders of Clarion, the previous equity holders of Clarion had the option, and exercised such option, to unwind ALPHAEON&#8217;s acquisition of Clarion. As a result, ALPHAEON owes the equity holders of Clarion an unwinding fee of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$9,550</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;(the &#8220;Unwinding Fee&#8221;). The Distribution Agreement sets forth that a portion of the proceeds received by the Company from each unit of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;purchased by Clarion shall be paid directly to the previous equity holders of Clarion, and will reduce, on a dollar-for-dollar basis, the amount of the Unwinding Fee ALPHAEON owes. In addition, ALPHAEON and SCH have agreed with Clarion to pay the unpaid amount of the Unwinding Fee on December 31, 2022, if demanded by the previous equity holders of Clarion. There were no sales of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174; </sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">in Canada under the Distribution Agreement in any of the periods presented in these financial statements. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">21</font></div></div><hr style="page-break-after:always"><div><a name="sE76CA68263A05C0AB9F9C1E18A617A38"></a></div><div><div style="line-height:120%;padding-bottom:4px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sA9B010344B1252489F229F26AB5A0DDF"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Evolus, Inc.</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Notes to Condensed Financial Statements</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">(in thousands, except share and per share data)</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">(Unaudited)</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Note 4. Accrued Expenses</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Accrued expenses consisted of:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.0079365079365%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:67%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Accrued professional services</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">4,488</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">931</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Accrued volume-based rebate and coupon liability</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">3,932</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Accrued payroll and related benefits</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">3,453</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2,577</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">EU milestone payment to Daewoong</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Other accrued expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,505</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">210</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">14,378</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">3,718</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div><a name="sE4274F712C4E55E6923BF3ECF46C8CB0"></a></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Note 5</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">.&#160;&#160;&#160;&#160;Goodwill and Intangible Assets</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The table below shows the weighted-average life, original cost, accumulated amortization and net book value by major intangible asset classification:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"></td></tr><tr><td style="width:30%;"></td><td style="width:18%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:21%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Weighted-Average Life (Years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Original Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Accumulated Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Net Book Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;">Definite-lived intangible assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Distribution right</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">20</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">59,076</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(1,940</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">57,136</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Capitalized software</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">3,303</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(582</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2,721</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Intangible assets, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">62,379</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(2,522</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">59,857</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;">Indefinite-lived intangible asset</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Goodwill</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">21,208</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">21,208</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Total as of September 30, 2019</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">83,587</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(2,522</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">81,065</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"></td></tr><tr><td style="width:30%;"></td><td style="width:19%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:21%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Weighted-Average Life (Years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Original Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Accumulated Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Net Book Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;">Indefinite-lived intangible assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">IPR&amp;D**</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">56,076</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">56,076</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Goodwill</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">*</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">21,208</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">21,208</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Total as of December 31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">77,284</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">77,284</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;&#32;&#32;&#32;________________________</font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:48px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#000000;">&#32;&#32;&#32;&#32;&#32;*   Intangible assets with indefinite lives have an indeterminable average life.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:60px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#000000;">** IPR&amp;D is presented as &#8220;intangible assets, net&#8221; in the accompanying condensed balance sheets.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">22</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:4px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sA9B010344B1252489F229F26AB5A0DDF"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Evolus, Inc.</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Notes to Condensed Financial Statements</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">(in thousands, except share and per share data)</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">(Unaudited)</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The following table outlines the estimated future amortization expense related to intangible assets held as of&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">September&#160;30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;that are subject to amortization:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:57.14285714285714%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:57%;"></td><td style="width:1%;"></td><td style="width:41%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Fiscal year</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Remaining in 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,168</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">4,674</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">3,528</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2022</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2,955</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">2023</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">2,955</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">44,577</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">59,857</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In connection with the acquisition of the Company by SCH in 2013, the Company recorded goodwill of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$21,208</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and IPR&amp;D of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$56,076</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. The IPR&amp;D recognized represents the license and associated distribution right to develop Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the initial term of which expires in September 2023 and is automatically extended for unlimited additional </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">three</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">-year terms provided that the Company meets certain performance requirements. Additionally, pursuant to the Daewoong Agreement, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$13,500</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;in additional cash consideration is due to Daewoong based upon the Company&#8217;s successful completion of certain technical and sales milestones. Upon FDA approval of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;on February 1, 2019, the Company paid Daewoong a </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$2,000</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;milestone payment which increased the cost basis of the IPR&amp;D, and the IPR&amp;D project was completed and reclassified as a definite-lived distribution right intangible asset, which is amortized on a straight-line basis over the estimated useful life of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">20</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;years. Upon EU approval of the product on September 27, 2019, the Company accrued a </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$1,000</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;milestone payment to Daewoong which also increased the cost basis of the IPR&amp;D. During the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">three and nine months ended September 30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the Company capitalized </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$761</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$3,303</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, respectively, related to costs of computer software developed for internal use. The software is amortized over a </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">two</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">-year period using the straight-line method. During the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">three and nine months ended September 30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, total intangible assets amortization expense of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$1,115</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$2,522</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;was recorded within depreciation and amortization on the accompanying condensed statements of operations and comprehensive loss, respectively.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div><a name="s37A3123AD6825AEB83473835E4872F90"></a></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Note 6</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">. Oxford Term Loans</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On March 15, 2019, the Company entered into a credit facility of up to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$100,000</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;with Oxford Finance (&#8220;Oxford&#8221;). Pursuant to the terms of the credit facility, the lender extended term loans (the &#8220;Term Loans&#8221;), available in two advances, to the Company. The first tranche of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$75,000</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;was funded on the closing date. The second tranche of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$25,000</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;may be drawn, at the request of the Company, no later than September 30, 2020, upon achieving specified minimum net sales milestones based on a trailing six-month basis and no event of default. As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">September&#160;30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the Company had not yet met the net sales milestone to draw the second tranche. The credit facility bears an annual interest rate equal to the greater of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">9.5%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, or the 30-day U.S. Dollar LIBOR rate plus </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">7.0%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. The Company agreed to pay interest-only on each tranche funded for the first </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">36</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;months until May 2022, which is followed by a </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">23</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">-month amortization period. Notwithstanding the foregoing, if the Company maintains compliance with the specified minimum net sales covenant and meets other conditions during the initial interest-only period, upon the Company&#8217;s request, the interest-only period may be extended by an additional </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">12</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;months to a total of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">48</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;months followed by an </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">11</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">-month amortization period.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Upon the earliest to occur of the maturity date, the acceleration of the term loans, or the prepayment of the term loans, the Company is required to pay to Oxford a final payment of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">5.5%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;of the full principal amount of the term loans funded (&#8220;Final Payment&#8221;). The Company may elect to prepay all amounts owed prior to the maturity date, provided that a prepayment fee is also paid, which shall be equal to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">3.0%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;of the amount prepaid if the prepayment occurs on or prior to March 15, 2020, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2.0%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;of the amount prepaid if the prepayment occurs after March 15, 2020 and on or prior to March 15, 2021, or </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">1.0%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;of the amount prepaid if the prepayment occurs thereafter (&#8220;Prepayment Fee&#8221;).  If the Term Loans are accelerated following the occurrence of an event of default, the Company is required to immediately pay to Oxford an amount equal to the sum of all outstanding principal of the term loans plus accrued and unpaid interest thereon through the prepayment date, the Final Payment, the Prepayment Fee and all other obligations that are due and payable, including payment of Oxford&#8217;s expenses and interest at the default rate with respect to any past due amounts.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">23</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:4px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sA9B010344B1252489F229F26AB5A0DDF"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Evolus, Inc.</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Notes to Condensed Financial Statements</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">(in thousands, except share and per share data)</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">(Unaudited)</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The credit facility is secured by substantially all of the Company&#8217;s assets. The credit facility includes affirmative and negative covenants applicable to the Company and any subsidiaries it may create in the future. The affirmative covenants include, among others, covenants requiring the Company to maintain its legal corporate existence and governmental approvals, deliver certain financial reports, maintain insurance coverage and satisfy certain requirements regarding deposit accounts. The negative covenants include, among others, restrictions on us transferring collateral, incurring additional indebtedness, engaging in mergers or acquisitions, paying dividends or making other distributions, making investments, creating liens, selling assets and suffering a change in control, in each case subject to certain exceptions.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The credit facility also includes events of default, the occurrence and continuation of which could cause interest to be charged at a default interest rate equal to the applicable rate plus </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">5.0%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and Oxford, as collateral agent, with the right to exercise remedies against the Company and the collateral securing the credit facility, including foreclosure against the property securing the credit facility, including the Company&#8217;s cash. These events of default include, among other things, any failure by the Company to pay principal or interest due under the credit facility, a breach of certain covenants under the credit facility, the Company&#8217;s insolvency, a material adverse change, the occurrence of any default under certain other indebtedness and one or more judgments against the Company, the institution of certain temporary or permanent relief in connection with pending litigation, or the breach, termination or other adverse events under the Daewoong Agreement. As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">September&#160;30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the Company was in compliance with its debt covenants.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">At the closing date, the Company incurred </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$1,094</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$2,205</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;in debt discounts and issuance costs related to the Term Loans, respectively. Debt&#160;discounts and issuance costs related to the entire Term Loans have been allocated pro rata between the funded and unfunded portions. Debt&#160;discounts and issuance costs allocated to the first tranche of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$75,000</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;have been presented as a deduction to the debt balance and are amortized into interest expense using the effective interest method. As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">September&#160;30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the borrowings outstanding under the Term Loans were classified as long-term debt in the accompanying condensed balance sheets. Debt discounts and issuance costs associated with the unfunded tranche are deferred as assets until the tranche is drawn and are amortized into interest expense using the straight-line method over the term of the debt. The overall effective interest rate was approximately </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">11.6%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;as of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">September&#160;30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">September&#160;30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the principal amounts of long-term debt maturities during each of the next five fiscal years, and the Final Payment in 2024 which is amortized into interest expense over the life of the Term Loans are as follows:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:88.4920634920635%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:56%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Fiscal year</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Principal</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Final Payment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2022</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">26,087</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">26,087</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2023</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">39,130</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">39,130</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">2024</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">9,783</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">4,125</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">13,908</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">75,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">4,125</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">79,125</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div><a name="s4B244F6870FC5C32A9818A12768F12F4"></a></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Note 7</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">. Fair Value Measurements and Short-Term Investments</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;">Short-Term Investments</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company did not have any short-term investments for the year ended December 31, 2018. As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">September&#160;30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, all of the Company&#8217;s investments had remaining maturities less than 12 months. The following is a summary of the Company&#8217;s short-term investments, considered available-for-sale, as of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">September&#160;30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.60317460317461%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:53%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Amortized</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Gross Unrealized</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Estimated</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;">Available-for-sale securities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">U.S treasury securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">34,894</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">19</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">34,913</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">September&#160;30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, no investments had been in a continuous unrealized loss position for more than 12 months, and the Company did not record any other-than-temporary impairments on these securities. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">24</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:4px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sA9B010344B1252489F229F26AB5A0DDF"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Evolus, Inc.</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Notes to Condensed Financial Statements</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">(in thousands, except share and per share data)</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">(Unaudited)</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;">Assets and Liabilities Measured at Fair Value on a Recurring Basis</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company measures and reports certain financial instruments as assets and liabilities at fair value on a recurring basis. The fair value of these instruments was as follows:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.60317460317461%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:53%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">As of September&#160;30, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Level 3</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;">Available-for-sale debt securities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">U.S treasury securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">34,913</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">34,913</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;">Liabilities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Contingent royalty obligation payable to Evolus Founders</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">48,895</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">48,895</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.60317460317461%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:53%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">As of December&#160;31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Level 3</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;">Liabilities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Contingent royalty obligation payable to Evolus Founders</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">50,200</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">50,200</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company did not transfer any assets or liabilities measured at fair value on a recurring basis between levels during the&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">nine months ended September 30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company determines the fair value of the contingent royalty obligation payable based on Level 3 inputs using a discounted cash flows method. The significant unobservable input assumptions that can significantly change the fair value include (i) timing of regulatory approvals of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, (ii) projected and timing of net revenues during the payment period, which terminates in the quarter following the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">10</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">-year anniversary of the first commercial sale of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;in the United States, (iii) the discount rate and (iv) the timing of payments. During the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">three and nine months ended September 30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the Company utilized discount rates between </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">16.0%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">25.0%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, reflecting changes in the Company&#8217;s risk profile. Net revenue projections are also updated to reflect changes in the timing of regulatory approval and expected sales. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The following table shows a reconciliation of the beginning and ending fair value measurements of the contingent royalty obligation payable:</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:center;padding-left:48px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:92.85714285714286%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Three Months Ended<br>September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Nine Months Ended<br>September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Fair value, beginning of period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">47,169</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">48,800</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">50,200</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">39,700</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Payments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(69</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(9,282</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Change in fair value recorded in operating expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,795</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2,300</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">7,977</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">11,400</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Fair value, end of period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">48,895</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">51,100</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">48,895</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">51,100</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;">Other Financial Assets and Liabilities</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company&#8217;s financial instruments consist primarily of cash and cash equivalents, short-term available-for-sale debt securities, accounts receivable, accounts payable, accrued expenses, lease liabilities, and long-term debt. The carrying amount of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses approximates their fair value because of the short-term maturity of such instruments. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company estimates the fair value of contingent promissory note payable to the Evolus Founders, long-term debt and operating lease liabilities using the discounted cash flow analysis based on the interest rates for similar rated debt securities (Level 2). As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">September&#160;30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the fair value of contingent promissory note and long-term debt was estimated to be </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">25</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:4px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sA9B010344B1252489F229F26AB5A0DDF"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Evolus, Inc.</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Notes to Condensed Financial Statements</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">(in thousands, except share and per share data)</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">(Unaudited)</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$16,072</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$74,947</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, respectively. The fair value of operating lease liabilities&#160;at </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">September&#160;30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;approximated their carrying value. As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the fair value of contingent promissory note was </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$17,181</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div><a name="s64CAA5911BA555DBA8CA585AAB49A60A"></a></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Note 8</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">.&#160;&#160;&#160;&#160;</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Commitments and Contingencies</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#32;</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Operating Leases</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company leases office facilities under various operating lease agreements. The Company&#8217;s corporate headquarters is located in Newport Beach, California, in a facility that it subleases under a non-cancelable operating lease for a fixed amount each month. The sublease for this facility expires on January 20, 2020. On May 15, 2019, the Company entered into a non-cancelable operating lease for the same office facility with the original lessor. This non-cancelable operating lease will commence on February 1, 2020 and expire on January 31, 2025. Lease payments increase based on an annual rent escalation clause that occurs each year on February 1. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company may, under certain circumstances, terminate the lease on the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">36</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;month anniversary of the lease commencement date by providing a written notice </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">12 months</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;prior to such anniversary and paying a termination fee&#160;equal to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">six months</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;basic rent plus certain other expenses. The Company has an option to extend the term of the lease for an additional </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">60 months</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, which is not recognized as part of its ROU assets and lease liabilities. The lease with the original lessor is a modification of the existing sublease that is not accounted for as a separate contract.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company also leases an office facility in Santa Barbara, California, under a non-cancelable operating lease, the payments of which include a </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">three</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;percent</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;annual rent escalation clause that occurs on each June 1 anniversary</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. The lease for this facility expires on May 31, 2020 and the Company has an option to extend the term of the lease for an additional </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">60 months</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. In June 2019, the Company subleased the Santa Barbara, California facility to a third-party for a term starting on June 1, 2019 and expiring on May 31, 2020. The </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">sublease</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;income was not significant. Upon signing the sublease, the Company recorded an impairment charge of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$80</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;to the right-of-use asset related to the original lease.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company&#8217;s lease agreements do not contain any residual value guarantees or material restrictive covenants. The payments associated with the renewal will only be included in the measurement of the lease liability and ROU assets if the exercise of the renewal option is determined to be reasonably certain. The Company considers the timing of the renewal period and other economic factors such as the financial implications of a decision to extend or not to extend a lease&#160;in&#160;determining&#160;if the renewal option is reasonably certain to be exercised.&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">For the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">three and nine months ended September 30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the components of operating lease expense and other quantitative information were as follows:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:93.25396825396825%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:63%;"></td><td style="width:1%;"></td><td style="width:16%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:16%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Three Months Ended<br>September 30, 2019</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Nine Months Ended<br>September 30, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Fixed operating lease expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">297</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">798</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Variable operating lease expense</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">31</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">92</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Short-term operating lease expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">24</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">73</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">352</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">963</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">As of September 30, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Weighted-average remaining lease term (years)</font></div></td><td colspan="7" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">5.2</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Weighted-average discount rate</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">9.4%</font></div></td></tr></table></div><font style="font-family:Times New Roman;font-size:8pt;color:#000000;">&#32;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Operating lease&#160;expenses were included in the selling, general and administration expenses in the accompanying condensed statements of operations and comprehensive loss. Operating lease right-of-use assets and related current and noncurrent operating lease liabilities are presented in the accompanying condensed balance sheets. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">26</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:4px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sA9B010344B1252489F229F26AB5A0DDF"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Evolus, Inc.</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Notes to Condensed Financial Statements</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">(in thousands, except share and per share data)</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">(Unaudited)</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The following table presents the maturity of the Company&#8217;s operating lease liabilities as of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">September&#160;30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, future minimum payments under the operating lease agreements with non-cancelable terms as follows:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;padding-left:9px;text-indent:26px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:58.333333333333336%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:78%;"></td><td style="width:1%;"></td><td style="width:20%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Fiscal year</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">Remainder of 2019</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">$</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">239</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">2020</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">1,201</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">2021</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">1,205</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">2022</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">1,258</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">2023</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">1,312</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">Thereafter</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">1,484</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">Total operating lease payments</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">6,699</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">Less: imputed interest</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">(1,484</font></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">Present value of operating lease liabilities</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">$</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">5,215</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As required by the new lease accounting standard, legacy disclosures are provided for periods prior to adoption.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, annual future minimum payments under the operating lease agreements with non-cancelable terms greater than one year are as follows:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:59.32539682539682%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:79%;"></td><td style="width:1%;"></td><td style="width:19%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;font-weight:bold;">Fiscal year</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">2019</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">$</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">890</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">2020</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">139</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">2021</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #231f20;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #231f20;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">$</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">1,029</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Purchase Commitments</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">September&#160;30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the Company has entered into commitments to purchase services and products for an aggregate amount of approximately </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$6,651</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. Certain minimum purchase commitments related to the purchase of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;are described below.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;">License and Supply Agreement</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In connection with the Daewoong Agreement, the Company is obligated to make future milestone payments to Daewoong for certain confidential development and commercial milestones associated with </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">September&#160;30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, Daewoong is eligible to receive contingent milestone payments of up to approximately </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$11,500</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, including the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$1,000</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;milestone payment accrued upon EC approval of the product in September 2019. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Daewoong Agreement also includes certain minimum annual purchases the Company is required to make in order to maintain the exclusivity of the license.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;The Company may, however, meet these minimum purchase obligations by achieving certain market share in its covered territories. These potential minimum purchase obligations were contingent upon the occurrence of future events, including receipt of governmental approvals and the Company&#8217;s future market share in various jurisdictions. </font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Legal Proceedings</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications. The Company&#8217;s exposure under these agreements is unknown because they involve claims that may be made against the Company in the future, but have not yet been made. The Company accrues a liability for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">No</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;amounts were accrued as of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">September&#160;30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">27</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:4px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sA9B010344B1252489F229F26AB5A0DDF"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Evolus, Inc.</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Notes to Condensed Financial Statements</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">(in thousands, except share and per share data)</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">(Unaudited)</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;">Medytox Litigation</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company, Daewoong and other individuals and entities are defendants to a lawsuit brought by Medytox, Inc. (&#8220;Medytox&#8221;) originally instituted </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">in the Superior Court of the State of California in June 2017. With specific regard to the Company, Medytox alleges that (i) the Company has violated California Uniform Trade Secrets Act, Cal. Civ. Code &#167; 3426 because Daewoong&#8217;s alleged knowledge of the misappropriation of certain trade secrets of Medytox is imputed to the Company as a result of the Company&#8217;s relationship with Daewoong, (ii) the Company has stolen the botulinum toxin bacterial strain of Medytox through our possession of and refusal to return the botulinum toxin bacterial strain, (iii) the Company has engaged in unlawful, unfair and fraudulent business acts and practices in violation of California Bus. &amp; Prof. Code &#167; 17200, including conversion of the botulinum toxin bacterial strain and misrepresentations to the public regarding the source of the botulinum toxin bacterial strain used to manufacture Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, and (iv) the Daewoong Agreement is invalid and in violation of Medytox&#8217;s rights</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;(the &#8220;Medytox Litigation&#8221;). </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Medytox seeks, among other things, (i) actual, consequential and punitive damages, (ii) a reasonable royalty, as appropriate, (iii) a declaration that the Daewoong Agreement is void and unenforceable and that Medytox is entitled to disgorgement of all property wrongfully and unjustly retained or acquired by the defendants, including unlawfully gained profits, (iv) injunctive relief prohibiting the Company from using the license under the Daewoong Agreement and distributing Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, and (v) attorneys&#8217; fees and costs.  </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company believes it has meritorious defenses and intends to vigorously defend Medytox&#8217;s claims. Given the early stage in the Medytox Litigation, the Company is unable to determine the likelihood of success of Medytox&#8217;s claims against the Company, and an estimate of the possible loss or range of loss cannot be made. While the Company is entitled to indemnity under the Daewoong Agreement, the indemnity may not be sufficient. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">An adverse ruling by the Superior Court against either us or Daewoong could materially adversely affect the Company&#8217;s ability to carry out its business and which would have a material adverse effect on the Company&#8217;s business, financial position, results of operations, or cash flows and could also result in reputational harm.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;">ITC Case</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On January 30, 2019, Allergan, plc and Allergan, Inc. (collectively, &#8220;Allergan&#8221;) and Medytox filed a complaint against us and Daewoong in the U.S. International Trade Commission (the &#8220;ITC&#8221;), containing substantially similar allegations to the Medytox Litigation, specifically that Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;is manufactured based on misappropriated trade secrets of Medytox and therefore the importation of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;is an unfair act. The ITC matter is entitled </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">In the Matter of Certain Botulinum Toxin Products</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;(the &#8220;ITC Complaint&#8221;).  The ITC instituted an investigation as ITC Inv. No. 337-TA-1145. The ITC complaint seeks (i) an investigation by the ITC pursuant to Section 337 of the Tariff Act of 1930, (ii) a hearing with the ITC on permanent relief, (iii) issuance of a limited exclusion order forbidding entry of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;into the United States, (iv) a cease and desist order prohibiting Daewoong and us from engaging in the importations, sale for importation, marketing, distribution, offering for sale, the sale after the importation of, or otherwise transferring Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;within the United States, (v) a bond issued during the presidential review period, (vi) the return of Medytox&#8217;s trade secrets and other confidential information including the alleged stolen botulinum toxin bacterial strain, and (vii) exclusion and cease and desist orders. The Company intends to defend itself vigorously in the proceedings. The ITC has set a target date for final determination of this matter for October 2020. An adverse ruling by the ITC against either us or Daewoong could result in the imposition of an exclusion order which would bar imports of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;into the United States and a cease and desist order which would bar sales and marketing of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;within the United Sates either of which would materially adversely affect the Company&#8217;s ability to carry out its business and which would have a material adverse effect on the Company&#8217;s business, financial position, results of operations, or cash flows and could also result in reputational harm.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Other Legal Matters</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company, from time to time, is involved in various litigation matters or regulatory encounters arising in the ordinary course of business that could result in unasserted or asserted claims or litigation. These other matters may raise difficult and complex legal issues and are subject to many uncertainties, including, but not limited to, the facts and circumstances of each particular case or claim, the jurisdiction in which each suit or regulatory encounter is brought, and differences in applicable laws and regulations. Except as set forth above, the Company does not believe that these other matters would have a material adverse effect on its accompanying financial position, results of operations or cash flows. However, the resolution of one or more of the other matters in any reporting period could have a material adverse impact on the Company&#8217;s financial results for that period.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">28</font></div></div><hr style="page-break-after:always"><div><a name="sD6A81E12DFE25EDD88A3ACD0F362E0AC"></a></div><div><div style="line-height:120%;padding-bottom:4px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sA9B010344B1252489F229F26AB5A0DDF"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Evolus, Inc.</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Notes to Condensed Financial Statements</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">(in thousands, except share and per share data)</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">(Unaudited)</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Note 9</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">.&#160;&#160;&#160;&#160;Stockholders&#8217; Equity</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Preferred Stock</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company has </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">10,000,000</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;authorized shares of preferred stock with a par value of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$0.00001</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;per share. As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">September&#160;30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">none</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;were issued and outstanding. </font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Common Stock</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company has </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">100,000,000</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;authorized shares of common stock with a par value of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$0.00001</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;per share. As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">September&#160;30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">27,425,230</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;shares were issued and outstanding. </font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">2017 Omnibus Incentive Plan and Stock-based Compensation Allocation</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company&#8217;s 2017 Omnibus Incentive Plan (the &#8220;Plan&#8221;) provides for the grant of incentive options to employees of the Company, and for the grant of nonstatutory options, restricted stock awards, restricted stock unit awards, stock appreciation rights, performance stock awards and other forms of stock compensation to the Company&#8217;s employees, including officers, directors, consultants and employees of the Company. The maximum number of shares of common stock that may be issued under the Plan is </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">4,361,291</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;shares, plus an annual increase on each anniversary of November 21 equal to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">4%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;of the total issued and outstanding shares of the Company&#8217;s common stock as of such anniversary (or such lesser number of shares as may be determined by the Company&#8217;s board of directors). On November 21, 2018, an additional </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">1,091,000</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;were reserved under the evergreen provision of the Plan. As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">September&#160;30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the Company has available an aggregate of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">971,684</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;shares of common stock for future issuance under the Plan.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Stock-Based Award Activity and Balances</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Options are granted at exercise prices based on the Company&#8217;s common stock price on the date of grant. The options and RSU grants generally vest over a </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">one</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">- to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">four</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">-year period. There have been no awards granted with performance conditions or market conditions for the periods presented. The options have a contractual term of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">10</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;years. The fair value of options is estimated using the Black&#8209;Scholes option pricing model, which has various inputs, including the grant date common share price, exercise price, risk&#8209;free interest rate, volatility, expected life and dividend yield. The change of any of these inputs could significantly impact the determination of the fair value of the Company&#8217;s options as well as significantly impact its results of operations. The fair value of RSU grants is determined at the grant date based on the common share price. The Company records stock&#8209;based compensation expense net of actual forfeitures when they occur.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The weighted-averages for key assumptions used in determining the fair value of stock options granted were as follows:    </font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.28571428571429%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:45%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:13%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Three Months Ended<br>September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Nine Months Ended<br>September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Volatility</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">59.5%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">59.0%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">59.3%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">57.7%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">1.75%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">2.87%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">2.49%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">2.64%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Expected life (years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">5.96</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">6.25</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">6.16</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">6.23</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Dividend yield rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">&#8212;%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">&#8212;%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">&#8212;%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">&#8212;%</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">29</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:4px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sA9B010344B1252489F229F26AB5A0DDF"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Evolus, Inc.</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Notes to Condensed Financial Statements</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">(in thousands, except share and per share data)</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">(Unaudited)</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">A summary of stock option activity under the Plan for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">nine months ended September 30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, is presented below:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:86.90476190476191%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:43%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Weighted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Weighted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Average</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Average</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Remaining</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Aggregate</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Exercise</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Contractual</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Intrinsic</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Per Share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Terms (Years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Outstanding, December 31, 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">3,257,801</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">11.99</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">9.26</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">7,119</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">1,202,981</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">19.16</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">(138,849</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">9.98</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Canceled/forfeited</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">(269,772</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">14.07</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Outstanding, September&#160;30, 2019</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">4,052,161</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">14.05</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">8.53</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">14,830</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Exercisable, September&#160;30, 2019</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">833,730</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">11.83</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">7.30</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">4,301</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The intrinsic values of outstanding and exercisable options were determined by multiplying the number of shares by the difference in exercise price of the options and the fair value of the common stock as of&#160;December&#160;31, 2018 and the first trading day preceding </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">September&#160;30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">A summary of RSU activity under the Plan for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">nine months ended September 30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, is presented below:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:70.03968253968253%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:58%;"></td><td style="width:20%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Weighted</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Average</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Restricted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Grant Date</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Units</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Per Share</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Outstanding, December 31, 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">271,404</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">16.53</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">3,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">18.33</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Vested</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">(22,125</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">25.69</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Forfeited</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">(19,409</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">13.71</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Outstanding, September&#160;30, 2019</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">232,870</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">15.92</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The following table summarizes stock-based compensation expense arising from the above Plan:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:88.29365079365078%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Three Months Ended<br>September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Nine Months Ended<br>September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Selling, general and administrative</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2,417</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,160</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">6,443</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">4,083</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Research and development</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">109</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">322</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">538</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">1,028</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">2,526</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">1,482</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">6,981</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">5,111</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In addition, during the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">three and nine months ended September 30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the Company capitalized </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$30</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$76</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, respectively, of stock-based compensation expense in capitalized software. Capitalized software is a component of intangible assets and is presented in the accompanying condensed balance sheets. See </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Note 5</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Goodwill and Intangible Assets</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for capitalized  software information. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">30</font></div></div><hr style="page-break-after:always"><div><a name="s41BD32CC1AC05E968606F550692A64A6"></a></div><div><br></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Item 2.&#160;&#160;&#160;&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">The following discussion contains management&#8217;s discussion and analysis of our financial condition and results of operations and should be read together with the unaudited condensed financial statements and related notes include in Part I, Item 1 of this Quarterly Report on Form 10-Q and in conjunction with our Annual Report on Form 10-K for the year ended </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">December&#160;31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">&#32;and other documents previously filed with the SEC. This discussion contains forward-looking statements that reflect our plans, estimates and beliefs and involve numerous risks and uncertainties, including but not limited to those described in Item 1A &#8220;Risk Factors&#8221; of this Quarterly Report on Form 10-Q. Actual results may differ materially from those contained in any forward-looking statements. You should carefully read &#8220;Special Note Regarding Forward-Looking Statements&#8221; and Item 1A &#8220;Risk Factors&#8221; of Part II of this Quarterly Report on Form 10-Q.</font></div><div><a name="sA02CB01ADE305559A14989C607EEC5AF"></a></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Overview</font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We are a performance beauty company with a customer-centric approach focused on delivering breakthrough products in the self-pay aesthetic market. In February 2019, we received the approval of our first product Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;(prabotulinumtoxinA-xvfs) from the U.S. Food and Drug Administration, or FDA. In May 2019, we commercially launched Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;in the United States.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;is a proprietary 900 kDa purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as &#8220;frown lines,&#8221; in adults. Our primary market is the self-pay aesthetic market, which includes medical products purchased by physicians that are then sold to consumers or used in procedures for aesthetic indications that are not reimbursed by any third-party payor, such as Medicaid, Medicare or commercial insurance. We believe we offer physicians and consumers a compelling value proposition with Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. Currently, onabotulinumtoxinA (BOTOX) is the neurotoxin market leader, and prior to the approval of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, was the only known 900 kDa botulinum toxin type A complex approved in the United States. We believe aesthetic physicians generally prefer the performance characteristics of the complete 900 kDa neurotoxin complex and are accustomed to injecting this formulation.</font><font style="font-family:Times New Roman;font-size:9pt;color:#000000;">&#32;</font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In May 2019, as part of our commercial launch, we introduced the Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;Experience Treatment, or J.E.T., an exclusive program for aesthetic providers and consumers to be the first to experience Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.  J.E.T. offered aesthetic providers the opportunity to receive multiple shipments of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and ended in August 2019.  The program was made available through our technology platform, &#8220;Evolus Practice,&#8221; which allows providers to open a new account, order Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, pay invoices and engage with our customer experience team and medical affairs representatives.  We did not recognize net revenues from shipments made through the J.E.T. program. We generate net revenues from aesthetic practices that purchase products directly from us after completion or outside of the J.E.T. program. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In August 2018, we received approval from Health Canada&#160;for the temporary improvement in the appearance of moderate to severe glabellar lines in adult patients under 65 years of age.&#160;We began marketing Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;in Canada in October 2019 through our distribution partner Clarion Medical Technologies, Inc., or Clarion. In September 2019, we also received approval from the European Commission, to market the product in all 28 EU member states, Iceland, Norway and Liechtenstein. We plan to launch Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;in Europe in 2020. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We have a limited history of generating revenue from Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and have never been profitable. As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">September&#160;30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, we had an accumulated deficit of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$198.6 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. We recorded net revenues of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$13.2 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$15.5 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">three and nine months ended September 30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, respectively. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;recorded net losses</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$27.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$75.5 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">three and nine months ended September 30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, respectively. We recorded net losses of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$11.8 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$34.4 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">three and nine months ended September 30, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, respectively. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We expect to continue to incur significant expenses for the foreseeable future as we increase marketing efforts for Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and maintain our regulatory approvals. </font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Daewoong License and Supply Agreement</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In 2013, we entered into the Daewoong Agreement, pursuant to which we have an exclusive distribution license to Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;from </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Daewoong Pharmaceuticals Co., Ltd., or Daewoong,</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for aesthetic indications in the United States, EU, Canada, Australia, Russia, C.I.S., and South Africa, as well as co-exclusive distribution rights with Daewoong in Japan.&#160;Under the Daewoong Agreement, we are required to make certain minimum annual purchases upon commercialization in order to maintain the exclusivity of the license. These potential minimum purchase obligations are contingent upon the occurrence of </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">31</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sA9B010344B1252489F229F26AB5A0DDF"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">future events, including receipt of governmental approvals and our future market share in various jurisdictions. In connection with our entry into the Daewoong Agreement, we made an upfront payment to Daewoong of $2.5 million. Upon the FDA approval of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;in February 2019, we paid Daewoong a $2.0 million milestone payment. Under the Daewoong Agreement, as of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">September&#160;30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the maximum remaining aggregate amount of future milestone payments that could be owed to Daewoong upon the satisfaction of all milestones is $11.5 million, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">including the $1.0 million milestone payment accrued upon approval in the European Union in September 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. Daewoong is responsible for all costs related to the manufacturing of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, including costs related to the operation and upkeep of its manufacturing facility, and we are responsible for all costs related to obtaining and maintaining regulatory approvals, including clinical expenses, and commercialization expenses.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Royalties and Notes Payable to Evolus Founders</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We are obligated to make the following future payments to the founders of Evolus (i) quarterly royalty payments of a low single digit percentage of net sales of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and (ii) a </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$20.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;promissory note that will mature in November 2021. The obligations set forth in (i) above will terminate in the quarter following the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">10</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">-year anniversary of the first commercial sale of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;in the United States. As these revised payment obligations are not perpetual, we do not have the right to terminate any future payments for a one-time lump sum payment. In the second quarter of 2019, the Evolus Founders ceased to be related parties and the respective captions on the condensed financial statements were updated to reflect this change.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Our&#160;Relationship with ALPHAEON Corporation</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Prior to our initial public offering, or IPO, in February 2018, we were wholly owned by ALPHAEON Corporation. In January 2018, we entered into a services agreement with ALPHAEON, or the services agreement, which became effective in connection with our IPO. The services agreement sets forth certain terms between ALPHAEON and us that govern the respective responsibilities and obligations between ALPHAEON and us, as it relates to the services to be performed between us. The fees charged for any services rendered pursuant to the services agreement are the actual cost incurred by ALPHAEON or us, as the case may be, in providing the services for the relevant period.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:8px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">September&#160;30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, ALPHAEON owned&#160;approximately </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">31.6%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;of our outstanding shares of common stock. As a result, we are no longer considered a controlled company within the meaning of the Nasdaq Marketplace Rules.</font></div><div><a name="sEF2FFAFCB00F5314A213D23FF47D01EC"></a></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Components of Results of Operations</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Net Revenues</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We currently operate in one reportable segment and all of our net revenues are derived from sales of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;to customers in the U.S. self-pay aesthetic market, net of customer rebates and coupons. We began shipping Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;in May 2019. Revenues are recognized when the control of the promised goods is transferred to the customer in an amount that reflects the consideration to which we expect to be entitled in exchange for those products or services. Because the purpose of our J.E.T. program was to give customers experience with our product, we did not generate any net revenues from shipments related to the J.E.T. program which ended in August 2019. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Cost of sales</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Cost of sales primarily reflects the aggregate costs to purchase Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;from Daewoong. We anticipate our cost of sales will increase as Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;sales increases. Our gross margin may also fluctuate in the future as we implement various marketing programs that may affect the average selling price of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Selling, General and Administrative Expenses</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our selling, general and administrative expenses primarily consist of expenses related to personnel, marketing programs, physician engagement, digital platform, conferences, travel, and professional services. Personnel-related expenses include salaries, sales commissions, bonuses, fringe benefits, and stock-based compensation for our employees in administrative, commercial and other operating functions. Professional services primarily include accounting, auditing, legal, and various consulting services. Selling, general and administrative expenses may fluctuate in the future primarily due to potential changes in marketing strategies, and performance-based personnel-related expenses, such as commissions and bonuses.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">32</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sA9B010344B1252489F229F26AB5A0DDF"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Research and Development Expenses</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Since our inception, we have focused on developing Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. We expense our research and development costs as we incur them. Our research and development expenses primarily consist of research personnel-related expenses, including salaries, fringe benefits, and stock-based compensation; costs of conducting clinical studies, including fees paid to clinical study sites and vendors, costs of acquiring and evaluating clinical study data, and fees paid to clinical consultants related to the execution of clinical trials; other outside consulting services; and the costs of materials, supplies and travel.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Expenses related to clinical studies are based on estimates of patient enrollment and related expenses at clinical investigator sites as well as estimates for the services received and efforts expended pursuant to contracts with clinical research organizations that we may use to conduct and manage our clinical studies on our behalf. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We expect our overall research and development expenses to increase if and when we seek to develop future product candidates and pursue regulatory approvals in other jurisdictions.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Revaluation of Contingent Royalty Obligation to Evolus Founders</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The fair value of the contingent royalty obligation payable to Evolus Founders is primarily driven by assumptions related to revenue forecasts, discount rate, and timing of cash flows.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Depreciation and amortization</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Depreciation and amortization expenses primarily consist of the amortization of the distribution right that was reclassified from IPR&amp;D asset upon FDA approval of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;in February 2019 as well as the amortization of internal-use software that was placed in service upon launching Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;in May 2019.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Non-Operating Income (Expense), Net</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Non-operating income (expense), net primarily consists of interest income derived from our short-term investments and interest expense incurred for our debt facilities.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Income Taxes (Benefit) Expense</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our tax provision is comprised of U.S. and state income taxes. We currently have a full valuation allowance against our net deferred tax assets. We have provided for the tax effects of uncertain tax positions in our tax provision.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">33</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sA9B010344B1252489F229F26AB5A0DDF"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Results of Operations </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Comparison of the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Three Months Ended September 30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">2018</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The following table summarizes our results of operations for the periods indicated:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:64%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Three Months Ended<br>September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">(in millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Change</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Net revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">13.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">13.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Cost of sales (excludes amortization of intangible assets)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">3.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">3.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Gross profit</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">9.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">9.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-style:italic;">As a percentage of net revenues</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">71.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Operating expenses:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Selling, general and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">30.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">7.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">23.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Research and development</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">0.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">2.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">(1.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Revaluation of contingent royalty obligation payable to Evolus Founders</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">1.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">2.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">(0.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Depreciation and amortization</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">1.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">1.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Total operating expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">34.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">11.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">23.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Loss from operations</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">(25.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">(11.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">(13.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Non operating income (expense), net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">(2.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">(0.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">(1.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Loss before income taxes:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">(27.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">(11.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">(15.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Income tax (benefit) expense</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">(0.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">(0.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Net loss</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">(27.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">(11.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">(15.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Net Revenues</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">During the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">three months ended September 30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, we recorded net revenues of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$13.2 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;consisting of sales of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, which was</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;commercially launched and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">began shipping to customers in the United States in May 2019. We did not record any net revenue during the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">three months ended September 30, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Cost of Sales</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our cost of sales was </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$3.7 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">three months ended September 30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, which primarily consisted of the cost of inventory that was purchased from Daewoong</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. We did not record any cost of sales during the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">three months ended September 30, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. Our gross profit as a percentage of net revenues was </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">71.8%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">three months ended September 30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Selling, General and Administrative</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Selling, general and administrative expenses </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">increase</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">d by </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$23.7 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$30.9 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">three months ended September 30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;from </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$7.2 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">three months ended September 30, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. The </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">increase</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;was primarily attributable to</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;the U.S. launch of </font><font style="font-family:Times New Roman;font-size:10pt;">Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. This included </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">higher personnel-related expenses as a result of hiring a U.S. sales force, building out our corporate and commercial infrastructure and incurring marketing expenses </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">including the J.E.T. program. Shipments under the J.E.T. program ended in August 2019. Personnel-related expenses, including stock-based compensation, increased by $12.0 million to $15.3 million for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">three months ended September 30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;from $3.3 million for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">three months ended September 30, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Research and Development</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Research and development expenses </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">decrease</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">d by </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$1.3 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$0.7 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">three months ended September 30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;from </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$2.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">three months ended September 30, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. The </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">decrease</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;was primarily attributable to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the completion of the U.S. clinical trial activities related to Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;in 2018.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">34</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sA9B010344B1252489F229F26AB5A0DDF"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Revaluation of Contingent Royalty Obligation Payable to Evolus Founders</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The change in the fair value is recorded in operating expenses in each reporting period. During the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">three months ended September 30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and 2018, the revaluation charges of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$1.8 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$2.3 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, respectively, were primarily driven by changes in management assumptions related to revenue forecasts, discount rate and timing of cash flows.&#160;</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Depreciation and Amortization</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Depreciation and amortization </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">increase</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">d by </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$1.2 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$1.2 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">three months ended September 30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;from a de minimis amount for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">three months ended September 30, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. This was primarily attributable to amortization of the distribution right asset related to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">over 20 years as well as amortization of the internal-use software costs over two years. </font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Non-Operating Income (Expense), Net</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Non-operating expense, net, increased by </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$1.7 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$2.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">three months ended September 30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;from </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$0.3 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">three months ended September 30, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. Interest income was </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$0.5 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">three months ended September 30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, which was primarily attributable to interest earned from short-term investments. During the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">three months ended September 30, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, we did not generate any interest income. Interest expense </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">increase</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">d by </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$2.1 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$2.5 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">three months ended September 30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;from </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$0.3 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">three months ended September 30, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, which </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">was primarily attributable to interest incurred on our long-term debt to Oxford Finance, LLC and the contingent promissory note payable to the Evolus Founders. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Income Taxes (Benefit) Expense</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Income tax benefit </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">decrease</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">d by </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$0.1 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$0.1 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">three months ended September 30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;from a de minimis amount for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">three months ended September 30, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">35</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sA9B010344B1252489F229F26AB5A0DDF"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Comparison of the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Nine Months Ended September 30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">2018</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The following table summarizes our results of operations for the periods indicated:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:64%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Nine Months Ended<br>September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">(in millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Change</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Net revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">15.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">15.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Cost of sales (excludes amortization of intangible assets)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">4.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">4.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Gross profit</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">11.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">11.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-style:italic;">As a percentage of net revenues</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">71.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Operating expenses:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Selling, general and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">83.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">16.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">66.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Research and development</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">3.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">5.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">(1.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Revaluation of contingent royalty obligation payable to Evolus Founders</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">8.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">11.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">(3.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Depreciation and amortization</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">2.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">2.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Total operating expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">97.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">33.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">63.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Loss from operations</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">(86.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">(33.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">(52.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Non operating income (expense), net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">(4.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">(0.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">(3.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Loss before income taxes:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">(90.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">(34.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">(56.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Income tax (benefit) expense</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">(14.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">(14.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Net loss</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">(75.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">(34.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">(41.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Net Revenues</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">During the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">nine months ended September 30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, we recorded net revenues of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$15.5 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;consisting of sales of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;which was commercially launched and began shipping to customers in the United States in May 2019. We did not record any net revenue during the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">nine months ended September 30, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Cost of Sales</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our cost of sales was </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$4.4 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">nine months ended September 30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, which primarily </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">consisted of the cost of inventory that was purchased from Daewoong. We did not record any cost of sales during the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">nine months ended September 30, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. Our gross profit as a percentage of net revenues was </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">71.7%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">nine months ended September 30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Selling, General and Administrative</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Selling, general and administrative expenses </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">increase</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">d by </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$66.4 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$83.3 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">nine months ended September 30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;from </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$16.9 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">nine months ended September 30, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">increase</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">was primarily attributable to</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;the U.S. launch of </font><font style="font-family:Times New Roman;font-size:10pt;">Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. This included </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">higher personnel-related expenses as a result of hiring a U.S. sales force, building out our corporate and commercial infrastructure and incurring marketing expenses </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">including the J.E.T. program. Shipments under the J.E.T. program ended in August 2019. Personnel-related expenses, including stock-based compensation, increased by $27.2 million to $36.7 million for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">nine months ended September 30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;from $9.5 million for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">nine months ended September 30, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. </font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Research and Development </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Research and development expenses </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">decrease</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">d by </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$1.7 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$3.6 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">nine months ended September 30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;from </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$5.3 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">nine months ended September 30, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. The </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">decrease</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;was primarily attributable to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the completion of the U.S. clinical trial activities related to Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;in 2018, partially offset by</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">one-time bonuses of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$1.6 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;to certain current and former employees upon FDA approval of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;in February 2019, including a one-time bonus of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$0.7 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;paid to the Company&#8217;s Chief Medical Officer and Head of Research &amp; Development. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">36</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sA9B010344B1252489F229F26AB5A0DDF"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Revaluation of Contingent Royalty Obligation Payable to Evolus Founders</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">During the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">nine months ended September 30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and 2018, the revaluation charges of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$8.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$11.4 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, respectively, were primarily driven by changes in management assumptions related to revenue forecasts, discount rate and timing of cash flows.&#160;</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Depreciation and Amortization</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Depreciation and amortization </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">increase</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">d by </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$2.7 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$2.7 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">nine months ended September 30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;from a de minimis amount for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">nine months ended September 30, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">This was primarily attributable to amortization of the distribution right asset related to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174; </sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">over 20 years as well as amortization of the internal-use software costs over two years. </font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Non-Operating Income (Expense), Net</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Non-operating expenses, net, increased by </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$3.3 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$4.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">nine months ended September 30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;from </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$0.8 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">nine months ended September 30, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. Interest income was </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$1.5 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">nine months ended September 30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, which was primarily attributable to interest earned from short-term investments</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. During the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">nine months ended September 30, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, we did not generate any interest income. Interest expense </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">increase</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">d by </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$4.7 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$5.5 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">nine months ended September 30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;from </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$0.8 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">nine months ended September 30, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, which</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;was primarily attributable to interest incurred on our long-term debt to Oxford Finance, LLC and the contingent promissory note payable to the Evolus Founders. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Income Taxes (Benefit) Expense</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Income tax benefit </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">increase</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">d by </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$14.9 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$14.9 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">nine months ended September 30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;from a de minimis amount for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">nine months ended September 30, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. This was primarily attributable to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">a partial release of the valuation allowance. Upon the reclassification of the indefinite-lived IPR&amp;D intangible asset to a definite-lived distribution right intangible asset in the first quarter of 2019, the related deferred tax liability became a source of future taxable income in the assessment of the realization of deferred tax assets, and as a result the related valuation allowance was released. </font></div><div><a name="sA1514F66BB2F59BA9AFD62DABDE8DC4D"></a></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Liquidity and Capital Resources</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As of September 30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, we had cash and cash equivalents of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$39.1 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, short-term investments of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$34.9 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, working capital of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$69.2 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, and stockholders&#8217; equity of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$17.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We have a limited history of generating revenues and only began shipping Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;in May 2019. We have incurred operating losses and have an accumulated deficit as a result of ongoing efforts to develop and commercialize Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, including providing selling, general and administrative support for these operations. As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">September&#160;30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, we had an accumulated deficit of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$198.6 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. We had net losses of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$75.5 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$34.4 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">nine months ended September 30,</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, respectively, and we used net cash in operating activities of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$77.5 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$13.7 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">nine months ended September 30,</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, respectively. We anticipate that we will continue to incur operating losses during the periods we are implementing our launch strategies for Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Loan and Security Agreement</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On March 15, 2019, or the closing date, we entered into a loan and security agreement, or the credit facility, with Oxford Finance, LLC, as collateral agent, or Oxford, and the lenders party thereto from time to time, pursuant to which the lender will make term loans available to us of up to $100.0 million. The credit facility provides that the term loans are funded in two advances. The first tranche of $75.0 million was funded on the closing date, and the second tranche of $25.0 million may be drawn, at our request, no later than September 30, 2020, upon achieving specified minimum net sales milestones with no event of default occurring. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As of September 30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, we had not yet met the net sales milestone to draw down the second tranche. The credit facility bears an annual interest rate equal to the greater of 9.5%, or the 30-day U.S. Dollar LIBOR rate plus 7.0%. We agreed to pay interest only on each tranche funded pursuant to the credit facility for the first 36 months until May 2022, which is followed by a 23-month amortization period. Notwithstanding the foregoing, if we maintain compliance with the specified minimum net sales covenant and meet other conditions during the initial interest-only period, upon our request, the interest only period may be extended by an additional 12 months to a total of 48 months followed by an 11-month amortization period.  </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">37</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sA9B010344B1252489F229F26AB5A0DDF"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Upon the earliest to occur of the maturity date, the acceleration of the term loans, or the prepayment of the term loans, we will be required to pay to Oxford a final payment of 5.5% of the full principal amount of the term loans funded, or the final payment. We may elect to prepay all amounts owed prior to the maturity date, provided that a prepayment fee is also paid, which shall be equal to 3.0% of the amount prepaid if the prepayment occurs on or prior to March 15, 2020, 2.0% of the amount prepaid if the prepayment occurs after March 15, 2020 and on or prior to March 15, 2021, or 1.0% of the amount prepaid if the prepayment occurs thereafter, or the Prepayment Fee.  If the term loans are accelerated following the occurrence of an event of default, we will be required to immediately pay to Oxford an amount equal to the sum of all outstanding principal of the term loans plus accrued and unpaid interest thereon through the prepayment date, the final payment, the Prepayment Fee, and all other obligations that are due and payable, including payment of Oxford&#8217;s expenses and interest at the default rate with respect to any past due amounts.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The credit facility is secured by substantially all of our assets. The credit facility includes affirmative and negative covenants applicable to us and any subsidiaries we may create in the future. The affirmative covenants include, among others, covenants requiring us to maintain our legal corporate existence and governmental approvals, deliver certain financial reports, maintain insurance coverage and satisfy certain requirements regarding deposit accounts. The negative covenants include, among others, restrictions on us transferring collateral, incurring additional indebtedness, engaging in mergers or acquisitions, paying dividends or making other distributions, making investments, creating liens, selling assets and suffering a change in control, in each case subject to certain exceptions. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The credit facility also includes events of default, the occurrence and continuation of which could cause interest to be charged at a default interest rate equal to the applicable rate plus 5.0% and Oxford, as collateral agent, with the right to exercise remedies against us and the collateral securing the credit facility, including foreclosure against the property securing the credit facility, including our cash. These events of default include, among other things, any failure by us to pay principal or interest due under the credit facility, a breach of certain covenants under the credit facility, our insolvency, a material adverse change, the occurrence of any default under certain other indebtedness and one or more judgments against us, the institution of certain temporary or permanent relief in connection with pending litigation, or the breach, termination or other adverse events under the Daewoong Agreement.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The credit facility also provides us with the ability, under certain conditions, to obtain up to a $25.0 million revolving line of credit secured by our inventory, accounts receivable and cash proceeds of both. Oxford has the right of first refusal, but not the obligation, to provide such a revolving line of credit. There is no guarantee that such a line would be available to us on terms favorable to us or at all. As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">September&#160;30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the Company had not met the conditions to enter into a $25.0 million revolving line of credit. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Operating Leases</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We lease office facilities under various operating lease agreements. Our corporate headquarters is located in Newport Beach, California, in a facility that we sublease under a non-cancelable operating lease for a fixed amount each month. The sublease for this facility expires on January 20, 2020. On May 15, 2019, we entered into a non-cancelable operating lease for the same office facility with the original lessor. This noncancellable operating lease commences on February 1, 2020 and expires on January 31, 2025 with an option to extend the term for an additional </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">60 months</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. Lease payments increase based on an annual rent escalation clause that occurs on each February 1 anniversary. We</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;may, under certain circumstances, terminate the lease on the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">36 months</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;anniversary of the lease commencement date by providing a written notice </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">12 months</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;prior to such anniversary and paying a termination fee&#160;equal to six months basic rent plus certain other expenses. We have an option to extend the term of the lease for an additional </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">60 months</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Current and Future Capital Requirements</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We believe that our current capital resources, which consist of cash, cash equivalents and short-term investments, will be sufficient to fund operations through at least the next twelve&#160;months based on our expected cash burn rate from the date of the issuance of this Quarterly Report on Form 10-Q. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity or debt financings, entering into licensing or collaboration agreements with partners or other sources of financing. Sufficient funds may not be available to us at all or on attractive terms when needed from these sources. To the extent that we raise additional capital through the future sale of equity, the ownership interests of our stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our existing common stockholders. If we raise additional funds through the issuance of debt securities, these securities could contain covenants that would restrict our operations. We may require additional capital beyond our currently anticipated </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">38</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sA9B010344B1252489F229F26AB5A0DDF"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">amounts.&#160;If we are unable to obtain additional funding from these or other sources when needed, we may need to significantly reduce our controllable and variable expenditures and current rate of spending through reductions in staff and delaying, scaling back, or suspend certain research and development, sales and marketing programs and other operational goals. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We have based our projections of operating capital requirements on assumptions that may prove to be incorrect and we may use all our available capital resources, which consist of cash, cash equivalents and short-term investments, sooner than we expect. Because of the numerous risks and uncertainties associated with research, development and commercialization of pharmaceutical products, we are unable to estimate the exact amount of our operating capital requirements. Our future funding requirements will depend on many factors, including, but not limited to:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the number and characteristics of any future product candidates we develop or acquire;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the timing of any cash milestone payments to Daewoong if we successfully achieve certain predetermined milestones; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">our ability to forecast demand for our products, scale our supply to meet that demand and manage working capital effectively</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the cost of manufacturing our product or any future product candidates and any products we successfully commercialize, including costs associated with building our supply chain; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the cost of commercialization activities for Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;or any future product candidates are approved or cleared for sale, including marketing, sales and distribution costs;  </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the cost of maintaining a sales force, the productivity of that sales force, and the market acceptance of our products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">our ability to establish and maintain strategic collaborations, licensing or other arrangements and the financial terms of any such agreements that we may enter into; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">any product liability or other lawsuits related to our products; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the expenses needed to attract and retain skilled personnel; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the costs associated with being a public company; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing patent claims, including ongoing litigation costs related to Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and the outcome of this and any other future patent litigation we may be involved in; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the timing, receipt and amount of sales of any future approved or cleared products, if any. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Cash Flows</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The following table summarizes our cash flows for the periods indicated:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:85.31746031746032%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:67%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #231f20;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;font-weight:bold;">Nine Months Ended<br>September 30,</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(in millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #231f20;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #231f20;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #231f20;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #231f20;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #231f20;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">Net cash (used in) provided by:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:1px;text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">Operating activities </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">(77.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">(13.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">Investing activities </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">(37.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">Financing activities </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">60.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">118.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">Change in cash and cash equivalents</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">(54.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">105.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">Cash and cash equivalents, beginning of period</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">93.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">Cash and cash equivalents, end of period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">39.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">105.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">39</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sA9B010344B1252489F229F26AB5A0DDF"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Operating Activities </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Operating activities used </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$77.5 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;of cash for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">nine months ended September 30,</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;which primarily resulted from our net loss of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$75.5 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;as adjusted for a non-cash income tax benefit of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$14.9 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;resulting from partial release of the valuation allowance, and certain non-cash charges </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">including stock-based compensation&#160;expense of&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$7.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, a </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$8.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;change in revaluation of our contingent royalty obligation and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$2.7 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;of depreciation and amortization. The change in net operating assets and liabilities of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$12.6 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;was primarily driven by significant cash outflows from inventory purchases, timing of accounts receivable collections, and timing of vendor billing and invoice payments. </font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Investing Activities</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Investing activities used </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$37.4 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;of cash for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">nine months ended September 30,</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;primarily resulting from purchases of short-term investments net of maturities and additions to capitalized software.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Financing Activities</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Cash provided by financing activities during the&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">nine months ended September 30,</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;was </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$60.8 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;which&#160;primarily resulted from the proceeds of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$71.7 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;received from our credit facility net of discounts and issuance costs and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$1.1 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;received from issuance of common stock related to the incentive equity plan. These net proceeds were partially offset by a </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$9.3 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;payment of contingent royalty obligations to the Evolus Founders and a </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$2.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;payment to Daewoong upon FDA approval of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;in February 2019.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Indebtedness</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Loan and Security Agreement</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">See &#8220;&#8212;Liquidity and Capital Resources&#8221; for a description of our credit facility with Oxford.</font></div><div><a name="s85028616DC3752A5B59192DE09B9C676"></a></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Off-Balance Sheet Arrangements</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We do not have any off-balance sheet arrangements as defined in the rules and regulations of the SEC. We do not have any relationships with unconsolidated entities or financial partnerships, such as entities often referred to as structured finance or special purpose entities, which would have been established for the purpose of facilitating off-balance sheet arrangements or for any other contractually narrow or limited purpose. </font></div><div><a name="s0C2FDD36027C5CAC88B6CD989CEDCAAF"></a></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Critical Accounting Policies</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Management&#8217;s discussion and analysis of our financial condition and results of operations are based on our financial statements, which have been prepared in accordance with GAAP. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and related disclosure of contingent assets and liabilities, revenue and expenses at the date of the financial statements as well as the expenses incurred during the reporting period. Generally, we base our estimates on historical experience and on various other assumptions in accordance with GAAP that we believe to be reasonable under the circumstances. Actual results may differ materially from these estimates under different assumptions or conditions and such differences could be material to the financial position and results of operations. On an ongoing basis, we evaluate our judgments and estimates in light of changes in circumstances, facts and experience. There have been no material changes to our critical accounting policies and estimates as discussed in our Annual Report on Form 10-K filed for the year ended </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, other than the adoption of the revenue recognition accounting standards described below. </font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;">Revenue Recognition</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We currently operate in one reportable segment and all of our net revenue is derived from sales of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. We </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">recognize revenue when control of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;is transferred to a customer upon receipt. We do not accept product returns except under limited circumstances such as damages in transit or ineffective product. Any amounts related to taxes assessed by governmental authorities are excluded from revenue measurement. Shipping and handling costs associated with outbound product freight are accounted for as fulfillment costs and are included in selling, general, and marketing expenses on the condensed statements of operations and comprehensive loss. Payment terms are short-term and customer contracts do not include significant financing components.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">40</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sA9B010344B1252489F229F26AB5A0DDF"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We provide customers with trade and volume discounts and prompt pay discounts that are directly reflected in the invoice price. Revenues are recorded net of sales-related adjustments, wherever applicable, for the volume rebates and coupon programs. Volume rebates are contractually offered to certain customers. Generally, the rebates payable to each customer are determined based on the contract and quarterly purchase volumes. Through the coupon program, customers receive coupons redeemable into gift cards funded by us for the benefit of consumers. The coupons are accounted for as variable consideration. The Company estimates the coupon redemption rates based on historical data and expectations of future redemptions prior to the coupon expiration date. The coupons are accrued based on estimated redemption rates and the volume of products purchased and recorded as a reduction to revenues on product delivery. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Accounts receivable are recorded at the invoiced amount and do not bear interest. We assess the probability that we will collect the entitled consideration in exchange for the goods sold, by considering the customer&#8217;s ability and intention to pay when consideration is due. On a recurring basis, we estimate the amounts of receivables considered uncollectible to reflect an allowance for doubtful accounts.&#160;There was no significant provision for allowance of doubtful accounts during the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">nine months ended September 30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Recently Issued and Adopted Accounting Pronouncements</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We describe the recently issued and adopted accounting pronouncements that apply to us in&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Note 2</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">,&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Summary of Significant Accounting Policies-Recent Accounting Pronouncements</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div><div><a name="sC929ADF3F4E254BBBDA8A6BBE596EDD8"></a></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Item 3.  &#160;&#160;&#160;&#160;Quantitative and Qualitative Disclosure About Market Risk.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Not applicable.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">41</font></div></div><hr style="page-break-after:always"><div><a name="s0DB814D41B8854A08B3ACF86B50C6028"></a></div><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sA9B010344B1252489F229F26AB5A0DDF"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Item 4. &#160;&#160;&#160;&#160;Controls and Procedures.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Evaluation of Disclosure Controls and Procedures</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">September&#160;30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, who serve as our principal executive officer and principal financial officer, respectively, performed an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act. Our disclosure controls and procedures are designed to ensure (a) that information required to be disclosed in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms, and (b) that information required to be disclosed by us in reports filed or submitted under the Exchange Act is accumulated and communicated to our management, including our Chief Executive Officer and our Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosures. Based on this evaluation, our Chief Executive Officer and our Chief Financial Officer concluded that, as of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">September&#160;30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, our disclosure controls and procedures were effective at a reasonable assurance level.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objective and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Changes in Internal Control over Financial Reporting</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">During the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">three months ended September 30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, there were no changes in our internal control over financial reporting identified in connection with the evaluation required by Rule 13a-15(d) and 15d-15(d) of the Exchange Act that occurred with respect to the quarter ended </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">September&#160;30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">42</font></div></div><hr style="page-break-after:always"><div><a name="sDA37A244A57555759317078C989B5A04"></a></div><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sA9B010344B1252489F229F26AB5A0DDF"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Part II</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">&#8212;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Other Information</font></div><div><a name="sAF90887A1ABB53988FCC4FE8AD5AB400"></a></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Item 1.  &#160;&#160;&#160;&#160;Legal Proceedings.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">There have been no material developments with respect to the information previously reported in Item 3 &#8220;Legal Proceedings&#8221; of Part I of our Annual Report on Form 10-K for the year ended December 31, 2018. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">43</font></div></div><hr style="page-break-after:always"><div><a name="sD55A2E11664753A58361FFD69480D0C0"></a></div><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sA9B010344B1252489F229F26AB5A0DDF"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Item 1A.&#160;&#160;&#160;&#160;Risk Factors.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">The risks and uncertainties discussed below update, supersede and replace the risks and uncertainties previously disclosed in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2018, which was filed with the SEC on March 20, 2019.&#160;&#160;With the exception of risks relating to the commercialization of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174; </sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">and our status as a controlled company, we do not believe any of the changes constitute material changes from the risk factors previously disclosed in such prior Annual Report on Form 10-K.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">An investment in our company involves a high degree of risk of loss.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">You should carefully consider the risks and uncertainties described below together with all the other information in this Quarterly Report on Form 10-Q, including Part I, Item 2&#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and the financial statements and the related notes included in Part I, Item 1. Additional risks and uncertainties that we are unaware of, or that we currently believe are not material, may also become important factors that adversely affect our business. If any of the following risks actually occurs, our business, reputation, financial condition, results of operations, revenue, and future prospects could be seriously harmed. In that event, the market price of our common stock could decline, and you could lose part or all of your investment.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Risks Related to Our Business and Strategy</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">We have a short operating history and have incurred significant losses since our inception and anticipate that we will continue to incur losses for the foreseeable future. We have only one product and limited commercial sales, which, together with our short operating history, make it difficult to assess our future viability. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We are a performance beauty company with a short operating history. To date, we have invested substantially all of our efforts and financial resources in the clinical development and regulatory approval of, and commercial planning for, Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, which is currently our only product. We began selling Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;in the United States in May 2019 and have a limited history of generating revenue. We are not profitable and have incurred losses in each year since our inception in 2012. We have a short operating history upon which you can evaluate our business and prospects. Consequently, any predictions about our future success, performance or viability may not be as accurate as they could be if we had a longer operating history or experience commercializing a product. In addition, we have limited experience and have not yet demonstrated an ability to successfully overcome many of the risks and uncertainties frequently encountered by companies in the medical aesthetics field. We continue to incur significant expenses related to the commercialization of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. We have recorded net losses of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$75.5 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, $46.9 million and $4.5 million for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">nine months ended September 30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, and years ended December 31, 2018 and 2017, respectively, and had an accumulated deficit as of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">September&#160;30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$198.6 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. We expect to continue to incur losses for the foreseeable future, and we anticipate these losses will continue as we commercialize Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. Our ability to achieve substantial revenue and profitability is dependent on our ability to successfully market and commercialize Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. Even if we achieve profitability in the future, we may not be able to sustain profitability in subsequent periods. Our prior losses, combined with expected future losses, may adversely affect the market price of our common stock and our ability to raise capital and continue operations. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">We currently depend entirely on the successful commercialization of our only product, Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">. If we are unable to successfully commercialize Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">, we may never generate sufficient revenue to continue our business.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We currently have only one product, Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, and our business presently depends entirely on our ability to successfully commercialize it in a timely manner. While the product was commercially launched in the United States in May 2019, we have a limited history of generating revenue for Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. Our near-term prospects, including our ability to finance our company and generate revenue, as well as our future growth, depend entirely on the successful commercialization of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. The commercial success of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;will depend on a number of factors, including the following:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">our success in educating physicians and consumers about the benefits, administration and use of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;">;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">the prevalence, duration and severity of potential side effects experienced with Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;">;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">achieving and maintaining compliance with all regulatory requirements applicable to Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;">;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">the ability to raise additional capital on acceptable terms, or at all, if needed, to support the commercial launch of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;">;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">the acceptance by physicians and consumers of the safety and efficacy of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;">;</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">44</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sA9B010344B1252489F229F26AB5A0DDF"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">our ability to successfully commercialize Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;">, whether alone or in collaboration with others, including our ability to hire, retain and train sales representatives in the United States;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">the ability of our current manufacturer and any third parties with whom we may contract to manufacture Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;">&#32;to remain in good standing with regulatory agencies and develop, validate and maintain commercially viable manufacturing processes that are compliant with current Good Manufacturing Practice, or cGMP, requirements; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">the availability, perceived advantages, relative cost, relative safety and relative efficacy of competing products, the timing of new product introductions by our competitors, and the sales and marketing tactics of our competitors, including bundling of multiple products, in response to our launch of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;">.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">If we do not achieve one or more of these factors, many of which are beyond our control, in a timely manner or at all, we could experience significant issues commercializing Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. Further, we may never be able to successfully commercialize Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;or any future product candidates. In addition, our experience as a commercial company is limited. Accordingly, we may not be able to generate sufficient revenue through the sale of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;or any future product candidates to continue our business.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">We rely on the license and supply agreement, the Daewoong Agreement, with Daewoong Pharmaceuticals Co. Ltd., or Daewoong, to provide us exclusive rights to distribute Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">&#32;in certain territories. Any termination or loss of significant rights, including exclusivity, under the Daewoong Agreement would materially and adversely affect our development or commercialization of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Pursuant to the Daewoong Agreement, we have secured an exclusive license from Daewoong, a South Korean pharmaceutical manufacturer, to import, distribute, promote, market, develop, offer for sale and otherwise commercialize and exploit Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for aesthetic indications in the United States, EU, Canada, Australia, Russia, C.I.S. and South Africa, as well as co-exclusive distribution rights with Daewoong in Japan. The Daewoong Agreement imposes on us obligations relating to exclusivity, territorial rights, development, commercialization, funding, payment, diligence, sublicensing, intellectual property protection and other matters. We are obligated to conduct development activities, obtain regulatory approval of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, obtain from Daewoong all of our product supply requirements for Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and pay to Daewoong regulatory milestone payments and other cash payments in connection with the net sales of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. In addition, under the Daewoong Agreement, we are required to submit our commercialization plan to a joint steering committee, or JSC, comprised of an equal number of development and commercial representatives from Daewoong and us, for review and input. Although the Daewoong Agreement provides us with final decision-making power regarding the marketing, promotion, sale and/or distribution of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, any disagreement among the JSC would be referred to Daewoong&#8217;s and our respective senior management for resolution </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">if the JSC is unable to reach a decision within thirty days, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">which may result in a delay in our ability to implement our commercialization plan or harm our working relationship with Daewoong. If we fail to achieve minimum annual purchase targets of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;under the Daewoong Agreement, Daewoong may, at its sole option, elect to convert the exclusive license to a non-exclusive license. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The initial term of the Daewoong Agreement will expire on the later of September 30, 2023 or the fifth anniversary of our receipt of marketing approval in any of the aforementioned territories. The Daewoong Agreement will renew for unlimited additional three-year terms after the expiration of the initial term, only if we meet certain performance requirements during the initial term or preceding renewal term, as applicable. We or Daewoong may terminate the Daewoong Agreement if the other party breaches any of its duties or obligations and such breach continues without cure for ninety days, or thirty days in the case of a payment breach, or if we declare bankruptcy or assign our business for the benefit of creditors. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">If we breach any material obligations, or use the intellectual property licensed to us in an unauthorized manner, we may be required to pay damages to Daewoong and Daewoong may have the right to terminate our license. In addition, if any of the regulatory milestones or other cash payments become due under the terms of the Daewoong Agreement, we may not have sufficient funds available to meet our obligations, which would allow Daewoong to terminate the Daewoong Agreement. Any termination or loss of rights (including exclusivity) under the Daewoong Agreement would materially and adversely affect our ability to commercialize Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, which in turn would have a material adverse effect on our business, operating results and prospects. If we were to lose our rights under the Daewoong Agreement, we believe it would be difficult for us to find an alternative supplier of a botulinum toxin type A complex. In addition, to the extent the alternative supplier has not secured regulatory approvals in a jurisdiction, we would have to expend significant resources to obtain regulatory approvals that may never be obtained or require several years to obtain, which could significantly delay commercialization. We may be unable to raise additional capital to fund our operations during this extended time on terms acceptable to us or at all. Additionally, if we experience delays as a result of a dispute with Daewoong, the demand for Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;could be materially and adversely </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">45</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sA9B010344B1252489F229F26AB5A0DDF"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">affected.  Additionally, if the Daewoong Agreement is terminated, breached or has certain other adverse actions, it may constitute an event of default under our loan and security agreement, or credit facility, with Oxford Finance, LLC, or Oxford. Under the credit facility, in the event of default, a default interest rate equal to the applicable rate plus 5.0% would apply and Oxford, as collateral agent, could exercise remedies against us and the collateral securing the credit facility, including foreclosure against the property securing the credit facility, including cash.  Any such action could materially and adversely affect our business and results of operations.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">We currently rely solely on Daewoong to manufacture Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">, and as such, any production or other problems with Daewoong could adversely affect us.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We depend solely upon Daewoong for the manufacturing of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. Although alternative sources of supply may exist, the number of third-party suppliers with the necessary manufacturing and regulatory expertise and facilities is limited, and it could be expensive and take a significant amount of time to arrange for and qualify alternative suppliers, which could have a material adverse effect on our business. Suppliers of any new product candidate would be required to qualify under applicable regulatory requirements and would need to have sufficient rights under applicable intellectual property laws to the method of manufacturing the product candidate. Obtaining the necessary FDA approvals or other qualifications under applicable regulatory requirements and ensuring non-infringement of third-party intellectual property rights could result in a significant interruption of supply and could require the new manufacturer to bear significant additional costs which may be passed on to us.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In addition, our reliance on Daewoong entails additional risks, including reliance on Daewoong for regulatory compliance and quality assurance, the possible breach of the Daewoong Agreement by Daewoong, and the possible termination or nonrenewal of the Daewoong Agreement at a time that is costly or inconvenient for us. Our failure, or the failure of Daewoong, to comply with applicable regulations could result in sanctions being imposed on us, including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of products, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. Our dependence on Daewoong also subjects us to all of the risks related to Daewoong&#8217;s business, which are all generally beyond our control. Daewoong&#8217;s ability to perform its obligations under the Daewoong Agreement is dependent on Daewoong&#8217;s operational and financial health, which could be negatively impacted by several factors, including changes in the economic, political and legislative conditions in South Korea and the broader region in general and the ability of Daewoong to continue to successfully attract customers and compete in its market. Furthermore, Daewoong&#8217;s recently constructed manufacturing facility is Daewoong&#8217;s only facility meeting FDA and European Medicines Agency, or EMA, cGMP requirements. Daewoong&#8217;s lack of familiarity with, or inability to effectively operate, the facility and produce products of consistent quality, may harm our ability to compete in our market.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Additionally, although we are ultimately responsible for ensuring compliance with regulatory requirements such as cGMPs, we are dependent on Daewoong for day-to-day compliance with cGMP for production of drug substance and finished products. Facilities used by Daewoong to produce the drug substance and materials or finished products for commercial sale must pass inspection and be approved by the FDA and other relevant regulatory authorities. If the safety of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;is compromised due to a failure to adhere to applicable laws or for other reasons, we may not be able to successfully commercialize our product and we may be held liable for injuries sustained as a result. In addition, the manufacturing facilities of certain of our suppliers are located outside of the United States. This may give rise to difficulties in importing our product into the United States or other countries as a result of, among other things, regulatory agency approval requirements, taxes, tariffs, local import requirements such as import duties or inspections, incomplete or inaccurate import documentation or defective packaging. Any of these factors could adversely impact our ability to effectively commercialize Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Any failure or refusal by Daewoong or any other third party to supply Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;or any other product candidates or products that we may develop could delay, prevent or impair our clinical development or commercialization efforts.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Third-party claims of intellectual property infringement</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">may prevent or delay our development and commercialization efforts.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our commercial success depends in part on our avoiding infringement of the proprietary rights of third parties. Competitors in the field of dermatology, aesthetic medicine and neurotoxins have developed large portfolios of patents and patent applications in fields relating to our business. In particular, there are patents held by third parties that relate to the treatment with neurotoxin-based products for the indication we are currently developing. There may also be patent applications that have been filed but not published that, when issued as patents, could be asserted against us. There is a substantial amount of litigation, both within and outside the United States, involving patent and other intellectual property rights in the technology, medical device and pharmaceutical industries, including patent infringement lawsuits, interferences, oppositions and inter-</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">46</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sA9B010344B1252489F229F26AB5A0DDF"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">party reexamination proceedings before the U.S. Patent and Trademark Office, or USPTO. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are developing Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. As the technology, medical device and pharmaceutical industries expand and more patents are issued, the risk increases that our product candidates may be subject to claims of infringement of the patent rights of third parties.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Third-parties may assert that we or any of our current or future licensors, including Daewoong, are employing their proprietary technology without authorization. There may be third-party patents or patent applications with claims to materials, methods of manufacture or methods for treatment related to the use or manufacture of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;or any future product candidates. Because patent applications can take many years to issue, there may be currently pending patent applications that may later result in issued patents that Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;or any future product candidates may infringe. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. If any third-party patents were held by a court of competent jurisdiction to cover the manufacturing process of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;or any future product candidates, the holders of any such patents may be able to block our ability to commercialize such product candidate unless we obtain a license under the applicable patents or until such patents expire. Similarly, if any third-party patent were held by a court of competent jurisdiction to cover aspects of our methods of use, the holders of any such patent may be able to block our ability to develop and commercialize the applicable product candidate unless we obtain a license or until such patent expires. In either case, such a license may not be available on commercially reasonable terms or at all.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In addition to claims of patent infringement, third parties may bring claims against us asserting misappropriation of proprietary technology or other information in the development, manufacture and commercialization of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;or any of our future product candidates. Defense of such a claim would require dedicated time and resources, which time and resources could otherwise be used by us toward the maintenance of our own intellectual property and the development and commercialization of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and any of our future product candidates or by any of our current or future licensors for operational upkeep and manufacturing of our products. Presently, we are a defendant in a lawsuit brought by Medytox, Inc., or Medytox, on June 7, 2017 in the Superior Court of the State of California, alleging, among other things, that Daewoong stole Medytox&#8217;s botulinum toxin bacterial strain, or the BTX strain, that Daewoong misappropriated certain trade secrets of Medytox, including the process used to manufacture Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;(which Medytox claims is similar to its biopharmaceutical drug, Meditoxin) using the BTX strain, and that Daewoong thereby interfered with Medytox&#8217;s plan to license Meditoxin to us, or the Medytox Litigation. Medytox claims that as a result of Daewoong&#8217;s conduct, we entered into the Daewoong Agreement instead of an agreement with Medytox to license Meditoxin.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Daewoong filed a motion to dismiss or stay for forum non conveniens, claiming that the place where the complaint has been filed, in the Superior Court of the State of California, is not the proper place for the trial of the claims in the complaint because, among other reasons, the underlying facts that gave rise to the complaint occurred in South Korea. Daewoong&#8217;s motion to dismiss was granted by the Superior Court of the State of California on October 12, 2017. As a result, the action filed with the Superior Court of the State of California is stayed pending resolution of the proceedings in South Korea. In October 2017, Medytox initiated a civil lawsuit against Daewoong and its parent company, Daewoong Co. Ltd., in the Seoul Central District Court in Seoul, South Korea, related to the same subject matter in the Medytox litigation and is seeking, among other things, money damages, injunctive relief and destruction of related documents and products. None of us, ALPHAEON or SCH are parties to the litigation in the Seoul Central District Court.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On April 27, 2018, pursuant to a motion to dismiss brought by Daewoong, the Superior Court of the State of California dismissed Medytox&#8217;s suit against Daewoong, without prejudice, on the basis that Medytox had brought a substantially similar proceeding against Daewoong in South Korea. The proceedings against us, ALPHAEON and SCH remain stayed in the Superior Court of the State of California pending resolution of the proceedings between Medytox and Daewoong in South Korea. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">While the proceedings between Medytox and Daewoong in South Korea are progressing, legal proceedings are inherently uncertain and we cannot predict what actions may be taken by the Seoul Central District Court in connection with such proceedings. Due to these factors and because we are not a direct party to the proceedings, we are unable to provide any assurances about when such proceedings may be resolved or whether&#160;such resolution may occur sooner or later than we otherwise anticipate.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">With specific regard to us, Medytox alleges that (i) we have violated California Uniform Trade Secrets Act, Cal. Civ. Code Section 3426 because Daewoong&#8217;s alleged knowledge of the misappropriation of certain trade secrets of Medytox is imputed to us as a result of our relationship with Daewoong, (ii) we have stolen the BTX strain through our possession of and refusal to return the BTX strain, (iii) we have engaged in unlawful, unfair and fraudulent business acts and practices in violation of California Bus. &amp; Prof. Code Section 17200, including conversion of the BTX strain and misrepresentations to the public regarding the source of the botulinum toxin bacterial strain used to manufacture Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, and (iv) the Daewoong Agreement is invalid and in violation of Medytox&#8217;s rights.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">47</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sA9B010344B1252489F229F26AB5A0DDF"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Medytox seeks, among other things, (i) actual, consequential and punitive damages, (ii) a reasonable royalty, as appropriate, (iii) a declaration that the Daewoong Agreement is void and unenforceable and that Medytox is entitled to disgorgement of all property wrongfully and unjustly retained or acquired by the defendants, including unlawfully gained profits, (iv) injunctive relief prohibiting us from using the license under the Daewoong Agreement and distributing Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, and (v) attorneys&#8217; fees and costs. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Given the early stage in the Medytox Litigation, we are unable to predict the likelihood of success of Medytox&#8217;s claims against us, ALPHAEON, SCH or Daewoong or to quantify any risk of loss. The Medytox Litigation and any other similar claims, suits, government investigations and proceedings are inherently uncertain and their results may not be favorable for us. For example, if the Medytox Litigation has a negative outcome for us, ALPHAEON or Daewoong, it could result in us losing access to Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and the manufacturing process and require us to negotiate a new license with Medytox for continued access to Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. We may not be able to successfully negotiate such license on terms acceptable to us or at all. If we are unable to license Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, we may not be able to find a replacement product, if at all, without expending significant resources and being required to seek additional regulatory approvals, which would be uncertain, time consuming and costly. Regardless of the outcome, such proceedings can have an adverse impact on us because of legal costs, diversion of management resources and other factors. An adverse ruling against either us or one of the other defendants of any such proceedings could adversely affect our business, financial position, results of operations, or cash flows and could also result in reputational harm. Any of these consequences could adversely affect our business and results of operations. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On January 30, 2019, Allergan and Medytox filed a complaint against us and Daewoong in the U.S. International Trade Commission, or the ITC, containing substantially similar allegations to the Medytox Litigation, specifically that Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;is manufactured based on misappropriated trade secrets of Medytox and therefore the importation of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;is an unfair act. The ITC matter is entitled </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">In the Matter of Certain Botulinum Toxin Products</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">,</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;or the ITC Complaint.  The ITC instituted an investigation </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">as ITC Inv. No. 337-TA-1145. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;The ITC complaint calls for an investigation by the ITC under Section 337 of the Tariff Act of 1930.  The ITC complaint seeks (i) an investigation pursuant to Section 337 of the Tariff Act of 1930, (ii) a hearing with the ITC on permanent relief, (iii) issuance of a limited exclusion order forbidding entry of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;into the United States, (iv) a cease and desist order prohibiting Daewoong and us from engaging in the importations, sale for importation, marketing, distribution, offering for sale, the sale after the importation of, or otherwise transferring Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;within the United States, (v) a bond issued during the presidential review period, (vi) the return of Medytox&#8217;s trade secrets and other confidential information including the alleged stolen BTX Strain, and (vii) exclusion and cease and desist orders. We intend to defend ourselves vigorously in the proceedings. The ITC has set a target date for the final determination of the matter for October 2020. An adverse ruling by the ITC against either us or Daewoong could result in the imposition of an exclusion order which would bar imports of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;into the United States and a cease and desist order which would bar sales and marketing of our sole product Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;within the United Sates either of which would adversely affect our ability to carry our out our business and which would have an adverse effect on our business, financial position, results of operations, or cash flows and could also result in reputational harm. Any of these consequences could adversely affect our business and results of operations.  </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Additionally, in certain cases if there is preliminary or permanent relief granted under the Medytox Litigation or the ITC matter, it may constitute an event of default under our credit facility.  Under the credit facility, in the event of default, a default interest rate equal to the applicable rate plus 5.0% would apply and Oxford, as collateral agent, could exercise remedies against us and the collateral securing the credit facility, including foreclosure against the property securing the credit facility, including cash.  Any such action could materially and adversely affect our business and results of operations.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Parties making claims against us or any of our current or future licensors may request and obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize one or more of our product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement, we or any of our current or future licensors may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, obtain one or more licenses from third parties which may not be commercially or more available, pay royalties or redesign our infringing products or manufacturing processes, which may be impossible or require substantial time and monetary expenditure. Furthermore, even in the absence of litigation, we may need to obtain licenses from third parties to advance our research, manufacture clinical trial supplies or allow commercialization of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;or any future product candidates. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. In that event, we would be unable to further develop and commercialize one or more of our product candidates, which could harm our business significantly. Similarly, third-party patents could exist that might be enforced against our products, resulting in either an injunction prohibiting our sales, or with respect to our sales, an obligation on our part to pay royalties and/or other forms of compensation to third parties.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">48</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sA9B010344B1252489F229F26AB5A0DDF"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Borrowings under our credit facility could adversely affect our financial condition and restrict our operating flexibility. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On March 15, 2019, or the closing date, we entered into a credit facility with Oxford, or the lender, pursuant to which the lender will make term loans available to us of up to $100.0 million, or the credit facility. The credit facility provides that the term loans will be funded in two advances. The first tranche of $75.0 million was funded on the closing date, and the second tranche of $25.0 million may be drawn, at our request, no later than September 30, 2020, upon achieving specified minimum net sales milestones with no event of default occurring. The credit facility bears an annual interest rate equal to the greater of 9.5%, or the 30-day U.S. Dollar LIBOR (London Inter-Bank Offered Rate) rate plus 7.0%. We have agreed to pay interest only on each tranche funded pursuant to the credit facility for the first 36 months until May 2022, which will be followed by a 23-month amortization period. Notwithstanding the foregoing, if we maintain compliance with the specified minimum net sales covenant and meet other conditions during the initial interest-only period, upon our request, the interest only period may be extended by an additional 12 months to a total of 48 months followed by an 11-month amortization period.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The credit facility is secured by substantially all of our assets. The credit facility contains customary affirmative and restrictive covenants and representations and warranties. We are bound by certain affirmative covenants setting forth actions that are required during the term of the credit facility including, without limitation, certain information delivery requirements, obligations to maintain certain insurance, and certain notice requirements. Additionally, we are bound by certain restrictive covenants setting forth actions that are not permitted to be taken during the term of the credit facility without Oxford&#8217;s prior written consent, including, without limitation, incurring certain additional indebtedness, consummating certain mergers, acquisitions or other business combination transactions, or incurring any non-permitted lien or other encumbrance on our assets. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Interest payments, fees, covenants and restrictions under the credit facility could have important consequences, including the following:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">limiting our ability to obtain additional financing on satisfactory terms to fund our working capital requirements, capital expenditures, potential acquisitions, debt obligations and other general corporate requirements, and making it more difficult for us to satisfy our obligations with respect to any such additional financing; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">increasing our vulnerability to general economic downturns, competition and industry conditions, which could place us at a competitive disadvantage compared to our competitors with no debt obligations or with debt obligations on more favorable terms; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">limiting our ability to pursue acquisition opportunities and to license intellectual property outside specified exceptions.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The occurrence of any one of these events could have an adverse effect on our business, financial condition, operating results or cash flows and ability to satisfy our obligations under the credit facility and any other indebtedness. If new debt is incurred in addition to debt incurred under the credit facility, the related risks that we face would be increased. The terms of the credit facility may restrict our current and future operations, particularly our ability to respond to changes in our business or to take certain actions. The credit facility contains, and the terms of any future indebtedness of ours would likely contain, a number of restrictive covenants that impose significant operating restrictions, including restrictions on our ability to engage in acts that may be in our best long-term interests. The credit facility includes covenants that, among other things and subject to certain exceptions and limits, restrict or otherwise limit our ability to:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">dispose of assets;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">undergo certain business, management, ownership, business and other fundamental changes;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">engage in certain merger, acquisition and consolidation transactions;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">incur additional indebtedness and create liens and other encumbrances;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">make restricted payments, including dividends and other distributions; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">engage in certain transactions with affiliates.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The credit facility also includes events of default including, among other things, any failure by us to pay principal or interest due under the credit facility, a breach of certain covenants under the credit facility, our insolvency, a material adverse change, the occurrence of any default under certain other indebtedness and one or more judgments against us, the institution of certain </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">49</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sA9B010344B1252489F229F26AB5A0DDF"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">temporary or permanent relief in connection with pending litigation, or the breach, termination or other adverse events under the Daewoong Agreement.  Under the credit facility, in the event of default, a default interest rate equal to the applicable rate plus 5.0% would apply and Oxford, as collateral agent, could exercise remedies against including the ability to declare any outstanding debt immediately due and payable. In addition, the credit facility is secured by certain of our existing and hereafter created or acquired assets, including our intellectual property, cash, accounts receivable, equipment, general intangibles, inventory and all of the proceeds and products of the foregoing. If we are unable to pay any amounts due and payable under the credit facility because we do not have sufficient cash on hand or are unable to obtain alternative financing on acceptable terms, the lenders could initiate a bankruptcy proceeding or proceed against any assets that serve as collateral to secure the credit facility. These restrictions could limit our ability to obtain future financings, make needed capital expenditures, withstand future downturns in the economy or otherwise conduct necessary corporate activities. We may also be prevented from taking advantage of business opportunities that arise because of limitations imposed on us by the restrictive covenants under the credit facility.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Increased regulatory oversight and uncertainty relating to the&#160;LIBOR&#160;calculation process and potential phasing out of&#160;LIBOR&#160;after 2021 may adversely affect the results of our operations.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On July 27, 2017, the United Kingdom&#8217;s Financial Conduct Authority, which regulates LIBOR, announced that it intends to stop persuading or compelling banks to submit rates for the calculation of&#160;LIBOR&#160;after 2021. The announcement indicates that the continuation of&#160;LIBOR&#160;on the current basis cannot and will not be guaranteed after 2021. It is impossible to predict whether and to what extent banks will continue to provide&#160;LIBOR&#160;submissions to the administrator of&#160;LIBOR, whether&#160;LIBOR&#160;rates will cease to be published or supported before or after 2021 or whether any additional reforms to&#160;LIBOR&#160;may be enacted in the United Kingdom or elsewhere. Efforts in the United States to identify a set of alternative U.S. dollar reference interest rates include proposals by the Alternative Reference Rates Committee of the Federal Reserve Board and the Federal Reserve Bank of New York. Uncertainty as to the nature of alternative reference rates and as to potential changes in other reforms to&#160;LIBOR&#160;may adversely affect&#160;LIBOR&#160;rates and may impact the availability and cost of borrowings, including the rates we pay on our credit facility with Oxford. If&#160;LIBOR&#160;rates are no longer available or do not remain an acceptable market benchmark, any successor or replacement interest rates may perform differently, which may adversely affect our interest expenses. We may incur significant costs to&#160;transition&#160;our borrowing arrangement with Oxford from&#160;LIBOR, which may have an adverse effect on our results of operations. The effect of a&#160;transition&#160;away from&#160;LIBOR&#160;on our company cannot yet be determined, and management continues to evaluate the LIBOR exposure risks.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We expect to require additional financing to fund our future operations, and a failure to obtain additional capital when so needed on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our operations.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We have utilized substantial amounts of cash since our inception in order to conduct clinical development to support regulatory approval of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;in the United States, EU and Canada. We expect that we will continue to expend substantial resources for the foreseeable future in order to commercialize Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and for the clinical development of any additional product candidates we may choose to pursue.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In the near term, these expenditures will include costs associated with the development and continuation of our marketing programs and commercialization infrastructure in connection with commercializing Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174; </sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">outside of the US. In the long term, these expenditures will include costs associated with the continued commercialization of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and any of our future product candidates, such as research and development, conducting preclinical studies and clinical trials and manufacturing and supplying as well as marketing and selling any products approved for sale. In addition, other unanticipated costs may arise. Because the regulatory approval process and commercialization expenditures needed to meet our sales objectives are highly uncertain, we cannot reasonably estimate the actual amounts necessary to successfully complete the development and commercialization of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;or any future product candidates. We expect to incur additional costs as we continue to operate as a public company, hire additional personnel and expand our operations.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We may require additional funds earlier than we currently expect in the event that market acceptance of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;is slower than expected. Our currently anticipated expenditures for the commercialization of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;may exceed existing cash, cash equivalents and investments, and we expect that we will need to seek additional debt or equity financing. Additionally, under our credit facility, in order to draw the final $25.0 million of the facility, we must meet a number of conditions including maintaining compliance with covenants under the credit facility and the achievement of specified net sales targets based on a trailing six-month basis. In the event we are unable to reach this net sales milestone, we will not be able to draw the additional $25.0 million.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We expect that we will need to raise additional capital to fund our operations and continue to support both our near and long-term expenditures. Our future capital requirements depend on many factors, including:</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">50</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sA9B010344B1252489F229F26AB5A0DDF"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the cost of commercialization activities for Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;or if any other future product candidates are approved for sale, including marketing, sales and distribution costs;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the scope, progress, results and costs of researching and developing any future product candidates, and conducting preclinical and clinical trials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">our ability to accurately forecast demand for our products, the ability of our third-party manufacturers to scale production to meet that demand and our ability to effectively manage our working capital requirements including the purchase of inventory and collection of receivables;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">costs under our third-party manufacturing and supply arrangements for our current and any future product candidates and any products we commercialize;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">our ability to establish and maintain strategic collaborations, licensing or other arrangements and the terms of and timing of such arrangements;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the timing of, and the costs involved in, obtaining and maintaining regulatory approvals for any future product candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the degree and rate of market acceptance of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;or any future approved products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the emergence, approval, availability, perceived advantages, relative cost, relative safety and relative efficacy of alternative and competing products, the timing of new product introductions by competitors and other actions by competitors in the marketplace;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">costs of operating as a public company; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">costs associated with any acquisition or in-license of products and product candidates, technologies or businesses.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">If we raise additional capital through marketing and distribution arrangements or other collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish certain valuable rights to our product candidates, technologies, future revenue streams or research programs or grant licenses on terms that may not be favorable to us. If we raise additional capital through public or private equity offerings or offerings of securities convertible into our equity, the ownership interest of our existing stockholders will be diluted and the terms of any such securities may have a preference over our common stock. Debt financing, receivables financing and royalty financing may also be coupled with an equity component, such as warrants to purchase our capital stock, which could also result in dilution of our existing stockholders&#8217; ownership, and such dilution may be material. Additionally, if we raise additional capital through debt financing, we will have increased fixed payment obligations and may be subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional debt or making capital expenditures to meet specified financial ratios, and other operational restrictions, any of which could restrict our ability to commercialize Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;or any future product candidates or operate as a business and may result in liens being placed on our assets. If we were to default on any of our indebtedness, we could lose such assets.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In the event we are unable to raise sufficient capital to fund our commercialization efforts to achieve specified minimum sales targets under the Daewoong Agreement, we will lose exclusivity of the license that we have been granted under the Daewoong Agreement.  In addition, if we are unable to raise additional capital when required or on acceptable terms, we may be required to significantly reduce operating expenses and delay, reduce the scope of or discontinue some of our development programs, commercialization efforts or other aspects of our business plan, out-license intellectual property rights to our product candidates and sell unsecured assets, or a combination of the above. As a result, our ability to achieve profitability or to respond to competitive pressures would be significantly limited and may have a material adverse effect on our business, results of operations, financial condition and/or our ability to fund our scheduled obligations on a timely basis or at all.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">&#32;may fail to achieve the broad degree of physician adoption and use necessary for commercial success. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;may fail to gain sufficient market acceptance by physicians, consumers and others in the medical aesthetics community. The commercial success of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and any future product candidates will depend significantly on the broad adoption and use of the resulting product by physicians for approved indications, including, in the case of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the treatment of glabellar lines and other aesthetic indications that we may seek to pursue. We are aware that other companies are seeking to develop alternative products and treatments, any of which could impact the demand for Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">51</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sA9B010344B1252489F229F26AB5A0DDF"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The degree and rate of physician adoption of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and any future product candidates depend on a number of factors, including: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">the effectiveness, ease of use and safety of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;">&#32;and any future product candidates as compared to existing products or treatments;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">physician and consumer willingness to adopt Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;">&#32;to treat glabellar lines or other aesthetic indications we may pursue over products and brands with which consumers and physicians may have more familiarity or recognition </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">or additional approved uses</font><font style="font-family:Times New Roman;font-size:10pt;">;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">overcoming any biases physicians or consumers may have toward the use, safety and efficacy of existing products or treatments </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">and successful marketing of the benefits of a 900 kDa botulinum toxin type A complex</font><font style="font-family:Times New Roman;font-size:10pt;">;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">the cost of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;">&#32;and any future product candidates in relation to alternative products or treatments and willingness to pay for the product or treatment on the part of consumers&#894;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">proper training and administration of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;">&#32;and any future product candidates by physicians and medical staff&#894;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">consumer satisfaction with the results and administration of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;">&#32;and any future product candidates and overall treatment experience;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">changes in pricing, </font><font style="font-family:Times New Roman;font-size:10pt;">promotional, negative sales tactics, promotion of longer-term purchase agreements</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and bundling efforts by competitors;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the filing of various lawsuits by competitors with the intent of preventing or delaying our product launches, to distract management&#8217;s attention from operating our business and to devote significant financial resources to defend such litigation attempts;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">consumer demand for the treatment of glabellar lines or other aesthetic indications that may be approved in the future;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">the willingness of consumers to pay for Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;">&#32;and any future product candidates relative to other discretionary items, especially during economically challenging times&#894;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">the revenue and profitability that Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;">&#32;and any future product candidates may offer a physician as compared to alternative products or treatments;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">the effectiveness of our sales, marketing and distribution efforts and our ability to develop our brand awareness;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">any adverse impact on our brand resulting from key opinion leader relationships with ALPHAEON or SCH, whether or not related to us; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">our ability to compete with our competitors&#8217; product bundling offerings as we initially launch Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;">&#32;as a stand-alone product; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">adverse </font><font style="font-family:Times New Roman;font-size:10pt;">publicity </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">about our product candidates, competitive products, or the industry as a whole, or favorable publicity about competitive products.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In addition, in its clinical trials, Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;was clinically tested with one Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;unit compared to one BOTOX unit. Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;is the only known neurotoxin product in the United States with a 900 kDa complex other than BOTOX. We believe that aesthetic physicians&#8217; familiarity with the 900 kDa complex&#8217;s handling, preparation and dosing will more easily facilitate incorporation of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;into their practices. However, the ease of integration of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;into a physician&#8217;s practice may not be as seamless as we anticipate.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">If Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;or any future product candidates fail to achieve the broad degree of physician adoption necessary for commercial success, our operating results and financial condition will be adversely affected, which may delay, prevent or limit our ability to generate revenue and continue our business.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">52</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sA9B010344B1252489F229F26AB5A0DDF"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">If there is not sufficient consumer demand for Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">, our financial results and future prospects will be harmed. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Treatment of glabellar lines with Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;is an elective procedure, the cost of which must be borne by the consumer, and we do not expect costs related to the treatment to be reimbursable through any third-party payor, such as Medicaid, Medicare or commercial insurance. The decision by a consumer to undergo treatment with Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for the treatment of glabellar lines or other aesthetic indications that we may pursue may be influenced by a number of factors, including: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">the success of any sales and marketing programs that we, or any third parties we engage, undertake, and as to which we have limited experience;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">the extent to which physicians recommend Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;">&#32;to their patients;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">the extent to which Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;">&#32;satisfies consumer expectations </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">and overcoming consumer loyalty with existing products and brands</font><font style="font-family:Times New Roman;font-size:10pt;">;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">our ability to properly train physicians in the use of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;">&#32;such that their consumers do not experience excessive discomfort during treatment or adverse side effects;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">the cost, safety and effectiveness of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;">&#32;versus other aesthetic treatments;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the development </font><font style="font-family:Times New Roman;font-size:10pt;">and</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;availability of alternative products and treatments that seek to address similar goals;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">consumer sentiment about the benefits and risks of aesthetic procedures generally and Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;">&#32;in particular;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">the success of any direct-to-consumer marketing efforts that we may initiate; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">the ability and ease with which physicians are able to incorporate Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;">&#32;into their practices; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">changes in demographic and social trends; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">general consumer </font><font style="font-family:Times New Roman;font-size:10pt;">confidence</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, which may be impacted by economic and political conditions.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;is the only U.S. neurotoxin without a therapeutic indication, although other companies may seek to develop a similar product in the future. We believe pursuing an aesthetic-only non-reimbursed product strategy will allow for meaningful strategic advantages in the United States, including pricing and marketing flexibility. However, physicians may choose to not pass any cost benefits received by them due to such pricing flexibility to their patients. In addition, companies offering aesthetic products competitive to Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, whether they pursue an aesthetic-only non-reimbursed product strategy or not, may nonetheless try to compete with Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;on price both directly through rebates, promotional programs and coupons and indirectly through attractive product bundling and customer loyalty programs. Our business, financial results and future prospects will be materially harmed if we cannot generate sufficient consumer demand for Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In addition, we have not pursued regulatory approval of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for indications other than for the treatment of glabellar lines, which may limit adoption of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. Many of our competitors have received approval of multiple aesthetic and therapeutic indications for their neurotoxin product and may be able to market such product for use in a way we cannot. For example, we are aware that one of our competitors, </font><font style="font-family:Times New Roman;font-size:10pt;font-style:normal;font-weight:normal;">Allergan plc</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, or Allergan, has obtained and plans to obtain additional indications for its neurotoxin product within medical aesthetics and therefore is able to market its product across a greater number of indications than Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. If we are unable to obtain approval for indications in addition to glabellar lines, our marketing efforts for Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;will be severely limited. As a result, we may not generate physician and consumer demand or approval of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">53</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sA9B010344B1252489F229F26AB5A0DDF"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">&#32;faces, and any of our future product candidates will face, significant competition and our failure to effectively compete may prevent us from achieving significant market penetration and expansion. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:normal;font-weight:normal;">In May 2019, we commercially launched Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;font-style:normal;font-weight:normal;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;font-style:normal;font-weight:normal;">&#32;into the highly competitive U.S. aesthetic neurotoxin market. In the long term, we expect to expand our focus to the broader self-pay healthcare market. While numerous companies are engaged in the development, patenting, manufacture and marketing of aesthetic neurotoxin products competitive with Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;font-style:normal;font-weight:normal;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;font-style:normal;font-weight:normal;">, Allergan, through its product BOTOX, held approximately 75.0% of the global market share in the aesthetic neurotoxin market by revenue in 2018. Allergan and many of these potential competitors are large, experienced companies that enjoy significant competitive advantages, such as substantially greater financial, research and development, manufacturing, personnel and marketing resources, greater brand recognition, larger sales forces and more experience and expertise in obtaining marketing approvals from the FDA and other regulatory authorities. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">These competitors may also try to compete with Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;on price both directly, through rebates and promotional programs to high volume physicians and coupons to consumers, and indirectly, through attractive product bundling with complimentary products, such as dermal fillers that offer convenience and an effectively lower price compared to the total price of purchasing each product separately. These companies may also seek to compete based on their longer operating history. Larger companies may be better capitalized than us and, accordingly, are able to offer greater customer loyalty benefits to encourage repeat use of their products and finance a sustained global advertising campaign to compete with our commercialization efforts at launch. A number of our larger competitors also have access to a significant amount of studies and publications that they could use to compete with us.  </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Competitors and other parties may also seek to impact regulatory approval of our future product applications through the filing of citizen petitions or other similar documents, which could require costly and time-consuming responses to the regulatory agencies. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Larger competitors could seek to prevent or delay our market entry via costly litigation which can be lengthy and expensive and serve to distract our management team&#8217;s attention. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We could face competition from other sources as well, including academic institutions, governmental agencies and public and private research institutions. In addition, we are aware of other companies also developing and/or marketing products in one or more of our target markets, including competing injectable botulinum toxin type A formulations that are currently in Phase III clinical development in North America for the treatment of glabellar lines. We would face similar risks with respect to any future product candidates that we may seek to develop or commercialize in the broader self-pay healthcare market. Successful competitors in that market have the ability to effectively discover, obtain patents, develop, test and obtain regulatory approvals for products, as well as the ability to effectively commercialize, market and promote approved products, including communicating the effectiveness, safety and value of products to actual and prospective customers and medical staff.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our strategy of competing in the aesthetic neurotoxin market is dependent on the marketing and pricing flexibility that we believe is afforded to a company with a portfolio limited to self-pay healthcare, comprised of products and procedures that are not reimbursed by third-party payors. In the event that regulations applicable to reimbursed products are changed to apply to self-pay healthcare products, we would no longer have this flexibility and we may not be able to compete as effectively with our competitors which may have a material effect on our business, financial condition and results of operations. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The first use of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;is in aesthetic medicine. The aesthetic product market, and the facial aesthetic market in particular, is highly competitive and dynamic and is characterized by rapid and substantial technological development and product innovations. We have received regulatory approval of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for the treatment of glabellar lines and launched commercially in the U.S. We anticipate that Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;will face significant competition from other facial aesthetic products, such as other injectable and topical botulinum toxins and dermal fillers. Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;may also compete with unapproved and off-label treatments. In addition, competitors may develop new technologies within the aesthetic market that may be superior in safety and efficacy to Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;or offer alternatives to the use of toxins, including surgical and radio frequency techniques. To compete successfully in the aesthetic market, we will have to demonstrate that Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;is at least as safe and effective as current products sold by our competitors. Competition in the aesthetic market could result in price-cutting and reduced profit margins, any of which would harm our business, financial condition and results of operations. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Due to less stringent regulatory requirements, there are many more aesthetic products and procedures available for use in international markets than are approved for use in the United States. There are also fewer limitations on the claims that our competitors in international markets can make about the effectiveness of their products and the manner in which they can market them. As a result, we face more competition in these markets than in the United States. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our commercial opportunity could also be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;or any other product that we may develop. Our competitors also may obtain FDA or other regulatory approval for these products </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">54</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sA9B010344B1252489F229F26AB5A0DDF"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">more rapidly than we may obtain approval for our products, which could result in our competitors establishing a strong market position before we are able to enter the market, which may create additional barriers to successfully commercializing Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and any future product candidates and attracting physician and consumer demand.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">&#32;or any other product candidate for which we seek approval as a biologic may face competition sooner than anticipated.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">With the enactment of the Biologics Price Competition and Innovation Act of 2009, or the BPCI Act, as part of the Patient Protection and Affordable Care Act, an abbreviated pathway for the approval of biosimilar or interchangeable biological products was created. The abbreviated regulatory pathway establishes legal authority for the FDA to review and approve biosimilar biologics. Under the BPCI Act, an application for a biosimilar product cannot be approved by the FDA until twelve years after the original branded product was approved under a Biologics License Application, or BLA. The law is complex and is still being interpreted and implemented by the FDA. For example, one company has filed a Citizen Petition requesting that the FDA not apply the BPCI Act to pre-enactment BLAs. As a result, its ultimate impact, implementation, and meaning are subject to uncertainty. While it is uncertain when such processes intended to implement the BPCI Act may be fully adopted by the FDA, any such processes could have a material adverse effect on the future commercial prospects for our biological products.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We believe that Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;should qualify for the twelve-year period of exclusivity. However, there is a risk that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not consider any of our product candidates to be a reference product for competing products, potentially creating the opportunity for competition sooner than anticipated. Moreover, the extent to which a biosimilar product, once approved, will be substituted for any one of our reference products in a way that is similar to traditional generic substitution for non-biological products is not yet clear and will depend on a number of marketplace and regulatory factors that are still developing.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">&#32;is manufactured exclusively in one facility located in South Korea, and we plan to utilize this facility to support commercial production of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">. If this facility were damaged or destroyed, or if there occurs a significant disruption in operations at this facility for any reason, our ability to continue to operate our business would be materially harmed.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Daewoong developed the manufacturing process for Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and manufactures Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;in a recently constructed facility located in South Korea. If this facility were to be damaged, destroyed or otherwise unable to operate or comply with regulatory requirements, whether due to earthquakes, fire, floods, hurricanes, storms, tornadoes, other natural disasters, employee malfeasance, terrorist acts, power outages or otherwise, or if operations at the facility is disrupted for any other reason, such an event could jeopardize Daewoong&#8217;s ability to manufacture Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;as promptly as we or our customers expect or possibly at all. If we experience delays in achieving our development objectives, or if Daewoong is unable to manufacture Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;within a timeframe that meets our and our customers&#8217; expectations, our business, prospects, financial results and reputation could be materially harmed. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">If these disruptions exceed coverage provided by Daewoong&#8217;s insurance policies, Daewoong may be unable to satisfy its obligations to us.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">We or the third parties upon whom we depend may be adversely affected by earthquakes or other natural disasters or political unrest and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster or political unrest. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Daewoong, the sole manufacturer of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, manufactures Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;in a facility located in South Korea. In addition, the underlying drug substance for Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;is also manufactured in a separate facility on the same campus. The risk of extreme weather and earthquakes in the Pacific Rim region is significant due to the proximity of major earthquake fault lines. There is also a level of political unrest and military conflict or uncertainty in South Korea and the broader region. Natural disasters or political unrest could severely disrupt Daewoong&#8217;s operations, and have a material adverse effect on our business, results of operations, financial condition and prospects.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">If a natural disaster, political unrest, power outage or other event occurred that prevented Daewoong from using all or a significant portion of its manufacturing facility, or prevented us from using all or a significant portion of our headquarters, that damaged critical infrastructure, or that otherwise disrupted operations, it may be difficult or, in certain cases, impossible for us to continue our business for a substantial period of time. In particular, because Daewoong manufactures Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;in its facility, in the event of a natural disaster, political unrest, power outage or other event affecting this facility, we would be required to seek additional manufacturing facilities and capabilities that have obtained the necessary approvals required by state, federal or other applicable authorities in order to continue or resume manufacturing activities, which we may not be </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">55</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sA9B010344B1252489F229F26AB5A0DDF"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">able to do on commercially reasonable terms if at all. Any disaster recovery and business continuity plans that we and Daewoong have in place or put in place may not be adequate in the event of a serious disaster or similar event. We may incur substantial expenses as a result of our or Daewoong&#8217;s lack of disaster recovery and business continuity plans, or the adequacy thereof, which could have a material adverse effect on our business. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Our ability to market Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">&#32;is limited to use for the treatment of glabellar lines, and if we want to expand the indications for which we market Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">, we will need to obtain additional regulatory approvals, which will be expensive and may not be granted. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We have received regulatory approval for Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;in the United States for the treatment of moderate to severe glabellar lines. The terms of that approval restrict our ability to market or advertise Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for other indications, which could limit physician and consumer adoption. Under the U.S. Federal Food Drug and Cosmetic Act, we may generally only market Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for approved indications. Many of our competitors have received approval of multiple aesthetic and therapeutic indications for their neurotoxin products and may be able to market such products for use in a way we cannot. For example, we are aware that one of our competitors, Allergan, has obtained and plans to obtain additional indications for its neurotoxin product within medical aesthetics and therefore is able to market its product across a greater number of indications than Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. If we are unable to obtain approval for indications in addition to our anticipated approval for glabellar lines, our marketing efforts for Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;will be severely limited. As a result, we may not generate physician and consumer demand or approval of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We have entered into an agreement with ALPHAEON relating to certain rights to the therapeutic indications of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">&#32;under the Daewoong Agreement and, as a result, we will not be able to pursue therapeutic indications for Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On December 18, 2017, we entered into the therapeutic agreement with ALPHAEON, or the therapeutic agreement, relating to certain rights to the therapeutic indications of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">botulinum toxin products</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;under the Daewoong Agreement. Pursuant to the Daewoong Agreement, we received an option to expand the permitted uses of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">botulinum toxin products</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;to cover all therapeutic uses in the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">United States, EU, Canada, Australia, Russia, C.I.S., and South Africa, or the covered</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;territories, and Japan, or the therapeutic option. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">However, pursuant to the therapeutic agreement, we agreed not to sell, sub-license or otherwise dispose in whole or in part the therapeutic option or the rights underlying the therapeutic option and hold the therapeutic option and the underlying rights in trust for ALPHAEON. In September 2018, ALPHAEON exercised the right to obtain the therapeutic option to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">botulinum toxin products</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and remitted the option exercise price directly to Daewoong.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In addition, under the therapeutic agreement, ALPHAEON has the right to negotiate the entry into an agreement with Daewoong for distribution rights for therapeutic indications of botulinum toxin products that are separate and distinct from the Daewoong Agreement, or the ALPHAEON-Daewoong agreement. We have agreed to ALPHAEON and Daewoong&#8217;s entry into the ALPHAEON-Daewoong agreement, so long as the terms do not diminish, interfere with or adversely affect our ability to distribute Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for aesthetic indications in the covered territories and Japan under the Daewoong Agreement.  </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our entry into the therapeutic agreement eliminates our ability to expand the permitted uses of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">botulinum toxin products</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for therapeutic indications.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">If we are found to have improperly promoted off-label uses, or if physicians misuse our products or use our products off-label, we may become subject to prohibitions on the sale or marketing of our products, significant fines, penalties, sanctions, or product liability claims, and our image and reputation within the industry and marketplace could be harmed. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The FDA and other regulatory agencies strictly regulate the marketing and promotional claims that are made about pharmaceutical products, such as Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. In particular, a product may not be promoted for uses or indications that are not approved by the FDA or </font><font style="font-family:Times New Roman;font-size:10pt;">other similar regulatory authorities</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;as reflected in the product&#8217;s approved labeling. Physicians could use Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;on their patients in a manner that is inconsistent with the approved label of the treatment of moderate to severe glabellar lines, potentially including for the treatment of other aesthetic or therapeutic indications. If we are found to have promoted such off-label uses, we may receive warning letters from and be subject to other enforcement actions by the FDA, EMA and other regulatory agencies, and become subject to significant liability, which would materially harm our business. The federal government has levied large civil and criminal fines against companies for alleged improper promotion and has enjoined several companies from engaging in off-label promotion. If we become the target of such an investigation or prosecution based on our marketing and promotional practices, we could face similar sanctions, which would materially harm our business. In addition, management&#8217;s attention could be diverted from our business operations, significant legal expenses could be incurred, and our reputation could be damaged. The FDA has also required that companies enter into consent </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">56</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sA9B010344B1252489F229F26AB5A0DDF"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">decrees or permanent injunctions under which specified promotional conduct is changed or curtailed in order to resolve FDA enforcement actions. If we are deemed by the FDA to have engaged in the promotion of our products for off-label use, we could be subject to FDA prohibitions or other restrictions on the sale or marketing of our products and other operations or significant fines and penalties, and the imposition of these sanctions could also affect our reputation and position within the industry. In addition, regulatory authorities outside the United States may impose similar fines, penalties or sanctions.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Physicians may also misuse Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;or any future product candidates or use improper techniques, potentially leading to adverse results, side effects or injury, which may lead to product liability claims. If Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;or any future product candidates are misused or used with improper techniques or are determined to cause or contribute to consumer harm, we may become subject to costly litigation by our customers or their patients. Product liability claims could divert management&#8217;s attention from our core business, be expensive to defend, result in sizable damage awards against us that may not be covered by insurance and subject us to negative publicity resulting in reduced sales of our products. Furthermore, the use of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;or any future product candidates for indications other than those cleared by the FDA may not effectively treat such conditions, which could harm our reputation in the marketplace among physicians and consumers. Any of these events could harm our business and results of operations and cause our stock price to decline. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">&#32;or any of our future product candidates may cause serious or undesirable side effects or possess other unexpected properties that could delay or prevent their regulatory approval, limit the commercial profile of approved labeling or result in post-approval regulatory action.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Unforeseen side effects from Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;or our future product candidates could arise either during clinical development or after marketing such product. Undesirable side effects caused by product candidates could cause us or regulatory authorities to interrupt, modify, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA, EMA or similar regulatory authorities. Results of clinical trials could reveal a high and unacceptable severity and prevalence of side effects. In such an event, trials could be suspended or terminated and the FDA, EMA or similar regulatory authorities could order us to cease further development of or deny approval of product candidates for any or all targeted indications. The drug-related side effects could affect patient recruitment or the ability of enrolled patients to complete the trial or result in product liability claims. Any of these occurrences may harm our business, financial condition, operating results and prospects.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Additionally, if we or others identify undesirable side effects, or other previously unknown problems, caused by Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, or any of our future product candidates, after obtaining regulatory approval in the United States or other jurisdictions, a number of potentially negative consequences could result, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">regulatory authorities may withdraw their approval of the product;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">regulatory authorities may require a recall of the product or we may voluntarily recall a product;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">regulatory authorities may require the addition of warnings or contraindications in the product labeling, narrowing of the indication in the product label or issuance of field alerts to physicians and pharmacies;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">regulatory authorities may require us to create a medication guide outlining the risks of such side effects for distribution to patients or institute a </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Risk Evaluation and Mitigation Strategies, or </font><font style="font-family:Times New Roman;font-size:10pt;">REMS;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">we may be subject to limitations as to how we market or promote the product;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">we may be required to change the way the product is administered or modify the product in some other way;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">regulatory authorities may require additional clinical trials or costly post-marketing testing and surveillance to monitor the safety or efficacy of the product;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">sales of the product may decrease significantly;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">we could be sued and held liable for harm caused to patients; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">our brand </font><font style="font-family:Times New Roman;font-size:10pt;">and</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;reputation may suffer.</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">57</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sA9B010344B1252489F229F26AB5A0DDF"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Any of the above events could prevent us from achieving or maintaining market acceptance of the affected product and could substantially increase the costs of commercializing our products. The demand for Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;could also be negatively impacted by any adverse effects of a competitor&#8217;s product or treatment.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Our failure to successfully in-license, acquire, develop and market additional product candidates or approved products would impair our ability to grow our business.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Although a substantial amount of our effort will focus on the commercialization of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, a key element of our long-term strategy is to in-license, acquire, develop, market and commercialize a portfolio of products to serve the self-pay aesthetic market. Because our internal research and development capabilities are limited, we may be dependent upon pharmaceutical and other companies, academic scientists and other researchers to sell or license products or technology to us. The success of this strategy depends partly upon our ability to identify and select promising pharmaceutical product candidates and products, negotiate licensing or acquisition agreements with their current owners and finance these arrangements.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The process of proposing, negotiating and implementing a license or acquisition of a product candidate or approved product is lengthy and complex. Other companies, including some with substantially greater financial, marketing, sales and other resources, may compete with us for the license or acquisition of product candidates and approved products. We have limited resources to identify and execute the acquisition or in-licensing of third-party products, businesses and technologies and integrate them into our current infrastructure. Moreover, we may devote resources to potential acquisitions or licensing opportunities that are never completed, or we may fail to realize the anticipated benefits of such efforts. We may not be able to acquire the rights to additional product candidates on terms that we find acceptable, or at all.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Further, any product candidate that we acquire may require additional development efforts prior to commercial sale, including preclinical or clinical testing and approval by the FDA, the EMA and other similar regulatory authorities. All product candidates are prone to risks of failure during pharmaceutical product development, including the possibility that a product candidate will not be shown to be sufficiently safe and effective for approval by regulatory authorities. In addition, any approved products that we acquire may not be manufactured or sold profitably or achieve market acceptance.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">If we are unable to establish sufficient sales and marketing capabilities on our own or through third parties, we will be unable to successfully commercialize Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">&#32;or any other future product candidates or generate significant product revenue. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In connection with the commercial launch of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;in the United States, we built sales and marketing capabilities. We have no prior experience in the marketing, sale and distribution of aesthetic medicine products, and there are significant risks involved in building and managing a sales organization, including our ability to retain and incentivize qualified individuals, provide adequate training to sales and marketing personnel, generate sufficient sales leads, effectively manage a geographically dispersed sales and marketing team, adequately provide complementary products to be offered by sales personnel, which may otherwise put us at a competitive disadvantage relative to companies with more extensive product lines, and handle any unforeseen costs and expenses. Any failure or delay in the development of our internal sales, marketing and distribution capabilities would adversely impact the commercialization of these products. We may choose to collaborate with third parties that have direct sales forces and established distribution systems, either to augment our own sales force and distribution systems or in lieu of our own sales force and distribution systems. If we are unable to enter into such arrangements on acceptable terms or at all, we may not be able to successfully commercialize Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;or any future product candidates. To the extent we commercialize our product candidates by entering into agreements with third-party collaborators, we may have limited or no control over the sales, marketing and distribution activities of these third parties, in which case our future revenues would depend heavily on the success of the efforts of these third parties. If we are not successful in commercializing Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;or any future product candidates, either on our own or through collaborations with one or more third parties, our future product revenue will suffer and we would incur significant additional losses.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">To successfully commercialize Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;outside the United States or any other future product candidates in the United States, EU, Canada and other jurisdictions we may seek to enter, we will need to build our marketing, sales, distribution, managerial and other capabilities or make arrangements with third parties to perform these services, and we may not be successful in doing so.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">We may need to increase the size of our organization, and we may experience difficulties in managing this growth. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">September&#160;30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, we had 228 employees, all of whom constituted full-time employees. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our management and personnel, systems and facilities currently in place may not be adequate to support future growth. Our need to effectively execute our growth strategy requires that we:</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">58</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sA9B010344B1252489F229F26AB5A0DDF"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">manage any of our future clinical trials effectively;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">identify, recruit, retain, incentivize and integrate any additional employees;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">manage our internal development efforts effectively while carrying out our contractual obligations to third parties; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">continue</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;to improve our operational, financial and management controls, reporting systems and procedures.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Due to our limited financial resources and our limited experience in managing a company with such anticipated growth, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. The physical expansion of our operations may lead to significant costs and may divert our management and business development resources. Any inability to manage growth could delay the execution of our development and strategic objectives or disrupt our operations.  </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Our employees, independent contractors, consultants, commercial collaborators, principal investigators, vendors and other agents may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We are exposed to the risk that our employees, independent contractors, consultants, commercial collaborators, principal investigators, vendors and other agents may engage in fraudulent conduct or other illegal activity. Misconduct by these parties could include intentional, reckless and/or negligent conduct or disclosure of unauthorized activities to us that violates applicable regulations, including those laws requiring the reporting of true, complete and accurate information to regulatory agencies, manufacturing standards and federal and state healthcare laws and regulations. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, kickbacks, self-dealing and other abusive practices. Although our strategy to focus only on the self-pay market will reduce our risk under the Anti-Kickback Statute, we could face liability under similar state laws that are not limited to products reimbursed by the government or if we obtain regulatory approval for products reimbursed by federal healthcare programs in the future. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, referrals, customer incentive programs and other business arrangements. Misconduct by these parties could also involve the improper use of individually identifiable information, including, without limitation, information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. The precautions we take to detect and prevent misconduct may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant civil, criminal and administrative penalties, including, without limitation, damages, fines, disgorgement, imprisonment and the curtailment or restructuring of our operations.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">In the future, we may rely on third-parties and consultants to conduct all of our preclinical studies and clinical trials. If these third parties or consultants do not successfully carry out their contractual duties or meet expected deadlines, we may be unable to obtain regulatory approval for any future product candidates. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In the future, we may rely on medical institutions, clinical investigators, contract laboratories, collaborative partners and other third-parties, such as contract research organizations, or CROs, to conduct clinical trials on our product candidates. The third-parties with whom we may contract for execution of any of our future clinical trials may play a significant role in the conduct of these trials and the subsequent collection and analysis of data. However, any of these third-parties may not be our employees, and except for contractual duties and obligations, we would have limited ability to control the amount or timing of resources that they devote to any of our future programs. Although we may rely on these third parties to conduct our preclinical studies and clinical trials, we would remain responsible for ensuring that each of our preclinical studies and clinical trials is conducted in accordance with the applicable investigational plan and protocol. Moreover, the FDA and other similar regulatory authorities require us to comply with, among other requirements, good clinical practices, or GCPs, for conducting, monitoring, recording and reporting the results of clinical trials to ensure that the data and results are scientifically credible and accurate, and that the trial subjects are adequately informed of the potential risks of participating in clinical trials. We may also rely on consultants to assist in the execution, including data collection and analysis, of any of our future clinical trials. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In addition, the execution of preclinical studies and clinical trials, and the subsequent compilation and analysis of the data produced, requires coordination among various parties. In order for these functions to be carried out effectively and </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">59</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sA9B010344B1252489F229F26AB5A0DDF"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">efficiently, it is imperative that these parties communicate and coordinate with one another. Moreover, these third-parties may also have relationships with other commercial entities, some of which may compete with us. If the third-parties or consultants conducting our clinical trials do not perform their contractual duties or obligations, experience work stoppages, do not meet expected deadlines, terminate their agreements with us or need to be replaced, or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical trial protocols or GCPs, or for any other reason, we may need to conduct additional clinical trials or enter into new arrangements with alternative third parties, which could be difficult, costly or impossible, and our clinical trials may be extended, delayed or terminated or may need to be repeated. If any of the foregoing were to occur, we may not be able to obtain, or may be delayed in obtaining, regulatory approval for and will not be able to, or may be delayed in our efforts to, successfully commercialize any future product candidates being tested in such trials. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">We plan to rely on third-party distribution partners for the distribution of our products, product candidates and services outside of the U.S., which could delay or limit our ability to generate revenue.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">With respect to certain markets for our products, product candidates and services outside of the U.S., we plan to retain third-party service providers to perform functions related to the marketing, distribution and sale of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and any future product candidates. Key aspects of those functions may be out of our direct control, including regulatory compliance, warehousing and inventory management, distribution, contract administration, accounts receivable management and call center management. Any future distribution partners may hold significant control over important aspects of the commercialization of our products, including market identification, regulatory compliance, marketing methods, pricing, composition of sales force and promotional activities.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We may not be able to control the amount and timing of resources that any current or future third-party distribution partners may devote to our products, or prevent any third-party distribution partners from pursuing the development of alternative technologies or products that compete with our products, except to the extent our contractual arrangements protect us against such activities. Also, we may not be able to prevent any other third-party distribution partners from withdrawing its support of our products.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">If third-party service providers fail to comply with applicable laws and regulations, fail to meet expected deadlines, encounter natural or other disasters at their facilities or otherwise fail to perform their services to us in a satisfactory or predicted manner, or at all, our ability to deliver product to meet commercial demand could be significantly impaired. In addition, we may use third parties to perform various other services for us relating to sample accountability and regulatory monitoring, including adverse event reporting, safety database management and other product maintenance services. If the quality or accuracy of the data maintained by these service providers is insufficient, our ability to continue to market our products could be jeopardized or we could be subject to regulatory sanctions, and any indemnity we may receive from such third-party service providers could be limited by such provider&#8217;s ability to pay and otherwise might not be sufficient to cover all losses we may experience.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We forecast the demand for commercial quantities of our products, and if our forecasts are inaccurate, we may experience delays in shipments, increased inventory costs or inventory levels, and reduced cash flow.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We purchase Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;from Daewoong. Pursuant to the Daewoong Agreement, we submit forecasts of anticipated product orders to Daewoong and may, from time to time, submit purchase orders on the basis of these forecasting requirements. Our limited historical experience may not provide us with enough data to accurately predict future demand. In addition, we expect Daewoong to manufacture its own product, Nabota, a botulinum toxin formulation, from this facility for sale in the South Korean market and other markets in which we do not have exclusive rights. If our business significantly expands, our demand for commercial products would increase and Daewoong may be unable to meet our increased demand. In addition, our product will have fixed future expiration dates. If we overestimate our component and material requirements, we will have excess inventory, which may have to be disposed of if such inventory exceeds approved expiration dates, which would result in lost revenues and increase our expenses. If we underestimate our component and material requirements, we may have inadequate inventory, which could interrupt, delay or prevent delivery of our products to our customers. Any of these occurrences would negatively affect our financial performance.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">60</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sA9B010344B1252489F229F26AB5A0DDF"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">If and when we expand internationally, our international operations will expose us to risks, and failure to manage these risks may adversely affect our operating results and financial condition.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We may have operations both within and outside the United States. International operations are subject to a number of inherent risks, and our future results could be adversely affected by a number of factors, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">requirements or preferences for domestic products or solutions, which could reduce demand for our products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">differing existing or future regulatory and certification requirements;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">management communication and integration problems resulting from cultural and geographic dispersion;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">greater difficulty in collecting accounts receivable and longer collection periods;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">difficulties in enforcing contracts;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">difficulties and costs of staffing and managing non-U.S. operations;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">the uncertainty of protection for intellectual property rights in some countries;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">tariffs and trade barriers, export regulations and other regulatory and contractual limitations on our ability to sell our products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">multiple, conflicting and changing laws and regulations such as privacy regulations, including General Data Protection Regulation, or GDPR, tax laws, export and import restrictions, employment laws, immigration laws, labor laws, regulatory requirements and other governmental approvals, permits and licenses;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">more stringent data protection standards in some countries;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">greater risk of a failure of foreign employees to comply with both U.S. and foreign laws, including export and antitrust regulations, the U.S. Foreign Corrupt Practices Act, or FCPA, quality assurance and other healthcare regulatory requirements and any trade regulations ensuring fair trade practices;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">heightened risk of unfair or corrupt business practices in certain geographies and of improper or fraudulent sales arrangements that may impact financial results and result in restatements of, or irregularities in, financial statements;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">foreign currency exchange rates and the generally lower average sales prices available in most international markets compared to those in the United States;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">potentially adverse tax consequences, including multiple and possibly overlapping tax structures and difficulties relating to repatriation of cash; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">economic, legal and regulatory uncertainty associated with the United Kingdom leaving the EU, or Brexit; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">political and </font><font style="font-family:Times New Roman;font-size:10pt;">economic</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;instability, political unrest and terrorism.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">These and other factors could harm our ability to gain future revenue and, consequently, materially impact our business, operating results and financial condition.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">A perception of a conflict of interest of our indirect physician investors by other physicians or consumers could negatively impact our future product sales or product approvals.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Prior to our initial public offering, we were indirectly funded through investments in our controlling stockholder, ALPHAEON, and its majority stockholder, SCH, in part, by leading physicians in the self-pay healthcare market, or the indirect physician investors.  As a result, through ALPHAEON and SCH, these indirect physician investors may have an indirect financial interest in our success (as our successes, if any, will in part be imputed to ALPHAEON and ultimately SCH) and may be more inclined to use, promote or recommend Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;to their patients and other physicians.  Other physicians may become aware of the indirect and potential financial interest and investments of these indirect physician investors, who realize additional incentives by recommending Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and any of our future product candidates. If other physicians perceive this to be a significant conflict, they may be unwilling to purchase Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;or any of our future product </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">61</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sA9B010344B1252489F229F26AB5A0DDF"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">candidates without obtaining additional third-party evidence of their benefits and efficacy. If consumers perceive these indirect physician investors have a conflict of interest in recommending Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;or any of our future product candidates, they may be unwilling to purchase Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;or any of our future product candidates and may have a negative view of our brand, which could harm our reputation in the market. If physicians do not recommend Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;or any of our future product candidates or consumers choose not to purchase any of our products as a result of these conflicts of interest, it could adversely affect our business.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In addition, ALPHAEON is presently a technology company focused on providing healthcare products and services, including patient financing services, and SCH is presently a holding company with direct and/or indirect interests, as the case may be, in ALPHAEON and various other healthcare related and energy related companies. ALPHAEON and SCH may engage in, acquire or otherwise conduct their business in a manner that partners with or otherwise collaborates with the business of our company, Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and any of our future product candidates. For example, ALPHAEON offers a patient financing service whereby a qualified patient can receive a line of credit for certain approved medical procedures. An aesthetic medical procedure sought by a qualified patient for the treatment of moderate to severe glabellar lines whereby the physician uses Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;may be an eligible procedure covered under ALPHAEON&#8217;s patient financing service. As a result, our indirect physician investors may receive an additional incremental benefit through a patient&#8217;s use of ALPHAEON&#8217;s patient financing service and the physician&#8217;s use of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. If other physicians or consumers perceive this to be a significant conflict, they or consumers may be unwilling to purchase Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;or any of our future product candidates without obtaining additional third-party evidence of their benefits and efficacy, and it may result in a negative view of our brand, which could harm our reputation in the market.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Further, for our two identical double blind, pivotal U.S. Phase III clinical trials of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;(EV-001 and EV-002), one of the 20 clinical investigators was at the time of the pivotal clinical trial an indirect physician investor in our company. For our pivotal double blind, European Phase III study of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;(EVB-003), one of the 19 clinical investigators was at the time an indirect physician investor in our company.&#160; Additionally, in our unblinded, non-pivotal U.S. Phase II clinical trials of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;(EV-004 and EV-006), eight of the 29 clinical investigators are or were at the time of the non-pivotal clinical trial indirect physician investors of our company. In the future, clinical investigators for any of our future pivotal or non-pivotal clinical trials may be indirect physician investors in our company. We believe it is likely that they will be required to report some of these relationships to the FDA or EMA to the extent not already disclosed. The FDA or EMA may conclude that a financial relationship, such as an indirect investment, between us and a clinical investigator has created a conflict of interest or otherwise affected interpretation of the study. The FDA or EMA may therefore question the integrity of the data generated at the applicable clinical trial site and the utility of the clinical trial itself may be jeopardized. This could result in a delay in approval, or rejection, of our marketing applications by the FDA or EMA and may ultimately lead to the denial of marketing approval of one or more of our future product candidates. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In addition, should our products become eligible for government reimbursement in the future, such indirect investments or other financial relationships with clinical investigators may become subject to additional regulations and disclosure requirements.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of any future products we develop. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We face an inherent risk of product liability as a result of the commercialization of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and any of our future product candidates. For example, we may be sued if any product we develop allegedly causes injury or is found to be otherwise unsuitable during product testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability and a breach of warranties. Claims could also be asserted against us under state consumer protection acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of our products. Even a successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">decreased demand for Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;">&#32;or any future product candidates or products we develop;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">termination of clinical trial sites or entire trial programs;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">injury to our reputation and significant negative media attention;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">withdrawal of clinical trial participants or cancellation of clinical trials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">significant costs to defend the related litigation;</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">62</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sA9B010344B1252489F229F26AB5A0DDF"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">a diversion of management&#8217;s time and our resources;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">substantial monetary awards to trial participants or patients;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">regulatory investigations, product recalls, withdrawals or labeling, marketing or promotional restrictions;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">loss of revenue; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">the inability to commercialize any products we develop; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">a decline in our share price.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our inability to obtain and maintain sufficient product liability insurance at an acceptable cost and scope of coverage to protect against potential product liability claims could prevent or inhibit the commercialization of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;or any future products that we develop. We currently carry product liability insurance covering our clinical trials. Although we maintain such insurance, any claim that may be brought against us could result in a court judgment or settlement in an amount that is not covered, in whole or in part, by our insurance or that is in excess of the limits of our insurance coverage. Our insurance policies also have various exclusions and deductibles, and we may be subject to a product liability claim for which we have no coverage. We will have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts. Moreover, in the future, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">If we fail to attract and keep senior management and key scientific personnel, we may be unable to commercialize Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">&#32;successfully, or any future products we develop. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our success depends in part on our continued ability to attract, retain and motivate highly qualified management. We believe that our future success is highly dependent upon the contributions of our senior management, particularly David Moatazedi, our President, Chief Executive Officer and member of our board of directors, Lauren Silvernail, our Chief Financial Officer and Executive Vice President, Corporate Development, Rui Avelar, our Chief Medical Officer and Head of R&amp;D, and Michael Jafar, our Chief Marketing Officer, as well as other members of our senior management team. The loss of services of any of these individuals could delay or prevent the successful development of our product pipeline, completion of our planned clinical trials or the commercialization of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;or any future products we develop. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In addition, we could experience difficulties attracting and retaining qualified employees in the future. For example, competition for qualified personnel in the pharmaceuticals field is intense due to the limited number of individuals who possess the skills and experience required by our industry. We may not be able to attract and retain quality personnel on acceptable terms, or at all. In addition, to the extent we hire personnel from competitors, we may be subject to allegations that they have been improperly solicited or that they have divulged proprietary or other confidential information or that their former employers own their research output. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Unfavorable global economic conditions could adversely affect our business, financial condition or results of operations. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our results of operations could be adversely affected by general conditions in the global economy and in the global financial markets. Furthermore, the market for aesthetic medical procedures may be particularly vulnerable to unfavorable economic conditions. We do not expect Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for the treatment of glabellar lines to be reimbursed by any government or third-party payor and, as a result, our product will be wholly paid for by the consumer. Demand for Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;is tied to discretionary spending levels of our targeted consumer population. A severe or prolonged economic downturn could result in a variety of risks to our business, including a decline in the discretionary spending of our target consumer population, which could lead to a weakened demand for Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;or any future product candidates. A severe or prolonged economic down turn may also affect our ability to raise additional capital when needed on acceptable terms, if at all. A weak or declining economy could also strain our suppliers, possibly resulting in supply disruption, or cause our customers to delay making payments for our services. Any of the foregoing could harm our business. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In addition, our business strategy was developed based on a number of important assumptions about the self-pay healthcare market. For example, we believe that the number of self-pay healthcare procedures will increase in the future. However, these trends are uncertain and limited sources exist to obtain reliable market data. Therefore, sales of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;or any of our future product candidates could differ materially from our projections if our assumptions are incorrect.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">63</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sA9B010344B1252489F229F26AB5A0DDF"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Our strategy of focusing exclusively on the self-pay healthcare market may limit our ability to increase sales or achieve profitability.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our near-term strategy of focusing exclusively on the self-pay healthcare market may limit our ability to increase sales or achieve profitability. For example, to maintain our business model, we cannot offer products or services available in the broader healthcare market that are reimbursed by third-party payors such as Medicare, Medicaid or commercial insurance. This eliminates our ability to offer a substantial number of products and indications for Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">We incur significant costs as a result of operating as a public company, and our management is required to devote substantial time to new compliance initiatives. We may fail to comply with the rules that apply to public companies, including Section 404 of the Sarbanes-Oxley Act of 2002, as amended, or the Sarbanes-Oxley Act, which could result in sanctions or other penalties that would harm our business.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We incur and expect to incur significant legal, accounting, information technology and other expenses as a public company, including costs resulting from public company reporting obligations under the Exchange Act and regulations regarding corporate governance practices. The listing requirements of the Nasdaq Global Market, or Nasdaq, and the rules of the SEC require that we satisfy certain corporate governance requirements. Our management and other personnel devote a substantial amount of time to ensure that we comply with all of these requirements. Moreover, the reporting requirements, rules and regulations increase our legal and financial compliance costs and make some activities more time-consuming and costly. Any changes we make to comply with these obligations may not be sufficient to allow us to satisfy our obligations as a public company on a timely basis, or at all. These reporting requirements, rules and regulations, coupled with the increase in potential litigation exposure associated with being a public company, could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors or board committees or to serve as executive officers, or to obtain certain types of insurance, including directors&#8217; and officers&#8217; insurance, on acceptable terms.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We are subject to Section 404 of the Sarbanes-Oxley Act, or Section 404, and the related rules of the SEC, which generally require our management and independent registered public accounting firm to report on the effectiveness of our internal control over financial reporting. In order to maintain effective internal controls, we will need additional financial personnel, systems and resources. However, for so long as we remain an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, we intend to take advantage of certain exemptions from various reporting requirements that are applicable to public companies that are not emerging growth companies, including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404(b). Once we are no longer an emerging growth company or, if prior to such date, we opt to no longer take advantage of the applicable exemption, we will be required to include an opinion from our independent registered public accounting firm on the effectiveness of our internal control over financial reporting. We will remain an emerging growth company until the earliest of: (i) December 31, 2023; (ii) the first fiscal year after our gross annual revenues are $1.07 billion or more; (iii) the date on which we have, during the immediately preceding three-year period, issued more than $1.0 billion in non-convertible debt securities; or (iv) the end of any fiscal year in which the market value of our common stock held by non-affiliates is $700 million or more as of the end of the second quarter of that fiscal year.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">While we have conducted a review of our internal controls for the purpose of providing the reports required by these rules, during the course of our review and testing, we may identify deficiencies and be unable to remediate them before we must provide the required reports. Furthermore, if we have a material weakness in our internal control over financial reporting, we may not detect errors on a timely basis and our financial statements may be materially misstated. We or our independent registered public accounting firm may not be able to conclude on an ongoing basis that we have effective internal control over financial reporting, which could harm our operating results, cause investors to lose confidence in our reported financial information and cause the trading price of our stock to fall. In addition, as a public company we will be required to file accurate and timely quarterly and annual reports with the SEC under the Exchange Act. Any failure to report our financial results on an accurate and timely basis could result in sanctions, lawsuits, delisting of our shares from the Nasdaq Global Market or other adverse consequences that would materially harm our business and reputation. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Our business involves the use of hazardous materials, and we and our third-party manufacturer and supplier must comply with environmental laws and regulations, which can be expensive and restrict how we do business. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our research and development and manufacturing activities in the future may, and Daewoong&#8217;s manufacturing and supplying activities presently do, involve the controlled storage, use and disposal of hazardous materials, including botulinum toxin type A, a key component of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, and other hazardous compounds. We and Daewoong are subject to laws and regulations governing the use, manufacture, storage, handling and disposal of these hazardous materials. In some cases, these hazardous materials and various wastes resulting from their use are stored at Daewoong&#8217;s facilities pending their use and </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">64</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sA9B010344B1252489F229F26AB5A0DDF"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">disposal. We and Daewoong cannot eliminate the risk of contamination, which could cause an interruption of Daewoong&#8217;s manufacturing processes, our commercialization efforts, business operations and environmental damage resulting in costly clean-up and liabilities under applicable laws and regulations governing the use, storage, handling and disposal of these materials and specified waste products. Although we believe that the safety procedures utilized by Daewoong for handling and disposing of these materials generally comply with the standards prescribed by these laws and regulations, this may not eliminate the risk of accidental contamination or injury from these materials. In such an event, we may be held liable for any resulting damages and such liability could exceed our resources, and state or federal or other applicable authorities may curtail our use of certain materials and interrupt our business operations. Furthermore, environmental laws and regulations are complex, change frequently and have tended to become more stringent. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">We may use third-party collaborators to help us develop, validate or commercialize any new products, and our ability to commercialize such products could be impaired or delayed if these collaborations are unsuccessful. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We may license or selectively pursue strategic collaborations for the development, validation and commercialization of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and any future product candidates. In any third-party collaboration, we would be dependent upon the success of the collaborators in performing their responsibilities and their continued cooperation. Our collaborators may not cooperate with us or perform their obligations under our agreements with them. Our collaborators may choose to pursue alternative technologies in preference to those being developed in collaboration with us. The development, validation and commercialization of our product candidates will be delayed if collaborators fail to conduct their responsibilities in a timely manner or in accordance with applicable regulatory requirements or if they breach or terminate their collaboration agreements with us. Disputes with our collaborators could also impair our reputation or result in development delays, decreased revenues and litigation expenses.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In addition, we may face significant competition in seeking appropriate collaborators. Whether we reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#8217;s evaluation of a number of factors. Those factors may include the design or results of clinical trials, the likelihood of approval by the FDA or similar regulatory authorities outside the United States, the potential market for the subject product candidate, the costs and complexities of manufacturing and delivering such product candidate to consumers, the potential of competing products, the existence of uncertainty with respect to our ownership of technology, which can exist if there is a challenge to such ownership without regard to the merits of the challenge and industry and market conditions generally. The collaborator may also consider alternative product candidates or technologies for similar indications that may be available to collaborate on and whether such a collaboration could be more attractive than the one with us for our product candidate. Collaborations are complex and time-consuming to negotiate and document. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to curtail the development of such product</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">candidate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to increase our expenditures to fund development or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to further develop our product</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">candidates or bring them to market and generate revenue.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">&#32;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We have incurred substantial losses during our history and do not expect to become profitable in the near future, and we may never achieve profitability. To the extent that we continue to generate taxable losses, unused losses will carry forward to offset future taxable income, if any, until such unused losses expire.  In addition, we currently do not have a tax sharing arrangement in place with ALPHAEON. Under Section 382 of the Internal Revenue Code of 1986, as amended, or the Code, if a corporation undergoes an &#8220;ownership change,&#8221; generally defined as a greater than 50% change (by value) in its equity ownership over a three-year period, the corporation&#8217;s ability to use its pre-change net operating loss carryforwards, or NOLs, and other pre-change tax attributes, such as research tax credits, to offset its post-change income may be limited. As of December&#160;31, 2018, we had $99.8 million of federal NOLs, available to offset our future taxable income, if any. As of December&#160;31, 2018, we had federal research and development credit carryforwards of $1.2 million. These federal NOLs and research and development tax credit carryforwards expire at various dates beginning in 2034. We may experience ownership changes in the future as a result of subsequent shifts in our stock ownership. As a result, if we earn net taxable income, our ability to use our pre-change NOLs to offset U.S. federal taxable income may be subject to limitations, which could </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">65</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sA9B010344B1252489F229F26AB5A0DDF"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">potentially result in increased future tax liability to us. In addition, at the state level, there may be periods during which the use of NOLs is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Our business and operations would suffer in the event of computer system failures or breach by hackers.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Despite the implementation of security measures, our internal computer systems, and those of third parties on which we rely, are vulnerable to damage from computer viruses, malware, natural disasters, terrorism, war, telecommunication and electrical failures, cyberattacks or cyber intrusions over the internet, attachments to emails, persons inside our organization, or persons with access to systems inside our organization. The risk of a security breach or disruption, particularly through cyberattacks or cyber intrusions, including by computer hackers, foreign governments and cyberterrorists, has generally increased as the number, intensity and sophistication of attempted attacks and intrusions from around the world have increased. If such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our current or future product development programs. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The costs to us to mitigate network security problems, bugs, viruses, worms, malicious software programs and security vulnerabilities could be significant, and while we have implemented security measures to protect our data security and information technology systems, our efforts to address these problems may not be successful, and these problems could result in unexpected interruptions, delays, cessation of service, government files or penalties and other harm to our business and our competitive position. If such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our product development programs. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">For example, the loss of clinical trial data from completed, ongoing or planned clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Moreover, if a computer security breach affects our systems or results in the unauthorized release of personally identifiable information, or PII, our reputation could be materially damaged. In addition, such a breach may require notification to governmental agencies, the media or individuals pursuant to various international, federal and state privacy and security laws, if applicable, including the GDPR, the Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology for Clinical Health Act of 2009, and its implementing rules and regulations, as well as regulations promulgated by the Federal Trade Commission and state breach notification laws. Additionally, the regulatory environment governing information, security and privacy laws is increasingly demanding and continues to evolve and a number of states have adopted laws and regulations that may affect our privacy and data security practices regarding the use, disclosure and protection of PII. For example, California recently enacted legislation, the California Consumer Privacy Act, that will, among other things, create new individual privacy rights and impose increased obligations on companies handling PII, when it goes into effect on January 1, 2020.  We would also be exposed to a risk of loss or litigation and potential liability, which could materially adversely affect our business, results of operations and financial condition.  </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">O</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">ur liability insurance may not be sufficient in type or amount to cover us against claims related to security breaches, cyberattacks and other related breaches.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Risks Related to Intellectual Property </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">If we or any of our current </font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">or</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">&#32;future licensors</font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">, including Daewoong, are unable to maintain, obtain or protect intellectual property rights related to Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">&#32;or any of our future product candidates, we may not be able to compete effectively in our market.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We and our current licensor Daewoong currently rely upon a combination of trademarks, trade secret protection, confidentiality agreements and proprietary know-how. Botulinum toxin cannot be patented, as it is produced by </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Clostridium</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">botulinum</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, a gram-positive, rod-shaped, anaerobic, spore-forming, motile bacterium with the ability to produce the neurotoxin botulinum. Only the manufacturing process for botulinum toxin can be patented, for which Daewoong has obtained a U.S. patent. Our trade secrets and other confidential proprietary information and those of our licensors could be disclosed or competitors could otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. Further, the laws of some foreign countries do not protect proprietary rights to the same extent or in the same manner as the laws of the United States. As a result, we or any of our current or future licensors may encounter significant problems in protecting and defending our or their intellectual property both in the United States and internationally. If we or any of our current or future licensors are unable to prevent material disclosure of the non-patented intellectual property related to Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;to third parties, we may not be able to establish or maintain a competitive advantage in our market, which could adversely affect our business.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In addition to the protection afforded by trademarks, confidentiality agreements and proprietary know-how, we may in the future rely upon in-licensed patents for any future product offerings. The strength of patents we may in-license in the technology and healthcare fields involves complex legal and scientific questions and can be uncertain. The patent </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">66</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sA9B010344B1252489F229F26AB5A0DDF"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">applications that we may in-license may fail to result in issued patents with claims that cover any of our future product candidates in the United States or in other foreign countries, and the issued patents that we may in-license may be declared invalid or unenforceable. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We are reliant on the ability of Daewoong, as the licensor of our only product, and will be reliant on future licensors of any future product candidates, to maintain their intellectual property and protect their intellectual property against misappropriation, infringement or other violation. We may not have primary control over our future licensors&#8217; patent prosecution activities. Furthermore, we may not be allowed to comment on prosecution strategies, and patent applications may be abandoned by the patent owner without our knowledge or consent. With respect to patents that are issued to our licensors, or patents that may be issued on patent applications, third parties may challenge their validity, enforceability or scope, which may result in such patents being narrowed or invalidated. As a licensee, we are reliant on Daewoong and our future licensors to defend any third-party claims, including Daewoong&#8217;s defense in connection with the Medytox Litigation, which is defined below. Our licensors may not defend or prosecute such actions as vigorously or in the manner that we would have if entitled to do so, and we will be subject to any judgment or settlement resulting from such actions. Also, a third-party may challenge the validity of our in-licensing transactions. Furthermore, even if they are unchallenged, any of our future in-licensed patents and patent applications may not adequately protect the licensors or our intellectual property or prevent others from designing around their or our claims.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">We may become involved in lawsuits to protect or enforce our intellectual property or the patents and other intellectual property of our licensors, which could be expensive and time-consuming. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Competitors may infringe our intellectual property, including any future patents we may acquire, or the patents and other intellectual property of our licensors, including Daewoong. As a result, we or any of our current or future licensors may be required to file infringement claims to stop third-party infringement or unauthorized use. This can be expensive, particularly for a company of our size, and time-consuming. In addition, in an infringement proceeding, a court may decide that a patent of ours or any of our current or future licensors is not valid or is unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our patent claims do not cover its technology or that the factors necessary to grant an injunction against an infringer are not satisfied. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">An adverse determination of any litigation or other proceedings could put one or more of such patents at risk of being invalidated or interpreted narrowly. Interference, derivation or other proceedings brought at the USPTO may be necessary to determine the priority or patentability of inventions with respect to any of our future patent applications or those of our licensors or collaborators. Litigation or USPTO proceedings brought by us or any of our current or future licensors may fail or may be invoked against us or our licensors by third parties. Even if we are successful, domestic or foreign litigation or USPTO or foreign patent office proceedings may result in substantial costs and distraction to our management or the management of any of our current or future licensors, including Daewoong. We may not be able, alone or with any of our current or future licensors or collaborators, to prevent misappropriation of our proprietary rights, particularly in countries where the laws may not protect such rights as fully as in the United States. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation or other proceedings, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation or proceedings. In addition, during the course of this kind of litigation or proceedings, there could be public announcements of the results of hearings, motions or other interim proceedings or developments or public access to related documents. If investors perceive these results to be negative, the market price for our common stock could be significantly harmed. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Most of our competitors are larger than we are and have substantially greater resources. They are, therefore, likely to be able to sustain the costs of complex patent litigation longer than we could. Accordingly, despite our efforts, we may not be able to prevent third parties from infringing upon or misappropriating our intellectual property. In addition, the uncertainties associated with litigation could compromise our ability to raise the funds necessary to continue our clinical trials, continue our internal research programs, or in-license needed technology or other product candidates. There could also be public announcements of the results of the hearing, motions, or other interim proceedings or developments. If securities analysts or investors perceive those results to be negative, it could cause the price of shares of our common stock to decline.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">We may not be able to protect our intellectual property rights throughout the world. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Filing, prosecuting and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">67</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sA9B010344B1252489F229F26AB5A0DDF"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">as federal and state laws in the United States and in some cases may even force us to grant a compulsory license to competitors or other third parties. Consequently, we may not be able to prevent third parties from using our inventions in all countries outside the United States or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and further, may export otherwise infringing products to territories where we have patent protection, but enforcement is not as strong as that in the United States. These products may compete with our products and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other intellectual property protection, particularly those relating to biopharmaceuticals, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In addition, our ability to protect and enforce our intellectual property rights may be adversely affected by unforeseen changes in domestic and foreign intellectual property laws. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In addition to seeking patents for our product candidates, we also rely on trade secrets, including unpatented know-how, technology and other proprietary information, to maintain our competitive position.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We seek to protect our trade secrets, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to them, such as our employees, collaborators, consultants, advisors and other third-parties. We expect to enter into confidentiality and invention assignment agreements with our employees and consultants. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts within and outside the United States are less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent them, or those to whom they communicate it, from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor, our competitive position would be harmed.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We employ individuals who were previously employed at other pharmaceutical companies. We may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed confidential information of our employees&#8217; former employers or other third parties. We may also be subject to claims that former employers or other third parties have an ownership interest in our patents. Litigation may be necessary to defend against these claims. We may not be successful in defending these claims, and even if we are successful, litigation could result in substantial cost and be a distraction to our management and other employees. Any litigation or the threat thereof may adversely affect our ability to hire employees. A loss of key personnel or their work product could diminish or prevent our ability to commercialize product candidates, which could have an adverse effect on our business, results of operations and financial condition.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">We may need to license intellectual property from third-parties, and such licenses may not be available or may not be available on commercially reasonable terms.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">A third-party may hold intellectual property, including patent rights that are important or necessary to the development of our future product candidates. It may be necessary for us to use the patented or proprietary technology of third parties to commercialize our product candidates, in which case we would be required to obtain a license from these third parties on commercially reasonable terms, or our business could be harmed, possibly materially.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">68</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sA9B010344B1252489F229F26AB5A0DDF"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our registered or unregistered trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition by potential partners or customers in our markets of interest. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business may be adversely affected.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Third-parties may assert that we are using trademarks or trade names that are confusingly similar to their marks. If any third-party were able to establish that our trademarks or trade names were infringing their marks, that third-party may be able to block our ability to use the infringing trademark or trade name. In addition, if a third-party were to bring such a claim, we would be required to dedicate time and resources to fight the claim, which time and resources could otherwise be used toward the maintenance of our own intellectual property.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Parties making claims against us may request and obtain injunctive or other equitable relief, which could prevent our ability to use the subject trademarks or trade names. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement. We may be required to re-brand one or more of our products, product candidates, or services offered under the infringing trademark or trade name, which may require substantial time and monetary expenditure. Third-parties could claim senior rights in marks which might be enforced against our use of trademarks or trade names, resulting in either an injunction prohibiting our sales under those trademarks or trade names.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Risks Related to Government Regulation </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Our business and products are subject to extensive government regulation. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We are subject to extensive, complex, costly and evolving regulation by federal and state governmental authorities in the United States, the EU, Canada and other countries, principally by the FDA, the U.S. Drug Enforcement Administration, the Centers for Disease Control and Prevention, the EMA and other similar regulatory authorities. Daewoong is also subject to extensive regulation by the FDA and the South Korean regulatory authorities as well as other regulatory authorities. Our failure to comply with all applicable regulatory requirements, or Daewoong&#8217;s failure to comply with applicable regulatory requirements, including those promulgated under the Federal Food, Drug, and Cosmetic Act, the Public Health Service Act, and the Controlled Substances Act, may subject us to operating restrictions and criminal prosecution, monetary penalties and other enforcement or administrative actions, including, sanctions, warnings, product seizures, recalls, fines, injunctions, suspension, revocation of approvals, or exclusion from future participation in the Medicare and Medicaid programs. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Following regulatory approval, we, and our direct and indirect suppliers, including Daewoong, remain subject to the periodic inspection of our plants and facilities, review of production processes, and testing of our products to confirm that we are in compliance with all applicable regulations. Adverse findings during regulatory inspections may result in requirements that we implement REMS programs, requirements that we complete government mandated clinical trials, and government enforcement actions including those relating to labeling, advertising, marketing and promotion, as well as regulations governing manufacturing controls. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">If we experience delays in obtaining approval or if we fail to obtain approval of our product candidates, the commercial prospects for our product candidates may be harmed and our ability to generate revenue will be materially impaired.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">We may not obtain regulatory approval for the commercialization of any future product candidates. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The research, testing, manufacturing, labeling, approval, selling, import, export, marketing and distribution of drug and biologic products are subject to extensive regulation by the FDA and other regulatory authorities in the United States and other countries, with regulations differing from country to country. If we, our products or the manufacturing facilities for our products fail to comply with applicable regulatory requirements, a regulatory agency may:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">impose restrictions on the marketing or manufacturing of the product, suspend or withdraw product approvals or revoke necessary licenses;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">issue warning letters, show cause notices or untitled letters describing alleged violations, which may be publicly available;</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">69</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sA9B010344B1252489F229F26AB5A0DDF"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">mandate modifications to promotional materials or require us to provide corrective information to healthcare practitioners;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">require us to enter into a consent decree, which can include imposition of various fines, reimbursements for inspection costs, required due dates for specific actions and penalties for noncompliance;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">commence criminal investigations and prosecutions;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">impose injunctions;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">impose other civil or criminal penalties;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">suspend any ongoing clinical trials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">delay or refuse to approve pending applications or supplements to approved applications filed by us;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">refuse to permit drugs or active ingredients to be imported or exported;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">suspend or impose restrictions on operations, including costly new manufacturing requirements; or </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">seize or detain products or require us to initiate a product recall.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Prior to obtaining approval to commercialize a product candidate in the United States or abroad, we or our collaborators must demonstrate with substantial evidence from well-controlled clinical trials, and to the satisfaction of the FDA, EMA or other similar foreign regulatory authorities, that such product candidates are safe and effective for their intended uses. Results from preclinical studies and clinical trials can be interpreted in different ways. Even if we and our collaborators believe the preclinical or clinical data for our product candidates are promising, such data may not be sufficient to support approval by the FDA, the EMA and other similar regulatory authorities. Administering product candidates to humans may produce undesirable side effects, which could interrupt, delay or halt clinical trials and result in the FDA, the EMA or other similar regulatory authorities delaying or denying approval of a product candidate for any or all targeted indications. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Regulatory approval of a BLA or BLA supplement, MAA, or other product approval is not guaranteed, and the approval process is expensive and may take several years. The FDA, EMA and other regulatory authorities have substantial discretion in the approval process. Despite the time and expense expended, failure can occur at any stage, and we could encounter problems that cause us to abandon, modify or repeat clinical trials, or perform additional preclinical studies and clinical trials. The number of preclinical studies and clinical trials that will be required for FDA, EMA or other regulatory approval varies depending on the product candidate, the disease or condition that the product candidate is designed to address and the regulations applicable to any particular product candidate. The FDA, EMA and other regulatory authorities can delay, limit or deny approval of a product candidate for many reasons, including the following:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">a product candidate may not be deemed safe, effective, pure or potent;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">the data from preclinical studies and clinical trials may not be deemed sufficient;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">the FDA or other regulatory authorities might not approve our third-party manufacturers&#8217; processes or facilities; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">deficiencies in the formulation, quality control, labeling, or specifications of a product candidate </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">or in response to citizen petitions or similar documents filed in connection with the product candidate</font><font style="font-family:Times New Roman;font-size:10pt;">;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">general requirements intended to address risks associated with a class of drugs, such as a new REMS requirement for neurotoxins;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">the enactment of new laws or promulgation of new regulations that change the approval requirements; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the FDA or other regulatory authorities may change their approval policies or adopt new regulations.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">If any future product candidates fail to demonstrate safety and efficacy in clinical trials or do not gain approval, our business and results of operations will be materially and adversely harmed. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">70</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sA9B010344B1252489F229F26AB5A0DDF"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">We are subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense, limit or delay regulatory approval and subject us to penalties if we fail to comply with applicable regulatory requirements.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and any other approved products are subject to continual regulatory review by the FDA, the EMA and other similar regulatory authorities.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Any regulatory approvals that we or our collaborators receive for any future product candidates may also be subject to limitations on the approved indications for which the product may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing, including Phase IV clinical trials, and surveillance to monitor the safety and efficacy of the product. In addition, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion and recordkeeping for Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and any other future product candidates will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with cGMP requirements and compliance with GCP requirements, for any clinical trials that we conduct post-approval. Later discovery of previously unknown problems with Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;or any future product candidates, including adverse events of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in, among other things:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">restrictions on the marketing or manufacturing of the product, withdrawal of the product from the market, or voluntary or mandatory product recalls;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">fines, warning letters or holds on clinical trials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">refusal by the FDA, EMA or other similar regulatory authorities to approve pending applications or supplements to approved applications filed by us or our strategic collaborators or suspension or revocation of product license approvals;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">product seizure or detention or refusal to permit the import or export of products; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">injunctions or the imposition of civil or criminal penalties.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our ongoing regulatory requirements may also change from time to time, potentially harming or making costlier our commercialization efforts. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability, which would adversely affect our business. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">If we fail to obtain regulatory approvals in foreign jurisdictions for Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">&#32;or any future product candidates, we will be unable to market our products outside of the United States. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In addition to regulations in the United States, we are and will be subject to a variety of foreign regulations governing manufacturing, clinical trials, commercial sales and distribution of our future products. Whether or not we obtain FDA approval for a product candidate, we must obtain approval of the product by the comparable regulatory authorities of foreign countries before commencing clinical trials or marketing in those countries. The approval procedures vary among countries and can involve additional clinical testing, and the time required to obtain approval may differ from that required to obtain FDA approval. Clinical trials conducted in one country may not be accepted by regulatory authorities in other countries. Approval by the FDA does not ensure approval by regulatory authorities in other countries, and approval by one or more foreign regulatory authorities does not ensure approval by regulatory authorities in other foreign countries or by the FDA. The foreign regulatory approval process may include all of the risks associated with obtaining FDA approval. We may not be able to file for regulatory approvals or to do so on a timely basis, and even if we do file, we may not receive necessary approvals to commercialize our products in markets outside of the United States. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">&#32;or any future products may cause or contribute to adverse medical events that we are required to report to regulatory agencies and if we fail to do so, we could be subject to sanctions that would materially harm our business. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Some participants in our clinical trials have reported adverse events after being treated with Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. If we are successful in commercializing Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;or any other product candidate, FDA and other regulatory agency regulations require that we report certain information about adverse medical events if those products may have caused or contributed to those adverse events. The timing of our obligation to report would be triggered by the date we become aware of the adverse event as well as </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">71</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sA9B010344B1252489F229F26AB5A0DDF"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the nature of the event. We may fail to report adverse events that we become aware of within the prescribed timeframe. We may also fail to appreciate that we have become aware of a reportable adverse event, especially if it is not reported to us as an adverse event or if it is an adverse event that is unexpected or removed in time from the use of our products. If we fail to comply with our reporting obligations, the FDA, the EMA or other similar regulatory authorities could take action including criminal prosecution, the imposition of civil monetary penalties, seizure of our products, or delay in approval or clearance of future products. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">We may in the future be subject to various U.S. federal and state laws pertaining to health care fraud and abuse, including anti-kickback, self-referral, false claims and fraud laws, and any violations by us of such laws could result in fines or other penalties. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">While we do not expect that Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;will subject us to the various U.S. federal and most state laws intended to prevent health care fraud and abuse, we may in the future become subject to such laws. The Anti-Kickback Statute prohibits the offer, receipt, or payment of remuneration in exchange for or to induce the referral of patients or the use of products or services that would be paid for in whole or part by Medicare, Medicaid or other federal health care programs. Remuneration has been broadly defined to include anything of value, including cash, improper discounts, and free or reduced price items and services. Many states have similar laws that apply to their state health care programs as well as private payors. Violations of anti-kickback and other applicable laws can result in exclusion from federal health care programs and substantial civil and criminal penalties. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The federal False Claims Act, or FCA, imposes liability on persons who, among other things, present or cause to be presented false or fraudulent claims for payment by a federal health care program. The FCA has been used to prosecute persons submitting claims for payment that are inaccurate or fraudulent, that are for services not provided as claimed, or for services that are not medically necessary. The FCA includes a whistleblower provision that allows individuals to bring actions on behalf of the federal government and share a portion of the recovery of successful claims. Some state law equivalents of the above federal laws, such as the Anti-Kickback Statute and FCA, apply to items or services regardless of whether the good or service was reimbursed by a government program, so called all-payor laws. These all-payor laws could apply to our sales and marketing activities even if the Anti-Kickback Statute and FCA laws are inapplicable.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">If our marketing or other arrangements were determined to violate anti-kickback or related laws, including the FCA or an all-payor law, then we could be subject to penalties, including administrative, civil and criminal penalties, damages, fines, disgorgement, the exclusion from participation in federal and state healthcare programs, individual imprisonment or the curtailment or restructuring of our operations, any of which could materially and adversely affect our ability to operate our business and our financial results. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">State and federal authorities have aggressively targeted pharmaceutical companies for alleged violations of these anti-fraud statutes, based on improper research or consulting contracts with doctors, certain marketing arrangements with pharmacies and other healthcare providers that rely on volume-based pricing, off-label marketing schemes, and other improper promotional practices. Companies targeted in such prosecutions have paid substantial fines, have been ordered to implement extensive corrective action plans, and have in many cases become subject to consent decrees severely restricting the manner in which they conduct their business, among other consequences. Additionally, federal and state regulators have brought criminal actions against individual employees responsible for alleged violations. If we become the target of such an investigation or prosecution based on our contractual relationships with providers or institutions, or our marketing and promotional practices, we could face similar sanctions, which would materially harm our business. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Also, the FCPA and similar worldwide anti-bribery laws generally prohibit companies and their intermediaries from making improper payments to non-U.S. officials for the purpose of obtaining or retaining business. Our internal control policies and procedures may not protect us from reckless or negligent acts committed by our employees, future distributors, partners, collaborators or agents. Violations of these laws, or allegations of such violations, could result in fines, penalties or prosecution and have a negative impact on our business, results of operations and reputation.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Legislative or regulatory healthcare reforms in the United States and other countries may make it more difficult and costly for us to obtain regulatory clearance or approval of any future product candidates and to produce, market, and distribute our products after clearance or approval is obtained. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">From time to time, legislation is drafted and introduced in the U.S. Congress or other countries that could significantly change the statutory provisions governing the regulatory clearance or approval, manufacture, and marketing of regulated products or the reimbursement thereof. In addition, regulations and guidance are often revised or reinterpreted by the FDA and other regulatory authorities in ways that may significantly affect our business and our products. Any new regulations or </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">72</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sA9B010344B1252489F229F26AB5A0DDF"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">revisions or reinterpretations of existing regulations may impose additional costs or lengthen review times of any future product candidates. Such changes could, among other things, require: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">changes to manufacturing or marketing methods;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">changes to product labeling or promotional materials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">recall, replacement, or discontinuance of one or more of our products; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">additional recordkeeping.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Each of these would likely entail substantial time and cost and could materially harm our business and our financial results. In addition, delays in receipt of or failure to receive regulatory clearances or approvals for any future products would harm our business, financial condition, and results of operations.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Risks Related to Our Relationship with ALPHAEON </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">ALPHAEON may exert significant influence over our business, and the concentrated ownership of our common stock and certain contractual rights of ALPHAEON may prevent you and other stockholders from influencing significant decisions</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">September&#160;30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, ALPHAEON owned&#160;approximately </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">31.6%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;of our outstanding shares of common stock. This concentrated ownership position may provide ALPHAEON with significant influence in determining the outcome of corporate actions requiring stockholder approval, including the election and removal of directors. This significant stock ownership may also discourage transactions involving a change-of-control of our company, including transactions in which you as a holder of our common stock might otherwise receive a premium for your shares.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Certain of our directors may have actual or potential conflicts of interest because of their ownership of debt and equity securities in ALPHAEON and their positions with ALPHAEON. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Vikram Malik, Simone Blank, Bosun Hau, Kristine Romine, M.D., and Robert Hayman serve on our board of directors.  Such directors or entities they are affiliated with currently own and may in the future own shares of common stock or preferred stock of ALPHAEON, debt instruments convertible into equity interests of ALPHAEON, options to purchase shares of common stock or other equity awards of ALPHAEON. These individuals&#8217; or entities&#8217; holdings of ALPHAEON debt or equity securities, options to purchase shares of ALPHAEON or other equity awards may be significant for some of these persons or entities compared to these persons&#8217; or entities&#8217; total assets. Additionally, each of Mr. Malik, and Ms. Blank serve on the board of directors of ALPHAEON and Mr. Malik serves as ALPHAEON&#8217;s acting President. Their positions at ALPHAEON and the ownership of any ALPHAEON equity or equity awards may create, or may create the appearance of, conflicts of interest when these directors are faced with decisions that could have different implications for ALPHAEON than the decisions have for us. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">These decisions include:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">corporate opportunities; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">the impact that operating decisions for our business may have on ALPHAEON&#8217;s consolidated financial statements; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">the impact that operating or capital decisions (including the incurrence of indebtedness) for our business may have on ALPHAEON&#8217;s current or future indebtedness or the covenants under that indebtedness; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the timing and amount of financing efforts, whether they are debt or equity, and the amount of resulting dilution to existing shareholders;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">business combinations involving us; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">our dividend policy; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">management stock ownership; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the related party services and agreements between ALPHAEON and us.</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">73</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sA9B010344B1252489F229F26AB5A0DDF"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Potential conflicts of interest could also arise if we decide to enter into any new commercial arrangements with ALPHAEON or SCH in the future or in connection with ALPHAEON&#8217;s desire to enter into new commercial arrangements with third parties.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Furthermore, disputes may arise between ALPHAEON and us relating to our past and ongoing relationship, and these potential conflicts of interest may make it more difficult for us to favorably resolve such disputes, including those related to:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">indemnification and other matters arising from our initial public offering;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">the nature, quality and pricing of services ALPHAEON agrees to provide to us;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">sales or other disposal by ALPHAEON of all or a portion of its ownership interest in us; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">business combinations involving us.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We may not be able to resolve any potential conflicts, and even if we do, the resolution may be less favorable to us than if we were dealing with an unaffiliated party. While we are not controlled by ALPHAEON, we may not have the leverage to negotiate amendments to these agreements, if required, on terms as favorable to us as those we would negotiate with an unaffiliated third-party.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">ALPHAEON and its directors and officers will have limited liability to us or you for breach of fiduciary duty. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our certificate of incorporation provides that, subject to any contractual provision to the contrary, ALPHAEON has no obligation to refrain from: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">engaging in the same or similar business activities or lines of business as we do;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">doing business with any of our clients or consumers; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">employing or otherwise engaging any of our officers or employees.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our certificate of incorporation provides for the allocation of certain corporate opportunities between us and ALPHAEON. Under these provisions, neither ALPHAEON nor its other affiliates, nor any of their officers, directors, agents, stockholders, members, partners, and subsidiaries (other than us), will have any obligation to present to us certain corporate opportunities.  ALPHAEON is presently a technology company focused on providing healthcare products and services, including patient financing services.  ALPHAEON may engage in other lines of business in the future. For example, a director or officer of our company who also serves as a director, officer or employee of ALPHAEON or any of its other affiliates may present to ALPHAEON certain acquisitions, in-licenses, potential development programs or other opportunities that may be complementary to our business, if he or she was not offered such corporate opportunity in his or her capacity as our director or officer, and, as a result, such opportunities may not be available to us. To the extent attractive corporate opportunities are allocated to ALPHAEON or its other affiliates instead of to us, we may not be able to benefit from these opportunities.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In addition, under our certificate of incorporation, neither ALPHAEON nor any officer or director of ALPHAEON, except as provided in our certificate of incorporation, will be liable to us or to our stockholders for breach of any fiduciary or other duty by reason of any of these activities. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">SCH is presently a holding company with direct and/or indirect interests, as the case may be, in ALPHAEON and various other healthcare related and energy related companies. SCH may engage in other lines of business in the future, including engaging, acquiring or otherwise conducting their business in a manner that partners with or otherwise collaborates with the business of our company, Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and any of our future product candidates. While our certificate of incorporation does not provide the same provision with respect to SCH, SCH may be able to exercise voting and investment control over ALPHAEON and effect the allocation of certain corporate opportunities between us and ALPHAEON. </font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Risks Related to Our Common Stock</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">The trading price of our common stock may be volatile, and purchasers of our common stock could incur substantial losses. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our stock price is volatile. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">For example, the closing price of our common stock since February 8, 2018, has ranged from a low of $6.85 to a high of $38.49. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The stock market in general and the market for earlier-stage pharmaceutical companies in </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">74</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sA9B010344B1252489F229F26AB5A0DDF"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. The market price for our common stock may be influenced by many factors, some of which are beyond our control, including: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">announcements of regulatory approval or disapproval of product candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">adverse results from or delays in clinical trials of any of our future product candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">unanticipated safety concerns related to the use of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;">&#32;or any of our future products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">any termination or loss of rights under the Daewoong Agreement;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">FDA or other U.S. or foreign regulatory or legal actions or changes affecting us or our industry;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">adverse developments concerning our manufacturer or any future strategic partnerships;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">introductions and announcements of new technologies and products by us, any commercialization partners or our competitors, and the timing of these introductions and announcements;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">variations in our financial results or those of companies that are perceived to be similar to us;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">success or failure of competitive products or medical aesthetic products generally;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">changes in the structure of healthcare payment systems;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">announcements by us or our competitors of significant acquisitions, licenses, strategic partnerships, new product approvals and introductions, joint ventures or capital commitments;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">overall financial market conditions for the pharmaceutical and biopharmaceutical sectors and issuance of securities analysts&#8217; reports or recommendations;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">quarterly variations in our results of operations or those of our competitors</font><font style="font-family:Times New Roman;font-size:10pt;">;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">changes in financial estimates or guidance, including our ability to meet our future revenue and operating profit or loss estimates or guidance;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">the public&#8217;s reaction to our earnings releases, other public announcements and filings with the SEC;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">rumors and market speculation involving us or other companies in our industry;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">short selling of our common stock or the publication of opinions regarding our business prospects in a manner that is designed to create negative market momentum;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">sales of substantial amounts of our stock by ALPHAEON or other significant stockholders or our insiders, or the expectation that such sales might occur;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">general economic, industry and market conditions, including the size and growth, if any, of the medical aesthetics market;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">news reports relating to trends, concerns and other issues in medical aesthetics market or the pharmaceutical or biopharmaceutical industry;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">operating and stock performance of other companies that investors deem comparable to us and overall performance of the equity markets;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">additions or departures of key personnel, including our Chief Executive Officer, Chief Financial Officer, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Chief Medical Officer and Chief Marketing Officer; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">intellectual property, product liability or other litigation against us, our manufacturer or other parties on which we rely or litigation against our general industry;</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">75</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sA9B010344B1252489F229F26AB5A0DDF"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">announcements or actions taken by ALPHAEON as our controlling stockholder, including sales of substantial amounts of our common stock by ALPHAEON; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">changes in our capital structure, such as future issuances of securities and the incurrence of additional debt;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">changes in accounting standards, policies, guidelines, interpretations or principles; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">other factors </font><font style="font-family:Times New Roman;font-size:10pt;">described</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;in this &#8220;Risk Factors&#8221; section.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In addition, the stock market in general, and the market for pharmaceutical companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of those companies. Broad market and industry factors may affect the market price of our common stock, regardless of our actual operating performance. In the past, following periods of volatility in the overall market and the market prices of a particular company&#8217;s securities, securities class action litigation has often been instituted against that company. We may become the target of this type of litigation in the future. Securities litigation, if instituted against us, could result in substantial costs and divert our management&#8217;s attention and resources from our business.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We are no longer a&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8220;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">controlled company</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8221;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">&#160;within the meaning of the Nasdaq Marketplace Rules. Prior to May 2019, we qualified for, and relied on, exemptions from certain corporate governance requirements and our stockholders were not afforded the same protections as the stockholders of companies that are subject to such requirements.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As a result of a sale of shares by ALPHAEON in May 2019, we are no longer be a &#8220;controlled company&#8221; within the meaning of the corporate governance standards of the Nasdaq Marketplace Rules. Under these rules, a listed company of which more than 50% of the voting power is held by an individual, group or another company is a &#8220;controlled company&#8221; and may elect not to comply with certain corporate governance requirements, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the requirement that a majority of our board of directors consist of independent directors;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the requirement that our nominating and corporate governance committee be comprised entirely of independent directors with a written charter addressing the committee's purpose and responsibilities;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the requirement that our compensation committee be comprised entirely of independent directors with a written charter addressing the committee's purpose and responsibilities; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the requirement for an annual performance evaluation of our nominating and corporate governance and compensation committees;</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Since we utilized certain of these exemptions, our nominating and corporate governance and compensation committees do not consist entirely of independent directors. As a result, we will be required to comply with the above-referenced requirements within one year. We may have difficulty complying with the requirements listed above and while we intend to do so, we cannot assure you that we will be able to comply with such requirements before the end of the phase-in period for compliance. Accordingly, unless and until we comply with these requirements, you will not have the same protections afforded to stockholders of companies that are subject to and in compliance with all of the corporate governance requirements of Nasdaq.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Our business could be negatively affected as a result of actions of activist stockholders, and such activism could impact the trading value of our securities.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Stockholders may, from time to time, engage in proxy solicitations or advance stockholder proposals, or otherwise attempt to effect changes and assert influence on our board of directors and management. Activist campaigns that contest or conflict with our strategic direction or seek changes in the composition of our board of directors</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">could have an adverse effect on our </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">operating results and financial condition. A proxy contest would require us to incur significant legal and advisory fees, proxy solicitation expenses and administrative and associated costs and require significant time and attention by our board of directors and management, diverting their attention from the pursuit of our business strategy. Any perceived uncertainties as to our future direction and control, our ability to execute on our strategy, or changes to the composition of our board of directors or senior management team arising from a proxy contest could lead to the perception of a change in the direction of our business or instability which may result in the loss of potential business opportunities, make it more difficult to pursue our strategic initiatives, or limit our ability to attract and retain qualified personnel and business partners, any of which could adversely affect our business and operating results. If individuals are ultimately elected to our board of directors with a specific agenda, it may adversely affect our ability to effectively implement our business strategy and create additional value </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">76</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sA9B010344B1252489F229F26AB5A0DDF"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">for our stockholders. We may choose to initiate, or may become subject to, litigation as a result of the proxy contest or matters arising from the proxy contest, which would serve as a further distraction to our board of directors and management and would require us to incur significant additional costs. In addition, actions such as those described above could cause significant fluctuations in our stock price based upon temporary or speculative market perceptions or other factors that do not necessarily reflect the underlying fundamentals and prospects of our business.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We may be subject to securities litigation, which is expensive and could divert management attention.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The market price of our common stock may be volatile, and in the past, companies that have experienced volatility in the market price of their stock have been subject to securities class action litigation. We may be the target of this type of litigation in the future. Securities litigation against us could result in substantial costs and divert our management&#8217;s attention from other business concerns, which could have a material and adverse effect on our business, financial condition, and results of operations.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">If securities or industry analysts publish unfavorable research about our business or decrease the frequency or cease to provide coverage of our company, our stock price and trading volume could decline.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The trading market for our common stock depends in part on the research and reports that equity research analysts publish about us and our business. If one or more of the equity research analysts who cover us downgrades our common stock or issues other unfavorable commentary or research the price of our common stock may decline. If one or more equity research analysts ceases coverage of our company or fails to publish reports on us regularly, demand for our common stock could decrease, which in turn could cause the trading price or trading volume of our common stock to decline.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Certain of our historical financial data is not necessarily representative of the results that we would have achieved as a stand-alone company and may not be a reliable indicator of our future results.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our historical financial data included in this Quarterly Report on Form 10-Q does not reflect the financial condition, results of operations or cash flows that we would have achieved as a stand-alone company during the periods presented or those we will achieve in the future. This is primarily the result of the following factors:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">our historical financial data reflects expense allocations for certain support functions that are provided on a centralized basis within ALPHAEON, such as expenses for business technology, facilities, legal, finance, human resources and business development, that may be higher or lower than the comparable expenses that we would have actually incurred, or will incur in the future, as a stand-alone company;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">significant</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;increases have and will continue to occur in our cost structure as a result of our being a public company, including costs related to public company reporting, investor relations and compliance with the Sarbanes-Oxley Act; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">our becoming a commercial company in 2019.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As a result, it may be difficult for investors to compare our future results to historical results or to evaluate our relative performance or trends in our business. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Future sales of our common stock by us, ALPHAEON or others, or the perception that such sales may occur, could depress the market price of our common stock.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We have </font><font style="font-family:Times New Roman;font-size:10pt;">27,425,230</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;shares of common stock issued and outstanding as of November 1, 2019. Sales by us of a substantial number of shares of our common stock in the public market, or the perception that these sales might occur, could significantly reduce the market price of our common stock and could impair our ability to raise capital through the sale of additional equity securities.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">September&#160;30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, ALPHAEON owned&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">31.6%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;of our outstanding shares of common stock. Subject to the restrictions described in the paragraph below, future sales of these shares in the public market will be subject to the volume and other restrictions of Rule 144 under the Securities Act for so long as ALPHAEON is deemed to be our affiliate, unless the shares to be sold are registered with the SEC. The sale by ALPHAEON of a substantial number of shares of our common stock, or a perception that such sales could occur, could significantly reduce the market price of our common stock. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We have filed a registration statement with the SEC covering shares of our common stock available for future issuance under our&#160;2017 Omnibus Incentive Plan and may file future registration statements covering shares of our common stock for future </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">77</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sA9B010344B1252489F229F26AB5A0DDF"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">issuance under any future plans. Upon effectiveness of such registration statements, any shares subsequently issued under such plans will be eligible for sale in the public market, except to the extent that they are restricted by the lock-up agreements referred to above and subject to compliance with Rule 144 in the case of our affiliates. Sales of a large number of the shares issued under these plans in the public market, or a perception that such sales could occur, could significantly reduce the market price of our common stock. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Anti-takeover provisions in our certificate of incorporation and bylaws, as well as Delaware law, could discourage a takeover.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our certificate of incorporation, bylaws and Delaware law contain provisions that might enable our management to resist a takeover and might make it more difficult for an investor to acquire a substantial block of our common stock. These include the following provisions:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">permit our board of directors to issue shares of preferred stock, with any rights, preferences and privileges as they may designate, without stockholder approval, which could be used to dilute the ownership of a hostile bidder significantly;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">provide that the authorized number of directors may be changed only by resolution of our board of directors </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">and that, f</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">rom and after the date on which ALPHAEON no longer beneficially owns </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">a majority of the voting power of all of the then-outstanding shares of our capital stock</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">a director may only be removed for cause by the affirmative vote of the holders of at least 66 2/3% of our voting stock</font><font style="font-family:Times New Roman;font-size:10pt;">;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">provide that all vacancies, including newly created directorships, may, except as otherwise required by law, be filled by the affirmative vote of a majority of directors then in office, even if less than a quorum;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">divide our board of directors into three classes, with each class serving staggered three-year terms, which may delay the ability of stockholders to change the membership of a majority of our board of directors;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">f</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">rom and after the date on which ALPHAEON no longer beneficially owns </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">a majority of the voting power of all of the then-outstanding shares of our capital stock</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, </font><font style="font-family:Times New Roman;font-size:10pt;">require that any action to be taken by our stockholders must be effected at a duly called annual or special meeting of stockholders and not be taken by written consent;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">provide that stockholders seeking to present proposals before a meeting of stockholders or to nominate candidates for election as directors at a meeting of stockholders must provide notice in writing in a timely manner and also specify requirements as to the form and content of a stockholder&#8217;s notice, which may discourage or deter a potential acquiror from conducting a solicitation of proxies to elect the acquiror&#8217;s own slate of directors or otherwise attempting to obtain control of our company;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">prohibit cumulative voting in the election of directors, which limits the ability of minority stockholders to elect director candidates; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">provide that special meetings of our stockholders may be called only by the chairman of the board, our Chief Executive Officer or by</font><font style="font-family:Times New Roman;font-size:10pt;">&#32;our</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;board of directors pursuant to a resolution adopted by a majority of the total number of authorized directors, which may delay the ability of our stockholders to force consideration by our company of a take-over proposal or to take certain corporate actions, including the removal of directors.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">These provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors, which is responsible for appointing the members of our management. In addition, our certificate of incorporation provides that, f</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">rom and after the date on which ALPHAEON no longer beneficially owns </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">a majority of the voting power of all of the then-outstanding shares of our capital stock, we will be subject to Section 203 of the General Corporation Law of the State of Delaware, or the DGCL, which generally prohibits a Delaware corporation from engaging in any of a broad range of business combinations with an interested stockholder who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner. This provision could have the effect of delaying or preventing a change-of-control, whether or not it is desired by or beneficial to our stockholders. Further, other provisions of Delaware law may also discourage, delay or prevent someone from acquiring us or merging with us.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">78</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sA9B010344B1252489F229F26AB5A0DDF"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In addition, our certificate of incorporation specifies that the Court of Chancery of the State of Delaware is the sole and exclusive forum for most legal actions involving actions brought against us by stockholders. We believe this provision benefits us by providing increased consistency in the application of Delaware law by chancellors particularly experienced in resolving corporate disputes, efficient administration of cases on a more expedited schedule relative to other forums and protection against the burdens of multi-forum litigation. However, the provision may have the effect of discouraging lawsuits against our directors and officers.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Our certificate of incorporation designates the Court of Chancery of the State of Delaware as the&#160;sole and exclusive forum&#160;for certain types of actions and proceedings that may be initiated by our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers, employees or agents.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our certificate of incorporation provides that, unless we consent in writing to an alternative forum, the Court of Chancery of the State of Delaware will be the&#160;sole and exclusive forum&#160;for all &#8220;internal corporate claims.&#8221; &#8220;Internal corporate claims&#8221; are claims that are based upon a violation of a duty by a current or former director, officer or stockholder in such capacity, or as to which Title 8 of the DGCL confers jurisdiction upon the Court of Chancery of the State of Delaware, or the Court of Chancery, in each case subject to the Court of Chancery having personal jurisdiction over the indispensable parties named as defendants and the claim not being one which is vested in the exclusive jurisdiction of a court or forum other than the Court of Chancery, or for which the Court of Chancery does not have subject matter jurisdiction. Any person purchasing or otherwise acquiring any interest in any shares of our capital stock shall be deemed to have notice of and to have consented to this provision of our certificate of incorporation. This choice of forum provision may limit our stockholders&#8217; ability to bring a claim in a judicial forum that they find favorable for disputes with us or our directors, officers, employees or agents, which may discourage such lawsuits against us and our directors, officers, employees and agents even though an action, if successful, might benefit our stockholders. Stockholders who do bring a claim in the Court of Chancery could face additional litigation costs in pursuing any such claim, particularly if they do not reside in or near Delaware. The Court of Chancery may also reach different judgments or results than would other courts, including courts where a stockholder considering an action may be located or would otherwise choose to bring the action, and such judgments or results may be more favorable to us than to our stockholders. Alternatively, if a court were to find this provision of our certificate of incorporation inapplicable to, or unenforceable in respect of, one or more of the specified types of actions or proceedings, we may incur additional costs associated with resolving such matters in other jurisdictions, which could have a material adverse effect on our business, financial condition or results of operations.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Claims for indemnification by our directors and officers may reduce our available funds to satisfy successful third-party claims against us and may reduce the amount of money available to us. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our certificate of incorporation and bylaws provide that we can indemnify our directors and officers, in each case to the fullest extent permitted by Delaware law. Separate indemnity agreements have been issued with each director and executive officer.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In addition, as permitted by Section 145 of the DGCL, our bylaws and our indemnification agreements that we have entered into with our directors and officers, among other things provide that:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We have indemnified our directors and officers for serving us in those capacities, or for serving as a director, officer, employee or agent of other business enterprises at our request, to the fullest extent permitted by Delaware law. Delaware law provides that we may indemnify such person if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to our best interest and, with respect to any criminal proceeding, had no reasonable cause to believe such person&#8217;s conduct was unlawful.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:48px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">We may, in our discretion, indemnify employees and agents in those circumstances where indemnification is permitted by applicable law.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">We will be required to advance expenses, as incurred, to our directors and officers in connection with defending a proceeding, except that such directors or officers shall undertake to repay such advances if it is ultimately determined that such person is not entitled to indemnification.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">The rights conferred in our bylaws will not be exclusive. W</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">e may not retroactively amend our bylaw provisions to reduce our indemnification obligations to directors, officers, employees and agents.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As a result, claims for indemnification by our directors and officers may reduce our available funds to satisfy successful </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">79</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sA9B010344B1252489F229F26AB5A0DDF"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">third-party claims against us and may reduce the amount of money available to us.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">We have not paid dividends in the past and do not expect to pay dividends in the future, and any return on investment may be limited to the value of our stock.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We have never paid cash dividends on our common stock and do not anticipate paying cash dividends on our common stock in the foreseeable future, and the payment of dividends is also restricted under our credit facility. The payment of dividends on our common stock will depend on our earnings, financial condition and other business and economic factors affecting us at such time as our board of directors may consider relevant. If we do not pay dividends, capital appreciation, if any, of our common stock will be your sole source of gain for the foreseeable future.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">We are an &#8220;emerging growth company,&#8221; and the reduced reporting requirements available to emerging growth companies could make our common stock less attractive to investors.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We qualify as an &#8220;emerging growth company,&#8221; as defined in the JOBS Act. For as long as we remain an emerging growth company, we may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies. These provisions include, but are not limited to:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">being permitted to have only two years of audited financial statements and only two years of related selected financial data and management&#8217;s discussion and analysis of financial condition and results of operations disclosure;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">an exemption from compliance with the auditor attestation requirement in the assessment of our internal control over financial reporting pursuant to the Sarbanes-Oxley Act;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">reduced disclosure about executive compensation arrangements in our periodic reports, registration statements and proxy statements; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">exemptions from the requirements to seek non-binding advisory votes on executive compensation or golden parachute arrangements.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">To the extent we take advantage of any of these exemptions, the information that we provide stockholders may be different than what is available with respect to other public companies. Investors may find our common stock less attractive because we will rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Even after we no longer qualify as an emerging growth company, we may still qualify as a &#8220;smaller reporting company&#8221; which would allow us to take advantage of many of the same exemptions from disclosure requirements, including exemption from compliance with the auditor attestation requirements of Section 404(b) and reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements. Investors could find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our trading price may be more volatile.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">The requirements of being a public company may strain our resources, divert management&#8217;s attention and affect our ability to attract and retain executive management and qualified board members.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As a public company, we are subject to the reporting requirements of the Exchange Act, the Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the Nasdaq Marketplace Rules and other applicable securities rules and regulations. Complying with these rules and regulations will increase our legal and financial compliance costs, make some activities more difficult, time-consuming or costly and increase demand on our systems and resources, particularly after we are no longer an &#8220;emerging growth company,&#8221; as defined in the JOBS Act. The Exchange Act requires, among other things, that we file annual, quarterly and current reports with respect to our business and operating results. The Sarbanes-Oxley Act requires, among other things, that we maintain effective disclosure controls and procedures and internal control over financial reporting. In order to maintain and, if required, improve our disclosure controls and procedures and internal control over financial reporting to meet this standard, significant resources and management oversight may be required. As a result, management&#8217;s attention may be diverted from other business concerns, which could adversely affect our business and operating results. We may need to hire more employees in the future or engage outside consultants to assist us in complying with these requirements, which will increase our costs and expenses.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In addition, changing laws, regulations and standards relating to corporate governance and public disclosure are creating uncertainty for public companies, increasing legal and financial compliance costs and making some activities more time </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">80</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sA9B010344B1252489F229F26AB5A0DDF"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">consuming. These laws, regulations and standards are subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. We intend to invest resources to comply with evolving laws, regulations and standards, and this investment may result in increased selling, general and administrative expenses and a diversion of our management&#8217;s time and attention from revenue-generating activities to compliance activities. If our efforts to comply with new laws, regulations and standards differ from the activities intended by regulatory or governing bodies due to ambiguities related to their application and practice, regulatory authorities may initiate legal proceedings against us and our business may be adversely affected.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">81</font></div></div><hr style="page-break-after:always"><div><a name="sADAF8E2F0EBB5D2C8F88390D3E1F8D45"></a></div><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sA9B010344B1252489F229F26AB5A0DDF"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Unregistered Sales of Equity Securities</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">None.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Use of Proceeds</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">None.</font></div><div><a name="s18AE933ADD7A586A85003EC23C2674E0"></a></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Item 3. Defaults Upon Senior Securities</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Not applicable.</font></div><div><a name="sEDD4A195A83A5A1681E8658D9DE2437C"></a></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Item 4.&#160;&#160;&#160;&#160;Mine Safety Disclosures.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Not applicable.</font></div><div><a name="sA9EACFD418205A75BECABB1973B9A48B"></a></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Item 5.  &#160;&#160;&#160;&#160;Other Information.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">None.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">82</font></div></div><hr style="page-break-after:always"><div><a name="s0E8D53C33CF25D3EBCB2753D7145F3B0"></a></div><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sA9B010344B1252489F229F26AB5A0DDF"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;-sec-extract:summary;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Item 6. &#160;&#160;&#160;&#160; Exhibits. </font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">EXHIBIT INDEX</font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90167158308752%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:47%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:9%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Incorporated by Reference</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;font-weight:bold;">Exhibit Number</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;font-weight:bold;">Exhibit Title</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;font-weight:bold;">Form</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;font-weight:bold;">File No.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;font-weight:bold;">Exhibit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;font-weight:bold;">Filing Date</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;font-weight:bold;">Filed Herewith</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;font-weight:bold;">(x)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exhibit31109301910q.htm"><font style="font-family:Times New Roman;font-size:10pt;">31.1</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exhibit31109301910q.htm"><font style="font-family:Times New Roman;font-size:10pt;">Certification of Principal Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended</font></a><font style="font-family:Times New Roman;font-size:10pt;">.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">X</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exhibit31209301910q.htm"><font style="font-family:Times New Roman;font-size:10pt;">31.2</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exhibit31209301910q.htm"><font style="font-family:Times New Roman;font-size:10pt;">Certification of Principal Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">X</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exhibit321093019.htm"><font style="font-family:Times New Roman;font-size:10pt;">32.1#</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exhibit321093019.htm"><font style="font-family:Times New Roman;font-size:10pt;">Certification of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">X</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">101.INS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">XBRL Instance Document.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">X</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">101.SCH</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">XBRL Taxonomy Extension Schema Document.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">X</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">101.CAL</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">XBRL Taxonomy Extension Calculation Linkbase Document.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">X</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">101.DEF</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">XBRL Taxonomy Extension Definition Linkbase Document.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">X</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">101.LAB</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">XBRL Taxonomy Extension Label Linkbase Document.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">X</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">101.PRE</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">XBRL Taxonomy Extension Presentation Linkbase Document.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">X</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">_____________</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90167158308752%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:3%;"></td><td style="width:97%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">#</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">The information in Exhibit 32.1 shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Exchange Act of 1934, as amended, or the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act (including this Quarterly Report on Form 10-Q), unless the Registrant specifically incorporates the foregoing information into those documents by reference.</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">83</font></div></div><hr style="page-break-after:always"><div><a name="sA5837C26E50A59DC9246E4281CA0FF9A"></a></div><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sA9B010344B1252489F229F26AB5A0DDF"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">SIGNATURES</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:16px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:93.25396825396825%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:6%;"></td><td style="width:21%;"></td><td style="width:27%;"></td><td style="width:5%;"></td><td style="width:27%;"></td><td style="width:14%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Evolus, Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Date:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">November&#160;4, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">/s/ David Moatazedi</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">David Moatazedi</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">President and Chief Executive Officer </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(Principal Executive Officer)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Date:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">November&#160;4, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">By:</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">/s/ Lauren Silvernail</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Lauren Silvernail</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Chief Financial Officer and Executive Vice President, Corporate Development</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(Principal Financial Officer)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div><br></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>exhibit31109301910q.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s5CC351AD651C50CFA349EEAC761DFA3B"></a></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;font-weight:bold;">Exhibit 31.1</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;font-weight:bold;">CERTIFICATION PURSUANT TO</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;font-weight:bold;">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;font-weight:bold;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:138%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I, </font><font style="font-family:inherit;font-size:10pt;">David Moatazedi</font><font style="font-family:inherit;font-size:10pt;">, certify that:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I have reviewed this Quarterly Report on Form 10-Q of Evolus, Inc.;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e)&#160;and&#160;15d-15(e))&#160;and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f)&#160;and&#160;15d-15(f))&#160;for the registrant and have:</font></div></td></tr></table><div style="line-height:138%;text-align:justify;padding-left:66px;text-indent:-31px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Designed such&#160;internal control over financial reporting, or caused such&#160;internal control over financial reporting&#160;to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">5.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div></td></tr></table><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:91.42300194931774%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:46%;"></td><td style="width:5%;"></td><td style="width:3%;"></td><td style="width:46%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: November&#160;4, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ David Moatazedi</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">David Moatazedi</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">President, Chief Executive Officer and Director</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(Principal Executive Officer)</font></div></td></tr></table></div></div><div><br></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>exhibit31209301910q.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s89C132CEC8F056A3ACE493A5824D6A36"></a></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 31.2</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;font-weight:bold;">CERTIFICATION PURSUANT TO</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;font-weight:bold;">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;font-weight:bold;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:138%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I, </font><font style="font-family:inherit;font-size:10pt;">Lauren Silvernail</font><font style="font-family:inherit;font-size:10pt;">, certify that:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I have reviewed this Quarterly Report on Form 10-Q of Evolus, Inc.;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e)&#160;and&#160;15d-15(e))&#160;and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f)&#160;and&#160;15d-15(f))&#160;for the registrant and have:</font></div></td></tr></table><div style="line-height:138%;text-align:justify;padding-left:66px;text-indent:-31px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Designed such&#160;internal control over financial reporting, or caused such&#160;internal control over financial reporting&#160;to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">5.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div></td></tr></table><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:91.6015625%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:46%;"></td><td style="width:5%;"></td><td style="width:3%;"></td><td style="width:46%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: November&#160;4, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;border-bottom:1px solid #000000;"><div style="padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Lauren Silvernail</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lauren Silvernail</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Financial Officer and Executive Vice President, Corporate Development</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(Principal Financial Officer)</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>exhibit321093019.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sA0A050F7B99D5F2B8839F6FF2385698B"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;font-weight:bold;">Exhibit 32.1</font></div><div style="line-height:120%;padding-top:24px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;font-weight:bold;">CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER AND</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;font-weight:bold;">CHIEF FINANCIAL OFFICER PURSUANT TO</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;font-weight:bold;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Each of the undersigned hereby certifies, in accordance with 18 U.S.C. &#167;&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, in his or her capacity as an officer of Evolus, Inc., that, to his or her knowledge, the Quarterly Report on Form&#160;10-Q of Evolus, Inc. for the quarter ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2019</font><font style="font-family:inherit;font-size:10pt;">&#32;fully complies with the requirements of Section&#160;13(a) or Section&#160;15(d) of the Securities Exchange Act of 1934 and that the information contained in such report fairly presents, in all material respects, the financial condition and results of operations of Evolus, Inc.</font></div><div style="line-height:138%;text-align:left;padding-left:33px;text-indent:-34px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:93.359375%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:44%;"></td><td style="width:5%;"></td><td style="width:5%;"></td><td style="width:46%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: November&#160;4, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ David Moatazedi</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">David Moatazedi</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">President and Chief Executive Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(Principal Executive Officer)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: November&#160;4, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Lauren Silvernail</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lauren Silvernail</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Financial Officer and Executive Vice President, Corporate Development</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(Principal Financial Officer)</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>5
<FILENAME>eols-20190930.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!--p:459DC50C0EA35BCEBB950EBE6256FF9E,x:99201ad33a94471b8d9ccbd70a7b0ea3-->
<xbrli:xbrl xmlns:acec="http://fasb.org/dis/acec/2019-01-31" xmlns:ap="http://fasb.org/dis/ap/2019-01-31" xmlns:aro="http://fasb.org/dis/aro/2019-01-31" xmlns:bc="http://fasb.org/dis/bc/2019-01-31" xmlns:bsoff="http://fasb.org/dis/bsoff/2019-01-31" xmlns:cc="http://fasb.org/dis/cc/2019-01-31" xmlns:cce="http://fasb.org/dis/cce/2019-01-31" xmlns:cecl="http://fasb.org/dis/cecl/2019-01-31" xmlns:ceclcalc2="http://fasb.org/dis/ceclcalc2/2019-01-31" xmlns:ceclcalc3l="http://fasb.org/dis/ceclcalc3l/2019-01-31" xmlns:cn-part="http://fasb.org/cn-part/2019-01-31" xmlns:codification-part="http://fasb.org/codification-part/2019-01-31" xmlns:com="http://fasb.org/stm/com/2019-01-31" xmlns:con="http://fasb.org/dis/con/2019-01-31" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:country-all="http://xbrl.sec.gov/country-all/2017-01-31" xmlns:country-ent-all="http://xbrl.sec.gov/country-ent-all/2017-01-31" xmlns:country-ent-std="http://xbrl.sec.gov/country-ent-std/2017-01-31" xmlns:country-std="http://xbrl.sec.gov/country-std/2017-01-31" xmlns:crcgen="http://fasb.org/dis/crcgen/2019-01-31" xmlns:crcpb="http://fasb.org/dis/crcpb/2019-01-31" xmlns:crcrb="http://fasb.org/dis/crcrb/2019-01-31" xmlns:crcsbp="http://fasb.org/dis/crcsbp/2019-01-31" xmlns:ctbl="http://fasb.org/dis/ctbl/2019-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2019-01-31" xmlns:currency-all="http://xbrl.sec.gov/currency-all/2019-01-31" xmlns:currency-ent-all="http://xbrl.sec.gov/currency-ent-all/2019-01-31" xmlns:currency-ent-dep="http://xbrl.sec.gov/currency-ent-dep/2019-01-31" xmlns:currency-ent-std="http://xbrl.sec.gov/currency-ent-std/2019-01-31" xmlns:currency-std="http://xbrl.sec.gov/currency-std/2019-01-31" xmlns:dccpoa="http://fasb.org/dis/dccpoa/2019-01-31" xmlns:debt="http://fasb.org/dis/debt/2019-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:dei-all="http://xbrl.sec.gov/dei-all/2019-01-31" xmlns:dei-ent-all="http://xbrl.sec.gov/dei-ent-all/2019-01-31" xmlns:dei-ent-std="http://xbrl.sec.gov/dei-ent-std/2019-01-31" xmlns:dei-std="http://xbrl.sec.gov/dei-std/2019-01-31" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/deprecated" xmlns:deprecated1="http://www.xbrl.org/2009/role/deprecated" xmlns:diha="http://fasb.org/dis/diha/2019-01-31" xmlns:disops="http://fasb.org/dis/disops/2019-01-31" xmlns:dr="http://fasb.org/dis/dr/2019-01-31" xmlns:edco="http://fasb.org/dis/edco/2019-01-31" xmlns:ei="http://fasb.org/dis/ei/2019-01-31" xmlns:emjv="http://fasb.org/dis/emjv/2019-01-31" xmlns:eols="http://www.evolus.com/20190930" xmlns:eps="http://fasb.org/dis/eps/2019-01-31" xmlns:equity="http://fasb.org/dis/equity/2019-01-31" xmlns:ero="http://fasb.org/dis/ero/2019-01-31" xmlns:eui="http://fasb.org/dis/eui/2019-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2019-01-31" xmlns:exch-all="http://xbrl.sec.gov/exch-all/2019-01-31" xmlns:exch-ent-all="http://xbrl.sec.gov/exch-ent-all/2019-01-31" xmlns:exch-ent-dep="http://xbrl.sec.gov/exch-ent-dep/2019-01-31" xmlns:exch-ent-std="http://xbrl.sec.gov/exch-ent-std/2019-01-31" xmlns:exch-std="http://xbrl.sec.gov/exch-std/2019-01-31" xmlns:fifvd="http://fasb.org/dis/fifvd/2019-01-31" xmlns:foct="http://fasb.org/dis/foct/2019-01-31" xmlns:fs-bd="http://fasb.org/dis/fs-bd/2019-01-31" xmlns:fs-bt="http://fasb.org/dis/fs-bt/2019-01-31" xmlns:fs-fhlb="http://fasb.org/dis/fs-fhlb/2019-01-31" xmlns:fs-ins="http://fasb.org/dis/fs-ins/2019-01-31" xmlns:fs-insa="http://fasb.org/dis/fs-insa/2019-01-31" xmlns:fs-interest="http://fasb.org/dis/fs-interest/2019-01-31" xmlns:fs-mort="http://fasb.org/dis/fs-mort/2019-01-31" xmlns:guar="http://fasb.org/dis/guar/2019-01-31" xmlns:hco="http://fasb.org/dis/hco/2019-01-31" xmlns:iago="http://fasb.org/dis/iago/2019-01-31" xmlns:iaoi="http://fasb.org/dis/iaoi/2019-01-31" xmlns:ides="http://fasb.org/dis/ides/2019-01-31" xmlns:inctax="http://fasb.org/dis/inctax/2019-01-31" xmlns:inv="http://fasb.org/dis/inv/2019-01-31" xmlns:invco="http://fasb.org/dis/invco/2019-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:invest-all="http://xbrl.sec.gov/invest-all/2013-01-31" xmlns:invest-ent-all="http://xbrl.sec.gov/invest-ent-all/2013-01-31" xmlns:invest-ent-std="http://xbrl.sec.gov/invest-ent-std/2013-01-31" xmlns:invest-std="http://xbrl.sec.gov/invest-std/2013-01-31" xmlns:ir="http://fasb.org/dis/ir/2019-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:lea="http://fasb.org/dis/lea/2019-01-31" xmlns:leas="http://fasb.org/dis/leas/2019-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:naics-all="http://xbrl.sec.gov/naics-all/2017-01-31" xmlns:naics-ent-all="http://xbrl.sec.gov/naics-ent-all/2017-01-31" xmlns:naics-ent-std="http://xbrl.sec.gov/naics-ent-std/2017-01-31" xmlns:naics-std="http://xbrl.sec.gov/naics-std/2017-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:ni="http://fasb.org/dis/ni/2019-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:nt="http://fasb.org/dis/nt/2019-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:ocpfs="http://fasb.org/dis/ocpfs/2019-01-31" xmlns:oi="http://fasb.org/dis/oi/2019-01-31" xmlns:otherexp="http://fasb.org/dis/otherexp/2019-01-31" xmlns:othliab="http://fasb.org/dis/othliab/2019-01-31" xmlns:pay="http://fasb.org/dis/pay/2019-01-31" xmlns:ppe="http://fasb.org/dis/ppe/2019-01-31" xmlns:rcc="http://fasb.org/dis/rcc/2019-01-31" xmlns:rd="http://fasb.org/dis/rd/2019-01-31" xmlns:re="http://fasb.org/dis/re/2019-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:reference="http://www.xbrl.org/2009/role/reference" xmlns:regop="http://fasb.org/dis/regop/2019-01-31" xmlns:reorg="http://fasb.org/dis/reorg/2019-01-31" xmlns:rlnro="http://fasb.org/dis/rlnro/2019-01-31" xmlns:rpd="http://fasb.org/dis/rpd/2019-01-31" xmlns:ru="http://fasb.org/dis/ru/2019-01-31" xmlns:scf-dbo="http://fasb.org/stm/scf-dbo/2019-01-31" xmlns:scf-dir="http://fasb.org/stm/scf-dir/2019-01-31" xmlns:scf-indir="http://fasb.org/stm/scf-indir/2019-01-31" xmlns:scf-indira="http://fasb.org/stm/scf-indira/2019-01-31" xmlns:scf-inv="http://fasb.org/stm/scf-inv/2019-01-31" xmlns:scf-re="http://fasb.org/stm/scf-re/2019-01-31" xmlns:scf-sbo="http://fasb.org/stm/scf-sbo/2019-01-31" xmlns:scf-sd="http://fasb.org/stm/scf-sd/2019-01-31" xmlns:schedoi-fednote="http://fasb.org/dis/schedoi-fednote/2019-01-31" xmlns:schedoi-hold="http://fasb.org/dis/schedoi-hold/2019-01-31" xmlns:schedoi-iiaa="http://fasb.org/dis/schedoi-iiaa/2019-01-31" xmlns:schedoi-oocw="http://fasb.org/dis/schedoi-oocw/2019-01-31" xmlns:schedoi-otsh="http://fasb.org/dis/schedoi-otsh/2019-01-31" xmlns:schedoi-shorthold="http://fasb.org/dis/schedoi-shorthold/2019-01-31" xmlns:schedoi-sumhold="http://fasb.org/dis/schedoi-sumhold/2019-01-31" xmlns:se="http://fasb.org/dis/se/2019-01-31" xmlns:sec-cndfir="http://fasb.org/dis/sec-cndfir/2019-01-31" xmlns:sec-mort="http://fasb.org/dis/sec-mort/2019-01-31" xmlns:sec-re="http://fasb.org/dis/sec-re/2019-01-31" xmlns:sec-reins="http://fasb.org/dis/sec-reins/2019-01-31" xmlns:sec-sum="http://fasb.org/dis/sec-sum/2019-01-31" xmlns:sec-supins="http://fasb.org/dis/sec-supins/2019-01-31" xmlns:sec-suppc="http://fasb.org/dis/sec-suppc/2019-01-31" xmlns:sec-vq="http://fasb.org/dis/sec-vq/2019-01-31" xmlns:sfp-clreo="http://fasb.org/stm/sfp-clreo/2019-01-31" xmlns:sfp-cls="http://fasb.org/stm/sfp-cls/2019-01-31" xmlns:sfp-dbo="http://fasb.org/stm/sfp-dbo/2019-01-31" xmlns:sfp-ibo="http://fasb.org/stm/sfp-ibo/2019-01-31" xmlns:sfp-sbo="http://fasb.org/stm/sfp-sbo/2019-01-31" xmlns:sfp-ucreo="http://fasb.org/stm/sfp-ucreo/2019-01-31" xmlns:sheci="http://fasb.org/stm/sheci/2019-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:sic-all="http://xbrl.sec.gov/sic-all/2011-01-31" xmlns:sic-ent-all="http://xbrl.sec.gov/sic-ent-all/2011-01-31" xmlns:sic-ent-std="http://xbrl.sec.gov/sic-ent-std/2011-01-31" xmlns:sic-std="http://xbrl.sec.gov/sic-std/2011-01-31" xmlns:soc="http://fasb.org/stm/soc/2019-01-31" xmlns:soi="http://fasb.org/stm/soi/2019-01-31" xmlns:soi-egm="http://fasb.org/stm/soi-egm/2019-01-31" xmlns:soi-indira="http://fasb.org/stm/soi-indira/2019-01-31" xmlns:soi-ins="http://fasb.org/stm/soi-ins/2019-01-31" xmlns:soi-int="http://fasb.org/stm/soi-int/2019-01-31" xmlns:soi-re="http://fasb.org/stm/soi-re/2019-01-31" xmlns:soi-reit="http://fasb.org/stm/soi-reit/2019-01-31" xmlns:soi-sbi="http://fasb.org/stm/soi-sbi/2019-01-31" xmlns:spc="http://fasb.org/stm/spc/2019-01-31" xmlns:sr="http://fasb.org/dis/sr/2019-01-31" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:srt-all="http://fasb.org/srt-all/2019-01-31" xmlns:srt-roles="http://fasb.org/srt-roles/2019-01-31" xmlns:srt-std="http://fasb.org/srt-std/2019-01-31" xmlns:srt-types="http://fasb.org/srt-types/2019-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:stpr-all="http://xbrl.sec.gov/stpr-all-all-all/2018-01-31" xmlns:stpr-ent-all="http://xbrl.sec.gov/stpr-ent-all-all-all/2018-01-31" xmlns:stpr-ent-std="http://xbrl.sec.gov/stpr-ent-std-std-std/2018-01-31" xmlns:stpr-std="http://xbrl.sec.gov/stpr-std-std-std/2018-01-31" xmlns:te="http://fasb.org/dis/te/2019-01-31" xmlns:tin-part="http://fasb.org/tin-part/2019-01-31" xmlns:ts="http://fasb.org/dis/ts/2019-01-31" xmlns:us-arcroles="http://fasb.org/us-arcroles/2019-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:us-gaap-all="http://fasb.org/us-gaap-all/2019-01-31" xmlns:us-gaap-ent-std="http://fasb.org/us-gaap-ent-std/2019-01-31" xmlns:us-gaap-entryPoint-all="http://fasb.org/us-gaap-entryPoint-all/2019-01-31" xmlns:us-gaap-std="http://fasb.org/us-gaap-std/2019-01-31" xmlns:us-roles="http://fasb.org/us-roles/2019-01-31" xmlns:us-types="http://fasb.org/us-types/2019-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
	<link:schemaRef xlink:href="eols-20190930.xsd" xlink:type="simple" />
	<xbrli:context id="FD2019Q3YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2019Q4Nov01">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-11-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q3">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q3QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q2_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1QTD_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q2QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q1_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q3_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q1">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q2QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q3">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q2">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q2_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1QTD_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q3_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q2">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q3YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_SoftwareDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q3QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q3YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DistributionRightsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DistributionRightsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2019Q1Feb28">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-02-01</xbrli:startDate>
			<xbrli:endDate>2019-02-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q3QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2019Q1Jan01">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2019Q1Jan01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q1Feb12_dei_LegalEntityAxis_eols_SCHAEONLLCMember_us-gaap_BusinessAcquisitionAxis_eols_EvolusIncMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">eols:SCHAEONLLCMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">eols:EvolusIncMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-02-12</xbrli:startDate>
			<xbrli:endDate>2018-02-12</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4Nov30_dei_LegalEntityAxis_eols_ALPHAEONMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">eols:ALPHAEONMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-11-30</xbrli:startDate>
			<xbrli:endDate>2017-11-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3QTD_dei_LegalEntityAxis_eols_ALPHAEONMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">eols:ALPHAEONMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4Dec14_dei_LegalEntityAxis_eols_SCHAEONLLCMember_us-gaap_BusinessAcquisitionAxis_eols_EvolusIncMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">eols:SCHAEONLLCMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">eols:EvolusIncMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-14</xbrli:startDate>
			<xbrli:endDate>2017-12-14</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3YTD_dei_LegalEntityAxis_eols_ALPHAEONMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">eols:ALPHAEONMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec14_us-gaap_BusinessAcquisitionAxis_eols_EvolusIncMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">eols:EvolusIncMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-14</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q1Feb12">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-02-12</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec14_us-gaap_BusinessAcquisitionAxis_eols_EvolusIncMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_eols_ChiefMedicalOfficerMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">eols:EvolusIncMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">eols:ChiefMedicalOfficerMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-14</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4Dec14_dei_LegalEntityAxis_eols_ALPHAEONMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">eols:ALPHAEONMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-14</xbrli:startDate>
			<xbrli:endDate>2017-12-14</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q3_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_ComputerSoftwareIntangibleAssetMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q3_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DistributionRightsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DistributionRightsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2013Q4_dei_LegalEntityAxis_eols_SCHAEONLLCMember_us-gaap_BusinessAcquisitionAxis_eols_EvolusIncMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">eols:SCHAEONLLCMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">eols:EvolusIncMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2013Q4Oct2013_dei_LegalEntityAxis_eols_SCHAEONLLCMember_us-gaap_BusinessAcquisitionAxis_eols_EvolusIncMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">eols:SCHAEONLLCMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">eols:EvolusIncMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-10-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2019Q1Feb01_dei_LegalEntityAxis_eols_SCHAEONLLCMember_us-gaap_BusinessAcquisitionAxis_eols_EvolusIncMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">eols:SCHAEONLLCMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">eols:EvolusIncMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-02-01</xbrli:startDate>
			<xbrli:endDate>2019-02-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q3YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_ComputerSoftwareIntangibleAssetMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2013Q4Oct_dei_LegalEntityAxis_eols_SCHAEONLLCMember_us-gaap_BusinessAcquisitionAxis_eols_EvolusIncMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">eols:SCHAEONLLCMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">eols:EvolusIncMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-10-01</xbrli:startDate>
			<xbrli:endDate>2013-10-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD_dei_LegalEntityAxis_eols_SCHAEONLLCMember_us-gaap_BusinessAcquisitionAxis_eols_EvolusIncMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">eols:SCHAEONLLCMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">eols:EvolusIncMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2019Q1Mar15_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-03-15</xbrli:startDate>
			<xbrli:endDate>2019-03-15</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2019Q1_us-gaap_DebtInstrumentAxis_eols_TermLoanFacilityTrancheTwoMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:TermLoanFacilityTrancheTwoMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-15</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2019Q1_us-gaap_DebtInstrumentAxis_eols_TermLoanFacilityMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:TermLoanFacilityMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-15</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2019Q1Mar15_us-gaap_DebtInstrumentAxis_eols_TermLoanFacilityMember_us-gaap_VariableRateAxis_eols_ApplicableRateMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:TermLoanFacilityMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">eols:ApplicableRateMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-03-15</xbrli:startDate>
			<xbrli:endDate>2019-03-15</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q3_us-gaap_DebtInstrumentAxis_eols_TermLoanFacilityMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:TermLoanFacilityMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2019Q1_us-gaap_DebtInstrumentAxis_eols_TermLoanFacilityTrancheOneMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:TermLoanFacilityTrancheOneMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-15</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2019Q1_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-15</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2019Q1Mar15_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember_us-gaap_VariableRateAxis_us-gaap_LondonInterbankOfferedRateLIBORMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-03-15</xbrli:startDate>
			<xbrli:endDate>2019-03-15</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FinancialInstrumentAxis_us-gaap_NotesPayableOtherPayablesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_NotesPayableOtherPayablesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FinancialInstrumentAxis_us-gaap_NotesPayableOtherPayablesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_NotesPayableOtherPayablesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FinancialInstrumentAxis_us-gaap_NotesPayableOtherPayablesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q3_us-gaap_FinancialInstrumentAxis_us-gaap_NotesPayableOtherPayablesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q3_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_NotesPayableOtherPayablesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FinancialInstrumentAxis_us-gaap_NotesPayableOtherPayablesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q3_us-gaap_DebtInstrumentAxis_eols_OxfordTermLoansMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:OxfordTermLoansMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q3_srt_RangeAxis_srt_MinimumMember_us-gaap_FinancialInstrumentAxis_eols_ContingentRoyaltyObligationMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">eols:ContingentRoyaltyObligationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q3_us-gaap_FinancialInstrumentAxis_eols_ContingentRoyaltyObligationMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">eols:ContingentRoyaltyObligationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q3_srt_RangeAxis_srt_MaximumMember_us-gaap_FinancialInstrumentAxis_eols_ContingentRoyaltyObligationMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">eols:ContingentRoyaltyObligationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q3_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q3_srt_RangeAxis_srt_MinimumMember_us-gaap_FinancialInstrumentAxis_eols_ContingentRoyaltyObligationMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">eols:ContingentRoyaltyObligationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q3_srt_RangeAxis_srt_MaximumMember_us-gaap_FinancialInstrumentAxis_eols_ContingentRoyaltyObligationMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">eols:ContingentRoyaltyObligationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q3YTD_dei_LegalEntityAxis_eols_DaewoongMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">eols:DaewoongMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q3QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q3_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q3_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q3YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q4Nov21">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-11-21</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Nov21">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-11-21</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q3YTD_srt_RangeAxis_srt_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4Nov21">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-11-21</xbrli:startDate>
			<xbrli:endDate>2017-11-21</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q3YTD_srt_RangeAxis_srt_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:unit id="usdPerShare">
		<xbrli:divide>
			<xbrli:unitNumerator>
				<xbrli:measure>iso4217:USD</xbrli:measure>
			</xbrli:unitNumerator>
			<xbrli:unitDenominator>
				<xbrli:measure>xbrli:shares</xbrli:measure>
			</xbrli:unitDenominator>
		</xbrli:divide>
	</xbrli:unit>
	<xbrli:unit id="unit">
		<xbrli:measure>eols:unit</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="year">
		<xbrli:measure>eols:year</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="usd">
		<xbrli:measure>iso4217:USD</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="number">
		<xbrli:measure>xbrli:pure</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="shares">
		<xbrli:measure>xbrli:shares</xbrli:measure>
	</xbrli:unit>
	<dei:AmendmentFlag contextRef="FD2019Q3YTD" id="Fact-F9D1587E5A9E7050B854453702FE0078">false</dei:AmendmentFlag>
	<dei:CurrentFiscalYearEndDate contextRef="FD2019Q3YTD" id="Fact-77177E26DADE0F682F79453702EF1E3D">--12-31</dei:CurrentFiscalYearEndDate>
	<dei:DocumentFiscalPeriodFocus contextRef="FD2019Q3YTD" id="Fact-9201E58AF75A0550287B45370343B251">Q3</dei:DocumentFiscalPeriodFocus>
	<dei:DocumentFiscalYearFocus contextRef="FD2019Q3YTD" id="Fact-3D353055F3E5D950BD7745370333A911">2019</dei:DocumentFiscalYearFocus>
	<dei:DocumentPeriodEndDate contextRef="FD2019Q3YTD" id="Fact-4B501838B4419B755FF8453702FE2755">2019-09-30</dei:DocumentPeriodEndDate>
	<dei:DocumentType contextRef="FD2019Q3YTD" id="Fact-D337F576F1C026C330A245370333A807">10-Q</dei:DocumentType>
	<dei:EntityCentralIndexKey contextRef="FD2019Q3YTD" id="Fact-531F67E1A173EA6456334537030E5AE8">0001570562</dei:EntityCentralIndexKey>
	<dei:EntityCommonStockSharesOutstanding contextRef="I2019Q4Nov01" decimals="INF" id="Fact-87A7534EF88B184C0E614537032D7B8A" unitRef="shares">27425230</dei:EntityCommonStockSharesOutstanding>
	<dei:EntityCurrentReportingStatus contextRef="FD2019Q3YTD" id="Fact-74E28422E4C3F386CF4245370343D5C4">Yes</dei:EntityCurrentReportingStatus>
	<dei:EntityEmergingGrowthCompany contextRef="FD2019Q3YTD" id="Fact-47B2262090C532BA1EB44537032D1D68">true</dei:EntityEmergingGrowthCompany>
	<dei:EntityExTransitionPeriod contextRef="FD2019Q3YTD" id="Fact-BDF4D53870C657B3FF044537032D4041">true</dei:EntityExTransitionPeriod>
	<dei:EntityFilerCategory contextRef="FD2019Q3YTD" id="Fact-2F70036B42CDA0F037D545370333F8CD">Non-accelerated Filer</dei:EntityFilerCategory>
	<dei:EntityRegistrantName contextRef="FD2019Q3YTD" id="Fact-5872DE829494032AC3FE4537031D3B8C">EVOLUS, INC.</dei:EntityRegistrantName>
	<dei:EntityShellCompany contextRef="FD2019Q3YTD" id="Fact-65010658B5A911149B234537030E6D28">false</dei:EntityShellCompany>
	<dei:EntitySmallBusiness contextRef="FD2019Q3YTD" id="Fact-4630828A30F4B5CFBEE44537031D145D">true</dei:EntitySmallBusiness>
	<eols:AccountsPayablePaidbyParent contextRef="FD2018Q3YTD" decimals="-3" id="Fact-F743C9103581F37502F1453703330F72" unitRef="usd">163000</eols:AccountsPayablePaidbyParent>
	<eols:AccountsPayablePaidbyParent contextRef="FD2019Q3YTD" decimals="-3" id="Fact-902443AAC9DB43E2DC7545370333879A" unitRef="usd">0</eols:AccountsPayablePaidbyParent>
	<eols:AccruedCouponAndRebateLiabilityCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-56DA3307CC838DEF92BFFF31F069FB52" unitRef="usd">0</eols:AccruedCouponAndRebateLiabilityCurrent>
	<eols:AccruedCouponAndRebateLiabilityCurrent contextRef="FI2019Q3" decimals="-3" id="Fact-673F3161395105F0ADBDFF31F03E1BEF" unitRef="usd">3932000</eols:AccruedCouponAndRebateLiabilityCurrent>
	<eols:AcquiredFinitelivedIntangibleAssetPeriodOfExtensionOfTermsBasedOnCertainPerformanceRequirements contextRef="D2013Q4Oct_dei_LegalEntityAxis_eols_SCHAEONLLCMember_us-gaap_BusinessAcquisitionAxis_eols_EvolusIncMember" id="Fact-D81F5E80DEDF57826D0E453702EFF91C">P3Y</eols:AcquiredFinitelivedIntangibleAssetPeriodOfExtensionOfTermsBasedOnCertainPerformanceRequirements>
	<eols:AllocatedShareBasedCompensationExpenseCapitalized contextRef="FD2019Q3QTD" decimals="-3" id="Fact-588C6EF43A8C8704B3E9FF5274729F5E" unitRef="usd">30000</eols:AllocatedShareBasedCompensationExpenseCapitalized>
	<eols:AllocatedShareBasedCompensationExpenseCapitalized contextRef="FD2019Q3YTD" decimals="-3" id="Fact-92AF07C750F7F3964819FF52746EA017" unitRef="usd">76000</eols:AllocatedShareBasedCompensationExpenseCapitalized>
	<eols:AmortizationOfDiscountOnShorttermInvestments contextRef="FD2018Q3YTD" decimals="-3" id="Fact-870F3B390D44BB204A654537033389FD" unitRef="usd">0</eols:AmortizationOfDiscountOnShorttermInvestments>
	<eols:AmortizationOfDiscountOnShorttermInvestments contextRef="FD2019Q3YTD" decimals="-3" id="Fact-3BF9DCB70715BED1EBC64537033390F0" unitRef="usd">-912000</eols:AmortizationOfDiscountOnShorttermInvestments>
	<eols:BusinessAcquisitionUnwindingFee contextRef="D2017Q4Nov30_dei_LegalEntityAxis_eols_ALPHAEONMember" decimals="-3" id="Fact-2081545593ED9E8240DB453702FEE132" unitRef="usd">9550000</eols:BusinessAcquisitionUnwindingFee>
	<eols:BusinessCombinationUpfrontPaymentUponObtainingFDAApproval contextRef="D2017Q4Dec14_dei_LegalEntityAxis_eols_SCHAEONLLCMember_us-gaap_BusinessAcquisitionAxis_eols_EvolusIncMember" decimals="-3" id="Fact-8D6023702AD1F29885444537030E1CE3" unitRef="usd">9200000</eols:BusinessCombinationUpfrontPaymentUponObtainingFDAApproval>
	<eols:CapitalContributionConvertibleNoteWriteOff contextRef="FD2018Q3YTD" decimals="-3" id="Fact-5314BE0172C01FF0B44B453703339BF6" unitRef="usd">66998000</eols:CapitalContributionConvertibleNoteWriteOff>
	<eols:CapitalContributionConvertibleNoteWriteOff contextRef="FD2019Q3YTD" decimals="-3" id="Fact-4CDB9248F53C829E2C8B45370333991B" unitRef="usd">0</eols:CapitalContributionConvertibleNoteWriteOff>
	<eols:CapitalContributionForgivenessofRelatedPartyBorrowings contextRef="FD2018Q3YTD" decimals="-3" id="Fact-CB79D2097BBE5610983245370333FC71" unitRef="usd">13188000</eols:CapitalContributionForgivenessofRelatedPartyBorrowings>
	<eols:CapitalContributionForgivenessofRelatedPartyBorrowings contextRef="FD2019Q3YTD" decimals="-3" id="Fact-16041808DCBD5F47B41945370333C169" unitRef="usd">0</eols:CapitalContributionForgivenessofRelatedPartyBorrowings>
	<eols:CapitalContributionFromParentForgivenessOfRelatedPartyBorrowings contextRef="FD2018Q1QTD" decimals="-3" id="Fact-4CDEA4EF3A37C5EA6487453702FEACDD" unitRef="usd">13188000</eols:CapitalContributionFromParentForgivenessOfRelatedPartyBorrowings>
	<eols:CapitalContributionFromParentForgivenessOfRelatedPartyBorrowings contextRef="FD2018Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-EF8E2C775987472A51D34537030E29AF" unitRef="usd">13188000</eols:CapitalContributionFromParentForgivenessOfRelatedPartyBorrowings>
	<eols:CommonStockAdditionalCapitalSharesReservedforFutureIssuance contextRef="I2018Q4Nov21" decimals="INF" id="Fact-CD02B12C773452EF16E84537030E3313" unitRef="shares">1091000</eols:CommonStockAdditionalCapitalSharesReservedforFutureIssuance>
	<eols:ContingentPromissoryNote contextRef="FD2018Q3YTD" decimals="-3" id="Fact-64BA98E2C693452C351F45370333AF16" unitRef="usd">16042000</eols:ContingentPromissoryNote>
	<eols:ContingentPromissoryNote contextRef="FD2019Q3YTD" decimals="-3" id="Fact-C3FC1198EA304C7765C6453703330699" unitRef="usd">0</eols:ContingentPromissoryNote>
	<eols:ContingentRoyaltyObligation contextRef="FD2018Q3YTD" decimals="-3" id="Fact-19F81A45AEFAA3346FD645370333FFBE" unitRef="usd">39700000</eols:ContingentRoyaltyObligation>
	<eols:ContingentRoyaltyObligation contextRef="FD2019Q3YTD" decimals="-3" id="Fact-44B3A2F7532CCC09F69E45370333AA02" unitRef="usd">0</eols:ContingentRoyaltyObligation>
	<eols:ContingentRoyaltyObligationPayabletoRelatedPartyCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-FFA0282193C52208881F453702FE291E" unitRef="usd">0</eols:ContingentRoyaltyObligationPayabletoRelatedPartyCurrent>
	<eols:ContingentRoyaltyObligationPayabletoRelatedPartyCurrent contextRef="FI2019Q3" decimals="-3" id="Fact-F25CBA06D1B9FFCC0BF0453702FEFEFC" unitRef="usd">4323000</eols:ContingentRoyaltyObligationPayabletoRelatedPartyCurrent>
	<eols:DebtInstrumentAdditionalAmortizationPeriod contextRef="D2019Q1Mar15_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember" id="Fact-7A3B63110BB4CCAD07614537030E9FDC">P11M</eols:DebtInstrumentAdditionalAmortizationPeriod>
	<eols:DebtInstrumentAdditionalPeriodOfAgreementOfInterestPayment contextRef="D2019Q1Mar15_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember" id="Fact-05D855A3EAE39F7E75954537031D284D">P12M</eols:DebtInstrumentAdditionalPeriodOfAgreementOfInterestPayment>
	<eols:DebtInstrumentAmortizationPeriod contextRef="D2019Q1Mar15_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember" id="Fact-0763F39FEB081735078B4537031D6B95">P23M</eols:DebtInstrumentAmortizationPeriod>
	<eols:DebtInstrumentDefaultInterestRate contextRef="D2019Q1Mar15_us-gaap_DebtInstrumentAxis_eols_TermLoanFacilityMember_us-gaap_VariableRateAxis_eols_ApplicableRateMember" decimals="INF" id="Fact-DC726D199A2B8698121B4537031DCA63" unitRef="number">0.05</eols:DebtInstrumentDefaultInterestRate>
	<eols:DebtInstrumentPercentageOfPrincipalAmountBalloonPayment contextRef="I2019Q1_us-gaap_DebtInstrumentAxis_eols_TermLoanFacilityMember" decimals="INF" id="Fact-038B84BE40849C7FD1964537030EB735" unitRef="number">0.055</eols:DebtInstrumentPercentageOfPrincipalAmountBalloonPayment>
	<eols:DebtInstrumentPeriodOfInterestOnlyPayments contextRef="D2019Q1Mar15_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember" id="Fact-FC171C147F5E13530D614537031D4E24">P36M</eols:DebtInstrumentPeriodOfInterestOnlyPayments>
	<eols:DebtInstrumentPrepaymentFeePercentageNextTwelveMonths contextRef="I2019Q1_us-gaap_DebtInstrumentAxis_eols_TermLoanFacilityMember" decimals="INF" id="Fact-AA0F5695AFF16285AB4D4537032D1097" unitRef="number">0.03</eols:DebtInstrumentPrepaymentFeePercentageNextTwelveMonths>
	<eols:DebtInstrumentPrepaymentFeePercentageThereafter contextRef="I2019Q1_us-gaap_DebtInstrumentAxis_eols_TermLoanFacilityMember" decimals="INF" id="Fact-DECD4F876924C95CBCC44537031DE771" unitRef="number">0.01</eols:DebtInstrumentPrepaymentFeePercentageThereafter>
	<eols:DebtInstrumentPrepaymentFeePercentageYearTwo contextRef="I2019Q1_us-gaap_DebtInstrumentAxis_eols_TermLoanFacilityMember" decimals="INF" id="Fact-766A9FE2BED6F1BDBE894537030EB60A" unitRef="number">0.02</eols:DebtInstrumentPrepaymentFeePercentageYearTwo>
	<eols:DebtInstrumentTermAggregatePeriod contextRef="D2019Q1Mar15_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember" id="Fact-BEAEED2749B8CC7BF33D4537031D7397">P48M</eols:DebtInstrumentTermAggregatePeriod>
	<eols:DeemedContributionFromParentIncreaseOfRelatedPartyReceivable contextRef="FD2018Q1QTD" decimals="-3" id="Fact-D38C7651E6E8CA6C82A245370333A92F" unitRef="usd">1051000</eols:DeemedContributionFromParentIncreaseOfRelatedPartyReceivable>
	<eols:DeemedContributionFromParentIncreaseOfRelatedPartyReceivable contextRef="FD2018Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-33FC81A590ADCF24A5F74537031DA7F8" unitRef="usd">1051000</eols:DeemedContributionFromParentIncreaseOfRelatedPartyReceivable>
	<eols:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityPayments contextRef="FD2018Q3QTD" decimals="-3" id="Fact-6FD82536023203A39A1645370333D659" unitRef="usd">0</eols:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityPayments>
	<eols:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityPayments contextRef="FD2018Q3YTD" decimals="-3" id="Fact-B836317BAB27C3E7C6084537030ED25A" unitRef="usd">0</eols:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityPayments>
	<eols:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityPayments contextRef="FD2019Q3QTD" decimals="-3" id="Fact-34E8EB27D6C3917B37B9453702FEDBFF" unitRef="usd">69000</eols:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityPayments>
	<eols:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityPayments contextRef="FD2019Q3YTD" decimals="-3" id="Fact-35C1674627457D4375A94537031D715B" unitRef="usd">9282000</eols:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityPayments>
	<eols:IncreasedecreaseInOperatingLeaseLiabilities contextRef="FD2018Q3YTD" decimals="-3" id="Fact-496F4C61D3D242151561453703332297" unitRef="usd">0</eols:IncreasedecreaseInOperatingLeaseLiabilities>
	<eols:IncreasedecreaseInOperatingLeaseLiabilities contextRef="FD2019Q3YTD" decimals="-3" id="Fact-3C750DE0AAC85E813F22453703335D35" unitRef="usd">-531000</eols:IncreasedecreaseInOperatingLeaseLiabilities>
	<eols:IntangibleAssetsGrossIncludingGoodwill contextRef="FI2019Q3" decimals="-3" id="Fact-622DCBAEB435AF3C439F4537030EBB63" unitRef="usd">83587000</eols:IntangibleAssetsGrossIncludingGoodwill>
	<eols:LesseeOperatingLeasePeriodOfWrittenNoticePriorToLeaseTerminateDate contextRef="FD2019Q3YTD" id="Fact-3D04AE311955847ED2FE4537032D92BC">P12M</eols:LesseeOperatingLeasePeriodOfWrittenNoticePriorToLeaseTerminateDate>
	<eols:LesseeOperatingLeaseTerminationFeePeriodOfRentEquivalent contextRef="FD2019Q3YTD" id="Fact-71FF68F05AA9E4C7A3774537031DA3B3">P6M</eols:LesseeOperatingLeaseTerminationFeePeriodOfRentEquivalent>
	<eols:LesseeOperatingLeaseTerminationPeriod contextRef="FD2019Q3YTD" id="Fact-B8C0347D0911C30BE56E4537032D4C6F">P36M</eols:LesseeOperatingLeaseTerminationPeriod>
	<eols:LongtermDebtMaturitiesFinalPayments contextRef="FI2019Q3" decimals="-3" id="Fact-EEA594CE31D50ECB02EA4537032D7AC6" unitRef="usd">4125000</eols:LongtermDebtMaturitiesFinalPayments>
	<eols:LongtermDebtMaturitiesFinalPaymentsInYearFive contextRef="FI2019Q3" decimals="-3" id="Fact-95AB187F71BB21F9D1374537032D8D7E" unitRef="usd">4125000</eols:LongtermDebtMaturitiesFinalPaymentsInYearFive>
	<eols:LongtermDebtMaturitiesFinalPaymentsInYearFour contextRef="FI2019Q3" decimals="-3" id="Fact-59EC0F7E066B2815F2A2453702FE4EDC" unitRef="usd">0</eols:LongtermDebtMaturitiesFinalPaymentsInYearFour>
	<eols:LongtermDebtMaturitiesFinalPaymentsInYearThree contextRef="FI2019Q3" decimals="-3" id="Fact-4C8DA3A79E85BE595B244537032D8F51" unitRef="usd">0</eols:LongtermDebtMaturitiesFinalPaymentsInYearThree>
	<eols:LongtermDebtMaturitiesPrincipalPaymentExcludingFinalPayment contextRef="FI2019Q3" decimals="-3" id="Fact-83FDAE5CABB6167F56114537030E8A23" unitRef="usd">75000000</eols:LongtermDebtMaturitiesPrincipalPaymentExcludingFinalPayment>
	<eols:LongtermDebtMaturitiesPrincipalPaymentExcludingFinalPaymentDueInYearFive contextRef="FI2019Q3" decimals="-3" id="Fact-4888DEC78577A98244C0453702FEACDE" unitRef="usd">9783000</eols:LongtermDebtMaturitiesPrincipalPaymentExcludingFinalPaymentDueInYearFive>
	<eols:LongtermDebtMaturitiesPrincipalPaymentExcludingFinalPaymentDueInYearFour contextRef="FI2019Q3" decimals="-3" id="Fact-EE6BF2356C6ED656EEAF453702FE7C08" unitRef="usd">39130000</eols:LongtermDebtMaturitiesPrincipalPaymentExcludingFinalPaymentDueInYearFour>
	<eols:LongtermDebtMaturitiesPrincipalPaymentExcludingFinalPaymentDueInYearThree contextRef="FI2019Q3" decimals="-3" id="Fact-D0C5B48BD733AABB603345370333FD03" unitRef="usd">26087000</eols:LongtermDebtMaturitiesPrincipalPaymentExcludingFinalPaymentDueInYearThree>
	<eols:MilestonePaymentCurrent contextRef="FI2018Q3" decimals="-3" id="Fact-D672F18077673B1656321843BD357C26" unitRef="usd">0</eols:MilestonePaymentCurrent>
	<eols:MilestonePaymentCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-C42FDBAA68D2831AF751453702EF3EC3" unitRef="usd">0</eols:MilestonePaymentCurrent>
	<eols:MilestonePaymentCurrent contextRef="FI2019Q3" decimals="-3" id="Fact-BA187DBBE8310A4C86201843BD63969A" unitRef="usd">1000000</eols:MilestonePaymentCurrent>
	<eols:MilestonePaymentInConnectionWithLicenseAndSupplyAgreement contextRef="FD2019Q3YTD_dei_LegalEntityAxis_eols_DaewoongMember" decimals="-3" id="Fact-291A3CA647148C37942045370333D16E" unitRef="usd">11500000</eols:MilestonePaymentInConnectionWithLicenseAndSupplyAgreement>
	<eols:MilestonePaymentsForIntangibleAssets contextRef="D2019Q1Feb01_dei_LegalEntityAxis_eols_SCHAEONLLCMember_us-gaap_BusinessAcquisitionAxis_eols_EvolusIncMember" decimals="-3" id="Fact-0A0529AE164C509FAA9C45370343D515" unitRef="usd">2000000</eols:MilestonePaymentsForIntangibleAssets>
	<eols:MilestonePaymentsForIntangibleAssets contextRef="FD2018Q3YTD" decimals="-3" id="Fact-0905F5C84D49C30C4951453703335909" unitRef="usd">0</eols:MilestonePaymentsForIntangibleAssets>
	<eols:MilestonePaymentsForIntangibleAssets contextRef="FD2019Q3YTD" decimals="-3" id="Fact-53A50BCF6AE35277D23545370343F40F" unitRef="usd">2000000</eols:MilestonePaymentsForIntangibleAssets>
	<eols:NonCashDeferredOfferingCosts contextRef="FD2018Q3YTD" decimals="-3" id="Fact-2EDF3989D891FC11FBF9453703331DC4" unitRef="usd">2885000</eols:NonCashDeferredOfferingCosts>
	<eols:NonCashDeferredOfferingCosts contextRef="FD2019Q3YTD" decimals="-3" id="Fact-8BA0D988BCD3F164CDD6453703335C83" unitRef="usd">0</eols:NonCashDeferredOfferingCosts>
	<eols:NonCashFinanceAndInsurancePayment contextRef="FD2018Q3YTD" decimals="-3" id="Fact-7515261EED80C755BBAF1844B1380A14" unitRef="usd">0</eols:NonCashFinanceAndInsurancePayment>
	<eols:NonCashFinanceAndInsurancePayment contextRef="FD2019Q3YTD" decimals="-3" id="Fact-3B66109FE861F57A808C1844B138858A" unitRef="usd">1561000</eols:NonCashFinanceAndInsurancePayment>
	<eols:NonCashLandlordPaidTenantImprovement contextRef="FD2018Q3YTD" decimals="-3" id="Fact-813846255ACE5EAB27261845499147D6" unitRef="usd">0</eols:NonCashLandlordPaidTenantImprovement>
	<eols:NonCashLandlordPaidTenantImprovement contextRef="FD2019Q3YTD" decimals="-3" id="Fact-EB72AC4C836FE107262C184549700D91" unitRef="usd">781000</eols:NonCashLandlordPaidTenantImprovement>
	<eols:NonCashNoteObligation contextRef="FD2018Q3YTD" decimals="-3" id="Fact-D534E66C9334E23CF508453703333536" unitRef="usd">140688000</eols:NonCashNoteObligation>
	<eols:NonCashNoteObligation contextRef="FD2019Q3YTD" decimals="-3" id="Fact-5943A61C938CDC7A171545370333E5C8" unitRef="usd">0</eols:NonCashNoteObligation>
	<eols:NonCashRelatedPartyBorrowings contextRef="FD2018Q3YTD" decimals="-3" id="Fact-A31C6ED40BAB19BEE14B4537033315D3" unitRef="usd">68767000</eols:NonCashRelatedPartyBorrowings>
	<eols:NonCashRelatedPartyBorrowings contextRef="FD2019Q3YTD" decimals="-3" id="Fact-913E980DB5628D8690AC45370333C39D" unitRef="usd">0</eols:NonCashRelatedPartyBorrowings>
	<eols:NonCashRelatedPartyReceivable contextRef="FD2018Q3YTD" decimals="-3" id="Fact-028609324BC04E28D46945370333A5B7" unitRef="usd">73690000</eols:NonCashRelatedPartyReceivable>
	<eols:NonCashRelatedPartyReceivable contextRef="FD2019Q3YTD" decimals="-3" id="Fact-CBD251BC9746616B3AD245370333E94B" unitRef="usd">0</eols:NonCashRelatedPartyReceivable>
	<eols:OperatingLeasePercentageOfAnnualRentEscalation contextRef="FD2019Q3YTD" decimals="2" id="Fact-C151748C48BA43971A5E453703332477" unitRef="number">0.03</eols:OperatingLeasePercentageOfAnnualRentEscalation>
	<eols:OperatingLeaseRightofUseAssetAmortization contextRef="FD2018Q3YTD" decimals="-3" id="Fact-ED58458A3A181BD0B16A453703338429" unitRef="usd">0</eols:OperatingLeaseRightofUseAssetAmortization>
	<eols:OperatingLeaseRightofUseAssetAmortization contextRef="FD2019Q3YTD" decimals="-3" id="Fact-7AA33E541BBD0B31EE2C453703338057" unitRef="usd">702000</eols:OperatingLeaseRightofUseAssetAmortization>
	<eols:PaymentsForProvisionsForAccruedVolumeBasedRebateAndCouponLiability contextRef="FD2019Q3QTD" decimals="-3" id="Fact-A8D1F9591B09E147DC7C284D90E90B18" unitRef="usd">2739000</eols:PaymentsForProvisionsForAccruedVolumeBasedRebateAndCouponLiability>
	<eols:PaymentsForProvisionsForAccruedVolumeBasedRebateAndCouponLiability contextRef="FD2019Q3YTD" decimals="-3" id="Fact-9DF69F021B3643529E703721B4D7DD19" unitRef="usd">2739000</eols:PaymentsForProvisionsForAccruedVolumeBasedRebateAndCouponLiability>
	<eols:PaymentsOfContingentRoyaltyObligation contextRef="FD2018Q3YTD" decimals="-3" id="Fact-859A51F14A0084C5575845370333E08C" unitRef="usd">0</eols:PaymentsOfContingentRoyaltyObligation>
	<eols:PaymentsOfContingentRoyaltyObligation contextRef="FD2019Q3YTD" decimals="-3" id="Fact-9469BB0265AD6B48E39C453703339CA8" unitRef="usd">9282000</eols:PaymentsOfContingentRoyaltyObligation>
	<eols:ProceedsFromPaymentsForIssuanceOfCommonStockInConnectionWithEquityIncentivePlan contextRef="FD2018Q3YTD" decimals="-3" id="Fact-6DC1E336AB9D6493144445370333E0F9" unitRef="usd">-239000</eols:ProceedsFromPaymentsForIssuanceOfCommonStockInConnectionWithEquityIncentivePlan>
	<eols:ProceedsFromPaymentsForIssuanceOfCommonStockInConnectionWithEquityIncentivePlan contextRef="FD2019Q3YTD" decimals="-3" id="Fact-2919E4561EDD766820C7453702EFD960" unitRef="usd">1109000</eols:ProceedsFromPaymentsForIssuanceOfCommonStockInConnectionWithEquityIncentivePlan>
	<eols:ProvisionsForAccruedVolumeBasedRebateAndCouponLiability contextRef="FD2019Q3QTD" decimals="-3" id="Fact-84885994B51F26BAC8EA284C6F704317" unitRef="usd">5740000</eols:ProvisionsForAccruedVolumeBasedRebateAndCouponLiability>
	<eols:ProvisionsForAccruedVolumeBasedRebateAndCouponLiability contextRef="FD2019Q3YTD" decimals="-3" id="Fact-6CCE2F0A9DF754C86314284C6F69C173" unitRef="usd">6671000</eols:ProvisionsForAccruedVolumeBasedRebateAndCouponLiability>
	<eols:ProvisionsForRebateAndCouponPrograms contextRef="FD2018Q3YTD" decimals="-3" id="Fact-8FEF39CC73E722D8199CFF15656229C1" unitRef="usd">0</eols:ProvisionsForRebateAndCouponPrograms>
	<eols:ProvisionsForRebateAndCouponPrograms contextRef="FD2019Q3YTD" decimals="-3" id="Fact-BFE26477A2D0F906ECACFF15653F8815" unitRef="usd">6671000</eols:ProvisionsForRebateAndCouponPrograms>
	<eols:RelatedPartyTransactionPeriodOfTerminationOfFirstCommercialSale contextRef="D2017Q4Dec14_dei_LegalEntityAxis_eols_SCHAEONLLCMember_us-gaap_BusinessAcquisitionAxis_eols_EvolusIncMember" id="Fact-2252290FD813AB9FD5874537030E45BA">P10Y</eols:RelatedPartyTransactionPeriodOfTerminationOfFirstCommercialSale>
	<eols:RevaluationofContingentRoyaltyObligationPayable contextRef="FD2018Q3QTD" decimals="-3" id="Fact-BE0AF02330FC043CA87F453703333CDD" unitRef="usd">2300000</eols:RevaluationofContingentRoyaltyObligationPayable>
	<eols:RevaluationofContingentRoyaltyObligationPayable contextRef="FD2018Q3YTD" decimals="-3" id="Fact-9465405271ACEAA333B1453702EFB031" unitRef="usd">11400000</eols:RevaluationofContingentRoyaltyObligationPayable>
	<eols:RevaluationofContingentRoyaltyObligationPayable contextRef="FD2019Q3QTD" decimals="-3" id="Fact-E3381493878920FA6330453703334306" unitRef="usd">1795000</eols:RevaluationofContingentRoyaltyObligationPayable>
	<eols:RevaluationofContingentRoyaltyObligationPayable contextRef="FD2019Q3YTD" decimals="-3" id="Fact-3BD13091D9C90C6DBED94537031DABB3" unitRef="usd">7977000</eols:RevaluationofContingentRoyaltyObligationPayable>
	<eols:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsForfeitedinPeriodIntrinsicValue contextRef="FD2019Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" id="Fact-A544868EB583FC8D64F24537030E1149" unitRef="usd" xsi:nil="true" />
	<eols:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsGrantedinPeriodIntrinsicValue contextRef="FD2019Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" id="Fact-400D794C454ADA5321914537030E3A5B" unitRef="usd" xsi:nil="true" />
	<eols:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermExercisable contextRef="FD2019Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" id="Fact-A47DC03D10E30D21DF784537030ED6C8">P7Y110D</eols:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermExercisable>
	<eols:StockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan contextRef="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-E8E8AF3813F0D3EF3009453703334585" unitRef="shares">34602</eols:StockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan>
	<eols:StockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-C6210364440A6CB86357453702FE4138" unitRef="shares">10372</eols:StockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan>
	<eols:StockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-B7ED9E4F1210535E5925453703334575" unitRef="shares">107641</eols:StockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan>
	<eols:StockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan contextRef="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-057C79A3500B2B542BC3FEF0470A3760" unitRef="shares">32226</eols:StockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan>
	<eols:StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan contextRef="FD2018Q2QTD" decimals="-3" id="Fact-E468986B79E7F79DB65F453702FEA8B5" unitRef="usd">-238000</eols:StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan>
	<eols:StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan contextRef="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-D3384E3464F4CD7F3FB5453703333B2A" unitRef="usd">-238000</eols:StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan>
	<eols:StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan contextRef="FD2019Q1QTD" decimals="-3" id="Fact-572B6D2D29A3A88B46F84537031D6589" unitRef="usd">-58000</eols:StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan>
	<eols:StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-8A4E7923687B0413A0E34537031D67BB" unitRef="usd">-58000</eols:StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan>
	<eols:StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan contextRef="FD2019Q2QTD" decimals="-3" id="Fact-4BD4A454030FADB74D2B453703334B60" unitRef="usd">853000</eols:StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan>
	<eols:StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-19EE5F7CD15FE355F45F4537031D2A6E" unitRef="usd">853000</eols:StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan>
	<eols:StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan contextRef="FD2019Q3QTD" decimals="-3" id="Fact-543CDF11DAA8788F7E62FEF04DB83804" unitRef="usd">314000</eols:StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan>
	<eols:StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan contextRef="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-4CC298636763A9C2C3B9FEF049D2CE15" unitRef="usd">314000</eols:StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan>
	<eols:StockPurchaseAgreementPeriodAvailabletoCureBreach contextRef="D2017Q4Dec14_dei_LegalEntityAxis_eols_ALPHAEONMember" id="Fact-0E10F0EDD8EFB8D92F004537030E0B07">P30D</eols:StockPurchaseAgreementPeriodAvailabletoCureBreach>
	<us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-E4FE888190C5C9D7FB23453703336F8F" unitRef="usd">3718000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
	<us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="FI2019Q3" decimals="-3" id="Fact-271C45CA5B0A55F67DEE45370333992B" unitRef="usd">14378000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
	<us-gaap:AccountsPayableCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-455DA8B05C7E416A0BD94537031D3AFA" unitRef="usd">1558000</us-gaap:AccountsPayableCurrent>
	<us-gaap:AccountsPayableCurrent contextRef="FI2019Q3" decimals="-3" id="Fact-98000036F5983CE0974C4537031DE830" unitRef="usd">6125000</us-gaap:AccountsPayableCurrent>
	<us-gaap:AccountsReceivableNetCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-174AE782ABE5AF646C234537031DC7DE" unitRef="usd">0</us-gaap:AccountsReceivableNetCurrent>
	<us-gaap:AccountsReceivableNetCurrent contextRef="FI2019Q3" decimals="-3" id="Fact-9350BBD7D45328D1AD874537030E322D" unitRef="usd">7206000</us-gaap:AccountsReceivableNetCurrent>
	<us-gaap:AccruedLiabilitiesCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-3D02A52F19CC69C188C6453702EFEB2C" unitRef="usd">3718000</us-gaap:AccruedLiabilitiesCurrent>
	<us-gaap:AccruedLiabilitiesCurrent contextRef="FI2019Q3" decimals="-3" id="Fact-EF77D4081D96306FD643453702FEE631" unitRef="usd">14378000</us-gaap:AccruedLiabilitiesCurrent>
	<us-gaap:AccruedProfessionalFeesCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-F0EE0E9338F22512F808453703435D83" unitRef="usd">931000</us-gaap:AccruedProfessionalFeesCurrent>
	<us-gaap:AccruedProfessionalFeesCurrent contextRef="FI2019Q3" decimals="-3" id="Fact-E57AE12EB473F3CDBA5745370333F075" unitRef="usd">4488000</us-gaap:AccruedProfessionalFeesCurrent>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2018Q4" decimals="-3" id="Fact-BFDB762FEC343E70685A4537030E6534" unitRef="usd">0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2019Q3" decimals="-3" id="Fact-12CF97C20CC0A5BD80584537030EFEB3" unitRef="usd">19000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AdditionalPaidInCapital contextRef="FI2018Q4" decimals="-3" id="Fact-7FA4B5290323DE4C1D934537031D8E93" unitRef="usd">207408000</us-gaap:AdditionalPaidInCapital>
	<us-gaap:AdditionalPaidInCapital contextRef="FI2019Q3" decimals="-3" id="Fact-DA6D3D24C04186C6CB904537031D9534" unitRef="usd">215574000</us-gaap:AdditionalPaidInCapital>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt contextRef="FD2018Q1QTD" decimals="-3" id="Fact-3575058B12EC1525110C453702EF63E6" unitRef="usd">66998000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt contextRef="FD2018Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-02F39CF2C0D76322B6DD453702FEB934" unitRef="usd">66998000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2018Q1QTD" decimals="-3" id="Fact-498C651BE454664E1B3945370333A827" unitRef="usd">1006000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2018Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-C33C3F5735F86B29E173453703333EFC" unitRef="usd">1006000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2018Q2QTD" decimals="-3" id="Fact-59F327516BDFDA54FAD24537030E7799" unitRef="usd">2623000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-C63898D21D1E73A4F08CFEEAAD788EDB" unitRef="usd">2623000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2018Q3QTD" decimals="-3" id="Fact-2E1A433FA66B832BA67CFEED62EFA170" unitRef="usd">1482000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-B91FCDD46E2CEAD9B99BFEED5F8D005B" unitRef="usd">1482000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2019Q1QTD" decimals="-3" id="Fact-957C3744F34D55714F544537031D8AE8" unitRef="usd">2015000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-C2EEC55392CE6EFDCC764537030E7A6A" unitRef="usd">2015000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2019Q2QTD" decimals="-3" id="Fact-209BB2908A8A5E721EB94537030E6D13" unitRef="usd">2486000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-C534294DD8403D3EB5924537030E9875" unitRef="usd">2486000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2019Q3QTD" decimals="-3" id="Fact-742FCD58C5C13B9E7440FEF053B8D377" unitRef="usd">2556000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-59D3DD664B603817C9DFFEF0505329CD" unitRef="usd">2556000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2018Q3QTD" decimals="-3" id="Fact-89DBEE2BC532324BF6AE453702FEF304" unitRef="usd">1482000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2018Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-3" id="Fact-E6E99B7187347E9C2E78453702FEA93E" unitRef="usd">322000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2018Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" decimals="-3" id="Fact-37C9EFBA156E068749C2453702FE4D59" unitRef="usd">1160000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2018Q3YTD" decimals="-3" id="Fact-3C69E634D9D14B55CA13453702FEDECF" unitRef="usd">5111000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2018Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-3" id="Fact-F8B4408A80A7DEBC9872453702FE9E31" unitRef="usd">1028000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2018Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" decimals="-3" id="Fact-179379513C8535C6D032453702FE6BE0" unitRef="usd">4083000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2019Q3QTD" decimals="-3" id="Fact-C298A8F7BCE25BD628AC453702FE6F86" unitRef="usd">2526000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2019Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-3" id="Fact-A800BFD325EB2AAE0C85453702FEB9B4" unitRef="usd">109000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2019Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" decimals="-3" id="Fact-E5C65C545C0E841BD2D54537030EBD14" unitRef="usd">2417000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2019Q3YTD" decimals="-3" id="Fact-F7B28CD77F955AACDE5D453702FE4928" unitRef="usd">6981000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2019Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-3" id="Fact-49019F9C29027DA2B6C4453702FE3CA8" unitRef="usd">538000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2019Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" decimals="-3" id="Fact-5D9065897188D6580E39453702FE62A5" unitRef="usd">6443000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AlternativeInvestmentMeasurementInput contextRef="FI2018Q3_srt_RangeAxis_srt_MaximumMember_us-gaap_FinancialInstrumentAxis_eols_ContingentRoyaltyObligationMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember" decimals="3" id="Fact-0AAB42E87784E950B7FE4537030ECB34" unitRef="number">0.250</us-gaap:AlternativeInvestmentMeasurementInput>
	<us-gaap:AlternativeInvestmentMeasurementInput contextRef="FI2018Q3_srt_RangeAxis_srt_MinimumMember_us-gaap_FinancialInstrumentAxis_eols_ContingentRoyaltyObligationMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember" decimals="3" id="Fact-0B079D0B480AD07EF1194537030E72A5" unitRef="number">0.160</us-gaap:AlternativeInvestmentMeasurementInput>
	<us-gaap:AlternativeInvestmentMeasurementInput contextRef="FI2019Q3_srt_RangeAxis_srt_MaximumMember_us-gaap_FinancialInstrumentAxis_eols_ContingentRoyaltyObligationMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember" decimals="3" id="Fact-F0C86B642C17BFFC20954537031D4EAD" unitRef="number">0.250</us-gaap:AlternativeInvestmentMeasurementInput>
	<us-gaap:AlternativeInvestmentMeasurementInput contextRef="FI2019Q3_srt_RangeAxis_srt_MinimumMember_us-gaap_FinancialInstrumentAxis_eols_ContingentRoyaltyObligationMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember" decimals="3" id="Fact-A80C9E3AE3CB8FB1EFBB4537031D925B" unitRef="number">0.160</us-gaap:AlternativeInvestmentMeasurementInput>
	<us-gaap:AlternativeInvestmentMeasurementInput contextRef="FI2019Q3_us-gaap_FinancialInstrumentAxis_eols_ContingentRoyaltyObligationMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember" decimals="INF" id="Fact-1B1CA8B7D272125DC0AB4537031DF2BC" unitRef="year">10</us-gaap:AlternativeInvestmentMeasurementInput>
	<us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="FD2018Q3YTD" decimals="-3" id="Fact-C6D16ACD96C17659808745370333C501" unitRef="usd">749000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
	<us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="FD2019Q3YTD" decimals="-3" id="Fact-705C90A6BEAC188D70E445370333739E" unitRef="usd">1513000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
	<us-gaap:AmortizationOfIntangibleAssets contextRef="FD2019Q3QTD" decimals="-3" id="Fact-C9E4B8F5F86A37A1D43E453702EFE42F" unitRef="usd">1115000</us-gaap:AmortizationOfIntangibleAssets>
	<us-gaap:AmortizationOfIntangibleAssets contextRef="FD2019Q3YTD" decimals="-3" id="Fact-05C36C70F127F8F96913453702FE43D0" unitRef="usd">2522000</us-gaap:AmortizationOfIntangibleAssets>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2019Q3QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact-F96CD06AB4FE71C22F560EF933126642" unitRef="shares">4052161.000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2019Q3QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="0" id="Fact-0A4ABF53108D7EC854A9FF25DACA35D0" unitRef="shares">182758</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2019Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember" decimals="0" id="Fact-C82AFFF5EECFDFE08CDB453702FEEFD7" unitRef="shares">4052161</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2019Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="0" id="Fact-46262A8ADEF8706A789045370333C4FE" unitRef="shares">182758</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:Assets contextRef="FI2018Q4" decimals="-3" id="Fact-1FA7CE25385C6CBB35664537031D9B75" unitRef="usd">171844000</us-gaap:Assets>
	<us-gaap:Assets contextRef="FI2019Q3" decimals="-3" id="Fact-FA1B090440471253B65A4537031DA873" unitRef="usd">182666000</us-gaap:Assets>
	<us-gaap:AssetsCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-E7339CB9AE16DBEAD9744537031DA350" unitRef="usd">94339000</us-gaap:AssetsCurrent>
	<us-gaap:AssetsCurrent contextRef="FI2019Q3" decimals="-3" id="Fact-79B1552E7910648DA23F4537032D9D53" unitRef="usd">95184000</us-gaap:AssetsCurrent>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2019Q3_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember" decimals="-3" id="Fact-6A5C9AC0EEC6C8DF32C1453702FEBEBD" unitRef="usd">19000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2019Q3_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember" decimals="-3" id="Fact-862E1240816F7E5BF243453702EF78E1" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="FI2019Q3_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember" decimals="-3" id="Fact-EFA1C26C2420FB0C2101453702FE52E4" unitRef="usd">34894000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2019Q3_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember" decimals="-3" id="Fact-29332F9D1F8D53F96BC9453702FEEF2C" unitRef="usd">34913000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-BD89F13BD7E560C3330F4537030E9E5E" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
	<us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="FI2019Q3" decimals="-3" id="Fact-B3EA574638FDF4DECBCB4537030EACD9" unitRef="usd">34913000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
	<us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired contextRef="I2017Q4Dec14_us-gaap_BusinessAcquisitionAxis_eols_EvolusIncMember" decimals="INF" id="Fact-21D5E9A17E55A022D6334537030E1C82" unitRef="number">0.5</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
	<us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="FD2018Q3YTD" decimals="-3" id="Fact-85CDB690B96F1348371745370333D3D9" unitRef="usd">11400000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
	<us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="FD2019Q3YTD" decimals="-3" id="Fact-9B878DCBCF323913A9FBFF11A5C05B46" unitRef="usd">7977000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="I2013Q4Oct2013_dei_LegalEntityAxis_eols_SCHAEONLLCMember_us-gaap_BusinessAcquisitionAxis_eols_EvolusIncMember" decimals="-3" id="Fact-7792D7529EBF31C88ADD45370343CFAF" unitRef="usd">13500000</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets contextRef="FI2013Q4_dei_LegalEntityAxis_eols_SCHAEONLLCMember_us-gaap_BusinessAcquisitionAxis_eols_EvolusIncMember" decimals="-3" id="Fact-83DE11C13839DBA3125C453702EFF548" unitRef="usd">56076000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
	<us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="FD2018Q3YTD" decimals="-3" id="Fact-15D4FC253DCB7FF680804537033348F2" unitRef="usd">0</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
	<us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="FD2019Q3YTD" decimals="-3" id="Fact-9C2A3D1153EDB9B28DE645370333CB9A" unitRef="usd">147000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
	<us-gaap:CapitalizedComputerSoftwareAdditions contextRef="FD2019Q3QTD" decimals="-3" id="Fact-8F6A369CCCB60C050BD145370333DF9B" unitRef="usd">761000</us-gaap:CapitalizedComputerSoftwareAdditions>
	<us-gaap:CapitalizedComputerSoftwareAdditions contextRef="FD2019Q3YTD" decimals="-3" id="Fact-5E09DC9BA1CFBAA56768453702EF2F18" unitRef="usd">3303000</us-gaap:CapitalizedComputerSoftwareAdditions>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2018Q4" decimals="-3" id="Fact-D4FBC5DCAEBB130A14484537032DC74B" unitRef="usd">93162000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2019Q3" decimals="-3" id="Fact-4791801053939219FBD14537032DE327" unitRef="usd">39116000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashCashEquivalentsAndShortTermInvestments contextRef="FI2019Q3" decimals="-3" id="Fact-70C91EA1C5FC810C09064537032DB136" unitRef="usd">74029000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
	<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="FI2017Q4" decimals="-3" id="Fact-6B72F61C0A20DD8C6ABE453703336AEA" unitRef="usd">0</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
	<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="FI2018Q3" decimals="-3" id="Fact-46254D66A5165FE95B2D453703332164" unitRef="usd">105168000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
	<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="FI2018Q4" decimals="-3" id="Fact-ED7AA01FD322FB5F9EAA453703333BC7" unitRef="usd">93162000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
	<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="FI2019Q3" decimals="-3" id="Fact-DB223335F3E21EC9DFB045370333EBED" unitRef="usd">39116000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
	<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="FD2018Q3YTD" decimals="-3" id="Fact-343D351521B492460489453702FE0C61" unitRef="usd">105168000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
	<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="FD2019Q3YTD" decimals="-3" id="Fact-FAB5D9A85B2E84AFE9E0453703339A02" unitRef="usd">-54046000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
	<us-gaap:CommitmentsAndContingencies contextRef="FI2018Q4" id="Fact-B9FF2E90B569401FD20E4537031DFDEB" unitRef="usd" xsi:nil="true" />
	<us-gaap:CommitmentsAndContingencies contextRef="FI2019Q3" id="Fact-81C13A932914B7E7BCFB4537031D013C" unitRef="usd" xsi:nil="true" />
	<us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="FI2019Q3" decimals="INF" id="Fact-368808EBA52D41E3CD3E453702FEB2E7" unitRef="shares">971684</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
	<us-gaap:CommonStockParOrStatedValuePerShare contextRef="FI2018Q4" decimals="INF" id="Fact-C575096725FB21432C10453702EF598C" unitRef="usdPerShare">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
	<us-gaap:CommonStockParOrStatedValuePerShare contextRef="FI2019Q3" decimals="INF" id="Fact-8510E5256111F8F49D7E4537030E1483" unitRef="usdPerShare">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
	<us-gaap:CommonStockSharesAuthorized contextRef="FI2018Q4" decimals="INF" id="Fact-DDBE0A9D2D8BF8477EA44537031D39FD" unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
	<us-gaap:CommonStockSharesAuthorized contextRef="FI2019Q3" decimals="INF" id="Fact-C13B590C885685711721453702FE7298" unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
	<us-gaap:CommonStockSharesIssued contextRef="FI2018Q4" decimals="INF" id="Fact-45306A9D9A0A9CB22C494537031D9115" unitRef="shares">27274991</us-gaap:CommonStockSharesIssued>
	<us-gaap:CommonStockSharesIssued contextRef="FI2019Q3" decimals="INF" id="Fact-F85C1AEF26002142F6114537031D44BE" unitRef="shares">27425230</us-gaap:CommonStockSharesIssued>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2018Q4" decimals="INF" id="Fact-4840A7FCEA38262435304537031D74FE" unitRef="shares">27274991</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2019Q3" decimals="INF" id="Fact-86FEBDCA0815462408A7453703430D5E" unitRef="shares">27425230</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockValue contextRef="FI2018Q4" decimals="-3" id="Fact-DD2FC6F9BBE2664736A64537031DEB0D" unitRef="usd">1000</us-gaap:CommonStockValue>
	<us-gaap:CommonStockValue contextRef="FI2019Q3" decimals="-3" id="Fact-11D56F7912341FDC60F84537030EA3C4" unitRef="usd">1000</us-gaap:CommonStockValue>
	<us-gaap:ComprehensiveIncomeNetOfTax contextRef="FD2018Q3QTD" decimals="-3" id="Fact-247ED68B0540EDAEA1EE453702EFDC91" unitRef="usd">-11830000</us-gaap:ComprehensiveIncomeNetOfTax>
	<us-gaap:ComprehensiveIncomeNetOfTax contextRef="FD2018Q3YTD" decimals="-3" id="Fact-3F1823BBC623A9037E7D4537030E1C93" unitRef="usd">-34425000</us-gaap:ComprehensiveIncomeNetOfTax>
	<us-gaap:ComprehensiveIncomeNetOfTax contextRef="FD2019Q1QTD" decimals="-3" id="Fact-28DB3CF6F4B376323DC7453702FE3216" unitRef="usd">-9000</us-gaap:ComprehensiveIncomeNetOfTax>
	<us-gaap:ComprehensiveIncomeNetOfTax contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-0DE690229549C9D7754D453703332D75" unitRef="usd">-9000</us-gaap:ComprehensiveIncomeNetOfTax>
	<us-gaap:ComprehensiveIncomeNetOfTax contextRef="FD2019Q3QTD" decimals="-3" id="Fact-F7D635969686046855FE453702EF52A9" unitRef="usd">-27008000</us-gaap:ComprehensiveIncomeNetOfTax>
	<us-gaap:ComprehensiveIncomeNetOfTax contextRef="FD2019Q3YTD" decimals="-3" id="Fact-9353CADCC8660A50DBAD453702FE7D09" unitRef="usd">-75507000</us-gaap:ComprehensiveIncomeNetOfTax>
	<us-gaap:ContractualObligation contextRef="FI2018Q4" decimals="-3" id="Fact-04D6B411CCC8CCB8E95C4537031D50B0" unitRef="usd">50200000</us-gaap:ContractualObligation>
	<us-gaap:ContractualObligation contextRef="FI2019Q3" decimals="-3" id="Fact-E5A7D3EE5F1D74FF22D14537032DF714" unitRef="usd">44572000</us-gaap:ContractualObligation>
	<us-gaap:ContractualObligation contextRef="I2018Q1Feb12" decimals="-3" id="Fact-50685836B37B9A42D54D453702FE9758" unitRef="usd">39700000</us-gaap:ContractualObligation>
	<us-gaap:CostOfGoodsAndServicesSold contextRef="FD2018Q3QTD" decimals="-3" id="Fact-87E2984A8C7E62EDD854453702FEAE4B" unitRef="usd">0</us-gaap:CostOfGoodsAndServicesSold>
	<us-gaap:CostOfGoodsAndServicesSold contextRef="FD2018Q3YTD" decimals="-3" id="Fact-15A5C88797BF7E3DDD1A453702FE9F44" unitRef="usd">0</us-gaap:CostOfGoodsAndServicesSold>
	<us-gaap:CostOfGoodsAndServicesSold contextRef="FD2019Q3QTD" decimals="-3" id="Fact-A976BB1F9FDDB807BB9C4537031D8505" unitRef="usd">3718000</us-gaap:CostOfGoodsAndServicesSold>
	<us-gaap:CostOfGoodsAndServicesSold contextRef="FD2019Q3YTD" decimals="-3" id="Fact-2DA8B70CDAF6FE22539F453702EF3901" unitRef="usd">4378000</us-gaap:CostOfGoodsAndServicesSold>
	<us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 contextRef="D2019Q1Mar15_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember_us-gaap_VariableRateAxis_us-gaap_LondonInterbankOfferedRateLIBORMember" decimals="INF" id="Fact-AD4F12BAC3779E74B6204537030E6365" unitRef="number">0.07</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="FI2019Q3_us-gaap_DebtInstrumentAxis_eols_TermLoanFacilityMember" decimals="INF" id="Fact-59D1ACAF6E3E55C576C24537030E583C" unitRef="number">0.116</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="I2019Q1_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember" decimals="INF" id="Fact-ACD5F94E12892CB8F3E5453702FE55C7" unitRef="number">0.095</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DebtInstrumentUnamortizedDiscount contextRef="FI2019Q3_us-gaap_DebtInstrumentAxis_eols_TermLoanFacilityMember" decimals="-3" id="Fact-5C4EF5E93E754FA8E1954537030ED02D" unitRef="usd">1094000</us-gaap:DebtInstrumentUnamortizedDiscount>
	<us-gaap:DeferredFinanceCostsGross contextRef="FI2019Q3_us-gaap_DebtInstrumentAxis_eols_TermLoanFacilityMember" decimals="-3" id="Fact-F6552C2F4BC19C4A4F9E4537030ED93C" unitRef="usd">2205000</us-gaap:DeferredFinanceCostsGross>
	<us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="FD2018Q3YTD" decimals="-3" id="Fact-6C69B4B04715A294C550453702FE259D" unitRef="usd">41000</us-gaap:DeferredIncomeTaxExpenseBenefit>
	<us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="FD2019Q3YTD" decimals="-3" id="Fact-21FE5347C44FEAF266024537034358E9" unitRef="usd">-14899000</us-gaap:DeferredIncomeTaxExpenseBenefit>
	<us-gaap:DeferredIncomeTaxLiabilitiesNet contextRef="FI2018Q4" decimals="-3" id="Fact-C2177FA5114B941EF7174537030EC970" unitRef="usd">15055000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
	<us-gaap:DeferredIncomeTaxLiabilitiesNet contextRef="FI2019Q3" decimals="-3" id="Fact-E8D103654896CF6A273C4537030EBF69" unitRef="usd">156000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
	<us-gaap:DeferredRentCreditNoncurrent contextRef="FI2018Q4" decimals="-3" id="Fact-5A465051A4383128BD01FEF5F224A5B8" unitRef="usd">25000</us-gaap:DeferredRentCreditNoncurrent>
	<us-gaap:DeferredRentCreditNoncurrent contextRef="FI2019Q3" decimals="-3" id="Fact-F3FDC8EC905DEF62564FFEF5F22862B7" unitRef="usd">0</us-gaap:DeferredRentCreditNoncurrent>
	<us-gaap:DeferredRentCreditNoncurrent contextRef="I2019Q1Jan01" decimals="-3" id="Fact-4670071EE1986B915CBEFF2C275EBA59" unitRef="usd">0</us-gaap:DeferredRentCreditNoncurrent>
	<us-gaap:DeferredRentCreditNoncurrent contextRef="I2019Q1Jan01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member" decimals="-3" id="Fact-A468348241635033D088FF2C27282122" unitRef="usd">-25000</us-gaap:DeferredRentCreditNoncurrent>
	<us-gaap:DepreciationDepletionAndAmortization contextRef="FD2018Q3QTD" decimals="-3" id="Fact-9A3B9AAC81DD020A2CAE4537031DCC0F" unitRef="usd">3000</us-gaap:DepreciationDepletionAndAmortization>
	<us-gaap:DepreciationDepletionAndAmortization contextRef="FD2018Q3YTD" decimals="-3" id="Fact-09708E424EA5ED39B969453702FEAC60" unitRef="usd">7000</us-gaap:DepreciationDepletionAndAmortization>
	<us-gaap:DepreciationDepletionAndAmortization contextRef="FD2019Q3QTD" decimals="-3" id="Fact-27129B7A7A29A33819B1453702EF3F3B" unitRef="usd">1202000</us-gaap:DepreciationDepletionAndAmortization>
	<us-gaap:DepreciationDepletionAndAmortization contextRef="FD2019Q3YTD" decimals="-3" id="Fact-477099883C809BBB9C44453702FEB0D9" unitRef="usd">2664000</us-gaap:DepreciationDepletionAndAmortization>
	<us-gaap:Dividends contextRef="FD2018Q1QTD" decimals="-3" id="Fact-8C3669939E06CA7A16CA4537032D8657" unitRef="usd">2002000</us-gaap:Dividends>
	<us-gaap:Dividends contextRef="FD2018Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-B91F7F84DECF09A0A4C64537030E2351" unitRef="usd">1387000</us-gaap:Dividends>
	<us-gaap:Dividends contextRef="FD2018Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-99CD52889DA0766BB3064537030E3BB4" unitRef="usd">615000</us-gaap:Dividends>
	<us-gaap:DueToRelatedPartiesCurrentAndNoncurrent contextRef="I2017Q4Dec14_us-gaap_BusinessAcquisitionAxis_eols_EvolusIncMember" decimals="-3" id="Fact-A24EC0EF925B3FF6D7584537030ED055" unitRef="usd">1575000</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
	<us-gaap:DueToRelatedPartiesCurrentAndNoncurrent contextRef="I2017Q4Dec14_us-gaap_BusinessAcquisitionAxis_eols_EvolusIncMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_eols_ChiefMedicalOfficerMember" decimals="-3" id="Fact-B534EC21190B6AC75FA44537030EEB7B" unitRef="usd">700000</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2018Q3QTD" decimals="2" id="Fact-A0FAEED3F1E00BA5DD46453702FE342E" unitRef="usdPerShare">-0.48</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2018Q3YTD" decimals="2" id="Fact-41612576845CA7AA792245370333E929" unitRef="usdPerShare">-1.47</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2019Q3QTD" decimals="2" id="Fact-D513697E452FB14749A94537030E9EEB" unitRef="usdPerShare">-0.98</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2019Q3YTD" decimals="2" id="Fact-F597E2307060D558ADEF4537033392B4" unitRef="usdPerShare">-2.76</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-4A456FEADDD18DBB64364537031D76CF" unitRef="usd">2577000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
	<us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="FI2019Q3" decimals="-3" id="Fact-990365397717DEB6AA0545370333B1BA" unitRef="usd">3453000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue contextRef="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember" decimals="-3" id="Fact-F6562A38FF024EAF2F564537030E6E08" unitRef="usd">34913000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue contextRef="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember" decimals="-3" id="Fact-0D3E1A4F0F85A21F2D68453702FEA7A4" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue contextRef="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember" decimals="-3" id="Fact-6C36C55921A6B45F4D2D4537031D27AB" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue contextRef="FI2019Q3_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember" decimals="-3" id="Fact-5400E76ACFE4387D1C2D4537030EB203" unitRef="usd">34913000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="FI2017Q4" decimals="-3" id="Fact-874953F6B736EF8EA431453702FE3D06" unitRef="usd">39700000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="FI2018Q2" decimals="-3" id="Fact-9FFCE283DB08C11150504537031D8260" unitRef="usd">48800000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="FI2018Q3" decimals="-3" id="Fact-63110F9D7D6D30C8AF7C453702FEFBBE" unitRef="usd">51100000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="FI2018Q4" decimals="-3" id="Fact-1847B0455E74F70A6D65453702FE15CD" unitRef="usd">50200000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FinancialInstrumentAxis_us-gaap_NotesPayableOtherPayablesMember" decimals="-3" id="Fact-623EEA8A3DCA323AB735453702EFE249" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_NotesPayableOtherPayablesMember" decimals="-3" id="Fact-925EFB29DCBBB3C21A714537031D0010" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FinancialInstrumentAxis_us-gaap_NotesPayableOtherPayablesMember" decimals="-3" id="Fact-3CB1F7B66CF741E2525D4537030EEBC8" unitRef="usd">50200000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="FI2018Q4_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember" decimals="-3" id="Fact-D2D4BBF7008053CE0D36FF40D3365B51" unitRef="usd">17181000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_NotesPayableOtherPayablesMember" decimals="-3" id="Fact-B82BD05E1024ED4AF3F3453702EF6AFF" unitRef="usd">50200000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="FI2019Q2" decimals="-3" id="Fact-47767B9C8DED553CC2E64537030E2DD8" unitRef="usd">47169000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="FI2019Q3" decimals="-3" id="Fact-D6ACCE04BA4612B211CA4537031D90BF" unitRef="usd">48895000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FinancialInstrumentAxis_us-gaap_NotesPayableOtherPayablesMember" decimals="-3" id="Fact-68A2DDBEA8BEA43470FB4537031DF5AA" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_NotesPayableOtherPayablesMember" decimals="-3" id="Fact-0933ADA494BED77F2FB3453702FEFB0F" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FinancialInstrumentAxis_us-gaap_NotesPayableOtherPayablesMember" decimals="-3" id="Fact-DDA9282A02F039874FB34537030E93E2" unitRef="usd">48895000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="FI2019Q3_us-gaap_FinancialInstrumentAxis_us-gaap_NotesPayableOtherPayablesMember" decimals="-3" id="Fact-69B3E94AC3D2CE6EE081FF3E1EF77358" unitRef="usd">48895000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
	<us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="FD2019Q3YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_ComputerSoftwareIntangibleAssetMember" id="Fact-415B5502017B7C83D60C4537031D9889">P2Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
	<us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="FD2019Q3YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DistributionRightsMember" id="Fact-2D20FB53D535566EA8814537030E6E40">P20Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
	<us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="FD2019Q3YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_SoftwareDevelopmentMember" id="Fact-B42E5CCADBE00B97A2BF453702FE4780">P2Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2019Q3" decimals="-3" id="Fact-62761307CA79F1645B1B453702FE4CFB" unitRef="usd">2522000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2019Q3_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_ComputerSoftwareIntangibleAssetMember" decimals="-3" id="Fact-CE8EBE4414776CFBB3C04537030E078A" unitRef="usd">582000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2019Q3_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DistributionRightsMember" decimals="-3" id="Fact-A21584787B38A088DD51453702EF0A2F" unitRef="usd">1940000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive contextRef="FI2019Q3" decimals="-3" id="Fact-6F111CE00B1F83260759453702EFA81B" unitRef="usd">44577000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
	<us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear contextRef="FI2019Q3" decimals="-3" id="Fact-5B799CA259145CC4B21B453702EF559E" unitRef="usd">1168000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
	<us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive contextRef="FI2019Q3" decimals="-3" id="Fact-0DA984533B9275CDD1B545370333124C" unitRef="usd">2955000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
	<us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour contextRef="FI2019Q3" decimals="-3" id="Fact-0FF9A96EFA58101ADB05453702EFD971" unitRef="usd">2955000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
	<us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="FI2019Q3" decimals="-3" id="Fact-4B14E3468AA3AB8A6352453702EFE341" unitRef="usd">3528000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
	<us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="FI2019Q3" decimals="-3" id="Fact-D308F72183B98B2C1684453702EF0CDC" unitRef="usd">4674000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
	<us-gaap:FiniteLivedIntangibleAssetsGross contextRef="FI2019Q3" decimals="-3" id="Fact-508A1E88EA32FD484B56453702FE55E8" unitRef="usd">62379000</us-gaap:FiniteLivedIntangibleAssetsGross>
	<us-gaap:FiniteLivedIntangibleAssetsGross contextRef="FI2019Q3_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_ComputerSoftwareIntangibleAssetMember" decimals="-3" id="Fact-DBD205A2BA86ED8C87D7453702EF7F5C" unitRef="usd">3303000</us-gaap:FiniteLivedIntangibleAssetsGross>
	<us-gaap:FiniteLivedIntangibleAssetsGross contextRef="FI2019Q3_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DistributionRightsMember" decimals="-3" id="Fact-5070FD5E419134C186F9453702EF8AE4" unitRef="usd">59076000</us-gaap:FiniteLivedIntangibleAssetsGross>
	<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="FI2019Q3" decimals="-3" id="Fact-D21C730D2A779F6038AE45370333A901" unitRef="usd">59857000</us-gaap:FiniteLivedIntangibleAssetsNet>
	<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="FI2019Q3_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_ComputerSoftwareIntangibleAssetMember" decimals="-3" id="Fact-3043D195B7434BE1AB88453702EFF281" unitRef="usd">2721000</us-gaap:FiniteLivedIntangibleAssetsNet>
	<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="FI2019Q3_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DistributionRightsMember" decimals="-3" id="Fact-1456FE2E08F9217C9675453702EFECA2" unitRef="usd">57136000</us-gaap:FiniteLivedIntangibleAssetsNet>
	<us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1 contextRef="FD2019Q3YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_ComputerSoftwareIntangibleAssetMember" id="Fact-A389270CEF2946D6EE7D453702EF748C">P2Y</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
	<us-gaap:Goodwill contextRef="FI2018Q4" decimals="-3" id="Fact-2FB28AC18547B5F985864537031DDA38" unitRef="usd">21208000</us-gaap:Goodwill>
	<us-gaap:Goodwill contextRef="FI2019Q3" decimals="-3" id="Fact-7E3DBA570FFE35A85A744537031D955D" unitRef="usd">21208000</us-gaap:Goodwill>
	<us-gaap:GoodwillAcquiredDuringPeriod contextRef="FD2013Q4YTD_dei_LegalEntityAxis_eols_SCHAEONLLCMember_us-gaap_BusinessAcquisitionAxis_eols_EvolusIncMember" decimals="-3" id="Fact-2E636B081342FD79EE47453702EF94D0" unitRef="usd">21208000</us-gaap:GoodwillAcquiredDuringPeriod>
	<us-gaap:GoodwillImpairmentLoss contextRef="FD2019Q3YTD" decimals="INF" id="Fact-90F0D899A77B95ED05F84537030E37BC" unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
	<us-gaap:GrossProfit contextRef="FD2018Q3QTD" decimals="-3" id="Fact-EB49C61C3F97EB15DBA145370343E436" unitRef="usd">0</us-gaap:GrossProfit>
	<us-gaap:GrossProfit contextRef="FD2018Q3YTD" decimals="-3" id="Fact-8198D0473FEB61D076784537032D3F06" unitRef="usd">0</us-gaap:GrossProfit>
	<us-gaap:GrossProfit contextRef="FD2019Q3QTD" decimals="-3" id="Fact-E44C277102B26058DF5C4537031DFF78" unitRef="usd">9449000</us-gaap:GrossProfit>
	<us-gaap:GrossProfit contextRef="FD2019Q3YTD" decimals="-3" id="Fact-D9EAC6B9FF93DC106EB045370333BBDC" unitRef="usd">11100000</us-gaap:GrossProfit>
	<us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill contextRef="FD2019Q3YTD" decimals="-3" id="Fact-54D17D99E5232E51E41F453703339E99" unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="FD2018Q3QTD" decimals="-3" id="Fact-3DFD6F3536C2924546864537032D0CAD" unitRef="usd">-11811000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="FD2018Q3YTD" decimals="-3" id="Fact-6AB8319A1E641BF1FE9B4537032D5B0F" unitRef="usd">-34384000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="FD2019Q3QTD" decimals="-3" id="Fact-0B76D86367A3367AA45C4537032DE105" unitRef="usd">-27133000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="FD2019Q3YTD" decimals="-3" id="Fact-54ACCCE0A3AB2197F6FE453702FE1E74" unitRef="usd">-90425000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2018Q3QTD" decimals="-3" id="Fact-A36BEF4836E75AFA5B3E45370333A057" unitRef="usd">19000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2018Q3YTD" decimals="-3" id="Fact-0EE9D3736663716F5B7C4537031DF7BB" unitRef="usd">41000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2019Q3QTD" decimals="-3" id="Fact-52C24853FD6F58B01CDF4537030E5BE0" unitRef="usd">-149000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2019Q3YTD" decimals="-3" id="Fact-B9E161928F75D0BB699E453702FE7A0C" unitRef="usd">-14899000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncreaseDecreaseInAccountsPayable contextRef="FD2018Q3YTD" decimals="-3" id="Fact-3C37B0EC65743FB902CD45370333B233" unitRef="usd">378000</us-gaap:IncreaseDecreaseInAccountsPayable>
	<us-gaap:IncreaseDecreaseInAccountsPayable contextRef="FD2019Q3YTD" decimals="-3" id="Fact-114C036665A25337F71445370343C653" unitRef="usd">736000</us-gaap:IncreaseDecreaseInAccountsPayable>
	<us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="FD2018Q3YTD" decimals="-3" id="Fact-330A73BCCD77BEC4C90445370333A841" unitRef="usd">0</us-gaap:IncreaseDecreaseInAccountsReceivable>
	<us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="FD2019Q3YTD" decimals="-3" id="Fact-E425E73D2BB4BDCEC45D453702FEB8D9" unitRef="usd">7206000</us-gaap:IncreaseDecreaseInAccountsReceivable>
	<us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="FD2018Q3YTD" decimals="-3" id="Fact-0503A5CD45094D96FF044537031D7F9E" unitRef="usd">3825000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
	<us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="FD2019Q3YTD" decimals="-3" id="Fact-9190BB8E1C6CEAB9C65745370333C10B" unitRef="usd">2000000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
	<us-gaap:IncreaseDecreaseInDeferredLiabilities contextRef="FD2018Q3YTD" decimals="-3" id="Fact-A0393ACA924208DCBB9F4537031D8E3D" unitRef="usd">-8000</us-gaap:IncreaseDecreaseInDeferredLiabilities>
	<us-gaap:IncreaseDecreaseInDeferredLiabilities contextRef="FD2019Q3YTD" decimals="-3" id="Fact-89DFDB8CE89C0997FFAC453702EFE5F2" unitRef="usd">0</us-gaap:IncreaseDecreaseInDeferredLiabilities>
	<us-gaap:IncreaseDecreaseInInventories contextRef="FD2018Q3YTD" decimals="-3" id="Fact-F1BA6568BDA13A9CCF6445370333FC53" unitRef="usd">0</us-gaap:IncreaseDecreaseInInventories>
	<us-gaap:IncreaseDecreaseInInventories contextRef="FD2019Q3YTD" decimals="-3" id="Fact-ACFADD879ED8E432D34E45370333A48F" unitRef="usd">6225000</us-gaap:IncreaseDecreaseInInventories>
	<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="FD2018Q3YTD" decimals="-3" id="Fact-C85CA7A3F0105849FB3C45370333F49C" unitRef="usd">739000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
	<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="FD2019Q3YTD" decimals="-3" id="Fact-1FBA5141ECA64201B48645370333FE94" unitRef="usd">1406000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
	<us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="FI2018Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" decimals="-3" id="Fact-5F5E717C392AFF356EF84537031DC099" unitRef="usd">56076000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
	<us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="FI2018Q4" decimals="-3" id="Fact-BE3F9FC1EF99B731E7974537030ED2EE" unitRef="usd">56076000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
	<us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="FI2019Q3" decimals="-3" id="Fact-5D0AE68BCCF5760351E44537032D2A80" unitRef="usd">59857000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
	<us-gaap:IntangibleAssetsNetIncludingGoodwill contextRef="FI2018Q4" decimals="-3" id="Fact-13DC93981DF18E3636E345370333B1B8" unitRef="usd">77284000</us-gaap:IntangibleAssetsNetIncludingGoodwill>
	<us-gaap:IntangibleAssetsNetIncludingGoodwill contextRef="FI2019Q3" decimals="-3" id="Fact-624606E4896F091F8638453702FEE3CC" unitRef="usd">81065000</us-gaap:IntangibleAssetsNetIncludingGoodwill>
	<us-gaap:InterestPaidNet contextRef="FD2018Q3YTD" decimals="-3" id="Fact-05A941F6B63E54F09D2745370333EAD8" unitRef="usd">0</us-gaap:InterestPaidNet>
	<us-gaap:InterestPaidNet contextRef="FD2019Q3YTD" decimals="-3" id="Fact-E1A5249412C7F7708F0145370333D9CA" unitRef="usd">3365000</us-gaap:InterestPaidNet>
	<us-gaap:InventoryNet contextRef="FI2018Q4" decimals="-3" id="Fact-B0D4E823E5E703F8F07F4537031D5AF6" unitRef="usd">0</us-gaap:InventoryNet>
	<us-gaap:InventoryNet contextRef="FI2019Q3" decimals="-3" id="Fact-73D0F6EDDCD6E6D5078C4537031D0237" unitRef="usd">10043000</us-gaap:InventoryNet>
	<us-gaap:InvestmentIncomeNet contextRef="FD2018Q3QTD" decimals="-3" id="Fact-269751591D491EE125814537032D183C" unitRef="usd">0</us-gaap:InvestmentIncomeNet>
	<us-gaap:InvestmentIncomeNet contextRef="FD2018Q3YTD" decimals="-3" id="Fact-FEF821E7788AFDD6600A45370333CB9F" unitRef="usd">0</us-gaap:InvestmentIncomeNet>
	<us-gaap:InvestmentIncomeNet contextRef="FD2019Q3QTD" decimals="-3" id="Fact-9443C51BF3A94C9DE67E453702FEEA18" unitRef="usd">460000</us-gaap:InvestmentIncomeNet>
	<us-gaap:InvestmentIncomeNet contextRef="FD2019Q3YTD" decimals="-3" id="Fact-B73BA875F05934E888FD4537031DC250" unitRef="usd">1464000</us-gaap:InvestmentIncomeNet>
	<us-gaap:LeaseCost contextRef="FD2019Q3QTD" decimals="-3" id="Fact-B3A1B1859A11F81FB4BF453703339DD1" unitRef="usd">352000</us-gaap:LeaseCost>
	<us-gaap:LeaseCost contextRef="FD2019Q3YTD" decimals="-3" id="Fact-0CC4260D79531E327DEE4537033384DB" unitRef="usd">963000</us-gaap:LeaseCost>
	<us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="FI2019Q3" decimals="-3" id="Fact-C366B02F72948E8098DD4537031DD9C9" unitRef="usd">6699000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
	<us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive contextRef="FI2019Q3" decimals="-3" id="Fact-C9F3B960F33E6688394B4537031DDF4D" unitRef="usd">1484000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
	<us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive contextRef="FI2019Q3" decimals="-3" id="Fact-71C1375943A22B8F45944537032D0F29" unitRef="usd">1312000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
	<us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour contextRef="FI2019Q3" decimals="-3" id="Fact-F42C4A582F3360D638CD4537031D7983" unitRef="usd">1258000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
	<us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="FI2019Q3" decimals="-3" id="Fact-12F8BA5233B4A8A94CAC4537032D9F9C" unitRef="usd">1205000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
	<us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="FI2019Q3" decimals="-3" id="Fact-492F50A3C18240E21A664537032D4B5C" unitRef="usd">1201000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
	<us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear contextRef="FI2019Q3" decimals="-3" id="Fact-04D06B612906DB0B3A614537031D5381" unitRef="usd">239000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
	<us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="FI2019Q3" decimals="-3" id="Fact-90F2A9FB49E231397DEC4537031DEF41" unitRef="usd">1484000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
	<us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="FI2019Q3" id="Fact-80DDED368386906A76524537032D7E72">P60M</us-gaap:LesseeOperatingLeaseRenewalTerm>
	<us-gaap:Liabilities contextRef="FI2018Q4" decimals="-3" id="Fact-E4B74EC8BD7CC7C856A34537031D3DBF" unitRef="usd">87460000</us-gaap:Liabilities>
	<us-gaap:Liabilities contextRef="FI2019Q3" decimals="-3" id="Fact-7A3351228B85F96B4FF94537030E862F" unitRef="usd">165623000</us-gaap:Liabilities>
	<us-gaap:LiabilitiesAndStockholdersEquity contextRef="FI2018Q4" decimals="-3" id="Fact-3A324CAFCFBC357FDC7E4537031D9E67" unitRef="usd">171844000</us-gaap:LiabilitiesAndStockholdersEquity>
	<us-gaap:LiabilitiesAndStockholdersEquity contextRef="FI2019Q3" decimals="-3" id="Fact-EA13F2D9D68D45FF77784537031D0074" unitRef="usd">182666000</us-gaap:LiabilitiesAndStockholdersEquity>
	<us-gaap:LiabilitiesCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-370DFD54F7F40ED3D27F4537032DF609" unitRef="usd">5276000</us-gaap:LiabilitiesCurrent>
	<us-gaap:LiabilitiesCurrent contextRef="FI2019Q3" decimals="-3" id="Fact-351118A8A4CA11A3F9E34537031D908F" unitRef="usd">25974000</us-gaap:LiabilitiesCurrent>
	<us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="FI2019Q3_us-gaap_DebtInstrumentAxis_eols_TermLoanFacilityMember" decimals="INF" id="Fact-9F2BF1FBF7552F004CFB4537030E683A" unitRef="usd">75000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
	<us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="I2019Q1_us-gaap_DebtInstrumentAxis_eols_TermLoanFacilityTrancheOneMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember" decimals="INF" id="Fact-2EDC4D76630576AC38274537031D076A" unitRef="usd">75000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
	<us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="I2019Q1_us-gaap_DebtInstrumentAxis_eols_TermLoanFacilityTrancheTwoMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember" decimals="INF" id="Fact-C412F50382CA0BBD20D54537031D0294" unitRef="usd">25000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
	<us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="I2019Q1_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember" decimals="INF" id="Fact-12953874239008645A394537031D727F" unitRef="usd">100000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
	<us-gaap:LongTermDebt contextRef="FI2019Q3" decimals="-3" id="Fact-4922B952E14ECEFA2CA1453702FE81FD" unitRef="usd">79125000</us-gaap:LongTermDebt>
	<us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive contextRef="FI2019Q3" decimals="-3" id="Fact-6A41662A55850EE3B19E453702FED5D7" unitRef="usd">13908000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive>
	<us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour contextRef="FI2019Q3" decimals="-3" id="Fact-21D56E72AC4A057E42EF4537033393A1" unitRef="usd">39130000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
	<us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree contextRef="FI2019Q3" decimals="-3" id="Fact-CD53A819B5C4DF44AE054537030E3A62" unitRef="usd">26087000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
	<us-gaap:LongTermDebtNoncurrent contextRef="FI2018Q4" decimals="-3" id="Fact-100E92F66F2D43BADB4A4537031DE526" unitRef="usd">0</us-gaap:LongTermDebtNoncurrent>
	<us-gaap:LongTermDebtNoncurrent contextRef="FI2019Q3" decimals="-3" id="Fact-745196EC93BF20AF26814537032D5B5F" unitRef="usd">73180000</us-gaap:LongTermDebtNoncurrent>
	<us-gaap:LongTermNotesPayable contextRef="FI2018Q4" decimals="-3" id="Fact-5DE82917D1B3259C14084537031D5A79" unitRef="usd">16904000</us-gaap:LongTermNotesPayable>
	<us-gaap:LongTermNotesPayable contextRef="FI2019Q3" decimals="-3" id="Fact-C0265D6E3EF2314863344537031DFF56" unitRef="usd">17674000</us-gaap:LongTermNotesPayable>
	<us-gaap:LongTermNotesPayable contextRef="I2018Q1Feb12" decimals="-3" id="Fact-104FCD70DC127E86BA9B4537030E851A" unitRef="usd">16042000</us-gaap:LongTermNotesPayable>
	<us-gaap:LossContingencyAccrualAtCarryingValue contextRef="FI2018Q4" decimals="INF" id="Fact-C08BBD73B844D250C33D453702FEBF2F" unitRef="usd">0</us-gaap:LossContingencyAccrualAtCarryingValue>
	<us-gaap:LossContingencyAccrualAtCarryingValue contextRef="FI2019Q3" decimals="INF" id="Fact-CCC669E42913937C457845370333CF09" unitRef="usd">0</us-gaap:LossContingencyAccrualAtCarryingValue>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="FD2018Q3YTD" decimals="-3" id="Fact-FB94EB6954C0E0625685453703336A99" unitRef="usd">118838000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="FD2019Q3YTD" decimals="-3" id="Fact-91D3DA7A0B64EE7F3ED9453702FE5549" unitRef="usd">60823000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="FD2018Q3YTD" decimals="-3" id="Fact-63EF913EA0498031CC56453703333E35" unitRef="usd">-9000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
	<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="FD2019Q3YTD" decimals="-3" id="Fact-F5F68EC42D4A24E8D6AD45370333610C" unitRef="usd">-37408000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="FD2018Q3YTD" decimals="-3" id="Fact-DF67ED16237BD2864BF44537033383F5" unitRef="usd">-13661000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="FD2019Q3YTD" decimals="-3" id="Fact-470E19FA4F9DBCC019844537030ECF57" unitRef="usd">-77461000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:NetIncomeLoss contextRef="FD2018Q1QTD" decimals="-3" id="Fact-A1CB887F2216354FC87F4537030EE058" unitRef="usd">-6162000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2018Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-5434A1651AF6A97E46B0453703437759" unitRef="usd">-6162000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2018Q2QTD" decimals="-3" id="Fact-392CCDF0D1F92754C910453702FEB9EC" unitRef="usd">-16433000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2018Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-DFF14A04A5289644A8E44537030ED3CB" unitRef="usd">-16433000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2018Q3QTD" decimals="-3" id="Fact-C21F7B37E966498DFAE24537030E5DFD" unitRef="usd">-11830000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-9B6C4E060C3D958484A8FEED66209100" unitRef="usd">-11830000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2018Q3YTD" decimals="-3" id="Fact-65CCAB685369B25C13B54537031D218F" unitRef="usd">-34425000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2019Q1QTD" decimals="-3" id="Fact-B051DA15CB42CCB9EACA4537031D0BFE" unitRef="usd">-10975000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2019Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-8FC2FC2F5863A3FA9D32453703439D1D" unitRef="usd">-10975000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2019Q2QTD" decimals="-3" id="Fact-B6D64759137A4A1F74B645370333D3D1" unitRef="usd">-37567000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-6DB812617F6D911B628C4537030E9BB7" unitRef="usd">-37567000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2019Q3QTD" decimals="-3" id="Fact-8AF2F9659FACAAA158FA4537031DEF7C" unitRef="usd">-26984000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-3D0C3B2778F6DFAD4F710EFC4579C4A0" unitRef="usd">-26984000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2019Q3YTD" decimals="-3" id="Fact-44E01C91D12CF00D73724537030E5545" unitRef="usd">-75526000</us-gaap:NetIncomeLoss>
	<us-gaap:NotesPayableFairValueDisclosure contextRef="FI2019Q3_us-gaap_DebtInstrumentAxis_eols_OxfordTermLoansMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember" decimals="-3" id="Fact-A802DBE14BDD4FEF5CFA4537031D210A" unitRef="usd">74947000</us-gaap:NotesPayableFairValueDisclosure>
	<us-gaap:NotesPayableFairValueDisclosure contextRef="FI2019Q3_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember" decimals="-3" id="Fact-9651BA7A7C2C1D430CDD453702FED34B" unitRef="usd">16072000</us-gaap:NotesPayableFairValueDisclosure>
	<us-gaap:NumberOfReportingUnits contextRef="FD2019Q3YTD" decimals="INF" id="Fact-366A8ED85039A1371F6D4537030E609C" unitRef="unit">1</us-gaap:NumberOfReportingUnits>
	<us-gaap:OperatingExpenses contextRef="FD2018Q3QTD" decimals="-3" id="Fact-C1A40F88A3E2E2819C5B4537031DCA25" unitRef="usd">11489000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingExpenses contextRef="FD2018Q3YTD" decimals="-3" id="Fact-06AF92458C7523809C65453703336345" unitRef="usd">33634000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingExpenses contextRef="FD2019Q3QTD" decimals="-3" id="Fact-9A042924ECDA67599DF34537030E8EAF" unitRef="usd">34587000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingExpenses contextRef="FD2019Q3YTD" decimals="-3" id="Fact-492130896F791DA6A5014537033349D3" unitRef="usd">97504000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingIncomeLoss contextRef="FD2018Q3QTD" decimals="-3" id="Fact-5C3519ECF006BD4474E04537030E0B07" unitRef="usd">-11489000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2018Q3YTD" decimals="-3" id="Fact-C86D90BEE0BE97E324874537030E85D7" unitRef="usd">-33634000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2019Q3QTD" decimals="-3" id="Fact-5255CBB7C7CC6E2DFD4745370333B661" unitRef="usd">-25138000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2019Q3YTD" decimals="-3" id="Fact-60745050938ABB1A7FD24537031D3EDC" unitRef="usd">-86404000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingLeaseCost contextRef="FD2019Q3QTD" decimals="-3" id="Fact-AB442C6D179D33934FEE4537032DC6E1" unitRef="usd">297000</us-gaap:OperatingLeaseCost>
	<us-gaap:OperatingLeaseCost contextRef="FD2019Q3YTD" decimals="-3" id="Fact-3C8022DB872F38E04E584537031DD9D7" unitRef="usd">798000</us-gaap:OperatingLeaseCost>
	<us-gaap:OperatingLeaseImpairmentLoss contextRef="FD2019Q3YTD" decimals="-3" id="Fact-FAE758C2F92C3B7463BA45370333445B" unitRef="usd">80000</us-gaap:OperatingLeaseImpairmentLoss>
	<us-gaap:OperatingLeaseLiability contextRef="FI2019Q3" decimals="-3" id="Fact-C44C90DD1AD7F9802B044537031D4635" unitRef="usd">5215000</us-gaap:OperatingLeaseLiability>
	<us-gaap:OperatingLeaseLiabilityCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-25D579C5C16F572F11784537031D4DD5" unitRef="usd">0</us-gaap:OperatingLeaseLiabilityCurrent>
	<us-gaap:OperatingLeaseLiabilityCurrent contextRef="FI2019Q3" decimals="-3" id="Fact-1BAE6E40677563F443D64537031DC2D7" unitRef="usd">1148000</us-gaap:OperatingLeaseLiabilityCurrent>
	<us-gaap:OperatingLeaseLiabilityCurrent contextRef="I2019Q1Jan01" decimals="-3" id="Fact-41040D71785585E7FCAE45370343DADD" unitRef="usd">916000</us-gaap:OperatingLeaseLiabilityCurrent>
	<us-gaap:OperatingLeaseLiabilityCurrent contextRef="I2019Q1Jan01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member" decimals="-3" id="Fact-2CAFB4767C5736DEAA504537032DFBA7" unitRef="usd">916000</us-gaap:OperatingLeaseLiabilityCurrent>
	<us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="FI2018Q4" decimals="-3" id="Fact-DC321EAAE51CBF81E13B453703339919" unitRef="usd">0</us-gaap:OperatingLeaseLiabilityNoncurrent>
	<us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="FI2019Q3" decimals="-3" id="Fact-46138D7D9C59ED4A5EA34537031DCBDE" unitRef="usd">4067000</us-gaap:OperatingLeaseLiabilityNoncurrent>
	<us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="I2019Q1Jan01" decimals="-3" id="Fact-F9FDF2008CC0F49ED51E453703335082" unitRef="usd">138000</us-gaap:OperatingLeaseLiabilityNoncurrent>
	<us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="I2019Q1Jan01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member" decimals="-3" id="Fact-83E0E64ADC4C9BFB6B4745370333A065" unitRef="usd">138000</us-gaap:OperatingLeaseLiabilityNoncurrent>
	<us-gaap:OperatingLeasePayments contextRef="FD2018Q3YTD" decimals="-3" id="Fact-6CEE4C721772428A7A6B45370333779A" unitRef="usd">0</us-gaap:OperatingLeasePayments>
	<us-gaap:OperatingLeasePayments contextRef="FD2019Q3YTD" decimals="-3" id="Fact-BD869661FCE3574E90E045370333C77A" unitRef="usd">716000</us-gaap:OperatingLeasePayments>
	<us-gaap:OperatingLeaseRightOfUseAsset contextRef="FI2018Q4" decimals="-3" id="Fact-29931E788E7DD4688529453703338AC6" unitRef="usd">0</us-gaap:OperatingLeaseRightOfUseAsset>
	<us-gaap:OperatingLeaseRightOfUseAsset contextRef="FI2019Q3" decimals="-3" id="Fact-9CAFA122E3A2AA83B69B4537031DBB3F" unitRef="usd">4238000</us-gaap:OperatingLeaseRightOfUseAsset>
	<us-gaap:OperatingLeaseRightOfUseAsset contextRef="I2019Q1Jan01" decimals="-3" id="Fact-F0AD65577A7082E418F3453702EF5FF6" unitRef="usd">1029000</us-gaap:OperatingLeaseRightOfUseAsset>
	<us-gaap:OperatingLeaseRightOfUseAsset contextRef="I2019Q1Jan01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member" decimals="-3" id="Fact-A462C6D0C1F349F88CDE4537033388F0" unitRef="usd">1029000</us-gaap:OperatingLeaseRightOfUseAsset>
	<us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="FI2019Q3" decimals="3" id="Fact-7319FECD9BE9B0F8F21CFF42967512F4" unitRef="number">0.094</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
	<us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="FI2019Q3" id="Fact-C3BC77A46E06C59CA70EFF427F0A28BC">P5Y88D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDue contextRef="FI2018Q4" decimals="-3" id="Fact-0634BAD1F62B1521B87AFF481ABBCB46" unitRef="usd">1029000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears contextRef="FI2018Q4" decimals="-3" id="Fact-D2C3CCE0FF3624CE6A04FF47EB122A2F" unitRef="usd">0</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears contextRef="FI2018Q4" decimals="-3" id="Fact-A074DD7FBF6A15AA011BFF47BB4EED48" unitRef="usd">139000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear contextRef="FI2018Q4" decimals="-3" id="Fact-753B276697A003A5A48DFF477ABD604D" unitRef="usd">890000</us-gaap:OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear>
	<us-gaap:OtherAccruedLiabilitiesCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-AB1DBD61FD5847BB5D7D4537032D0F02" unitRef="usd">210000</us-gaap:OtherAccruedLiabilitiesCurrent>
	<us-gaap:OtherAccruedLiabilitiesCurrent contextRef="FI2019Q3" decimals="-3" id="Fact-E0A74F4C655663D50525453702EF65ED" unitRef="usd">1505000</us-gaap:OtherAccruedLiabilitiesCurrent>
	<us-gaap:OtherAssetsNoncurrent contextRef="FI2018Q4" decimals="-3" id="Fact-6DBAEC7A20FD8104BD054537031D873E" unitRef="usd">221000</us-gaap:OtherAssetsNoncurrent>
	<us-gaap:OtherAssetsNoncurrent contextRef="FI2019Q3" decimals="-3" id="Fact-E394A32F83B11490EB924537031D337F" unitRef="usd">1195000</us-gaap:OtherAssetsNoncurrent>
	<us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="FD2019Q2QTD" decimals="-3" id="Fact-38FB6A809CBDA240A385453702FEB97C" unitRef="usd">52000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="FD2019Q2QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-1E669CAFC4EDB85B4DD94537030ECCBF" unitRef="usd">52000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="FD2019Q3QTD" decimals="-3" id="Fact-F58DCA0895883F098326FEF2230508EA" unitRef="usd">-24000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-4524C449ED00154F025DFEF2208A813D" unitRef="usd">-24000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
	<us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="FD2018Q3QTD" decimals="-3" id="Fact-D3522DB9A507B88C03124537032DAEFE" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
	<us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="FD2018Q3YTD" decimals="-3" id="Fact-F3F1F9E7A472BAC2E96A453702FEA350" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
	<us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="FD2019Q3QTD" decimals="-3" id="Fact-0B8074881649AB58E14A4537033325D1" unitRef="usd">-24000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
	<us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="FD2019Q3YTD" decimals="-3" id="Fact-FE06033B8D2843C2F037453703335200" unitRef="usd">19000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2018Q3QTD" decimals="-3" id="Fact-398BE2994D6B209D15DB4537032DC62B" unitRef="usd">-322000</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2018Q3YTD" decimals="-3" id="Fact-8DED8C28F59175992FAF45370343FD61" unitRef="usd">-750000</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2019Q3QTD" decimals="-3" id="Fact-2404F20A609AAFC209E7453702FE1C57" unitRef="usd">-2455000</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2019Q3YTD" decimals="-3" id="Fact-47C33990A85819523596453703339465" unitRef="usd">-5485000</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:PaymentsForSoftware contextRef="FD2018Q3YTD" decimals="-3" id="Fact-78A0DDA323628EB6C8EE453702FE5C05" unitRef="usd">0</us-gaap:PaymentsForSoftware>
	<us-gaap:PaymentsForSoftware contextRef="FD2019Q3YTD" decimals="-3" id="Fact-92D2F51F9202C396A505453702FE5212" unitRef="usd">3080000</us-gaap:PaymentsForSoftware>
	<us-gaap:PaymentsOfDebtIssuanceCosts contextRef="FD2018Q3YTD" decimals="-3" id="Fact-F614BF40D977A4F3DFC045370333A9D6" unitRef="usd">0</us-gaap:PaymentsOfDebtIssuanceCosts>
	<us-gaap:PaymentsOfDebtIssuanceCosts contextRef="FD2019Q3YTD" decimals="-3" id="Fact-7BBE7187810FBB7324174537031DD9D6" unitRef="usd">2205000</us-gaap:PaymentsOfDebtIssuanceCosts>
	<us-gaap:PaymentsOfStockIssuanceCosts contextRef="FD2018Q3YTD" decimals="-3" id="Fact-DEF70C0B20A1DBB6EAB345370343D76B" unitRef="usd">1060000</us-gaap:PaymentsOfStockIssuanceCosts>
	<us-gaap:PaymentsOfStockIssuanceCosts contextRef="FD2019Q3YTD" decimals="-3" id="Fact-4DC62FA2B18006F557EE4537034377A0" unitRef="usd">0</us-gaap:PaymentsOfStockIssuanceCosts>
	<us-gaap:PaymentsToAcquireInvestments contextRef="FD2018Q3YTD" decimals="-3" id="Fact-C59143CBAAB7E906F039453703336151" unitRef="usd">0</us-gaap:PaymentsToAcquireInvestments>
	<us-gaap:PaymentsToAcquireInvestments contextRef="FD2019Q3YTD" decimals="-3" id="Fact-F261D4373326191AAB5D453702EFFBDE" unitRef="usd">98982000</us-gaap:PaymentsToAcquireInvestments>
	<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="FD2018Q3YTD" decimals="-3" id="Fact-1EA6FFC0117458D1B6FC45370333B215" unitRef="usd">9000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
	<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="FD2019Q3YTD" decimals="-3" id="Fact-786DBB85DD200872C62B453703330BF0" unitRef="usd">346000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
	<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="FI2018Q4" decimals="INF" id="Fact-62470FB88B286BDE632C453702FE5B78" unitRef="usdPerShare">0.00001</us-gaap:PreferredStockParOrStatedValuePerShare>
	<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="FI2019Q3" decimals="INF" id="Fact-AA872B323C3408941FF64537031DC642" unitRef="usdPerShare">0.00001</us-gaap:PreferredStockParOrStatedValuePerShare>
	<us-gaap:PreferredStockSharesAuthorized contextRef="FI2018Q4" decimals="INF" id="Fact-C5747496F0480C4BAE184537031DAA37" unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
	<us-gaap:PreferredStockSharesAuthorized contextRef="FI2019Q3" decimals="INF" id="Fact-A8C3D36EB7D6E9C5DDAB4537031DB516" unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
	<us-gaap:PreferredStockSharesIssued contextRef="FI2018Q4" decimals="INF" id="Fact-52EE79D035E436C6B00E4537030EE230" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
	<us-gaap:PreferredStockSharesIssued contextRef="FI2019Q3" decimals="INF" id="Fact-64A927C6C8075D6BA7EE453702FEF1EE" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
	<us-gaap:PreferredStockSharesOutstanding contextRef="FI2018Q4" decimals="INF" id="Fact-E0C9E899E3623D378E5B4537030E2330" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
	<us-gaap:PreferredStockSharesOutstanding contextRef="FI2019Q3" decimals="INF" id="Fact-7BFBA1301052C61822A0453702FE9844" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
	<us-gaap:PreferredStockValue contextRef="FI2018Q4" decimals="-3" id="Fact-D5E71182FF46763863EA4537030E5346" unitRef="usd">0</us-gaap:PreferredStockValue>
	<us-gaap:PreferredStockValue contextRef="FI2019Q3" decimals="-3" id="Fact-A78D577D62120054CD804537032D9CA6" unitRef="usd">0</us-gaap:PreferredStockValue>
	<us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-18A255C10F19D572CA314537031D13D0" unitRef="usd">1177000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
	<us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="FI2019Q3" decimals="-3" id="Fact-E348F2D95E48BCA55F884537031D691F" unitRef="usd">3906000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
	<us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="FD2018Q3YTD" decimals="-3" id="Fact-5F74108128BFCF4A919A453703338193" unitRef="usd">67680000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
	<us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="FD2019Q3YTD" decimals="-5" id="Fact-826B49648DEB7D06973D4537031DF5BC" unitRef="usd">0</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
	<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="FD2018Q3YTD" decimals="-3" id="Fact-C51D029B8DC7C0F5B8D2453702FE9F25" unitRef="usd">56330000</us-gaap:ProceedsFromIssuanceOfCommonStock>
	<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="FD2019Q3YTD" decimals="-3" id="Fact-6ABE8FAB318E9844033D453702FE8A17" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
	<us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="FD2018Q3YTD" decimals="-3" id="Fact-6FA80690919122CDF079453702FEC34E" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
	<us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="FD2019Q3YTD" decimals="-3" id="Fact-E826BB14CD270047BE914537030E6B3E" unitRef="usd">73906000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
	<us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments contextRef="FD2018Q3YTD" decimals="-3" id="Fact-8F4ADB1AEDA240CDF6ED45370343A1CA" unitRef="usd">0</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments>
	<us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments contextRef="FD2019Q3YTD" decimals="-3" id="Fact-E7CB80CECB2252AC473445370333E429" unitRef="usd">65000000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments>
	<us-gaap:ProceedsFromRelatedPartyDebt contextRef="FD2018Q3YTD" decimals="-3" id="Fact-53AC70FE0DD0A9BC64CA453702FE2F49" unitRef="usd">1127000</us-gaap:ProceedsFromRelatedPartyDebt>
	<us-gaap:ProceedsFromRelatedPartyDebt contextRef="FD2019Q3YTD" decimals="-3" id="Fact-E6E8492974B6A21358D6453702FE3572" unitRef="usd">0</us-gaap:ProceedsFromRelatedPartyDebt>
	<us-gaap:PropertyPlantAndEquipmentNet contextRef="FI2018Q4" decimals="-3" id="Fact-65FEAAF6CEFC312272244537032D0C3D" unitRef="usd">0</us-gaap:PropertyPlantAndEquipmentNet>
	<us-gaap:PropertyPlantAndEquipmentNet contextRef="FI2019Q3" decimals="-3" id="Fact-7F2D51A842099C4055174537031D2C53" unitRef="usd">984000</us-gaap:PropertyPlantAndEquipmentNet>
	<us-gaap:PurchaseObligation contextRef="FI2019Q3" decimals="-3" id="Fact-BC9EF77CDD663B6A20044537031D0677" unitRef="usd">6651000</us-gaap:PurchaseObligation>
	<us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="D2017Q4Dec14_dei_LegalEntityAxis_eols_SCHAEONLLCMember_us-gaap_BusinessAcquisitionAxis_eols_EvolusIncMember" decimals="-3" id="Fact-508A672F2F440BD19D4D4537030E012E" unitRef="usd">20000000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
	<us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="D2018Q1Feb12_dei_LegalEntityAxis_eols_SCHAEONLLCMember_us-gaap_BusinessAcquisitionAxis_eols_EvolusIncMember" decimals="-3" id="Fact-B0A234CEEA3D2A6CC4F94537030E388D" unitRef="usd">55742000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
	<us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="FD2018Q3QTD_dei_LegalEntityAxis_eols_ALPHAEONMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" decimals="-3" id="Fact-40A722728E704246FE174537030E1DD5" unitRef="usd">0</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
	<us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="FD2018Q3YTD_dei_LegalEntityAxis_eols_ALPHAEONMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" decimals="-3" id="Fact-C90A9B5DE5EEC14F3ECD4537030EB951" unitRef="usd">383000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
	<us-gaap:RepaymentsOfLongTermDebt contextRef="FD2018Q3YTD" decimals="-3" id="Fact-88C44CD30B69EDDBBE0BFF19804D772A" unitRef="usd">0</us-gaap:RepaymentsOfLongTermDebt>
	<us-gaap:RepaymentsOfLongTermDebt contextRef="FD2019Q3YTD" decimals="-3" id="Fact-13D2D846E4D674C29A2AFF198082C9AD" unitRef="usd">705000</us-gaap:RepaymentsOfLongTermDebt>
	<us-gaap:RepaymentsOfRelatedPartyDebt contextRef="FD2018Q3YTD" decimals="-3" id="Fact-DD198789BB8FB5691C9045370333C033" unitRef="usd">5000000</us-gaap:RepaymentsOfRelatedPartyDebt>
	<us-gaap:RepaymentsOfRelatedPartyDebt contextRef="FD2019Q3YTD" decimals="-3" id="Fact-566FEDB79CCB1D76D99645370343173C" unitRef="usd">0</us-gaap:RepaymentsOfRelatedPartyDebt>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2018Q3QTD" decimals="-3" id="Fact-B90326C9D21DA9CBC3A445370343104C" unitRef="usd">1977000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2018Q3YTD" decimals="-3" id="Fact-9FD69E011E14CCF05B23453703439E64" unitRef="usd">5303000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2019Q3QTD" decimals="-3" id="Fact-C190AF689A245E51A1824537030E5916" unitRef="usd">693000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2019Q3YTD" decimals="-3" id="Fact-3884CF7CF1943F5D0208453702FE936F" unitRef="usd">3555000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="FI2018Q4" decimals="-3" id="Fact-5A5FEFD7747FC81E9E264537030E39BC" unitRef="usd">-123025000</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="FI2019Q3" decimals="-3" id="Fact-816CE6E08FFAE8DC26034537031DB684" unitRef="usd">-198551000</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="FD2018Q3QTD" decimals="-3" id="Fact-940601F9147FB687E52B4537030EC8DA" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="FD2018Q3YTD" decimals="-3" id="Fact-FE19F759390391879EE245370333927F" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="FD2019Q3QTD" decimals="-3" id="Fact-C9C88B971BBFF1BBE39E453703438722" unitRef="usd">13167000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="FD2019Q3YTD" decimals="-3" id="Fact-34570F2ABCD8A40FAA0A453702EFC8B3" unitRef="usd">15478000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="FD2018Q3YTD" decimals="-3" id="Fact-596535DA15AA57CE293445370333E353" unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
	<us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="FD2019Q3YTD" decimals="-3" id="Fact-23660FE95B40933A835245370333A029" unitRef="usd">5565000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
	<us-gaap:SellingGeneralAndAdministrativeExpense contextRef="FD2018Q3QTD" decimals="-3" id="Fact-3EDD2281B527DEC6D45F4537031D57DF" unitRef="usd">7209000</us-gaap:SellingGeneralAndAdministrativeExpense>
	<us-gaap:SellingGeneralAndAdministrativeExpense contextRef="FD2018Q3YTD" decimals="-3" id="Fact-3F4C7DC5403581A855244537033384AE" unitRef="usd">16924000</us-gaap:SellingGeneralAndAdministrativeExpense>
	<us-gaap:SellingGeneralAndAdministrativeExpense contextRef="FD2019Q3QTD" decimals="-3" id="Fact-0BBA8C57C87CF41A5E564537031DAA8D" unitRef="usd">30897000</us-gaap:SellingGeneralAndAdministrativeExpense>
	<us-gaap:SellingGeneralAndAdministrativeExpense contextRef="FD2019Q3YTD" decimals="-3" id="Fact-27202B1D737363B5D1EE4537031D473F" unitRef="usd">83308000</us-gaap:SellingGeneralAndAdministrativeExpense>
	<us-gaap:ShareBasedCompensation contextRef="FD2018Q3YTD" decimals="-3" id="Fact-5DD494945BC7F1582F6D4537034371E1" unitRef="usd">5111000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensation contextRef="FD2019Q3YTD" decimals="-3" id="Fact-8193434CA135DC6BBE26453703339E80" unitRef="usd">6981000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="FD2019Q3YTD_srt_RangeAxis_srt_MaximumMember" id="Fact-5126AC69251E7314FEC34537031D7FFE">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="FD2019Q3YTD_srt_RangeAxis_srt_MinimumMember" id="Fact-DDCD63F4A3170040E672453702EF31AE">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod contextRef="FD2019Q3YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="INF" id="Fact-B8FC3CCE171BFC830351453702EFB500" unitRef="shares">19409</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue contextRef="FD2019Q3YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="2" id="Fact-E3FC84C8EB0BFAAF46E8453702EFA78E" unitRef="usdPerShare">13.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="FD2019Q3YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="INF" id="Fact-70D67DA3B277DA2AF21C453702EFE13A" unitRef="shares">3000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="FD2019Q3YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="2" id="Fact-59F17330B6C4A7BFA5E0453702FECE0B" unitRef="usdPerShare">18.33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="INF" id="Fact-2601488A47FF4B9AE3E3453702FEF48C" unitRef="shares">271404</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="FI2019Q3_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="INF" id="Fact-4F5C1ABDB4D614B2A20F453702FEB1DF" unitRef="shares">232870</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="2" id="Fact-B4145CD407DC7B268236453702EF7943" unitRef="usdPerShare">16.53</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="FI2019Q3_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="2" id="Fact-7DF71A32FA2EA64B5155453702EF531E" unitRef="usdPerShare">15.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="FD2019Q3YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="INF" id="Fact-43C174A8A2EDA1065074453702FE9AD4" unitRef="shares">22125</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue contextRef="FD2019Q3YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="2" id="Fact-5D4226AC8ABCD80EA6BE453702FE14F7" unitRef="usdPerShare">25.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="FD2018Q3QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact-F005516F58C072029D89453702EFFFD2" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="FD2018Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact-F2C71647153B565CEC6E453702EF74FE" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="FD2019Q3QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact-02492D235A68FE6EAD73453702FE7F9F" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="FD2019Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact-2354A7B821198DA4AA05453702FE0F0E" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="FD2018Q3QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="3" id="Fact-5E8BE56BC5E685BB24ED453702FE91E4" unitRef="number">0.590</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="FD2018Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="3" id="Fact-0032129510005B8147D54537032D1AD3" unitRef="number">0.577</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="FD2019Q3QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="3" id="Fact-115D0037E457E8CFF1BF453702EF39B6" unitRef="number">0.595</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="FD2019Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="3" id="Fact-8B1A38EF5E6066BA051E453702FEFD8D" unitRef="number">0.593</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="FD2018Q3QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="4" id="Fact-F46C5EB18E54F1EFA055453702FE0E81" unitRef="number">0.0287</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="FD2018Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="4" id="Fact-5E982BF5F12354FCB0A44537032D5B91" unitRef="number">0.0264</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="FD2019Q3QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="4" id="Fact-4C8B61C34C73CE27F52A453702FE0BA7" unitRef="number">0.0175</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="FD2019Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="4" id="Fact-65F365C7FD705D98D961453702EF162B" unitRef="number">0.0249</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="I2017Q4Nov21" decimals="INF" id="Fact-C07E1A39939EADE52E3B453702FE83C5" unitRef="shares">4361291</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="FI2019Q3_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact-E003AEA4381700AAA0514537030ECA04" unitRef="shares">833730</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="FI2019Q3_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-3B4AC316C8BDD2A6429B4537030E12DC" unitRef="usdPerShare">11.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="FD2019Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" id="Fact-E0EEBFB83070D69FA6DA453702FE9229" unitRef="usd" xsi:nil="true" />
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="FD2019Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact-A4E44866A1D5546C600D4537030E13F1" unitRef="shares">269772</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="FD2019Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact-E3694FB7D86FFC5601344537030EBF69" unitRef="shares">1202981</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="-3" id="Fact-DBAAD4029619AE8EBAFA453702FEC2CB" unitRef="usd">7119000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="FI2019Q3_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="-3" id="Fact-5F92924CE28827387BF54537030E0852" unitRef="usd">14830000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact-E4F70A48F8DF053969184537030E8CFF" unitRef="shares">3257801</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="FI2019Q3_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact-D9DEF0AEDBEE729240494537030E7100" unitRef="shares">4052161</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-891B380465AF79BD683E453702FE1604" unitRef="usdPerShare">11.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="FI2019Q3_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-4AA81CED3DEB8E53F29C453702FE59AD" unitRef="usdPerShare">14.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum contextRef="D2017Q4Nov21" decimals="INF" id="Fact-9F66DEE7922E74B669BB453702FE3E68" unitRef="number">0.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="FD2019Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-7AE05FBC358BA5FF63AF4537030EC4DD" unitRef="usdPerShare">9.98</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="FD2019Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-2B68982E0D1DD7D761FE4537030E259B" unitRef="usdPerShare">14.07</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="FD2019Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-B465C0EEA0E7466E514F4537030ECF10" unitRef="usdPerShare">19.16</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="FD2018Q3QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" id="Fact-8E0BBFB17F35852B7008453702FE8AC4">P6Y90D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="FD2018Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" id="Fact-CD0637481D3E93CF1299453702FE5422">P6Y84D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="FD2019Q3QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" id="Fact-53D9192A01A2FE252943453702FEDD35">P5Y351D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="FD2019Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" id="Fact-9EFDB31C7ACC63E56A4A453702FE95BD">P6Y60D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="FI2019Q3_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="-3" id="Fact-E9A551A5C902DD1D5189453702FE4DCE" unitRef="usd">4301000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" id="Fact-51D82F3247BA59D610D24537030E7840">P9Y3M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="FD2019Q3YTD" id="Fact-565D8C89CC0E9EDF4888453702FE105C">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="FD2019Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" id="Fact-0BB91CAC6440DAAA334F4537030E1D77">P8Y6M10D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
	<us-gaap:SharesIssued contextRef="FI2017Q4_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="INF" id="Fact-09B4106B57355DC66D4A4537031D54FA" unitRef="shares">1250000</us-gaap:SharesIssued>
	<us-gaap:SharesIssued contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-27333DA06080239CA3334537033310F7" unitRef="shares">16527000</us-gaap:SharesIssued>
	<us-gaap:SharesIssued contextRef="FI2018Q1_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="INF" id="Fact-A958D47DDC073FEAC521453702FE4818" unitRef="shares">0</us-gaap:SharesIssued>
	<us-gaap:SharesIssued contextRef="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-85DF66B8E3910BEAAE6E453702FE6EE3" unitRef="shares">23640389</us-gaap:SharesIssued>
	<us-gaap:SharesIssued contextRef="FI2018Q2_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="INF" id="Fact-F8D46C501B161805BFDCFEECC2CE1440" unitRef="shares">0</us-gaap:SharesIssued>
	<us-gaap:SharesIssued contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-91F546790FE247850E77FEECC7306D79" unitRef="shares">23674991</us-gaap:SharesIssued>
	<us-gaap:SharesIssued contextRef="FI2018Q3_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="INF" id="Fact-1ABBC417EC56F2567DE14537033344AC" unitRef="shares">0</us-gaap:SharesIssued>
	<us-gaap:SharesIssued contextRef="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-DAEB86D82FE889F75350453702FE186F" unitRef="shares">27274991</us-gaap:SharesIssued>
	<us-gaap:SharesIssued contextRef="FI2018Q4_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="INF" id="Fact-3051EF4ECE0310A8FC25453702EFB3B2" unitRef="shares">0</us-gaap:SharesIssued>
	<us-gaap:SharesIssued contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-BF0059F4458187E8538A453702FECA70" unitRef="shares">27274991</us-gaap:SharesIssued>
	<us-gaap:SharesIssued contextRef="FI2019Q1_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="INF" id="Fact-8EB396542628EE5A03F5453702FEB056" unitRef="shares">0</us-gaap:SharesIssued>
	<us-gaap:SharesIssued contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-6AE88C7A3B099F8A894E453702FE0B32" unitRef="shares">27285363</us-gaap:SharesIssued>
	<us-gaap:SharesIssued contextRef="FI2019Q2_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="INF" id="Fact-B30799E5C1364DA5CD1BFEEFD687BC5B" unitRef="shares">0</us-gaap:SharesIssued>
	<us-gaap:SharesIssued contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-A2C13F5EB62E9D68D30EFEEFDAE3BCF5" unitRef="shares">27393004</us-gaap:SharesIssued>
	<us-gaap:SharesIssued contextRef="FI2019Q3_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="INF" id="Fact-7479FBB15B8ED3961D534537030EB13A" unitRef="shares">0</us-gaap:SharesIssued>
	<us-gaap:ShortTermLeaseCost contextRef="FD2019Q3QTD" decimals="-3" id="Fact-160054963A8DB98E8FB14537032D862A" unitRef="usd">24000</us-gaap:ShortTermLeaseCost>
	<us-gaap:ShortTermLeaseCost contextRef="FD2019Q3YTD" decimals="-3" id="Fact-514B5DC586C8AFFD1D734537032DFA0D" unitRef="usd">73000</us-gaap:ShortTermLeaseCost>
	<us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="FD2018Q1QTD_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="INF" id="Fact-85A9B36532C42584D5BA453702FED8F0" unitRef="shares">1250000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
	<us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="FD2018Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-60AF0A520EF0E9506F004537030E87F7" unitRef="shares">2065875</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="FD2018Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" decimals="INF" id="Fact-5071ABACD45E3B6FA24E453702EFBF08" unitRef="shares">5047514</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-48A0772066335CA7C95BFEED2AD35C78" unitRef="shares">3600000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="FD2019Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact-14E2E72EBBD0D4FEEED3453702EFE3BA" unitRef="shares">138849</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2018Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" decimals="-3" id="Fact-97CD39B1FA82EC452B034537030E15E7" unitRef="usd">53445000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2018Q1QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" decimals="-3" id="Fact-53491C70F7CC43A782BD453702FE6256" unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2018Q1QTD_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" decimals="-3" id="Fact-BDD1006E9D7785D2FDBA4537032DCFDD" unitRef="usd">53446000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2018Q3QTD" decimals="-3" id="Fact-8DF6E1F61966C63A306AFEED32BFBB40" unitRef="usd">67380000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2018Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-6CEE8324E2FF38A5EE0DFEED2F14828C" unitRef="usd">67380000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockholdersEquity contextRef="FI2017Q4" decimals="-3" id="Fact-AD099F0DF961EB4A596345370333B84C" unitRef="usd">-75543000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2017Q4_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="-3" id="Fact-FFE85C8B9CDD41AE0239453702FE34B6" unitRef="usd">0</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-03DABBEDBD8AA3739B90453702FE29E5" unitRef="usd">0</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-484984D7018F86AC8D3B453702FE5DBE" unitRef="usd">0</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-C4E08DBCD0C6B62DD09A4537033357C5" unitRef="usd">0</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-C948D2C8436EF810AE394537031D82F9" unitRef="usd">-75543000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2018Q1" decimals="-3" id="Fact-5B1567BB652FA60C84AA453702EF4EC9" unitRef="usd">51982000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2018Q1_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="-3" id="Fact-FCE26DF4DD70EE8C2E5C453703438F71" unitRef="usd">0</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-7403747CDAA6562BDBDB453702FE963A" unitRef="usd">0</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-E37195D31250BA95F2104537030EEBBC" unitRef="usd">134301000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-5896C77E0DFF1A102D07453702FEFC32" unitRef="usd">1000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2018Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-36B9F3A56667FB97953E4537030E3026" unitRef="usd">-82320000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2018Q2" decimals="-3" id="Fact-2F41C01081C94D95F23AFEECCEFEE5B8" unitRef="usd">37934000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2018Q2_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="-3" id="Fact-FD6665EDE0F9CC63493AFEECC53FF561" unitRef="usd">0</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-2F113748048A0C7669CBFEECCC1316B9" unitRef="usd">0</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-51B2AAC527529D073BB3FEECCA938E2B" unitRef="usd">136686000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-F35B0223444D7AA90BF0FEECC8F389D0" unitRef="usd">1000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2018Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-B2BD79CF76CA9C054357FEECCD847EFD" unitRef="usd">-98753000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2018Q3" decimals="-3" id="Fact-0BB00B1EA9D34EA793ED4537030E53EA" unitRef="usd">94966000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2018Q3_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="-3" id="Fact-C69BDBE3439CED92E690453702FEB484" unitRef="usd">0</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-82E13289D5CA7BEE5D134537030E3451" unitRef="usd">0</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-DA410F03E6FB10B84836453702FE654A" unitRef="usd">205548000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-E520064247F4B1F8225C4537031D5715" unitRef="usd">1000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2018Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-C8D5BC3BB9F843DAA80B4537030E58D6" unitRef="usd">-110583000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2018Q4" decimals="-3" id="Fact-DC6E9DAD73B284E7145D4537032D092B" unitRef="usd">84384000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2018Q4_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="-3" id="Fact-C7FDB8819C61A7FB2339453702EFB100" unitRef="usd">0</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-05738476A328278D50BB453702EFED67" unitRef="usd">0</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-0C7F3055FF7CE43E85FD453702EF7186" unitRef="usd">207408000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-DDF4FE0392FE4FCED2984537031D6EA9" unitRef="usd">1000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-E2D31BF0AFC892FE04DD453702FEF075" unitRef="usd">-123025000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2019Q1" decimals="-3" id="Fact-EB94728B8EA85E019069453702FE1218" unitRef="usd">75357000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2019Q1_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="-3" id="Fact-7846FB6EC2D4C573AF40453702EF6D83" unitRef="usd">0</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-0706611E340B021A7CEB4537031D5522" unitRef="usd">-9000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-3BB77E67BE91E08CD6714537030E0A09" unitRef="usd">209365000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-7D2703BFB39AAE89DE134537031D6B2A" unitRef="usd">1000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2019Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-17C88F020AD8E7260855453703334D8A" unitRef="usd">-134000000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2019Q2" decimals="-3" id="Fact-AC5B4887A5DBF2564EFFFEEFE2AF8EB9" unitRef="usd">41181000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2019Q2_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="-3" id="Fact-A1134100D28EFEFE40CDFEEFD8F2C4EB" unitRef="usd">0</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-4B61D733C684F97FEA6FFEEFDFC974D7" unitRef="usd">43000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-4C4D466A295A84187DFEFEEFDE565509" unitRef="usd">212704000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-53C0F7B9B4835CEE1F7EFEEFDCB4FADA" unitRef="usd">1000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-3BAF9A05B3C582218A01FEEFE143019D" unitRef="usd">-171567000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2019Q3" decimals="-3" id="Fact-C812192B9E13A1298B7F4537030EB168" unitRef="usd">17043000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2019Q3_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="-3" id="Fact-CA0FDF956B38655CF83D45370343A922" unitRef="usd">0</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-8D415044B26297A024814537032D3027" unitRef="usd">19000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-1483F46965C41C22E2544537030E9533" unitRef="usd">215574000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-56E912D75B34E2A79C424537032D2E0A" unitRef="usd">1000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-ED76AA671CB696172777453702EF96B3" unitRef="usd">-198551000</us-gaap:StockholdersEquity>
	<us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="D2019Q1Feb28" decimals="-3" id="Fact-65BA06AFC5D12DCFCA571E292FC6CCE8" unitRef="usd">-14402000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
	<us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="FD2018Q4YTD" decimals="-3" id="Fact-B85B8F651C6C05E4E5B14537031D6420" unitRef="usd">34500000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
	<us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="FD2019Q3QTD" decimals="-3" id="Fact-E925934E4FEA793C57DA1E236E6A13D0" unitRef="usd">-149000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
	<us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="FD2019Q3YTD" decimals="-3" id="Fact-C8EC7138687F310F8CB91E236E745878" unitRef="usd">-497000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
	<us-gaap:VariableLeaseCost contextRef="FD2019Q3QTD" decimals="-3" id="Fact-C7C6100E1650E83053C74537031D71D8" unitRef="usd">31000</us-gaap:VariableLeaseCost>
	<us-gaap:VariableLeaseCost contextRef="FD2019Q3YTD" decimals="-3" id="Fact-1B46F6885CC81299B913453702FE8372" unitRef="usd">92000</us-gaap:VariableLeaseCost>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="FD2018Q3QTD" decimals="0" id="Fact-A72DF1DF6BBEE67392A1453702FE024E" unitRef="shares">24768581</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="FD2018Q3YTD" decimals="0" id="Fact-3257D9E67355D714B1554537030E35C4" unitRef="shares">23417417</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="FD2019Q3QTD" decimals="0" id="Fact-11649C35E5AFAD31F41B4537031DB100" unitRef="shares">27470558</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="FD2019Q3YTD" decimals="0" id="Fact-6B7726F304C8B7A3BE474537031D5674" unitRef="shares">27403683</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="FD2019Q3YTD" id="Fact-F762B202B28B06DEDE3A45370343FD1D">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Accrued Expenses&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Accrued expenses consisted of:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.0079365079365%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Accrued professional services&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;4,488&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;931&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Accrued volume-based rebate and coupon liability&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;3,932&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Accrued payroll and related benefits&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;3,453&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2,577&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;EU milestone payment to Daewoong&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;1,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Other accrued expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;1,505&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;210&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;14,378&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;3,718&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
	<us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="FD2019Q3YTD" id="Fact-3CEF6F21D22E8B1EC34A4537032D8E0D">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Basis of Presentation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;T&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;he accompanying unaudited condensed financial statements have been prepared &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;on a consistent basis with the annual financial statements and&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;in accordance with accounting principles generally accepted in the United States of America (&amp;#8220;GAAP&amp;#8221;) and the requirements of the Securities and Exchange Commission (&amp;#8220;SEC&amp;#8221;) for interim reporting&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;. Pursuant to these SEC rules and regulations, the Company has condensed or omitted certain financial information and disclosures normally included in annual financial statements prepared in accordance with GAAP. In the opinion of management, the interim financial statements reflect all adjustments, which include normal recurring adjustments, considered necessary for a fair statement of the interim periods. The interim results presented herein are not necessarily indicative of the results of operations to be expected for the full year ending &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; or for any other interim period.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The accompanying unaudited condensed financial statements and related disclosures should be read in conjunction with the financial statements and notes included in the Company&amp;#8217;s Annual Report on Form 10-K for the year ended December 31, 2018, as filed with the SEC on March 20, 2019.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
	<us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="FD2019Q3YTD" id="Fact-27868DE11E91739EEC934537031D4B90">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Cash and Cash Equivalents&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Cash and cash equivalents consist of cash and highly liquid investments with remaining maturities at purchase of three months or less that can be liquidated without prior notice or penalty. Cash and cash equivalents may include deposits, money market funds and debt securities. &amp;#160;Amounts receivable from credit card issuers are typically converted to cash within two to four days of the original sales transaction and are considered to be cash equivalents. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company places its cash and cash equivalents with high credit quality financial institutions.&amp;#160;At times, such investments may be in excess of the Federal Deposit Insurance Corporation (&amp;#8220;FDIC&amp;#8221;) limit. Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash deposits.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
	<us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="FD2019Q3YTD" id="Fact-DE6D095E7E792AEBE535453703336C71">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Commitments and Contingencies&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt; &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Operating Leases&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company leases office facilities under various operating lease agreements. The Company&amp;#8217;s corporate headquarters is located in Newport Beach, California, in a facility that it subleases under a non-cancelable operating lease for a fixed amount each month. The sublease for this facility expires on January 20, 2020. On May 15, 2019, the Company entered into a non-cancelable operating lease for the same office facility with the original lessor. This non-cancelable operating lease will commence on February 1, 2020 and expire on January 31, 2025. Lease payments increase based on an annual rent escalation clause that occurs each year on February 1. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company may, under certain circumstances, terminate the lease on the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;36&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; month anniversary of the lease commencement date by providing a written notice &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;12 months&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; prior to such anniversary and paying a termination fee&amp;#160;equal to &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;six months&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; basic rent plus certain other expenses. The Company has an option to extend the term of the lease for an additional &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;60 months&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, which is not recognized as part of its ROU assets and lease liabilities. The lease with the original lessor is a modification of the existing sublease that is not accounted for as a separate contract.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company also leases an office facility in Santa Barbara, California, under a non-cancelable operating lease, the payments of which include a &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;three&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; percent&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; annual rent escalation clause that occurs on each June 1 anniversary&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;. The lease for this facility expires on May 31, 2020 and the Company has an option to extend the term of the lease for an additional &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;60 months&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;. In June 2019, the Company subleased the Santa Barbara, California facility to a third-party for a term starting on June 1, 2019 and expiring on May 31, 2020. The &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;sublease&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; income was not significant. Upon signing the sublease, the Company recorded an impairment charge of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$80&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; to the right-of-use asset related to the original lease.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company&amp;#8217;s lease agreements do not contain any residual value guarantees or material restrictive covenants. The payments associated with the renewal will only be included in the measurement of the lease liability and ROU assets if the exercise of the renewal option is determined to be reasonably certain. The Company considers the timing of the renewal period and other economic factors such as the financial implications of a decision to extend or not to extend a lease&amp;#160;in&amp;#160;determining&amp;#160;if the renewal option is reasonably certain to be exercised.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;For the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;three and nine months ended September 30, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, the components of operating lease expense and other quantitative information were as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:93.25396825396825%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:63%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:16%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:16%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Three Months Ended&lt;br clear="none"/&gt;September 30, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Nine Months Ended&lt;br clear="none"/&gt;September 30, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Fixed operating lease expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;297&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;798&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Variable operating lease expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;31&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;92&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Short-term operating lease expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;24&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;73&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;352&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;963&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;As of September 30, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Weighted-average remaining lease term (years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;5.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Weighted-average discount rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;9.4%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;color:#000000;"&gt; &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Operating lease&amp;#160;expenses were included in the selling, general and administration expenses in the accompanying condensed statements of operations and comprehensive loss. Operating lease right-of-use assets and related current and noncurrent operating lease liabilities are presented in the accompanying condensed balance sheets. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The following table presents the maturity of the Company&amp;#8217;s operating lease liabilities as of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;September&amp;#160;30, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, future minimum payments under the operating lease agreements with non-cancelable terms as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:center;padding-left:9px;text-indent:26px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:58.333333333333336%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:78%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:20%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Fiscal year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#231f20;"&gt;Remainder of 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#231f20;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#231f20;"&gt;239&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:2px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#231f20;"&gt;2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#231f20;"&gt;1,201&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:2px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#231f20;"&gt;2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#231f20;"&gt;1,205&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:2px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#231f20;"&gt;2022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#231f20;"&gt;1,258&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:2px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#231f20;"&gt;2023&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#231f20;"&gt;1,312&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:2px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#231f20;"&gt;Thereafter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#231f20;"&gt;1,484&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:2px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#231f20;"&gt;Total operating lease payments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#231f20;"&gt;6,699&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:2px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#231f20;"&gt;Less: imputed interest&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#231f20;"&gt;(1,484&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#231f20;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:2px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#231f20;"&gt;Present value of operating lease liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#231f20;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#231f20;"&gt;5,215&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;As required by the new lease accounting standard, legacy disclosures are provided for periods prior to adoption.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, annual future minimum payments under the operating lease agreements with non-cancelable terms greater than one year are as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:59.32539682539682%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:79%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:19%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:2px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#231f20;font-weight:bold;"&gt;Fiscal year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:2px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#231f20;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#231f20;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#231f20;"&gt;890&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:2px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#231f20;"&gt;2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#231f20;"&gt;139&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:2px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#231f20;"&gt;2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #231f20;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#231f20;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #231f20;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#231f20;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#231f20;"&gt;1,029&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Purchase Commitments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;September&amp;#160;30, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, the Company has entered into commitments to purchase services and products for an aggregate amount of approximately &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$6,651&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;. Certain minimum purchase commitments related to the purchase of Jeuveau&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; are described below.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;"&gt;License and Supply Agreement&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;In connection with the Daewoong Agreement, the Company is obligated to make future milestone payments to Daewoong for certain confidential development and commercial milestones associated with &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Jeuveau&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;September&amp;#160;30, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, Daewoong is eligible to receive contingent milestone payments of up to approximately &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$11,500&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, including the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$1,000&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; milestone payment accrued upon EC approval of the product in September 2019. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Daewoong Agreement also includes certain minimum annual purchases the Company is required to make in order to maintain the exclusivity of the license.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; The Company may, however, meet these minimum purchase obligations by achieving certain market share in its covered territories. These potential minimum purchase obligations were contingent upon the occurrence of future events, including receipt of governmental approvals and the Company&amp;#8217;s future market share in various jurisdictions. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Legal Proceedings&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications. The Company&amp;#8217;s exposure under these agreements is unknown because they involve claims that may be made against the Company in the future, but have not yet been made. The Company accrues a liability for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;No&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; amounts were accrued as of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;September&amp;#160;30, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;"&gt;Medytox Litigation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company, Daewoong and other individuals and entities are defendants to a lawsuit brought by Medytox, Inc. (&amp;#8220;Medytox&amp;#8221;) originally instituted &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;in the Superior Court of the State of California in June 2017. With specific regard to the Company, Medytox alleges that (i) the Company has violated California Uniform Trade Secrets Act, Cal. Civ. Code &amp;#167; 3426 because Daewoong&amp;#8217;s alleged knowledge of the misappropriation of certain trade secrets of Medytox is imputed to the Company as a result of the Company&amp;#8217;s relationship with Daewoong, (ii) the Company has stolen the botulinum toxin bacterial strain of Medytox through our possession of and refusal to return the botulinum toxin bacterial strain, (iii) the Company has engaged in unlawful, unfair and fraudulent business acts and practices in violation of California Bus. &amp;amp; Prof. Code &amp;#167; 17200, including conversion of the botulinum toxin bacterial strain and misrepresentations to the public regarding the source of the botulinum toxin bacterial strain used to manufacture Jeuveau&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, and (iv) the Daewoong Agreement is invalid and in violation of Medytox&amp;#8217;s rights&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; (the &amp;#8220;Medytox Litigation&amp;#8221;). &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Medytox seeks, among other things, (i) actual, consequential and punitive damages, (ii) a reasonable royalty, as appropriate, (iii) a declaration that the Daewoong Agreement is void and unenforceable and that Medytox is entitled to disgorgement of all property wrongfully and unjustly retained or acquired by the defendants, including unlawfully gained profits, (iv) injunctive relief prohibiting the Company from using the license under the Daewoong Agreement and distributing Jeuveau&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, and (v) attorneys&amp;#8217; fees and costs.  &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company believes it has meritorious defenses and intends to vigorously defend Medytox&amp;#8217;s claims. Given the early stage in the Medytox Litigation, the Company is unable to determine the likelihood of success of Medytox&amp;#8217;s claims against the Company, and an estimate of the possible loss or range of loss cannot be made. While the Company is entitled to indemnity under the Daewoong Agreement, the indemnity may not be sufficient. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;An adverse ruling by the Superior Court against either us or Daewoong could materially adversely affect the Company&amp;#8217;s ability to carry out its business and which would have a material adverse effect on the Company&amp;#8217;s business, financial position, results of operations, or cash flows and could also result in reputational harm.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;"&gt;ITC Case&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;On January 30, 2019, Allergan, plc and Allergan, Inc. (collectively, &amp;#8220;Allergan&amp;#8221;) and Medytox filed a complaint against us and Daewoong in the U.S. International Trade Commission (the &amp;#8220;ITC&amp;#8221;), containing substantially similar allegations to the Medytox Litigation, specifically that Jeuveau&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; is manufactured based on misappropriated trade secrets of Medytox and therefore the importation of Jeuveau&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; is an unfair act. The ITC matter is entitled &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;In the Matter of Certain Botulinum Toxin Products&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; (the &amp;#8220;ITC Complaint&amp;#8221;).  The ITC instituted an investigation as ITC Inv. No. 337-TA-1145. The ITC complaint seeks (i) an investigation by the ITC pursuant to Section 337 of the Tariff Act of 1930, (ii) a hearing with the ITC on permanent relief, (iii) issuance of a limited exclusion order forbidding entry of Jeuveau&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; into the United States, (iv) a cease and desist order prohibiting Daewoong and us from engaging in the importations, sale for importation, marketing, distribution, offering for sale, the sale after the importation of, or otherwise transferring Jeuveau&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; within the United States, (v) a bond issued during the presidential review period, (vi) the return of Medytox&amp;#8217;s trade secrets and other confidential information including the alleged stolen botulinum toxin bacterial strain, and (vii) exclusion and cease and desist orders. The Company intends to defend itself vigorously in the proceedings. The ITC has set a target date for final determination of this matter for October 2020. An adverse ruling by the ITC against either us or Daewoong could result in the imposition of an exclusion order which would bar imports of Jeuveau&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; into the United States and a cease and desist order which would bar sales and marketing of Jeuveau&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; within the United Sates either of which would materially adversely affect the Company&amp;#8217;s ability to carry out its business and which would have a material adverse effect on the Company&amp;#8217;s business, financial position, results of operations, or cash flows and could also result in reputational harm.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Other Legal Matters&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company, from time to time, is involved in various litigation matters or regulatory encounters arising in the ordinary course of business that could result in unasserted or asserted claims or litigation. These other matters may raise difficult and complex legal issues and are subject to many uncertainties, including, but not limited to, the facts and circumstances of each particular case or claim, the jurisdiction in which each suit or regulatory encounter is brought, and differences in applicable laws and regulations. Except as set forth above, the Company does not believe that these other matters would have a material adverse effect on its accompanying financial position, results of operations or cash flows. However, the resolution of one or more of the other matters in any reporting period could have a material adverse impact on the Company&amp;#8217;s financial results for that period.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
	<us-gaap:CommitmentsAndContingenciesPolicyTextBlock contextRef="FD2019Q3YTD" id="Fact-FF8B5853AD95E227E06A45370333D49E">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Contingent Royalty Obligation Payable to the Evolus Founders&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company determines the fair value of the contingent royalty obligation payable at each reporting period end based on Level 3 inputs using a discounted cash flows method. Changes in the fair value of the contingent royalty obligation payable are determined at each reporting period end and recorded in operating expenses in the accompanying statements of operations and comprehensive loss and as a liability in the condensed balance sheets.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Contingent Promissory Note Payable to Evolus Founders&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;On February 12, 2018, the Company recognized a contingent promissory note payable at present value using a discount rate for similar rated debt securities based on an estimated date that the Company believed the contingent promissory note will mature. Discount amortization related to the contingent promissory note is recorded in interest expense in the condensed statements of operations and comprehensive loss with a corresponding increase to the non-current liabilities in the condensed balance sheets. &lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesPolicyTextBlock>
	<us-gaap:ConcentrationRiskCreditRisk contextRef="FD2019Q3YTD" id="Fact-AF8A39D801EF87BD671B453703330E40">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Risk and Uncertainties&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;In 2013, Evolus and Daewoong Pharmaceuticals Co., Ltd. (&amp;#8220;Daewoong&amp;#8221;) entered into an agreement (the &amp;#8220;Daewoong Agreement&amp;#8221;), pursuant to which, the Company has an exclusive distribution license to Jeuveau&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; from Daewoong for aesthetic indications in the United States, European Union, Canada, Australia, Russia, Commonwealth of Independent States, and South Africa, as well as co-exclusive distribution rights with Daewoong in Japan. Jeuveau&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; is manufactured by Daewoong in a facility in South Korea. The Company also has the option to negotiate first with Daewoong to secure a distribution license for any product that Daewoong directly or indirectly develops or commercializes that is classified as an injectable botulinum toxin (other than Jeuveau&amp;#174;) in a territory covered by the Daewoong Agreement. The Company relies on Daewoong, its exclusive and sole supplier, to manufacture Jeuveau&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;. Any termination or loss of significant rights, including exclusivity, under the Daewoong Agreement would materially and adversely affect the Company&amp;#8217;s commercialization of Jeuveau&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;. The Daewoong Agreement, and Daewoong&amp;#8217;s rights relating to Jeuveau&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, are subject to litigation. See &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Note 8&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Commitments and Contingencies&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; for additional information regarding such litigation.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company commercially launched Jeuveau&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; in the United States in May 2019 and, as such, has a limited history of sales. Jeuveau&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; also requires regulatory approval from certain regulatory authorities prior to commercial sales in the related jurisdictions. If any previously granted approval is retracted or the Company is denied approval or approval is delayed by any other regulators, it may have a material adverse impact on the Company&amp;#8217;s business and its financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company is subject to risks common to early stage companies in the pharmaceutical industry including, but not limited to, dependency on the clinical and commercial success of Jeuveau&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; and any future product candidates, ability to obtain and maintain regulatory approval of Jeuveau&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; and any future product candidates in the jurisdictions where approval is sought, the need for additional financing to achieve its goals, uncertainty of broad adoption of its approved products, if any, by physicians and patients, significant competition and untested manufacturing capabilities.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"&gt;&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
	<us-gaap:DebtDisclosureTextBlock contextRef="FD2019Q3YTD" id="Fact-9FC2363B31F7B6E22AA04537030E20D8">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Oxford Term Loans&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;On March 15, 2019, the Company entered into a credit facility of up to &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$100,000&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; with Oxford Finance (&amp;#8220;Oxford&amp;#8221;). Pursuant to the terms of the credit facility, the lender extended term loans (the &amp;#8220;Term Loans&amp;#8221;), available in two advances, to the Company. The first tranche of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$75,000&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; was funded on the closing date. The second tranche of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$25,000&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; may be drawn, at the request of the Company, no later than September 30, 2020, upon achieving specified minimum net sales milestones based on a trailing six-month basis and no event of default. As of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;September&amp;#160;30, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, the Company had not yet met the net sales milestone to draw the second tranche. The credit facility bears an annual interest rate equal to the greater of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;9.5%&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, or the 30-day U.S. Dollar LIBOR rate plus &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;7.0%&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;. The Company agreed to pay interest-only on each tranche funded for the first &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;36&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; months until May 2022, which is followed by a &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;23&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;-month amortization period. Notwithstanding the foregoing, if the Company maintains compliance with the specified minimum net sales covenant and meets other conditions during the initial interest-only period, upon the Company&amp;#8217;s request, the interest-only period may be extended by an additional &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;12&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; months to a total of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;48&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; months followed by an &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;11&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;-month amortization period.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Upon the earliest to occur of the maturity date, the acceleration of the term loans, or the prepayment of the term loans, the Company is required to pay to Oxford a final payment of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;5.5%&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; of the full principal amount of the term loans funded (&amp;#8220;Final Payment&amp;#8221;). The Company may elect to prepay all amounts owed prior to the maturity date, provided that a prepayment fee is also paid, which shall be equal to &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;3.0%&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; of the amount prepaid if the prepayment occurs on or prior to March 15, 2020, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;2.0%&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; of the amount prepaid if the prepayment occurs after March 15, 2020 and on or prior to March 15, 2021, or &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;1.0%&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; of the amount prepaid if the prepayment occurs thereafter (&amp;#8220;Prepayment Fee&amp;#8221;).  If the Term Loans are accelerated following the occurrence of an event of default, the Company is required to immediately pay to Oxford an amount equal to the sum of all outstanding principal of the term loans plus accrued and unpaid interest thereon through the prepayment date, the Final Payment, the Prepayment Fee and all other obligations that are due and payable, including payment of Oxford&amp;#8217;s expenses and interest at the default rate with respect to any past due amounts.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The credit facility is secured by substantially all of the Company&amp;#8217;s assets. The credit facility includes affirmative and negative covenants applicable to the Company and any subsidiaries it may create in the future. The affirmative covenants include, among others, covenants requiring the Company to maintain its legal corporate existence and governmental approvals, deliver certain financial reports, maintain insurance coverage and satisfy certain requirements regarding deposit accounts. The negative covenants include, among others, restrictions on us transferring collateral, incurring additional indebtedness, engaging in mergers or acquisitions, paying dividends or making other distributions, making investments, creating liens, selling assets and suffering a change in control, in each case subject to certain exceptions.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The credit facility also includes events of default, the occurrence and continuation of which could cause interest to be charged at a default interest rate equal to the applicable rate plus &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;5.0%&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; and Oxford, as collateral agent, with the right to exercise remedies against the Company and the collateral securing the credit facility, including foreclosure against the property securing the credit facility, including the Company&amp;#8217;s cash. These events of default include, among other things, any failure by the Company to pay principal or interest due under the credit facility, a breach of certain covenants under the credit facility, the Company&amp;#8217;s insolvency, a material adverse change, the occurrence of any default under certain other indebtedness and one or more judgments against the Company, the institution of certain temporary or permanent relief in connection with pending litigation, or the breach, termination or other adverse events under the Daewoong Agreement. As of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;September&amp;#160;30, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, the Company was in compliance with its debt covenants.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;At the closing date, the Company incurred &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$1,094&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$2,205&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; in debt discounts and issuance costs related to the Term Loans, respectively. Debt&amp;#160;discounts and issuance costs related to the entire Term Loans have been allocated pro rata between the funded and unfunded portions. Debt&amp;#160;discounts and issuance costs allocated to the first tranche of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$75,000&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; have been presented as a deduction to the debt balance and are amortized into interest expense using the effective interest method. As of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;September&amp;#160;30, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, the borrowings outstanding under the Term Loans were classified as long-term debt in the accompanying condensed balance sheets. Debt discounts and issuance costs associated with the unfunded tranche are deferred as assets until the tranche is drawn and are amortized into interest expense using the straight-line method over the term of the debt. The overall effective interest rate was approximately &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;11.6%&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; as of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;September&amp;#160;30, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;September&amp;#160;30, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, the principal amounts of long-term debt maturities during each of the next five fiscal years, and the Final Payment in 2024 which is amortized into interest expense over the life of the Term Loans are as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:88.4920634920635%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:56%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Fiscal year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Principal&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Final Payment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;26,087&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;26,087&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2023&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;39,130&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;39,130&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;2024&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;9,783&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;4,125&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;13,908&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;75,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;4,125&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;79,125&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
	<us-gaap:DebtPolicyTextBlock contextRef="FD2019Q3YTD" id="Fact-F1038E9764E351984757453702EF3814">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Long-Term Debt&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company recorded borrowings classified as long-term debt in the accompanying condensed balance sheets. Debt issuance costs represent legal, lender and consulting costs or fees associated with debt financing. Debt&amp;#160;discounts and issuance costs are allocated pro rata between the funded and unfunded portions of the debt and are amortized into interest expense over the term of the debt.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DebtPolicyTextBlock>
	<us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock contextRef="FD2019Q3YTD" id="Fact-4A68DA742108EAC78DBB4537031D8F67">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The following is a summary of the Company&amp;#8217;s short-term investments, considered available-for-sale, as of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;September&amp;#160;30, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.60317460317461%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:53%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Amortized&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Gross Unrealized&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Estimated&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;"&gt;Available-for-sale securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;U.S treasury securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;34,894&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;19&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;34,913&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
	<us-gaap:EarningsPerSharePolicyTextBlock contextRef="FD2019Q3YTD" id="Fact-312D8CDD464A1C1224064537031DC3D7">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Net Loss Per Share&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Basic net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock outstanding during the period including contingently issuable shares. Diluted earnings per share is based on the treasury stock method and includes the effect from potential issuance of ordinary shares, such as shares issuable pursuant to the exercise of stock options and the vesting of restricted stock units. Because the impact of the options and non-vested RSUs are anti-dilutive during periods of net loss, there was no difference between the weighted-average number of shares used to calculate basic and diluted net loss per common share for the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;three and nine months ended September 30, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;2018&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;. &lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
	<us-gaap:FairValueDisclosuresTextBlock contextRef="FD2019Q3YTD" id="Fact-47E07F7BE68D65B1E5594537030EA85B">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Fair Value Measurements and Short-Term Investments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;"&gt;Short-Term Investments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company did not have any short-term investments for the year ended December 31, 2018. As of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;September&amp;#160;30, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, all of the Company&amp;#8217;s investments had remaining maturities less than 12 months. The following is a summary of the Company&amp;#8217;s short-term investments, considered available-for-sale, as of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;September&amp;#160;30, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.60317460317461%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:53%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Amortized&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Gross Unrealized&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Estimated&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;"&gt;Available-for-sale securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;U.S treasury securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;34,894&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;19&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;34,913&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;September&amp;#160;30, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, no investments had been in a continuous unrealized loss position for more than 12 months, and the Company did not record any other-than-temporary impairments on these securities. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;"&gt;Assets and Liabilities Measured at Fair Value on a Recurring Basis&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company measures and reports certain financial instruments as assets and liabilities at fair value on a recurring basis. The fair value of these instruments was as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.60317460317461%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:53%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;As of September&amp;#160;30, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Level 1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Level 2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Level 3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;"&gt;Available-for-sale debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;U.S treasury securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;34,913&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;34,913&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;"&gt;Liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Contingent royalty obligation payable to Evolus Founders&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;48,895&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;48,895&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.60317460317461%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:53%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;As of December&amp;#160;31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Level 1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Level 2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Level 3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;"&gt;Liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Contingent royalty obligation payable to Evolus Founders&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;50,200&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;50,200&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company did not transfer any assets or liabilities measured at fair value on a recurring basis between levels during the&amp;#160;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;nine months ended September 30, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company determines the fair value of the contingent royalty obligation payable based on Level 3 inputs using a discounted cash flows method. The significant unobservable input assumptions that can significantly change the fair value include (i) timing of regulatory approvals of Jeuveau&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, (ii) projected and timing of net revenues during the payment period, which terminates in the quarter following the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;10&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;-year anniversary of the first commercial sale of Jeuveau&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; in the United States, (iii) the discount rate and (iv) the timing of payments. During the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;three and nine months ended September 30, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;2018&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, the Company utilized discount rates between &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;16.0%&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;25.0%&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, reflecting changes in the Company&amp;#8217;s risk profile. Net revenue projections are also updated to reflect changes in the timing of regulatory approval and expected sales. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The following table shows a reconciliation of the beginning and ending fair value measurements of the contingent royalty obligation payable:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:center;padding-left:48px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:92.85714285714286%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Three Months Ended&lt;br clear="none"/&gt;September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Nine Months Ended&lt;br clear="none"/&gt;September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Fair value, beginning of period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;47,169&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;48,800&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;50,200&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;39,700&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Payments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;(69&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;(9,282&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Change in fair value recorded in operating expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;1,795&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2,300&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;7,977&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;11,400&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Fair value, end of period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;48,895&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;51,100&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;48,895&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;51,100&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;"&gt;Other Financial Assets and Liabilities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company&amp;#8217;s financial instruments consist primarily of cash and cash equivalents, short-term available-for-sale debt securities, accounts receivable, accounts payable, accrued expenses, lease liabilities, and long-term debt. The carrying amount of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses approximates their fair value because of the short-term maturity of such instruments. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company estimates the fair value of contingent promissory note payable to the Evolus Founders, long-term debt and operating lease liabilities using the discounted cash flow analysis based on the interest rates for similar rated debt securities (Level 2). As of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;September&amp;#160;30, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, the fair value of contingent promissory note and long-term debt was estimated to be &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$16,072&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$74,947&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, respectively. The fair value of operating lease liabilities&amp;#160;at &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;September&amp;#160;30, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; approximated their carrying value. As of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, the fair value of contingent promissory note was &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$17,181&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
	<us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="FD2019Q3YTD" id="Fact-7331374D86B118BC2BEF4537031DB411">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The following table shows a reconciliation of the beginning and ending fair value measurements of the contingent royalty obligation payable:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:center;padding-left:48px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:92.85714285714286%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Three Months Ended&lt;br clear="none"/&gt;September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Nine Months Ended&lt;br clear="none"/&gt;September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Fair value, beginning of period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;47,169&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;48,800&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;50,200&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;39,700&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Payments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;(69&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;(9,282&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Change in fair value recorded in operating expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;1,795&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2,300&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;7,977&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;11,400&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Fair value, end of period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;48,895&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;51,100&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;48,895&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;51,100&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
	<us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="FD2019Q3YTD" id="Fact-F7749C04A6BC27126DB34537030E91E1">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Fair Value of Financial Instruments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Fair value is defined as the exchange price that would be received for an asset or an exit price paid to transfer a liability in an orderly transaction between market participants in a principal market on the measurement date.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The fair value hierarchy defines a three-tiered valuation hierarchy for disclosure of fair value measurement is classified and disclosed by the Company in one of the three categories as follows:&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Level 1&amp;#8212;Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Level 2&amp;#8212;Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities in active markets; quoted prices in markets that are not active; or other inputs that are observable, either directly or indirectly, or can be corroborated by observable market data for substantially the full term of the asset or liability; and&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Level 3&amp;#8212;Prices or valuation techniques that require inputs that are unobservable that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
	<us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock contextRef="FD2019Q3YTD" id="Fact-48723F1BDFA70762B6BB453702EF97CF">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Goodwill and Intangible Assets&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The table below shows the weighted-average life, original cost, accumulated amortization and net book value by major intangible asset classification:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="14" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:30%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:21%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Weighted-Average Life (Years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Original Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Accumulated Amortization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Net Book Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;"&gt;Definite-lived intangible assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Distribution right&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;20&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;59,076&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;(1,940&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;57,136&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Capitalized software&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;3,303&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;(582&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2,721&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Intangible assets, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;62,379&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;(2,522&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;59,857&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;"&gt;Indefinite-lived intangible asset&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Goodwill&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;*&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;21,208&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;21,208&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Total as of September 30, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;83,587&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;(2,522&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;81,065&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="14" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:30%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:19%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:21%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Weighted-Average Life (Years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Original Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Accumulated Amortization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Net Book Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;"&gt;Indefinite-lived intangible assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;IPR&amp;amp;D**&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;*&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;56,076&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;56,076&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Goodwill&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;*&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;21,208&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;21,208&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Total as of December 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;77,284&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;77,284&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;    ________________________&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:48px;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;color:#000000;"&gt;     *   Intangible assets with indefinite lives have an indeterminable average life.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:60px;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;color:#000000;"&gt;** IPR&amp;amp;D is presented as &amp;#8220;intangible assets, net&amp;#8221; in the accompanying condensed balance sheets.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The following table outlines the estimated future amortization expense related to intangible assets held as of&amp;#160;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;September&amp;#160;30, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; that are subject to amortization:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:57.14285714285714%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:57%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Fiscal year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Remaining in 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;1,168&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;4,674&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;3,528&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2,955&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;2023&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;2,955&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Thereafter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;44,577&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;59,857&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;In connection with the acquisition of the Company by SCH in 2013, the Company recorded goodwill of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$21,208&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; and IPR&amp;amp;D of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$56,076&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;. The IPR&amp;amp;D recognized represents the license and associated distribution right to develop Jeuveau&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, the initial term of which expires in September 2023 and is automatically extended for unlimited additional &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;three&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;-year terms provided that the Company meets certain performance requirements. Additionally, pursuant to the Daewoong Agreement, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$13,500&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; in additional cash consideration is due to Daewoong based upon the Company&amp;#8217;s successful completion of certain technical and sales milestones. Upon FDA approval of Jeuveau&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; on February 1, 2019, the Company paid Daewoong a &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$2,000&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; milestone payment which increased the cost basis of the IPR&amp;amp;D, and the IPR&amp;amp;D project was completed and reclassified as a definite-lived distribution right intangible asset, which is amortized on a straight-line basis over the estimated useful life of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;20&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; years. Upon EU approval of the product on September 27, 2019, the Company accrued a &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$1,000&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; milestone payment to Daewoong which also increased the cost basis of the IPR&amp;amp;D. During the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;three and nine months ended September 30, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, the Company capitalized &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$761&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$3,303&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, respectively, related to costs of computer software developed for internal use. The software is amortized over a &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;two&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;-year period using the straight-line method. During the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;three and nine months ended September 30, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, total intangible assets amortization expense of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$1,115&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$2,522&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; was recorded within depreciation and amortization on the accompanying condensed statements of operations and comprehensive loss, respectively.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
	<us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy contextRef="FD2019Q3YTD" id="Fact-1A25A12C2552050047D04537031DE9B2">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Goodwill&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Goodwill represents the excess of the purchase price over the fair value of the net tangible and intangible assets acquired in a business combination. The Company reviews goodwill for impairment annually and whenever events or changes in circumstances indicate the carrying amount of goodwill may not be recoverable. The Company performs an annual qualitative assessment of its goodwill in the fourth quarter of each calendar year to determine if any events or circumstances exist, such as an adverse change in business climate or a decline in the overall industry demand, that would indicate that it would more likely than not reduce the fair value of a reporting unit below its carrying amount, including goodwill. If events or circumstances do not indicate that the fair value of a reporting unit is below its carrying amount, then goodwill is not considered to be impaired and no further testing is required. If further testing is required, the Company performs a two-step process. The first step involves comparing the fair value of the Company&amp;#8217;s reporting unit to its carrying value, including goodwill. If the carrying value of the reporting unit exceeds its fair value, the second step of the test is performed by comparing the carrying value of the goodwill in the reporting unit to its implied fair value. An impairment charge is recognized for the excess of the carrying value of goodwill over its implied fair value. For the purpose of impairment testing, the Company has determined that it has &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;one&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; reporting unit.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
	<us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy contextRef="FD2019Q3YTD" id="Fact-54AFA4C3FEDE49B45AA04537030E75ED">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Intangible Assets&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Upon FDA approval of Jeuveau&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; in February 2019, in process research and development (&amp;#8220;IPR&amp;amp;D&amp;#8221;) related to Jeuveau&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; was evaluated as completed and reclassified to a definite-lived distribution right intangible asset, which is amortized over the period the asset is expected to contribute to the future cash flows of the Company. The Company determined the pattern of this intangible asset&amp;#8217;s future cash flows could not be readily determined with a high level of precision. As a result, the distribution right intangible asset is being amortized on a straight-line basis over the estimated useful life of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;20&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; years.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company capitalizes certain internal-use software costs associated with the development of its mobile and web-based customer platforms. These costs include personnel expenses and external costs that are directly associated with the software projects. These costs are included as intangible assets in the accompanying condensed balance sheets. The capitalized internal-use software costs are amortized on a straight-line basis over the estimated useful life of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;two years&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; upon being placed in service. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company reviews long-term and identifiable definite-lived intangible assets or asset groups for impairment when events or changes in circumstances indicate that the carrying amount of an asset or asset group may not be recoverable. If the sum of the expected future undiscounted cash flows is less than the carrying amount of the asset or an asset group, further impairment analysis is performed. An impairment loss is measured as the amount by which the carrying amount of the asset or asset groups exceeds the fair value for assets to be held and used or fair value less cost to sell for assets to be disposed of. The Company also reviews the useful lives of its assets periodically to determine whether events and circumstances warrant a revision to the remaining useful life. Changes in the useful life are adjusted prospectively by revising the remaining period over which the asset is amortized. There was &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;no&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; material impairment of long-lived assets for any periods presented.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy>
	<us-gaap:IncomeTaxPolicyTextBlock contextRef="FD2019Q3YTD" id="Fact-F6A63F13D982D196C1DA453702EF66BE">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Income Taxes&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company applies an estimated annual effective tax rate (&amp;#8220;ETR&amp;#8221;) approach for calculating a tax provision or benefit for interim periods, as required under GAAP.&amp;#160; The Company recorded a benefit for income taxes of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$149&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$14,899&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; for the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;three and nine months ended September 30, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, respectively, and did not record a significant tax provision or benefit for the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;three and nine months ended September 30, 2018&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;.&amp;#160;The Company&amp;#8217;s ETR differs from the U.S. federal statutory tax rate of 21% primarily as a result of the impact of a valuation allowance on its deferred tax assets.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company accounts for income taxes using the asset and liability method. Under this method, deferred tax assets and liabilities are determined on the basis of differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;A valuation allowance is recorded against deferred tax assets to reduce the net carrying value when it is more likely than not that some portion or all of a deferred tax asset will not be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, and ongoing prudent and feasible tax planning strategies in assessing the amount of the valuation allowance. When the Company establishes or reduces the valuation allowance against its deferred tax assets, its provision for income taxes will increase or decrease, respectively, in the period such determination is made.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;As of each reporting date, the Company considers evidence, both positive and negative, that could affect its view of the future realization of deferred tax assets.&amp;#160;As of December 31, 2018, the deferred tax assets were primarily the result of U.S. net operating loss and tax credit carryforwards, and a valuation allowance of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$34,500&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; was recorded against the gross deferred tax asset balance.&amp;#160;Upon FDA approval of Jeuveau&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; in February 2019, the Company&amp;#8217;s IPR&amp;amp;D intangible asset was reclassified to a definite-lived distribution right intangible asset. As a result, management determined that it was more likely than not that certain deferred tax assets became realizable due to the future reversals of the deferred tax liability associated with such intangible asset.&amp;#160;Accordingly, the Company released &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$14,402&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; of its valuation allowance as a discrete item upon FDA approval in February 2019. For the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;three and nine months ended September 30, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, the Company released an additional &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$149&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$497&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, respectively, from its valuation allowance.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Additionally, the Company recognizes the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities based on the technical merits of the position. The tax benefit recognized in the financial statements for a particular tax position is based on the largest benefit that is more likely than not to be realized upon settlement. Accordingly, the Company establishes reserves for uncertain tax positions. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;In accordance with SEC Staff Accounting Bulletin No. 118, the Company&amp;#8217;s accounting for the elements of the Tax Cuts and Jobs Act was complete as of December 31, 2018 and no adjustments were made to the original provisional estimate recorded in 2017.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
	<us-gaap:InventoryPolicyTextBlock contextRef="FD2019Q3YTD" id="Fact-3943F63FA24E3C4DA80D4537031D9C1B">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Inventories&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Inventories consist of finished goods held for sale and distribution. Cost is determined using the first&amp;#8209;in, first&amp;#8209;out method. However, the Company ships products with the earliest expiration dates.&amp;#160;Inventory valuation reserves are established based on a number of factors including, but not limited to, finished goods not meeting product specifications, product excess and obsolescence, or application of the lower of cost or net realizable value concepts. The determination of events requiring the establishment of inventory valuation reserves, together with the calculation of the amount of such reserves may require judgment. No material inventory valuation reserves have been recorded for the periods presented. Adverse changes in assumptions utilized in the Company&amp;#8217;s inventory reserve calculations could result in an increase to its inventory valuation reserves.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:InventoryPolicyTextBlock>
	<us-gaap:InvestmentPolicyTextBlock contextRef="FD2019Q3YTD" id="Fact-174348DBFAD433C788F14537030E2158">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Short-Term Investments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Short-term investments as of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;September&amp;#160;30, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; consisted of available-for-sale U.S. Treasury securities with original maturities greater than three months and remaining maturities of less than twelve months. These investments are recorded at fair value based on quoted prices in active markets, with unrealized gains and losses reported in other comprehensive (loss) gain in the Company&amp;#8217;s condensed statements of operations and comprehensive loss. Purchase premiums and discounts are recognized in interest expense using the effective interest method over the terms of the securities. Realized gains and losses and declines in fair value that are deemed to be other than temporary are reflected in the condensed statements of operations and comprehensive loss using the specific-identification method. The Company periodically reviews all available-for-sale securities for other than temporary declines in fair value below the cost basis whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company also evaluates whether it has plans or is required to sell short-term investments before recovery of their amortized cost bases. To date, the Company has not identified any other than temporary declines in fair value of its short-term investments. &lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:InvestmentPolicyTextBlock>
	<us-gaap:LeaseCostTableTextBlock contextRef="FD2019Q3YTD" id="Fact-A8D165D1F2FFFD52D5BF45370333966B">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;For the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;three and nine months ended September 30, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, the components of operating lease expense and other quantitative information were as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:93.25396825396825%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:63%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:16%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:16%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Three Months Ended&lt;br clear="none"/&gt;September 30, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Nine Months Ended&lt;br clear="none"/&gt;September 30, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Fixed operating lease expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;297&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;798&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Variable operating lease expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;31&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;92&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Short-term operating lease expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;24&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;73&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;352&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;963&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;As of September 30, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Weighted-average remaining lease term (years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;5.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Weighted-average discount rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;9.4%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
	<us-gaap:LesseeLeasesPolicyTextBlock contextRef="FD2019Q3YTD" id="Fact-98E3A4AF44CBE090254D453703330D12">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Leases&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;In accordance with Accounting Standards Update (&amp;#8220;ASU&amp;#8221;) No. 2016-02 as adopted on January 1, 2019, at the inception of a contractual arrangement, the Company determines whether the contract contains a lease by assessing whether there is an identified asset and whether the contract conveys the right to control the use of the identified asset in exchange for consideration over a period of time. If both criteria are met, upon lease commencement, the Company records a lease liability which represents the Company&amp;#8217;s obligation to make lease payments arising from the lease, and a corresponding right-of-use (&amp;#8220;ROU&amp;#8221;) asset which represents the Company&amp;#8217;s right to use an underlying asset during the lease term. Operating lease assets and liabilities are included in ROU assets, current portion of operating lease liabilities and noncurrent operating lease liabilities in the accompanying condensed balance sheets. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Operating lease ROU assets and lease liabilities are initially recognized based on the present value of the future minimum lease payments over the lease term at commencement date calculated using the Company&amp;#8217;s incremental borrowing rate applicable to the underlying asset unless the implicit rate is readily determinable. Operating lease ROU assets also include any lease payments made at or before lease commencement and exclude any lease incentives received, if any. The Company determines the lease term as the noncancellable period of the lease and may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise such options. The Company&amp;#8217;s leases do not contain any residual value guarantees. Leases with a term of 12 months or less are not recognized on the condensed balance sheets. For operating leases, the Company recognized rent expense on a straight-line basis over the lease term. There were no significant finance leases as of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;September&amp;#160;30, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
	<us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="FD2019Q3YTD" id="Fact-6C9004455E281CB53D4E4537031D3184">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The following table presents the maturity of the Company&amp;#8217;s operating lease liabilities as of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;September&amp;#160;30, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, future minimum payments under the operating lease agreements with non-cancelable terms as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:center;padding-left:9px;text-indent:26px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:58.333333333333336%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:78%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:20%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Fiscal year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#231f20;"&gt;Remainder of 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#231f20;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#231f20;"&gt;239&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:2px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#231f20;"&gt;2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#231f20;"&gt;1,201&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:2px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#231f20;"&gt;2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#231f20;"&gt;1,205&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:2px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#231f20;"&gt;2022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#231f20;"&gt;1,258&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:2px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#231f20;"&gt;2023&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#231f20;"&gt;1,312&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:2px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#231f20;"&gt;Thereafter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#231f20;"&gt;1,484&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:2px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#231f20;"&gt;Total operating lease payments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#231f20;"&gt;6,699&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:2px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#231f20;"&gt;Less: imputed interest&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#231f20;"&gt;(1,484&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#231f20;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:2px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#231f20;"&gt;Present value of operating lease liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#231f20;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#231f20;"&gt;5,215&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
	<us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="FD2019Q3YTD" id="Fact-8E186B9890699E0F94514537031D68BD">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Recently Adopted Accounting Pronouncements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;In August 2018, the SEC adopted the final rule under SEC Release No. 33-10532,&amp;#160;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Disclosure Update and Simplification&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, amending certain disclosure requirements that were redundant, duplicative, overlapping, outdated or superseded. In addition, the amendments expanded the disclosure requirements on the analysis of stockholders&amp;#8217; equity for interim financial statements. Under the amendments, an analysis of changes in each caption of stockholders&amp;#8217; equity presented in the balance sheet must be provided in a note or separate statement. The analysis should present a reconciliation of the beginning balance to the ending balance of each period for which a statement of comprehensive income is required to be filed. This final rule was effective on November 5, 2018 and it did not have a material impact on the Company&amp;#8217;s financial statements upon adoption on January 1, 2019.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;In July 2018, the Financial Accounting Standards Board (the &amp;#8220;FASB&amp;#8221;) issued&amp;#160;ASU No. 2018-09,&amp;#160;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Codification Improvements&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, which clarifies certain amendments to guidance that may have been incorrectly or inconsistently applied by certain entities and includes Amendments to Subtopic 718-740, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Compensation - Stock Compensation - Income Taxes&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;. The guidance in paragraph 718-740-35-2, as amended by the amendments in&amp;#160;ASU 2016-09, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, is unclear on whether an entity should recognize excess tax benefits (or tax deficiencies) for compensation expense that is taken on the entity&amp;#8217;s tax return. The amendment to paragraph 718-740-35-2 in this update clarifies that an entity should recognize excess tax benefits in the period in which the amount of deduction is determined. The Company adopted the guidance on January 1, 2019, and such adoption did not have a material impact on its financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;In June 2018, the FASB issued ASU No. 2018-07,&amp;#160;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Compensation&amp;#8212;Stock Compensation (Topic 718): Improvements to Nonemployee Share-based Payment Accounting,&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; which amends the financial reporting for stock-based payments issued to nonemployees and also expands the scope of ASC 718,&amp;#160;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Compensation - Stock Compensation&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;,&amp;#160;to also include stock-based payments issued to nonemployees for goods and services. The amendment substantially aligns accounting for stock-based payments to employees and nonemployees. The Company early adopted the guidance in the quarter ended December 31, 2018. The adoption did not have a material impact on the Company&amp;#8217;s financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;In February 2016, the FASB issued ASU No. 2016-02 and its related amendments which introduced &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Leases (Topic 842, or &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&amp;#8220;ASC 842&amp;#8221;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;)&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, a new comprehensive lease accounting model that supersedes the current lease guidance under&amp;#160;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Leases (Topic 840)&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;. The new accounting standard requires lessees to recognize ROU assets and corresponding lease liabilities for all leases with lease terms of greater than 12 months. It also changes the definition of a lease and expands the disclosure requirements of lease arrangements. In July 2018, the FASB added a transition option for implementation that allows companies to continue to use the legacy guidance in ASC 840, Leases, including its disclosure requirements, in the comparative periods presented in the year of adoption. The Company adopted the guidance effective January 1, 2019. The Company elected the transition package of three practical expedients and elected the optional transition method that allows for a cumulative-effect adjustment in the period of adoption without a restatement of prior periods. Further, the Company elected a short-term lease exception policy, permitting the Company to not apply the recognition requirements of this standard to short-term leases (i.e. leases with terms of 12 months or less) and an accounting policy to account for lease and non-lease components as a single component for certain classes of assets. As a result of the adoption, the Company adjusted its beginning balance of 2019 by recording operating lease ROU assets and liabilities through a cumulative-effect adjustment. The adoption impacted the accompanying condensed balance sheet, but did not have an impact on the condensed statements of operations and comprehensive loss. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The impact of the adoption of ASC 842 on the accompanying condensed balance sheet as of January 1, 2019 was as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.8015873015873%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:44%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:16%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:16%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:16%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;December 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Adjustments Due to the Adoption of ASC 842&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;January 1, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Operating lease right-of-use assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;1,029&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;1,029&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Current portion of operating lease liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;916&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;916&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Operating lease liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;138&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;138&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Deferred rent&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;25&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;(25&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Recent Accounting Pronouncements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;In November 2018, the FASB issued ASU No. 2018-18,&amp;#160;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Clarifying the Interaction between Topic 808 and Topic 606&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, which requires transactions in collaborative arrangements to be accounted for under ASC 606,&amp;#160;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Revenue from Contracts with Customers&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;,&amp;#160;if the counter-party is a customer for a good or service that is a distinct unit of account. The amendments also preclude entities from presenting consideration from transactions with a collaborator that is not a customer together with revenue recognized from contracts with customers. The guidance is effective for interim and annual reporting periods during the year ending December 31, 2020. Early adoption is permitted, including in any interim period.&amp;#160;The Company is currently evaluating the impact that the adoption of this guidance will have on its financial statements and related disclosures.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;In August 2018, the FASB issued&amp;#160;ASU No. 2018-15,&amp;#160;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Intangibles-Goodwill and Other-Internal-Use Software: Customer&amp;#8217;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement that is a Service Contract&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;.&amp;#160;ASU 2018-15&amp;#160;requires implementation costs incurred by customers in cloud computing arrangements (i.e., hosting arrangements) to be capitalized under the same premises of authoritative guidance for internal-use software, and deferred over the noncancellable term of the cloud computing arrangements plus any option renewal periods that are reasonably certain to be exercised by the customer or for which the exercise is controlled by the service provider. The guidance is effective for interim and annual reporting periods during the year ending December 31, 2020. Early adoption is permitted. The Company is in the process of determining the effects the adoption will have on its financial statements as well as whether to early adopt the new guidance.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;In August 2018, the FASB issued&amp;#160;ASU No. 2018-13,&amp;#160;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Fair Value Measurement (Topic 820): Disclosure Framework &amp;#8212; Changes to the Disclosure Requirements for Fair Value Measurement&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;.&amp;#160;The update&amp;#160;is part of the disclosure framework project and eliminates certain disclosure requirements for fair value measurements, requires entities to disclose new information, and modifies existing disclosure requirements. Under the new guidance,&amp;#160;entities will no longer be required to disclose the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy, or valuation processes for Level 3 fair value measurements. However, public companies will be required to disclose the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and related changes in unrealized gains and losses included in other comprehensive income. The guidance is effective for interim and annual reporting periods during the year ending December 31, 2020. Early adoption is permitted. The Company is currently evaluating the impact this change will have on its financial statements as well as whether to early adopt the new guidance.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;In January 2017, the FASB issued ASU No. 2017-04,&amp;#160;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Intangibles&amp;#8212;Goodwill and Other (Topic 350):&amp;#160;Simplifying the Test for Goodwill Impairment&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;. The update simplifies the accounting for goodwill impairment by removing step two of the goodwill impairment test, which requires a hypothetical purchase price allocation. A goodwill impairment will be the amount by which a reporting unit&amp;#8217;s carrying amount, including goodwill, exceeds its fair value. The impairment charge will be limited to the amount of goodwill allocated to that reporting unit. The update is effective for the Company beginning January&amp;#160;1, 2020. The standard requires prospective application. Early adoption is permitted. The Company is evaluating the effect of this standard on its financial statements and related disclosures as well as whether to early adopt the new guidance.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;In June 2016, the FASB issued ASU No. 2016-13,&amp;#160;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, which modifies the measurement and recognition of credit losses for most financial assets and certain other instruments. The new standard requires the use of forward-looking expected credit loss models based on historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount, which may result in earlier recognition of credit losses under the new standard. The new guidance also modifies the impairment models for available-for-sale debt securities and for purchased financial assets with credit deterioration since their origination. Subsequent to the issuance of ASU 2016-13, the FASB issued ASU 2018-19,&amp;#160;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Codification Improvements to Topic 326, Financial Instruments - Credit Losses&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;. This ASU does not change the core principle of the guidance in ASU 2016-13, instead these amendments are intended to clarify and improve operability of certain topics included within the credit losses standard.&amp;#160;The FASB also subsequently issued ASU 2019-04 which did not change the core principle of the guidance in ASU 2016-13 but clarified that expected recoveries of amounts previously written off and expected to be written off should be included in the valuation account and should not exceed amounts previously written off and expected to be written off. The guidance is effective for interim and annual reporting periods beginning after December 15, 2019 and interim periods within those periods, and early adoption is permitted. The guidance will be effective for the Company during the first quarter of 2020. The Company is in the process of determining the effects the adoption will have on its financial statements and reviewing credit loss models to assess the impact of the adoption of the standard on the financial statements. Based on initial assessments, the Company believes that while adoption will modify the way it analyzes financial instruments, it does not expect adoption of this guidance will have a material impact to its financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Other recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the American Institute of Certified Public Accountants, and the SEC did not, or are not believed by management to, have a material impact on the Company&amp;#8217;s present or future financial position, results of operations or cash flows.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
	<us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="FD2019Q3YTD" id="Fact-F88F8D3F2A194EB6914845370333254A">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Description of Business and Basis of Presentation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Description of Business&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Evolus, Inc., (&amp;#8220;Evolus&amp;#8221; or the &amp;#8220;Company&amp;#8221;) is a performance beauty company focused on delivering products in the self-pay aesthetic market. The Company received the approval of its first product Jeuveau&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; (prabotulinumtoxinA-xvfs) from the U.S. Food and Drug Administration (the &amp;#8220;FDA&amp;#8221;) in February 2019.  The product was approved by Health Canada in August 2018 and the European Commission (&amp;#8220;EC&amp;#8221;) in 31 countries in September 2019. Jeuveau&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; is a proprietary 900 kDa purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as &amp;#8220;frown lines,&amp;#8221; in adults. In May 2019, the Company commercially launched Jeuveau&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; in the United States and launched in Canada through a distributor in October 2019. The Company is headquartered in Newport Beach, California.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Liquidity and Financial Condition &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The accompanying unaudited condensed financial statements&amp;#160;have been prepared&amp;#160;on a basis that&amp;#160;assumes that&amp;#160;the Company will continue as a going concern. Since inception&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, the Company has incurred recurring net operating losses. T&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;he Company has recorded net losses&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$26,984&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$75,526&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; for the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;three and nine months ended September 30, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, respectively. Additionally, the Company used cash of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$77,461&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; in operations during the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;nine months ended September 30, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;. As of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;September&amp;#160;30, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, the Company had &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$74,029&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; in &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;cash and cash equivalents and short-term investments, and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;an accumulated deficit of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$198,551&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company&amp;#8217;s ability to execute on its business strategy, meet its future liquidity requirements, and achieve profitable operations, is dependent on a number of factors, including its ability to gain market acceptance of Jeuveau&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; and achieve a level of revenues adequate to support its cost structure, and operate its business without infringing third party intellectual property rights.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company believes that its current capital resources, which consist of cash, cash equivalents, and short-term investments, are sufficient to fund operations through at least the next twelve months from the date the accompanying financial statements are issued based on the expected cash burn rate. The Company may be required to raise additional capital to fund future operations through the sale of its equity securities, the incurrence of debt &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;to the extent allowed under existing debt arrangements&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, the entry into licensing or collaboration agreements with partners, or other sources of financing. Sufficient funds may not be available to the Company at all or on attractive terms when needed from equity or debt financings. If the Company is unable to obtain additional funding from these or other sources when needed, or to the extent needed, it may be necessary to significantly reduce its controllable and variable expenditures and current rate of spending through reductions in staff and delaying, scaling back, or suspending certain research and development, sales and marketing programs and other operational goals.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Basis of Presentation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;T&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;he accompanying unaudited condensed financial statements have been prepared &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;on a consistent basis with the annual financial statements and&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;in accordance with accounting principles generally accepted in the United States of America (&amp;#8220;GAAP&amp;#8221;) and the requirements of the Securities and Exchange Commission (&amp;#8220;SEC&amp;#8221;) for interim reporting&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;. Pursuant to these SEC rules and regulations, the Company has condensed or omitted certain financial information and disclosures normally included in annual financial statements prepared in accordance with GAAP. In the opinion of management, the interim financial statements reflect all adjustments, which include normal recurring adjustments, considered necessary for a fair statement of the interim periods. The interim results presented herein are not necessarily indicative of the results of operations to be expected for the full year ending &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; or for any other interim period.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The accompanying unaudited condensed financial statements and related disclosures should be read in conjunction with the financial statements and notes included in the Company&amp;#8217;s Annual Report on Form 10-K for the year ended December 31, 2018, as filed with the SEC on March 20, 2019.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
	<us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="FD2019Q3YTD" id="Fact-5F6DDA0CE4C50E996AF04537030E5A6A">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Related Party Transactions&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt; &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Services with ALPHAEON&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Prior to the Company&amp;#8217;s initial public offering (&amp;#8220;IPO&amp;#8221;) in February 2018, the Company had funded its operations primarily through contributions and related party borrowings from ALPHAEON Corporation (&amp;#8220;ALPHAEON&amp;#8221;). For the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;three and nine months ended September 30, 2018&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$0&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$383&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, respectively, were included in Evolus&amp;#8217; selling, general and administrative expenses that were generated by transactions with ALPHAEON. After completion of the Company&amp;#8217;s IPO on February 12, 2018, ALPHAEON did not incur any administrative or research and development expenses on the Company&amp;#8217;s behalf. As of December 31, 2018 and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;September&amp;#160;30, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, there were no related party accounts receivable, payable, or debt with ALPHAEON, respectively. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:normal;font-weight:normal;"&gt;  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Evolus Founders&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Certain of the Evolus Founders from whom SCH-AEON, LLC (&amp;#8220;SCH&amp;#8221;) purchased its equity interests include individuals who were previously employed by the Company in operational roles, including the Company&amp;#8217;s former Chief Operating Officer. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Payment Obligations Related to the Acquisition by ALPHAEON&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company was acquired by SCH in 2013 and subsequently by its subsidiary, ALPHAEON Corporation, by means of a stock purchase agreement (&amp;#8220;Stock Purchase Agreement&amp;#8221;) pursuant to which ALPHAEON assumed certain payment obligations related to the acquisition. On December 14, 2017, the Stock Purchase Agreement was amended (&amp;#8220;Amended Stock Purchase Agreement&amp;#8221;), and, as a result, effective upon the closing of the Company&amp;#8217;s IPO, the Company assumed all of ALPHAEON&amp;#8217;s payment obligations under the Amended Stock Purchase Agreement. Refer to the notes to the financial statements in the Company&amp;#8217;s Annual Report on Form 10-K for the year ended December 31, 2018 for details of the acquisition of the Company.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Under the Amended Stock Purchase Agreement, the payment obligations consisted of (i) a &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$9,200&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; up-front payment upon obtaining FDA approval for Jeuveau&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; for the treatment of glabellar lines which was paid in full during the first quarter of 2019, (ii) quarterly royalty payments of a low single digit percentage of net sales of Jeuveau&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, and (iii) a &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$20,000&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; promissory note that matures in November 2021. The payment obligations set forth in (ii) above terminates in the quarter following the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;10&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;-year anniversary of the first commercial sale of Jeuveau&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; in the United States. Under the Amended Stock Purchase Agreement, the Company recorded the fair value of all revised payment obligations and the promissory note owed to the Evolus Founders of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$55,742&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; (comprised of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$39,700&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; related to the contingent royalty obligation payable and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$16,042&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; related to the contingent promissory note) as of February 12, 2018. See &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Note 7&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Fair&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;"&gt; Value Measurements&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;"&gt;and Short-Term Investments&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;"&gt; for more information about the Company&amp;#8217;s accounting thereof. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;In addition, the outstanding related party borrowings from ALPHAEON as of February 12, 2018 were offset and reduced, on a dollar-for-dollar basis, taking into account the then-fair value of all payment obligations the Company assumed from ALPHAEON, the fair value of which, as of February 12, 2018, was &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$55,742&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Under the Amended Stock Purchase Agreement, Evolus paid one-time bonuses of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$1,575&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; to certain current and former employees upon FDA approval of Jeuveau&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; in February 2019, including a one-time bonus of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$700&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; paid to the Company&amp;#8217;s Chief Medical Officer and Head of Research &amp;amp; Development. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The payment is included in research and development expenses in the accompanying condensed statements of operations and comprehensive loss for the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;three and nine months ended September 30, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company has the right to prepay the promissory note, in whole or in part, at any time and from time to time without penalty. Upon an event of default under the promissory note, all unpaid principal becomes immediately due and payable at the option of the holder. An event of default occurs under the terms of the promissory note upon any of the following events: (i) Evolus fails to meet the obligations to make the required payments thereunder, (ii) Evolus makes an assignment for the benefit of creditors, (iii) Evolus commences any bankruptcy proceeding, or (iv) Evolus materially breaches the Amended Stock Purchase Agreement or Tax Indemnity Agreement (which is defined below) and such breach is not cured within &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;30&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; days. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;In addition, upon a change-of-control of Evolus, all unpaid principal becomes immediately due and payable. Under the terms of the promissory note, a change-of-control is defined as (i) the sale of all or substantially all of Evolus&amp;#8217; assets, (ii) the exclusive license of Jeuveau&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; or the business related to Jeuveau&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; to a third-party (other than a sublicense under the Daewoong Agreement), or (iii) any merger, consolidation, or acquisition of Evolus, except a merger, consolidation, or acquisition of Evolus in which the holders of capital stock of Evolus immediately prior to such merger, consolidation, or acquisition hold at least &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;50%&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; of the voting power of the capital stock of Evolus or the surviving entity. Notwithstanding the foregoing, the promissory note expressly provides that neither the IPO or any merger with or acquisition by ALPHAEON or any of its subsidiaries or affiliates constitutes a change-of-control. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;In connection with the Amended Stock Purchase Agreement, the Company entered into a tax indemnity agreement with the Evolus Founders (&amp;#8220;Tax Indemnity Agreement&amp;#8221;). Pursuant to the Tax Indemnity Agreement, the Company is obligated to indemnify the Evolus Founders for any tax liability resulting from the Company&amp;#8217;s assumption of the revised payment obligations under the Amended Stock Purchase Agreement from ALPHAEON. Such assumption of the revised payment obligations occurred upon the completion of the IPO. Under the Amended Stock Purchase Agreement, the payment obligations are contingent and thus eligible for installment sale reporting under Section 453 of the Internal Revenue Code of 1986, as amended. Under the Tax Indemnity Agreement, the Company was obligated to indemnify the Evolus Founders for any taxes or penalties required to be paid by the Evolus Founders in the event the U.S. Internal Revenue Service or other taxing authority were to determine that Company&amp;#8217;s assumption of the revised payment obligations under the Amended Stock Purchase Agreement rendered continued installment sale reporting unavailable to the Evolus Founders. Any taxes or penalties paid by us on behalf of the Evolus Founders under the Tax Indemnity Agreement will be offset dollar-for-dollar against the promissory note and future royalties that will be payable to the Evolus Founders under the Amended Stock Purchase Agreement. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Exclusive Distribution and Supply Agreement with Clarion Medical Technologies Inc.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;On November 30, 2017, the Company entered into an exclusive distribution and supply agreement (the &amp;#8220;Distribution Agreement&amp;#8221;), with Clarion Medical Technologies Inc. (&amp;#8220;Clarion&amp;#8221;). The Distribution Agreement provides terms pursuant to which the Company will exclusively supply &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Jeuveau&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; to Clarion in Canada.&amp;#160; Clarion was previously a wholly-owned subsidiary of ALPHAEON. However, pursuant to previous agreements among ALPHAEON, Clarion, and previous equity holders of Clarion, the previous equity holders of Clarion had the option, and exercised such option, to unwind ALPHAEON&amp;#8217;s acquisition of Clarion. As a result, ALPHAEON owes the equity holders of Clarion an unwinding fee of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$9,550&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; (the &amp;#8220;Unwinding Fee&amp;#8221;). The Distribution Agreement sets forth that a portion of the proceeds received by the Company from each unit of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Jeuveau&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; purchased by Clarion shall be paid directly to the previous equity holders of Clarion, and will reduce, on a dollar-for-dollar basis, the amount of the Unwinding Fee ALPHAEON owes. In addition, ALPHAEON and SCH have agreed with Clarion to pay the unpaid amount of the Unwinding Fee on December 31, 2022, if demanded by the previous equity holders of Clarion. There were no sales of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Jeuveau&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174; &lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;in Canada under the Distribution Agreement in any of the periods presented in these financial statements.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
	<us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="FD2019Q3YTD" id="Fact-B73C1783F1DDBE888D71453703338073">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Revenue Recognition&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company applies Accounting Standards Codification 606, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Revenue from Contracts with Customers&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; (&amp;#8220;ASC 606&amp;#8221;), to account for revenue generated since the commercial launch of Jeuveau&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; in May 2019. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;General&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company currently generates all of its revenue from the sale of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Jeuveau&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; in the United States.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company recognizes revenue when control of the promised goods under a contract is transferred to a customer, in an amount that reflects the consideration the Company expects to receive in exchange for those goods as specified in the customer contract. The transfer of control occurs upon receipt of the goods by the customer since that is when the customer has obtained control of the goods&amp;#8217; economic benefits. The Company does not provide any service-type warranties and does not accept product returns except under limited circumstances such as damages in transit or ineffective product. The Company also excludes any amounts related to taxes assessed by governmental authorities from revenue measurement. Shipping and handling costs associated with outbound product freight are accounted for as fulfillment costs and are included in selling, general and marketing expenses in the accompanying condensed statements of operations and comprehensive loss.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Disaggregation of Revenue&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company&amp;#8217;s disaggregation of revenue is consistent with its operating segment as disclosed above, and all of the Company&amp;#8217;s net sales are considered revenue from contracts with customers.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Gross-to-Net Revenue Adjustments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company provides customers with trade and volume discounts and prompt pay discounts that are directly reflected in the invoice price. Revenues are recorded net of sales-related adjustments, wherever applicable, for rebates and coupon programs. Accrued rebate and coupon balances are recorded in accrued expenses on the accompanying condensed balance sheets.&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Volume-based Rebates - &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Volume-based rebates are contractually offered to certain customers. The rebates payable to each customer are determined based on the contract and quarterly purchase volumes. &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Coupons - &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company implemented a program by which customers receive coupons redeemable into gift cards funded by the Company for the benefit of patients. The coupons are accounted for as variable consideration. The Company estimates the coupon redemption rates based on historical data. The coupons are accrued based on estimated redemption rates and the volume of products purchased and are recorded as a reduction to revenues on product delivery. &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;September&amp;#160;30, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, accrued volume-based rebate and coupon liability was &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$3,932&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;.  During the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;three and nine months ended September 30, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, provisions for accrued volume-based rebate and coupon liability were &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$5,740&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$6,671&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, respectively, which were offset by related payments of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$2,739&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; in the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;three and nine months ended September 30, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; .&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Contract balances&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;A contract with a customer states the terms of the sale, including the description, quantity and price of each product purchased. Amounts are recorded as accounts receivable when the Company&amp;#8217;s right to consideration becomes unconditional. As payment terms are short-term, the Company does not have any significant financing components in customer contracts given the expected time between transfer of the promised products and the payment of the associated consideration is less than one year. As of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;September&amp;#160;30, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, all amounts included in accounts receivable, net on the accompanying condensed balance sheets are related to contracts with customers.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company did not have any contract assets nor unbilled receivables as of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;September&amp;#160;30, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;. Sales commissions are included in selling, general and administrative expenses when incurred.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Contract liabilities reflect estimated amounts that the Company is obligated to pay to customers or patients under the rebate and coupon programs. The Company&amp;#8217;s contract liabilities are included in accounts payable and accrued expenses in the condensed balance sheets.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;During the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;three and nine months ended September 30, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, the Company did not recognize any revenue related to changes in transaction prices regarding its contracts with customers and did not recognize any material changes in revenue related to amounts included in contract liabilities at the beginning of the period.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Collectability&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Accounts receivable are recorded at the invoiced amount and do not bear interest. At the time of contract inception or new customer account set-up, the Company performs a collectability assessment of the customer&amp;#8217;s creditworthiness. The Company assesses the probability that the Company will collect the entitled consideration in exchange for the goods sold, by considering the customer&amp;#8217;s ability and intention to pay when consideration is due. On a recurring basis, the Company estimates the amount of receivables considered uncollectable to reflect an allowance for doubtful accounts.&amp;#160;There was no significant provision for allowance or write-off of doubtful accounts during the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;nine months ended September 30, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Practical Expedients&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company expenses sales commissions when incurred as the amortization period is one year or less. These costs are recorded within selling, general and administrative expenses in the accompanying condensed statements of operations and comprehensive loss. The Company does not adjust the amount of promised consideration for the effects of the time value of money for contracts in which the anticipated period between when the Company transfers the goods or services to the customer and when the customer pays within one year.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
	<us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock contextRef="FD2019Q3YTD" id="Fact-E31D4ECA188916D33CF145370333FC25">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Accrued expenses consisted of:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.0079365079365%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Accrued professional services&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;4,488&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;931&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Accrued volume-based rebate and coupon liability&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;3,932&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Accrued payroll and related benefits&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;3,453&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2,577&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;EU milestone payment to Daewoong&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;1,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Other accrued expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;1,505&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;210&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;14,378&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;3,718&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
	<us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="FD2019Q3YTD" id="Fact-D3E29CEBF7BDC7B495D0453702EFC8A6">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The following table summarizes stock-based compensation expense arising from the above Plan:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:88.29365079365078%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Three Months Ended&lt;br clear="none"/&gt;September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Nine Months Ended&lt;br clear="none"/&gt;September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Selling, general and administrative&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2,417&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;1,160&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;6,443&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;4,083&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Research and development&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;109&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;322&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;538&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;1,028&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;2,526&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;1,482&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;6,981&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;5,111&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
	<us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="FD2019Q3YTD" id="Fact-87411A615EA7DBE6391B4537032DB2AD">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The fair value of these instruments was as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.60317460317461%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:53%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;As of September&amp;#160;30, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Level 1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Level 2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Level 3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;"&gt;Available-for-sale debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;U.S treasury securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;34,913&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;34,913&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;"&gt;Liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Contingent royalty obligation payable to Evolus Founders&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;48,895&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;48,895&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.60317460317461%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:53%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;As of December&amp;#160;31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Level 1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Level 2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Level 3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;"&gt;Liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Contingent royalty obligation payable to Evolus Founders&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;50,200&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;50,200&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
	<us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock contextRef="FD2019Q3YTD" id="Fact-EE0672B23DBB2DC89BEDFF469D29D9D6">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, annual future minimum payments under the operating lease agreements with non-cancelable terms greater than one year are as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:59.32539682539682%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:79%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:19%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:2px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#231f20;font-weight:bold;"&gt;Fiscal year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:2px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#231f20;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#231f20;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#231f20;"&gt;890&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:2px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#231f20;"&gt;2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#231f20;"&gt;139&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:2px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#231f20;"&gt;2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #231f20;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#231f20;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #231f20;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#231f20;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#231f20;"&gt;1,029&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
	<us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock contextRef="FD2019Q3YTD" id="Fact-0791912D27B7E0AA5156453702EF9552">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The table below shows the weighted-average life, original cost, accumulated amortization and net book value by major intangible asset classification:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="14" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:30%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:21%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Weighted-Average Life (Years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Original Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Accumulated Amortization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Net Book Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;"&gt;Definite-lived intangible assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Distribution right&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;20&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;59,076&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;(1,940&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;57,136&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Capitalized software&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;3,303&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;(582&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2,721&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Intangible assets, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;62,379&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;(2,522&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;59,857&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;"&gt;Indefinite-lived intangible asset&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Goodwill&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;*&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;21,208&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;21,208&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Total as of September 30, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;83,587&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;(2,522&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;81,065&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="14" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:30%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:19%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:21%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Weighted-Average Life (Years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Original Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Accumulated Amortization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Net Book Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;"&gt;Indefinite-lived intangible assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;IPR&amp;amp;D**&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;*&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;56,076&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;56,076&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Goodwill&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;*&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;21,208&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;21,208&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Total as of December 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;77,284&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;77,284&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;    ________________________&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:48px;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;color:#000000;"&gt;     *   Intangible assets with indefinite lives have an indeterminable average life.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:60px;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;color:#000000;"&gt;** IPR&amp;amp;D is presented as &amp;#8220;intangible assets, net&amp;#8221; in the accompanying condensed balance sheets.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock>
	<us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock contextRef="FD2019Q3YTD" id="Fact-24FF87ADE213CF7DE13E4537030E005F">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;September&amp;#160;30, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, the principal amounts of long-term debt maturities during each of the next five fiscal years, and the Final Payment in 2024 which is amortized into interest expense over the life of the Term Loans are as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:88.4920634920635%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:56%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Fiscal year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Principal&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Final Payment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;26,087&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;26,087&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2023&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;39,130&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;39,130&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;2024&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;9,783&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;4,125&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;13,908&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;75,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;4,125&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;79,125&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
	<us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock contextRef="FD2019Q3YTD" id="Fact-BEF03861C36D21E2CB5245370333DA05">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The impact of the adoption of ASC 842 on the accompanying condensed balance sheet as of January 1, 2019 was as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.8015873015873%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:44%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:16%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:16%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:16%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;December 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Adjustments Due to the Adoption of ASC 842&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;January 1, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Operating lease right-of-use assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;1,029&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;1,029&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Current portion of operating lease liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;916&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;916&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Operating lease liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;138&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;138&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Deferred rent&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;25&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;(25&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock>
	<us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock contextRef="FD2019Q3YTD" id="Fact-1FD8108FFBFC01C09FFB453702EFE35A">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;A summary of RSU activity under the Plan for the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;nine months ended September 30, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, is presented below:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:70.03968253968253%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:58%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:20%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;"&gt;Restricted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;"&gt;Grant Date&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;"&gt;Stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;"&gt;Units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;"&gt;Per Share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Outstanding, December 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;271,404&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;16.53&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;3,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;18.33&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Vested&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;(22,125&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;25.69&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Forfeited&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;(19,409&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;13.71&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Outstanding, September&amp;#160;30, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;232,870&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;15.92&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
	<us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="FD2019Q3YTD" id="Fact-296E8354FA433ABBA77F4537030EB6DE">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;A summary of stock option activity under the Plan for the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;nine months ended September 30, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, is presented below:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:86.90476190476191%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:43%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:15%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;"&gt;Remaining&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;"&gt;Aggregate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;"&gt;Stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;"&gt;Exercise&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;"&gt;Contractual&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;"&gt;Intrinsic&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;"&gt;Options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;"&gt;Per Share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;"&gt;Terms (Years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Outstanding, December 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;3,257,801&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;11.99&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;9.26&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;7,119&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;1,202,981&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;19.16&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Exercised&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;(138,849&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;9.98&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Canceled/forfeited&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;(269,772&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;14.07&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Outstanding, September&amp;#160;30, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;4,052,161&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;14.05&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;8.53&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;14,830&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Exercisable, September&amp;#160;30, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;833,730&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;11.83&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;7.30&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;4,301&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
	<us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="FD2019Q3YTD" id="Fact-A76C93B1112BDA67B499453702EF232F">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The weighted-averages for key assumptions used in determining the fair value of stock options granted were as follows:    &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.28571428571429%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Three Months Ended&lt;br clear="none"/&gt;September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Nine Months Ended&lt;br clear="none"/&gt;September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Volatility&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;59.5%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;59.0%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;59.3%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;57.7%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Risk-free interest rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;1.75%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;2.87%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;2.49%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;2.64%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Expected life (years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;5.96&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;6.25&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;6.16&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;6.23&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Dividend yield rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;&amp;#8212;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;&amp;#8212;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;&amp;#8212;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;&amp;#8212;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
	<us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="FD2019Q3YTD" id="Fact-3BD64D61BE38F0163EAC453702EFCF97">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The following table outlines the estimated future amortization expense related to intangible assets held as of&amp;#160;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;September&amp;#160;30, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; that are subject to amortization:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:57.14285714285714%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:57%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Fiscal year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Remaining in 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;1,168&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;4,674&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;3,528&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2,955&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;2023&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;2,955&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Thereafter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;44,577&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;59,857&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
	<us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="FD2019Q3YTD" id="Fact-E24DE46869590E718A7245370333442F">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Segment Reporting&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company has determined that it operates in a single &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;operating and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;reportable segment. The Company&amp;#8217;s chief operating decision maker is its Chief Executive Officer who manages operations and reviews the financial information as a single operating segment for purposes of allocating resources and evaluating its financial performance.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
	<us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="FD2019Q3YTD" id="Fact-7B2175D6412F352D5E854537031DB349">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Stock-Based Compensation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company recognizes stock-based compensation expense for employees, consultants and members of the Board of Directors based on the fair value at the date of grant. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company uses the Black-Scholes option pricing model to value stock option grants. The Black-Scholes option pricing model requires the input of subjective assumptions, including the expected volatility of the Company&amp;#8217;s common stock, expected risk-free interest rate and the option&amp;#8217;s expected life. The fair value of the Company&amp;#8217;s restricted stock units (&amp;#8220;RSUs&amp;#8221;) is based on the fair value on the grant date of the Company&amp;#8217;s common stock. The Company also evaluates the impact of modifications made to the original terms of equity awards when they occur.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The fair value of equity awards that are expected to vest is amortized on a straight-line basis over the requisite service period. Stock-based compensation expense is recognized net of actual forfeitures when they occur, as an increase to additional paid-in capital in the condensed balance sheets and in the selling, general and administrative or research and development expenses in the condensed statements of operations and comprehensive loss. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"&gt;&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
	<us-gaap:SignificantAccountingPoliciesTextBlock contextRef="FD2019Q3YTD" id="Fact-5A2F92ED867BF315FFA34537031D7EF8">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Summary of Significant Accounting Policies&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;There have been no material changes in the Company&amp;#8217;s significant accounting policies during the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;nine months ended September 30, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; as compared with those disclosed in the Annual Report other than the adoption of the new lease and revenue recognition accounting standards described below. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Use of Estimates&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates, judgments, and assumptions that affect the amounts reported in the financial statements and disclosures made in the accompanying notes. Actual results could materially differ from those estimates, judgments, and assumptions. Management considers many factors in selecting appropriate financial accounting policies and controls and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes, and management must select an amount that falls within that range of reasonable estimates.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;On an ongoing basis, the Company evaluates the most significant estimates, including those related to net revenues, allowance for doubtful accounts, fair value measurements, goodwill and long-lived asset valuations and impairment assessments, inventory valuations, income tax valuations and stock-based compensation expense, among others. Although the Company bases estimates on historical experience, knowledge of current events and actions it may undertake in the future, and on various other assumptions that are believed to be reasonable, this process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Risk and Uncertainties&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;In 2013, Evolus and Daewoong Pharmaceuticals Co., Ltd. (&amp;#8220;Daewoong&amp;#8221;) entered into an agreement (the &amp;#8220;Daewoong Agreement&amp;#8221;), pursuant to which, the Company has an exclusive distribution license to Jeuveau&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; from Daewoong for aesthetic indications in the United States, European Union, Canada, Australia, Russia, Commonwealth of Independent States, and South Africa, as well as co-exclusive distribution rights with Daewoong in Japan. Jeuveau&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; is manufactured by Daewoong in a facility in South Korea. The Company also has the option to negotiate first with Daewoong to secure a distribution license for any product that Daewoong directly or indirectly develops or commercializes that is classified as an injectable botulinum toxin (other than Jeuveau&amp;#174;) in a territory covered by the Daewoong Agreement. The Company relies on Daewoong, its exclusive and sole supplier, to manufacture Jeuveau&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;. Any termination or loss of significant rights, including exclusivity, under the Daewoong Agreement would materially and adversely affect the Company&amp;#8217;s commercialization of Jeuveau&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;. The Daewoong Agreement, and Daewoong&amp;#8217;s rights relating to Jeuveau&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, are subject to litigation. See &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Note 8&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Commitments and Contingencies&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; for additional information regarding such litigation.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company commercially launched Jeuveau&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; in the United States in May 2019 and, as such, has a limited history of sales. Jeuveau&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; also requires regulatory approval from certain regulatory authorities prior to commercial sales in the related jurisdictions. If any previously granted approval is retracted or the Company is denied approval or approval is delayed by any other regulators, it may have a material adverse impact on the Company&amp;#8217;s business and its financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company is subject to risks common to early stage companies in the pharmaceutical industry including, but not limited to, dependency on the clinical and commercial success of Jeuveau&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; and any future product candidates, ability to obtain and maintain regulatory approval of Jeuveau&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; and any future product candidates in the jurisdictions where approval is sought, the need for additional financing to achieve its goals, uncertainty of broad adoption of its approved products, if any, by physicians and patients, significant competition and untested manufacturing capabilities.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Segment Reporting&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company has determined that it operates in a single &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;operating and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;reportable segment. The Company&amp;#8217;s chief operating decision maker is its Chief Executive Officer who manages operations and reviews the financial information as a single operating segment for purposes of allocating resources and evaluating its financial performance.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Cash and Cash Equivalents&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Cash and cash equivalents consist of cash and highly liquid investments with remaining maturities at purchase of three months or less that can be liquidated without prior notice or penalty. Cash and cash equivalents may include deposits, money market funds and debt securities. &amp;#160;Amounts receivable from credit card issuers are typically converted to cash within two to four days of the original sales transaction and are considered to be cash equivalents. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company places its cash and cash equivalents with high credit quality financial institutions.&amp;#160;At times, such investments may be in excess of the Federal Deposit Insurance Corporation (&amp;#8220;FDIC&amp;#8221;) limit. Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash deposits.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Short-Term Investments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Short-term investments as of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;September&amp;#160;30, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; consisted of available-for-sale U.S. Treasury securities with original maturities greater than three months and remaining maturities of less than twelve months. These investments are recorded at fair value based on quoted prices in active markets, with unrealized gains and losses reported in other comprehensive (loss) gain in the Company&amp;#8217;s condensed statements of operations and comprehensive loss. Purchase premiums and discounts are recognized in interest expense using the effective interest method over the terms of the securities. Realized gains and losses and declines in fair value that are deemed to be other than temporary are reflected in the condensed statements of operations and comprehensive loss using the specific-identification method. The Company periodically reviews all available-for-sale securities for other than temporary declines in fair value below the cost basis whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company also evaluates whether it has plans or is required to sell short-term investments before recovery of their amortized cost bases. To date, the Company has not identified any other than temporary declines in fair value of its short-term investments. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Inventories&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Inventories consist of finished goods held for sale and distribution. Cost is determined using the first&amp;#8209;in, first&amp;#8209;out method. However, the Company ships products with the earliest expiration dates.&amp;#160;Inventory valuation reserves are established based on a number of factors including, but not limited to, finished goods not meeting product specifications, product excess and obsolescence, or application of the lower of cost or net realizable value concepts. The determination of events requiring the establishment of inventory valuation reserves, together with the calculation of the amount of such reserves may require judgment. No material inventory valuation reserves have been recorded for the periods presented. Adverse changes in assumptions utilized in the Company&amp;#8217;s inventory reserve calculations could result in an increase to its inventory valuation reserves.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Fair Value of Financial Instruments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Fair value is defined as the exchange price that would be received for an asset or an exit price paid to transfer a liability in an orderly transaction between market participants in a principal market on the measurement date.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The fair value hierarchy defines a three-tiered valuation hierarchy for disclosure of fair value measurement is classified and disclosed by the Company in one of the three categories as follows:&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Level 1&amp;#8212;Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Level 2&amp;#8212;Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities in active markets; quoted prices in markets that are not active; or other inputs that are observable, either directly or indirectly, or can be corroborated by observable market data for substantially the full term of the asset or liability; and&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Level 3&amp;#8212;Prices or valuation techniques that require inputs that are unobservable that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Goodwill&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Goodwill represents the excess of the purchase price over the fair value of the net tangible and intangible assets acquired in a business combination. The Company reviews goodwill for impairment annually and whenever events or changes in circumstances indicate the carrying amount of goodwill may not be recoverable. The Company performs an annual qualitative assessment of its goodwill in the fourth quarter of each calendar year to determine if any events or circumstances exist, such as an adverse change in business climate or a decline in the overall industry demand, that would indicate that it would more likely than not reduce the fair value of a reporting unit below its carrying amount, including goodwill. If events or circumstances do not indicate that the fair value of a reporting unit is below its carrying amount, then goodwill is not considered to be impaired and no further testing is required. If further testing is required, the Company performs a two-step process. The first step involves comparing the fair value of the Company&amp;#8217;s reporting unit to its carrying value, including goodwill. If the carrying value of the reporting unit exceeds its fair value, the second step of the test is performed by comparing the carrying value of the goodwill in the reporting unit to its implied fair value. An impairment charge is recognized for the excess of the carrying value of goodwill over its implied fair value. For the purpose of impairment testing, the Company has determined that it has &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;one&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; reporting unit. There was &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;no&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; impairment of goodwill for any of the periods presented.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Intangible Assets&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Upon FDA approval of Jeuveau&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; in February 2019, in process research and development (&amp;#8220;IPR&amp;amp;D&amp;#8221;) related to Jeuveau&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; was evaluated as completed and reclassified to a definite-lived distribution right intangible asset, which is amortized over the period the asset is expected to contribute to the future cash flows of the Company. The Company determined the pattern of this intangible asset&amp;#8217;s future cash flows could not be readily determined with a high level of precision. As a result, the distribution right intangible asset is being amortized on a straight-line basis over the estimated useful life of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;20&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; years.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company capitalizes certain internal-use software costs associated with the development of its mobile and web-based customer platforms. These costs include personnel expenses and external costs that are directly associated with the software projects. These costs are included as intangible assets in the accompanying condensed balance sheets. The capitalized internal-use software costs are amortized on a straight-line basis over the estimated useful life of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;two years&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; upon being placed in service. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company reviews long-term and identifiable definite-lived intangible assets or asset groups for impairment when events or changes in circumstances indicate that the carrying amount of an asset or asset group may not be recoverable. If the sum of the expected future undiscounted cash flows is less than the carrying amount of the asset or an asset group, further impairment analysis is performed. An impairment loss is measured as the amount by which the carrying amount of the asset or asset groups exceeds the fair value for assets to be held and used or fair value less cost to sell for assets to be disposed of. The Company also reviews the useful lives of its assets periodically to determine whether events and circumstances warrant a revision to the remaining useful life. Changes in the useful life are adjusted prospectively by revising the remaining period over which the asset is amortized. There was &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;no&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; material impairment of long-lived assets for any periods presented.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Leases&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;In accordance with Accounting Standards Update (&amp;#8220;ASU&amp;#8221;) No. 2016-02 as adopted on January 1, 2019, at the inception of a contractual arrangement, the Company determines whether the contract contains a lease by assessing whether there is an identified asset and whether the contract conveys the right to control the use of the identified asset in exchange for consideration over a period of time. If both criteria are met, upon lease commencement, the Company records a lease liability which represents the Company&amp;#8217;s obligation to make lease payments arising from the lease, and a corresponding right-of-use (&amp;#8220;ROU&amp;#8221;) asset which represents the Company&amp;#8217;s right to use an underlying asset during the lease term. Operating lease assets and liabilities are included in ROU assets, current portion of operating lease liabilities and noncurrent operating lease liabilities in the accompanying condensed balance sheets. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Operating lease ROU assets and lease liabilities are initially recognized based on the present value of the future minimum lease payments over the lease term at commencement date calculated using the Company&amp;#8217;s incremental borrowing rate applicable to the underlying asset unless the implicit rate is readily determinable. Operating lease ROU assets also include any lease payments made at or before lease commencement and exclude any lease incentives received, if any. The Company determines the lease term as the noncancellable period of the lease and may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise such options. The Company&amp;#8217;s leases do not contain any residual value guarantees. Leases with a term of 12 months or less are not recognized on the condensed balance sheets. For operating leases, the Company recognized rent expense on a straight-line basis over the lease term. There were no significant finance leases as of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;September&amp;#160;30, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Contingent Royalty Obligation Payable to the Evolus Founders&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company determines the fair value of the contingent royalty obligation payable at each reporting period end based on Level 3 inputs using a discounted cash flows method. Changes in the fair value of the contingent royalty obligation payable are determined at each reporting period end and recorded in operating expenses in the accompanying statements of operations and comprehensive loss and as a liability in the condensed balance sheets.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Contingent Promissory Note Payable to Evolus Founders&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;On February 12, 2018, the Company recognized a contingent promissory note payable at present value using a discount rate for similar rated debt securities based on an estimated date that the Company believed the contingent promissory note will mature. Discount amortization related to the contingent promissory note is recorded in interest expense in the condensed statements of operations and comprehensive loss with a corresponding increase to the non-current liabilities in the condensed balance sheets. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Long-Term Debt&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company recorded borrowings classified as long-term debt in the accompanying condensed balance sheets. Debt issuance costs represent legal, lender and consulting costs or fees associated with debt financing. Debt&amp;#160;discounts and issuance costs are allocated pro rata between the funded and unfunded portions of the debt and are amortized into interest expense over the term of the debt.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Revenue Recognition&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company applies Accounting Standards Codification 606, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Revenue from Contracts with Customers&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; (&amp;#8220;ASC 606&amp;#8221;), to account for revenue generated since the commercial launch of Jeuveau&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; in May 2019. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;General&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company currently generates all of its revenue from the sale of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Jeuveau&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; in the United States.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company recognizes revenue when control of the promised goods under a contract is transferred to a customer, in an amount that reflects the consideration the Company expects to receive in exchange for those goods as specified in the customer contract. The transfer of control occurs upon receipt of the goods by the customer since that is when the customer has obtained control of the goods&amp;#8217; economic benefits. The Company does not provide any service-type warranties and does not accept product returns except under limited circumstances such as damages in transit or ineffective product. The Company also excludes any amounts related to taxes assessed by governmental authorities from revenue measurement. Shipping and handling costs associated with outbound product freight are accounted for as fulfillment costs and are included in selling, general and marketing expenses in the accompanying condensed statements of operations and comprehensive loss.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Disaggregation of Revenue&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company&amp;#8217;s disaggregation of revenue is consistent with its operating segment as disclosed above, and all of the Company&amp;#8217;s net sales are considered revenue from contracts with customers.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Gross-to-Net Revenue Adjustments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company provides customers with trade and volume discounts and prompt pay discounts that are directly reflected in the invoice price. Revenues are recorded net of sales-related adjustments, wherever applicable, for rebates and coupon programs. Accrued rebate and coupon balances are recorded in accrued expenses on the accompanying condensed balance sheets.&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Volume-based Rebates - &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Volume-based rebates are contractually offered to certain customers. The rebates payable to each customer are determined based on the contract and quarterly purchase volumes. &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Coupons - &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company implemented a program by which customers receive coupons redeemable into gift cards funded by the Company for the benefit of patients. The coupons are accounted for as variable consideration. The Company estimates the coupon redemption rates based on historical data. The coupons are accrued based on estimated redemption rates and the volume of products purchased and are recorded as a reduction to revenues on product delivery. &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;September&amp;#160;30, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, accrued volume-based rebate and coupon liability was &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$3,932&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;.  During the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;three and nine months ended September 30, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, provisions for accrued volume-based rebate and coupon liability were &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$5,740&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$6,671&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, respectively, which were offset by related payments of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$2,739&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; in the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;three and nine months ended September 30, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; .&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Contract balances&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;A contract with a customer states the terms of the sale, including the description, quantity and price of each product purchased. Amounts are recorded as accounts receivable when the Company&amp;#8217;s right to consideration becomes unconditional. As payment terms are short-term, the Company does not have any significant financing components in customer contracts given the expected time between transfer of the promised products and the payment of the associated consideration is less than one year. As of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;September&amp;#160;30, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, all amounts included in accounts receivable, net on the accompanying condensed balance sheets are related to contracts with customers.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company did not have any contract assets nor unbilled receivables as of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;September&amp;#160;30, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;. Sales commissions are included in selling, general and administrative expenses when incurred.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Contract liabilities reflect estimated amounts that the Company is obligated to pay to customers or patients under the rebate and coupon programs. The Company&amp;#8217;s contract liabilities are included in accounts payable and accrued expenses in the condensed balance sheets.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;During the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;three and nine months ended September 30, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, the Company did not recognize any revenue related to changes in transaction prices regarding its contracts with customers and did not recognize any material changes in revenue related to amounts included in contract liabilities at the beginning of the period.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Collectability&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Accounts receivable are recorded at the invoiced amount and do not bear interest. At the time of contract inception or new customer account set-up, the Company performs a collectability assessment of the customer&amp;#8217;s creditworthiness. The Company assesses the probability that the Company will collect the entitled consideration in exchange for the goods sold, by considering the customer&amp;#8217;s ability and intention to pay when consideration is due. On a recurring basis, the Company estimates the amount of receivables considered uncollectable to reflect an allowance for doubtful accounts.&amp;#160;There was no significant provision for allowance or write-off of doubtful accounts during the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;nine months ended September 30, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Practical Expedients&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company expenses sales commissions when incurred as the amortization period is one year or less. These costs are recorded within selling, general and administrative expenses in the accompanying condensed statements of operations and comprehensive loss. The Company does not adjust the amount of promised consideration for the effects of the time value of money for contracts in which the anticipated period between when the Company transfers the goods or services to the customer and when the customer pays within one year.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Stock-Based Compensation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company recognizes stock-based compensation expense for employees, consultants and members of the Board of Directors based on the fair value at the date of grant. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company uses the Black-Scholes option pricing model to value stock option grants. The Black-Scholes option pricing model requires the input of subjective assumptions, including the expected volatility of the Company&amp;#8217;s common stock, expected risk-free interest rate and the option&amp;#8217;s expected life. The fair value of the Company&amp;#8217;s restricted stock units (&amp;#8220;RSUs&amp;#8221;) is based on the fair value on the grant date of the Company&amp;#8217;s common stock. The Company also evaluates the impact of modifications made to the original terms of equity awards when they occur.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The fair value of equity awards that are expected to vest is amortized on a straight-line basis over the requisite service period. Stock-based compensation expense is recognized net of actual forfeitures when they occur, as an increase to additional paid-in capital in the condensed balance sheets and in the selling, general and administrative or research and development expenses in the condensed statements of operations and comprehensive loss. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Income Taxes&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company applies an estimated annual effective tax rate (&amp;#8220;ETR&amp;#8221;) approach for calculating a tax provision or benefit for interim periods, as required under GAAP.&amp;#160; The Company recorded a benefit for income taxes of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$149&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$14,899&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; for the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;three and nine months ended September 30, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, respectively, and did not record a significant tax provision or benefit for the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;three and nine months ended September 30, 2018&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;.&amp;#160;The Company&amp;#8217;s ETR differs from the U.S. federal statutory tax rate of 21% primarily as a result of the impact of a valuation allowance on its deferred tax assets.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company accounts for income taxes using the asset and liability method. Under this method, deferred tax assets and liabilities are determined on the basis of differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;A valuation allowance is recorded against deferred tax assets to reduce the net carrying value when it is more likely than not that some portion or all of a deferred tax asset will not be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, and ongoing prudent and feasible tax planning strategies in assessing the amount of the valuation allowance. When the Company establishes or reduces the valuation allowance against its deferred tax assets, its provision for income taxes will increase or decrease, respectively, in the period such determination is made.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;As of each reporting date, the Company considers evidence, both positive and negative, that could affect its view of the future realization of deferred tax assets.&amp;#160;As of December 31, 2018, the deferred tax assets were primarily the result of U.S. net operating loss and tax credit carryforwards, and a valuation allowance of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$34,500&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; was recorded against the gross deferred tax asset balance.&amp;#160;Upon FDA approval of Jeuveau&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; in February 2019, the Company&amp;#8217;s IPR&amp;amp;D intangible asset was reclassified to a definite-lived distribution right intangible asset. As a result, management determined that it was more likely than not that certain deferred tax assets became realizable due to the future reversals of the deferred tax liability associated with such intangible asset.&amp;#160;Accordingly, the Company released &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$14,402&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; of its valuation allowance as a discrete item upon FDA approval in February 2019. For the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;three and nine months ended September 30, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, the Company released an additional &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$149&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$497&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, respectively, from its valuation allowance.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Additionally, the Company recognizes the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities based on the technical merits of the position. The tax benefit recognized in the financial statements for a particular tax position is based on the largest benefit that is more likely than not to be realized upon settlement. Accordingly, the Company establishes reserves for uncertain tax positions. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;In accordance with SEC Staff Accounting Bulletin No. 118, the Company&amp;#8217;s accounting for the elements of the Tax Cuts and Jobs Act was complete as of December 31, 2018 and no adjustments were made to the original provisional estimate recorded in 2017.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Net Loss Per Share&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Basic net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock outstanding during the period including contingently issuable shares. Diluted earnings per share is based on the treasury stock method and includes the effect from potential issuance of ordinary shares, such as shares issuable pursuant to the exercise of stock options and the vesting of restricted stock units. Because the impact of the options and non-vested RSUs are anti-dilutive during periods of net loss, there was no difference between the weighted-average number of shares used to calculate basic and diluted net loss per common share for the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;three and nine months ended September 30, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;2018&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;. Excluded from the dilutive net loss per share computation were &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;4,052,161&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; stock options and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;182,758&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; non-vested RSUs for the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;three and nine months ended September 30, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; because their inclusion would have been anti-dilutive. Although these securities were anti-dilutive for these periods, they could be dilutive in future periods.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Recently Adopted Accounting Pronouncements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;In August 2018, the SEC adopted the final rule under SEC Release No. 33-10532,&amp;#160;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Disclosure Update and Simplification&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, amending certain disclosure requirements that were redundant, duplicative, overlapping, outdated or superseded. In addition, the amendments expanded the disclosure requirements on the analysis of stockholders&amp;#8217; equity for interim financial statements. Under the amendments, an analysis of changes in each caption of stockholders&amp;#8217; equity presented in the balance sheet must be provided in a note or separate statement. The analysis should present a reconciliation of the beginning balance to the ending balance of each period for which a statement of comprehensive income is required to be filed. This final rule was effective on November 5, 2018 and it did not have a material impact on the Company&amp;#8217;s financial statements upon adoption on January 1, 2019.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;In July 2018, the Financial Accounting Standards Board (the &amp;#8220;FASB&amp;#8221;) issued&amp;#160;ASU No. 2018-09,&amp;#160;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Codification Improvements&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, which clarifies certain amendments to guidance that may have been incorrectly or inconsistently applied by certain entities and includes Amendments to Subtopic 718-740, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Compensation - Stock Compensation - Income Taxes&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;. The guidance in paragraph 718-740-35-2, as amended by the amendments in&amp;#160;ASU 2016-09, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, is unclear on whether an entity should recognize excess tax benefits (or tax deficiencies) for compensation expense that is taken on the entity&amp;#8217;s tax return. The amendment to paragraph 718-740-35-2 in this update clarifies that an entity should recognize excess tax benefits in the period in which the amount of deduction is determined. The Company adopted the guidance on January 1, 2019, and such adoption did not have a material impact on its financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;In June 2018, the FASB issued ASU No. 2018-07,&amp;#160;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Compensation&amp;#8212;Stock Compensation (Topic 718): Improvements to Nonemployee Share-based Payment Accounting,&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; which amends the financial reporting for stock-based payments issued to nonemployees and also expands the scope of ASC 718,&amp;#160;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Compensation - Stock Compensation&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;,&amp;#160;to also include stock-based payments issued to nonemployees for goods and services. The amendment substantially aligns accounting for stock-based payments to employees and nonemployees. The Company early adopted the guidance in the quarter ended December 31, 2018. The adoption did not have a material impact on the Company&amp;#8217;s financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;In February 2016, the FASB issued ASU No. 2016-02 and its related amendments which introduced &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Leases (Topic 842, or &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&amp;#8220;ASC 842&amp;#8221;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;)&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, a new comprehensive lease accounting model that supersedes the current lease guidance under&amp;#160;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Leases (Topic 840)&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;. The new accounting standard requires lessees to recognize ROU assets and corresponding lease liabilities for all leases with lease terms of greater than 12 months. It also changes the definition of a lease and expands the disclosure requirements of lease arrangements. In July 2018, the FASB added a transition option for implementation that allows companies to continue to use the legacy guidance in ASC 840, Leases, including its disclosure requirements, in the comparative periods presented in the year of adoption. The Company adopted the guidance effective January 1, 2019. The Company elected the transition package of three practical expedients and elected the optional transition method that allows for a cumulative-effect adjustment in the period of adoption without a restatement of prior periods. Further, the Company elected a short-term lease exception policy, permitting the Company to not apply the recognition requirements of this standard to short-term leases (i.e. leases with terms of 12 months or less) and an accounting policy to account for lease and non-lease components as a single component for certain classes of assets. As a result of the adoption, the Company adjusted its beginning balance of 2019 by recording operating lease ROU assets and liabilities through a cumulative-effect adjustment. The adoption impacted the accompanying condensed balance sheet, but did not have an impact on the condensed statements of operations and comprehensive loss. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The impact of the adoption of ASC 842 on the accompanying condensed balance sheet as of January 1, 2019 was as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.8015873015873%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:44%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:16%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:16%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:16%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;December 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Adjustments Due to the Adoption of ASC 842&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;January 1, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Operating lease right-of-use assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;1,029&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;1,029&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Current portion of operating lease liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;916&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;916&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Operating lease liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;138&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;138&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Deferred rent&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;25&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;(25&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Recent Accounting Pronouncements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;In November 2018, the FASB issued ASU No. 2018-18,&amp;#160;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Clarifying the Interaction between Topic 808 and Topic 606&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, which requires transactions in collaborative arrangements to be accounted for under ASC 606,&amp;#160;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Revenue from Contracts with Customers&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;,&amp;#160;if the counter-party is a customer for a good or service that is a distinct unit of account. The amendments also preclude entities from presenting consideration from transactions with a collaborator that is not a customer together with revenue recognized from contracts with customers. The guidance is effective for interim and annual reporting periods during the year ending December 31, 2020. Early adoption is permitted, including in any interim period.&amp;#160;The Company is currently evaluating the impact that the adoption of this guidance will have on its financial statements and related disclosures.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;In August 2018, the FASB issued&amp;#160;ASU No. 2018-15,&amp;#160;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Intangibles-Goodwill and Other-Internal-Use Software: Customer&amp;#8217;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement that is a Service Contract&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;.&amp;#160;ASU 2018-15&amp;#160;requires implementation costs incurred by customers in cloud computing arrangements (i.e., hosting arrangements) to be capitalized under the same premises of authoritative guidance for internal-use software, and deferred over the noncancellable term of the cloud computing arrangements plus any option renewal periods that are reasonably certain to be exercised by the customer or for which the exercise is controlled by the service provider. The guidance is effective for interim and annual reporting periods during the year ending December 31, 2020. Early adoption is permitted. The Company is in the process of determining the effects the adoption will have on its financial statements as well as whether to early adopt the new guidance.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;In August 2018, the FASB issued&amp;#160;ASU No. 2018-13,&amp;#160;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Fair Value Measurement (Topic 820): Disclosure Framework &amp;#8212; Changes to the Disclosure Requirements for Fair Value Measurement&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;.&amp;#160;The update&amp;#160;is part of the disclosure framework project and eliminates certain disclosure requirements for fair value measurements, requires entities to disclose new information, and modifies existing disclosure requirements. Under the new guidance,&amp;#160;entities will no longer be required to disclose the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy, or valuation processes for Level 3 fair value measurements. However, public companies will be required to disclose the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and related changes in unrealized gains and losses included in other comprehensive income. The guidance is effective for interim and annual reporting periods during the year ending December 31, 2020. Early adoption is permitted. The Company is currently evaluating the impact this change will have on its financial statements as well as whether to early adopt the new guidance.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;In January 2017, the FASB issued ASU No. 2017-04,&amp;#160;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Intangibles&amp;#8212;Goodwill and Other (Topic 350):&amp;#160;Simplifying the Test for Goodwill Impairment&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;. The update simplifies the accounting for goodwill impairment by removing step two of the goodwill impairment test, which requires a hypothetical purchase price allocation. A goodwill impairment will be the amount by which a reporting unit&amp;#8217;s carrying amount, including goodwill, exceeds its fair value. The impairment charge will be limited to the amount of goodwill allocated to that reporting unit. The update is effective for the Company beginning January&amp;#160;1, 2020. The standard requires prospective application. Early adoption is permitted. The Company is evaluating the effect of this standard on its financial statements and related disclosures as well as whether to early adopt the new guidance.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;In June 2016, the FASB issued ASU No. 2016-13,&amp;#160;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, which modifies the measurement and recognition of credit losses for most financial assets and certain other instruments. The new standard requires the use of forward-looking expected credit loss models based on historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount, which may result in earlier recognition of credit losses under the new standard. The new guidance also modifies the impairment models for available-for-sale debt securities and for purchased financial assets with credit deterioration since their origination. Subsequent to the issuance of ASU 2016-13, the FASB issued ASU 2018-19,&amp;#160;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Codification Improvements to Topic 326, Financial Instruments - Credit Losses&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;. This ASU does not change the core principle of the guidance in ASU 2016-13, instead these amendments are intended to clarify and improve operability of certain topics included within the credit losses standard.&amp;#160;The FASB also subsequently issued ASU 2019-04 which did not change the core principle of the guidance in ASU 2016-13 but clarified that expected recoveries of amounts previously written off and expected to be written off should be included in the valuation account and should not exceed amounts previously written off and expected to be written off. The guidance is effective for interim and annual reporting periods beginning after December 15, 2019 and interim periods within those periods, and early adoption is permitted. The guidance will be effective for the Company during the first quarter of 2020. The Company is in the process of determining the effects the adoption will have on its financial statements and reviewing credit loss models to assess the impact of the adoption of the standard on the financial statements. Based on initial assessments, the Company believes that while adoption will modify the way it analyzes financial instruments, it does not expect adoption of this guidance will have a material impact to its financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Other recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the American Institute of Certified Public Accountants, and the SEC did not, or are not believed by management to, have a material impact on the Company&amp;#8217;s present or future financial position, results of operations or cash flows.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
	<us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="FD2019Q3YTD" id="Fact-AE26A1774B2C70C2BF54453702FED2ED">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Stockholders&amp;#8217; Equity&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Preferred Stock&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company has &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;10,000,000&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; authorized shares of preferred stock with a par value of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$0.00001&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; per share. As of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;September&amp;#160;30, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;none&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; were issued and outstanding. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Common Stock&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company has &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;100,000,000&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; authorized shares of common stock with a par value of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$0.00001&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; per share. As of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;September&amp;#160;30, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;27,425,230&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; shares were issued and outstanding. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"&gt;2017 Omnibus Incentive Plan and Stock-based Compensation Allocation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company&amp;#8217;s 2017 Omnibus Incentive Plan (the &amp;#8220;Plan&amp;#8221;) provides for the grant of incentive options to employees of the Company, and for the grant of nonstatutory options, restricted stock awards, restricted stock unit awards, stock appreciation rights, performance stock awards and other forms of stock compensation to the Company&amp;#8217;s employees, including officers, directors, consultants and employees of the Company. The maximum number of shares of common stock that may be issued under the Plan is &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;4,361,291&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; shares, plus an annual increase on each anniversary of November 21 equal to &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;4%&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; of the total issued and outstanding shares of the Company&amp;#8217;s common stock as of such anniversary (or such lesser number of shares as may be determined by the Company&amp;#8217;s board of directors). On November 21, 2018, an additional &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;1,091,000&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; were reserved under the evergreen provision of the Plan. As of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;September&amp;#160;30, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, the Company has available an aggregate of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;971,684&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; shares of common stock for future issuance under the Plan.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Stock-Based Award Activity and Balances&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Options are granted at exercise prices based on the Company&amp;#8217;s common stock price on the date of grant. The options and RSU grants generally vest over a &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;one&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;- to &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;four&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;-year period. There have been no awards granted with performance conditions or market conditions for the periods presented. The options have a contractual term of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;10&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; years. The fair value of options is estimated using the Black&amp;#8209;Scholes option pricing model, which has various inputs, including the grant date common share price, exercise price, risk&amp;#8209;free interest rate, volatility, expected life and dividend yield. The change of any of these inputs could significantly impact the determination of the fair value of the Company&amp;#8217;s options as well as significantly impact its results of operations. The fair value of RSU grants is determined at the grant date based on the common share price. The Company records stock&amp;#8209;based compensation expense net of actual forfeitures when they occur.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The weighted-averages for key assumptions used in determining the fair value of stock options granted were as follows:    &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.28571428571429%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Three Months Ended&lt;br clear="none"/&gt;September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Nine Months Ended&lt;br clear="none"/&gt;September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Volatility&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;59.5%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;59.0%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;59.3%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;57.7%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Risk-free interest rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;1.75%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;2.87%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;2.49%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;2.64%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Expected life (years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;5.96&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;6.25&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;6.16&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;6.23&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Dividend yield rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;&amp;#8212;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;&amp;#8212;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;&amp;#8212;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;&amp;#8212;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;A summary of stock option activity under the Plan for the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;nine months ended September 30, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, is presented below:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:86.90476190476191%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:43%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:15%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;"&gt;Remaining&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;"&gt;Aggregate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;"&gt;Stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;"&gt;Exercise&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;"&gt;Contractual&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;"&gt;Intrinsic&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;"&gt;Options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;"&gt;Per Share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;"&gt;Terms (Years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Outstanding, December 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;3,257,801&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;11.99&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;9.26&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;7,119&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;1,202,981&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;19.16&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Exercised&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;(138,849&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;9.98&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Canceled/forfeited&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;(269,772&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;14.07&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Outstanding, September&amp;#160;30, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;4,052,161&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;14.05&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;8.53&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;14,830&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Exercisable, September&amp;#160;30, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;833,730&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;11.83&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;7.30&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;4,301&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The intrinsic values of outstanding and exercisable options were determined by multiplying the number of shares by the difference in exercise price of the options and the fair value of the common stock as of&amp;#160;December&amp;#160;31, 2018 and the first trading day preceding &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;September&amp;#160;30, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;A summary of RSU activity under the Plan for the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;nine months ended September 30, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, is presented below:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:70.03968253968253%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:58%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:20%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;"&gt;Restricted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;"&gt;Grant Date&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;"&gt;Stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;"&gt;Units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;"&gt;Per Share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Outstanding, December 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;271,404&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;16.53&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;3,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;18.33&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Vested&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;(22,125&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;25.69&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Forfeited&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;(19,409&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;13.71&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Outstanding, September&amp;#160;30, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;232,870&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;15.92&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The following table summarizes stock-based compensation expense arising from the above Plan:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:88.29365079365078%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Three Months Ended&lt;br clear="none"/&gt;September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Nine Months Ended&lt;br clear="none"/&gt;September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Selling, general and administrative&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2,417&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;1,160&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;6,443&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;4,083&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Research and development&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;109&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;322&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;538&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;1,028&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;2,526&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;1,482&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;6,981&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;5,111&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;In addition, during the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;three and nine months ended September 30, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, the Company capitalized &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$30&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$76&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, respectively, of stock-based compensation expense in capitalized software. Capitalized software is a component of intangible assets and is presented in the accompanying condensed balance sheets. See &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Note 5&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Goodwill and Intangible Assets&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; for capitalized  software information.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
	<us-gaap:UseOfEstimates contextRef="FD2019Q3YTD" id="Fact-EEB5E364566F192539414537031DC16D">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Use of Estimates&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates, judgments, and assumptions that affect the amounts reported in the financial statements and disclosures made in the accompanying notes. Actual results could materially differ from those estimates, judgments, and assumptions. Management considers many factors in selecting appropriate financial accounting policies and controls and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes, and management must select an amount that falls within that range of reasonable estimates.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;On an ongoing basis, the Company evaluates the most significant estimates, including those related to net revenues, allowance for doubtful accounts, fair value measurements, goodwill and long-lived asset valuations and impairment assessments, inventory valuations, income tax valuations and stock-based compensation expense, among others. Although the Company bases estimates on historical experience, knowledge of current events and actions it may undertake in the future, and on various other assumptions that are believed to be reasonable, this process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
	<link:footnoteLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
	</link:footnoteLink>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>eols-20190930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<xsd:schema attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.evolus.com/20190930" xmlns:eols="http://www.evolus.com/20190930" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import namespace="http://fasb.org/srt-types/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/srt/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-types/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/currency/2019-01-31" schemaLocation="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/exch/2019-01-31" schemaLocation="https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/naics/2017-01-31" schemaLocation="http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2018-01-31" schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="eols-20190930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="eols-20190930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="eols-20190930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="eols-20190930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple" />
      <link:roleType id="AccruedExpenses" roleURI="http://www.evolus.com/role/AccruedExpenses">
        <link:definition>2104100 - Disclosure - Accrued Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesDetails" roleURI="http://www.evolus.com/role/AccruedExpensesDetails">
        <link:definition>2404402 - Disclosure - Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesTables" roleURI="http://www.evolus.com/role/AccruedExpensesTables">
        <link:definition>2304301 - Disclosure - Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingencies" roleURI="http://www.evolus.com/role/CommitmentsAndContingencies">
        <link:definition>2107100 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingenciesLeaseCostDetails" roleURI="http://www.evolus.com/role/CommitmentsAndContingenciesLeaseCostDetails">
        <link:definition>2407403 - Disclosure - Commitments and Contingencies - Lease Cost (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingenciesNarrativeDetails" roleURI="http://www.evolus.com/role/CommitmentsAndContingenciesNarrativeDetails">
        <link:definition>2407402 - Disclosure - Commitments and Contingencies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingenciesOperatingLeaseMaturityDetails" roleURI="http://www.evolus.com/role/CommitmentsAndContingenciesOperatingLeaseMaturityDetails">
        <link:definition>2407404 - Disclosure - Commitments and Contingencies - Operating Lease Maturity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingenciesOperatingLeaseMaturityDetailsCalc2" roleURI="http://www.evolus.com/role/CommitmentsAndContingenciesOperatingLeaseMaturityDetailsCalc2">
        <link:definition>2407404 - Disclosure - Commitments and Contingencies - Operating Lease Maturity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingenciesTables" roleURI="http://www.evolus.com/role/CommitmentsAndContingenciesTables">
        <link:definition>2307301 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedBalanceSheets" roleURI="http://www.evolus.com/role/CondensedBalanceSheets">
        <link:definition>1001000 - Statement - Condensed Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedBalanceSheetsParenthetical" roleURI="http://www.evolus.com/role/CondensedBalanceSheetsParenthetical">
        <link:definition>1001001 - Statement - Condensed Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedStatementsOfCashFlows" roleURI="http://www.evolus.com/role/CondensedStatementsOfCashFlows">
        <link:definition>1004000 - Statement - Condensed Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedStatementsOfOperationsAndComprehensiveLoss" roleURI="http://www.evolus.com/role/CondensedStatementsOfOperationsAndComprehensiveLoss">
        <link:definition>1002000 - Statement - Condensed Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedStatementsOfStockholdersEquity" roleURI="http://www.evolus.com/role/CondensedStatementsOfStockholdersEquity">
        <link:definition>1003000 - Statement - Condensed Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionOfBusinessAndBasisOfPresentation" roleURI="http://www.evolus.com/role/DescriptionOfBusinessAndBasisOfPresentation">
        <link:definition>2101100 - Disclosure - Description of Business and Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionOfBusinessAndBasisOfPresentationDetails" roleURI="http://www.evolus.com/role/DescriptionOfBusinessAndBasisOfPresentationDetails">
        <link:definition>2401401 - Disclosure - Description of Business and Basis of Presentation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DocumentAndEntityInformation" roleURI="http://www.evolus.com/role/DocumentAndEntityInformation">
        <link:definition>0001000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsAndShortTermInvestments" roleURI="http://www.evolus.com/role/FairValueMeasurementsAndShortTermInvestments">
        <link:definition>2106100 - Disclosure - Fair Value Measurements and Short-Term Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsAndShortTermInvestmentsAssetsAndLiabilitiesOnRecurringBasisDetails" roleURI="http://www.evolus.com/role/FairValueMeasurementsAndShortTermInvestmentsAssetsAndLiabilitiesOnRecurringBasisDetails">
        <link:definition>2406403 - Disclosure - Fair Value Measurements and Short-Term Investments - Assets and Liabilities on a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsAndShortTermInvestmentsContingentRoyaltyObligationDetails" roleURI="http://www.evolus.com/role/FairValueMeasurementsAndShortTermInvestmentsContingentRoyaltyObligationDetails">
        <link:definition>2406405 - Disclosure - Fair Value Measurements and Short-Term Investments - Contingent Royalty Obligation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsAndShortTermInvestmentsNarrativeDetails" roleURI="http://www.evolus.com/role/FairValueMeasurementsAndShortTermInvestmentsNarrativeDetails">
        <link:definition>2406404 - Disclosure - Fair Value Measurements and Short-Term Investments - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsAndShortTermInvestmentsScheduleOfShortTermInvestmentsDetails" roleURI="http://www.evolus.com/role/FairValueMeasurementsAndShortTermInvestmentsScheduleOfShortTermInvestmentsDetails">
        <link:definition>2406402 - Disclosure - Fair Value Measurements and Short-Term Investments - Schedule of Short-term Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsAndShortTermInvestmentsTables" roleURI="http://www.evolus.com/role/FairValueMeasurementsAndShortTermInvestmentsTables">
        <link:definition>2306301 - Disclosure - Fair Value Measurements and Short-Term Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillAndIntangibleAssetNarrativeDetails" roleURI="http://www.evolus.com/role/GoodwillAndIntangibleAssetNarrativeDetails">
        <link:definition>2404404 - Disclosure - Goodwill and Intangible Asset - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillAndIntangibleAssets" roleURI="http://www.evolus.com/role/GoodwillAndIntangibleAssets">
        <link:definition>2104100 - Disclosure - Goodwill and Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillAndIntangibleAssetsFutureAmortizationExpenseDetails" roleURI="http://www.evolus.com/role/GoodwillAndIntangibleAssetsFutureAmortizationExpenseDetails">
        <link:definition>2404403 - Disclosure - Goodwill and Intangible Assets - Future Amortization Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillAndIntangibleAssetsScheduleOfDefiniteAndIndefiniteLivedIntangibleAssetsDetails" roleURI="http://www.evolus.com/role/GoodwillAndIntangibleAssetsScheduleOfDefiniteAndIndefiniteLivedIntangibleAssetsDetails">
        <link:definition>2404402 - Disclosure - Goodwill and Intangible Assets - Schedule of Definite and Indefinite-Lived Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillAndIntangibleAssetsTables" roleURI="http://www.evolus.com/role/GoodwillAndIntangibleAssetsTables">
        <link:definition>2304301 - Disclosure - Goodwill and Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OxfordTermLoans" roleURI="http://www.evolus.com/role/OxfordTermLoans">
        <link:definition>2105100 - Disclosure - Oxford Term Loans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OxfordTermLoansMaturitiesOfDebtDetails" roleURI="http://www.evolus.com/role/OxfordTermLoansMaturitiesOfDebtDetails">
        <link:definition>2405403 - Disclosure - Oxford Term Loans - Maturities of Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OxfordTermLoansMaturitiesOfDebtDetailsCalc2" roleURI="http://www.evolus.com/role/OxfordTermLoansMaturitiesOfDebtDetailsCalc2">
        <link:definition>2405403 - Disclosure - Oxford Term Loans - Maturities of Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OxfordTermLoansNarrativeDetails" roleURI="http://www.evolus.com/role/OxfordTermLoansNarrativeDetails">
        <link:definition>2405402 - Disclosure - Oxford Term Loans - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OxfordTermLoansTables" roleURI="http://www.evolus.com/role/OxfordTermLoansTables">
        <link:definition>2305301 - Disclosure - Oxford Term Loans (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactions" roleURI="http://www.evolus.com/role/RelatedPartyTransactions">
        <link:definition>2103100 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsDetails" roleURI="http://www.evolus.com/role/RelatedPartyTransactionsDetails">
        <link:definition>2403401 - Disclosure - Related Party Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.evolus.com/role/StockholdersEquity">
        <link:definition>2108100 - Disclosure - Stockholders&#8217; Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityNarrativeDetails" roleURI="http://www.evolus.com/role/StockholdersEquityNarrativeDetails">
        <link:definition>2408402 - Disclosure - Stockholder's Equity - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityRestrictedStockUnitDetails" roleURI="http://www.evolus.com/role/StockholdersEquityRestrictedStockUnitDetails">
        <link:definition>2408405 - Disclosure - Stockholders&#8217; Equity - Restricted Stock Unit (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityScheduleOfStockOptionActivityDetails" roleURI="http://www.evolus.com/role/StockholdersEquityScheduleOfStockOptionActivityDetails">
        <link:definition>2408404 - Disclosure - Stockholders&#8217; Equity - Schedule of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityScheduleOfValuationAssumptionsDetails" roleURI="http://www.evolus.com/role/StockholdersEquityScheduleOfValuationAssumptionsDetails">
        <link:definition>2408403 - Disclosure - Stockholders&#8217; Equity - Schedule of Valuation Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityStockBasedCompensationExpenseAllocationDetails" roleURI="http://www.evolus.com/role/StockholdersEquityStockBasedCompensationExpenseAllocationDetails">
        <link:definition>2408406 - Disclosure - Stockholder's Equity - Stock-based Compensation Expense Allocation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityTables" roleURI="http://www.evolus.com/role/StockholdersEquityTables">
        <link:definition>2308301 - Disclosure - Stockholder's Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPolicies" roleURI="http://www.evolus.com/role/SummaryOfSignificantAccountingPolicies">
        <link:definition>2102100 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.evolus.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails">
        <link:definition>2402403 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesNewAccountingPronouncementsDetails" roleURI="http://www.evolus.com/role/SummaryOfSignificantAccountingPoliciesNewAccountingPronouncementsDetails">
        <link:definition>2402404 - Disclosure - Summary of Significant Accounting Policies - New Accounting Pronouncements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.evolus.com/role/SummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>2202201 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesTables" roleURI="http://www.evolus.com/role/SummaryOfSignificantAccountingPoliciesTables">
        <link:definition>2302302 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element abstract="true" id="eols_ALPHAEONMember" name="ALPHAEONMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="eols_AccountingPoliciesLineItems" name="AccountingPoliciesLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="eols_AccountingPoliciesTable" name="AccountingPoliciesTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="eols_AccountsPayablePaidbyParent" name="AccountsPayablePaidbyParent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="eols_AccruedCouponAndRebateLiabilityCurrent" name="AccruedCouponAndRebateLiabilityCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="eols_AcquiredFinitelivedIntangibleAssetPeriodOfExtensionOfTermsBasedOnCertainPerformanceRequirements" name="AcquiredFinitelivedIntangibleAssetPeriodOfExtensionOfTermsBasedOnCertainPerformanceRequirements" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="eols_AllocatedShareBasedCompensationExpenseCapitalized" name="AllocatedShareBasedCompensationExpenseCapitalized" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="eols_AmortizationOfDiscountOnShorttermInvestments" name="AmortizationOfDiscountOnShorttermInvestments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="eols_ApplicableRateMember" name="ApplicableRateMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="eols_BusinessAcquisitionUnwindingFee" name="BusinessAcquisitionUnwindingFee" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="eols_BusinessCombinationUpfrontPaymentUponObtainingFDAApproval" name="BusinessCombinationUpfrontPaymentUponObtainingFDAApproval" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="eols_CapitalContributionConvertibleNoteWriteOff" name="CapitalContributionConvertibleNoteWriteOff" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="eols_CapitalContributionForgivenessofRelatedPartyBorrowings" name="CapitalContributionForgivenessofRelatedPartyBorrowings" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="eols_CapitalContributionFromParentForgivenessOfRelatedPartyBorrowings" name="CapitalContributionFromParentForgivenessOfRelatedPartyBorrowings" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="eols_ChiefMedicalOfficerMember" name="ChiefMedicalOfficerMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="eols_CommonStockAdditionalCapitalSharesReservedforFutureIssuance" name="CommonStockAdditionalCapitalSharesReservedforFutureIssuance" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element id="eols_ContingentPromissoryNote" name="ContingentPromissoryNote" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="eols_ContingentRoyaltyObligation" name="ContingentRoyaltyObligation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="eols_ContingentRoyaltyObligationMember" name="ContingentRoyaltyObligationMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="eols_ContingentRoyaltyObligationPayabletoRelatedPartyCurrent" name="ContingentRoyaltyObligationPayabletoRelatedPartyCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="eols_DaewoongMember" name="DaewoongMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="eols_DebtInstrumentAdditionalAmortizationPeriod" name="DebtInstrumentAdditionalAmortizationPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="eols_DebtInstrumentAdditionalPeriodOfAgreementOfInterestPayment" name="DebtInstrumentAdditionalPeriodOfAgreementOfInterestPayment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="eols_DebtInstrumentAmortizationPeriod" name="DebtInstrumentAmortizationPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="eols_DebtInstrumentDefaultInterestRate" name="DebtInstrumentDefaultInterestRate" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="eols_DebtInstrumentPercentageOfPrincipalAmountBalloonPayment" name="DebtInstrumentPercentageOfPrincipalAmountBalloonPayment" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="eols_DebtInstrumentPeriodOfInterestOnlyPayments" name="DebtInstrumentPeriodOfInterestOnlyPayments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="eols_DebtInstrumentPrepaymentFeePercentageNextTwelveMonths" name="DebtInstrumentPrepaymentFeePercentageNextTwelveMonths" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="eols_DebtInstrumentPrepaymentFeePercentageThereafter" name="DebtInstrumentPrepaymentFeePercentageThereafter" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="eols_DebtInstrumentPrepaymentFeePercentageYearTwo" name="DebtInstrumentPrepaymentFeePercentageYearTwo" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="eols_DebtInstrumentTermAggregatePeriod" name="DebtInstrumentTermAggregatePeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="eols_DeemedContributionFromParentIncreaseOfRelatedPartyReceivable" name="DeemedContributionFromParentIncreaseOfRelatedPartyReceivable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="eols_DocumentAndEntityInformationAbstract" name="DocumentAndEntityInformationAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="eols_EvolusIncMember" name="EvolusIncMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="eols_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityPayments" name="FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityPayments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="eols_IncreasedecreaseInOperatingLeaseLiabilities" name="IncreasedecreaseInOperatingLeaseLiabilities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="eols_IntangibleAssetsGrossIncludingGoodwill" name="IntangibleAssetsGrossIncludingGoodwill" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="eols_LesseeOperatingLeasePeriodOfWrittenNoticePriorToLeaseTerminateDate" name="LesseeOperatingLeasePeriodOfWrittenNoticePriorToLeaseTerminateDate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="eols_LesseeOperatingLeaseTerminationFeePeriodOfRentEquivalent" name="LesseeOperatingLeaseTerminationFeePeriodOfRentEquivalent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="eols_LesseeOperatingLeaseTerminationPeriod" name="LesseeOperatingLeaseTerminationPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="eols_LongTermDebtByMaturityTotalAbstract" name="LongTermDebtByMaturityTotalAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="eols_LongTermDebtFinalPaymentAbstract" name="LongTermDebtFinalPaymentAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="eols_LongtermDebtMaturitiesFinalPayments" name="LongtermDebtMaturitiesFinalPayments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="eols_LongtermDebtMaturitiesFinalPaymentsInYearFive" name="LongtermDebtMaturitiesFinalPaymentsInYearFive" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="eols_LongtermDebtMaturitiesFinalPaymentsInYearFour" name="LongtermDebtMaturitiesFinalPaymentsInYearFour" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="eols_LongtermDebtMaturitiesFinalPaymentsInYearThree" name="LongtermDebtMaturitiesFinalPaymentsInYearThree" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="eols_LongtermDebtMaturitiesPrincipalPaymentExcludingFinalPayment" name="LongtermDebtMaturitiesPrincipalPaymentExcludingFinalPayment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="eols_LongtermDebtMaturitiesPrincipalPaymentExcludingFinalPaymentDueInYearFive" name="LongtermDebtMaturitiesPrincipalPaymentExcludingFinalPaymentDueInYearFive" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="eols_LongtermDebtMaturitiesPrincipalPaymentExcludingFinalPaymentDueInYearFour" name="LongtermDebtMaturitiesPrincipalPaymentExcludingFinalPaymentDueInYearFour" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="eols_LongtermDebtMaturitiesPrincipalPaymentExcludingFinalPaymentDueInYearThree" name="LongtermDebtMaturitiesPrincipalPaymentExcludingFinalPaymentDueInYearThree" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="eols_MilestonePaymentCurrent" name="MilestonePaymentCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="eols_MilestonePaymentInConnectionWithLicenseAndSupplyAgreement" name="MilestonePaymentInConnectionWithLicenseAndSupplyAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="eols_MilestonePaymentsForIntangibleAssets" name="MilestonePaymentsForIntangibleAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="eols_NonCashDeferredOfferingCosts" name="NonCashDeferredOfferingCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="eols_NonCashFinanceAndInsurancePayment" name="NonCashFinanceAndInsurancePayment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="eols_NonCashLandlordPaidTenantImprovement" name="NonCashLandlordPaidTenantImprovement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="eols_NonCashNoteObligation" name="NonCashNoteObligation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="eols_NonCashRelatedPartyBorrowings" name="NonCashRelatedPartyBorrowings" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="eols_NonCashRelatedPartyReceivable" name="NonCashRelatedPartyReceivable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="eols_OperatingLeasePercentageOfAnnualRentEscalation" name="OperatingLeasePercentageOfAnnualRentEscalation" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="eols_OperatingLeaseRightofUseAssetAmortization" name="OperatingLeaseRightofUseAssetAmortization" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="eols_OxfordTermLoansMember" name="OxfordTermLoansMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="eols_PaymentsForProvisionsForAccruedVolumeBasedRebateAndCouponLiability" name="PaymentsForProvisionsForAccruedVolumeBasedRebateAndCouponLiability" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="eols_PaymentsOfContingentRoyaltyObligation" name="PaymentsOfContingentRoyaltyObligation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="eols_ProceedsFromPaymentsForIssuanceOfCommonStockInConnectionWithEquityIncentivePlan" name="ProceedsFromPaymentsForIssuanceOfCommonStockInConnectionWithEquityIncentivePlan" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="eols_ProvisionsForAccruedVolumeBasedRebateAndCouponLiability" name="ProvisionsForAccruedVolumeBasedRebateAndCouponLiability" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="eols_ProvisionsForRebateAndCouponPrograms" name="ProvisionsForRebateAndCouponPrograms" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="eols_RelatedPartyTransactionPeriodOfTerminationOfFirstCommercialSale" name="RelatedPartyTransactionPeriodOfTerminationOfFirstCommercialSale" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="eols_RevaluationofContingentRoyaltyObligationPayable" name="RevaluationofContingentRoyaltyObligationPayable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="eols_SCHAEONLLCMember" name="SCHAEONLLCMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsForfeitedinPeriodIntrinsicValue" name="SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsForfeitedinPeriodIntrinsicValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsGrantedinPeriodIntrinsicValue" name="SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsGrantedinPeriodIntrinsicValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract" name="SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermExercisable" name="SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermExercisable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="eols_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan" name="StockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="eols_StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan" name="StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="eols_StockPurchaseAgreementPeriodAvailabletoCureBreach" name="StockPurchaseAgreementPeriodAvailabletoCureBreach" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="eols_TermLoanFacilityMember" name="TermLoanFacilityMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="eols_TermLoanFacilityTrancheOneMember" name="TermLoanFacilityTrancheOneMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="eols_TermLoanFacilityTrancheTwoMember" name="TermLoanFacilityTrancheTwoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>eols-20190930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.evolus.com/role/AccruedExpenses" xlink:href="eols-20190930.xsd#AccruedExpenses" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/AccruedExpensesDetails" xlink:href="eols-20190930.xsd#AccruedExpensesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/AccruedExpensesTables" xlink:href="eols-20190930.xsd#AccruedExpensesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/CommitmentsAndContingencies" xlink:href="eols-20190930.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/CommitmentsAndContingenciesLeaseCostDetails" xlink:href="eols-20190930.xsd#CommitmentsAndContingenciesLeaseCostDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/CommitmentsAndContingenciesNarrativeDetails" xlink:href="eols-20190930.xsd#CommitmentsAndContingenciesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/CommitmentsAndContingenciesOperatingLeaseMaturityDetails" xlink:href="eols-20190930.xsd#CommitmentsAndContingenciesOperatingLeaseMaturityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/CommitmentsAndContingenciesOperatingLeaseMaturityDetailsCalc2" xlink:href="eols-20190930.xsd#CommitmentsAndContingenciesOperatingLeaseMaturityDetailsCalc2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/CommitmentsAndContingenciesTables" xlink:href="eols-20190930.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/CondensedBalanceSheets" xlink:href="eols-20190930.xsd#CondensedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/CondensedBalanceSheetsParenthetical" xlink:href="eols-20190930.xsd#CondensedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/CondensedStatementsOfCashFlows" xlink:href="eols-20190930.xsd#CondensedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/CondensedStatementsOfOperationsAndComprehensiveLoss" xlink:href="eols-20190930.xsd#CondensedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/CondensedStatementsOfStockholdersEquity" xlink:href="eols-20190930.xsd#CondensedStatementsOfStockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/DescriptionOfBusinessAndBasisOfPresentation" xlink:href="eols-20190930.xsd#DescriptionOfBusinessAndBasisOfPresentation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/DescriptionOfBusinessAndBasisOfPresentationDetails" xlink:href="eols-20190930.xsd#DescriptionOfBusinessAndBasisOfPresentationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/DocumentAndEntityInformation" xlink:href="eols-20190930.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/FairValueMeasurementsAndShortTermInvestments" xlink:href="eols-20190930.xsd#FairValueMeasurementsAndShortTermInvestments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/FairValueMeasurementsAndShortTermInvestmentsAssetsAndLiabilitiesOnRecurringBasisDetails" xlink:href="eols-20190930.xsd#FairValueMeasurementsAndShortTermInvestmentsAssetsAndLiabilitiesOnRecurringBasisDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/FairValueMeasurementsAndShortTermInvestmentsContingentRoyaltyObligationDetails" xlink:href="eols-20190930.xsd#FairValueMeasurementsAndShortTermInvestmentsContingentRoyaltyObligationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/FairValueMeasurementsAndShortTermInvestmentsNarrativeDetails" xlink:href="eols-20190930.xsd#FairValueMeasurementsAndShortTermInvestmentsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/FairValueMeasurementsAndShortTermInvestmentsScheduleOfShortTermInvestmentsDetails" xlink:href="eols-20190930.xsd#FairValueMeasurementsAndShortTermInvestmentsScheduleOfShortTermInvestmentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/FairValueMeasurementsAndShortTermInvestmentsTables" xlink:href="eols-20190930.xsd#FairValueMeasurementsAndShortTermInvestmentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/GoodwillAndIntangibleAssetNarrativeDetails" xlink:href="eols-20190930.xsd#GoodwillAndIntangibleAssetNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/GoodwillAndIntangibleAssets" xlink:href="eols-20190930.xsd#GoodwillAndIntangibleAssets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/GoodwillAndIntangibleAssetsFutureAmortizationExpenseDetails" xlink:href="eols-20190930.xsd#GoodwillAndIntangibleAssetsFutureAmortizationExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/GoodwillAndIntangibleAssetsScheduleOfDefiniteAndIndefiniteLivedIntangibleAssetsDetails" xlink:href="eols-20190930.xsd#GoodwillAndIntangibleAssetsScheduleOfDefiniteAndIndefiniteLivedIntangibleAssetsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/GoodwillAndIntangibleAssetsTables" xlink:href="eols-20190930.xsd#GoodwillAndIntangibleAssetsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/OxfordTermLoans" xlink:href="eols-20190930.xsd#OxfordTermLoans" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/OxfordTermLoansMaturitiesOfDebtDetails" xlink:href="eols-20190930.xsd#OxfordTermLoansMaturitiesOfDebtDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/OxfordTermLoansMaturitiesOfDebtDetailsCalc2" xlink:href="eols-20190930.xsd#OxfordTermLoansMaturitiesOfDebtDetailsCalc2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/OxfordTermLoansNarrativeDetails" xlink:href="eols-20190930.xsd#OxfordTermLoansNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/OxfordTermLoansTables" xlink:href="eols-20190930.xsd#OxfordTermLoansTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/RelatedPartyTransactions" xlink:href="eols-20190930.xsd#RelatedPartyTransactions" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/RelatedPartyTransactionsDetails" xlink:href="eols-20190930.xsd#RelatedPartyTransactionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/StockholdersEquity" xlink:href="eols-20190930.xsd#StockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/StockholdersEquityNarrativeDetails" xlink:href="eols-20190930.xsd#StockholdersEquityNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/StockholdersEquityRestrictedStockUnitDetails" xlink:href="eols-20190930.xsd#StockholdersEquityRestrictedStockUnitDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/StockholdersEquityScheduleOfStockOptionActivityDetails" xlink:href="eols-20190930.xsd#StockholdersEquityScheduleOfStockOptionActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/StockholdersEquityScheduleOfValuationAssumptionsDetails" xlink:href="eols-20190930.xsd#StockholdersEquityScheduleOfValuationAssumptionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/StockholdersEquityStockBasedCompensationExpenseAllocationDetails" xlink:href="eols-20190930.xsd#StockholdersEquityStockBasedCompensationExpenseAllocationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/StockholdersEquityTables" xlink:href="eols-20190930.xsd#StockholdersEquityTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="eols-20190930.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:href="eols-20190930.xsd#SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/SummaryOfSignificantAccountingPoliciesNewAccountingPronouncementsDetails" xlink:href="eols-20190930.xsd#SummaryOfSignificantAccountingPoliciesNewAccountingPronouncementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="eols-20190930.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="eols-20190930.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:calculationLink xlink:role="http://www.evolus.com/role/AccruedExpenses" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.evolus.com/role/AccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_9a34fc5e-00bc-420c-8698-6e19b92b8e39" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_3aae0f17-e5b2-b861-7c74-9a4f42f6d1c8" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_9a34fc5e-00bc-420c-8698-6e19b92b8e39" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_3aae0f17-e5b2-b861-7c74-9a4f42f6d1c8" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_AccruedCouponAndRebateLiabilityCurrent" xlink:label="loc_eols_AccruedCouponAndRebateLiabilityCurrent_E3255C90384648A2C2ACFF31E562530E" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_9a34fc5e-00bc-420c-8698-6e19b92b8e39" xlink:to="loc_eols_AccruedCouponAndRebateLiabilityCurrent_E3255C90384648A2C2ACFF31E562530E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_a2b836a7-cc87-0e4f-38a0-c91a29535622" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_9a34fc5e-00bc-420c-8698-6e19b92b8e39" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_a2b836a7-cc87-0e4f-38a0-c91a29535622" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_MilestonePaymentCurrent" xlink:label="loc_eols_MilestonePaymentCurrent_E754E14F28AC8608998C0F0534F87B76" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_9a34fc5e-00bc-420c-8698-6e19b92b8e39" xlink:to="loc_eols_MilestonePaymentCurrent_E754E14F28AC8608998C0F0534F87B76" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_fa7787c9-a33c-d084-bb97-5e2455f77a4c" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_9a34fc5e-00bc-420c-8698-6e19b92b8e39" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_fa7787c9-a33c-d084-bb97-5e2455f77a4c" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.evolus.com/role/AccruedExpensesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.evolus.com/role/CommitmentsAndContingencies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.evolus.com/role/CommitmentsAndContingenciesLeaseCostDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaap_LeaseCost_ac3b1889-9651-365f-e4fc-e6474385db69" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaap_OperatingLeaseCost_88d5ba82-39dd-36ed-37fe-92977ff632df" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_ac3b1889-9651-365f-e4fc-e6474385db69" xlink:to="loc_us-gaap_OperatingLeaseCost_88d5ba82-39dd-36ed-37fe-92977ff632df" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableLeaseCost" xlink:label="loc_us-gaap_VariableLeaseCost_3df88f41-850d-02ae-dd0b-ab0215935a95" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_ac3b1889-9651-365f-e4fc-e6474385db69" xlink:to="loc_us-gaap_VariableLeaseCost_3df88f41-850d-02ae-dd0b-ab0215935a95" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermLeaseCost" xlink:label="loc_us-gaap_ShortTermLeaseCost_4efa230c-b1e9-e41e-ae56-b6a8565f3216" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_ac3b1889-9651-365f-e4fc-e6474385db69" xlink:to="loc_us-gaap_ShortTermLeaseCost_4efa230c-b1e9-e41e-ae56-b6a8565f3216" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.evolus.com/role/CommitmentsAndContingenciesNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.evolus.com/role/CommitmentsAndContingenciesOperatingLeaseMaturityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_07815ffa-512a-3133-dcbb-38e09d2626b9" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_07815ffa-512a-3133-dcbb-38e09d2626b9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_b983c2d8-8318-0a7e-1a5c-6ab2933f7be5" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:to="loc_us-gaap_OperatingLeaseLiability_b983c2d8-8318-0a7e-1a5c-6ab2933f7be5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_acfb1bbb-4a5b-18c4-ab71-d62ae0aecfa0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_0595fc12-0026-682e-b8ca-580675617e69" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_acfb1bbb-4a5b-18c4-ab71-d62ae0aecfa0" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_0595fc12-0026-682e-b8ca-580675617e69" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_f2a573e7-27e5-db11-63c6-c460733b5ea3" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_acfb1bbb-4a5b-18c4-ab71-d62ae0aecfa0" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_f2a573e7-27e5-db11-63c6-c460733b5ea3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_398384fb-b756-b11a-1ea4-5a5cd4372c82" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_acfb1bbb-4a5b-18c4-ab71-d62ae0aecfa0" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_398384fb-b756-b11a-1ea4-5a5cd4372c82" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.evolus.com/role/CommitmentsAndContingenciesOperatingLeaseMaturityDetailsCalc2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_7C218A4DD333D220B41BFEEBEEE5D68C_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_7C218A4DD333D220B41BFEEBEEE5D68C_48abcf97-737b-2b2c-8a8c-c74539d0b215" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_7C218A4DD333D220B41BFEEBEEE5D68C_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_7C218A4DD333D220B41BFEEBEEE5D68C_48abcf97-737b-2b2c-8a8c-c74539d0b215" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_7C218A4DD333D220B41BFEEBEEE5D68C_9b040bc1-f43c-735d-05f7-679f319d2bb6" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_7C218A4DD333D220B41BFEEBEEE5D68C_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_7C218A4DD333D220B41BFEEBEEE5D68C_9b040bc1-f43c-735d-05f7-679f319d2bb6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_7C218A4DD333D220B41BFEEBEEE5D68C_2f0ec234-4f20-7099-efb3-3c0ab4d024dd" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_7C218A4DD333D220B41BFEEBEEE5D68C_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_7C218A4DD333D220B41BFEEBEEE5D68C_2f0ec234-4f20-7099-efb3-3c0ab4d024dd" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_7C218A4DD333D220B41BFEEBEEE5D68C_1ed751b1-5f94-4f6f-41e9-ef873c9f2bab" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_7C218A4DD333D220B41BFEEBEEE5D68C_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_7C218A4DD333D220B41BFEEBEEE5D68C_1ed751b1-5f94-4f6f-41e9-ef873c9f2bab" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_7C218A4DD333D220B41BFEEBEEE5D68C_8a8de21f-aadc-3af7-8c96-d54cf42b401b" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_7C218A4DD333D220B41BFEEBEEE5D68C_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_7C218A4DD333D220B41BFEEBEEE5D68C_8a8de21f-aadc-3af7-8c96-d54cf42b401b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_7C218A4DD333D220B41BFEEBEEE5D68C_b411eec9-2a0a-356b-e751-bd0680ab4d58" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_7C218A4DD333D220B41BFEEBEEE5D68C_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_7C218A4DD333D220B41BFEEBEEE5D68C_b411eec9-2a0a-356b-e751-bd0680ab4d58" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.evolus.com/role/CommitmentsAndContingenciesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.evolus.com/role/CondensedBalanceSheets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_d7f1ad03-6ed4-706a-15fc-eae794dee33a" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_d7f1ad03-6ed4-706a-15fc-eae794dee33a" xlink:to="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_f05ab245-2bd1-7865-e7ed-1461a5a6155f" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:to="loc_us-gaap_CommonStockValue_f05ab245-2bd1-7865-e7ed-1461a5a6155f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_3d5a0ca6-0f59-67e6-adb5-6aecd22b693b" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:to="loc_us-gaap_AdditionalPaidInCapital_3d5a0ca6-0f59-67e6-adb5-6aecd22b693b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_62305d8f-d807-0fe8-d0ab-f2c2b3d03011" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_62305d8f-d807-0fe8-d0ab-f2c2b3d03011" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_988c1346-b444-a867-fe80-f3aec1443d54" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_988c1346-b444-a867-fe80-f3aec1443d54" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_4d934b0d-59bc-ae5c-ffb9-b6ced82ff9f8" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_d7f1ad03-6ed4-706a-15fc-eae794dee33a" xlink:to="loc_us-gaap_CommitmentsAndContingencies_4d934b0d-59bc-ae5c-ffb9-b6ced82ff9f8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_d7f1ad03-6ed4-706a-15fc-eae794dee33a" xlink:to="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:to="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_9c889623-7b4f-c89a-bbb3-2bc9fb9ad9f5" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:to="loc_us-gaap_AccountsPayableCurrent_9c889623-7b4f-c89a-bbb3-2bc9fb9ad9f5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_b91d2f01-85c2-f9fb-3250-26a4b1b39c5e" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_b91d2f01-85c2-f9fb-3250-26a4b1b39c5e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_c90cf113-b51b-4312-22d0-4adb9883d309" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_c90cf113-b51b-4312-22d0-4adb9883d309" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_ContingentRoyaltyObligationPayabletoRelatedPartyCurrent" xlink:label="loc_eols_ContingentRoyaltyObligationPayabletoRelatedPartyCurrent_102cf023-53db-cf58-02b1-453717351e05" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:to="loc_eols_ContingentRoyaltyObligationPayabletoRelatedPartyCurrent_102cf023-53db-cf58-02b1-453717351e05" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractualObligation" xlink:label="loc_us-gaap_ContractualObligation_6006a94d-54bf-b592-67ad-cc2e5783ac49" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:to="loc_us-gaap_ContractualObligation_6006a94d-54bf-b592-67ad-cc2e5783ac49" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaap_LongTermNotesPayable_622e5770-f948-044b-c6fe-ee319e65b163" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:to="loc_us-gaap_LongTermNotesPayable_622e5770-f948-044b-c6fe-ee319e65b163" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_64993a75-9b0c-349a-1011-cc5a81c58412" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_64993a75-9b0c-349a-1011-cc5a81c58412" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_aa2e73c1-d03e-7f76-3502-7a650f99607c" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_aa2e73c1-d03e-7f76-3502-7a650f99607c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="loc_us-gaap_DeferredRentCreditNoncurrent_5d3f3f8e-8f06-ee35-6076-a0312a3c4f12" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:to="loc_us-gaap_DeferredRentCreditNoncurrent_5d3f3f8e-8f06-ee35-6076-a0312a3c4f12" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_d18f979c-644d-9e92-9e89-21cfd1312948" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_d18f979c-644d-9e92-9e89-21cfd1312948" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1de780cc-9607-daa3-0bed-03c88ae94769" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1de780cc-9607-daa3-0bed-03c88ae94769" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5fd9c643-899e-95d7-aab9-c3a9d6240218" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5fd9c643-899e-95d7-aab9-c3a9d6240218" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_cc720f44-4c90-5acc-2e7e-b88e80f2af28" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:to="loc_us-gaap_InventoryNet_cc720f44-4c90-5acc-2e7e-b88e80f2af28" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_dd2cbe99-77d2-db20-3c91-750589881c79" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_dd2cbe99-77d2-db20-3c91-750589881c79" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_e2b10c93-5dbd-d345-d7e4-6144b8287c24" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_e2b10c93-5dbd-d345-d7e4-6144b8287c24" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_8889606b-88fa-2d5e-3fb9-238bccdf9597" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_8889606b-88fa-2d5e-3fb9-238bccdf9597" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_37b440e2-656c-b624-0688-b7cf681bf981" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_us-gaap_Goodwill_37b440e2-656c-b624-0688-b7cf681bf981" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_bd8545de-cfc2-6f31-bff6-ed0d4012c357" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_bd8545de-cfc2-6f31-bff6-ed0d4012c357" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_dcf3df0d-2155-35f6-715d-83a9bc9cf3fb" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_dcf3df0d-2155-35f6-715d-83a9bc9cf3fb" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_4246ec24-1a4c-19dd-57c9-32d4a8e0cbaa" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_4246ec24-1a4c-19dd-57c9-32d4a8e0cbaa" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.evolus.com/role/CondensedBalanceSheetsParenthetical" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.evolus.com/role/CondensedStatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_50231013-f048-89e7-0e20-ba139224c5f7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_50231013-f048-89e7-0e20-ba139224c5f7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_PaymentsOfContingentRoyaltyObligation" xlink:label="loc_eols_PaymentsOfContingentRoyaltyObligation_1324f141-ce07-0f4a-07d6-453716b79def" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:to="loc_eols_PaymentsOfContingentRoyaltyObligation_1324f141-ce07-0f4a-07d6-453716b79def" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_MilestonePaymentsForIntangibleAssets" xlink:label="loc_eols_MilestonePaymentsForIntangibleAssets_f1e7c55e-b4d6-3af1-4bcc-453716ee9972" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:to="loc_eols_MilestonePaymentsForIntangibleAssets_f1e7c55e-b4d6-3af1-4bcc-453716ee9972" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_f58bb86e-8b52-c30f-7b3a-554d3e73586f" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_f58bb86e-8b52-c30f-7b3a-554d3e73586f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_50c96d39-6558-6bd8-b3d6-7ed1c558807e" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_50c96d39-6558-6bd8-b3d6-7ed1c558807e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_d03b640f-8d2c-4108-a1c4-1354103a7ee2" xlink:type="locator" />
    <link:calculationArc order="5" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_d03b640f-8d2c-4108-a1c4-1354103a7ee2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_0f0975d6-8500-76a0-c74f-5d2f0ed8b620" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_0f0975d6-8500-76a0-c74f-5d2f0ed8b620" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_505a1499-71a2-e5de-2af8-1565f94fa52c" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_505a1499-71a2-e5de-2af8-1565f94fa52c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_5df585f7-cbd5-fdda-5710-23eacb1392b0" xlink:type="locator" />
    <link:calculationArc order="8" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_5df585f7-cbd5-fdda-5710-23eacb1392b0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaap_ProceedsFromRelatedPartyDebt_88656187-4ecc-4d4b-14df-6b01b08b0a04" xlink:type="locator" />
    <link:calculationArc order="9" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:to="loc_us-gaap_ProceedsFromRelatedPartyDebt_88656187-4ecc-4d4b-14df-6b01b08b0a04" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaap_RepaymentsOfRelatedPartyDebt_e79de075-60b8-fab9-9c8a-37a71e0e62c4" xlink:type="locator" />
    <link:calculationArc order="10" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:to="loc_us-gaap_RepaymentsOfRelatedPartyDebt_e79de075-60b8-fab9-9c8a-37a71e0e62c4" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_ProceedsFromPaymentsForIssuanceOfCommonStockInConnectionWithEquityIncentivePlan" xlink:label="loc_eols_ProceedsFromPaymentsForIssuanceOfCommonStockInConnectionWithEquityIncentivePlan_a482a123-1352-4128-24cb-453716c9e689" xlink:type="locator" />
    <link:calculationArc order="11" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:to="loc_eols_ProceedsFromPaymentsForIssuanceOfCommonStockInConnectionWithEquityIncentivePlan_a482a123-1352-4128-24cb-453716c9e689" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_50231013-f048-89e7-0e20-ba139224c5f7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_e170ce1e-c3a8-e8ee-88b0-37e8dd7b1d11" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_NetIncomeLoss_e170ce1e-c3a8-e8ee-88b0-37e8dd7b1d11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_ebef248a-da21-637d-9d28-3d42ff90e8e2" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_ebef248a-da21-637d-9d28-3d42ff90e8e2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_f0b9d825-b0b9-37fd-4d25-9294a8598890" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_ShareBasedCompensation_f0b9d825-b0b9-37fd-4d25-9294a8598890" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_ProvisionsForRebateAndCouponPrograms" xlink:label="loc_eols_ProvisionsForRebateAndCouponPrograms_7E8077638A4E4DB0052BFF155B36F5EF" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_eols_ProvisionsForRebateAndCouponPrograms_7E8077638A4E4DB0052BFF155B36F5EF" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_AmortizationOfDiscountOnShorttermInvestments" xlink:label="loc_eols_AmortizationOfDiscountOnShorttermInvestments_c867519c-2ac4-e18a-1ec1-4537172b2834" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_eols_AmortizationOfDiscountOnShorttermInvestments_c867519c-2ac4-e18a-1ec1-4537172b2834" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_OperatingLeaseRightofUseAssetAmortization" xlink:label="loc_eols_OperatingLeaseRightofUseAssetAmortization_f368600e-2db9-0e21-7449-4537170a9edc" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_eols_OperatingLeaseRightofUseAssetAmortization_f368600e-2db9-0e21-7449-4537170a9edc" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_c839a0d8-dfea-e1a5-fc91-ef95e7aed9cb" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_c839a0d8-dfea-e1a5-fc91-ef95e7aed9cb" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_3421bed6-296e-da4e-f0e9-a2a8fa1f6d19" xlink:type="locator" />
    <link:calculationArc order="8" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_3421bed6-296e-da4e-f0e9-a2a8fa1f6d19" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_64118bb2-1b72-460a-8e47-0026dedd2749" xlink:type="locator" />
    <link:calculationArc order="9" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_64118bb2-1b72-460a-8e47-0026dedd2749" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_f2b34f8d-2445-12ee-2c68-fa0c5409d5e0" xlink:type="locator" />
    <link:calculationArc order="10" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_f2b34f8d-2445-12ee-2c68-fa0c5409d5e0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_09b7b41a-f5a1-c45e-d61b-846fff462802" xlink:type="locator" />
    <link:calculationArc order="11" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_09b7b41a-f5a1-c45e-d61b-846fff462802" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_dfcbd6f7-83fa-00c2-bd9e-6c5c1de7d890" xlink:type="locator" />
    <link:calculationArc order="12" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_dfcbd6f7-83fa-00c2-bd9e-6c5c1de7d890" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_792166b2-b561-55ef-12fd-ca8b50f64a38" xlink:type="locator" />
    <link:calculationArc order="13" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_792166b2-b561-55ef-12fd-ca8b50f64a38" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_c8705fc2-a98a-ac1d-2832-812bd5cae0da" xlink:type="locator" />
    <link:calculationArc order="14" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_c8705fc2-a98a-ac1d-2832-812bd5cae0da" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_IncreasedecreaseInOperatingLeaseLiabilities" xlink:label="loc_eols_IncreasedecreaseInOperatingLeaseLiabilities_3a69f7b9-9eab-d9e6-5159-4537173f08bb" xlink:type="locator" />
    <link:calculationArc order="15" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_eols_IncreasedecreaseInOperatingLeaseLiabilities_3a69f7b9-9eab-d9e6-5159-4537173f08bb" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredLiabilities_63533ece-96f1-cea4-48da-7ccc623599bb" xlink:type="locator" />
    <link:calculationArc order="16" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredLiabilities_63533ece-96f1-cea4-48da-7ccc623599bb" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_50231013-f048-89e7-0e20-ba139224c5f7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForSoftware" xlink:label="loc_us-gaap_PaymentsForSoftware_762299f1-2b7a-2409-b4a1-e33b683b691b" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:to="loc_us-gaap_PaymentsForSoftware_762299f1-2b7a-2409-b4a1-e33b683b691b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_d3769ff7-3f7d-8a64-ea69-f16e64d6f178" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_d3769ff7-3f7d-8a64-ea69-f16e64d6f178" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_36fa2e8f-8278-9ee7-fcfb-31ef0fe41d05" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_36fa2e8f-8278-9ee7-fcfb-31ef0fe41d05" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0f8df60b-841f-6df5-83c3-e4049d366459" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0f8df60b-841f-6df5-83c3-e4049d366459" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.evolus.com/role/CondensedStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_5c8b3520-1ca2-0a91-0912-70d62831826c" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_e88bd855-1cc4-7d92-7586-c29e344f0391" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_5c8b3520-1ca2-0a91-0912-70d62831826c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_e88bd855-1cc4-7d92-7586-c29e344f0391" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_e170ce1e-c3a8-e8ee-88b0-37e8dd7b1d11" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_5c8b3520-1ca2-0a91-0912-70d62831826c" xlink:to="loc_us-gaap_NetIncomeLoss_e170ce1e-c3a8-e8ee-88b0-37e8dd7b1d11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_489b61b6-7c39-240c-7f68-1c1675bca3b7" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_e170ce1e-c3a8-e8ee-88b0-37e8dd7b1d11" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_489b61b6-7c39-240c-7f68-1c1675bca3b7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_8db01d6d-ae17-523f-94b9-8ab4add4a22e" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_489b61b6-7c39-240c-7f68-1c1675bca3b7" xlink:to="loc_us-gaap_OperatingIncomeLoss_8db01d6d-ae17-523f-94b9-8ab4add4a22e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_56807cce-1c23-b2ed-01fd-e029fa0d6e79" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_8db01d6d-ae17-523f-94b9-8ab4add4a22e" xlink:to="loc_us-gaap_OperatingExpenses_56807cce-1c23-b2ed-01fd-e029fa0d6e79" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_ef2ac9e8-006f-b467-3389-9a8ceec4bee5" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_56807cce-1c23-b2ed-01fd-e029fa0d6e79" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_ef2ac9e8-006f-b467-3389-9a8ceec4bee5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_89fcc343-1933-1e77-588e-68d1c2f1a04f" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_56807cce-1c23-b2ed-01fd-e029fa0d6e79" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_89fcc343-1933-1e77-588e-68d1c2f1a04f" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_RevaluationofContingentRoyaltyObligationPayable" xlink:label="loc_eols_RevaluationofContingentRoyaltyObligationPayable_37156f95-f408-4ced-ed0b-4537172001d7" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_56807cce-1c23-b2ed-01fd-e029fa0d6e79" xlink:to="loc_eols_RevaluationofContingentRoyaltyObligationPayable_37156f95-f408-4ced-ed0b-4537172001d7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_ebef248a-da21-637d-9d28-3d42ff90e8e2" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_56807cce-1c23-b2ed-01fd-e029fa0d6e79" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_ebef248a-da21-637d-9d28-3d42ff90e8e2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit_98c25af7-47ba-69a3-12c4-e52bd51b359e" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_8db01d6d-ae17-523f-94b9-8ab4add4a22e" xlink:to="loc_us-gaap_GrossProfit_98c25af7-47ba-69a3-12c4-e52bd51b359e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b88c060f-09b3-b6c0-4cdb-a77cb8e75ec8" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_98c25af7-47ba-69a3-12c4-e52bd51b359e" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b88c060f-09b3-b6c0-4cdb-a77cb8e75ec8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_3549c1c0-2f2a-e44b-026b-b4042153e489" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_98c25af7-47ba-69a3-12c4-e52bd51b359e" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_3549c1c0-2f2a-e44b-026b-b4042153e489" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_7a3a9730-2927-590e-4e76-6aeb4157256e" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_489b61b6-7c39-240c-7f68-1c1675bca3b7" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_7a3a9730-2927-590e-4e76-6aeb4157256e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeNet" xlink:label="loc_us-gaap_InvestmentIncomeNet_b6bcc6f9-d6bd-b7ec-6d33-5c8babf7b60a" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_489b61b6-7c39-240c-7f68-1c1675bca3b7" xlink:to="loc_us-gaap_InvestmentIncomeNet_b6bcc6f9-d6bd-b7ec-6d33-5c8babf7b60a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_666ca9f0-28f1-b21a-025e-36222808a6c3" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_e170ce1e-c3a8-e8ee-88b0-37e8dd7b1d11" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_666ca9f0-28f1-b21a-025e-36222808a6c3" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.evolus.com/role/CondensedStatementsOfStockholdersEquity" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.evolus.com/role/DescriptionOfBusinessAndBasisOfPresentation" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.evolus.com/role/DescriptionOfBusinessAndBasisOfPresentationDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.evolus.com/role/DocumentAndEntityInformation" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.evolus.com/role/FairValueMeasurementsAndShortTermInvestments" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.evolus.com/role/FairValueMeasurementsAndShortTermInvestmentsAssetsAndLiabilitiesOnRecurringBasisDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.evolus.com/role/FairValueMeasurementsAndShortTermInvestmentsContingentRoyaltyObligationDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.evolus.com/role/FairValueMeasurementsAndShortTermInvestmentsNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.evolus.com/role/FairValueMeasurementsAndShortTermInvestmentsScheduleOfShortTermInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_27940abc-0cb4-eab4-8ef0-df4a4c0bb415" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_9fbaf9cb-468f-3b91-9cf2-18d26152173d" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_27940abc-0cb4-eab4-8ef0-df4a4c0bb415" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_9fbaf9cb-468f-3b91-9cf2-18d26152173d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_a23ab896-034e-8e96-1a84-63ffb40e496e" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_27940abc-0cb4-eab4-8ef0-df4a4c0bb415" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_a23ab896-034e-8e96-1a84-63ffb40e496e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e562c48b-3e99-2c57-8e96-c3b81056b58c" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_27940abc-0cb4-eab4-8ef0-df4a4c0bb415" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e562c48b-3e99-2c57-8e96-c3b81056b58c" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.evolus.com/role/FairValueMeasurementsAndShortTermInvestmentsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.evolus.com/role/GoodwillAndIntangibleAssetNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.evolus.com/role/GoodwillAndIntangibleAssets" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.evolus.com/role/GoodwillAndIntangibleAssetsFutureAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e87bd6a3-2026-a858-f41a-bc281e5d594b" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_161efa93-4fc3-b3e6-9a97-d8d9aeebe0cc" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e87bd6a3-2026-a858-f41a-bc281e5d594b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_161efa93-4fc3-b3e6-9a97-d8d9aeebe0cc" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_52d5fc42-d7bd-e657-728c-68a54a8a27d9" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e87bd6a3-2026-a858-f41a-bc281e5d594b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_52d5fc42-d7bd-e657-728c-68a54a8a27d9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_28209536-91f9-47af-f5bd-6accbeed43b7" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e87bd6a3-2026-a858-f41a-bc281e5d594b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_28209536-91f9-47af-f5bd-6accbeed43b7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_716ff456-95a9-c7d8-efd5-2047c2ac3646" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e87bd6a3-2026-a858-f41a-bc281e5d594b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_716ff456-95a9-c7d8-efd5-2047c2ac3646" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_db859267-14f1-73e3-47c3-03bfc9627628" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e87bd6a3-2026-a858-f41a-bc281e5d594b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_db859267-14f1-73e3-47c3-03bfc9627628" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_fa802f8f-3c6f-18ed-005d-e578d38097d8" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e87bd6a3-2026-a858-f41a-bc281e5d594b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_fa802f8f-3c6f-18ed-005d-e578d38097d8" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.evolus.com/role/GoodwillAndIntangibleAssetsScheduleOfDefiniteAndIndefiniteLivedIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_8889606b-88fa-2d5e-3fb9-238bccdf9597" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_e11e8784-8f2d-ca3c-a9e8-a8115d54520c" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_8889606b-88fa-2d5e-3fb9-238bccdf9597" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_e11e8784-8f2d-ca3c-a9e8-a8115d54520c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_65140cb5-12a8-2030-97e2-fa6daceadf40" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_8889606b-88fa-2d5e-3fb9-238bccdf9597" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_65140cb5-12a8-2030-97e2-fa6daceadf40" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e87bd6a3-2026-a858-f41a-bc281e5d594b" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e87bd6a3-2026-a858-f41a-bc281e5d594b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_e11e8784-8f2d-ca3c-a9e8-a8115d54520c" xlink:type="arc" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e87bd6a3-2026-a858-f41a-bc281e5d594b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_65140cb5-12a8-2030-97e2-fa6daceadf40" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_0572c4a5-7251-883f-b3a9-f968acd71b9b" xlink:type="locator" />
    <link:loc xlink:href="eols-20190930.xsd#eols_IntangibleAssetsGrossIncludingGoodwill" xlink:label="loc_eols_IntangibleAssetsGrossIncludingGoodwill_93d4f69b-bb72-4f0f-9406-4537174ecb08" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_0572c4a5-7251-883f-b3a9-f968acd71b9b" xlink:to="loc_eols_IntangibleAssetsGrossIncludingGoodwill_93d4f69b-bb72-4f0f-9406-4537174ecb08" xlink:type="arc" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_eols_IntangibleAssetsGrossIncludingGoodwill_93d4f69b-bb72-4f0f-9406-4537174ecb08" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_e11e8784-8f2d-ca3c-a9e8-a8115d54520c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_37b440e2-656c-b624-0688-b7cf681bf981" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_eols_IntangibleAssetsGrossIncludingGoodwill_93d4f69b-bb72-4f0f-9406-4537174ecb08" xlink:to="loc_us-gaap_Goodwill_37b440e2-656c-b624-0688-b7cf681bf981" xlink:type="arc" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_0572c4a5-7251-883f-b3a9-f968acd71b9b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_65140cb5-12a8-2030-97e2-fa6daceadf40" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.evolus.com/role/GoodwillAndIntangibleAssetsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.evolus.com/role/OxfordTermLoans" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.evolus.com/role/OxfordTermLoansMaturitiesOfDebtDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_a2f199ce-3001-c200-d488-633bc54206dc" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_d39bb101-f79f-a162-9929-01083e9d64b5" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_a2f199ce-3001-c200-d488-633bc54206dc" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_d39bb101-f79f-a162-9929-01083e9d64b5" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_LongtermDebtMaturitiesPrincipalPaymentExcludingFinalPaymentDueInYearThree" xlink:label="loc_eols_LongtermDebtMaturitiesPrincipalPaymentExcludingFinalPaymentDueInYearThree_0fce96b9-fbec-ef77-bdd0-453717403726" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_d39bb101-f79f-a162-9929-01083e9d64b5" xlink:to="loc_eols_LongtermDebtMaturitiesPrincipalPaymentExcludingFinalPaymentDueInYearThree_0fce96b9-fbec-ef77-bdd0-453717403726" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_LongtermDebtMaturitiesFinalPaymentsInYearThree" xlink:label="loc_eols_LongtermDebtMaturitiesFinalPaymentsInYearThree_62ef6cb2-5cd8-c73f-af8e-45371740d6b3" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_d39bb101-f79f-a162-9929-01083e9d64b5" xlink:to="loc_eols_LongtermDebtMaturitiesFinalPaymentsInYearThree_62ef6cb2-5cd8-c73f-af8e-45371740d6b3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_73238937-86a2-9126-69f0-c70629155ebe" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_a2f199ce-3001-c200-d488-633bc54206dc" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_73238937-86a2-9126-69f0-c70629155ebe" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_LongtermDebtMaturitiesPrincipalPaymentExcludingFinalPaymentDueInYearFour" xlink:label="loc_eols_LongtermDebtMaturitiesPrincipalPaymentExcludingFinalPaymentDueInYearFour_f840d148-83ed-eab8-9d05-4537170cabf4" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_73238937-86a2-9126-69f0-c70629155ebe" xlink:to="loc_eols_LongtermDebtMaturitiesPrincipalPaymentExcludingFinalPaymentDueInYearFour_f840d148-83ed-eab8-9d05-4537170cabf4" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_LongtermDebtMaturitiesFinalPaymentsInYearFour" xlink:label="loc_eols_LongtermDebtMaturitiesFinalPaymentsInYearFour_1f678f91-8edd-7b2b-d87b-453717455d35" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_73238937-86a2-9126-69f0-c70629155ebe" xlink:to="loc_eols_LongtermDebtMaturitiesFinalPaymentsInYearFour_1f678f91-8edd-7b2b-d87b-453717455d35" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_a170264f-50ba-a4bb-6d22-ec86b5249633" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_a2f199ce-3001-c200-d488-633bc54206dc" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_a170264f-50ba-a4bb-6d22-ec86b5249633" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_LongtermDebtMaturitiesPrincipalPaymentExcludingFinalPaymentDueInYearFive" xlink:label="loc_eols_LongtermDebtMaturitiesPrincipalPaymentExcludingFinalPaymentDueInYearFive_f6f4c244-7d2c-3db9-1fc1-45371700b0af" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_a170264f-50ba-a4bb-6d22-ec86b5249633" xlink:to="loc_eols_LongtermDebtMaturitiesPrincipalPaymentExcludingFinalPaymentDueInYearFive_f6f4c244-7d2c-3db9-1fc1-45371700b0af" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_LongtermDebtMaturitiesFinalPaymentsInYearFive" xlink:label="loc_eols_LongtermDebtMaturitiesFinalPaymentsInYearFive_91f7a242-aa8a-4fd8-ae64-45371720131a" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_a170264f-50ba-a4bb-6d22-ec86b5249633" xlink:to="loc_eols_LongtermDebtMaturitiesFinalPaymentsInYearFive_91f7a242-aa8a-4fd8-ae64-45371720131a" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_LongtermDebtMaturitiesFinalPayments" xlink:label="loc_eols_LongtermDebtMaturitiesFinalPayments_6b6cf2e4-83be-fd4b-ad72-45371716cfa6" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_eols_LongtermDebtMaturitiesFinalPayments_6b6cf2e4-83be-fd4b-ad72-45371716cfa6" xlink:to="loc_eols_LongtermDebtMaturitiesFinalPaymentsInYearThree_62ef6cb2-5cd8-c73f-af8e-45371740d6b3" xlink:type="arc" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_eols_LongtermDebtMaturitiesFinalPayments_6b6cf2e4-83be-fd4b-ad72-45371716cfa6" xlink:to="loc_eols_LongtermDebtMaturitiesFinalPaymentsInYearFour_1f678f91-8edd-7b2b-d87b-453717455d35" xlink:type="arc" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_eols_LongtermDebtMaturitiesFinalPayments_6b6cf2e4-83be-fd4b-ad72-45371716cfa6" xlink:to="loc_eols_LongtermDebtMaturitiesFinalPaymentsInYearFive_91f7a242-aa8a-4fd8-ae64-45371720131a" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_LongtermDebtMaturitiesPrincipalPaymentExcludingFinalPayment" xlink:label="loc_eols_LongtermDebtMaturitiesPrincipalPaymentExcludingFinalPayment_5dbea1d6-1cb8-1ba8-8912-4537172b00f5" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_eols_LongtermDebtMaturitiesPrincipalPaymentExcludingFinalPayment_5dbea1d6-1cb8-1ba8-8912-4537172b00f5" xlink:to="loc_eols_LongtermDebtMaturitiesPrincipalPaymentExcludingFinalPaymentDueInYearThree_0fce96b9-fbec-ef77-bdd0-453717403726" xlink:type="arc" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_eols_LongtermDebtMaturitiesPrincipalPaymentExcludingFinalPayment_5dbea1d6-1cb8-1ba8-8912-4537172b00f5" xlink:to="loc_eols_LongtermDebtMaturitiesPrincipalPaymentExcludingFinalPaymentDueInYearFour_f840d148-83ed-eab8-9d05-4537170cabf4" xlink:type="arc" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_eols_LongtermDebtMaturitiesPrincipalPaymentExcludingFinalPayment_5dbea1d6-1cb8-1ba8-8912-4537172b00f5" xlink:to="loc_eols_LongtermDebtMaturitiesPrincipalPaymentExcludingFinalPaymentDueInYearFive_f6f4c244-7d2c-3db9-1fc1-45371700b0af" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.evolus.com/role/OxfordTermLoansMaturitiesOfDebtDetailsCalc2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_A393674A6B2351F25B5B45374E45A279_a2f199ce-3001-c200-d488-633bc54206dc" xlink:type="locator" />
    <link:loc xlink:href="eols-20190930.xsd#eols_LongtermDebtMaturitiesPrincipalPaymentExcludingFinalPayment" xlink:label="loc_eols_LongtermDebtMaturitiesPrincipalPaymentExcludingFinalPayment_A393674A6B2351F25B5B45374E45A279_5dbea1d6-1cb8-1ba8-8912-4537172b00f5" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_A393674A6B2351F25B5B45374E45A279_a2f199ce-3001-c200-d488-633bc54206dc" xlink:to="loc_eols_LongtermDebtMaturitiesPrincipalPaymentExcludingFinalPayment_A393674A6B2351F25B5B45374E45A279_5dbea1d6-1cb8-1ba8-8912-4537172b00f5" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_LongtermDebtMaturitiesFinalPayments" xlink:label="loc_eols_LongtermDebtMaturitiesFinalPayments_A393674A6B2351F25B5B45374E45A279_6b6cf2e4-83be-fd4b-ad72-45371716cfa6" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_A393674A6B2351F25B5B45374E45A279_a2f199ce-3001-c200-d488-633bc54206dc" xlink:to="loc_eols_LongtermDebtMaturitiesFinalPayments_A393674A6B2351F25B5B45374E45A279_6b6cf2e4-83be-fd4b-ad72-45371716cfa6" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.evolus.com/role/OxfordTermLoansNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.evolus.com/role/OxfordTermLoansTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.evolus.com/role/RelatedPartyTransactions" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.evolus.com/role/RelatedPartyTransactionsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.evolus.com/role/StockholdersEquity" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.evolus.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.evolus.com/role/StockholdersEquityRestrictedStockUnitDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.evolus.com/role/StockholdersEquityScheduleOfStockOptionActivityDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.evolus.com/role/StockholdersEquityScheduleOfValuationAssumptionsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.evolus.com/role/StockholdersEquityStockBasedCompensationExpenseAllocationDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.evolus.com/role/StockholdersEquityTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.evolus.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.evolus.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.evolus.com/role/SummaryOfSignificantAccountingPoliciesNewAccountingPronouncementsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.evolus.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.evolus.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>eols-20190930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.evolus.com/role/AccruedExpenses" xlink:href="eols-20190930.xsd#AccruedExpenses" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/AccruedExpensesDetails" xlink:href="eols-20190930.xsd#AccruedExpensesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/AccruedExpensesTables" xlink:href="eols-20190930.xsd#AccruedExpensesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/CommitmentsAndContingencies" xlink:href="eols-20190930.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/CommitmentsAndContingenciesLeaseCostDetails" xlink:href="eols-20190930.xsd#CommitmentsAndContingenciesLeaseCostDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/CommitmentsAndContingenciesNarrativeDetails" xlink:href="eols-20190930.xsd#CommitmentsAndContingenciesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/CommitmentsAndContingenciesOperatingLeaseMaturityDetails" xlink:href="eols-20190930.xsd#CommitmentsAndContingenciesOperatingLeaseMaturityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/CommitmentsAndContingenciesTables" xlink:href="eols-20190930.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/CondensedBalanceSheets" xlink:href="eols-20190930.xsd#CondensedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/CondensedBalanceSheetsParenthetical" xlink:href="eols-20190930.xsd#CondensedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/CondensedStatementsOfCashFlows" xlink:href="eols-20190930.xsd#CondensedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/CondensedStatementsOfOperationsAndComprehensiveLoss" xlink:href="eols-20190930.xsd#CondensedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/CondensedStatementsOfStockholdersEquity" xlink:href="eols-20190930.xsd#CondensedStatementsOfStockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/DescriptionOfBusinessAndBasisOfPresentation" xlink:href="eols-20190930.xsd#DescriptionOfBusinessAndBasisOfPresentation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/DescriptionOfBusinessAndBasisOfPresentationDetails" xlink:href="eols-20190930.xsd#DescriptionOfBusinessAndBasisOfPresentationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/DocumentAndEntityInformation" xlink:href="eols-20190930.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/FairValueMeasurementsAndShortTermInvestments" xlink:href="eols-20190930.xsd#FairValueMeasurementsAndShortTermInvestments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/FairValueMeasurementsAndShortTermInvestmentsAssetsAndLiabilitiesOnRecurringBasisDetails" xlink:href="eols-20190930.xsd#FairValueMeasurementsAndShortTermInvestmentsAssetsAndLiabilitiesOnRecurringBasisDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/FairValueMeasurementsAndShortTermInvestmentsContingentRoyaltyObligationDetails" xlink:href="eols-20190930.xsd#FairValueMeasurementsAndShortTermInvestmentsContingentRoyaltyObligationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/FairValueMeasurementsAndShortTermInvestmentsNarrativeDetails" xlink:href="eols-20190930.xsd#FairValueMeasurementsAndShortTermInvestmentsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/FairValueMeasurementsAndShortTermInvestmentsScheduleOfShortTermInvestmentsDetails" xlink:href="eols-20190930.xsd#FairValueMeasurementsAndShortTermInvestmentsScheduleOfShortTermInvestmentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/FairValueMeasurementsAndShortTermInvestmentsTables" xlink:href="eols-20190930.xsd#FairValueMeasurementsAndShortTermInvestmentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/GoodwillAndIntangibleAssetNarrativeDetails" xlink:href="eols-20190930.xsd#GoodwillAndIntangibleAssetNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/GoodwillAndIntangibleAssets" xlink:href="eols-20190930.xsd#GoodwillAndIntangibleAssets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/GoodwillAndIntangibleAssetsFutureAmortizationExpenseDetails" xlink:href="eols-20190930.xsd#GoodwillAndIntangibleAssetsFutureAmortizationExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/GoodwillAndIntangibleAssetsScheduleOfDefiniteAndIndefiniteLivedIntangibleAssetsDetails" xlink:href="eols-20190930.xsd#GoodwillAndIntangibleAssetsScheduleOfDefiniteAndIndefiniteLivedIntangibleAssetsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/GoodwillAndIntangibleAssetsTables" xlink:href="eols-20190930.xsd#GoodwillAndIntangibleAssetsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/OxfordTermLoans" xlink:href="eols-20190930.xsd#OxfordTermLoans" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/OxfordTermLoansMaturitiesOfDebtDetails" xlink:href="eols-20190930.xsd#OxfordTermLoansMaturitiesOfDebtDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/OxfordTermLoansNarrativeDetails" xlink:href="eols-20190930.xsd#OxfordTermLoansNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/OxfordTermLoansTables" xlink:href="eols-20190930.xsd#OxfordTermLoansTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/RelatedPartyTransactions" xlink:href="eols-20190930.xsd#RelatedPartyTransactions" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/RelatedPartyTransactionsDetails" xlink:href="eols-20190930.xsd#RelatedPartyTransactionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/StockholdersEquity" xlink:href="eols-20190930.xsd#StockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/StockholdersEquityNarrativeDetails" xlink:href="eols-20190930.xsd#StockholdersEquityNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/StockholdersEquityRestrictedStockUnitDetails" xlink:href="eols-20190930.xsd#StockholdersEquityRestrictedStockUnitDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/StockholdersEquityScheduleOfStockOptionActivityDetails" xlink:href="eols-20190930.xsd#StockholdersEquityScheduleOfStockOptionActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/StockholdersEquityScheduleOfValuationAssumptionsDetails" xlink:href="eols-20190930.xsd#StockholdersEquityScheduleOfValuationAssumptionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/StockholdersEquityStockBasedCompensationExpenseAllocationDetails" xlink:href="eols-20190930.xsd#StockholdersEquityStockBasedCompensationExpenseAllocationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/StockholdersEquityTables" xlink:href="eols-20190930.xsd#StockholdersEquityTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="eols-20190930.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:href="eols-20190930.xsd#SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/SummaryOfSignificantAccountingPoliciesNewAccountingPronouncementsDetails" xlink:href="eols-20190930.xsd#SummaryOfSignificantAccountingPoliciesNewAccountingPronouncementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="eols-20190930.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="eols-20190930.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple" />
  <link:definitionLink xlink:role="http://www.evolus.com/role/AccruedExpenses" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.evolus.com/role/AccruedExpensesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.evolus.com/role/AccruedExpensesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.evolus.com/role/CommitmentsAndContingencies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.evolus.com/role/CommitmentsAndContingenciesLeaseCostDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.evolus.com/role/CommitmentsAndContingenciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaap_LossContingenciesLineItems_464E35EBE56D7DBE11D50F0251C5B8FF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaap_LossContingenciesTable_1E48E21CE8AEE3626CAF0F0251C4915E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_464E35EBE56D7DBE11D50F0251C5B8FF" xlink:to="loc_us-gaap_LossContingenciesTable_1E48E21CE8AEE3626CAF0F0251C4915E" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_670F070667BCF2CCD5FE0F0251C4D29D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_1E48E21CE8AEE3626CAF0F0251C4915E" xlink:to="loc_dei_LegalEntityAxis_670F070667BCF2CCD5FE0F0251C4D29D" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_931F9D87EF9E56660C860F0251C5F5D9_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_670F070667BCF2CCD5FE0F0251C4D29D" xlink:to="loc_dei_EntityDomain_931F9D87EF9E56660C860F0251C5F5D9_default" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_931F9D87EF9E56660C860F0251C5F5D9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_670F070667BCF2CCD5FE0F0251C4D29D" xlink:to="loc_dei_EntityDomain_931F9D87EF9E56660C860F0251C5F5D9" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_DaewoongMember" xlink:label="loc_eols_DaewoongMember_05578B193FEBABCE4A580F0251C51666" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_931F9D87EF9E56660C860F0251C5F5D9" xlink:to="loc_eols_DaewoongMember_05578B193FEBABCE4A580F0251C51666" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_LesseeOperatingLeaseTerminationPeriod" xlink:label="loc_eols_LesseeOperatingLeaseTerminationPeriod_98A9FDDAD479CF2D24CD0F0251C68591" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_464E35EBE56D7DBE11D50F0251C5B8FF" xlink:to="loc_eols_LesseeOperatingLeaseTerminationPeriod_98A9FDDAD479CF2D24CD0F0251C68591" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_LesseeOperatingLeasePeriodOfWrittenNoticePriorToLeaseTerminateDate" xlink:label="loc_eols_LesseeOperatingLeasePeriodOfWrittenNoticePriorToLeaseTerminateDate_0DADB223E557869B42D60F0251C667A5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_464E35EBE56D7DBE11D50F0251C5B8FF" xlink:to="loc_eols_LesseeOperatingLeasePeriodOfWrittenNoticePriorToLeaseTerminateDate_0DADB223E557869B42D60F0251C667A5" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_LesseeOperatingLeaseTerminationFeePeriodOfRentEquivalent" xlink:label="loc_eols_LesseeOperatingLeaseTerminationFeePeriodOfRentEquivalent_D38BD5C3F979DF2D2BF90F0251C69BAC" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_464E35EBE56D7DBE11D50F0251C5B8FF" xlink:to="loc_eols_LesseeOperatingLeaseTerminationFeePeriodOfRentEquivalent_D38BD5C3F979DF2D2BF90F0251C69BAC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_D1C8ABB841C0E7CB30C10F0251C68F46" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_464E35EBE56D7DBE11D50F0251C5B8FF" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_D1C8ABB841C0E7CB30C10F0251C68F46" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_OperatingLeasePercentageOfAnnualRentEscalation" xlink:label="loc_eols_OperatingLeasePercentageOfAnnualRentEscalation_FF211E41B041A0E6AFD30F0251C62CBF" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_464E35EBE56D7DBE11D50F0251C5B8FF" xlink:to="loc_eols_OperatingLeasePercentageOfAnnualRentEscalation_FF211E41B041A0E6AFD30F0251C62CBF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseImpairmentLoss" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss_951CCD07F029A493F6840F0251C6B933" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_464E35EBE56D7DBE11D50F0251C5B8FF" xlink:to="loc_us-gaap_OperatingLeaseImpairmentLoss_951CCD07F029A493F6840F0251C6B933" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseObligation" xlink:label="loc_us-gaap_PurchaseObligation_C171B27C6335B662D15F0F0251C78BB7" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_464E35EBE56D7DBE11D50F0251C5B8FF" xlink:to="loc_us-gaap_PurchaseObligation_C171B27C6335B662D15F0F0251C78BB7" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_MilestonePaymentInConnectionWithLicenseAndSupplyAgreement" xlink:label="loc_eols_MilestonePaymentInConnectionWithLicenseAndSupplyAgreement_E5875EBFE4B24592EA8E0F0251C7BF54" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_464E35EBE56D7DBE11D50F0251C5B8FF" xlink:to="loc_eols_MilestonePaymentInConnectionWithLicenseAndSupplyAgreement_E5875EBFE4B24592EA8E0F0251C7BF54" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_MilestonePaymentCurrent" xlink:label="loc_eols_MilestonePaymentCurrent_357555C5E8440F9A45360F06F9834B36" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_464E35EBE56D7DBE11D50F0251C5B8FF" xlink:to="loc_eols_MilestonePaymentCurrent_357555C5E8440F9A45360F06F9834B36" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_B4D4A370D23E52C3BC240F0251C706DC" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_464E35EBE56D7DBE11D50F0251C5B8FF" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_B4D4A370D23E52C3BC240F0251C706DC" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.evolus.com/role/CommitmentsAndContingenciesOperatingLeaseMaturityDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.evolus.com/role/CommitmentsAndContingenciesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.evolus.com/role/CondensedBalanceSheets" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.evolus.com/role/CondensedBalanceSheetsParenthetical" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.evolus.com/role/CondensedStatementsOfCashFlows" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.evolus.com/role/CondensedStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.evolus.com/role/CondensedStatementsOfStockholdersEquity" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_10AD680306A7621BD9B01E20339E87AC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_DAA36AEA17C4524777BD1E20339B00A7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_10AD680306A7621BD9B01E20339E87AC" xlink:to="loc_us-gaap_StatementTable_DAA36AEA17C4524777BD1E20339B00A7" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_CAA5F0E4A6393AD62FF91E20339BD3CB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_DAA36AEA17C4524777BD1E20339B00A7" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_CAA5F0E4A6393AD62FF91E20339BD3CB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_A7072A595A2AC29EBF371E20339B17F5_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_CAA5F0E4A6393AD62FF91E20339BD3CB" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_A7072A595A2AC29EBF371E20339B17F5_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_A7072A595A2AC29EBF371E20339B17F5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_CAA5F0E4A6393AD62FF91E20339BD3CB" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_A7072A595A2AC29EBF371E20339B17F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_0059C702302448EF94AB1E20339C6150" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_A7072A595A2AC29EBF371E20339B17F5" xlink:to="loc_us-gaap_IPOMember_0059C702302448EF94AB1E20339C6150" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_0E95FC2A3A6C0F4825961E20339C8880" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_DAA36AEA17C4524777BD1E20339B00A7" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_0E95FC2A3A6C0F4825961E20339C8880" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_F05F420169BD2F6A09C71E20339C63D0_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_0E95FC2A3A6C0F4825961E20339C8880" xlink:to="loc_us-gaap_EquityComponentDomain_F05F420169BD2F6A09C71E20339C63D0_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_F05F420169BD2F6A09C71E20339C63D0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_0E95FC2A3A6C0F4825961E20339C8880" xlink:to="loc_us-gaap_EquityComponentDomain_F05F420169BD2F6A09C71E20339C63D0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_BB144F88EC266DE68CF41E20339C8582" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_F05F420169BD2F6A09C71E20339C63D0" xlink:to="loc_us-gaap_PreferredStockMember_BB144F88EC266DE68CF41E20339C8582" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_EA19271852CC70B6EB5A1E20339CFDF6" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_F05F420169BD2F6A09C71E20339C63D0" xlink:to="loc_us-gaap_CommonStockMember_EA19271852CC70B6EB5A1E20339CFDF6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_B0910A213D430EFF1B7E1E20339D3244" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_F05F420169BD2F6A09C71E20339C63D0" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_B0910A213D430EFF1B7E1E20339D3244" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_26BDD9039C8476153C381E20339DA7C1" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_F05F420169BD2F6A09C71E20339C63D0" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_26BDD9039C8476153C381E20339DA7C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_0809E414A42511BCFF231E20339DBD4A" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_F05F420169BD2F6A09C71E20339C63D0" xlink:to="loc_us-gaap_RetainedEarningsMember_0809E414A42511BCFF231E20339DBD4A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_C4AAC72D1631D5EE6F0B1E20339D0ADB" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_DAA36AEA17C4524777BD1E20339B00A7" xlink:to="loc_us-gaap_StatementClassOfStockAxis_C4AAC72D1631D5EE6F0B1E20339D0ADB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_8E59374AF305BA13BEB41E20339D8691_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_C4AAC72D1631D5EE6F0B1E20339D0ADB" xlink:to="loc_us-gaap_ClassOfStockDomain_8E59374AF305BA13BEB41E20339D8691_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_8E59374AF305BA13BEB41E20339D8691" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_C4AAC72D1631D5EE6F0B1E20339D0ADB" xlink:to="loc_us-gaap_ClassOfStockDomain_8E59374AF305BA13BEB41E20339D8691" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_01B99BEF9596C37E55E61E20339D5A06" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_8E59374AF305BA13BEB41E20339D8691" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_01B99BEF9596C37E55E61E20339D5A06" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_0B0D804A596A6926FC831E20339E9C15" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_10AD680306A7621BD9B01E20339E87AC" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_0B0D804A596A6926FC831E20339E9C15" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_642A7DAFD8538002FA6B1E20339EB702" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_10AD680306A7621BD9B01E20339E87AC" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_642A7DAFD8538002FA6B1E20339EB702" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_5F4D4CA6B073104DD10E1E20339E0F1C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_642A7DAFD8538002FA6B1E20339EB702" xlink:to="loc_us-gaap_SharesIssued_5F4D4CA6B073104DD10E1E20339E0F1C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_72DE7DFD7B7C714C64931E20339F8A92" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_642A7DAFD8538002FA6B1E20339EB702" xlink:to="loc_us-gaap_StockholdersEquity_72DE7DFD7B7C714C64931E20339F8A92" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_DeemedContributionFromParentIncreaseOfRelatedPartyReceivable" xlink:label="loc_eols_DeemedContributionFromParentIncreaseOfRelatedPartyReceivable_15673E7BAAF838400DB81E20339FABDF" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_642A7DAFD8538002FA6B1E20339EB702" xlink:to="loc_eols_DeemedContributionFromParentIncreaseOfRelatedPartyReceivable_15673E7BAAF838400DB81E20339FABDF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Dividends" xlink:label="loc_us-gaap_Dividends_9771A66945D1C182761E1E20339F9F79" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_642A7DAFD8538002FA6B1E20339EB702" xlink:to="loc_us-gaap_Dividends_9771A66945D1C182761E1E20339F9F79" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_C8861EB44ED0B870EE201E20339F4EBE" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_642A7DAFD8538002FA6B1E20339EB702" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_C8861EB44ED0B870EE201E20339F4EBE" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_CapitalContributionFromParentForgivenessOfRelatedPartyBorrowings" xlink:label="loc_eols_CapitalContributionFromParentForgivenessOfRelatedPartyBorrowings_E5622A933517C718095D1E20339F59DB" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_642A7DAFD8538002FA6B1E20339EB702" xlink:to="loc_eols_CapitalContributionFromParentForgivenessOfRelatedPartyBorrowings_E5622A933517C718095D1E20339F59DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_87E80F2381B11F85CED41E20339F3736" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_642A7DAFD8538002FA6B1E20339EB702" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_87E80F2381B11F85CED41E20339F3736" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_D5AC9BE8AE97214217181E2033A0A250" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_642A7DAFD8538002FA6B1E20339EB702" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_D5AC9BE8AE97214217181E2033A0A250" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_B03EBD87602E126FBDE01E2033A0C801" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_642A7DAFD8538002FA6B1E20339EB702" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_B03EBD87602E126FBDE01E2033A0C801" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan" xlink:label="loc_eols_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan_45C06B2BB774CAC11F951E2033A0F663" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_642A7DAFD8538002FA6B1E20339EB702" xlink:to="loc_eols_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan_45C06B2BB774CAC11F951E2033A0F663" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan" xlink:label="loc_eols_StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan_32743583593F49C6ED531E2033A07918" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_642A7DAFD8538002FA6B1E20339EB702" xlink:to="loc_eols_StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan_32743583593F49C6ED531E2033A07918" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_77A6732ED232E91746351E2033A0AE03" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_642A7DAFD8538002FA6B1E20339EB702" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_77A6732ED232E91746351E2033A0AE03" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_9EB42640B319FA0905421E2033A024A2" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_642A7DAFD8538002FA6B1E20339EB702" xlink:to="loc_us-gaap_NetIncomeLoss_9EB42640B319FA0905421E2033A024A2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_F30FAB31BA237AD751D91E2033A02622" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_642A7DAFD8538002FA6B1E20339EB702" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_F30FAB31BA237AD751D91E2033A02622" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_C3EC881E2AC6231859DF1E2033A1F1B8" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_642A7DAFD8538002FA6B1E20339EB702" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_C3EC881E2AC6231859DF1E2033A1F1B8" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.evolus.com/role/DescriptionOfBusinessAndBasisOfPresentation" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.evolus.com/role/DescriptionOfBusinessAndBasisOfPresentationDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.evolus.com/role/DocumentAndEntityInformation" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.evolus.com/role/FairValueMeasurementsAndShortTermInvestments" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.evolus.com/role/FairValueMeasurementsAndShortTermInvestmentsAssetsAndLiabilitiesOnRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_EEDDAC65994FBF269A22FEEBEF18CF38" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_B461F57BE487DDB9D8BDFEEBEF151D25" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_EEDDAC65994FBF269A22FEEBEF18CF38" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_B461F57BE487DDB9D8BDFEEBEF151D25" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_994A01A8E38BDA26D14DFEEBEF1533A4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_B461F57BE487DDB9D8BDFEEBEF151D25" xlink:to="loc_us-gaap_FinancialInstrumentAxis_994A01A8E38BDA26D14DFEEBEF1533A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_773138481A4B5667F3DEFEEBEF16095F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_994A01A8E38BDA26D14DFEEBEF1533A4" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_773138481A4B5667F3DEFEEBEF16095F_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_773138481A4B5667F3DEFEEBEF16095F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_994A01A8E38BDA26D14DFEEBEF1533A4" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_773138481A4B5667F3DEFEEBEF16095F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_B1EC52D65C8639DC56E2FEEBEF16F0F6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_773138481A4B5667F3DEFEEBEF16095F" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_B1EC52D65C8639DC56E2FEEBEF16F0F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_2DBA83E08D24CF1025C2FEEBEF1654A3" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_773138481A4B5667F3DEFEEBEF16095F" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_2DBA83E08D24CF1025C2FEEBEF1654A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_40EFBF892FEA7C855F33FEEBEF175B6B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_B461F57BE487DDB9D8BDFEEBEF151D25" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_40EFBF892FEA7C855F33FEEBEF175B6B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_10F5E386F6159F14B358FEEBEF17EC3C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_40EFBF892FEA7C855F33FEEBEF175B6B" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_10F5E386F6159F14B358FEEBEF17EC3C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_10F5E386F6159F14B358FEEBEF17EC3C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_40EFBF892FEA7C855F33FEEBEF175B6B" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_10F5E386F6159F14B358FEEBEF17EC3C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_4B47C5931F9C69B301BCFEEBEF17909D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_10F5E386F6159F14B358FEEBEF17EC3C" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_4B47C5931F9C69B301BCFEEBEF17909D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_2187AE9D0A373C350FB3FEEBEF17351F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_10F5E386F6159F14B358FEEBEF17EC3C" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_2187AE9D0A373C350FB3FEEBEF17351F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_824006330E63FB66CBA3FEEBEF17775F" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_10F5E386F6159F14B358FEEBEF17EC3C" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_824006330E63FB66CBA3FEEBEF17775F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_9985BC9B5B88058B8CBDFEEBEF1876EF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_EEDDAC65994FBF269A22FEEBEF18CF38" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_9985BC9B5B88058B8CBDFEEBEF1876EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_9E07431CCB87C00CF366FEEBEF1853CE" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_EEDDAC65994FBF269A22FEEBEF18CF38" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_9E07431CCB87C00CF366FEEBEF1853CE" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.evolus.com/role/FairValueMeasurementsAndShortTermInvestmentsContingentRoyaltyObligationDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.evolus.com/role/FairValueMeasurementsAndShortTermInvestmentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_C285D6B8E715028F6AADFEEBEF06AA0D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_E540B8C49CD8B221B6DAFEEBEF01E381" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_C285D6B8E715028F6AADFEEBEF06AA0D" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_E540B8C49CD8B221B6DAFEEBEF01E381" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_070F3E651C49E123C300FEEBEF02AFDB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_E540B8C49CD8B221B6DAFEEBEF01E381" xlink:to="loc_us-gaap_DebtInstrumentAxis_070F3E651C49E123C300FEEBEF02AFDB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_6ED9D41B4FF1F9776678FEEBEF027EB8_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_070F3E651C49E123C300FEEBEF02AFDB" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_6ED9D41B4FF1F9776678FEEBEF027EB8_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_6ED9D41B4FF1F9776678FEEBEF027EB8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_070F3E651C49E123C300FEEBEF02AFDB" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_6ED9D41B4FF1F9776678FEEBEF027EB8" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_OxfordTermLoansMember" xlink:label="loc_eols_OxfordTermLoansMember_8B193CBD594B49E006ECFEEBEF021C23" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_6ED9D41B4FF1F9776678FEEBEF027EB8" xlink:to="loc_eols_OxfordTermLoansMember_8B193CBD594B49E006ECFEEBEF021C23" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_CE756E96EE84D3E81464FEEBEF029C88" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_E540B8C49CD8B221B6DAFEEBEF01E381" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_CE756E96EE84D3E81464FEEBEF029C88" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_3F81A530ABAAEF208FD1FEEBEF03A001_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_CE756E96EE84D3E81464FEEBEF029C88" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_3F81A530ABAAEF208FD1FEEBEF03A001_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_2C172F29F4B4EB921902FEEBEF02A737" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_CE756E96EE84D3E81464FEEBEF029C88" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_2C172F29F4B4EB921902FEEBEF02A737" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_3F81A530ABAAEF208FD1FEEBEF03A001" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_2C172F29F4B4EB921902FEEBEF02A737" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_3F81A530ABAAEF208FD1FEEBEF03A001" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_22CABA68359D3C7D91D5FEEBEF03AA6A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_2C172F29F4B4EB921902FEEBEF02A737" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_22CABA68359D3C7D91D5FEEBEF03AA6A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_D36D1D7EA913398A7C6EFEEBEF031D0A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_E540B8C49CD8B221B6DAFEEBEF01E381" xlink:to="loc_us-gaap_FinancialInstrumentAxis_D36D1D7EA913398A7C6EFEEBEF031D0A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3CE7614028C31BFE3D26FEEBEF037714_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_D36D1D7EA913398A7C6EFEEBEF031D0A" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3CE7614028C31BFE3D26FEEBEF037714_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3CE7614028C31BFE3D26FEEBEF037714" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_D36D1D7EA913398A7C6EFEEBEF031D0A" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3CE7614028C31BFE3D26FEEBEF037714" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_ContingentRoyaltyObligationMember" xlink:label="loc_eols_ContingentRoyaltyObligationMember_78C18887C48031B8C99DFEEBEF04D3B9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3CE7614028C31BFE3D26FEEBEF037714" xlink:to="loc_eols_ContingentRoyaltyObligationMember_78C18887C48031B8C99DFEEBEF04D3B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_2505B847A84004010E09FEEBEF046156" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_E540B8C49CD8B221B6DAFEEBEF01E381" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_2505B847A84004010E09FEEBEF046156" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_4304D949E47D18E67F48FEEBEF043F23_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_2505B847A84004010E09FEEBEF046156" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_4304D949E47D18E67F48FEEBEF043F23_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_4304D949E47D18E67F48FEEBEF043F23" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_2505B847A84004010E09FEEBEF046156" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_4304D949E47D18E67F48FEEBEF043F23" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_2057FA256B875C5AA88BFEEBEF04DBAA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_4304D949E47D18E67F48FEEBEF043F23" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_2057FA256B875C5AA88BFEEBEF04DBAA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_51E1AB92B3AC6B99BE38FEEBEF055775" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_4304D949E47D18E67F48FEEBEF043F23" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_51E1AB92B3AC6B99BE38FEEBEF055775" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_453F87F9761B0E1AF937FEEBEF058947" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_E540B8C49CD8B221B6DAFEEBEF01E381" xlink:to="loc_srt_RangeAxis_453F87F9761B0E1AF937FEEBEF058947" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_4A97477283E41C1DCDD9FEEBEF05EAC2_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_453F87F9761B0E1AF937FEEBEF058947" xlink:to="loc_srt_RangeMember_4A97477283E41C1DCDD9FEEBEF05EAC2_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_4A97477283E41C1DCDD9FEEBEF05EAC2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_453F87F9761B0E1AF937FEEBEF058947" xlink:to="loc_srt_RangeMember_4A97477283E41C1DCDD9FEEBEF05EAC2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_8B7B32C75C182DEFCE28FEEBEF05BDC9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_4A97477283E41C1DCDD9FEEBEF05EAC2" xlink:to="loc_srt_MinimumMember_8B7B32C75C182DEFCE28FEEBEF05BDC9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_ADA58D01B6E11945D2B0FEEBEF055059" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_4A97477283E41C1DCDD9FEEBEF05EAC2" xlink:to="loc_srt_MaximumMember_ADA58D01B6E11945D2B0FEEBEF055059" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AlternativeInvestmentMeasurementInput" xlink:label="loc_us-gaap_AlternativeInvestmentMeasurementInput_5256F0A5B671ED36B8C9FEEBEF066627" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_C285D6B8E715028F6AADFEEBEF06AA0D" xlink:to="loc_us-gaap_AlternativeInvestmentMeasurementInput_5256F0A5B671ED36B8C9FEEBEF066627" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure_61F681322F21F33EAEDEFEEBEF06DA1A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_C285D6B8E715028F6AADFEEBEF06AA0D" xlink:to="loc_us-gaap_NotesPayableFairValueDisclosure_61F681322F21F33EAEDEFEEBEF06DA1A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_BA508AE0314C0E6F67F7FF40D323AC88" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_C285D6B8E715028F6AADFEEBEF06AA0D" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_BA508AE0314C0E6F67F7FF40D323AC88" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.evolus.com/role/FairValueMeasurementsAndShortTermInvestmentsScheduleOfShortTermInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_DA068C5BB97FC9D67A9645374E501A66" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_D91795B44DE1DF2D763F45374E4F2269" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_DA068C5BB97FC9D67A9645374E501A66" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_D91795B44DE1DF2D763F45374E4F2269" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_694BA90308CAE9E2255A45374E4F73C3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_D91795B44DE1DF2D763F45374E4F2269" xlink:to="loc_us-gaap_FinancialInstrumentAxis_694BA90308CAE9E2255A45374E4F73C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0D28E54022D2421BD20945374E50A67C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_694BA90308CAE9E2255A45374E4F73C3" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0D28E54022D2421BD20945374E50A67C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0D28E54022D2421BD20945374E50A67C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_694BA90308CAE9E2255A45374E4F73C3" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0D28E54022D2421BD20945374E50A67C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_A3822B052EA571CA986145374E506A61" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0D28E54022D2421BD20945374E50A67C" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_A3822B052EA571CA986145374E506A61" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_1E22D68F6056C6CFF5B145374E50C8AD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_DA068C5BB97FC9D67A9645374E501A66" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_1E22D68F6056C6CFF5B145374E50C8AD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTaxAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTaxAbstract_7D4D0878D655723E38E645374E51A6D1" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_DA068C5BB97FC9D67A9645374E501A66" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTaxAbstract_7D4D0878D655723E38E645374E51A6D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_CC3AE7B95DB9E32667C545374E51808F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTaxAbstract_7D4D0878D655723E38E645374E51A6D1" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_CC3AE7B95DB9E32667C545374E51808F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_32CF58437C3534D1EC4045374E51BA76" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTaxAbstract_7D4D0878D655723E38E645374E51A6D1" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_32CF58437C3534D1EC4045374E51BA76" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_17DF5DF4D7E4FAFED76545374E516E9B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_DA068C5BB97FC9D67A9645374E501A66" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_17DF5DF4D7E4FAFED76545374E516E9B" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.evolus.com/role/FairValueMeasurementsAndShortTermInvestmentsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.evolus.com/role/GoodwillAndIntangibleAssetNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_7B11ABAFEABF9D7793CD0F0252592B2B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_89E13F4BDA88ECCF2B420F0252563B5C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7B11ABAFEABF9D7793CD0F0252592B2B" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_89E13F4BDA88ECCF2B420F0252563B5C" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0C745DA3298F2BF837C90F0252570506" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_89E13F4BDA88ECCF2B420F0252563B5C" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0C745DA3298F2BF837C90F0252570506" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_83348E9E98BF42E1A6BA0F025257F3CF_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0C745DA3298F2BF837C90F0252570506" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_83348E9E98BF42E1A6BA0F025257F3CF_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_83348E9E98BF42E1A6BA0F025257F3CF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0C745DA3298F2BF837C90F0252570506" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_83348E9E98BF42E1A6BA0F025257F3CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DistributionRightsMember" xlink:label="loc_us-gaap_DistributionRightsMember_E1F2E840506CC381B56C0F02525798AE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_83348E9E98BF42E1A6BA0F025257F3CF" xlink:to="loc_us-gaap_DistributionRightsMember_E1F2E840506CC381B56C0F02525798AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_7615190F17ABB8E9D5700F02525849C1" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_83348E9E98BF42E1A6BA0F025257F3CF" xlink:to="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_7615190F17ABB8E9D5700F02525849C1" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_0C169964A8B6EF104F9A0F0252584451" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_89E13F4BDA88ECCF2B420F0252563B5C" xlink:to="loc_dei_LegalEntityAxis_0C169964A8B6EF104F9A0F0252584451" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_397F0968AC9ED9F1CB500F025258DA35_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_0C169964A8B6EF104F9A0F0252584451" xlink:to="loc_dei_EntityDomain_397F0968AC9ED9F1CB500F025258DA35_default" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_397F0968AC9ED9F1CB500F025258DA35" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_0C169964A8B6EF104F9A0F0252584451" xlink:to="loc_dei_EntityDomain_397F0968AC9ED9F1CB500F025258DA35" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_SCHAEONLLCMember" xlink:label="loc_eols_SCHAEONLLCMember_667367216AB44B7622CF0F0252582E11" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_397F0968AC9ED9F1CB500F025258DA35" xlink:to="loc_eols_SCHAEONLLCMember_667367216AB44B7622CF0F0252582E11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1249E4F89749F22085F20F0252589D44" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_89E13F4BDA88ECCF2B420F0252563B5C" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1249E4F89749F22085F20F0252589D44" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9C76E67B17F45CB7BA650F02525981E4_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1249E4F89749F22085F20F0252589D44" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9C76E67B17F45CB7BA650F02525981E4_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9C76E67B17F45CB7BA650F02525981E4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1249E4F89749F22085F20F0252589D44" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9C76E67B17F45CB7BA650F02525981E4" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_EvolusIncMember" xlink:label="loc_eols_EvolusIncMember_F97D123DCB74BA495A200F025259C2B2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9C76E67B17F45CB7BA650F02525981E4" xlink:to="loc_eols_EvolusIncMember_F97D123DCB74BA495A200F025259C2B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_6704FD075CD5A2115DD60F02525988A3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7B11ABAFEABF9D7793CD0F0252592B2B" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_6704FD075CD5A2115DD60F02525988A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_947EAFAF4A83DF2572B80F02525AD2CE" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7B11ABAFEABF9D7793CD0F0252592B2B" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_947EAFAF4A83DF2572B80F02525AD2CE" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_AcquiredFinitelivedIntangibleAssetPeriodOfExtensionOfTermsBasedOnCertainPerformanceRequirements" xlink:label="loc_eols_AcquiredFinitelivedIntangibleAssetPeriodOfExtensionOfTermsBasedOnCertainPerformanceRequirements_DA9E0793A77F285DB33F0F02525A6EED" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7B11ABAFEABF9D7793CD0F0252592B2B" xlink:to="loc_eols_AcquiredFinitelivedIntangibleAssetPeriodOfExtensionOfTermsBasedOnCertainPerformanceRequirements_DA9E0793A77F285DB33F0F02525A6EED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_5E7A4B640899CAE32A590F02525A0F2A" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7B11ABAFEABF9D7793CD0F0252592B2B" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_5E7A4B640899CAE32A590F02525A0F2A" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_MilestonePaymentsForIntangibleAssets" xlink:label="loc_eols_MilestonePaymentsForIntangibleAssets_4F2E736B012193829E440F02525A9EEE" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7B11ABAFEABF9D7793CD0F0252592B2B" xlink:to="loc_eols_MilestonePaymentsForIntangibleAssets_4F2E736B012193829E440F02525A9EEE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_EFC9BC4E2D4EFF7BD7BA0F02525A7E9D" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7B11ABAFEABF9D7793CD0F0252592B2B" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_EFC9BC4E2D4EFF7BD7BA0F02525A7E9D" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_MilestonePaymentCurrent" xlink:label="loc_eols_MilestonePaymentCurrent_6AD30C339A844981D4250F06F8092ABE" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7B11ABAFEABF9D7793CD0F0252592B2B" xlink:to="loc_eols_MilestonePaymentCurrent_6AD30C339A844981D4250F06F8092ABE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalizedComputerSoftwareAdditions" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareAdditions_93385DC9E5964F28A0810F02525ADBB9" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7B11ABAFEABF9D7793CD0F0252592B2B" xlink:to="loc_us-gaap_CapitalizedComputerSoftwareAdditions_93385DC9E5964F28A0810F02525ADBB9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_8193A3E2CD2BDA5B04350F02525BCD7B" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7B11ABAFEABF9D7793CD0F0252592B2B" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_8193A3E2CD2BDA5B04350F02525BCD7B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_D21891A11368DA33B9E80F02525BEEF8" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7B11ABAFEABF9D7793CD0F0252592B2B" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_D21891A11368DA33B9E80F02525BEEF8" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.evolus.com/role/GoodwillAndIntangibleAssets" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.evolus.com/role/GoodwillAndIntangibleAssetsFutureAmortizationExpenseDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.evolus.com/role/GoodwillAndIntangibleAssetsScheduleOfDefiniteAndIndefiniteLivedIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_263B4790F344A157BF2345374F02EAED" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_03B082C06081D7B8C12A45374F00407F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_263B4790F344A157BF2345374F02EAED" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_03B082C06081D7B8C12A45374F00407F" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_A1794D6EDF1E050F359D45374F009988" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_03B082C06081D7B8C12A45374F00407F" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_A1794D6EDF1E050F359D45374F009988" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_C97441DA954FFEE9E8EB45374F019ADF_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_A1794D6EDF1E050F359D45374F009988" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_C97441DA954FFEE9E8EB45374F019ADF_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_C97441DA954FFEE9E8EB45374F019ADF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_A1794D6EDF1E050F359D45374F009988" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_C97441DA954FFEE9E8EB45374F019ADF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_53FD0DF6698B6199DEAC45374F01A169" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_C97441DA954FFEE9E8EB45374F019ADF" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_53FD0DF6698B6199DEAC45374F01A169" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_07AB8EF3D1BD5068A6AE45374F01E140" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_03B082C06081D7B8C12A45374F00407F" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_07AB8EF3D1BD5068A6AE45374F01E140" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_E1E598BC322150F9BABB45374F01F15F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_07AB8EF3D1BD5068A6AE45374F01E140" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_E1E598BC322150F9BABB45374F01F15F_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_E1E598BC322150F9BABB45374F01F15F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_07AB8EF3D1BD5068A6AE45374F01E140" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_E1E598BC322150F9BABB45374F01F15F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DistributionRightsMember" xlink:label="loc_us-gaap_DistributionRightsMember_CC8A9C1EA67D49CC900445374F02B63F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_E1E598BC322150F9BABB45374F01F15F" xlink:to="loc_us-gaap_DistributionRightsMember_CC8A9C1EA67D49CC900445374F02B63F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_22F9A5E7024B1C73BED845374F02C9B1" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_E1E598BC322150F9BABB45374F01F15F" xlink:to="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_22F9A5E7024B1C73BED845374F02C9B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_A18E6305F69760D915C745374F02990E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_263B4790F344A157BF2345374F02EAED" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_A18E6305F69760D915C745374F02990E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_9082F04AA5B2FF178FF345374F03FCD8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_A18E6305F69760D915C745374F02990E" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_9082F04AA5B2FF178FF345374F03FCD8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_7084DFBD9D709FDB7D9645374F03C8FB" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_A18E6305F69760D915C745374F02990E" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_7084DFBD9D709FDB7D9645374F03C8FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_CDE43F0DDB641CFC6C5545374F033E3B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_A18E6305F69760D915C745374F02990E" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_CDE43F0DDB641CFC6C5545374F033E3B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_586ED507059C00A3BB6B45374F03B056" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_A18E6305F69760D915C745374F02990E" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_586ED507059C00A3BB6B45374F03B056" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_DEB7C65514C5D1E1703945374F0414BB" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_A18E6305F69760D915C745374F02990E" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_DEB7C65514C5D1E1703945374F0414BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_EA175C97796BF38294DF45374F041B62" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_263B4790F344A157BF2345374F02EAED" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_EA175C97796BF38294DF45374F041B62" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_DAA37CFFBDF5D44BE31C45374F04D4FD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_EA175C97796BF38294DF45374F041B62" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_DAA37CFFBDF5D44BE31C45374F04D4FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_0EDBE648D581F15C484B45374F041560" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_EA175C97796BF38294DF45374F041B62" xlink:to="loc_us-gaap_Goodwill_0EDBE648D581F15C484B45374F041560" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_IntangibleAssetsGrossIncludingGoodwill" xlink:label="loc_eols_IntangibleAssetsGrossIncludingGoodwill_A72DD75CA14273CAD14A45374F045518" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_263B4790F344A157BF2345374F02EAED" xlink:to="loc_eols_IntangibleAssetsGrossIncludingGoodwill_A72DD75CA14273CAD14A45374F045518" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_B1A7E9B3218DF0EAD00445374F054119" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_263B4790F344A157BF2345374F02EAED" xlink:to="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_B1A7E9B3218DF0EAD00445374F054119" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.evolus.com/role/GoodwillAndIntangibleAssetsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.evolus.com/role/OxfordTermLoans" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.evolus.com/role/OxfordTermLoansMaturitiesOfDebtDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.evolus.com/role/OxfordTermLoansNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_7D8DE52E76877D70DE0A45374E351877" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_1ED429D4C0F1ADF21BA045374E329BF9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7D8DE52E76877D70DE0A45374E351877" xlink:to="loc_us-gaap_DebtInstrumentTable_1ED429D4C0F1ADF21BA045374E329BF9" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_93C9A8E9D0BF5C30B03D45374E32AFD5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1ED429D4C0F1ADF21BA045374E329BF9" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_93C9A8E9D0BF5C30B03D45374E32AFD5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_16615FCCE008C6E8CB0345374E3347AA_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_93C9A8E9D0BF5C30B03D45374E32AFD5" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_16615FCCE008C6E8CB0345374E3347AA_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_16615FCCE008C6E8CB0345374E3347AA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_93C9A8E9D0BF5C30B03D45374E32AFD5" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_16615FCCE008C6E8CB0345374E3347AA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SecuredDebtMember" xlink:label="loc_us-gaap_SecuredDebtMember_E81801399283DCA20B0B45374E33A755" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_16615FCCE008C6E8CB0345374E3347AA" xlink:to="loc_us-gaap_SecuredDebtMember_E81801399283DCA20B0B45374E33A755" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_7650F7B84559E95A6A0A45374E330E44" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1ED429D4C0F1ADF21BA045374E329BF9" xlink:to="loc_us-gaap_DebtInstrumentAxis_7650F7B84559E95A6A0A45374E330E44" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_ECBA6DAD5C882B35D9BB45374E33C47F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_7650F7B84559E95A6A0A45374E330E44" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_ECBA6DAD5C882B35D9BB45374E33C47F_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_ECBA6DAD5C882B35D9BB45374E33C47F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_7650F7B84559E95A6A0A45374E330E44" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_ECBA6DAD5C882B35D9BB45374E33C47F" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_TermLoanFacilityTrancheOneMember" xlink:label="loc_eols_TermLoanFacilityTrancheOneMember_5BBA1F6725720632EFED45374E340218" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_ECBA6DAD5C882B35D9BB45374E33C47F" xlink:to="loc_eols_TermLoanFacilityTrancheOneMember_5BBA1F6725720632EFED45374E340218" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_TermLoanFacilityTrancheTwoMember" xlink:label="loc_eols_TermLoanFacilityTrancheTwoMember_ED8A8E84CD7D0CBC07CC45374E344D54" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_ECBA6DAD5C882B35D9BB45374E33C47F" xlink:to="loc_eols_TermLoanFacilityTrancheTwoMember_ED8A8E84CD7D0CBC07CC45374E344D54" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_TermLoanFacilityMember" xlink:label="loc_eols_TermLoanFacilityMember_88A7F07C7460A0B896A645374E341000" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_ECBA6DAD5C882B35D9BB45374E33C47F" xlink:to="loc_eols_TermLoanFacilityMember_88A7F07C7460A0B896A645374E341000" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaap_VariableRateAxis_C181B7D0BE95A6D8C89745374E34FCB1" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1ED429D4C0F1ADF21BA045374E329BF9" xlink:to="loc_us-gaap_VariableRateAxis_C181B7D0BE95A6D8C89745374E34FCB1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_170DE32D32E7B375554945374E340847_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_C181B7D0BE95A6D8C89745374E34FCB1" xlink:to="loc_us-gaap_VariableRateDomain_170DE32D32E7B375554945374E340847_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_170DE32D32E7B375554945374E340847" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_C181B7D0BE95A6D8C89745374E34FCB1" xlink:to="loc_us-gaap_VariableRateDomain_170DE32D32E7B375554945374E340847" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_364162F36F9613FA939C45374E35D791" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_170DE32D32E7B375554945374E340847" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_364162F36F9613FA939C45374E35D791" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_ApplicableRateMember" xlink:label="loc_eols_ApplicableRateMember_20B0D79E808B1CE19F4E45374E35DF35" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_170DE32D32E7B375554945374E340847" xlink:to="loc_eols_ApplicableRateMember_20B0D79E808B1CE19F4E45374E35DF35" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_DE873B6485DF1CF60A2A45374E35FD66" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7D8DE52E76877D70DE0A45374E351877" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_DE873B6485DF1CF60A2A45374E35FD66" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_12BA82887AAC9D64A6CF45374E36D073" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7D8DE52E76877D70DE0A45374E351877" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_12BA82887AAC9D64A6CF45374E36D073" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_E02CD5338D0ED6DD633945374E364BE5" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7D8DE52E76877D70DE0A45374E351877" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_E02CD5338D0ED6DD633945374E364BE5" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_DebtInstrumentPeriodOfInterestOnlyPayments" xlink:label="loc_eols_DebtInstrumentPeriodOfInterestOnlyPayments_73605DDFAF0F46136D1145374E36A042" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7D8DE52E76877D70DE0A45374E351877" xlink:to="loc_eols_DebtInstrumentPeriodOfInterestOnlyPayments_73605DDFAF0F46136D1145374E36A042" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_DebtInstrumentAmortizationPeriod" xlink:label="loc_eols_DebtInstrumentAmortizationPeriod_805997E3697DFD3295B745374E366DB4" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7D8DE52E76877D70DE0A45374E351877" xlink:to="loc_eols_DebtInstrumentAmortizationPeriod_805997E3697DFD3295B745374E366DB4" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_DebtInstrumentAdditionalPeriodOfAgreementOfInterestPayment" xlink:label="loc_eols_DebtInstrumentAdditionalPeriodOfAgreementOfInterestPayment_1E63C0661BDE5E299F5F45374E36E5AF" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7D8DE52E76877D70DE0A45374E351877" xlink:to="loc_eols_DebtInstrumentAdditionalPeriodOfAgreementOfInterestPayment_1E63C0661BDE5E299F5F45374E36E5AF" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_DebtInstrumentTermAggregatePeriod" xlink:label="loc_eols_DebtInstrumentTermAggregatePeriod_19B38B01C229318BF88145374E37457F" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7D8DE52E76877D70DE0A45374E351877" xlink:to="loc_eols_DebtInstrumentTermAggregatePeriod_19B38B01C229318BF88145374E37457F" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_DebtInstrumentAdditionalAmortizationPeriod" xlink:label="loc_eols_DebtInstrumentAdditionalAmortizationPeriod_E47C1802E09FB28A664A45374E37C4E3" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7D8DE52E76877D70DE0A45374E351877" xlink:to="loc_eols_DebtInstrumentAdditionalAmortizationPeriod_E47C1802E09FB28A664A45374E37C4E3" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_DebtInstrumentPercentageOfPrincipalAmountBalloonPayment" xlink:label="loc_eols_DebtInstrumentPercentageOfPrincipalAmountBalloonPayment_B37379F9750DA970DAA845374E376AE8" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7D8DE52E76877D70DE0A45374E351877" xlink:to="loc_eols_DebtInstrumentPercentageOfPrincipalAmountBalloonPayment_B37379F9750DA970DAA845374E376AE8" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_DebtInstrumentPrepaymentFeePercentageNextTwelveMonths" xlink:label="loc_eols_DebtInstrumentPrepaymentFeePercentageNextTwelveMonths_05064D151E0B423BA49145374E371858" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7D8DE52E76877D70DE0A45374E351877" xlink:to="loc_eols_DebtInstrumentPrepaymentFeePercentageNextTwelveMonths_05064D151E0B423BA49145374E371858" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_DebtInstrumentPrepaymentFeePercentageYearTwo" xlink:label="loc_eols_DebtInstrumentPrepaymentFeePercentageYearTwo_82D15EF1991BE751076D45374E386248" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7D8DE52E76877D70DE0A45374E351877" xlink:to="loc_eols_DebtInstrumentPrepaymentFeePercentageYearTwo_82D15EF1991BE751076D45374E386248" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_DebtInstrumentPrepaymentFeePercentageThereafter" xlink:label="loc_eols_DebtInstrumentPrepaymentFeePercentageThereafter_4F3652043956750B737245374E38E6A7" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7D8DE52E76877D70DE0A45374E351877" xlink:to="loc_eols_DebtInstrumentPrepaymentFeePercentageThereafter_4F3652043956750B737245374E38E6A7" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_DebtInstrumentDefaultInterestRate" xlink:label="loc_eols_DebtInstrumentDefaultInterestRate_D3CEEDD6F6C18198FC6245374E38ECA6" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7D8DE52E76877D70DE0A45374E351877" xlink:to="loc_eols_DebtInstrumentDefaultInterestRate_D3CEEDD6F6C18198FC6245374E38ECA6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_4A797881620D90D2845D45374E38BB2D" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7D8DE52E76877D70DE0A45374E351877" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_4A797881620D90D2845D45374E38BB2D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredFinanceCostsGross" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_F7909D2767B14A28B55345374E38B180" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7D8DE52E76877D70DE0A45374E351877" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_F7909D2767B14A28B55345374E38B180" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.evolus.com/role/OxfordTermLoansTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.evolus.com/role/RelatedPartyTransactions" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.evolus.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_278BE927F2AF05412CBC0F0252B8FC6E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1AD48FE492B3B1E77DD30F0252B2E15B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_278BE927F2AF05412CBC0F0252B8FC6E" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1AD48FE492B3B1E77DD30F0252B2E15B" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_E1C19A7D074962993B390F0252B2D072" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1AD48FE492B3B1E77DD30F0252B2E15B" xlink:to="loc_srt_CounterpartyNameAxis_E1C19A7D074962993B390F0252B2D072" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_A3D56864C77473B92E340F0252B2BC91_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_E1C19A7D074962993B390F0252B2D072" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_A3D56864C77473B92E340F0252B2BC91_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_A3D56864C77473B92E340F0252B2BC91" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_E1C19A7D074962993B390F0252B2D072" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_A3D56864C77473B92E340F0252B2BC91" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_ALPHAEONMember" xlink:label="loc_eols_ALPHAEONMember_52428684978D5065727D0F0252B389F1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_A3D56864C77473B92E340F0252B2BC91" xlink:to="loc_eols_ALPHAEONMember_52428684978D5065727D0F0252B389F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_5681CDB3BE239F32B88E0F0252B30308" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1AD48FE492B3B1E77DD30F0252B2E15B" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_5681CDB3BE239F32B88E0F0252B30308" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_F45C8ABB457BAE1063920F0252B343C4_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_5681CDB3BE239F32B88E0F0252B30308" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_F45C8ABB457BAE1063920F0252B343C4_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_F45C8ABB457BAE1063920F0252B343C4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_5681CDB3BE239F32B88E0F0252B30308" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_F45C8ABB457BAE1063920F0252B343C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_7308DB2E8E3B7C0E67ED0F0252B375B1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_F45C8ABB457BAE1063920F0252B343C4" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_7308DB2E8E3B7C0E67ED0F0252B375B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_373C6744772776ABB7B80F0252B419EC" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1AD48FE492B3B1E77DD30F0252B2E15B" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_373C6744772776ABB7B80F0252B419EC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_318A1F5470D94F6006780F0252B468FA_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_373C6744772776ABB7B80F0252B419EC" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_318A1F5470D94F6006780F0252B468FA_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_318A1F5470D94F6006780F0252B468FA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_373C6744772776ABB7B80F0252B419EC" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_318A1F5470D94F6006780F0252B468FA" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_EvolusIncMember" xlink:label="loc_eols_EvolusIncMember_B9A3738D58044184FEEB0F0252B400CF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_318A1F5470D94F6006780F0252B468FA" xlink:to="loc_eols_EvolusIncMember_B9A3738D58044184FEEB0F0252B400CF" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_AE1CD3FD743E96DBF5950F0252B44A6F" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1AD48FE492B3B1E77DD30F0252B2E15B" xlink:to="loc_dei_LegalEntityAxis_AE1CD3FD743E96DBF5950F0252B44A6F" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1287C4A90595A70DD1580F0252B421E1_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_AE1CD3FD743E96DBF5950F0252B44A6F" xlink:to="loc_dei_EntityDomain_1287C4A90595A70DD1580F0252B421E1_default" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1287C4A90595A70DD1580F0252B421E1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_AE1CD3FD743E96DBF5950F0252B44A6F" xlink:to="loc_dei_EntityDomain_1287C4A90595A70DD1580F0252B421E1" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_ALPHAEONMember" xlink:label="loc_eols_ALPHAEONMember_550C1DD9AAA621D4B2AC0F0252B5E03A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1287C4A90595A70DD1580F0252B421E1" xlink:to="loc_eols_ALPHAEONMember_550C1DD9AAA621D4B2AC0F0252B5E03A" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_SCHAEONLLCMember" xlink:label="loc_eols_SCHAEONLLCMember_9049CD4CE7EB8E93EBD10F0252B5550C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1287C4A90595A70DD1580F0252B421E1" xlink:to="loc_eols_SCHAEONLLCMember_9049CD4CE7EB8E93EBD10F0252B5550C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8EF1C02844AE837E70410F0252B7906C" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1AD48FE492B3B1E77DD30F0252B2E15B" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8EF1C02844AE837E70410F0252B7906C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_A595E998A45E0E39FAA60F0252B777C2_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8EF1C02844AE837E70410F0252B7906C" xlink:to="loc_us-gaap_RelatedPartyDomain_A595E998A45E0E39FAA60F0252B777C2_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_A595E998A45E0E39FAA60F0252B777C2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8EF1C02844AE837E70410F0252B7906C" xlink:to="loc_us-gaap_RelatedPartyDomain_A595E998A45E0E39FAA60F0252B777C2" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_ChiefMedicalOfficerMember" xlink:label="loc_eols_ChiefMedicalOfficerMember_533AA1A4DC93837A59F50F0252B854A8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_A595E998A45E0E39FAA60F0252B777C2" xlink:to="loc_eols_ChiefMedicalOfficerMember_533AA1A4DC93837A59F50F0252B854A8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_B44ACAB55F20680A86F60F0252B89F3E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_278BE927F2AF05412CBC0F0252B8FC6E" xlink:to="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_B44ACAB55F20680A86F60F0252B89F3E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_69F89A223D88169840340F0252B8E638" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_278BE927F2AF05412CBC0F0252B8FC6E" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_69F89A223D88169840340F0252B8E638" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2721DD83389B0A2DA3010F0252B95719" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_278BE927F2AF05412CBC0F0252B8FC6E" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2721DD83389B0A2DA3010F0252B95719" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_NonCashRelatedPartyReceivable" xlink:label="loc_eols_NonCashRelatedPartyReceivable_EB6CDEA3901A71B2BEA60F0252B984CF" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_278BE927F2AF05412CBC0F0252B8FC6E" xlink:to="loc_eols_NonCashRelatedPartyReceivable_EB6CDEA3901A71B2BEA60F0252B984CF" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_BusinessCombinationUpfrontPaymentUponObtainingFDAApproval" xlink:label="loc_eols_BusinessCombinationUpfrontPaymentUponObtainingFDAApproval_C7A94D3D98651C6CB7500F0252BA2535" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_278BE927F2AF05412CBC0F0252B8FC6E" xlink:to="loc_eols_BusinessCombinationUpfrontPaymentUponObtainingFDAApproval_C7A94D3D98651C6CB7500F0252BA2535" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_RelatedPartyTransactionPeriodOfTerminationOfFirstCommercialSale" xlink:label="loc_eols_RelatedPartyTransactionPeriodOfTerminationOfFirstCommercialSale_B26CB9D437A0613572BE0F0252BAB5F7" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_278BE927F2AF05412CBC0F0252B8FC6E" xlink:to="loc_eols_RelatedPartyTransactionPeriodOfTerminationOfFirstCommercialSale_B26CB9D437A0613572BE0F0252BAB5F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractualObligation" xlink:label="loc_us-gaap_ContractualObligation_5E046A959D59AFDDD3040F0252BA78C6" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_278BE927F2AF05412CBC0F0252B8FC6E" xlink:to="loc_us-gaap_ContractualObligation_5E046A959D59AFDDD3040F0252BA78C6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaap_LongTermNotesPayable_9781711748BC5ED016F10F0252BA78D3" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_278BE927F2AF05412CBC0F0252B8FC6E" xlink:to="loc_us-gaap_LongTermNotesPayable_9781711748BC5ED016F10F0252BA78D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_7E1CEA6D76A8C0EA6A710F0252BAFDD6" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_278BE927F2AF05412CBC0F0252B8FC6E" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_7E1CEA6D76A8C0EA6A710F0252BAFDD6" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_StockPurchaseAgreementPeriodAvailabletoCureBreach" xlink:label="loc_eols_StockPurchaseAgreementPeriodAvailabletoCureBreach_B16DCC8A03A79C17832C0F0252BAB482" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_278BE927F2AF05412CBC0F0252B8FC6E" xlink:to="loc_eols_StockPurchaseAgreementPeriodAvailabletoCureBreach_B16DCC8A03A79C17832C0F0252BAB482" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_9940796C556A981B610F0F0252BBE2DD" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_278BE927F2AF05412CBC0F0252B8FC6E" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_9940796C556A981B610F0F0252BBE2DD" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_BusinessAcquisitionUnwindingFee" xlink:label="loc_eols_BusinessAcquisitionUnwindingFee_D2342640DC5408ACF0DD0F0252BBAD43" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_278BE927F2AF05412CBC0F0252B8FC6E" xlink:to="loc_eols_BusinessAcquisitionUnwindingFee_D2342640DC5408ACF0DD0F0252BBAD43" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.evolus.com/role/StockholdersEquity" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.evolus.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_1122475C92242EF6B057FEEBEED869B3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_D3CC8BFAB2736AE8D141FEEBEED66509" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_1122475C92242EF6B057FEEBEED869B3" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_D3CC8BFAB2736AE8D141FEEBEED66509" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_3F04C68BE701A4485E45FEEBEED792C9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_D3CC8BFAB2736AE8D141FEEBEED66509" xlink:to="loc_srt_RangeAxis_3F04C68BE701A4485E45FEEBEED792C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_8F1D378B2D7D3AB06A07FEEBEED7EF86_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_3F04C68BE701A4485E45FEEBEED792C9" xlink:to="loc_srt_RangeMember_8F1D378B2D7D3AB06A07FEEBEED7EF86_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_8F1D378B2D7D3AB06A07FEEBEED7EF86" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_3F04C68BE701A4485E45FEEBEED792C9" xlink:to="loc_srt_RangeMember_8F1D378B2D7D3AB06A07FEEBEED7EF86" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_81A8B03387CB4184E4E5FEEBEED7F7D9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_8F1D378B2D7D3AB06A07FEEBEED7EF86" xlink:to="loc_srt_MinimumMember_81A8B03387CB4184E4E5FEEBEED7F7D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_01EDF2BE51666E37843AFEEBEED73C8A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_8F1D378B2D7D3AB06A07FEEBEED7EF86" xlink:to="loc_srt_MaximumMember_01EDF2BE51666E37843AFEEBEED73C8A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_60EE219685BE2EBD9DE6FEEBEED8D0BF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1122475C92242EF6B057FEEBEED869B3" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_60EE219685BE2EBD9DE6FEEBEED8D0BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_E77EE55D9382868F26F9FEEBEED8CAA6" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1122475C92242EF6B057FEEBEED869B3" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_E77EE55D9382868F26F9FEEBEED8CAA6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_7C4972E741E51DDBFBECFEEBEED87801" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1122475C92242EF6B057FEEBEED869B3" xlink:to="loc_us-gaap_PreferredStockSharesIssued_7C4972E741E51DDBFBECFEEBEED87801" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_9ACDBE30A4BFEAA9D1A6FEEBEED81E50" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1122475C92242EF6B057FEEBEED869B3" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_9ACDBE30A4BFEAA9D1A6FEEBEED81E50" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_F50CDD8F8221412D449CFEEBEED89CDA" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1122475C92242EF6B057FEEBEED869B3" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_F50CDD8F8221412D449CFEEBEED89CDA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_7DCE433BE2879F15C250FEEBEED99FA1" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1122475C92242EF6B057FEEBEED869B3" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_7DCE433BE2879F15C250FEEBEED99FA1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_CEB026B401A62E75B2CAFEEBEED9FF50" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1122475C92242EF6B057FEEBEED869B3" xlink:to="loc_us-gaap_CommonStockSharesIssued_CEB026B401A62E75B2CAFEEBEED9FF50" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_310B77970C854072A350FEEBEED97B2F" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1122475C92242EF6B057FEEBEED869B3" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_310B77970C854072A350FEEBEED97B2F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_1D213A73D0279F1B44D8FEEBEED99FEA" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1122475C92242EF6B057FEEBEED869B3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_1D213A73D0279F1B44D8FEEBEED99FEA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_CAE150B2A87562E13C55FEEBEED9EA25" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1122475C92242EF6B057FEEBEED869B3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_CAE150B2A87562E13C55FEEBEED9EA25" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_CommonStockAdditionalCapitalSharesReservedforFutureIssuance" xlink:label="loc_eols_CommonStockAdditionalCapitalSharesReservedforFutureIssuance_E7B221C075894214B4ABFEEBEED9C9FF" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1122475C92242EF6B057FEEBEED869B3" xlink:to="loc_eols_CommonStockAdditionalCapitalSharesReservedforFutureIssuance_E7B221C075894214B4ABFEEBEED9C9FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_E59B5034CD149CC296CBFEEBEED9344B" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1122475C92242EF6B057FEEBEED869B3" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_E59B5034CD149CC296CBFEEBEED9344B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_B5703FC7C639ABA52044FEEBEEDA5722" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1122475C92242EF6B057FEEBEED869B3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_B5703FC7C639ABA52044FEEBEEDA5722" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_EE558FFF06519B1F5333FEEBEEDA0871" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1122475C92242EF6B057FEEBEED869B3" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_EE558FFF06519B1F5333FEEBEEDA0871" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_AllocatedShareBasedCompensationExpenseCapitalized" xlink:label="loc_eols_AllocatedShareBasedCompensationExpenseCapitalized_B7AF77EA6E9EC4A5D31AFEEBEEDA515F" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1122475C92242EF6B057FEEBEED869B3" xlink:to="loc_eols_AllocatedShareBasedCompensationExpenseCapitalized_B7AF77EA6E9EC4A5D31AFEEBEEDA515F" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.evolus.com/role/StockholdersEquityRestrictedStockUnitDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_688D4BAFBE3CFDE0C73945374F57C636" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6F645C7441520ECA36C845374F56097D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_688D4BAFBE3CFDE0C73945374F57C636" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6F645C7441520ECA36C845374F56097D" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_D965A7AF5B2C5F2C513D45374F57A870" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6F645C7441520ECA36C845374F56097D" xlink:to="loc_us-gaap_AwardTypeAxis_D965A7AF5B2C5F2C513D45374F57A870" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_53B722ECBF8313EB9DEB45374F57F9C0_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_D965A7AF5B2C5F2C513D45374F57A870" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_53B722ECBF8313EB9DEB45374F57F9C0_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_53B722ECBF8313EB9DEB45374F57F9C0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_D965A7AF5B2C5F2C513D45374F57A870" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_53B722ECBF8313EB9DEB45374F57F9C0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_6BAEE73E9A8273B5079F45374F57B57B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_53B722ECBF8313EB9DEB45374F57F9C0" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_6BAEE73E9A8273B5079F45374F57B57B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9B31E8796ADBE46220BE45374F587EED" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_688D4BAFBE3CFDE0C73945374F57C636" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9B31E8796ADBE46220BE45374F587EED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_B2D903DF15D797CA038545374F585C3A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9B31E8796ADBE46220BE45374F587EED" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_B2D903DF15D797CA038545374F585C3A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_A6388630CC1C59A8953045374F5883E5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9B31E8796ADBE46220BE45374F587EED" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_A6388630CC1C59A8953045374F5883E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_C6BC2A82AE84ED10F74545374F58ACE8" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9B31E8796ADBE46220BE45374F587EED" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_C6BC2A82AE84ED10F74545374F58ACE8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_A6C5B9489CDFF441B26145374F59713D" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9B31E8796ADBE46220BE45374F587EED" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_A6C5B9489CDFF441B26145374F59713D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_2C054314F62C9665040045374F5988CD" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_688D4BAFBE3CFDE0C73945374F57C636" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_2C054314F62C9665040045374F5988CD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_AEBD9D91A2F27678B38445374F59987A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_2C054314F62C9665040045374F5988CD" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_AEBD9D91A2F27678B38445374F59987A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_E88A7833EB1DDFAF20C445374F593810" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_2C054314F62C9665040045374F5988CD" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_E88A7833EB1DDFAF20C445374F593810" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_35C932577D4BA89E6E8C45374F5918D5" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_2C054314F62C9665040045374F5988CD" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_35C932577D4BA89E6E8C45374F5918D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_4E4689D8C5D40BE1DFC345374F5A3E27" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_2C054314F62C9665040045374F5988CD" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_4E4689D8C5D40BE1DFC345374F5A3E27" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.evolus.com/role/StockholdersEquityScheduleOfStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_602243EF8520793568D50F02518C2130" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_CA58A9F1B8B90CBEDF460F02518B71E2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_602243EF8520793568D50F02518C2130" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_CA58A9F1B8B90CBEDF460F02518B71E2" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_AB9407685687C9CAF9FE0F02518CEEE1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_CA58A9F1B8B90CBEDF460F02518B71E2" xlink:to="loc_us-gaap_AwardTypeAxis_AB9407685687C9CAF9FE0F02518CEEE1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_AB684578DA55D82231040F02518C4E42_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_AB9407685687C9CAF9FE0F02518CEEE1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_AB684578DA55D82231040F02518C4E42_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_AB684578DA55D82231040F02518C4E42" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_AB9407685687C9CAF9FE0F02518CEEE1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_AB684578DA55D82231040F02518C4E42" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_87F2C175C9F0553D54250F02518CC6B1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_AB684578DA55D82231040F02518C4E42" xlink:to="loc_us-gaap_EmployeeStockOptionMember_87F2C175C9F0553D54250F02518CC6B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_655828E1E22E3DE61DDC0F02518DE0C5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_602243EF8520793568D50F02518C2130" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_655828E1E22E3DE61DDC0F02518DE0C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_C30ECCB9C8C08EC4DEBD0F02518D1FAD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_655828E1E22E3DE61DDC0F02518DE0C5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_C30ECCB9C8C08EC4DEBD0F02518D1FAD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_4591A2B656151298D7A30F02518DDE59" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_655828E1E22E3DE61DDC0F02518DE0C5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_4591A2B656151298D7A30F02518DDE59" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_099D486CF5F1BDCEE9DB0F02518DF70E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_655828E1E22E3DE61DDC0F02518DE0C5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_099D486CF5F1BDCEE9DB0F02518DF70E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_44B74CF9ED4BAABB3B800F02518D8642" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_655828E1E22E3DE61DDC0F02518DE0C5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_44B74CF9ED4BAABB3B800F02518D8642" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_93C3945072BF3045A7020F02518EBF1B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_602243EF8520793568D50F02518C2130" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_93C3945072BF3045A7020F02518EBF1B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8B128698F1217E304DA50F02518EDC82" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_602243EF8520793568D50F02518C2130" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8B128698F1217E304DA50F02518EDC82" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3CA4FBBF12A925ECCE6A0F02518E5CD6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8B128698F1217E304DA50F02518EDC82" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3CA4FBBF12A925ECCE6A0F02518E5CD6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_46ED59FA076786C991120F02518E2158" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8B128698F1217E304DA50F02518EDC82" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_46ED59FA076786C991120F02518E2158" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_50CD54E2914DA251FA6D0F02518F5FD1" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8B128698F1217E304DA50F02518EDC82" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_50CD54E2914DA251FA6D0F02518F5FD1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_9E085A64773A11D678420F02518F9354" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8B128698F1217E304DA50F02518EDC82" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_9E085A64773A11D678420F02518F9354" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_EEF1DFD749A9B7A4A6A10F02518F5D4C" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_602243EF8520793568D50F02518C2130" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_EEF1DFD749A9B7A4A6A10F02518F5D4C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_CAE44C5B0DB8EDECB5300F02518F123B" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_602243EF8520793568D50F02518C2130" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_CAE44C5B0DB8EDECB5300F02518F123B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_575873D8A98EEDFD4A700F02518F36BF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_CAE44C5B0DB8EDECB5300F02518F123B" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_575873D8A98EEDFD4A700F02518F36BF" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermExercisable" xlink:label="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermExercisable_4457B1367B7773875B180F025190A5E7" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_CAE44C5B0DB8EDECB5300F02518F123B" xlink:to="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermExercisable_4457B1367B7773875B180F025190A5E7" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:label="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract_BD837264AA149B4B60F80F02519031BF" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_602243EF8520793568D50F02518C2130" xlink:to="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract_BD837264AA149B4B60F80F02519031BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_E779FE025FBD223EB4A60F025190C7F3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract_BD837264AA149B4B60F80F02519031BF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_E779FE025FBD223EB4A60F025190C7F3" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsGrantedinPeriodIntrinsicValue" xlink:label="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsGrantedinPeriodIntrinsicValue_94FFCBB0F29500110FBF0F0251906C88" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract_BD837264AA149B4B60F80F02519031BF" xlink:to="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsGrantedinPeriodIntrinsicValue_94FFCBB0F29500110FBF0F0251906C88" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_12B8FC49B8B0E03DB4740F025191EC25" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract_BD837264AA149B4B60F80F02519031BF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_12B8FC49B8B0E03DB4740F025191EC25" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsForfeitedinPeriodIntrinsicValue" xlink:label="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsForfeitedinPeriodIntrinsicValue_BB2D25C2B13A179B198F0F025191FB5B" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract_BD837264AA149B4B60F80F02519031BF" xlink:to="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsForfeitedinPeriodIntrinsicValue_BB2D25C2B13A179B198F0F025191FB5B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_3AEB9B13A0F805BFCD240F0251910ECE" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_602243EF8520793568D50F02518C2130" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_3AEB9B13A0F805BFCD240F0251910ECE" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.evolus.com/role/StockholdersEquityScheduleOfValuationAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_B9EFD77387BAC2E5792EB5DED54A3E1B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_72E34AFA742ABAC9EC62B5DED549C5D7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_B9EFD77387BAC2E5792EB5DED54A3E1B" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_72E34AFA742ABAC9EC62B5DED549C5D7" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_9B606042FA8F6D4CC593B5DED5491520" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_72E34AFA742ABAC9EC62B5DED549C5D7" xlink:to="loc_us-gaap_AwardTypeAxis_9B606042FA8F6D4CC593B5DED5491520" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_D4D99CFD3C7E7AAA3CAEB5DED54AD756_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_9B606042FA8F6D4CC593B5DED5491520" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_D4D99CFD3C7E7AAA3CAEB5DED54AD756_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_D4D99CFD3C7E7AAA3CAEB5DED54AD756" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_9B606042FA8F6D4CC593B5DED5491520" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_D4D99CFD3C7E7AAA3CAEB5DED54AD756" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_98747E28619CE232388CB5DED54A7689" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_D4D99CFD3C7E7AAA3CAEB5DED54AD756" xlink:to="loc_us-gaap_EmployeeStockOptionMember_98747E28619CE232388CB5DED54A7689" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_AD0496E3F2E5C0BFEE5FB5DED54ADD74" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_B9EFD77387BAC2E5792EB5DED54A3E1B" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_AD0496E3F2E5C0BFEE5FB5DED54ADD74" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_9402ED79E4B21E88DE7FB5DED54B9DB9" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_B9EFD77387BAC2E5792EB5DED54A3E1B" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_9402ED79E4B21E88DE7FB5DED54B9DB9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_887A84DC4E5403AC73CDB5DED54B6A63" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_B9EFD77387BAC2E5792EB5DED54A3E1B" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_887A84DC4E5403AC73CDB5DED54B6A63" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_FE0A37335F52F0089B07B5DED54B5A25" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_B9EFD77387BAC2E5792EB5DED54A3E1B" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_FE0A37335F52F0089B07B5DED54B5A25" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.evolus.com/role/StockholdersEquityStockBasedCompensationExpenseAllocationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0248B13CE9C5A7182DEB45374EE43D37" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_89D21E0A1C381BC0418445374EE3F484" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0248B13CE9C5A7182DEB45374EE43D37" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_89D21E0A1C381BC0418445374EE3F484" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_5EE2DACEF8620B01F4F145374EE3270B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_89D21E0A1C381BC0418445374EE3F484" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_5EE2DACEF8620B01F4F145374EE3270B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_F8B892BB46E558DA224A45374EE4D731_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_5EE2DACEF8620B01F4F145374EE3270B" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_F8B892BB46E558DA224A45374EE4D731_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_F8B892BB46E558DA224A45374EE4D731" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_5EE2DACEF8620B01F4F145374EE3270B" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_F8B892BB46E558DA224A45374EE4D731" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_77702E1679F4EC7B5D5445374EE475E1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_F8B892BB46E558DA224A45374EE4D731" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_77702E1679F4EC7B5D5445374EE475E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_8899F1A62635826AA05845374EE49F7C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_F8B892BB46E558DA224A45374EE4D731" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_8899F1A62635826AA05845374EE49F7C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_D803503548C41E338F9045374EE5A2BE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0248B13CE9C5A7182DEB45374EE43D37" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_D803503548C41E338F9045374EE5A2BE" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.evolus.com/role/StockholdersEquityTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.evolus.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.evolus.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="eols-20190930.xsd#eols_AccountingPoliciesLineItems" xlink:label="loc_eols_AccountingPoliciesLineItems_2347D9E561310B28597E371E11BEDED2" xlink:type="locator" />
    <link:loc xlink:href="eols-20190930.xsd#eols_AccountingPoliciesTable" xlink:label="loc_eols_AccountingPoliciesTable_6F83B4E2CB3EA830A723371E11BE3357" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_eols_AccountingPoliciesLineItems_2347D9E561310B28597E371E11BEDED2" xlink:to="loc_eols_AccountingPoliciesTable_6F83B4E2CB3EA830A723371E11BE3357" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_0888B51FE6252D1415A0371E11BE0648" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_eols_AccountingPoliciesTable_6F83B4E2CB3EA830A723371E11BE3357" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_0888B51FE6252D1415A0371E11BE0648" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3E2CDC4C941D7B4F5C21371E11BEEDA5_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_0888B51FE6252D1415A0371E11BE0648" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3E2CDC4C941D7B4F5C21371E11BEEDA5_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3E2CDC4C941D7B4F5C21371E11BEEDA5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_0888B51FE6252D1415A0371E11BE0648" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3E2CDC4C941D7B4F5C21371E11BEEDA5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_774A8105865E14189018371E11BE429F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3E2CDC4C941D7B4F5C21371E11BEEDA5" xlink:to="loc_us-gaap_EmployeeStockOptionMember_774A8105865E14189018371E11BE429F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_EE5A2093BA5D0663FB5B371E11BE2140" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3E2CDC4C941D7B4F5C21371E11BEEDA5" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_EE5A2093BA5D0663FB5B371E11BE2140" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_D9F48F31CAC5B2F6AC83371E11BE318F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_eols_AccountingPoliciesTable_6F83B4E2CB3EA830A723371E11BE3357" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_D9F48F31CAC5B2F6AC83371E11BE318F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6135F075CD7AC0C3C8B0371E11BE668B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_D9F48F31CAC5B2F6AC83371E11BE318F" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6135F075CD7AC0C3C8B0371E11BE668B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6135F075CD7AC0C3C8B0371E11BE668B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_D9F48F31CAC5B2F6AC83371E11BE318F" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6135F075CD7AC0C3C8B0371E11BE668B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DistributionRightsMember" xlink:label="loc_us-gaap_DistributionRightsMember_75557EC4E660F3FA94BD371E11BE006F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6135F075CD7AC0C3C8B0371E11BE668B" xlink:to="loc_us-gaap_DistributionRightsMember_75557EC4E660F3FA94BD371E11BE006F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SoftwareDevelopmentMember" xlink:label="loc_us-gaap_SoftwareDevelopmentMember_BFA0C5F640B54CE2A8D5371E11BEABE3" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6135F075CD7AC0C3C8B0371E11BE668B" xlink:to="loc_us-gaap_SoftwareDevelopmentMember_BFA0C5F640B54CE2A8D5371E11BEABE3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NumberOfReportingUnits" xlink:label="loc_us-gaap_NumberOfReportingUnits_343543727BAF8E5B083B371E11BEEC98" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eols_AccountingPoliciesLineItems_2347D9E561310B28597E371E11BEDED2" xlink:to="loc_us-gaap_NumberOfReportingUnits_343543727BAF8E5B083B371E11BEEC98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_3E0AD6478C88FB507CB0371E11BE6CBD" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eols_AccountingPoliciesLineItems_2347D9E561310B28597E371E11BEDED2" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_3E0AD6478C88FB507CB0371E11BE6CBD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_E3C0F9A4AF9F37BC58C8371E11BE9BB7" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eols_AccountingPoliciesLineItems_2347D9E561310B28597E371E11BEDED2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_E3C0F9A4AF9F37BC58C8371E11BE9BB7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_DF5E9AD3001D66209D1B371E11BE2174" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eols_AccountingPoliciesLineItems_2347D9E561310B28597E371E11BEDED2" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_DF5E9AD3001D66209D1B371E11BE2174" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_AccruedCouponAndRebateLiabilityCurrent" xlink:label="loc_eols_AccruedCouponAndRebateLiabilityCurrent_FCA235A064EDCE2AE9E5371E11BE1CDC" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eols_AccountingPoliciesLineItems_2347D9E561310B28597E371E11BEDED2" xlink:to="loc_eols_AccruedCouponAndRebateLiabilityCurrent_FCA235A064EDCE2AE9E5371E11BE1CDC" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_ProvisionsForAccruedVolumeBasedRebateAndCouponLiability" xlink:label="loc_eols_ProvisionsForAccruedVolumeBasedRebateAndCouponLiability_F53355FB41C3C46878BD371E11BE851E" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eols_AccountingPoliciesLineItems_2347D9E561310B28597E371E11BEDED2" xlink:to="loc_eols_ProvisionsForAccruedVolumeBasedRebateAndCouponLiability_F53355FB41C3C46878BD371E11BE851E" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_PaymentsForProvisionsForAccruedVolumeBasedRebateAndCouponLiability" xlink:label="loc_eols_PaymentsForProvisionsForAccruedVolumeBasedRebateAndCouponLiability_C6B3AE839A0D8B6009FF371E11BEC169" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eols_AccountingPoliciesLineItems_2347D9E561310B28597E371E11BEDED2" xlink:to="loc_eols_PaymentsForProvisionsForAccruedVolumeBasedRebateAndCouponLiability_C6B3AE839A0D8B6009FF371E11BEC169" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_1192FA22A5764B681BAF371E11BEADF4" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eols_AccountingPoliciesLineItems_2347D9E561310B28597E371E11BEDED2" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_1192FA22A5764B681BAF371E11BEADF4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_DADCDE0F29F2F4FC4D4B371E11BE9AF6" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eols_AccountingPoliciesLineItems_2347D9E561310B28597E371E11BEDED2" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_DADCDE0F29F2F4FC4D4B371E11BE9AF6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_BDE3DDCB2B96F4CD7C60371E11BE4917" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eols_AccountingPoliciesLineItems_2347D9E561310B28597E371E11BEDED2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_BDE3DDCB2B96F4CD7C60371E11BE4917" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.evolus.com/role/SummaryOfSignificantAccountingPoliciesNewAccountingPronouncementsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_34A682CC5743AD04DF470EF6E151EB3E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_27B3440615772490C5220EF6E14F0A7C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_34A682CC5743AD04DF470EF6E151EB3E" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_27B3440615772490C5220EF6E14F0A7C" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_B0DD478C69CEB484652C0EF6E150B6D1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_27B3440615772490C5220EF6E14F0A7C" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_B0DD478C69CEB484652C0EF6E150B6D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_06DD188E3BF67D1D09210EF6E1501420_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_B0DD478C69CEB484652C0EF6E150B6D1" xlink:to="loc_us-gaap_TypeOfAdoptionMember_06DD188E3BF67D1D09210EF6E1501420_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_06DD188E3BF67D1D09210EF6E1501420" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_B0DD478C69CEB484652C0EF6E150B6D1" xlink:to="loc_us-gaap_TypeOfAdoptionMember_06DD188E3BF67D1D09210EF6E1501420" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_6097BFA444F12996F9000EF6E150890F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_06DD188E3BF67D1D09210EF6E1501420" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_6097BFA444F12996F9000EF6E150890F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_52D3374BC416E99A33B30EF6E151EF71" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_34A682CC5743AD04DF470EF6E151EB3E" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_52D3374BC416E99A33B30EF6E151EF71" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_DE02D2877123A1AF3B6B0EF6E1511B9C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_34A682CC5743AD04DF470EF6E151EB3E" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_DE02D2877123A1AF3B6B0EF6E1511B9C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_E855C31495F9093F13180EF6E151619B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_34A682CC5743AD04DF470EF6E151EB3E" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_E855C31495F9093F13180EF6E151619B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="loc_us-gaap_DeferredRentCreditNoncurrent_99E302C63767313671290EFDCF90944D" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_34A682CC5743AD04DF470EF6E151EB3E" xlink:to="loc_us-gaap_DeferredRentCreditNoncurrent_99E302C63767313671290EFDCF90944D" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.evolus.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.evolus.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>eols-20190930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_431E0D88C9623AC1A7A0FEEBEEEDDA40_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_431E0D88C9623AC1A7A0FEEBEEEDDA40" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_431E0D88C9623AC1A7A0FEEBEEEDDA40" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_431E0D88C9623AC1A7A0FEEBEEEDDA40" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_431E0D88C9623AC1A7A0FEEBEEEDDA40" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseCost_E4DD5742E71AC01E5DEEFEEBEEEDB1A0_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost_E4DD5742E71AC01E5DEEFEEBEEEDB1A0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Fixed operating lease expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_E4DD5742E71AC01E5DEEFEEBEEEDB1A0_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost_E4DD5742E71AC01E5DEEFEEBEEEDB1A0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaap_OperatingLeaseCost_E4DD5742E71AC01E5DEEFEEBEEEDB1A0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost_E4DD5742E71AC01E5DEEFEEBEEEDB1A0" xlink:to="lab_us-gaap_OperatingLeaseCost_E4DD5742E71AC01E5DEEFEEBEEEDB1A0" xlink:type="arc" />
    <link:label id="lab_us-gaap_VariableLeaseCost_DE44854FBC7D4A7F7001FEEBEEEE5698_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost_DE44854FBC7D4A7F7001FEEBEEEE5698" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable operating lease expense</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_DE44854FBC7D4A7F7001FEEBEEEE5698_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost_DE44854FBC7D4A7F7001FEEBEEEE5698" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableLeaseCost" xlink:label="loc_us-gaap_VariableLeaseCost_DE44854FBC7D4A7F7001FEEBEEEE5698" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost_DE44854FBC7D4A7F7001FEEBEEEE5698" xlink:to="lab_us-gaap_VariableLeaseCost_DE44854FBC7D4A7F7001FEEBEEEE5698" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShortTermLeaseCost_C4402B8A5D3B5F26A9F1FEEBEEEE9C4E_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost_C4402B8A5D3B5F26A9F1FEEBEEEE9C4E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term operating lease expense</link:label>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_C4402B8A5D3B5F26A9F1FEEBEEEE9C4E_label_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost_C4402B8A5D3B5F26A9F1FEEBEEEE9C4E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-term Lease, Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermLeaseCost" xlink:label="loc_us-gaap_ShortTermLeaseCost_C4402B8A5D3B5F26A9F1FEEBEEEE9C4E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermLeaseCost_C4402B8A5D3B5F26A9F1FEEBEEEE9C4E" xlink:to="lab_us-gaap_ShortTermLeaseCost_C4402B8A5D3B5F26A9F1FEEBEEEE9C4E" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeaseCost_1596ADD6B3FF42DAA24BFEEBEEEE10EF_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost_1596ADD6B3FF42DAA24BFEEBEEEE10EF" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Lease, cost</link:label>
    <link:label id="lab_us-gaap_LeaseCost_1596ADD6B3FF42DAA24BFEEBEEEE10EF_label_en-US" xlink:label="lab_us-gaap_LeaseCost_1596ADD6B3FF42DAA24BFEEBEEEE10EF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaap_LeaseCost_1596ADD6B3FF42DAA24BFEEBEEEE10EF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost_1596ADD6B3FF42DAA24BFEEBEEEE10EF" xlink:to="lab_us-gaap_LeaseCost_1596ADD6B3FF42DAA24BFEEBEEEE10EF" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_6BBC37A099DA03C2D5FCFEEBEEEEFAE1_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_6BBC37A099DA03C2D5FCFEEBEEEEFAE1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average remaining lease term (years)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_6BBC37A099DA03C2D5FCFEEBEEEEFAE1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_6BBC37A099DA03C2D5FCFEEBEEEEFAE1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_6BBC37A099DA03C2D5FCFEEBEEEEFAE1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_6BBC37A099DA03C2D5FCFEEBEEEEFAE1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_6BBC37A099DA03C2D5FCFEEBEEEEFAE1" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_7832705C22F9198ADDAFFEEBEEEE9DE3_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_7832705C22F9198ADDAFFEEBEEEE9DE3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_7832705C22F9198ADDAFFEEBEEEE9DE3_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_7832705C22F9198ADDAFFEEBEEEE9DE3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_7832705C22F9198ADDAFFEEBEEEE9DE3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_7832705C22F9198ADDAFFEEBEEEE9DE3" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_7832705C22F9198ADDAFFEEBEEEE9DE3" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_3556F7AEAE6960D7079F45374E4F9806_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract_3556F7AEAE6960D7079F45374E4F9806" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_3556F7AEAE6960D7079F45374E4F9806" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_3556F7AEAE6960D7079F45374E4F9806" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract_3556F7AEAE6960D7079F45374E4F9806" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_D91795B44DE1DF2D763F45374E4F2269_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_D91795B44DE1DF2D763F45374E4F2269" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_D91795B44DE1DF2D763F45374E4F2269_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_D91795B44DE1DF2D763F45374E4F2269" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_D91795B44DE1DF2D763F45374E4F2269" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_D91795B44DE1DF2D763F45374E4F2269" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_D91795B44DE1DF2D763F45374E4F2269" xlink:type="arc" />
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_694BA90308CAE9E2255A45374E4F73C3_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis_694BA90308CAE9E2255A45374E4F73C3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_694BA90308CAE9E2255A45374E4F73C3_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis_694BA90308CAE9E2255A45374E4F73C3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_694BA90308CAE9E2255A45374E4F73C3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis_694BA90308CAE9E2255A45374E4F73C3" xlink:to="lab_us-gaap_FinancialInstrumentAxis_694BA90308CAE9E2255A45374E4F73C3" xlink:type="arc" />
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0D28E54022D2421BD20945374E50A67C_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0D28E54022D2421BD20945374E50A67C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0D28E54022D2421BD20945374E50A67C_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0D28E54022D2421BD20945374E50A67C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0D28E54022D2421BD20945374E50A67C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0D28E54022D2421BD20945374E50A67C" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0D28E54022D2421BD20945374E50A67C" xlink:type="arc" />
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_A3822B052EA571CA986145374E506A61_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember_A3822B052EA571CA986145374E506A61" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S treasury securities</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_A3822B052EA571CA986145374E506A61_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember_A3822B052EA571CA986145374E506A61" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_A3822B052EA571CA986145374E506A61" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember_A3822B052EA571CA986145374E506A61" xlink:to="lab_us-gaap_USTreasurySecuritiesMember_A3822B052EA571CA986145374E506A61" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_DA068C5BB97FC9D67A9645374E501A66_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_DA068C5BB97FC9D67A9645374E501A66" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_DA068C5BB97FC9D67A9645374E501A66_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_DA068C5BB97FC9D67A9645374E501A66" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_DA068C5BB97FC9D67A9645374E501A66" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_DA068C5BB97FC9D67A9645374E501A66" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_DA068C5BB97FC9D67A9645374E501A66" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_1E22D68F6056C6CFF5B145374E50C8AD_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_1E22D68F6056C6CFF5B145374E50C8AD" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_1E22D68F6056C6CFF5B145374E50C8AD_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_1E22D68F6056C6CFF5B145374E50C8AD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_1E22D68F6056C6CFF5B145374E50C8AD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_1E22D68F6056C6CFF5B145374E50C8AD" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_1E22D68F6056C6CFF5B145374E50C8AD" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTaxAbstract_7D4D0878D655723E38E645374E51A6D1_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTaxAbstract_7D4D0878D655723E38E645374E51A6D1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTaxAbstract_7D4D0878D655723E38E645374E51A6D1_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTaxAbstract_7D4D0878D655723E38E645374E51A6D1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain (Loss), before Tax [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTaxAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTaxAbstract_7D4D0878D655723E38E645374E51A6D1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTaxAbstract_7D4D0878D655723E38E645374E51A6D1" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTaxAbstract_7D4D0878D655723E38E645374E51A6D1" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_CC3AE7B95DB9E32667C545374E51808F_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_CC3AE7B95DB9E32667C545374E51808F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_CC3AE7B95DB9E32667C545374E51808F_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_CC3AE7B95DB9E32667C545374E51808F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_CC3AE7B95DB9E32667C545374E51808F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_CC3AE7B95DB9E32667C545374E51808F" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_CC3AE7B95DB9E32667C545374E51808F" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_32CF58437C3534D1EC4045374E51BA76_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_32CF58437C3534D1EC4045374E51BA76" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_32CF58437C3534D1EC4045374E51BA76_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_32CF58437C3534D1EC4045374E51BA76" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_32CF58437C3534D1EC4045374E51BA76" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_32CF58437C3534D1EC4045374E51BA76" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_32CF58437C3534D1EC4045374E51BA76" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_17DF5DF4D7E4FAFED76545374E516E9B_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_17DF5DF4D7E4FAFED76545374E516E9B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_17DF5DF4D7E4FAFED76545374E516E9B_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_17DF5DF4D7E4FAFED76545374E516E9B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_17DF5DF4D7E4FAFED76545374E516E9B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_17DF5DF4D7E4FAFED76545374E516E9B" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_17DF5DF4D7E4FAFED76545374E516E9B" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_11129F66D3DCEDEEAE5145374E3F8D43_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract_11129F66D3DCEDEEAE5145374E3F8D43" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_11129F66D3DCEDEEAE5145374E3F8D43" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract_11129F66D3DCEDEEAE5145374E3F8D43" xlink:to="lab_us-gaap_DebtDisclosureAbstract_11129F66D3DCEDEEAE5145374E3F8D43" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtByMaturityAbstract_7F638FCB6C2F3BC3FF7345374E3F6452_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtByMaturityAbstract_7F638FCB6C2F3BC3FF7345374E3F6452" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Principal</link:label>
    <link:label id="lab_us-gaap_LongTermDebtByMaturityAbstract_7F638FCB6C2F3BC3FF7345374E3F6452_label_en-US" xlink:label="lab_us-gaap_LongTermDebtByMaturityAbstract_7F638FCB6C2F3BC3FF7345374E3F6452" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtByMaturityAbstract" xlink:label="loc_us-gaap_LongTermDebtByMaturityAbstract_7F638FCB6C2F3BC3FF7345374E3F6452" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_7F638FCB6C2F3BC3FF7345374E3F6452" xlink:to="lab_us-gaap_LongTermDebtByMaturityAbstract_7F638FCB6C2F3BC3FF7345374E3F6452" xlink:type="arc" />
    <link:label id="lab_eols_LongtermDebtMaturitiesPrincipalPaymentExcludingFinalPaymentDueInYearThree_5C5635B19A765A77B33D45374E3F22C0_terseLabel_en-US" xlink:label="lab_eols_LongtermDebtMaturitiesPrincipalPaymentExcludingFinalPaymentDueInYearThree_5C5635B19A765A77B33D45374E3F22C0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2022</link:label>
    <link:label id="lab_eols_LongtermDebtMaturitiesPrincipalPaymentExcludingFinalPaymentDueInYearThree_5C5635B19A765A77B33D45374E3F22C0_label_en-US" xlink:label="lab_eols_LongtermDebtMaturitiesPrincipalPaymentExcludingFinalPaymentDueInYearThree_5C5635B19A765A77B33D45374E3F22C0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Maturities, Principal Payment Excluding Final Payment Due In Year Three</link:label>
    <link:label id="lab_eols_LongtermDebtMaturitiesPrincipalPaymentExcludingFinalPaymentDueInYearThree_5C5635B19A765A77B33D45374E3F22C0_documentation_en-US" xlink:label="lab_eols_LongtermDebtMaturitiesPrincipalPaymentExcludingFinalPaymentDueInYearThree_5C5635B19A765A77B33D45374E3F22C0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Long-term Debt, Maturities, Principal Payment Excluding Final Payment Due In Year Three</link:label>
    <link:loc xlink:href="eols-20190930.xsd#eols_LongtermDebtMaturitiesPrincipalPaymentExcludingFinalPaymentDueInYearThree" xlink:label="loc_eols_LongtermDebtMaturitiesPrincipalPaymentExcludingFinalPaymentDueInYearThree_5C5635B19A765A77B33D45374E3F22C0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_LongtermDebtMaturitiesPrincipalPaymentExcludingFinalPaymentDueInYearThree_5C5635B19A765A77B33D45374E3F22C0" xlink:to="lab_eols_LongtermDebtMaturitiesPrincipalPaymentExcludingFinalPaymentDueInYearThree_5C5635B19A765A77B33D45374E3F22C0" xlink:type="arc" />
    <link:label id="lab_eols_LongtermDebtMaturitiesPrincipalPaymentExcludingFinalPaymentDueInYearFour_D7D944D07A0EBA7C426345374E4091F1_terseLabel_en-US" xlink:label="lab_eols_LongtermDebtMaturitiesPrincipalPaymentExcludingFinalPaymentDueInYearFour_D7D944D07A0EBA7C426345374E4091F1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2023</link:label>
    <link:label id="lab_eols_LongtermDebtMaturitiesPrincipalPaymentExcludingFinalPaymentDueInYearFour_D7D944D07A0EBA7C426345374E4091F1_label_en-US" xlink:label="lab_eols_LongtermDebtMaturitiesPrincipalPaymentExcludingFinalPaymentDueInYearFour_D7D944D07A0EBA7C426345374E4091F1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Maturities, Principal Payment Excluding Final Payment Due In Year Four</link:label>
    <link:label id="lab_eols_LongtermDebtMaturitiesPrincipalPaymentExcludingFinalPaymentDueInYearFour_D7D944D07A0EBA7C426345374E4091F1_documentation_en-US" xlink:label="lab_eols_LongtermDebtMaturitiesPrincipalPaymentExcludingFinalPaymentDueInYearFour_D7D944D07A0EBA7C426345374E4091F1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Long-term Debt, Maturities, Principal Payment Excluding Final Payment Due In Year Four</link:label>
    <link:loc xlink:href="eols-20190930.xsd#eols_LongtermDebtMaturitiesPrincipalPaymentExcludingFinalPaymentDueInYearFour" xlink:label="loc_eols_LongtermDebtMaturitiesPrincipalPaymentExcludingFinalPaymentDueInYearFour_D7D944D07A0EBA7C426345374E4091F1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_LongtermDebtMaturitiesPrincipalPaymentExcludingFinalPaymentDueInYearFour_D7D944D07A0EBA7C426345374E4091F1" xlink:to="lab_eols_LongtermDebtMaturitiesPrincipalPaymentExcludingFinalPaymentDueInYearFour_D7D944D07A0EBA7C426345374E4091F1" xlink:type="arc" />
    <link:label id="lab_eols_LongtermDebtMaturitiesPrincipalPaymentExcludingFinalPaymentDueInYearFive_3BA320E87ADCC9059A1B45374E406F8E_terseLabel_en-US" xlink:label="lab_eols_LongtermDebtMaturitiesPrincipalPaymentExcludingFinalPaymentDueInYearFive_3BA320E87ADCC9059A1B45374E406F8E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2024</link:label>
    <link:label id="lab_eols_LongtermDebtMaturitiesPrincipalPaymentExcludingFinalPaymentDueInYearFive_3BA320E87ADCC9059A1B45374E406F8E_label_en-US" xlink:label="lab_eols_LongtermDebtMaturitiesPrincipalPaymentExcludingFinalPaymentDueInYearFive_3BA320E87ADCC9059A1B45374E406F8E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Maturities, Principal Payment Excluding Final Payment Due In Year Five</link:label>
    <link:label id="lab_eols_LongtermDebtMaturitiesPrincipalPaymentExcludingFinalPaymentDueInYearFive_3BA320E87ADCC9059A1B45374E406F8E_documentation_en-US" xlink:label="lab_eols_LongtermDebtMaturitiesPrincipalPaymentExcludingFinalPaymentDueInYearFive_3BA320E87ADCC9059A1B45374E406F8E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Long-term Debt, Maturities, Principal Payment Excluding Final Payment Due In Year Five</link:label>
    <link:loc xlink:href="eols-20190930.xsd#eols_LongtermDebtMaturitiesPrincipalPaymentExcludingFinalPaymentDueInYearFive" xlink:label="loc_eols_LongtermDebtMaturitiesPrincipalPaymentExcludingFinalPaymentDueInYearFive_3BA320E87ADCC9059A1B45374E406F8E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_LongtermDebtMaturitiesPrincipalPaymentExcludingFinalPaymentDueInYearFive_3BA320E87ADCC9059A1B45374E406F8E" xlink:to="lab_eols_LongtermDebtMaturitiesPrincipalPaymentExcludingFinalPaymentDueInYearFive_3BA320E87ADCC9059A1B45374E406F8E" xlink:type="arc" />
    <link:label id="lab_eols_LongtermDebtMaturitiesPrincipalPaymentExcludingFinalPayment_96BC57975C31BAF492C445374E406684_totalLabel_en-US" xlink:label="lab_eols_LongtermDebtMaturitiesPrincipalPaymentExcludingFinalPayment_96BC57975C31BAF492C445374E406684" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Principal payment excluding final payment</link:label>
    <link:label id="lab_eols_LongtermDebtMaturitiesPrincipalPaymentExcludingFinalPayment_96BC57975C31BAF492C445374E406684_label_en-US" xlink:label="lab_eols_LongtermDebtMaturitiesPrincipalPaymentExcludingFinalPayment_96BC57975C31BAF492C445374E406684" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Maturities, Principal Payment Excluding Final Payment</link:label>
    <link:label id="lab_eols_LongtermDebtMaturitiesPrincipalPaymentExcludingFinalPayment_96BC57975C31BAF492C445374E406684_documentation_en-US" xlink:label="lab_eols_LongtermDebtMaturitiesPrincipalPaymentExcludingFinalPayment_96BC57975C31BAF492C445374E406684" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Long-term Debt, Maturities, Principal Payment Excluding Final Payment</link:label>
    <link:loc xlink:href="eols-20190930.xsd#eols_LongtermDebtMaturitiesPrincipalPaymentExcludingFinalPayment" xlink:label="loc_eols_LongtermDebtMaturitiesPrincipalPaymentExcludingFinalPayment_96BC57975C31BAF492C445374E406684" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_LongtermDebtMaturitiesPrincipalPaymentExcludingFinalPayment_96BC57975C31BAF492C445374E406684" xlink:to="lab_eols_LongtermDebtMaturitiesPrincipalPaymentExcludingFinalPayment_96BC57975C31BAF492C445374E406684" xlink:type="arc" />
    <link:label id="lab_eols_LongTermDebtFinalPaymentAbstract_4AB254A98E610BEDF05145374E405FE6_terseLabel_en-US" xlink:label="lab_eols_LongTermDebtFinalPaymentAbstract_4AB254A98E610BEDF05145374E405FE6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Final Payment</link:label>
    <link:label id="lab_eols_LongTermDebtFinalPaymentAbstract_4AB254A98E610BEDF05145374E405FE6_label_en-US" xlink:label="lab_eols_LongTermDebtFinalPaymentAbstract_4AB254A98E610BEDF05145374E405FE6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">LongTerm Debt Final Payment [Abstract]</link:label>
    <link:label id="lab_eols_LongTermDebtFinalPaymentAbstract_4AB254A98E610BEDF05145374E405FE6_documentation_en-US" xlink:label="lab_eols_LongTermDebtFinalPaymentAbstract_4AB254A98E610BEDF05145374E405FE6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">LongTerm Debt Final Payment [Abstract]</link:label>
    <link:loc xlink:href="eols-20190930.xsd#eols_LongTermDebtFinalPaymentAbstract" xlink:label="loc_eols_LongTermDebtFinalPaymentAbstract_4AB254A98E610BEDF05145374E405FE6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_LongTermDebtFinalPaymentAbstract_4AB254A98E610BEDF05145374E405FE6" xlink:to="lab_eols_LongTermDebtFinalPaymentAbstract_4AB254A98E610BEDF05145374E405FE6" xlink:type="arc" />
    <link:label id="lab_eols_LongtermDebtMaturitiesFinalPaymentsInYearThree_63D28D92DCAA4FA2832845374E4032AC_terseLabel_en-US" xlink:label="lab_eols_LongtermDebtMaturitiesFinalPaymentsInYearThree_63D28D92DCAA4FA2832845374E4032AC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2022</link:label>
    <link:label id="lab_eols_LongtermDebtMaturitiesFinalPaymentsInYearThree_63D28D92DCAA4FA2832845374E4032AC_label_en-US" xlink:label="lab_eols_LongtermDebtMaturitiesFinalPaymentsInYearThree_63D28D92DCAA4FA2832845374E4032AC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Maturities, Final Payments In Year Three</link:label>
    <link:label id="lab_eols_LongtermDebtMaturitiesFinalPaymentsInYearThree_63D28D92DCAA4FA2832845374E4032AC_documentation_en-US" xlink:label="lab_eols_LongtermDebtMaturitiesFinalPaymentsInYearThree_63D28D92DCAA4FA2832845374E4032AC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Long-term Debt, Maturities, Final Payments In Year Three</link:label>
    <link:loc xlink:href="eols-20190930.xsd#eols_LongtermDebtMaturitiesFinalPaymentsInYearThree" xlink:label="loc_eols_LongtermDebtMaturitiesFinalPaymentsInYearThree_63D28D92DCAA4FA2832845374E4032AC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_LongtermDebtMaturitiesFinalPaymentsInYearThree_63D28D92DCAA4FA2832845374E4032AC" xlink:to="lab_eols_LongtermDebtMaturitiesFinalPaymentsInYearThree_63D28D92DCAA4FA2832845374E4032AC" xlink:type="arc" />
    <link:label id="lab_eols_LongtermDebtMaturitiesFinalPaymentsInYearFour_7C655A1D8B7CE68232CF45374E417873_terseLabel_en-US" xlink:label="lab_eols_LongtermDebtMaturitiesFinalPaymentsInYearFour_7C655A1D8B7CE68232CF45374E417873" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2023</link:label>
    <link:label id="lab_eols_LongtermDebtMaturitiesFinalPaymentsInYearFour_7C655A1D8B7CE68232CF45374E417873_label_en-US" xlink:label="lab_eols_LongtermDebtMaturitiesFinalPaymentsInYearFour_7C655A1D8B7CE68232CF45374E417873" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Maturities, Final Payments In Year Four</link:label>
    <link:label id="lab_eols_LongtermDebtMaturitiesFinalPaymentsInYearFour_7C655A1D8B7CE68232CF45374E417873_documentation_en-US" xlink:label="lab_eols_LongtermDebtMaturitiesFinalPaymentsInYearFour_7C655A1D8B7CE68232CF45374E417873" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Long-term Debt, Maturities, Final Payments In Year Four</link:label>
    <link:loc xlink:href="eols-20190930.xsd#eols_LongtermDebtMaturitiesFinalPaymentsInYearFour" xlink:label="loc_eols_LongtermDebtMaturitiesFinalPaymentsInYearFour_7C655A1D8B7CE68232CF45374E417873" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_LongtermDebtMaturitiesFinalPaymentsInYearFour_7C655A1D8B7CE68232CF45374E417873" xlink:to="lab_eols_LongtermDebtMaturitiesFinalPaymentsInYearFour_7C655A1D8B7CE68232CF45374E417873" xlink:type="arc" />
    <link:label id="lab_eols_LongtermDebtMaturitiesFinalPaymentsInYearFive_EB2AB42838314B03E5F845374E41713C_terseLabel_en-US" xlink:label="lab_eols_LongtermDebtMaturitiesFinalPaymentsInYearFive_EB2AB42838314B03E5F845374E41713C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2024</link:label>
    <link:label id="lab_eols_LongtermDebtMaturitiesFinalPaymentsInYearFive_EB2AB42838314B03E5F845374E41713C_label_en-US" xlink:label="lab_eols_LongtermDebtMaturitiesFinalPaymentsInYearFive_EB2AB42838314B03E5F845374E41713C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Maturities, Final Payments In Year Five</link:label>
    <link:label id="lab_eols_LongtermDebtMaturitiesFinalPaymentsInYearFive_EB2AB42838314B03E5F845374E41713C_documentation_en-US" xlink:label="lab_eols_LongtermDebtMaturitiesFinalPaymentsInYearFive_EB2AB42838314B03E5F845374E41713C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Long-term Debt, Maturities, Final Payments In Year Five</link:label>
    <link:loc xlink:href="eols-20190930.xsd#eols_LongtermDebtMaturitiesFinalPaymentsInYearFive" xlink:label="loc_eols_LongtermDebtMaturitiesFinalPaymentsInYearFive_EB2AB42838314B03E5F845374E41713C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_LongtermDebtMaturitiesFinalPaymentsInYearFive_EB2AB42838314B03E5F845374E41713C" xlink:to="lab_eols_LongtermDebtMaturitiesFinalPaymentsInYearFive_EB2AB42838314B03E5F845374E41713C" xlink:type="arc" />
    <link:label id="lab_eols_LongtermDebtMaturitiesFinalPayments_2587A0F31226DF3954B845374E41D2EA_totalLabel_en-US" xlink:label="lab_eols_LongtermDebtMaturitiesFinalPayments_2587A0F31226DF3954B845374E41D2EA" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Final payments</link:label>
    <link:label id="lab_eols_LongtermDebtMaturitiesFinalPayments_2587A0F31226DF3954B845374E41D2EA_label_en-US" xlink:label="lab_eols_LongtermDebtMaturitiesFinalPayments_2587A0F31226DF3954B845374E41D2EA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Maturities, Final Payments</link:label>
    <link:label id="lab_eols_LongtermDebtMaturitiesFinalPayments_2587A0F31226DF3954B845374E41D2EA_documentation_en-US" xlink:label="lab_eols_LongtermDebtMaturitiesFinalPayments_2587A0F31226DF3954B845374E41D2EA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Long-term Debt, Maturities, Final Payments</link:label>
    <link:loc xlink:href="eols-20190930.xsd#eols_LongtermDebtMaturitiesFinalPayments" xlink:label="loc_eols_LongtermDebtMaturitiesFinalPayments_2587A0F31226DF3954B845374E41D2EA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_LongtermDebtMaturitiesFinalPayments_2587A0F31226DF3954B845374E41D2EA" xlink:to="lab_eols_LongtermDebtMaturitiesFinalPayments_2587A0F31226DF3954B845374E41D2EA" xlink:type="arc" />
    <link:label id="lab_eols_LongTermDebtByMaturityTotalAbstract_1702B91F574D83EC41D445374E415D06_terseLabel_en-US" xlink:label="lab_eols_LongTermDebtByMaturityTotalAbstract_1702B91F574D83EC41D445374E415D06" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_eols_LongTermDebtByMaturityTotalAbstract_1702B91F574D83EC41D445374E415D06_label_en-US" xlink:label="lab_eols_LongTermDebtByMaturityTotalAbstract_1702B91F574D83EC41D445374E415D06" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long Term Debt By Maturity Total [Abstract]</link:label>
    <link:label id="lab_eols_LongTermDebtByMaturityTotalAbstract_1702B91F574D83EC41D445374E415D06_documentation_en-US" xlink:label="lab_eols_LongTermDebtByMaturityTotalAbstract_1702B91F574D83EC41D445374E415D06" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Long Term Debt By Maturity Total [Abstract]</link:label>
    <link:loc xlink:href="eols-20190930.xsd#eols_LongTermDebtByMaturityTotalAbstract" xlink:label="loc_eols_LongTermDebtByMaturityTotalAbstract_1702B91F574D83EC41D445374E415D06" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_LongTermDebtByMaturityTotalAbstract_1702B91F574D83EC41D445374E415D06" xlink:to="lab_eols_LongTermDebtByMaturityTotalAbstract_1702B91F574D83EC41D445374E415D06" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_C73E1915A51513149D5A45374E41FA9B_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_C73E1915A51513149D5A45374E41FA9B" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_C73E1915A51513149D5A45374E41FA9B_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_C73E1915A51513149D5A45374E41FA9B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Year Three</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_C73E1915A51513149D5A45374E41FA9B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_C73E1915A51513149D5A45374E41FA9B" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_C73E1915A51513149D5A45374E41FA9B" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_F98F19D1524DB87F646B45374E42D4E8_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_F98F19D1524DB87F646B45374E42D4E8" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_F98F19D1524DB87F646B45374E42D4E8_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_F98F19D1524DB87F646B45374E42D4E8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Year Four</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_F98F19D1524DB87F646B45374E42D4E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_F98F19D1524DB87F646B45374E42D4E8" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_F98F19D1524DB87F646B45374E42D4E8" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_110F9467719664BE133245374E42D6F3_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_110F9467719664BE133245374E42D6F3" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_110F9467719664BE133245374E42D6F3_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_110F9467719664BE133245374E42D6F3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_110F9467719664BE133245374E42D6F3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_110F9467719664BE133245374E42D6F3" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_110F9467719664BE133245374E42D6F3" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebt_8FCC8D5280255A259A6C45374E4231FC_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt_8FCC8D5280255A259A6C45374E4231FC" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_8FCC8D5280255A259A6C45374E4231FC_label_en-US" xlink:label="lab_us-gaap_LongTermDebt_8FCC8D5280255A259A6C45374E4231FC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_8FCC8D5280255A259A6C45374E4231FC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt_8FCC8D5280255A259A6C45374E4231FC" xlink:to="lab_us-gaap_LongTermDebt_8FCC8D5280255A259A6C45374E4231FC" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9C93F80CCDC9FC3D5CC645374EE3805F_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9C93F80CCDC9FC3D5CC645374EE3805F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9C93F80CCDC9FC3D5CC645374EE3805F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9C93F80CCDC9FC3D5CC645374EE3805F" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9C93F80CCDC9FC3D5CC645374EE3805F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_89D21E0A1C381BC0418445374EE3F484_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_89D21E0A1C381BC0418445374EE3F484" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_89D21E0A1C381BC0418445374EE3F484_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_89D21E0A1C381BC0418445374EE3F484" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_89D21E0A1C381BC0418445374EE3F484" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_89D21E0A1C381BC0418445374EE3F484" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_89D21E0A1C381BC0418445374EE3F484" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_5EE2DACEF8620B01F4F145374EE3270B_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_5EE2DACEF8620B01F4F145374EE3270B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_5EE2DACEF8620B01F4F145374EE3270B_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_5EE2DACEF8620B01F4F145374EE3270B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_5EE2DACEF8620B01F4F145374EE3270B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_5EE2DACEF8620B01F4F145374EE3270B" xlink:to="lab_us-gaap_IncomeStatementLocationAxis_5EE2DACEF8620B01F4F145374EE3270B" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_F8B892BB46E558DA224A45374EE4D731_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_F8B892BB46E558DA224A45374EE4D731" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_F8B892BB46E558DA224A45374EE4D731_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_F8B892BB46E558DA224A45374EE4D731" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_F8B892BB46E558DA224A45374EE4D731" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_F8B892BB46E558DA224A45374EE4D731" xlink:to="lab_us-gaap_IncomeStatementLocationDomain_F8B892BB46E558DA224A45374EE4D731" xlink:type="arc" />
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_77702E1679F4EC7B5D5445374EE475E1_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_77702E1679F4EC7B5D5445374EE475E1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_77702E1679F4EC7B5D5445374EE475E1_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_77702E1679F4EC7B5D5445374EE475E1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_77702E1679F4EC7B5D5445374EE475E1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_77702E1679F4EC7B5D5445374EE475E1" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_77702E1679F4EC7B5D5445374EE475E1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_8899F1A62635826AA05845374EE49F7C_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_8899F1A62635826AA05845374EE49F7C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_8899F1A62635826AA05845374EE49F7C_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_8899F1A62635826AA05845374EE49F7C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_8899F1A62635826AA05845374EE49F7C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember_8899F1A62635826AA05845374EE49F7C" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember_8899F1A62635826AA05845374EE49F7C" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0248B13CE9C5A7182DEB45374EE43D37_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0248B13CE9C5A7182DEB45374EE43D37" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0248B13CE9C5A7182DEB45374EE43D37_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0248B13CE9C5A7182DEB45374EE43D37" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0248B13CE9C5A7182DEB45374EE43D37" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0248B13CE9C5A7182DEB45374EE43D37" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0248B13CE9C5A7182DEB45374EE43D37" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_D803503548C41E338F9045374EE5A2BE_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_D803503548C41E338F9045374EE5A2BE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Allocated stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_D803503548C41E338F9045374EE5A2BE_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_D803503548C41E338F9045374EE5A2BE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_D803503548C41E338F9045374EE5A2BE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense_D803503548C41E338F9045374EE5A2BE" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense_D803503548C41E338F9045374EE5A2BE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_72E34AFA742ABAC9EC62B5DED549C5D7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable_72E34AFA742ABAC9EC62B5DED549C5D7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_72E34AFA742ABAC9EC62B5DED549C5D7_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable_72E34AFA742ABAC9EC62B5DED549C5D7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_72E34AFA742ABAC9EC62B5DED549C5D7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_72E34AFA742ABAC9EC62B5DED549C5D7" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable_72E34AFA742ABAC9EC62B5DED549C5D7" xlink:type="arc" />
    <link:label id="lab_us-gaap_AwardTypeAxis_9B606042FA8F6D4CC593B5DED5491520_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_9B606042FA8F6D4CC593B5DED5491520" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_9B606042FA8F6D4CC593B5DED5491520_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_9B606042FA8F6D4CC593B5DED5491520" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_9B606042FA8F6D4CC593B5DED5491520" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis_9B606042FA8F6D4CC593B5DED5491520" xlink:to="lab_us-gaap_AwardTypeAxis_9B606042FA8F6D4CC593B5DED5491520" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_D4D99CFD3C7E7AAA3CAEB5DED54AD756_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_D4D99CFD3C7E7AAA3CAEB5DED54AD756" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_D4D99CFD3C7E7AAA3CAEB5DED54AD756_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_D4D99CFD3C7E7AAA3CAEB5DED54AD756" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_D4D99CFD3C7E7AAA3CAEB5DED54AD756" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_D4D99CFD3C7E7AAA3CAEB5DED54AD756" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_D4D99CFD3C7E7AAA3CAEB5DED54AD756" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_98747E28619CE232388CB5DED54A7689_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_98747E28619CE232388CB5DED54A7689" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_98747E28619CE232388CB5DED54A7689_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_98747E28619CE232388CB5DED54A7689" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_98747E28619CE232388CB5DED54A7689" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember_98747E28619CE232388CB5DED54A7689" xlink:to="lab_us-gaap_EmployeeStockOptionMember_98747E28619CE232388CB5DED54A7689" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfStockLineItems_B9EFD77387BAC2E5792EB5DED54A3E1B_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems_B9EFD77387BAC2E5792EB5DED54A3E1B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_B9EFD77387BAC2E5792EB5DED54A3E1B_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems_B9EFD77387BAC2E5792EB5DED54A3E1B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_B9EFD77387BAC2E5792EB5DED54A3E1B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems_B9EFD77387BAC2E5792EB5DED54A3E1B" xlink:to="lab_us-gaap_ClassOfStockLineItems_B9EFD77387BAC2E5792EB5DED54A3E1B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_AD0496E3F2E5C0BFEE5FB5DED54ADD74_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_AD0496E3F2E5C0BFEE5FB5DED54ADD74" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_AD0496E3F2E5C0BFEE5FB5DED54ADD74_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_AD0496E3F2E5C0BFEE5FB5DED54ADD74" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_AD0496E3F2E5C0BFEE5FB5DED54ADD74" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_AD0496E3F2E5C0BFEE5FB5DED54ADD74" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_AD0496E3F2E5C0BFEE5FB5DED54ADD74" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_9402ED79E4B21E88DE7FB5DED54B9DB9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_9402ED79E4B21E88DE7FB5DED54B9DB9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_9402ED79E4B21E88DE7FB5DED54B9DB9_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_9402ED79E4B21E88DE7FB5DED54B9DB9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_9402ED79E4B21E88DE7FB5DED54B9DB9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_9402ED79E4B21E88DE7FB5DED54B9DB9" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_9402ED79E4B21E88DE7FB5DED54B9DB9" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_887A84DC4E5403AC73CDB5DED54B6A63_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_887A84DC4E5403AC73CDB5DED54B6A63" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected life (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_887A84DC4E5403AC73CDB5DED54B6A63_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_887A84DC4E5403AC73CDB5DED54B6A63" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_887A84DC4E5403AC73CDB5DED54B6A63" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_887A84DC4E5403AC73CDB5DED54B6A63" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_887A84DC4E5403AC73CDB5DED54B6A63" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_FE0A37335F52F0089B07B5DED54B5A25_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_FE0A37335F52F0089B07B5DED54B5A25" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividend yield rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_FE0A37335F52F0089B07B5DED54B5A25_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_FE0A37335F52F0089B07B5DED54B5A25" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_FE0A37335F52F0089B07B5DED54B5A25" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_FE0A37335F52F0089B07B5DED54B5A25" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_FE0A37335F52F0089B07B5DED54B5A25" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_423A457965AC71AE0B451835DAD53408_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract_423A457965AC71AE0B451835DAD53408" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_423A457965AC71AE0B451835DAD53408" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_423A457965AC71AE0B451835DAD53408" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract_423A457965AC71AE0B451835DAD53408" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9A51797BE59EC65E43DF1835DAD6B114_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9A51797BE59EC65E43DF1835DAD6B114" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9A51797BE59EC65E43DF1835DAD6B114_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9A51797BE59EC65E43DF1835DAD6B114" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9A51797BE59EC65E43DF1835DAD6B114" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9A51797BE59EC65E43DF1835DAD6B114" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9A51797BE59EC65E43DF1835DAD6B114" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_27DFB00E9F3B143687BD1835DAD682E0_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_27DFB00E9F3B143687BD1835DAD682E0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_27DFB00E9F3B143687BD1835DAD682E0_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_27DFB00E9F3B143687BD1835DAD682E0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_27DFB00E9F3B143687BD1835DAD682E0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_27DFB00E9F3B143687BD1835DAD682E0" xlink:to="lab_us-gaap_NetIncomeLoss_27DFB00E9F3B143687BD1835DAD682E0" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_D863E70D4A8C84F93F4B1835DAD6FDB6_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_D863E70D4A8C84F93F4B1835DAD6FDB6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_D863E70D4A8C84F93F4B1835DAD6FDB6_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_D863E70D4A8C84F93F4B1835DAD6FDB6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_D863E70D4A8C84F93F4B1835DAD6FDB6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_D863E70D4A8C84F93F4B1835DAD6FDB6" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_D863E70D4A8C84F93F4B1835DAD6FDB6" xlink:type="arc" />
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_6AE64675CB8B77A87BAC1835DAD66407_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization_6AE64675CB8B77A87BAC1835DAD66407" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_6AE64675CB8B77A87BAC1835DAD66407_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization_6AE64675CB8B77A87BAC1835DAD66407" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_6AE64675CB8B77A87BAC1835DAD66407" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization_6AE64675CB8B77A87BAC1835DAD66407" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization_6AE64675CB8B77A87BAC1835DAD66407" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensation_8A15F9ADDDB9984174B71835DAD74C23_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_8A15F9ADDDB9984174B71835DAD74C23" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_8A15F9ADDDB9984174B71835DAD74C23_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_8A15F9ADDDB9984174B71835DAD74C23" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_8A15F9ADDDB9984174B71835DAD74C23" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_8A15F9ADDDB9984174B71835DAD74C23" xlink:to="lab_us-gaap_ShareBasedCompensation_8A15F9ADDDB9984174B71835DAD74C23" xlink:type="arc" />
    <link:label id="lab_eols_ProvisionsForRebateAndCouponPrograms_223672EE4B953B57F2351835DAD76907_terseLabel_en-US" xlink:label="lab_eols_ProvisionsForRebateAndCouponPrograms_223672EE4B953B57F2351835DAD76907" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provisions for rebate and coupon programs</link:label>
    <link:label id="lab_eols_ProvisionsForRebateAndCouponPrograms_223672EE4B953B57F2351835DAD76907_label_en-US" xlink:label="lab_eols_ProvisionsForRebateAndCouponPrograms_223672EE4B953B57F2351835DAD76907" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Provisions For Rebate And Coupon Programs</link:label>
    <link:label id="lab_eols_ProvisionsForRebateAndCouponPrograms_223672EE4B953B57F2351835DAD76907_documentation_en-US" xlink:label="lab_eols_ProvisionsForRebateAndCouponPrograms_223672EE4B953B57F2351835DAD76907" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Provisions For Rebate And Coupon Programs</link:label>
    <link:loc xlink:href="eols-20190930.xsd#eols_ProvisionsForRebateAndCouponPrograms" xlink:label="loc_eols_ProvisionsForRebateAndCouponPrograms_223672EE4B953B57F2351835DAD76907" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_ProvisionsForRebateAndCouponPrograms_223672EE4B953B57F2351835DAD76907" xlink:to="lab_eols_ProvisionsForRebateAndCouponPrograms_223672EE4B953B57F2351835DAD76907" xlink:type="arc" />
    <link:label id="lab_eols_AmortizationOfDiscountOnShorttermInvestments_B2425D67354B13F9BCF61835DAD7C45B_terseLabel_en-US" xlink:label="lab_eols_AmortizationOfDiscountOnShorttermInvestments_B2425D67354B13F9BCF61835DAD7C45B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accretion of discount on short-term investments</link:label>
    <link:label id="lab_eols_AmortizationOfDiscountOnShorttermInvestments_B2425D67354B13F9BCF61835DAD7C45B_label_en-US" xlink:label="lab_eols_AmortizationOfDiscountOnShorttermInvestments_B2425D67354B13F9BCF61835DAD7C45B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization Of Discount On Short-term Investments</link:label>
    <link:label id="lab_eols_AmortizationOfDiscountOnShorttermInvestments_B2425D67354B13F9BCF61835DAD7C45B_documentation_en-US" xlink:label="lab_eols_AmortizationOfDiscountOnShorttermInvestments_B2425D67354B13F9BCF61835DAD7C45B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amortization Of Discount On Short-term Investments</link:label>
    <link:loc xlink:href="eols-20190930.xsd#eols_AmortizationOfDiscountOnShorttermInvestments" xlink:label="loc_eols_AmortizationOfDiscountOnShorttermInvestments_B2425D67354B13F9BCF61835DAD7C45B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_AmortizationOfDiscountOnShorttermInvestments_B2425D67354B13F9BCF61835DAD7C45B" xlink:to="lab_eols_AmortizationOfDiscountOnShorttermInvestments_B2425D67354B13F9BCF61835DAD7C45B" xlink:type="arc" />
    <link:label id="lab_eols_OperatingLeaseRightofUseAssetAmortization_2B47AEDF4B92277224A01835DAD73A15_terseLabel_en-US" xlink:label="lab_eols_OperatingLeaseRightofUseAssetAmortization_2B47AEDF4B92277224A01835DAD73A15" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of operating lease right-of-use assets</link:label>
    <link:label id="lab_eols_OperatingLeaseRightofUseAssetAmortization_2B47AEDF4B92277224A01835DAD73A15_label_en-US" xlink:label="lab_eols_OperatingLeaseRightofUseAssetAmortization_2B47AEDF4B92277224A01835DAD73A15" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Amortization</link:label>
    <link:label id="lab_eols_OperatingLeaseRightofUseAssetAmortization_2B47AEDF4B92277224A01835DAD73A15_documentation_en-US" xlink:label="lab_eols_OperatingLeaseRightofUseAssetAmortization_2B47AEDF4B92277224A01835DAD73A15" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Amortization</link:label>
    <link:loc xlink:href="eols-20190930.xsd#eols_OperatingLeaseRightofUseAssetAmortization" xlink:label="loc_eols_OperatingLeaseRightofUseAssetAmortization_2B47AEDF4B92277224A01835DAD73A15" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_OperatingLeaseRightofUseAssetAmortization_2B47AEDF4B92277224A01835DAD73A15" xlink:to="lab_eols_OperatingLeaseRightofUseAssetAmortization_2B47AEDF4B92277224A01835DAD73A15" xlink:type="arc" />
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_7668AA262C90F16018CD1835DAD73CAA_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_7668AA262C90F16018CD1835DAD73CAA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of debt discount and issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_7668AA262C90F16018CD1835DAD73CAA_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_7668AA262C90F16018CD1835DAD73CAA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_7668AA262C90F16018CD1835DAD73CAA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_7668AA262C90F16018CD1835DAD73CAA" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_7668AA262C90F16018CD1835DAD73CAA" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_2DFAF2B1812E996A1A3B1835DAD7CBB5_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_2DFAF2B1812E996A1A3B1835DAD7CBB5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_2DFAF2B1812E996A1A3B1835DAD7CBB5_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_2DFAF2B1812E996A1A3B1835DAD7CBB5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_2DFAF2B1812E996A1A3B1835DAD7CBB5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_2DFAF2B1812E996A1A3B1835DAD7CBB5" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_2DFAF2B1812E996A1A3B1835DAD7CBB5" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_E5942EE24C455CF07CD51835DAD87FAB_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_E5942EE24C455CF07CD51835DAD87FAB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revaluation of contingent royalty obligation payable to Evolus Founders</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_E5942EE24C455CF07CD51835DAD87FAB_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_E5942EE24C455CF07CD51835DAD87FAB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_E5942EE24C455CF07CD51835DAD87FAB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_E5942EE24C455CF07CD51835DAD87FAB" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_E5942EE24C455CF07CD51835DAD87FAB" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_45DCBEC19FC1BE03BF051835DAD8429D_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_45DCBEC19FC1BE03BF051835DAD8429D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_45DCBEC19FC1BE03BF051835DAD8429D_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_45DCBEC19FC1BE03BF051835DAD8429D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_45DCBEC19FC1BE03BF051835DAD8429D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_45DCBEC19FC1BE03BF051835DAD8429D" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_45DCBEC19FC1BE03BF051835DAD8429D" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_080BBC8D0212AEA5DA4C1835DAD8CD30_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories_080BBC8D0212AEA5DA4C1835DAD8CD30" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_080BBC8D0212AEA5DA4C1835DAD8CD30_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories_080BBC8D0212AEA5DA4C1835DAD8CD30" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_080BBC8D0212AEA5DA4C1835DAD8CD30" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories_080BBC8D0212AEA5DA4C1835DAD8CD30" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories_080BBC8D0212AEA5DA4C1835DAD8CD30" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_461072F78F2005BDAC921835DAD8C69B_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_461072F78F2005BDAC921835DAD8C69B" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_461072F78F2005BDAC921835DAD8C69B_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_461072F78F2005BDAC921835DAD8C69B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_461072F78F2005BDAC921835DAD8C69B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_461072F78F2005BDAC921835DAD8C69B" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_461072F78F2005BDAC921835DAD8C69B" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_C6DD5D962B647CE919161835DAD826BF_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_C6DD5D962B647CE919161835DAD826BF" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_C6DD5D962B647CE919161835DAD826BF_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_C6DD5D962B647CE919161835DAD826BF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_C6DD5D962B647CE919161835DAD826BF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_C6DD5D962B647CE919161835DAD826BF" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_C6DD5D962B647CE919161835DAD826BF" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_CDEB8F695CD24DC6AFDF1835DAD87A6C_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_CDEB8F695CD24DC6AFDF1835DAD87A6C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_CDEB8F695CD24DC6AFDF1835DAD87A6C_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_CDEB8F695CD24DC6AFDF1835DAD87A6C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_CDEB8F695CD24DC6AFDF1835DAD87A6C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_CDEB8F695CD24DC6AFDF1835DAD87A6C" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_CDEB8F695CD24DC6AFDF1835DAD87A6C" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_6ABD2080661EDA2BF8D91835DAD8D96E_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable_6ABD2080661EDA2BF8D91835DAD8D96E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_6ABD2080661EDA2BF8D91835DAD8D96E_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable_6ABD2080661EDA2BF8D91835DAD8D96E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_6ABD2080661EDA2BF8D91835DAD8D96E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable_6ABD2080661EDA2BF8D91835DAD8D96E" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable_6ABD2080661EDA2BF8D91835DAD8D96E" xlink:type="arc" />
    <link:label id="lab_eols_IncreasedecreaseInOperatingLeaseLiabilities_F1E1CF29DBB69BF31A321835DAD91762_terseLabel_en-US" xlink:label="lab_eols_IncreasedecreaseInOperatingLeaseLiabilities_F1E1CF29DBB69BF31A321835DAD91762" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_eols_IncreasedecreaseInOperatingLeaseLiabilities_F1E1CF29DBB69BF31A321835DAD91762_label_en-US" xlink:label="lab_eols_IncreasedecreaseInOperatingLeaseLiabilities_F1E1CF29DBB69BF31A321835DAD91762" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) In Operating Lease Liabilities</link:label>
    <link:label id="lab_eols_IncreasedecreaseInOperatingLeaseLiabilities_F1E1CF29DBB69BF31A321835DAD91762_documentation_en-US" xlink:label="lab_eols_IncreasedecreaseInOperatingLeaseLiabilities_F1E1CF29DBB69BF31A321835DAD91762" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (decrease) In Operating Lease Liabilities</link:label>
    <link:loc xlink:href="eols-20190930.xsd#eols_IncreasedecreaseInOperatingLeaseLiabilities" xlink:label="loc_eols_IncreasedecreaseInOperatingLeaseLiabilities_F1E1CF29DBB69BF31A321835DAD91762" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_IncreasedecreaseInOperatingLeaseLiabilities_F1E1CF29DBB69BF31A321835DAD91762" xlink:to="lab_eols_IncreasedecreaseInOperatingLeaseLiabilities_F1E1CF29DBB69BF31A321835DAD91762" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredLiabilities_B9F7DBCD269B076A34401835DAD9F181_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredLiabilities_B9F7DBCD269B076A34401835DAD9F181" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred rent</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredLiabilities_B9F7DBCD269B076A34401835DAD9F181_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredLiabilities_B9F7DBCD269B076A34401835DAD9F181" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Deferred Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredLiabilities_B9F7DBCD269B076A34401835DAD9F181" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredLiabilities_B9F7DBCD269B076A34401835DAD9F181" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredLiabilities_B9F7DBCD269B076A34401835DAD9F181" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_5066AEB44A67D04B3D081835DAD9100E_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_5066AEB44A67D04B3D081835DAD9100E" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_5066AEB44A67D04B3D081835DAD9100E_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_5066AEB44A67D04B3D081835DAD9100E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5066AEB44A67D04B3D081835DAD9100E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5066AEB44A67D04B3D081835DAD9100E" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_5066AEB44A67D04B3D081835DAD9100E" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6A00B59BC07F63884B6C1835DAD921AC_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6A00B59BC07F63884B6C1835DAD921AC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6A00B59BC07F63884B6C1835DAD921AC_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6A00B59BC07F63884B6C1835DAD921AC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6A00B59BC07F63884B6C1835DAD921AC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6A00B59BC07F63884B6C1835DAD921AC" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6A00B59BC07F63884B6C1835DAD921AC" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_ED9F50C0919047EED8FB1835DAD93452_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_ED9F50C0919047EED8FB1835DAD93452" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_ED9F50C0919047EED8FB1835DAD93452_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_ED9F50C0919047EED8FB1835DAD93452" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_ED9F50C0919047EED8FB1835DAD93452" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_ED9F50C0919047EED8FB1835DAD93452" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_ED9F50C0919047EED8FB1835DAD93452" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsForSoftware_2BF2DF6E23AADAED8EC51835DADAF7D1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForSoftware_2BF2DF6E23AADAED8EC51835DADAF7D1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Additions to capitalized software</link:label>
    <link:label id="lab_us-gaap_PaymentsForSoftware_2BF2DF6E23AADAED8EC51835DADAF7D1_label_en-US" xlink:label="lab_us-gaap_PaymentsForSoftware_2BF2DF6E23AADAED8EC51835DADAF7D1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Software</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForSoftware" xlink:label="loc_us-gaap_PaymentsForSoftware_2BF2DF6E23AADAED8EC51835DADAF7D1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForSoftware_2BF2DF6E23AADAED8EC51835DADAF7D1" xlink:to="lab_us-gaap_PaymentsForSoftware_2BF2DF6E23AADAED8EC51835DADAF7D1" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_F29824A98FD8A94B10561835DADACEEF_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments_F29824A98FD8A94B10561835DADACEEF" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchases of short-term investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_F29824A98FD8A94B10561835DADACEEF_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments_F29824A98FD8A94B10561835DADACEEF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_F29824A98FD8A94B10561835DADACEEF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInvestments_F29824A98FD8A94B10561835DADACEEF" xlink:to="lab_us-gaap_PaymentsToAcquireInvestments_F29824A98FD8A94B10561835DADACEEF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_E60BFB6215A5E187AD581835DADA346D_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_E60BFB6215A5E187AD581835DADA346D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maturities of short-term investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_E60BFB6215A5E187AD581835DADA346D_label_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_E60BFB6215A5E187AD581835DADA346D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Maturities, Prepayments and Calls of Short-term Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_E60BFB6215A5E187AD581835DADA346D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_E60BFB6215A5E187AD581835DADA346D" xlink:to="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_E60BFB6215A5E187AD581835DADA346D" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_41A9FC93FA516AF1D5E41835DADA2811_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_41A9FC93FA516AF1D5E41835DADA2811" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_41A9FC93FA516AF1D5E41835DADA2811_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_41A9FC93FA516AF1D5E41835DADA2811" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_41A9FC93FA516AF1D5E41835DADA2811" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_41A9FC93FA516AF1D5E41835DADA2811" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_41A9FC93FA516AF1D5E41835DADA2811" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_FB418C8BC986B29DC5521835DADAB6F5_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_FB418C8BC986B29DC5521835DADAB6F5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_FB418C8BC986B29DC5521835DADAB6F5_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_FB418C8BC986B29DC5521835DADAB6F5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_FB418C8BC986B29DC5521835DADAB6F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_FB418C8BC986B29DC5521835DADAB6F5" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_FB418C8BC986B29DC5521835DADAB6F5" xlink:type="arc" />
    <link:label id="lab_eols_PaymentsOfContingentRoyaltyObligation_E9CECED7BBFA18B38E871835DADA8066_negatedTerseLabel_en-US" xlink:label="lab_eols_PaymentsOfContingentRoyaltyObligation_E9CECED7BBFA18B38E871835DADA8066" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payment of contingent royalty obligation to Evolus Founders</link:label>
    <link:label id="lab_eols_PaymentsOfContingentRoyaltyObligation_E9CECED7BBFA18B38E871835DADA8066_label_en-US" xlink:label="lab_eols_PaymentsOfContingentRoyaltyObligation_E9CECED7BBFA18B38E871835DADA8066" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments Of Contingent Royalty Obligation</link:label>
    <link:label id="lab_eols_PaymentsOfContingentRoyaltyObligation_E9CECED7BBFA18B38E871835DADA8066_documentation_en-US" xlink:label="lab_eols_PaymentsOfContingentRoyaltyObligation_E9CECED7BBFA18B38E871835DADA8066" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments Of Contingent Royalty Obligation</link:label>
    <link:loc xlink:href="eols-20190930.xsd#eols_PaymentsOfContingentRoyaltyObligation" xlink:label="loc_eols_PaymentsOfContingentRoyaltyObligation_E9CECED7BBFA18B38E871835DADA8066" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_PaymentsOfContingentRoyaltyObligation_E9CECED7BBFA18B38E871835DADA8066" xlink:to="lab_eols_PaymentsOfContingentRoyaltyObligation_E9CECED7BBFA18B38E871835DADA8066" xlink:type="arc" />
    <link:label id="lab_eols_MilestonePaymentsForIntangibleAssets_C2306104C7DC5160ED871835DADBB330_negatedTerseLabel_en-US" xlink:label="lab_eols_MilestonePaymentsForIntangibleAssets_C2306104C7DC5160ED871835DADBB330" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Milestone payment for intangible assets</link:label>
    <link:label id="lab_eols_MilestonePaymentsForIntangibleAssets_C2306104C7DC5160ED871835DADBB330_label_en-US" xlink:label="lab_eols_MilestonePaymentsForIntangibleAssets_C2306104C7DC5160ED871835DADBB330" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Milestone Payments For Intangible Assets</link:label>
    <link:label id="lab_eols_MilestonePaymentsForIntangibleAssets_C2306104C7DC5160ED871835DADBB330_documentation_en-US" xlink:label="lab_eols_MilestonePaymentsForIntangibleAssets_C2306104C7DC5160ED871835DADBB330" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Milestone Payments For Intangible Assets</link:label>
    <link:loc xlink:href="eols-20190930.xsd#eols_MilestonePaymentsForIntangibleAssets" xlink:label="loc_eols_MilestonePaymentsForIntangibleAssets_C2306104C7DC5160ED871835DADBB330" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_MilestonePaymentsForIntangibleAssets_C2306104C7DC5160ED871835DADBB330" xlink:to="lab_eols_MilestonePaymentsForIntangibleAssets_C2306104C7DC5160ED871835DADBB330" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_14C55FFB7DBE971BB40F1835DADB1E30_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_14C55FFB7DBE971BB40F1835DADB1E30" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of long-term debt, net of discounts</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_14C55FFB7DBE971BB40F1835DADB1E30_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_14C55FFB7DBE971BB40F1835DADB1E30" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Long-term Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_14C55FFB7DBE971BB40F1835DADB1E30" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_14C55FFB7DBE971BB40F1835DADB1E30" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_14C55FFB7DBE971BB40F1835DADB1E30" xlink:type="arc" />
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_4C8C14BA38AAA8BFDCBC1835DADB4CCA_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt_4C8C14BA38AAA8BFDCBC1835DADB4CCA" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payment for debt obligation</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_4C8C14BA38AAA8BFDCBC1835DADB4CCA_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt_4C8C14BA38AAA8BFDCBC1835DADB4CCA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Long-term Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_4C8C14BA38AAA8BFDCBC1835DADB4CCA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt_4C8C14BA38AAA8BFDCBC1835DADB4CCA" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt_4C8C14BA38AAA8BFDCBC1835DADB4CCA" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_F77A68FF2EB4F4BFB0861835DADBF48F_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts_F77A68FF2EB4F4BFB0861835DADBF48F" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payments for debt issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_F77A68FF2EB4F4BFB0861835DADBF48F_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts_F77A68FF2EB4F4BFB0861835DADBF48F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Debt Issuance Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_F77A68FF2EB4F4BFB0861835DADBF48F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtIssuanceCosts_F77A68FF2EB4F4BFB0861835DADBF48F" xlink:to="lab_us-gaap_PaymentsOfDebtIssuanceCosts_F77A68FF2EB4F4BFB0861835DADBF48F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_0CBF55DB802BF422EEC51835DADBF576_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_0CBF55DB802BF422EEC51835DADBF576" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from initial public offering, net of underwriters fees</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_0CBF55DB802BF422EEC51835DADBF576_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_0CBF55DB802BF422EEC51835DADBF576" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_0CBF55DB802BF422EEC51835DADBF576" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_0CBF55DB802BF422EEC51835DADBF576" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_0CBF55DB802BF422EEC51835DADBF576" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_72FCC68DA4E6CBFD494F1835DADCFAAD_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_72FCC68DA4E6CBFD494F1835DADCFAAD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from follow-on offering, net of underwriters fees</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_72FCC68DA4E6CBFD494F1835DADCFAAD_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_72FCC68DA4E6CBFD494F1835DADCFAAD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance Initial Public Offering</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_72FCC68DA4E6CBFD494F1835DADCFAAD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_72FCC68DA4E6CBFD494F1835DADCFAAD" xlink:to="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_72FCC68DA4E6CBFD494F1835DADCFAAD" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_6F9E297487F449EA616E1835DADCD1CB_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts_6F9E297487F449EA616E1835DADCD1CB" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payments for offering costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_6F9E297487F449EA616E1835DADCD1CB_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts_6F9E297487F449EA616E1835DADCD1CB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_6F9E297487F449EA616E1835DADCD1CB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts_6F9E297487F449EA616E1835DADCD1CB" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts_6F9E297487F449EA616E1835DADCD1CB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromRelatedPartyDebt_30A0DB6834860B144E9C1835DADCB8D6_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromRelatedPartyDebt_30A0DB6834860B144E9C1835DADCB8D6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related party borrowings</link:label>
    <link:label id="lab_us-gaap_ProceedsFromRelatedPartyDebt_30A0DB6834860B144E9C1835DADCB8D6_label_en-US" xlink:label="lab_us-gaap_ProceedsFromRelatedPartyDebt_30A0DB6834860B144E9C1835DADCB8D6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Related Party Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaap_ProceedsFromRelatedPartyDebt_30A0DB6834860B144E9C1835DADCB8D6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromRelatedPartyDebt_30A0DB6834860B144E9C1835DADCB8D6" xlink:to="lab_us-gaap_ProceedsFromRelatedPartyDebt_30A0DB6834860B144E9C1835DADCB8D6" xlink:type="arc" />
    <link:label id="lab_us-gaap_RepaymentsOfRelatedPartyDebt_B2E9BD6EF8A6813C5AF91835DADC15E8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfRelatedPartyDebt_B2E9BD6EF8A6813C5AF91835DADC15E8" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payments on related party borrowings</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfRelatedPartyDebt_B2E9BD6EF8A6813C5AF91835DADC15E8_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfRelatedPartyDebt_B2E9BD6EF8A6813C5AF91835DADC15E8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Related Party Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaap_RepaymentsOfRelatedPartyDebt_B2E9BD6EF8A6813C5AF91835DADC15E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfRelatedPartyDebt_B2E9BD6EF8A6813C5AF91835DADC15E8" xlink:to="lab_us-gaap_RepaymentsOfRelatedPartyDebt_B2E9BD6EF8A6813C5AF91835DADC15E8" xlink:type="arc" />
    <link:label id="lab_eols_ProceedsFromPaymentsForIssuanceOfCommonStockInConnectionWithEquityIncentivePlan_96F974B38CED97FF13681835DADCDEE9_terseLabel_en-US" xlink:label="lab_eols_ProceedsFromPaymentsForIssuanceOfCommonStockInConnectionWithEquityIncentivePlan_96F974B38CED97FF13681835DADCDEE9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock in connection with incentive equity plan</link:label>
    <link:label id="lab_eols_ProceedsFromPaymentsForIssuanceOfCommonStockInConnectionWithEquityIncentivePlan_96F974B38CED97FF13681835DADCDEE9_label_en-US" xlink:label="lab_eols_ProceedsFromPaymentsForIssuanceOfCommonStockInConnectionWithEquityIncentivePlan_96F974B38CED97FF13681835DADCDEE9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds From (Payments For) Issuance Of Common Stock In Connection With Equity Incentive Plan</link:label>
    <link:label id="lab_eols_ProceedsFromPaymentsForIssuanceOfCommonStockInConnectionWithEquityIncentivePlan_96F974B38CED97FF13681835DADCDEE9_documentation_en-US" xlink:label="lab_eols_ProceedsFromPaymentsForIssuanceOfCommonStockInConnectionWithEquityIncentivePlan_96F974B38CED97FF13681835DADCDEE9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds From (Payments For) Issuance Of Common Stock In Connection With Equity Incentive Plan</link:label>
    <link:loc xlink:href="eols-20190930.xsd#eols_ProceedsFromPaymentsForIssuanceOfCommonStockInConnectionWithEquityIncentivePlan" xlink:label="loc_eols_ProceedsFromPaymentsForIssuanceOfCommonStockInConnectionWithEquityIncentivePlan_96F974B38CED97FF13681835DADCDEE9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_ProceedsFromPaymentsForIssuanceOfCommonStockInConnectionWithEquityIncentivePlan_96F974B38CED97FF13681835DADCDEE9" xlink:to="lab_eols_ProceedsFromPaymentsForIssuanceOfCommonStockInConnectionWithEquityIncentivePlan_96F974B38CED97FF13681835DADCDEE9" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_2FB7ADBDF41FA83369381835DADC0229_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_2FB7ADBDF41FA83369381835DADC0229" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_2FB7ADBDF41FA83369381835DADC0229_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_2FB7ADBDF41FA83369381835DADC0229" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2FB7ADBDF41FA83369381835DADC0229" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2FB7ADBDF41FA83369381835DADC0229" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_2FB7ADBDF41FA83369381835DADC0229" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_A9402C48E033B24527831835DADC938D_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_A9402C48E033B24527831835DADC938D" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Change in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_A9402C48E033B24527831835DADC938D_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_A9402C48E033B24527831835DADC938D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_A9402C48E033B24527831835DADC938D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_A9402C48E033B24527831835DADC938D" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_A9402C48E033B24527831835DADC938D" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9B385291230204FCFF031835DADDA2CF_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9B385291230204FCFF031835DADDA2CF" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9B385291230204FCFF031835DADDA2CF_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9B385291230204FCFF031835DADDA2CF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9B385291230204FCFF031835DADDA2CF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9B385291230204FCFF031835DADDA2CF" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9B385291230204FCFF031835DADDA2CF" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_29904181EE5907EF37FB1835DADD6224_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_29904181EE5907EF37FB1835DADD6224" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, end of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_29904181EE5907EF37FB1835DADD6224" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_29904181EE5907EF37FB1835DADD6224" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_29904181EE5907EF37FB1835DADD6224" xlink:type="arc" />
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_3902C55A9BDEA6CC2B8F1835DADDC8ED_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract_3902C55A9BDEA6CC2B8F1835DADDC8ED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental disclosure of cash flow information</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_3902C55A9BDEA6CC2B8F1835DADDC8ED_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract_3902C55A9BDEA6CC2B8F1835DADDC8ED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_3902C55A9BDEA6CC2B8F1835DADDC8ED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_3902C55A9BDEA6CC2B8F1835DADDC8ED" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract_3902C55A9BDEA6CC2B8F1835DADDC8ED" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestPaidNet_A6AF02D5AE0EF83966FB1835DADDC8CB_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet_A6AF02D5AE0EF83966FB1835DADDC8CB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_A6AF02D5AE0EF83966FB1835DADDC8CB_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet_A6AF02D5AE0EF83966FB1835DADDC8CB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet_A6AF02D5AE0EF83966FB1835DADDC8CB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet_A6AF02D5AE0EF83966FB1835DADDC8CB" xlink:to="lab_us-gaap_InterestPaidNet_A6AF02D5AE0EF83966FB1835DADDC8CB" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasePayments_59AD2B65108EB324D6EA1835DADD491D_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments_59AD2B65108EB324D6EA1835DADD491D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_59AD2B65108EB324D6EA1835DADD491D_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments_59AD2B65108EB324D6EA1835DADD491D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments_59AD2B65108EB324D6EA1835DADD491D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments_59AD2B65108EB324D6EA1835DADD491D" xlink:to="lab_us-gaap_OperatingLeasePayments_59AD2B65108EB324D6EA1835DADD491D" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_8DD2C208C8AFA45511AF1835DADD88F6_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_8DD2C208C8AFA45511AF1835DADD88F6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash investing and financing information:</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_8DD2C208C8AFA45511AF1835DADD88F6_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_8DD2C208C8AFA45511AF1835DADD88F6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_8DD2C208C8AFA45511AF1835DADD88F6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_8DD2C208C8AFA45511AF1835DADD88F6" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_8DD2C208C8AFA45511AF1835DADD88F6" xlink:type="arc" />
    <link:label id="lab_eols_NonCashRelatedPartyReceivable_0455832BB58119A9265C1835DADE6160_terseLabel_en-US" xlink:label="lab_eols_NonCashRelatedPartyReceivable_0455832BB58119A9265C1835DADE6160" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related party receivable</link:label>
    <link:label id="lab_eols_NonCashRelatedPartyReceivable_0455832BB58119A9265C1835DADE6160_label_en-US" xlink:label="lab_eols_NonCashRelatedPartyReceivable_0455832BB58119A9265C1835DADE6160" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non Cash Related Party Receivable</link:label>
    <link:label id="lab_eols_NonCashRelatedPartyReceivable_0455832BB58119A9265C1835DADE6160_documentation_en-US" xlink:label="lab_eols_NonCashRelatedPartyReceivable_0455832BB58119A9265C1835DADE6160" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non Cash Related Party Receivable</link:label>
    <link:loc xlink:href="eols-20190930.xsd#eols_NonCashRelatedPartyReceivable" xlink:label="loc_eols_NonCashRelatedPartyReceivable_0455832BB58119A9265C1835DADE6160" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_NonCashRelatedPartyReceivable_0455832BB58119A9265C1835DADE6160" xlink:to="lab_eols_NonCashRelatedPartyReceivable_0455832BB58119A9265C1835DADE6160" xlink:type="arc" />
    <link:label id="lab_eols_NonCashRelatedPartyBorrowings_8FC041DB7B50A3AD49E51835DADE0079_negatedTerseLabel_en-US" xlink:label="lab_eols_NonCashRelatedPartyBorrowings_8FC041DB7B50A3AD49E51835DADE0079" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Related party borrowings</link:label>
    <link:label id="lab_eols_NonCashRelatedPartyBorrowings_8FC041DB7B50A3AD49E51835DADE0079_label_en-US" xlink:label="lab_eols_NonCashRelatedPartyBorrowings_8FC041DB7B50A3AD49E51835DADE0079" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Cash Related Party Borrowings</link:label>
    <link:label id="lab_eols_NonCashRelatedPartyBorrowings_8FC041DB7B50A3AD49E51835DADE0079_documentation_en-US" xlink:label="lab_eols_NonCashRelatedPartyBorrowings_8FC041DB7B50A3AD49E51835DADE0079" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non-Cash Related Party Borrowings</link:label>
    <link:loc xlink:href="eols-20190930.xsd#eols_NonCashRelatedPartyBorrowings" xlink:label="loc_eols_NonCashRelatedPartyBorrowings_8FC041DB7B50A3AD49E51835DADE0079" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_NonCashRelatedPartyBorrowings_8FC041DB7B50A3AD49E51835DADE0079" xlink:to="lab_eols_NonCashRelatedPartyBorrowings_8FC041DB7B50A3AD49E51835DADE0079" xlink:type="arc" />
    <link:label id="lab_eols_NonCashNoteObligation_A9DD994C46C46CF7B1FF1835DADE5ECE_negatedTerseLabel_en-US" xlink:label="lab_eols_NonCashNoteObligation_A9DD994C46C46CF7B1FF1835DADE5ECE" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Note obligation</link:label>
    <link:label id="lab_eols_NonCashNoteObligation_A9DD994C46C46CF7B1FF1835DADE5ECE_label_en-US" xlink:label="lab_eols_NonCashNoteObligation_A9DD994C46C46CF7B1FF1835DADE5ECE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Cash Note Obligation</link:label>
    <link:label id="lab_eols_NonCashNoteObligation_A9DD994C46C46CF7B1FF1835DADE5ECE_documentation_en-US" xlink:label="lab_eols_NonCashNoteObligation_A9DD994C46C46CF7B1FF1835DADE5ECE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non-Cash Note Obligation</link:label>
    <link:loc xlink:href="eols-20190930.xsd#eols_NonCashNoteObligation" xlink:label="loc_eols_NonCashNoteObligation_A9DD994C46C46CF7B1FF1835DADE5ECE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_NonCashNoteObligation_A9DD994C46C46CF7B1FF1835DADE5ECE" xlink:to="lab_eols_NonCashNoteObligation_A9DD994C46C46CF7B1FF1835DADE5ECE" xlink:type="arc" />
    <link:label id="lab_eols_ContingentRoyaltyObligation_E2B566F7B10F590FAAD11835DADEDB61_terseLabel_en-US" xlink:label="lab_eols_ContingentRoyaltyObligation_E2B566F7B10F590FAAD11835DADEDB61" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent royalty obligation payable to Evolus Founders</link:label>
    <link:label id="lab_eols_ContingentRoyaltyObligation_E2B566F7B10F590FAAD11835DADEDB61_label_en-US" xlink:label="lab_eols_ContingentRoyaltyObligation_E2B566F7B10F590FAAD11835DADEDB61" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Royalty Obligation</link:label>
    <link:label id="lab_eols_ContingentRoyaltyObligation_E2B566F7B10F590FAAD11835DADEDB61_documentation_en-US" xlink:label="lab_eols_ContingentRoyaltyObligation_E2B566F7B10F590FAAD11835DADEDB61" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contingent Royalty Obligation</link:label>
    <link:loc xlink:href="eols-20190930.xsd#eols_ContingentRoyaltyObligation" xlink:label="loc_eols_ContingentRoyaltyObligation_E2B566F7B10F590FAAD11835DADEDB61" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_ContingentRoyaltyObligation_E2B566F7B10F590FAAD11835DADEDB61" xlink:to="lab_eols_ContingentRoyaltyObligation_E2B566F7B10F590FAAD11835DADEDB61" xlink:type="arc" />
    <link:label id="lab_eols_ContingentPromissoryNote_DA7FD6D33324E93DC2CB1835DADEFD4C_terseLabel_en-US" xlink:label="lab_eols_ContingentPromissoryNote_DA7FD6D33324E93DC2CB1835DADEFD4C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent promissory note payable to Evolus Founders</link:label>
    <link:label id="lab_eols_ContingentPromissoryNote_DA7FD6D33324E93DC2CB1835DADEFD4C_label_en-US" xlink:label="lab_eols_ContingentPromissoryNote_DA7FD6D33324E93DC2CB1835DADEFD4C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Promissory Note</link:label>
    <link:label id="lab_eols_ContingentPromissoryNote_DA7FD6D33324E93DC2CB1835DADEFD4C_documentation_en-US" xlink:label="lab_eols_ContingentPromissoryNote_DA7FD6D33324E93DC2CB1835DADEFD4C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contingent Promissory Note</link:label>
    <link:loc xlink:href="eols-20190930.xsd#eols_ContingentPromissoryNote" xlink:label="loc_eols_ContingentPromissoryNote_DA7FD6D33324E93DC2CB1835DADEFD4C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_ContingentPromissoryNote_DA7FD6D33324E93DC2CB1835DADEFD4C" xlink:to="lab_eols_ContingentPromissoryNote_DA7FD6D33324E93DC2CB1835DADEFD4C" xlink:type="arc" />
    <link:label id="lab_eols_CapitalContributionConvertibleNoteWriteOff_4656FC3F7C06D99149BB1835DADFCEE8_terseLabel_en-US" xlink:label="lab_eols_CapitalContributionConvertibleNoteWriteOff_4656FC3F7C06D99149BB1835DADFCEE8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capital contribution from Parent, convertible note write-off</link:label>
    <link:label id="lab_eols_CapitalContributionConvertibleNoteWriteOff_4656FC3F7C06D99149BB1835DADFCEE8_label_en-US" xlink:label="lab_eols_CapitalContributionConvertibleNoteWriteOff_4656FC3F7C06D99149BB1835DADFCEE8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Contribution, Convertible Note Write-Off</link:label>
    <link:label id="lab_eols_CapitalContributionConvertibleNoteWriteOff_4656FC3F7C06D99149BB1835DADFCEE8_documentation_en-US" xlink:label="lab_eols_CapitalContributionConvertibleNoteWriteOff_4656FC3F7C06D99149BB1835DADFCEE8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Capital Contribution, Convertible Note Write-Off</link:label>
    <link:loc xlink:href="eols-20190930.xsd#eols_CapitalContributionConvertibleNoteWriteOff" xlink:label="loc_eols_CapitalContributionConvertibleNoteWriteOff_4656FC3F7C06D99149BB1835DADFCEE8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_CapitalContributionConvertibleNoteWriteOff_4656FC3F7C06D99149BB1835DADFCEE8" xlink:to="lab_eols_CapitalContributionConvertibleNoteWriteOff_4656FC3F7C06D99149BB1835DADFCEE8" xlink:type="arc" />
    <link:label id="lab_eols_CapitalContributionForgivenessofRelatedPartyBorrowings_DD9BBAFF5692518917AA1835DADF1E98_terseLabel_en-US" xlink:label="lab_eols_CapitalContributionForgivenessofRelatedPartyBorrowings_DD9BBAFF5692518917AA1835DADF1E98" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capital contribution from Parent, forgiveness of related party borrowings</link:label>
    <link:label id="lab_eols_CapitalContributionForgivenessofRelatedPartyBorrowings_DD9BBAFF5692518917AA1835DADF1E98_label_en-US" xlink:label="lab_eols_CapitalContributionForgivenessofRelatedPartyBorrowings_DD9BBAFF5692518917AA1835DADF1E98" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Contribution, Forgiveness of Related Party Borrowings</link:label>
    <link:label id="lab_eols_CapitalContributionForgivenessofRelatedPartyBorrowings_DD9BBAFF5692518917AA1835DADF1E98_documentation_en-US" xlink:label="lab_eols_CapitalContributionForgivenessofRelatedPartyBorrowings_DD9BBAFF5692518917AA1835DADF1E98" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Capital Contribution, Forgiveness of Related Party Borrowings</link:label>
    <link:loc xlink:href="eols-20190930.xsd#eols_CapitalContributionForgivenessofRelatedPartyBorrowings" xlink:label="loc_eols_CapitalContributionForgivenessofRelatedPartyBorrowings_DD9BBAFF5692518917AA1835DADF1E98" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_CapitalContributionForgivenessofRelatedPartyBorrowings_DD9BBAFF5692518917AA1835DADF1E98" xlink:to="lab_eols_CapitalContributionForgivenessofRelatedPartyBorrowings_DD9BBAFF5692518917AA1835DADF1E98" xlink:type="arc" />
    <link:label id="lab_eols_NonCashDeferredOfferingCosts_E078A9E163E968267D3B1835DADF0D6C_negatedTerseLabel_en-US" xlink:label="lab_eols_NonCashDeferredOfferingCosts_E078A9E163E968267D3B1835DADF0D6C" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Deferred offering costs</link:label>
    <link:label id="lab_eols_NonCashDeferredOfferingCosts_E078A9E163E968267D3B1835DADF0D6C_label_en-US" xlink:label="lab_eols_NonCashDeferredOfferingCosts_E078A9E163E968267D3B1835DADF0D6C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Cash Deferred Offering Costs</link:label>
    <link:label id="lab_eols_NonCashDeferredOfferingCosts_E078A9E163E968267D3B1835DADF0D6C_documentation_en-US" xlink:label="lab_eols_NonCashDeferredOfferingCosts_E078A9E163E968267D3B1835DADF0D6C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non-Cash Deferred Offering Costs</link:label>
    <link:loc xlink:href="eols-20190930.xsd#eols_NonCashDeferredOfferingCosts" xlink:label="loc_eols_NonCashDeferredOfferingCosts_E078A9E163E968267D3B1835DADF0D6C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_NonCashDeferredOfferingCosts_E078A9E163E968267D3B1835DADF0D6C" xlink:to="lab_eols_NonCashDeferredOfferingCosts_E078A9E163E968267D3B1835DADF0D6C" xlink:type="arc" />
    <link:label id="lab_eols_AccountsPayablePaidbyParent_29D38C92B8E7C12988FB1835DADF811E_negatedTerseLabel_en-US" xlink:label="lab_eols_AccountsPayablePaidbyParent_29D38C92B8E7C12988FB1835DADF811E" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable, paid by Parent</link:label>
    <link:label id="lab_eols_AccountsPayablePaidbyParent_29D38C92B8E7C12988FB1835DADF811E_label_en-US" xlink:label="lab_eols_AccountsPayablePaidbyParent_29D38C92B8E7C12988FB1835DADF811E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Paid by Parent</link:label>
    <link:label id="lab_eols_AccountsPayablePaidbyParent_29D38C92B8E7C12988FB1835DADF811E_documentation_en-US" xlink:label="lab_eols_AccountsPayablePaidbyParent_29D38C92B8E7C12988FB1835DADF811E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accounts Payable, Paid by Parent</link:label>
    <link:loc xlink:href="eols-20190930.xsd#eols_AccountsPayablePaidbyParent" xlink:label="loc_eols_AccountsPayablePaidbyParent_29D38C92B8E7C12988FB1835DADF811E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_AccountsPayablePaidbyParent_29D38C92B8E7C12988FB1835DADF811E" xlink:to="lab_eols_AccountsPayablePaidbyParent_29D38C92B8E7C12988FB1835DADF811E" xlink:type="arc" />
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_E9191E8EF7FBF0B9F95C1835DADF777E_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_E9191E8EF7FBF0B9F95C1835DADF777E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease right-of-use assets obtained in exchange for operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_E9191E8EF7FBF0B9F95C1835DADF777E_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_E9191E8EF7FBF0B9F95C1835DADF777E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_E9191E8EF7FBF0B9F95C1835DADF777E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_E9191E8EF7FBF0B9F95C1835DADF777E" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_E9191E8EF7FBF0B9F95C1835DADF777E" xlink:type="arc" />
    <link:label id="lab_eols_NonCashLandlordPaidTenantImprovement_A10D33423EEB5190924F18454908B732_terseLabel_en-US" xlink:label="lab_eols_NonCashLandlordPaidTenantImprovement_A10D33423EEB5190924F18454908B732" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Landlord paid tenant improvements</link:label>
    <link:label id="lab_eols_NonCashLandlordPaidTenantImprovement_A10D33423EEB5190924F18454908B732_label_en-US" xlink:label="lab_eols_NonCashLandlordPaidTenantImprovement_A10D33423EEB5190924F18454908B732" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Cash Landlord Paid Tenant Improvement</link:label>
    <link:label id="lab_eols_NonCashLandlordPaidTenantImprovement_A10D33423EEB5190924F18454908B732_documentation_en-US" xlink:label="lab_eols_NonCashLandlordPaidTenantImprovement_A10D33423EEB5190924F18454908B732" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non-Cash Landlord Paid Tenant Improvement</link:label>
    <link:loc xlink:href="eols-20190930.xsd#eols_NonCashLandlordPaidTenantImprovement" xlink:label="loc_eols_NonCashLandlordPaidTenantImprovement_A10D33423EEB5190924F18454908B732" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_NonCashLandlordPaidTenantImprovement_A10D33423EEB5190924F18454908B732" xlink:to="lab_eols_NonCashLandlordPaidTenantImprovement_A10D33423EEB5190924F18454908B732" xlink:type="arc" />
    <link:label id="lab_eols_NonCashFinanceAndInsurancePayment_65440467FF01AF9F9B261844B1196698_terseLabel_en-US" xlink:label="lab_eols_NonCashFinanceAndInsurancePayment_65440467FF01AF9F9B261844B1196698" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financed D &amp; O insurance payment</link:label>
    <link:label id="lab_eols_NonCashFinanceAndInsurancePayment_65440467FF01AF9F9B261844B1196698_label_en-US" xlink:label="lab_eols_NonCashFinanceAndInsurancePayment_65440467FF01AF9F9B261844B1196698" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Cash Finance And Insurance Payment</link:label>
    <link:label id="lab_eols_NonCashFinanceAndInsurancePayment_65440467FF01AF9F9B261844B1196698_documentation_en-US" xlink:label="lab_eols_NonCashFinanceAndInsurancePayment_65440467FF01AF9F9B261844B1196698" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non-Cash Finance And Insurance Payment</link:label>
    <link:loc xlink:href="eols-20190930.xsd#eols_NonCashFinanceAndInsurancePayment" xlink:label="loc_eols_NonCashFinanceAndInsurancePayment_65440467FF01AF9F9B261844B1196698" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_NonCashFinanceAndInsurancePayment_65440467FF01AF9F9B261844B1196698" xlink:to="lab_eols_NonCashFinanceAndInsurancePayment_65440467FF01AF9F9B261844B1196698" xlink:type="arc" />
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_CFAD7D816414A240E8011835DADFBA34_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_CFAD7D816414A240E8011835DADFBA34" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capitalized software recorded in accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_CFAD7D816414A240E8011835DADFBA34_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_CFAD7D816414A240E8011835DADFBA34" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_CFAD7D816414A240E8011835DADFBA34" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_CFAD7D816414A240E8011835DADFBA34" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_CFAD7D816414A240E8011835DADFBA34" xlink:type="arc" />
    <link:label id="lab_eols_MilestonePaymentCurrent_B90F00620092219BAB881843C067D832_verboseLabel_en-US" xlink:label="lab_eols_MilestonePaymentCurrent_B90F00620092219BAB881843C067D832" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accrued milestone payment for intangible assets</link:label>
    <link:label id="lab_eols_MilestonePaymentCurrent_B90F00620092219BAB881843C067D832_label_en-US" xlink:label="lab_eols_MilestonePaymentCurrent_B90F00620092219BAB881843C067D832" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Milestone Payment, Current</link:label>
    <link:label id="lab_eols_MilestonePaymentCurrent_B90F00620092219BAB881843C067D832_documentation_en-US" xlink:label="lab_eols_MilestonePaymentCurrent_B90F00620092219BAB881843C067D832" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Milestone Payment, Current</link:label>
    <link:loc xlink:href="eols-20190930.xsd#eols_MilestonePaymentCurrent" xlink:label="loc_eols_MilestonePaymentCurrent_B90F00620092219BAB881843C067D832" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_MilestonePaymentCurrent_B90F00620092219BAB881843C067D832" xlink:to="lab_eols_MilestonePaymentCurrent_B90F00620092219BAB881843C067D832" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_C07AF3517DBD92BEC8CB45374F0043E1_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_C07AF3517DBD92BEC8CB45374F0043E1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_C07AF3517DBD92BEC8CB45374F0043E1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_C07AF3517DBD92BEC8CB45374F0043E1" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_C07AF3517DBD92BEC8CB45374F0043E1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_03B082C06081D7B8C12A45374F00407F_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_03B082C06081D7B8C12A45374F00407F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_03B082C06081D7B8C12A45374F00407F_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_03B082C06081D7B8C12A45374F00407F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_03B082C06081D7B8C12A45374F00407F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_03B082C06081D7B8C12A45374F00407F" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_03B082C06081D7B8C12A45374F00407F" xlink:type="arc" />
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_A1794D6EDF1E050F359D45374F009988_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_A1794D6EDF1E050F359D45374F009988" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_A1794D6EDF1E050F359D45374F009988_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_A1794D6EDF1E050F359D45374F009988" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_A1794D6EDF1E050F359D45374F009988" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_A1794D6EDF1E050F359D45374F009988" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_A1794D6EDF1E050F359D45374F009988" xlink:type="arc" />
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_C97441DA954FFEE9E8EB45374F019ADF_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_C97441DA954FFEE9E8EB45374F019ADF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_C97441DA954FFEE9E8EB45374F019ADF_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_C97441DA954FFEE9E8EB45374F019ADF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_C97441DA954FFEE9E8EB45374F019ADF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_C97441DA954FFEE9E8EB45374F019ADF" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_C97441DA954FFEE9E8EB45374F019ADF" xlink:type="arc" />
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_53FD0DF6698B6199DEAC45374F01A169_terseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember_53FD0DF6698B6199DEAC45374F01A169" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">IPR&amp;D</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_53FD0DF6698B6199DEAC45374F01A169_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember_53FD0DF6698B6199DEAC45374F01A169" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">In Process Research and Development [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_53FD0DF6698B6199DEAC45374F01A169" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentMember_53FD0DF6698B6199DEAC45374F01A169" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentMember_53FD0DF6698B6199DEAC45374F01A169" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_07AB8EF3D1BD5068A6AE45374F01E140_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_07AB8EF3D1BD5068A6AE45374F01E140" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_07AB8EF3D1BD5068A6AE45374F01E140_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_07AB8EF3D1BD5068A6AE45374F01E140" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_07AB8EF3D1BD5068A6AE45374F01E140" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_07AB8EF3D1BD5068A6AE45374F01E140" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_07AB8EF3D1BD5068A6AE45374F01E140" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_E1E598BC322150F9BABB45374F01F15F_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_E1E598BC322150F9BABB45374F01F15F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_E1E598BC322150F9BABB45374F01F15F_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_E1E598BC322150F9BABB45374F01F15F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_E1E598BC322150F9BABB45374F01F15F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_E1E598BC322150F9BABB45374F01F15F" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_E1E598BC322150F9BABB45374F01F15F" xlink:type="arc" />
    <link:label id="lab_us-gaap_DistributionRightsMember_CC8A9C1EA67D49CC900445374F02B63F_terseLabel_en-US" xlink:label="lab_us-gaap_DistributionRightsMember_CC8A9C1EA67D49CC900445374F02B63F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Distribution right</link:label>
    <link:label id="lab_us-gaap_DistributionRightsMember_CC8A9C1EA67D49CC900445374F02B63F_label_en-US" xlink:label="lab_us-gaap_DistributionRightsMember_CC8A9C1EA67D49CC900445374F02B63F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Distribution Rights [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DistributionRightsMember" xlink:label="loc_us-gaap_DistributionRightsMember_CC8A9C1EA67D49CC900445374F02B63F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DistributionRightsMember_CC8A9C1EA67D49CC900445374F02B63F" xlink:to="lab_us-gaap_DistributionRightsMember_CC8A9C1EA67D49CC900445374F02B63F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComputerSoftwareIntangibleAssetMember_22F9A5E7024B1C73BED845374F02C9B1_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerSoftwareIntangibleAssetMember_22F9A5E7024B1C73BED845374F02C9B1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capitalized software</link:label>
    <link:label id="lab_us-gaap_ComputerSoftwareIntangibleAssetMember_22F9A5E7024B1C73BED845374F02C9B1_label_en-US" xlink:label="lab_us-gaap_ComputerSoftwareIntangibleAssetMember_22F9A5E7024B1C73BED845374F02C9B1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computer Software, Intangible Asset [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_22F9A5E7024B1C73BED845374F02C9B1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_22F9A5E7024B1C73BED845374F02C9B1" xlink:to="lab_us-gaap_ComputerSoftwareIntangibleAssetMember_22F9A5E7024B1C73BED845374F02C9B1" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_263B4790F344A157BF2345374F02EAED_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_263B4790F344A157BF2345374F02EAED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_263B4790F344A157BF2345374F02EAED_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_263B4790F344A157BF2345374F02EAED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_263B4790F344A157BF2345374F02EAED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_263B4790F344A157BF2345374F02EAED" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_263B4790F344A157BF2345374F02EAED" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_A18E6305F69760D915C745374F02990E_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_A18E6305F69760D915C745374F02990E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Definite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_A18E6305F69760D915C745374F02990E_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_A18E6305F69760D915C745374F02990E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Net [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_A18E6305F69760D915C745374F02990E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_A18E6305F69760D915C745374F02990E" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_A18E6305F69760D915C745374F02990E" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_9082F04AA5B2FF178FF345374F03FCD8_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross_9082F04AA5B2FF178FF345374F03FCD8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Original Cost</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_9082F04AA5B2FF178FF345374F03FCD8_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross_9082F04AA5B2FF178FF345374F03FCD8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_9082F04AA5B2FF178FF345374F03FCD8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross_9082F04AA5B2FF178FF345374F03FCD8" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross_9082F04AA5B2FF178FF345374F03FCD8" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_7084DFBD9D709FDB7D9645374F03C8FB_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_7084DFBD9D709FDB7D9645374F03C8FB" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_7084DFBD9D709FDB7D9645374F03C8FB_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_7084DFBD9D709FDB7D9645374F03C8FB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_7084DFBD9D709FDB7D9645374F03C8FB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_7084DFBD9D709FDB7D9645374F03C8FB" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_7084DFBD9D709FDB7D9645374F03C8FB" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_CDE43F0DDB641CFC6C5545374F033E3B_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet_CDE43F0DDB641CFC6C5545374F033E3B" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net Book Value</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_CDE43F0DDB641CFC6C5545374F033E3B_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet_CDE43F0DDB641CFC6C5545374F033E3B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_CDE43F0DDB641CFC6C5545374F033E3B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_CDE43F0DDB641CFC6C5545374F033E3B" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet_CDE43F0DDB641CFC6C5545374F033E3B" xlink:type="arc" />
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_586ED507059C00A3BB6B45374F03B056_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_586ED507059C00A3BB6B45374F03B056" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_586ED507059C00A3BB6B45374F03B056_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_586ED507059C00A3BB6B45374F03B056" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_586ED507059C00A3BB6B45374F03B056" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_586ED507059C00A3BB6B45374F03B056" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_586ED507059C00A3BB6B45374F03B056" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_DEB7C65514C5D1E1703945374F0414BB_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_DEB7C65514C5D1E1703945374F0414BB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Useful life</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_DEB7C65514C5D1E1703945374F0414BB_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_DEB7C65514C5D1E1703945374F0414BB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_DEB7C65514C5D1E1703945374F0414BB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_DEB7C65514C5D1E1703945374F0414BB" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_DEB7C65514C5D1E1703945374F0414BB" xlink:type="arc" />
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_EA175C97796BF38294DF45374F041B62_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_EA175C97796BF38294DF45374F041B62" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite-lived intangible asset</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_EA175C97796BF38294DF45374F041B62_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_EA175C97796BF38294DF45374F041B62" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets (Excluding Goodwill) [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_EA175C97796BF38294DF45374F041B62" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_EA175C97796BF38294DF45374F041B62" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_EA175C97796BF38294DF45374F041B62" xlink:type="arc" />
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_DAA37CFFBDF5D44BE31C45374F04D4FD_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_DAA37CFFBDF5D44BE31C45374F04D4FD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite-lived intangible assets (IPR&amp;D)</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_DAA37CFFBDF5D44BE31C45374F04D4FD_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_DAA37CFFBDF5D44BE31C45374F04D4FD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_DAA37CFFBDF5D44BE31C45374F04D4FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_DAA37CFFBDF5D44BE31C45374F04D4FD" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_DAA37CFFBDF5D44BE31C45374F04D4FD" xlink:type="arc" />
    <link:label id="lab_us-gaap_Goodwill_0EDBE648D581F15C484B45374F041560_verboseLabel_en-US" xlink:label="lab_us-gaap_Goodwill_0EDBE648D581F15C484B45374F041560" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_0EDBE648D581F15C484B45374F041560_label_en-US" xlink:label="lab_us-gaap_Goodwill_0EDBE648D581F15C484B45374F041560" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_0EDBE648D581F15C484B45374F041560" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill_0EDBE648D581F15C484B45374F041560" xlink:to="lab_us-gaap_Goodwill_0EDBE648D581F15C484B45374F041560" xlink:type="arc" />
    <link:label id="lab_eols_IntangibleAssetsGrossIncludingGoodwill_A72DD75CA14273CAD14A45374F045518_totalLabel_en-US" xlink:label="lab_eols_IntangibleAssetsGrossIncludingGoodwill_A72DD75CA14273CAD14A45374F045518" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Intangible assets, gross (including goodwill)</link:label>
    <link:label id="lab_eols_IntangibleAssetsGrossIncludingGoodwill_A72DD75CA14273CAD14A45374F045518_label_en-US" xlink:label="lab_eols_IntangibleAssetsGrossIncludingGoodwill_A72DD75CA14273CAD14A45374F045518" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Gross (Including Goodwill)</link:label>
    <link:label id="lab_eols_IntangibleAssetsGrossIncludingGoodwill_A72DD75CA14273CAD14A45374F045518_documentation_en-US" xlink:label="lab_eols_IntangibleAssetsGrossIncludingGoodwill_A72DD75CA14273CAD14A45374F045518" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Intangible Assets, Gross (Including Goodwill)</link:label>
    <link:loc xlink:href="eols-20190930.xsd#eols_IntangibleAssetsGrossIncludingGoodwill" xlink:label="loc_eols_IntangibleAssetsGrossIncludingGoodwill_A72DD75CA14273CAD14A45374F045518" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_IntangibleAssetsGrossIncludingGoodwill_A72DD75CA14273CAD14A45374F045518" xlink:to="lab_eols_IntangibleAssetsGrossIncludingGoodwill_A72DD75CA14273CAD14A45374F045518" xlink:type="arc" />
    <link:label id="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill_B1A7E9B3218DF0EAD00445374F054119_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill_B1A7E9B3218DF0EAD00445374F054119" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total net book value</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill_B1A7E9B3218DF0EAD00445374F054119_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill_B1A7E9B3218DF0EAD00445374F054119" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net (Including Goodwill)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_B1A7E9B3218DF0EAD00445374F054119" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_B1A7E9B3218DF0EAD00445374F054119" xlink:to="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill_B1A7E9B3218DF0EAD00445374F054119" xlink:type="arc" />
    <link:label id="lab_srt_RangeAxis_3F04C68BE701A4485E45FEEBEED792C9_terseLabel_en-US" xlink:label="lab_srt_RangeAxis_3F04C68BE701A4485E45FEEBEED792C9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_3F04C68BE701A4485E45FEEBEED792C9_label_en-US" xlink:label="lab_srt_RangeAxis_3F04C68BE701A4485E45FEEBEED792C9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_3F04C68BE701A4485E45FEEBEED792C9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis_3F04C68BE701A4485E45FEEBEED792C9" xlink:to="lab_srt_RangeAxis_3F04C68BE701A4485E45FEEBEED792C9" xlink:type="arc" />
    <link:label id="lab_srt_RangeMember_8F1D378B2D7D3AB06A07FEEBEED7EF86_terseLabel_en-US" xlink:label="lab_srt_RangeMember_8F1D378B2D7D3AB06A07FEEBEED7EF86" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_8F1D378B2D7D3AB06A07FEEBEED7EF86_label_en-US" xlink:label="lab_srt_RangeMember_8F1D378B2D7D3AB06A07FEEBEED7EF86" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_8F1D378B2D7D3AB06A07FEEBEED7EF86" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember_8F1D378B2D7D3AB06A07FEEBEED7EF86" xlink:to="lab_srt_RangeMember_8F1D378B2D7D3AB06A07FEEBEED7EF86" xlink:type="arc" />
    <link:label id="lab_srt_MinimumMember_81A8B03387CB4184E4E5FEEBEED7F7D9_terseLabel_en-US" xlink:label="lab_srt_MinimumMember_81A8B03387CB4184E4E5FEEBEED7F7D9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_81A8B03387CB4184E4E5FEEBEED7F7D9_label_en-US" xlink:label="lab_srt_MinimumMember_81A8B03387CB4184E4E5FEEBEED7F7D9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_81A8B03387CB4184E4E5FEEBEED7F7D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember_81A8B03387CB4184E4E5FEEBEED7F7D9" xlink:to="lab_srt_MinimumMember_81A8B03387CB4184E4E5FEEBEED7F7D9" xlink:type="arc" />
    <link:label id="lab_srt_MaximumMember_01EDF2BE51666E37843AFEEBEED73C8A_terseLabel_en-US" xlink:label="lab_srt_MaximumMember_01EDF2BE51666E37843AFEEBEED73C8A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_01EDF2BE51666E37843AFEEBEED73C8A_label_en-US" xlink:label="lab_srt_MaximumMember_01EDF2BE51666E37843AFEEBEED73C8A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_01EDF2BE51666E37843AFEEBEED73C8A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember_01EDF2BE51666E37843AFEEBEED73C8A" xlink:to="lab_srt_MaximumMember_01EDF2BE51666E37843AFEEBEED73C8A" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_60EE219685BE2EBD9DE6FEEBEED8D0BF_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_60EE219685BE2EBD9DE6FEEBEED8D0BF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_60EE219685BE2EBD9DE6FEEBEED8D0BF_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_60EE219685BE2EBD9DE6FEEBEED8D0BF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_60EE219685BE2EBD9DE6FEEBEED8D0BF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized_60EE219685BE2EBD9DE6FEEBEED8D0BF" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized_60EE219685BE2EBD9DE6FEEBEED8D0BF" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_E77EE55D9382868F26F9FEEBEED8CAA6_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_E77EE55D9382868F26F9FEEBEED8CAA6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_E77EE55D9382868F26F9FEEBEED8CAA6_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_E77EE55D9382868F26F9FEEBEED8CAA6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_E77EE55D9382868F26F9FEEBEED8CAA6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare_E77EE55D9382868F26F9FEEBEED8CAA6" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare_E77EE55D9382868F26F9FEEBEED8CAA6" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_7C4972E741E51DDBFBECFEEBEED87801_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued_7C4972E741E51DDBFBECFEEBEED87801" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_7C4972E741E51DDBFBECFEEBEED87801_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued_7C4972E741E51DDBFBECFEEBEED87801" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_7C4972E741E51DDBFBECFEEBEED87801" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued_7C4972E741E51DDBFBECFEEBEED87801" xlink:to="lab_us-gaap_PreferredStockSharesIssued_7C4972E741E51DDBFBECFEEBEED87801" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_9ACDBE30A4BFEAA9D1A6FEEBEED81E50_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding_9ACDBE30A4BFEAA9D1A6FEEBEED81E50" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_9ACDBE30A4BFEAA9D1A6FEEBEED81E50_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding_9ACDBE30A4BFEAA9D1A6FEEBEED81E50" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_9ACDBE30A4BFEAA9D1A6FEEBEED81E50" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding_9ACDBE30A4BFEAA9D1A6FEEBEED81E50" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding_9ACDBE30A4BFEAA9D1A6FEEBEED81E50" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_F50CDD8F8221412D449CFEEBEED89CDA_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_F50CDD8F8221412D449CFEEBEED89CDA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_F50CDD8F8221412D449CFEEBEED89CDA_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_F50CDD8F8221412D449CFEEBEED89CDA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_F50CDD8F8221412D449CFEEBEED89CDA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized_F50CDD8F8221412D449CFEEBEED89CDA" xlink:to="lab_us-gaap_CommonStockSharesAuthorized_F50CDD8F8221412D449CFEEBEED89CDA" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_7DCE433BE2879F15C250FEEBEED99FA1_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_7DCE433BE2879F15C250FEEBEED99FA1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_7DCE433BE2879F15C250FEEBEED99FA1_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_7DCE433BE2879F15C250FEEBEED99FA1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_7DCE433BE2879F15C250FEEBEED99FA1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare_7DCE433BE2879F15C250FEEBEED99FA1" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare_7DCE433BE2879F15C250FEEBEED99FA1" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesIssued_CEB026B401A62E75B2CAFEEBEED9FF50_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_CEB026B401A62E75B2CAFEEBEED9FF50" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares, issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_CEB026B401A62E75B2CAFEEBEED9FF50_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_CEB026B401A62E75B2CAFEEBEED9FF50" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_CEB026B401A62E75B2CAFEEBEED9FF50" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued_CEB026B401A62E75B2CAFEEBEED9FF50" xlink:to="lab_us-gaap_CommonStockSharesIssued_CEB026B401A62E75B2CAFEEBEED9FF50" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_310B77970C854072A350FEEBEED97B2F_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_310B77970C854072A350FEEBEED97B2F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares, outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_310B77970C854072A350FEEBEED97B2F_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_310B77970C854072A350FEEBEED97B2F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_310B77970C854072A350FEEBEED97B2F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_310B77970C854072A350FEEBEED97B2F" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_310B77970C854072A350FEEBEED97B2F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_1D213A73D0279F1B44D8FEEBEED99FEA_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_1D213A73D0279F1B44D8FEEBEED99FEA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum number of shares authorized under the plan (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_1D213A73D0279F1B44D8FEEBEED99FEA_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_1D213A73D0279F1B44D8FEEBEED99FEA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_1D213A73D0279F1B44D8FEEBEED99FEA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_1D213A73D0279F1B44D8FEEBEED99FEA" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_1D213A73D0279F1B44D8FEEBEED99FEA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_CAE150B2A87562E13C55FEEBEED9EA25_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_CAE150B2A87562E13C55FEEBEED9EA25" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Annual increase percentage of maximum shares outstanding (equal to)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_CAE150B2A87562E13C55FEEBEED9EA25_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_CAE150B2A87562E13C55FEEBEED9EA25" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_CAE150B2A87562E13C55FEEBEED9EA25" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_CAE150B2A87562E13C55FEEBEED9EA25" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_CAE150B2A87562E13C55FEEBEED9EA25" xlink:type="arc" />
    <link:label id="lab_eols_CommonStockAdditionalCapitalSharesReservedforFutureIssuance_E7B221C075894214B4ABFEEBEED9C9FF_terseLabel_en-US" xlink:label="lab_eols_CommonStockAdditionalCapitalSharesReservedforFutureIssuance_E7B221C075894214B4ABFEEBEED9C9FF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional capital shares reserved for future issuance (in shares)</link:label>
    <link:label id="lab_eols_CommonStockAdditionalCapitalSharesReservedforFutureIssuance_E7B221C075894214B4ABFEEBEED9C9FF_label_en-US" xlink:label="lab_eols_CommonStockAdditionalCapitalSharesReservedforFutureIssuance_E7B221C075894214B4ABFEEBEED9C9FF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Additional Capital Shares Reserved for Future Issuance</link:label>
    <link:label id="lab_eols_CommonStockAdditionalCapitalSharesReservedforFutureIssuance_E7B221C075894214B4ABFEEBEED9C9FF_documentation_en-US" xlink:label="lab_eols_CommonStockAdditionalCapitalSharesReservedforFutureIssuance_E7B221C075894214B4ABFEEBEED9C9FF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common Stock, Additional Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:href="eols-20190930.xsd#eols_CommonStockAdditionalCapitalSharesReservedforFutureIssuance" xlink:label="loc_eols_CommonStockAdditionalCapitalSharesReservedforFutureIssuance_E7B221C075894214B4ABFEEBEED9C9FF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_CommonStockAdditionalCapitalSharesReservedforFutureIssuance_E7B221C075894214B4ABFEEBEED9C9FF" xlink:to="lab_eols_CommonStockAdditionalCapitalSharesReservedforFutureIssuance_E7B221C075894214B4ABFEEBEED9C9FF" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_E59B5034CD149CC296CBFEEBEED9344B_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_E59B5034CD149CC296CBFEEBEED9344B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capital shares reserved for future issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_E59B5034CD149CC296CBFEEBEED9344B_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_E59B5034CD149CC296CBFEEBEED9344B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_E59B5034CD149CC296CBFEEBEED9344B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_E59B5034CD149CC296CBFEEBEED9344B" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_E59B5034CD149CC296CBFEEBEED9344B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_B5703FC7C639ABA52044FEEBEEDA5722_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_B5703FC7C639ABA52044FEEBEEDA5722" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_B5703FC7C639ABA52044FEEBEEDA5722_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_B5703FC7C639ABA52044FEEBEEDA5722" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_B5703FC7C639ABA52044FEEBEEDA5722" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_B5703FC7C639ABA52044FEEBEEDA5722" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_B5703FC7C639ABA52044FEEBEEDA5722" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_EE558FFF06519B1F5333FEEBEEDA0871_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_EE558FFF06519B1F5333FEEBEEDA0871" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contractual term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_EE558FFF06519B1F5333FEEBEEDA0871_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_EE558FFF06519B1F5333FEEBEEDA0871" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_EE558FFF06519B1F5333FEEBEEDA0871" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_EE558FFF06519B1F5333FEEBEEDA0871" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_EE558FFF06519B1F5333FEEBEEDA0871" xlink:type="arc" />
    <link:label id="lab_eols_AllocatedShareBasedCompensationExpenseCapitalized_B7AF77EA6E9EC4A5D31AFEEBEEDA515F_terseLabel_en-US" xlink:label="lab_eols_AllocatedShareBasedCompensationExpenseCapitalized_B7AF77EA6E9EC4A5D31AFEEBEEDA515F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capitalized compensation expense</link:label>
    <link:label id="lab_eols_AllocatedShareBasedCompensationExpenseCapitalized_B7AF77EA6E9EC4A5D31AFEEBEEDA515F_label_en-US" xlink:label="lab_eols_AllocatedShareBasedCompensationExpenseCapitalized_B7AF77EA6E9EC4A5D31AFEEBEEDA515F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Allocated Share-Based Compensation Expense Capitalized</link:label>
    <link:label id="lab_eols_AllocatedShareBasedCompensationExpenseCapitalized_B7AF77EA6E9EC4A5D31AFEEBEEDA515F_documentation_en-US" xlink:label="lab_eols_AllocatedShareBasedCompensationExpenseCapitalized_B7AF77EA6E9EC4A5D31AFEEBEEDA515F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Allocated Share-Based Compensation Expense Capitalized</link:label>
    <link:loc xlink:href="eols-20190930.xsd#eols_AllocatedShareBasedCompensationExpenseCapitalized" xlink:label="loc_eols_AllocatedShareBasedCompensationExpenseCapitalized_B7AF77EA6E9EC4A5D31AFEEBEEDA515F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_AllocatedShareBasedCompensationExpenseCapitalized_B7AF77EA6E9EC4A5D31AFEEBEEDA515F" xlink:to="lab_eols_AllocatedShareBasedCompensationExpenseCapitalized_B7AF77EA6E9EC4A5D31AFEEBEEDA515F" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentAxis_070F3E651C49E123C300FEEBEF02AFDB_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis_070F3E651C49E123C300FEEBEF02AFDB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_070F3E651C49E123C300FEEBEF02AFDB_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis_070F3E651C49E123C300FEEBEF02AFDB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_070F3E651C49E123C300FEEBEF02AFDB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis_070F3E651C49E123C300FEEBEF02AFDB" xlink:to="lab_us-gaap_DebtInstrumentAxis_070F3E651C49E123C300FEEBEF02AFDB" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_6ED9D41B4FF1F9776678FEEBEF027EB8_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain_6ED9D41B4FF1F9776678FEEBEF027EB8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_6ED9D41B4FF1F9776678FEEBEF027EB8_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain_6ED9D41B4FF1F9776678FEEBEF027EB8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_6ED9D41B4FF1F9776678FEEBEF027EB8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_6ED9D41B4FF1F9776678FEEBEF027EB8" xlink:to="lab_us-gaap_DebtInstrumentNameDomain_6ED9D41B4FF1F9776678FEEBEF027EB8" xlink:type="arc" />
    <link:label id="lab_eols_OxfordTermLoansMember_8B193CBD594B49E006ECFEEBEF021C23_terseLabel_en-US" xlink:label="lab_eols_OxfordTermLoansMember_8B193CBD594B49E006ECFEEBEF021C23" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Oxford Term Loans</link:label>
    <link:label id="lab_eols_OxfordTermLoansMember_8B193CBD594B49E006ECFEEBEF021C23_label_en-US" xlink:label="lab_eols_OxfordTermLoansMember_8B193CBD594B49E006ECFEEBEF021C23" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Oxford Term Loans [Member]</link:label>
    <link:label id="lab_eols_OxfordTermLoansMember_8B193CBD594B49E006ECFEEBEF021C23_documentation_en-US" xlink:label="lab_eols_OxfordTermLoansMember_8B193CBD594B49E006ECFEEBEF021C23" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Oxford Term Loans [Member]</link:label>
    <link:loc xlink:href="eols-20190930.xsd#eols_OxfordTermLoansMember" xlink:label="loc_eols_OxfordTermLoansMember_8B193CBD594B49E006ECFEEBEF021C23" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_OxfordTermLoansMember_8B193CBD594B49E006ECFEEBEF021C23" xlink:to="lab_eols_OxfordTermLoansMember_8B193CBD594B49E006ECFEEBEF021C23" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_CE756E96EE84D3E81464FEEBEF029C88_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis_CE756E96EE84D3E81464FEEBEF029C88" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_CE756E96EE84D3E81464FEEBEF029C88_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis_CE756E96EE84D3E81464FEEBEF029C88" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_CE756E96EE84D3E81464FEEBEF029C88" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_CE756E96EE84D3E81464FEEBEF029C88" xlink:to="lab_us-gaap_FairValueByMeasurementBasisAxis_CE756E96EE84D3E81464FEEBEF029C88" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_2C172F29F4B4EB921902FEEBEF02A737_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain_2C172F29F4B4EB921902FEEBEF02A737" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_2C172F29F4B4EB921902FEEBEF02A737_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain_2C172F29F4B4EB921902FEEBEF02A737" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_2C172F29F4B4EB921902FEEBEF02A737" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_2C172F29F4B4EB921902FEEBEF02A737" xlink:to="lab_us-gaap_FairValueDisclosureItemAmountsDomain_2C172F29F4B4EB921902FEEBEF02A737" xlink:type="arc" />
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_3F81A530ABAAEF208FD1FEEBEF03A001_terseLabel_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_3F81A530ABAAEF208FD1FEEBEF03A001" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Portion at Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_3F81A530ABAAEF208FD1FEEBEF03A001_label_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_3F81A530ABAAEF208FD1FEEBEF03A001" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Portion at Fair Value Measurement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_3F81A530ABAAEF208FD1FEEBEF03A001" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_3F81A530ABAAEF208FD1FEEBEF03A001" xlink:to="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_3F81A530ABAAEF208FD1FEEBEF03A001" xlink:type="arc" />
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_22CABA68359D3C7D91D5FEEBEF03AA6A_terseLabel_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_22CABA68359D3C7D91D5FEEBEF03AA6A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimate of Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_22CABA68359D3C7D91D5FEEBEF03AA6A_label_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_22CABA68359D3C7D91D5FEEBEF03AA6A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Estimate of Fair Value Measurement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_22CABA68359D3C7D91D5FEEBEF03AA6A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_22CABA68359D3C7D91D5FEEBEF03AA6A" xlink:to="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_22CABA68359D3C7D91D5FEEBEF03AA6A" xlink:type="arc" />
    <link:label id="lab_eols_ContingentRoyaltyObligationMember_78C18887C48031B8C99DFEEBEF04D3B9_terseLabel_en-US" xlink:label="lab_eols_ContingentRoyaltyObligationMember_78C18887C48031B8C99DFEEBEF04D3B9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent Royalty Obligation</link:label>
    <link:label id="lab_eols_ContingentRoyaltyObligationMember_78C18887C48031B8C99DFEEBEF04D3B9_label_en-US" xlink:label="lab_eols_ContingentRoyaltyObligationMember_78C18887C48031B8C99DFEEBEF04D3B9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Royalty Obligation [Member]</link:label>
    <link:label id="lab_eols_ContingentRoyaltyObligationMember_78C18887C48031B8C99DFEEBEF04D3B9_documentation_en-US" xlink:label="lab_eols_ContingentRoyaltyObligationMember_78C18887C48031B8C99DFEEBEF04D3B9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contingent Royalty Obligation [Member]</link:label>
    <link:loc xlink:href="eols-20190930.xsd#eols_ContingentRoyaltyObligationMember" xlink:label="loc_eols_ContingentRoyaltyObligationMember_78C18887C48031B8C99DFEEBEF04D3B9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_ContingentRoyaltyObligationMember_78C18887C48031B8C99DFEEBEF04D3B9" xlink:to="lab_eols_ContingentRoyaltyObligationMember_78C18887C48031B8C99DFEEBEF04D3B9" xlink:type="arc" />
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_2505B847A84004010E09FEEBEF046156_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis_2505B847A84004010E09FEEBEF046156" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_2505B847A84004010E09FEEBEF046156_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis_2505B847A84004010E09FEEBEF046156" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_2505B847A84004010E09FEEBEF046156" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_2505B847A84004010E09FEEBEF046156" xlink:to="lab_us-gaap_MeasurementInputTypeAxis_2505B847A84004010E09FEEBEF046156" xlink:type="arc" />
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_4304D949E47D18E67F48FEEBEF043F23_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain_4304D949E47D18E67F48FEEBEF043F23" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_4304D949E47D18E67F48FEEBEF043F23_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain_4304D949E47D18E67F48FEEBEF043F23" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_4304D949E47D18E67F48FEEBEF043F23" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_4304D949E47D18E67F48FEEBEF043F23" xlink:to="lab_us-gaap_MeasurementInputTypeDomain_4304D949E47D18E67F48FEEBEF043F23" xlink:type="arc" />
    <link:label id="lab_us-gaap_MeasurementInputExpectedTermMember_2057FA256B875C5AA88BFEEBEF04DBAA_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember_2057FA256B875C5AA88BFEEBEF04DBAA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Input, Expected Term</link:label>
    <link:label id="lab_us-gaap_MeasurementInputExpectedTermMember_2057FA256B875C5AA88BFEEBEF04DBAA_label_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember_2057FA256B875C5AA88BFEEBEF04DBAA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Expected Term [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_2057FA256B875C5AA88BFEEBEF04DBAA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedTermMember_2057FA256B875C5AA88BFEEBEF04DBAA" xlink:to="lab_us-gaap_MeasurementInputExpectedTermMember_2057FA256B875C5AA88BFEEBEF04DBAA" xlink:type="arc" />
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_51E1AB92B3AC6B99BE38FEEBEF055775_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember_51E1AB92B3AC6B99BE38FEEBEF055775" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Input, Discount Rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_51E1AB92B3AC6B99BE38FEEBEF055775_label_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember_51E1AB92B3AC6B99BE38FEEBEF055775" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Discount Rate [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_51E1AB92B3AC6B99BE38FEEBEF055775" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputDiscountRateMember_51E1AB92B3AC6B99BE38FEEBEF055775" xlink:to="lab_us-gaap_MeasurementInputDiscountRateMember_51E1AB92B3AC6B99BE38FEEBEF055775" xlink:type="arc" />
    <link:label id="lab_us-gaap_AlternativeInvestmentMeasurementInput_5256F0A5B671ED36B8C9FEEBEF066627_terseLabel_en-US" xlink:label="lab_us-gaap_AlternativeInvestmentMeasurementInput_5256F0A5B671ED36B8C9FEEBEF066627" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement input</link:label>
    <link:label id="lab_us-gaap_AlternativeInvestmentMeasurementInput_5256F0A5B671ED36B8C9FEEBEF066627_label_en-US" xlink:label="lab_us-gaap_AlternativeInvestmentMeasurementInput_5256F0A5B671ED36B8C9FEEBEF066627" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alternative Investment, Measurement Input</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AlternativeInvestmentMeasurementInput" xlink:label="loc_us-gaap_AlternativeInvestmentMeasurementInput_5256F0A5B671ED36B8C9FEEBEF066627" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AlternativeInvestmentMeasurementInput_5256F0A5B671ED36B8C9FEEBEF066627" xlink:to="lab_us-gaap_AlternativeInvestmentMeasurementInput_5256F0A5B671ED36B8C9FEEBEF066627" xlink:type="arc" />
    <link:label id="lab_us-gaap_NotesPayableFairValueDisclosure_61F681322F21F33EAEDEFEEBEF06DA1A_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableFairValueDisclosure_61F681322F21F33EAEDEFEEBEF06DA1A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent promissory note payable</link:label>
    <link:label id="lab_us-gaap_NotesPayableFairValueDisclosure_61F681322F21F33EAEDEFEEBEF06DA1A_label_en-US" xlink:label="lab_us-gaap_NotesPayableFairValueDisclosure_61F681322F21F33EAEDEFEEBEF06DA1A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes Payable, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure_61F681322F21F33EAEDEFEEBEF06DA1A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableFairValueDisclosure_61F681322F21F33EAEDEFEEBEF06DA1A" xlink:to="lab_us-gaap_NotesPayableFairValueDisclosure_61F681322F21F33EAEDEFEEBEF06DA1A" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_BA508AE0314C0E6F67F7FF40D323AC88_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_BA508AE0314C0E6F67F7FF40D323AC88" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent royalty obligation payable to Evolus Founders</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_BA508AE0314C0E6F67F7FF40D323AC88_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_BA508AE0314C0E6F67F7FF40D323AC88" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_BA508AE0314C0E6F67F7FF40D323AC88" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_BA508AE0314C0E6F67F7FF40D323AC88" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_BA508AE0314C0E6F67F7FF40D323AC88" xlink:type="arc" />
    <link:label id="lab_eols_DocumentAndEntityInformationAbstract_12FA04BA27FCC306294C45374EE9B4FE_label_en-US" xlink:label="lab_eols_DocumentAndEntityInformationAbstract_12FA04BA27FCC306294C45374EE9B4FE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document And Entity Information [Abstract]</link:label>
    <link:label id="lab_eols_DocumentAndEntityInformationAbstract_12FA04BA27FCC306294C45374EE9B4FE_documentation_en-US" xlink:label="lab_eols_DocumentAndEntityInformationAbstract_12FA04BA27FCC306294C45374EE9B4FE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Document and Entity Information [Abstract]</link:label>
    <link:loc xlink:href="eols-20190930.xsd#eols_DocumentAndEntityInformationAbstract" xlink:label="loc_eols_DocumentAndEntityInformationAbstract_12FA04BA27FCC306294C45374EE9B4FE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_DocumentAndEntityInformationAbstract_12FA04BA27FCC306294C45374EE9B4FE" xlink:to="lab_eols_DocumentAndEntityInformationAbstract_12FA04BA27FCC306294C45374EE9B4FE" xlink:type="arc" />
    <link:label id="lab_dei_DocumentType_9468B7E1DEDB174997DA45374EE9001B_terseLabel_en-US" xlink:label="lab_dei_DocumentType_9468B7E1DEDB174997DA45374EE9001B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_9468B7E1DEDB174997DA45374EE9001B_label_en-US" xlink:label="lab_dei_DocumentType_9468B7E1DEDB174997DA45374EE9001B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_9468B7E1DEDB174997DA45374EE9001B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType_9468B7E1DEDB174997DA45374EE9001B" xlink:to="lab_dei_DocumentType_9468B7E1DEDB174997DA45374EE9001B" xlink:type="arc" />
    <link:label id="lab_dei_AmendmentFlag_A2021231754DB63972BB45374EE90E98_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag_A2021231754DB63972BB45374EE90E98" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_A2021231754DB63972BB45374EE90E98_label_en-US" xlink:label="lab_dei_AmendmentFlag_A2021231754DB63972BB45374EE90E98" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_A2021231754DB63972BB45374EE90E98" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag_A2021231754DB63972BB45374EE90E98" xlink:to="lab_dei_AmendmentFlag_A2021231754DB63972BB45374EE90E98" xlink:type="arc" />
    <link:label id="lab_dei_DocumentPeriodEndDate_E191FBA8865B055B421B45374EE9DC43_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_E191FBA8865B055B421B45374EE9DC43" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_E191FBA8865B055B421B45374EE9DC43_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_E191FBA8865B055B421B45374EE9DC43" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_E191FBA8865B055B421B45374EE9DC43" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate_E191FBA8865B055B421B45374EE9DC43" xlink:to="lab_dei_DocumentPeriodEndDate_E191FBA8865B055B421B45374EE9DC43" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalYearFocus_9804748F59B19C71B9A445374EE94E70_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_9804748F59B19C71B9A445374EE94E70" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_9804748F59B19C71B9A445374EE94E70_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_9804748F59B19C71B9A445374EE94E70" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_9804748F59B19C71B9A445374EE94E70" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus_9804748F59B19C71B9A445374EE94E70" xlink:to="lab_dei_DocumentFiscalYearFocus_9804748F59B19C71B9A445374EE94E70" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_538B071CD546F70916A745374EE96957_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_538B071CD546F70916A745374EE96957" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_538B071CD546F70916A745374EE96957_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_538B071CD546F70916A745374EE96957" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_538B071CD546F70916A745374EE96957" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus_538B071CD546F70916A745374EE96957" xlink:to="lab_dei_DocumentFiscalPeriodFocus_538B071CD546F70916A745374EE96957" xlink:type="arc" />
    <link:label id="lab_dei_EntityRegistrantName_4CB8D2D00966413B7A3E45374EEA0CB4_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName_4CB8D2D00966413B7A3E45374EEA0CB4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_4CB8D2D00966413B7A3E45374EEA0CB4_label_en-US" xlink:label="lab_dei_EntityRegistrantName_4CB8D2D00966413B7A3E45374EEA0CB4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_4CB8D2D00966413B7A3E45374EEA0CB4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName_4CB8D2D00966413B7A3E45374EEA0CB4" xlink:to="lab_dei_EntityRegistrantName_4CB8D2D00966413B7A3E45374EEA0CB4" xlink:type="arc" />
    <link:label id="lab_dei_EntityCentralIndexKey_659D796DBA6EB95F0D5345374EEAC3A0_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey_659D796DBA6EB95F0D5345374EEAC3A0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_659D796DBA6EB95F0D5345374EEAC3A0_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey_659D796DBA6EB95F0D5345374EEAC3A0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_659D796DBA6EB95F0D5345374EEAC3A0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey_659D796DBA6EB95F0D5345374EEAC3A0" xlink:to="lab_dei_EntityCentralIndexKey_659D796DBA6EB95F0D5345374EEAC3A0" xlink:type="arc" />
    <link:label id="lab_dei_CurrentFiscalYearEndDate_2A52BD65445A549F2E4345374EEA015D_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_2A52BD65445A549F2E4345374EEA015D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_2A52BD65445A549F2E4345374EEA015D_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_2A52BD65445A549F2E4345374EEA015D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_2A52BD65445A549F2E4345374EEA015D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate_2A52BD65445A549F2E4345374EEA015D" xlink:to="lab_dei_CurrentFiscalYearEndDate_2A52BD65445A549F2E4345374EEA015D" xlink:type="arc" />
    <link:label id="lab_dei_EntityFilerCategory_10F6C745C66EE81221EE45374EEAD290_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory_10F6C745C66EE81221EE45374EEAD290" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_10F6C745C66EE81221EE45374EEAD290_label_en-US" xlink:label="lab_dei_EntityFilerCategory_10F6C745C66EE81221EE45374EEAD290" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_10F6C745C66EE81221EE45374EEAD290" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory_10F6C745C66EE81221EE45374EEAD290" xlink:to="lab_dei_EntityFilerCategory_10F6C745C66EE81221EE45374EEAD290" xlink:type="arc" />
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_A0D13F27A4C4DBE3CD0D45374EEAD100_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_A0D13F27A4C4DBE3CD0D45374EEAD100" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding (in shares)</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_A0D13F27A4C4DBE3CD0D45374EEAD100_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_A0D13F27A4C4DBE3CD0D45374EEAD100" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_A0D13F27A4C4DBE3CD0D45374EEAD100" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding_A0D13F27A4C4DBE3CD0D45374EEAD100" xlink:to="lab_dei_EntityCommonStockSharesOutstanding_A0D13F27A4C4DBE3CD0D45374EEAD100" xlink:type="arc" />
    <link:label id="lab_dei_EntityEmergingGrowthCompany_9FB73C8A9828EF0803E945374EEA99D8_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany_9FB73C8A9828EF0803E945374EEA99D8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_9FB73C8A9828EF0803E945374EEA99D8_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany_9FB73C8A9828EF0803E945374EEA99D8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_9FB73C8A9828EF0803E945374EEA99D8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany_9FB73C8A9828EF0803E945374EEA99D8" xlink:to="lab_dei_EntityEmergingGrowthCompany_9FB73C8A9828EF0803E945374EEA99D8" xlink:type="arc" />
    <link:label id="lab_dei_EntitySmallBusiness_CF12D45CAFB9D09D645545374EEB032E_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness_CF12D45CAFB9D09D645545374EEB032E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Smaller Reporting Company</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_CF12D45CAFB9D09D645545374EEB032E_label_en-US" xlink:label="lab_dei_EntitySmallBusiness_CF12D45CAFB9D09D645545374EEB032E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_CF12D45CAFB9D09D645545374EEB032E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness_CF12D45CAFB9D09D645545374EEB032E" xlink:to="lab_dei_EntitySmallBusiness_CF12D45CAFB9D09D645545374EEB032E" xlink:type="arc" />
    <link:label id="lab_dei_EntityExTransitionPeriod_E0B9EDFEC5253A0FE34B45374EEB06E8_terseLabel_en-US" xlink:label="lab_dei_EntityExTransitionPeriod_E0B9EDFEC5253A0FE34B45374EEB06E8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Transition Period</link:label>
    <link:label id="lab_dei_EntityExTransitionPeriod_E0B9EDFEC5253A0FE34B45374EEB06E8_label_en-US" xlink:label="lab_dei_EntityExTransitionPeriod_E0B9EDFEC5253A0FE34B45374EEB06E8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod_E0B9EDFEC5253A0FE34B45374EEB06E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod_E0B9EDFEC5253A0FE34B45374EEB06E8" xlink:to="lab_dei_EntityExTransitionPeriod_E0B9EDFEC5253A0FE34B45374EEB06E8" xlink:type="arc" />
    <link:label id="lab_dei_EntityCurrentReportingStatus_65CF788687A50F8D22C145374EEB3674_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus_65CF788687A50F8D22C145374EEB3674" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_65CF788687A50F8D22C145374EEB3674_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus_65CF788687A50F8D22C145374EEB3674" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_65CF788687A50F8D22C145374EEB3674" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus_65CF788687A50F8D22C145374EEB3674" xlink:to="lab_dei_EntityCurrentReportingStatus_65CF788687A50F8D22C145374EEB3674" xlink:type="arc" />
    <link:label id="lab_dei_EntityShellCompany_C99FA02A648B4EAB0E2945374EEB6DA9_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany_C99FA02A648B4EAB0E2945374EEB6DA9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_C99FA02A648B4EAB0E2945374EEB6DA9_label_en-US" xlink:label="lab_dei_EntityShellCompany_C99FA02A648B4EAB0E2945374EEB6DA9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_C99FA02A648B4EAB0E2945374EEB6DA9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany_C99FA02A648B4EAB0E2945374EEB6DA9" xlink:to="lab_dei_EntityShellCompany_C99FA02A648B4EAB0E2945374EEB6DA9" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_DF934ECD03F99BBB3397453920A0D55F_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_DF934ECD03F99BBB3397453920A0D55F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_DF934ECD03F99BBB3397453920A0D55F_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_DF934ECD03F99BBB3397453920A0D55F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_DF934ECD03F99BBB3397453920A0D55F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_DF934ECD03F99BBB3397453920A0D55F" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_DF934ECD03F99BBB3397453920A0D55F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_7449E0EA470E97945D1D453920A07D31_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_7449E0EA470E97945D1D453920A07D31" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_7449E0EA470E97945D1D453920A07D31_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_7449E0EA470E97945D1D453920A07D31" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_7449E0EA470E97945D1D453920A07D31" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_7449E0EA470E97945D1D453920A07D31" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_7449E0EA470E97945D1D453920A07D31" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_325728DEE88D729DD550453920A0D5C0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_325728DEE88D729DD550453920A0D5C0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Financial Instruments Recorded at Fair Value on a Recurring Basis</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_325728DEE88D729DD550453920A0D5C0_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_325728DEE88D729DD550453920A0D5C0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_325728DEE88D729DD550453920A0D5C0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_325728DEE88D729DD550453920A0D5C0" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_325728DEE88D729DD550453920A0D5C0" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_2A718766F326E06A9B361E20339AB158_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract_2A718766F326E06A9B361E20339AB158" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_2A718766F326E06A9B361E20339AB158" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_2A718766F326E06A9B361E20339AB158" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract_2A718766F326E06A9B361E20339AB158" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementTable_DAA36AEA17C4524777BD1E20339B00A7_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable_DAA36AEA17C4524777BD1E20339B00A7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_DAA36AEA17C4524777BD1E20339B00A7_label_en-US" xlink:label="lab_us-gaap_StatementTable_DAA36AEA17C4524777BD1E20339B00A7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_DAA36AEA17C4524777BD1E20339B00A7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable_DAA36AEA17C4524777BD1E20339B00A7" xlink:to="lab_us-gaap_StatementTable_DAA36AEA17C4524777BD1E20339B00A7" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_CAA5F0E4A6393AD62FF91E20339BD3CB_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis_CAA5F0E4A6393AD62FF91E20339BD3CB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_CAA5F0E4A6393AD62FF91E20339BD3CB_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis_CAA5F0E4A6393AD62FF91E20339BD3CB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_CAA5F0E4A6393AD62FF91E20339BD3CB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_CAA5F0E4A6393AD62FF91E20339BD3CB" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis_CAA5F0E4A6393AD62FF91E20339BD3CB" xlink:type="arc" />
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_A7072A595A2AC29EBF371E20339B17F5_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain_A7072A595A2AC29EBF371E20339B17F5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_A7072A595A2AC29EBF371E20339B17F5_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain_A7072A595A2AC29EBF371E20339B17F5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_A7072A595A2AC29EBF371E20339B17F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_A7072A595A2AC29EBF371E20339B17F5" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain_A7072A595A2AC29EBF371E20339B17F5" xlink:type="arc" />
    <link:label id="lab_us-gaap_IPOMember_0059C702302448EF94AB1E20339C6150_terseLabel_en-US" xlink:label="lab_us-gaap_IPOMember_0059C702302448EF94AB1E20339C6150" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">IPO</link:label>
    <link:label id="lab_us-gaap_IPOMember_0059C702302448EF94AB1E20339C6150_label_en-US" xlink:label="lab_us-gaap_IPOMember_0059C702302448EF94AB1E20339C6150" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">IPO [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_0059C702302448EF94AB1E20339C6150" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IPOMember_0059C702302448EF94AB1E20339C6150" xlink:to="lab_us-gaap_IPOMember_0059C702302448EF94AB1E20339C6150" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_0E95FC2A3A6C0F4825961E20339C8880_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_0E95FC2A3A6C0F4825961E20339C8880" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_0E95FC2A3A6C0F4825961E20339C8880_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_0E95FC2A3A6C0F4825961E20339C8880" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_0E95FC2A3A6C0F4825961E20339C8880" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_0E95FC2A3A6C0F4825961E20339C8880" xlink:to="lab_us-gaap_StatementEquityComponentsAxis_0E95FC2A3A6C0F4825961E20339C8880" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityComponentDomain_F05F420169BD2F6A09C71E20339C63D0_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_F05F420169BD2F6A09C71E20339C63D0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_F05F420169BD2F6A09C71E20339C63D0_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_F05F420169BD2F6A09C71E20339C63D0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_F05F420169BD2F6A09C71E20339C63D0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain_F05F420169BD2F6A09C71E20339C63D0" xlink:to="lab_us-gaap_EquityComponentDomain_F05F420169BD2F6A09C71E20339C63D0" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockMember_BB144F88EC266DE68CF41E20339C8582_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockMember_BB144F88EC266DE68CF41E20339C8582" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred Stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockMember_BB144F88EC266DE68CF41E20339C8582_label_en-US" xlink:label="lab_us-gaap_PreferredStockMember_BB144F88EC266DE68CF41E20339C8582" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_BB144F88EC266DE68CF41E20339C8582" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember_BB144F88EC266DE68CF41E20339C8582" xlink:to="lab_us-gaap_PreferredStockMember_BB144F88EC266DE68CF41E20339C8582" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockMember_EA19271852CC70B6EB5A1E20339CFDF6_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember_EA19271852CC70B6EB5A1E20339CFDF6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_EA19271852CC70B6EB5A1E20339CFDF6_label_en-US" xlink:label="lab_us-gaap_CommonStockMember_EA19271852CC70B6EB5A1E20339CFDF6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_EA19271852CC70B6EB5A1E20339CFDF6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember_EA19271852CC70B6EB5A1E20339CFDF6" xlink:to="lab_us-gaap_CommonStockMember_EA19271852CC70B6EB5A1E20339CFDF6" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_B0910A213D430EFF1B7E1E20339D3244_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_B0910A213D430EFF1B7E1E20339D3244" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Paid In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_B0910A213D430EFF1B7E1E20339D3244_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_B0910A213D430EFF1B7E1E20339D3244" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_B0910A213D430EFF1B7E1E20339D3244" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember_B0910A213D430EFF1B7E1E20339D3244" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember_B0910A213D430EFF1B7E1E20339D3244" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_26BDD9039C8476153C381E20339DA7C1_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_26BDD9039C8476153C381E20339DA7C1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive (Loss) Gain</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_26BDD9039C8476153C381E20339DA7C1_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_26BDD9039C8476153C381E20339DA7C1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_26BDD9039C8476153C381E20339DA7C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_26BDD9039C8476153C381E20339DA7C1" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_26BDD9039C8476153C381E20339DA7C1" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsMember_0809E414A42511BCFF231E20339DBD4A_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_0809E414A42511BCFF231E20339DBD4A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_0809E414A42511BCFF231E20339DBD4A_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_0809E414A42511BCFF231E20339DBD4A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_0809E414A42511BCFF231E20339DBD4A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember_0809E414A42511BCFF231E20339DBD4A" xlink:to="lab_us-gaap_RetainedEarningsMember_0809E414A42511BCFF231E20339DBD4A" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_C4AAC72D1631D5EE6F0B1E20339D0ADB_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis_C4AAC72D1631D5EE6F0B1E20339D0ADB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_C4AAC72D1631D5EE6F0B1E20339D0ADB_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis_C4AAC72D1631D5EE6F0B1E20339D0ADB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_C4AAC72D1631D5EE6F0B1E20339D0ADB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis_C4AAC72D1631D5EE6F0B1E20339D0ADB" xlink:to="lab_us-gaap_StatementClassOfStockAxis_C4AAC72D1631D5EE6F0B1E20339D0ADB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfStockDomain_8E59374AF305BA13BEB41E20339D8691_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain_8E59374AF305BA13BEB41E20339D8691" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_8E59374AF305BA13BEB41E20339D8691_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain_8E59374AF305BA13BEB41E20339D8691" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_8E59374AF305BA13BEB41E20339D8691" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain_8E59374AF305BA13BEB41E20339D8691" xlink:to="lab_us-gaap_ClassOfStockDomain_8E59374AF305BA13BEB41E20339D8691" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConvertiblePreferredStockMember_01B99BEF9596C37E55E61E20339D5A06_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember_01B99BEF9596C37E55E61E20339D5A06" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series A Preferred Stock</link:label>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockMember_01B99BEF9596C37E55E61E20339D5A06_label_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember_01B99BEF9596C37E55E61E20339D5A06" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_01B99BEF9596C37E55E61E20339D5A06" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockMember_01B99BEF9596C37E55E61E20339D5A06" xlink:to="lab_us-gaap_ConvertiblePreferredStockMember_01B99BEF9596C37E55E61E20339D5A06" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementLineItems_10AD680306A7621BD9B01E20339E87AC_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems_10AD680306A7621BD9B01E20339E87AC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_10AD680306A7621BD9B01E20339E87AC_label_en-US" xlink:label="lab_us-gaap_StatementLineItems_10AD680306A7621BD9B01E20339E87AC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_10AD680306A7621BD9B01E20339E87AC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems_10AD680306A7621BD9B01E20339E87AC" xlink:to="lab_us-gaap_StatementLineItems_10AD680306A7621BD9B01E20339E87AC" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_642A7DAFD8538002FA6B1E20339EB702_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_642A7DAFD8538002FA6B1E20339EB702" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_642A7DAFD8538002FA6B1E20339EB702_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_642A7DAFD8538002FA6B1E20339EB702" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_642A7DAFD8538002FA6B1E20339EB702" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_642A7DAFD8538002FA6B1E20339EB702" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_642A7DAFD8538002FA6B1E20339EB702" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharesIssued_5F4D4CA6B073104DD10E1E20339E0F1C_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesIssued_5F4D4CA6B073104DD10E1E20339E0F1C" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_5F4D4CA6B073104DD10E1E20339E0F1C_label_en-US" xlink:label="lab_us-gaap_SharesIssued_5F4D4CA6B073104DD10E1E20339E0F1C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_5F4D4CA6B073104DD10E1E20339E0F1C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued_5F4D4CA6B073104DD10E1E20339E0F1C" xlink:to="lab_us-gaap_SharesIssued_5F4D4CA6B073104DD10E1E20339E0F1C" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_72DE7DFD7B7C714C64931E20339F8A92_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_72DE7DFD7B7C714C64931E20339F8A92" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_72DE7DFD7B7C714C64931E20339F8A92_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity_72DE7DFD7B7C714C64931E20339F8A92" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_72DE7DFD7B7C714C64931E20339F8A92" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_72DE7DFD7B7C714C64931E20339F8A92" xlink:to="lab_us-gaap_StockholdersEquity_72DE7DFD7B7C714C64931E20339F8A92" xlink:type="arc" />
    <link:label id="lab_eols_DeemedContributionFromParentIncreaseOfRelatedPartyReceivable_15673E7BAAF838400DB81E20339FABDF_terseLabel_en-US" xlink:label="lab_eols_DeemedContributionFromParentIncreaseOfRelatedPartyReceivable_15673E7BAAF838400DB81E20339FABDF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deemed contribution from Parent, increase of related-party receivable</link:label>
    <link:label id="lab_eols_DeemedContributionFromParentIncreaseOfRelatedPartyReceivable_15673E7BAAF838400DB81E20339FABDF_label_en-US" xlink:label="lab_eols_DeemedContributionFromParentIncreaseOfRelatedPartyReceivable_15673E7BAAF838400DB81E20339FABDF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deemed Contribution From Parent, Increase Of Related-Party Receivable</link:label>
    <link:label id="lab_eols_DeemedContributionFromParentIncreaseOfRelatedPartyReceivable_15673E7BAAF838400DB81E20339FABDF_documentation_en-US" xlink:label="lab_eols_DeemedContributionFromParentIncreaseOfRelatedPartyReceivable_15673E7BAAF838400DB81E20339FABDF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deemed Contribution From Parent, Increase Of Related-Party Receivable</link:label>
    <link:loc xlink:href="eols-20190930.xsd#eols_DeemedContributionFromParentIncreaseOfRelatedPartyReceivable" xlink:label="loc_eols_DeemedContributionFromParentIncreaseOfRelatedPartyReceivable_15673E7BAAF838400DB81E20339FABDF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_DeemedContributionFromParentIncreaseOfRelatedPartyReceivable_15673E7BAAF838400DB81E20339FABDF" xlink:to="lab_eols_DeemedContributionFromParentIncreaseOfRelatedPartyReceivable_15673E7BAAF838400DB81E20339FABDF" xlink:type="arc" />
    <link:label id="lab_us-gaap_Dividends_9771A66945D1C182761E1E20339F9F79_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_Dividends_9771A66945D1C182761E1E20339F9F79" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Deemed distribution to Parent, increase of convertible note obligation</link:label>
    <link:label id="lab_us-gaap_Dividends_9771A66945D1C182761E1E20339F9F79_label_en-US" xlink:label="lab_us-gaap_Dividends_9771A66945D1C182761E1E20339F9F79" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Dividends" xlink:label="loc_us-gaap_Dividends_9771A66945D1C182761E1E20339F9F79" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Dividends_9771A66945D1C182761E1E20339F9F79" xlink:to="lab_us-gaap_Dividends_9771A66945D1C182761E1E20339F9F79" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_C8861EB44ED0B870EE201E20339F4EBE_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_C8861EB44ED0B870EE201E20339F4EBE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capital contribution from Parent, convertible note write-off</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_C8861EB44ED0B870EE201E20339F4EBE_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_C8861EB44ED0B870EE201E20339F4EBE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_C8861EB44ED0B870EE201E20339F4EBE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_C8861EB44ED0B870EE201E20339F4EBE" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_C8861EB44ED0B870EE201E20339F4EBE" xlink:type="arc" />
    <link:label id="lab_eols_CapitalContributionFromParentForgivenessOfRelatedPartyBorrowings_E5622A933517C718095D1E20339F59DB_terseLabel_en-US" xlink:label="lab_eols_CapitalContributionFromParentForgivenessOfRelatedPartyBorrowings_E5622A933517C718095D1E20339F59DB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capital contribution from Parent, forgiveness of related party borrowings</link:label>
    <link:label id="lab_eols_CapitalContributionFromParentForgivenessOfRelatedPartyBorrowings_E5622A933517C718095D1E20339F59DB_label_en-US" xlink:label="lab_eols_CapitalContributionFromParentForgivenessOfRelatedPartyBorrowings_E5622A933517C718095D1E20339F59DB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Contribution From Parent, Forgiveness Of Related-Party Borrowings</link:label>
    <link:label id="lab_eols_CapitalContributionFromParentForgivenessOfRelatedPartyBorrowings_E5622A933517C718095D1E20339F59DB_documentation_en-US" xlink:label="lab_eols_CapitalContributionFromParentForgivenessOfRelatedPartyBorrowings_E5622A933517C718095D1E20339F59DB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Capital Contribution From Parent, Forgiveness Of Related-Party Borrowings</link:label>
    <link:loc xlink:href="eols-20190930.xsd#eols_CapitalContributionFromParentForgivenessOfRelatedPartyBorrowings" xlink:label="loc_eols_CapitalContributionFromParentForgivenessOfRelatedPartyBorrowings_E5622A933517C718095D1E20339F59DB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_CapitalContributionFromParentForgivenessOfRelatedPartyBorrowings_E5622A933517C718095D1E20339F59DB" xlink:to="lab_eols_CapitalContributionFromParentForgivenessOfRelatedPartyBorrowings_E5622A933517C718095D1E20339F59DB" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_87E80F2381B11F85CED41E20339F3736_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_87E80F2381B11F85CED41E20339F3736" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock conversion upon initial public offering (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_87E80F2381B11F85CED41E20339F3736_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_87E80F2381B11F85CED41E20339F3736" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_87E80F2381B11F85CED41E20339F3736" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_87E80F2381B11F85CED41E20339F3736" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_87E80F2381B11F85CED41E20339F3736" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_D5AC9BE8AE97214217181E2033A0A250_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_D5AC9BE8AE97214217181E2033A0A250" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock upon initial public offering, net of issuance costs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_D5AC9BE8AE97214217181E2033A0A250_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_D5AC9BE8AE97214217181E2033A0A250" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_D5AC9BE8AE97214217181E2033A0A250" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_D5AC9BE8AE97214217181E2033A0A250" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_D5AC9BE8AE97214217181E2033A0A250" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_B03EBD87602E126FBDE01E2033A0C801_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_B03EBD87602E126FBDE01E2033A0C801" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock upon initial public offering, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_B03EBD87602E126FBDE01E2033A0C801_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_B03EBD87602E126FBDE01E2033A0C801" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_B03EBD87602E126FBDE01E2033A0C801" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_B03EBD87602E126FBDE01E2033A0C801" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_B03EBD87602E126FBDE01E2033A0C801" xlink:type="arc" />
    <link:label id="lab_eols_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan_45C06B2BB774CAC11F951E2033A0F663_terseLabel_en-US" xlink:label="lab_eols_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan_45C06B2BB774CAC11F951E2033A0F663" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock in connection with the incentive equity plan (in shares)</link:label>
    <link:label id="lab_eols_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan_45C06B2BB774CAC11F951E2033A0F663_label_en-US" xlink:label="lab_eols_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan_45C06B2BB774CAC11F951E2033A0F663" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Issuance Of Common Stock In Connection With Incentive Equity Plan</link:label>
    <link:label id="lab_eols_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan_45C06B2BB774CAC11F951E2033A0F663_documentation_en-US" xlink:label="lab_eols_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan_45C06B2BB774CAC11F951E2033A0F663" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Issuance Of Common Stock In Connection With Incentive Equity Plan</link:label>
    <link:loc xlink:href="eols-20190930.xsd#eols_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan" xlink:label="loc_eols_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan_45C06B2BB774CAC11F951E2033A0F663" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan_45C06B2BB774CAC11F951E2033A0F663" xlink:to="lab_eols_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan_45C06B2BB774CAC11F951E2033A0F663" xlink:type="arc" />
    <link:label id="lab_eols_StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan_32743583593F49C6ED531E2033A07918_terseLabel_en-US" xlink:label="lab_eols_StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan_32743583593F49C6ED531E2033A07918" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock in connection with the incentive equity plan</link:label>
    <link:label id="lab_eols_StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan_32743583593F49C6ED531E2033A07918_label_en-US" xlink:label="lab_eols_StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan_32743583593F49C6ED531E2033A07918" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Issuance Of Common Stock In Connection With Incentive Equity Plan</link:label>
    <link:label id="lab_eols_StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan_32743583593F49C6ED531E2033A07918_documentation_en-US" xlink:label="lab_eols_StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan_32743583593F49C6ED531E2033A07918" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Issuance Of Common Stock In Connection With Incentive Equity Plan</link:label>
    <link:loc xlink:href="eols-20190930.xsd#eols_StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan" xlink:label="loc_eols_StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan_32743583593F49C6ED531E2033A07918" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan_32743583593F49C6ED531E2033A07918" xlink:to="lab_eols_StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan_32743583593F49C6ED531E2033A07918" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_77A6732ED232E91746351E2033A0AE03_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_77A6732ED232E91746351E2033A0AE03" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_77A6732ED232E91746351E2033A0AE03_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_77A6732ED232E91746351E2033A0AE03" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_77A6732ED232E91746351E2033A0AE03" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_77A6732ED232E91746351E2033A0AE03" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_77A6732ED232E91746351E2033A0AE03" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_9EB42640B319FA0905421E2033A024A2_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_9EB42640B319FA0905421E2033A024A2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income (loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_9EB42640B319FA0905421E2033A024A2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_9EB42640B319FA0905421E2033A024A2" xlink:to="lab_us-gaap_NetIncomeLoss_9EB42640B319FA0905421E2033A024A2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_F30FAB31BA237AD751D91E2033A02622_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_F30FAB31BA237AD751D91E2033A02622" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_F30FAB31BA237AD751D91E2033A02622_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_F30FAB31BA237AD751D91E2033A02622" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_F30FAB31BA237AD751D91E2033A02622" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_F30FAB31BA237AD751D91E2033A02622" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax_F30FAB31BA237AD751D91E2033A02622" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_C3EC881E2AC6231859DF1E2033A1F1B8_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_C3EC881E2AC6231859DF1E2033A1F1B8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_C3EC881E2AC6231859DF1E2033A1F1B8_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_C3EC881E2AC6231859DF1E2033A1F1B8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, after Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_C3EC881E2AC6231859DF1E2033A1F1B8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_C3EC881E2AC6231859DF1E2033A1F1B8" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_C3EC881E2AC6231859DF1E2033A1F1B8" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharesIssued_B29141A6B28A12C5D1431E2033A16D0D_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesIssued_B29141A6B28A12C5D1431E2033A16D0D" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_B29141A6B28A12C5D1431E2033A16D0D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued_B29141A6B28A12C5D1431E2033A16D0D" xlink:to="lab_us-gaap_SharesIssued_B29141A6B28A12C5D1431E2033A16D0D" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_54CDA1473F2BE72C63771E2033A1DCE5_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_54CDA1473F2BE72C63771E2033A1DCE5" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_54CDA1473F2BE72C63771E2033A1DCE5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_54CDA1473F2BE72C63771E2033A1DCE5" xlink:to="lab_us-gaap_StockholdersEquity_54CDA1473F2BE72C63771E2033A1DCE5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_36D0EC98228A4366BA5845374F5005B6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_36D0EC98228A4366BA5845374F5005B6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Maturities of Long-term Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_36D0EC98228A4366BA5845374F5005B6_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_36D0EC98228A4366BA5845374F5005B6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Maturities of Long-term Debt [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_36D0EC98228A4366BA5845374F5005B6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_36D0EC98228A4366BA5845374F5005B6" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_36D0EC98228A4366BA5845374F5005B6" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_58B8A6BD46E6E92DA41E45374E763EEF_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract_58B8A6BD46E6E92DA41E45374E763EEF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_58B8A6BD46E6E92DA41E45374E763EEF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_58B8A6BD46E6E92DA41E45374E763EEF" xlink:to="lab_us-gaap_AccountingPoliciesAbstract_58B8A6BD46E6E92DA41E45374E763EEF" xlink:type="arc" />
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_7638844F5C24A87F46F945374E7673F7_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_7638844F5C24A87F46F945374E7673F7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_7638844F5C24A87F46F945374E7673F7_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_7638844F5C24A87F46F945374E7673F7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_7638844F5C24A87F46F945374E7673F7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock_7638844F5C24A87F46F945374E7673F7" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock_7638844F5C24A87F46F945374E7673F7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_5AE8E20E006D26F843F845374E923B30_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_5AE8E20E006D26F843F845374E923B30" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of New Accounting Pronouncements and Changes in Accounting Principles</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_5AE8E20E006D26F843F845374E923B30_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_5AE8E20E006D26F843F845374E923B30" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of New Accounting Pronouncements and Changes in Accounting Principles [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:label="loc_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_5AE8E20E006D26F843F845374E923B30" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_5AE8E20E006D26F843F845374E923B30" xlink:to="lab_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_5AE8E20E006D26F843F845374E923B30" xlink:type="arc" />
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_B1EC52D65C8639DC56E2FEEBEF16F0F6_verboseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember_B1EC52D65C8639DC56E2FEEBEF16F0F6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">U.S treasury securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_B1EC52D65C8639DC56E2FEEBEF16F0F6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember_B1EC52D65C8639DC56E2FEEBEF16F0F6" xlink:to="lab_us-gaap_USTreasurySecuritiesMember_B1EC52D65C8639DC56E2FEEBEF16F0F6" xlink:type="arc" />
    <link:label id="lab_us-gaap_NotesPayableOtherPayablesMember_2DBA83E08D24CF1025C2FEEBEF1654A3_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableOtherPayablesMember_2DBA83E08D24CF1025C2FEEBEF1654A3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes Payable, Other Payables</link:label>
    <link:label id="lab_us-gaap_NotesPayableOtherPayablesMember_2DBA83E08D24CF1025C2FEEBEF1654A3_label_en-US" xlink:label="lab_us-gaap_NotesPayableOtherPayablesMember_2DBA83E08D24CF1025C2FEEBEF1654A3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes Payable, Other Payables [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_2DBA83E08D24CF1025C2FEEBEF1654A3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableOtherPayablesMember_2DBA83E08D24CF1025C2FEEBEF1654A3" xlink:to="lab_us-gaap_NotesPayableOtherPayablesMember_2DBA83E08D24CF1025C2FEEBEF1654A3" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_40EFBF892FEA7C855F33FEEBEF175B6B_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_40EFBF892FEA7C855F33FEEBEF175B6B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_40EFBF892FEA7C855F33FEEBEF175B6B_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_40EFBF892FEA7C855F33FEEBEF175B6B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_40EFBF892FEA7C855F33FEEBEF175B6B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_40EFBF892FEA7C855F33FEEBEF175B6B" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_40EFBF892FEA7C855F33FEEBEF175B6B" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_10F5E386F6159F14B358FEEBEF17EC3C_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_10F5E386F6159F14B358FEEBEF17EC3C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_10F5E386F6159F14B358FEEBEF17EC3C_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_10F5E386F6159F14B358FEEBEF17EC3C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_10F5E386F6159F14B358FEEBEF17EC3C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_10F5E386F6159F14B358FEEBEF17EC3C" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_10F5E386F6159F14B358FEEBEF17EC3C" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_4B47C5931F9C69B301BCFEEBEF17909D_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_4B47C5931F9C69B301BCFEEBEF17909D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_4B47C5931F9C69B301BCFEEBEF17909D_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_4B47C5931F9C69B301BCFEEBEF17909D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_4B47C5931F9C69B301BCFEEBEF17909D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member_4B47C5931F9C69B301BCFEEBEF17909D" xlink:to="lab_us-gaap_FairValueInputsLevel1Member_4B47C5931F9C69B301BCFEEBEF17909D" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_2187AE9D0A373C350FB3FEEBEF17351F_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_2187AE9D0A373C350FB3FEEBEF17351F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_2187AE9D0A373C350FB3FEEBEF17351F_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_2187AE9D0A373C350FB3FEEBEF17351F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_2187AE9D0A373C350FB3FEEBEF17351F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member_2187AE9D0A373C350FB3FEEBEF17351F" xlink:to="lab_us-gaap_FairValueInputsLevel2Member_2187AE9D0A373C350FB3FEEBEF17351F" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_824006330E63FB66CBA3FEEBEF17775F_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member_824006330E63FB66CBA3FEEBEF17775F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_824006330E63FB66CBA3FEEBEF17775F_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member_824006330E63FB66CBA3FEEBEF17775F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_824006330E63FB66CBA3FEEBEF17775F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member_824006330E63FB66CBA3FEEBEF17775F" xlink:to="lab_us-gaap_FairValueInputsLevel3Member_824006330E63FB66CBA3FEEBEF17775F" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_9985BC9B5B88058B8CBDFEEBEF1876EF_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_9985BC9B5B88058B8CBDFEEBEF1876EF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Available-for-sale debt securities</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_9985BC9B5B88058B8CBDFEEBEF1876EF_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_9985BC9B5B88058B8CBDFEEBEF1876EF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_9985BC9B5B88058B8CBDFEEBEF1876EF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_9985BC9B5B88058B8CBDFEEBEF1876EF" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_9985BC9B5B88058B8CBDFEEBEF1876EF" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_8B2596815FD25E33877545374EA030A2_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract_8B2596815FD25E33877545374EA030A2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_8B2596815FD25E33877545374EA030A2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_8B2596815FD25E33877545374EA030A2" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract_8B2596815FD25E33877545374EA030A2" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_299671A51C42D297CF4C45374EA0ED11_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_299671A51C42D297CF4C45374EA0ED11" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transactions</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_299671A51C42D297CF4C45374EA0ED11_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_299671A51C42D297CF4C45374EA0ED11" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_299671A51C42D297CF4C45374EA0ED11" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_299671A51C42D297CF4C45374EA0ED11" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_299671A51C42D297CF4C45374EA0ED11" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_ED493476090E8F4DA371FEEBEEF84D99_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock_ED493476090E8F4DA371FEEBEEF84D99" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease, Cost</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_ED493476090E8F4DA371FEEBEEF84D99_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock_ED493476090E8F4DA371FEEBEEF84D99" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_ED493476090E8F4DA371FEEBEEF84D99" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock_ED493476090E8F4DA371FEEBEEF84D99" xlink:to="lab_us-gaap_LeaseCostTableTextBlock_ED493476090E8F4DA371FEEBEEF84D99" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_B01BC7AFBCCB0AAB7A3FFEEBEEF8EB38_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_B01BC7AFBCCB0AAB7A3FFEEBEEF8EB38" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_B01BC7AFBCCB0AAB7A3FFEEBEEF8EB38_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_B01BC7AFBCCB0AAB7A3FFEEBEEF8EB38" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_B01BC7AFBCCB0AAB7A3FFEEBEEF8EB38" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_B01BC7AFBCCB0AAB7A3FFEEBEEF8EB38" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_B01BC7AFBCCB0AAB7A3FFEEBEEF8EB38" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_8E75F682F4D0A27F0435FF469D05720D_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_8E75F682F4D0A27F0435FF469D05720D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Future Minimum Rental Payments for Operating Leases</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_8E75F682F4D0A27F0435FF469D05720D_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_8E75F682F4D0A27F0435FF469D05720D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_8E75F682F4D0A27F0435FF469D05720D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_8E75F682F4D0A27F0435FF469D05720D" xlink:to="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_8E75F682F4D0A27F0435FF469D05720D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_CA58A9F1B8B90CBEDF460F02518B71E2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_CA58A9F1B8B90CBEDF460F02518B71E2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_CA58A9F1B8B90CBEDF460F02518B71E2_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_CA58A9F1B8B90CBEDF460F02518B71E2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_CA58A9F1B8B90CBEDF460F02518B71E2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_CA58A9F1B8B90CBEDF460F02518B71E2" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_CA58A9F1B8B90CBEDF460F02518B71E2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_602243EF8520793568D50F02518C2130_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_602243EF8520793568D50F02518C2130" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_602243EF8520793568D50F02518C2130_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_602243EF8520793568D50F02518C2130" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_602243EF8520793568D50F02518C2130" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_602243EF8520793568D50F02518C2130" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_602243EF8520793568D50F02518C2130" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_655828E1E22E3DE61DDC0F02518DE0C5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_655828E1E22E3DE61DDC0F02518DE0C5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_655828E1E22E3DE61DDC0F02518DE0C5_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_655828E1E22E3DE61DDC0F02518DE0C5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_655828E1E22E3DE61DDC0F02518DE0C5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_655828E1E22E3DE61DDC0F02518DE0C5" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_655828E1E22E3DE61DDC0F02518DE0C5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_C30ECCB9C8C08EC4DEBD0F02518D1FAD_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_C30ECCB9C8C08EC4DEBD0F02518D1FAD" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_C30ECCB9C8C08EC4DEBD0F02518D1FAD_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_C30ECCB9C8C08EC4DEBD0F02518D1FAD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_C30ECCB9C8C08EC4DEBD0F02518D1FAD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_C30ECCB9C8C08EC4DEBD0F02518D1FAD" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_C30ECCB9C8C08EC4DEBD0F02518D1FAD" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_4591A2B656151298D7A30F02518DDE59_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_4591A2B656151298D7A30F02518DDE59" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_4591A2B656151298D7A30F02518DDE59_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_4591A2B656151298D7A30F02518DDE59" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_4591A2B656151298D7A30F02518DDE59" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_4591A2B656151298D7A30F02518DDE59" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_4591A2B656151298D7A30F02518DDE59" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_099D486CF5F1BDCEE9DB0F02518DF70E_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_099D486CF5F1BDCEE9DB0F02518DF70E" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_099D486CF5F1BDCEE9DB0F02518DF70E_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_099D486CF5F1BDCEE9DB0F02518DF70E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_099D486CF5F1BDCEE9DB0F02518DF70E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_099D486CF5F1BDCEE9DB0F02518DF70E" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_099D486CF5F1BDCEE9DB0F02518DF70E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_44B74CF9ED4BAABB3B800F02518D8642_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_44B74CF9ED4BAABB3B800F02518D8642" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Cancelled/forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_44B74CF9ED4BAABB3B800F02518D8642_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_44B74CF9ED4BAABB3B800F02518D8642" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_44B74CF9ED4BAABB3B800F02518D8642" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_44B74CF9ED4BAABB3B800F02518D8642" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_44B74CF9ED4BAABB3B800F02518D8642" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_E514AE89E5A7054E56830F02518E6F27_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_E514AE89E5A7054E56830F02518E6F27" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_E514AE89E5A7054E56830F02518E6F27" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_E514AE89E5A7054E56830F02518E6F27" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_E514AE89E5A7054E56830F02518E6F27" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_93C3945072BF3045A7020F02518EBF1B_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_93C3945072BF3045A7020F02518EBF1B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_93C3945072BF3045A7020F02518EBF1B_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_93C3945072BF3045A7020F02518EBF1B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_93C3945072BF3045A7020F02518EBF1B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_93C3945072BF3045A7020F02518EBF1B" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_93C3945072BF3045A7020F02518EBF1B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8B128698F1217E304DA50F02518EDC82_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8B128698F1217E304DA50F02518EDC82" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8B128698F1217E304DA50F02518EDC82_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8B128698F1217E304DA50F02518EDC82" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8B128698F1217E304DA50F02518EDC82" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8B128698F1217E304DA50F02518EDC82" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8B128698F1217E304DA50F02518EDC82" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3CA4FBBF12A925ECCE6A0F02518E5CD6_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3CA4FBBF12A925ECCE6A0F02518E5CD6" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3CA4FBBF12A925ECCE6A0F02518E5CD6_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3CA4FBBF12A925ECCE6A0F02518E5CD6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3CA4FBBF12A925ECCE6A0F02518E5CD6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3CA4FBBF12A925ECCE6A0F02518E5CD6" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3CA4FBBF12A925ECCE6A0F02518E5CD6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_46ED59FA076786C991120F02518E2158_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_46ED59FA076786C991120F02518E2158" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_46ED59FA076786C991120F02518E2158_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_46ED59FA076786C991120F02518E2158" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_46ED59FA076786C991120F02518E2158" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_46ED59FA076786C991120F02518E2158" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_46ED59FA076786C991120F02518E2158" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_50CD54E2914DA251FA6D0F02518F5FD1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_50CD54E2914DA251FA6D0F02518F5FD1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_50CD54E2914DA251FA6D0F02518F5FD1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_50CD54E2914DA251FA6D0F02518F5FD1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_50CD54E2914DA251FA6D0F02518F5FD1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_50CD54E2914DA251FA6D0F02518F5FD1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_50CD54E2914DA251FA6D0F02518F5FD1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_9E085A64773A11D678420F02518F9354_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_9E085A64773A11D678420F02518F9354" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cancelled/forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_9E085A64773A11D678420F02518F9354_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_9E085A64773A11D678420F02518F9354" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_9E085A64773A11D678420F02518F9354" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_9E085A64773A11D678420F02518F9354" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_9E085A64773A11D678420F02518F9354" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_F21FEA337BD62004D3CE0F02518F30A5_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_F21FEA337BD62004D3CE0F02518F30A5" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in dollars per share)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_F21FEA337BD62004D3CE0F02518F30A5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_F21FEA337BD62004D3CE0F02518F30A5" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_F21FEA337BD62004D3CE0F02518F30A5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_EEF1DFD749A9B7A4A6A10F02518F5D4C_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_EEF1DFD749A9B7A4A6A10F02518F5D4C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_EEF1DFD749A9B7A4A6A10F02518F5D4C_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_EEF1DFD749A9B7A4A6A10F02518F5D4C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_EEF1DFD749A9B7A4A6A10F02518F5D4C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_EEF1DFD749A9B7A4A6A10F02518F5D4C" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_EEF1DFD749A9B7A4A6A10F02518F5D4C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_CAE44C5B0DB8EDECB5300F02518F123B_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_CAE44C5B0DB8EDECB5300F02518F123B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Contractual Term</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_CAE44C5B0DB8EDECB5300F02518F123B_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_CAE44C5B0DB8EDECB5300F02518F123B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_CAE44C5B0DB8EDECB5300F02518F123B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_CAE44C5B0DB8EDECB5300F02518F123B" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_CAE44C5B0DB8EDECB5300F02518F123B" xlink:type="arc" />
    <link:label id="lab_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermExercisable_4457B1367B7773875B180F025190A5E7_terseLabel_en-US" xlink:label="lab_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermExercisable_4457B1367B7773875B180F025190A5E7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable</link:label>
    <link:label id="lab_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermExercisable_4457B1367B7773875B180F025190A5E7_label_en-US" xlink:label="lab_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermExercisable_4457B1367B7773875B180F025190A5E7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Exercisable</link:label>
    <link:label id="lab_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermExercisable_4457B1367B7773875B180F025190A5E7_documentation_en-US" xlink:label="lab_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermExercisable_4457B1367B7773875B180F025190A5E7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Exercisable</link:label>
    <link:loc xlink:href="eols-20190930.xsd#eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermExercisable" xlink:label="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermExercisable_4457B1367B7773875B180F025190A5E7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermExercisable_4457B1367B7773875B180F025190A5E7" xlink:to="lab_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermExercisable_4457B1367B7773875B180F025190A5E7" xlink:type="arc" />
    <link:label id="lab_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract_BD837264AA149B4B60F80F02519031BF_terseLabel_en-US" xlink:label="lab_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract_BD837264AA149B4B60F80F02519031BF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Intrinsic Value</link:label>
    <link:label id="lab_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract_BD837264AA149B4B60F80F02519031BF_label_en-US" xlink:label="lab_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract_BD837264AA149B4B60F80F02519031BF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Intrinsic Value [Abstract]</link:label>
    <link:label id="lab_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract_BD837264AA149B4B60F80F02519031BF_documentation_en-US" xlink:label="lab_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract_BD837264AA149B4B60F80F02519031BF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Intrinsic Value [Abstract]</link:label>
    <link:loc xlink:href="eols-20190930.xsd#eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:label="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract_BD837264AA149B4B60F80F02519031BF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract_BD837264AA149B4B60F80F02519031BF" xlink:to="lab_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract_BD837264AA149B4B60F80F02519031BF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_E779FE025FBD223EB4A60F025190C7F3_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_E779FE025FBD223EB4A60F025190C7F3" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_E779FE025FBD223EB4A60F025190C7F3_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_E779FE025FBD223EB4A60F025190C7F3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_E779FE025FBD223EB4A60F025190C7F3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_E779FE025FBD223EB4A60F025190C7F3" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_E779FE025FBD223EB4A60F025190C7F3" xlink:type="arc" />
    <link:label id="lab_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsGrantedinPeriodIntrinsicValue_94FFCBB0F29500110FBF0F0251906C88_terseLabel_en-US" xlink:label="lab_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsGrantedinPeriodIntrinsicValue_94FFCBB0F29500110FBF0F0251906C88" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted</link:label>
    <link:label id="lab_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsGrantedinPeriodIntrinsicValue_94FFCBB0F29500110FBF0F0251906C88_label_en-US" xlink:label="lab_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsGrantedinPeriodIntrinsicValue_94FFCBB0F29500110FBF0F0251906C88" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Granted in Period, Intrinsic Value</link:label>
    <link:label id="lab_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsGrantedinPeriodIntrinsicValue_94FFCBB0F29500110FBF0F0251906C88_documentation_en-US" xlink:label="lab_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsGrantedinPeriodIntrinsicValue_94FFCBB0F29500110FBF0F0251906C88" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Granted in Period, Intrinsic Value</link:label>
    <link:loc xlink:href="eols-20190930.xsd#eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsGrantedinPeriodIntrinsicValue" xlink:label="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsGrantedinPeriodIntrinsicValue_94FFCBB0F29500110FBF0F0251906C88" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsGrantedinPeriodIntrinsicValue_94FFCBB0F29500110FBF0F0251906C88" xlink:to="lab_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsGrantedinPeriodIntrinsicValue_94FFCBB0F29500110FBF0F0251906C88" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_12B8FC49B8B0E03DB4740F025191EC25_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_12B8FC49B8B0E03DB4740F025191EC25" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_12B8FC49B8B0E03DB4740F025191EC25_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_12B8FC49B8B0E03DB4740F025191EC25" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_12B8FC49B8B0E03DB4740F025191EC25" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_12B8FC49B8B0E03DB4740F025191EC25" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_12B8FC49B8B0E03DB4740F025191EC25" xlink:type="arc" />
    <link:label id="lab_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsForfeitedinPeriodIntrinsicValue_BB2D25C2B13A179B198F0F025191FB5B_terseLabel_en-US" xlink:label="lab_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsForfeitedinPeriodIntrinsicValue_BB2D25C2B13A179B198F0F025191FB5B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Canceled/forfeited</link:label>
    <link:label id="lab_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsForfeitedinPeriodIntrinsicValue_BB2D25C2B13A179B198F0F025191FB5B_label_en-US" xlink:label="lab_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsForfeitedinPeriodIntrinsicValue_BB2D25C2B13A179B198F0F025191FB5B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeited in Period, Intrinsic Value</link:label>
    <link:label id="lab_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsForfeitedinPeriodIntrinsicValue_BB2D25C2B13A179B198F0F025191FB5B_documentation_en-US" xlink:label="lab_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsForfeitedinPeriodIntrinsicValue_BB2D25C2B13A179B198F0F025191FB5B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeited in Period, Intrinsic Value</link:label>
    <link:loc xlink:href="eols-20190930.xsd#eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsForfeitedinPeriodIntrinsicValue" xlink:label="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsForfeitedinPeriodIntrinsicValue_BB2D25C2B13A179B198F0F025191FB5B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsForfeitedinPeriodIntrinsicValue_BB2D25C2B13A179B198F0F025191FB5B" xlink:to="lab_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsForfeitedinPeriodIntrinsicValue_BB2D25C2B13A179B198F0F025191FB5B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_0CCDC68D2D651784E0C10F0251911220_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_0CCDC68D2D651784E0C10F0251911220" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_0CCDC68D2D651784E0C10F0251911220" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_0CCDC68D2D651784E0C10F0251911220" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_0CCDC68D2D651784E0C10F0251911220" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_3AEB9B13A0F805BFCD240F0251910ECE_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_3AEB9B13A0F805BFCD240F0251910ECE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_3AEB9B13A0F805BFCD240F0251910ECE_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_3AEB9B13A0F805BFCD240F0251910ECE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_3AEB9B13A0F805BFCD240F0251910ECE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_3AEB9B13A0F805BFCD240F0251910ECE" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_3AEB9B13A0F805BFCD240F0251910ECE" xlink:type="arc" />
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_DEC2817484D01838C5561835DA5AB362_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract_DEC2817484D01838C5561835DA5AB362" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_DEC2817484D01838C5561835DA5AB362" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_DEC2817484D01838C5561835DA5AB362" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract_DEC2817484D01838C5561835DA5AB362" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_B6A9299E5F58FE0301D91835DA5A3B7D_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_B6A9299E5F58FE0301D91835DA5A3B7D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_B6A9299E5F58FE0301D91835DA5A3B7D_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_B6A9299E5F58FE0301D91835DA5A3B7D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_B6A9299E5F58FE0301D91835DA5A3B7D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_B6A9299E5F58FE0301D91835DA5A3B7D" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_B6A9299E5F58FE0301D91835DA5A3B7D" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_B8F13031E625839398690EF6E21B74C3_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract_B8F13031E625839398690EF6E21B74C3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_B8F13031E625839398690EF6E21B74C3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_B8F13031E625839398690EF6E21B74C3" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract_B8F13031E625839398690EF6E21B74C3" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsAbstract_2F458A811A44FB73EE670EF6E21BD614_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract_2F458A811A44FB73EE670EF6E21BD614" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_2F458A811A44FB73EE670EF6E21BD614_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract_2F458A811A44FB73EE670EF6E21BD614" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_2F458A811A44FB73EE670EF6E21BD614" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract_2F458A811A44FB73EE670EF6E21BD614" xlink:to="lab_us-gaap_AssetsAbstract_2F458A811A44FB73EE670EF6E21BD614" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_278C98CFCF331B6C7C450EF6E21B531C_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_278C98CFCF331B6C7C450EF6E21B531C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_278C98CFCF331B6C7C450EF6E21B531C_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_278C98CFCF331B6C7C450EF6E21B531C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_278C98CFCF331B6C7C450EF6E21B531C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract_278C98CFCF331B6C7C450EF6E21B531C" xlink:to="lab_us-gaap_AssetsCurrentAbstract_278C98CFCF331B6C7C450EF6E21B531C" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_2CD7A35344706DA74ED30EF6E21B338C_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_2CD7A35344706DA74ED30EF6E21B338C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_2CD7A35344706DA74ED30EF6E21B338C_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_2CD7A35344706DA74ED30EF6E21B338C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2CD7A35344706DA74ED30EF6E21B338C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2CD7A35344706DA74ED30EF6E21B338C" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_2CD7A35344706DA74ED30EF6E21B338C" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_D7869C8C8A381588CE000EF6E21B498C_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_D7869C8C8A381588CE000EF6E21B498C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_D7869C8C8A381588CE000EF6E21B498C_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_D7869C8C8A381588CE000EF6E21B498C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_D7869C8C8A381588CE000EF6E21B498C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_D7869C8C8A381588CE000EF6E21B498C" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_D7869C8C8A381588CE000EF6E21B498C" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_4BFC79BF13792AE223130EF6E21B1D98_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_4BFC79BF13792AE223130EF6E21B1D98" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_4BFC79BF13792AE223130EF6E21B1D98_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_4BFC79BF13792AE223130EF6E21B1D98" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_4BFC79BF13792AE223130EF6E21B1D98" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_4BFC79BF13792AE223130EF6E21B1D98" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent_4BFC79BF13792AE223130EF6E21B1D98" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryNet_1833D8D70CDCE4A652640EF6E21B2A74_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet_1833D8D70CDCE4A652640EF6E21B2A74" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_1833D8D70CDCE4A652640EF6E21B2A74_label_en-US" xlink:label="lab_us-gaap_InventoryNet_1833D8D70CDCE4A652640EF6E21B2A74" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_1833D8D70CDCE4A652640EF6E21B2A74" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet_1833D8D70CDCE4A652640EF6E21B2A74" xlink:to="lab_us-gaap_InventoryNet_1833D8D70CDCE4A652640EF6E21B2A74" xlink:type="arc" />
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_50EABAF176BBE27F13470EF6E21B2277_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_50EABAF176BBE27F13470EF6E21B2277" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_50EABAF176BBE27F13470EF6E21B2277_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_50EABAF176BBE27F13470EF6E21B2277" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_50EABAF176BBE27F13470EF6E21B2277" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_50EABAF176BBE27F13470EF6E21B2277" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_50EABAF176BBE27F13470EF6E21B2277" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrent_CF8F5603A36ACC706C400EF6E21B88E4_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent_CF8F5603A36ACC706C400EF6E21B88E4" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_CF8F5603A36ACC706C400EF6E21B88E4_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent_CF8F5603A36ACC706C400EF6E21B88E4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_CF8F5603A36ACC706C400EF6E21B88E4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent_CF8F5603A36ACC706C400EF6E21B88E4" xlink:to="lab_us-gaap_AssetsCurrent_CF8F5603A36ACC706C400EF6E21B88E4" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_516C2645603A80DF13280EF6E21B0BAF_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_516C2645603A80DF13280EF6E21B0BAF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_516C2645603A80DF13280EF6E21B0BAF_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_516C2645603A80DF13280EF6E21B0BAF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_516C2645603A80DF13280EF6E21B0BAF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_516C2645603A80DF13280EF6E21B0BAF" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_516C2645603A80DF13280EF6E21B0BAF" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_5F6AA08ED91C77C2F3960EF6E21BDA76_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset_5F6AA08ED91C77C2F3960EF6E21BDA76" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_5F6AA08ED91C77C2F3960EF6E21BDA76_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset_5F6AA08ED91C77C2F3960EF6E21BDA76" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_5F6AA08ED91C77C2F3960EF6E21BDA76" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset_5F6AA08ED91C77C2F3960EF6E21BDA76" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset_5F6AA08ED91C77C2F3960EF6E21BDA76" xlink:type="arc" />
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_C6BBFCAD021B9EC1D0E90EF6E21BC28C_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_C6BBFCAD021B9EC1D0E90EF6E21BC28C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets, net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_C6BBFCAD021B9EC1D0E90EF6E21BC28C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_C6BBFCAD021B9EC1D0E90EF6E21BC28C" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_C6BBFCAD021B9EC1D0E90EF6E21BC28C" xlink:type="arc" />
    <link:label id="lab_us-gaap_Goodwill_B559EB2EF8841E1105210EF6E21BBBE4_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill_B559EB2EF8841E1105210EF6E21BBBE4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_B559EB2EF8841E1105210EF6E21BBBE4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill_B559EB2EF8841E1105210EF6E21BBBE4" xlink:to="lab_us-gaap_Goodwill_B559EB2EF8841E1105210EF6E21BBBE4" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_A1679CB1109C8E9BAF8D0EF6E21B4406_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_A1679CB1109C8E9BAF8D0EF6E21B4406" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_A1679CB1109C8E9BAF8D0EF6E21B4406_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_A1679CB1109C8E9BAF8D0EF6E21B4406" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_A1679CB1109C8E9BAF8D0EF6E21B4406" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_A1679CB1109C8E9BAF8D0EF6E21B4406" xlink:to="lab_us-gaap_OtherAssetsNoncurrent_A1679CB1109C8E9BAF8D0EF6E21B4406" xlink:type="arc" />
    <link:label id="lab_us-gaap_Assets_49276E681F476394FC340EF6E21BF3EB_totalLabel_en-US" xlink:label="lab_us-gaap_Assets_49276E681F476394FC340EF6E21BF3EB" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_49276E681F476394FC340EF6E21BF3EB_label_en-US" xlink:label="lab_us-gaap_Assets_49276E681F476394FC340EF6E21BF3EB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_49276E681F476394FC340EF6E21BF3EB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_49276E681F476394FC340EF6E21BF3EB" xlink:to="lab_us-gaap_Assets_49276E681F476394FC340EF6E21BF3EB" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_589FA61E08D0C276B07D0EF6E21B1560_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_589FA61E08D0C276B07D0EF6E21B1560" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_589FA61E08D0C276B07D0EF6E21B1560_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_589FA61E08D0C276B07D0EF6E21B1560" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_589FA61E08D0C276B07D0EF6E21B1560" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_589FA61E08D0C276B07D0EF6E21B1560" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_589FA61E08D0C276B07D0EF6E21B1560" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_26084C3ED497004483E10EF6E21BE26F_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_26084C3ED497004483E10EF6E21BE26F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_26084C3ED497004483E10EF6E21BE26F_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_26084C3ED497004483E10EF6E21BE26F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_26084C3ED497004483E10EF6E21BE26F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_26084C3ED497004483E10EF6E21BE26F" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract_26084C3ED497004483E10EF6E21BE26F" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsPayableCurrent_334DFD8DC5C3062AB4D10EF6E21B1663_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_334DFD8DC5C3062AB4D10EF6E21B1663" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_334DFD8DC5C3062AB4D10EF6E21B1663_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_334DFD8DC5C3062AB4D10EF6E21B1663" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_334DFD8DC5C3062AB4D10EF6E21B1663" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent_334DFD8DC5C3062AB4D10EF6E21B1663" xlink:to="lab_us-gaap_AccountsPayableCurrent_334DFD8DC5C3062AB4D10EF6E21B1663" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_C79317B9E64C8C62EAED0EF6E21BD8EC_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_C79317B9E64C8C62EAED0EF6E21BD8EC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_C79317B9E64C8C62EAED0EF6E21BD8EC_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_C79317B9E64C8C62EAED0EF6E21BD8EC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_C79317B9E64C8C62EAED0EF6E21BD8EC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_C79317B9E64C8C62EAED0EF6E21BD8EC" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent_C79317B9E64C8C62EAED0EF6E21BD8EC" xlink:type="arc" />
    <link:label id="lab_eols_ContingentRoyaltyObligationPayabletoRelatedPartyCurrent_E58F10EC8C711CFE0CD70EF6E21B6A08_terseLabel_en-US" xlink:label="lab_eols_ContingentRoyaltyObligationPayabletoRelatedPartyCurrent_E58F10EC8C711CFE0CD70EF6E21B6A08" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent royalty obligation payable to Evolus Founders</link:label>
    <link:label id="lab_eols_ContingentRoyaltyObligationPayabletoRelatedPartyCurrent_E58F10EC8C711CFE0CD70EF6E21B6A08_label_en-US" xlink:label="lab_eols_ContingentRoyaltyObligationPayabletoRelatedPartyCurrent_E58F10EC8C711CFE0CD70EF6E21B6A08" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Royalty Obligation Payable to Related Party, Current</link:label>
    <link:label id="lab_eols_ContingentRoyaltyObligationPayabletoRelatedPartyCurrent_E58F10EC8C711CFE0CD70EF6E21B6A08_documentation_en-US" xlink:label="lab_eols_ContingentRoyaltyObligationPayabletoRelatedPartyCurrent_E58F10EC8C711CFE0CD70EF6E21B6A08" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contingent Royalty Obligation Payable to Related Party, Current</link:label>
    <link:loc xlink:href="eols-20190930.xsd#eols_ContingentRoyaltyObligationPayabletoRelatedPartyCurrent" xlink:label="loc_eols_ContingentRoyaltyObligationPayabletoRelatedPartyCurrent_E58F10EC8C711CFE0CD70EF6E21B6A08" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_ContingentRoyaltyObligationPayabletoRelatedPartyCurrent_E58F10EC8C711CFE0CD70EF6E21B6A08" xlink:to="lab_eols_ContingentRoyaltyObligationPayabletoRelatedPartyCurrent_E58F10EC8C711CFE0CD70EF6E21B6A08" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_73A01B71DFCC4FA614F40EF6E21B50ED_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent_73A01B71DFCC4FA614F40EF6E21B50ED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_73A01B71DFCC4FA614F40EF6E21B50ED_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent_73A01B71DFCC4FA614F40EF6E21B50ED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_73A01B71DFCC4FA614F40EF6E21B50ED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent_73A01B71DFCC4FA614F40EF6E21B50ED" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent_73A01B71DFCC4FA614F40EF6E21B50ED" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrent_A098A96CE3AA4437A4E30EF6E21B4612_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_A098A96CE3AA4437A4E30EF6E21B4612" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_A098A96CE3AA4437A4E30EF6E21B4612_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_A098A96CE3AA4437A4E30EF6E21B4612" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_A098A96CE3AA4437A4E30EF6E21B4612" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent_A098A96CE3AA4437A4E30EF6E21B4612" xlink:to="lab_us-gaap_LiabilitiesCurrent_A098A96CE3AA4437A4E30EF6E21B4612" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_F23CFC40F34CD4CF6AC80EF6E21BBD11_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_F23CFC40F34CD4CF6AC80EF6E21BBD11" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_F23CFC40F34CD4CF6AC80EF6E21BBD11_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_F23CFC40F34CD4CF6AC80EF6E21BBD11" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_F23CFC40F34CD4CF6AC80EF6E21BBD11" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_F23CFC40F34CD4CF6AC80EF6E21BBD11" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_F23CFC40F34CD4CF6AC80EF6E21BBD11" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredRentCreditNoncurrent_A16F1CB1390002DAD6D80EFE5E0D80D3_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRentCreditNoncurrent_A16F1CB1390002DAD6D80EFE5E0D80D3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred rent</link:label>
    <link:label id="lab_us-gaap_DeferredRentCreditNoncurrent_A16F1CB1390002DAD6D80EFE5E0D80D3_label_en-US" xlink:label="lab_us-gaap_DeferredRentCreditNoncurrent_A16F1CB1390002DAD6D80EFE5E0D80D3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Rent Credit, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="loc_us-gaap_DeferredRentCreditNoncurrent_A16F1CB1390002DAD6D80EFE5E0D80D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRentCreditNoncurrent_A16F1CB1390002DAD6D80EFE5E0D80D3" xlink:to="lab_us-gaap_DeferredRentCreditNoncurrent_A16F1CB1390002DAD6D80EFE5E0D80D3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractualObligation_C3D8FC9B8D3BD0F895500EF6E21BE83B_terseLabel_en-US" xlink:label="lab_us-gaap_ContractualObligation_C3D8FC9B8D3BD0F895500EF6E21BE83B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent royalty obligation payable to Evolus Founders</link:label>
    <link:label id="lab_us-gaap_ContractualObligation_C3D8FC9B8D3BD0F895500EF6E21BE83B_label_en-US" xlink:label="lab_us-gaap_ContractualObligation_C3D8FC9B8D3BD0F895500EF6E21BE83B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contractual Obligation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractualObligation" xlink:label="loc_us-gaap_ContractualObligation_C3D8FC9B8D3BD0F895500EF6E21BE83B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractualObligation_C3D8FC9B8D3BD0F895500EF6E21BE83B" xlink:to="lab_us-gaap_ContractualObligation_C3D8FC9B8D3BD0F895500EF6E21BE83B" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermNotesPayable_0B1885296A39FABD51240EF6E21B2DEA_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermNotesPayable_0B1885296A39FABD51240EF6E21B2DEA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent promissory note payable to Evolus Founders</link:label>
    <link:label id="lab_us-gaap_LongTermNotesPayable_0B1885296A39FABD51240EF6E21B2DEA_label_en-US" xlink:label="lab_us-gaap_LongTermNotesPayable_0B1885296A39FABD51240EF6E21B2DEA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes Payable, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaap_LongTermNotesPayable_0B1885296A39FABD51240EF6E21B2DEA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermNotesPayable_0B1885296A39FABD51240EF6E21B2DEA" xlink:to="lab_us-gaap_LongTermNotesPayable_0B1885296A39FABD51240EF6E21B2DEA" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_83115134960350A15AF00EF6E21BF584_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent_83115134960350A15AF00EF6E21BF584" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term debt, net of discounts and issuance costs</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_83115134960350A15AF00EF6E21BF584_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent_83115134960350A15AF00EF6E21BF584" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_83115134960350A15AF00EF6E21BF584" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent_83115134960350A15AF00EF6E21BF584" xlink:to="lab_us-gaap_LongTermDebtNoncurrent_83115134960350A15AF00EF6E21BF584" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_AA2B3B44365FAE8F0E5B0EF6E21B1612_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_AA2B3B44365FAE8F0E5B0EF6E21B1612" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liability</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_AA2B3B44365FAE8F0E5B0EF6E21B1612_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_AA2B3B44365FAE8F0E5B0EF6E21B1612" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_AA2B3B44365FAE8F0E5B0EF6E21B1612" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_AA2B3B44365FAE8F0E5B0EF6E21B1612" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_AA2B3B44365FAE8F0E5B0EF6E21B1612" xlink:type="arc" />
    <link:label id="lab_us-gaap_Liabilities_1654196692E5FD6A4EB30EF6E21B4992_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities_1654196692E5FD6A4EB30EF6E21B4992" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_1654196692E5FD6A4EB30EF6E21B4992_label_en-US" xlink:label="lab_us-gaap_Liabilities_1654196692E5FD6A4EB30EF6E21B4992" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_1654196692E5FD6A4EB30EF6E21B4992" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities_1654196692E5FD6A4EB30EF6E21B4992" xlink:to="lab_us-gaap_Liabilities_1654196692E5FD6A4EB30EF6E21B4992" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_4A032372AE4D426E185E0EF6E21B0F6B_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_4A032372AE4D426E185E0EF6E21B0F6B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and contingencies (Note 8)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_4A032372AE4D426E185E0EF6E21B0F6B_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_4A032372AE4D426E185E0EF6E21B0F6B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_4A032372AE4D426E185E0EF6E21B0F6B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies_4A032372AE4D426E185E0EF6E21B0F6B" xlink:to="lab_us-gaap_CommitmentsAndContingencies_4A032372AE4D426E185E0EF6E21B0F6B" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_8FEE722206AC9FF88ABC0EF6E21B696F_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_8FEE722206AC9FF88ABC0EF6E21B696F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_8FEE722206AC9FF88ABC0EF6E21B696F_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_8FEE722206AC9FF88ABC0EF6E21B696F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_8FEE722206AC9FF88ABC0EF6E21B696F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract_8FEE722206AC9FF88ABC0EF6E21B696F" xlink:to="lab_us-gaap_StockholdersEquityAbstract_8FEE722206AC9FF88ABC0EF6E21B696F" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockValue_82C0DC3416A462D6D43B0EF6E21B6004_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue_82C0DC3416A462D6D43B0EF6E21B6004" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, $0.00001 par value; 10,000,000 shares authorized; no shares issued and outstanding at September 30, 2019 and December 31, 2018, respectively</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_82C0DC3416A462D6D43B0EF6E21B6004_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue_82C0DC3416A462D6D43B0EF6E21B6004" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_82C0DC3416A462D6D43B0EF6E21B6004" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue_82C0DC3416A462D6D43B0EF6E21B6004" xlink:to="lab_us-gaap_PreferredStockValue_82C0DC3416A462D6D43B0EF6E21B6004" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockValue_7F660A100D52443421AD0EF6E225B212_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue_7F660A100D52443421AD0EF6E225B212" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, $0.00001 par value; 100,000,000 shares authorized; 27,425,230 and 27,274,991 shares issued and outstanding at September 30, 2019 and December 31, 2018, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_7F660A100D52443421AD0EF6E225B212_label_en-US" xlink:label="lab_us-gaap_CommonStockValue_7F660A100D52443421AD0EF6E225B212" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_7F660A100D52443421AD0EF6E225B212" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue_7F660A100D52443421AD0EF6E225B212" xlink:to="lab_us-gaap_CommonStockValue_7F660A100D52443421AD0EF6E225B212" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_BD04AA2D1F3DD24AE3360EF6E225186F_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital_BD04AA2D1F3DD24AE3360EF6E225186F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_BD04AA2D1F3DD24AE3360EF6E225186F_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital_BD04AA2D1F3DD24AE3360EF6E225186F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_BD04AA2D1F3DD24AE3360EF6E225186F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital_BD04AA2D1F3DD24AE3360EF6E225186F" xlink:to="lab_us-gaap_AdditionalPaidInCapital_BD04AA2D1F3DD24AE3360EF6E225186F" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_6A220BA3538552EC54C20EF6E225032F_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_6A220BA3538552EC54C20EF6E225032F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive gain</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_6A220BA3538552EC54C20EF6E225032F_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_6A220BA3538552EC54C20EF6E225032F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_6A220BA3538552EC54C20EF6E225032F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_6A220BA3538552EC54C20EF6E225032F" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_6A220BA3538552EC54C20EF6E225032F" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_1F0C09A6842E632F9AC80EF6E225F41F_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_1F0C09A6842E632F9AC80EF6E225F41F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_1F0C09A6842E632F9AC80EF6E225F41F_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_1F0C09A6842E632F9AC80EF6E225F41F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_1F0C09A6842E632F9AC80EF6E225F41F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_1F0C09A6842E632F9AC80EF6E225F41F" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_1F0C09A6842E632F9AC80EF6E225F41F" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_D186A1A8C7FC0655D8410EF6E225DD74_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_D186A1A8C7FC0655D8410EF6E225DD74" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_D186A1A8C7FC0655D8410EF6E225DD74" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_D186A1A8C7FC0655D8410EF6E225DD74" xlink:to="lab_us-gaap_StockholdersEquity_D186A1A8C7FC0655D8410EF6E225DD74" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_CF10D0AF24A8AB7091180EF6E2253B54_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_CF10D0AF24A8AB7091180EF6E2253B54" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_CF10D0AF24A8AB7091180EF6E2253B54_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_CF10D0AF24A8AB7091180EF6E2253B54" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_CF10D0AF24A8AB7091180EF6E2253B54" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_CF10D0AF24A8AB7091180EF6E2253B54" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity_CF10D0AF24A8AB7091180EF6E2253B54" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_D208B93E08CA60E4AF4E45374F528357_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_D208B93E08CA60E4AF4E45374F528357" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_D208B93E08CA60E4AF4E45374F528357_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_D208B93E08CA60E4AF4E45374F528357" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_D208B93E08CA60E4AF4E45374F528357" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_D208B93E08CA60E4AF4E45374F528357" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_D208B93E08CA60E4AF4E45374F528357" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_6267B2AABB2ECD062C691835DA583F98_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_6267B2AABB2ECD062C691835DA583F98" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Accounts Payable and Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_6267B2AABB2ECD062C691835DA583F98_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_6267B2AABB2ECD062C691835DA583F98" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_6267B2AABB2ECD062C691835DA583F98" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_6267B2AABB2ECD062C691835DA583F98" xlink:to="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_6267B2AABB2ECD062C691835DA583F98" xlink:type="arc" />
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4FE31DB613082886E3501835DA9DDFD6_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4FE31DB613082886E3501835DA9DDFD6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4FE31DB613082886E3501835DA9DDFD6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4FE31DB613082886E3501835DA9DDFD6" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4FE31DB613082886E3501835DA9DDFD6" xlink:type="arc" />
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_7C41BB4611FC737B70041835DA9D6D5A_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_7C41BB4611FC737B70041835DA9D6D5A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Description of Business and Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_7C41BB4611FC737B70041835DA9D6D5A_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_7C41BB4611FC737B70041835DA9D6D5A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_7C41BB4611FC737B70041835DA9D6D5A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_7C41BB4611FC737B70041835DA9D6D5A" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_7C41BB4611FC737B70041835DA9D6D5A" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementAbstract_206ED27E48806F0E7EB0FEEBF09F9220_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract_206ED27E48806F0E7EB0FEEBF09F9220" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_206ED27E48806F0E7EB0FEEBF09F9220" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract_206ED27E48806F0E7EB0FEEBF09F9220" xlink:to="lab_us-gaap_IncomeStatementAbstract_206ED27E48806F0E7EB0FEEBF09F9220" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2684A2F5FB1E60A25EB6FEEBF09F3DF2_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2684A2F5FB1E60A25EB6FEEBF09F3DF2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2684A2F5FB1E60A25EB6FEEBF09F3DF2_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2684A2F5FB1E60A25EB6FEEBF09F3DF2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2684A2F5FB1E60A25EB6FEEBF09F3DF2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2684A2F5FB1E60A25EB6FEEBF09F3DF2" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2684A2F5FB1E60A25EB6FEEBF09F3DF2" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_AE6E0E6CF0C6A68DFEEFFEEBF09F2AC0_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold_AE6E0E6CF0C6A68DFEEFFEEBF09F2AC0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of sales (excludes amortization of intangible assets)</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_AE6E0E6CF0C6A68DFEEFFEEBF09F2AC0_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold_AE6E0E6CF0C6A68DFEEFFEEBF09F2AC0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_AE6E0E6CF0C6A68DFEEFFEEBF09F2AC0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold_AE6E0E6CF0C6A68DFEEFFEEBF09F2AC0" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold_AE6E0E6CF0C6A68DFEEFFEEBF09F2AC0" xlink:type="arc" />
    <link:label id="lab_us-gaap_GrossProfit_A33E1EF8C0F16BE59AF4FEEBF0A0A02E_totalLabel_en-US" xlink:label="lab_us-gaap_GrossProfit_A33E1EF8C0F16BE59AF4FEEBF0A0A02E" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Gross profit</link:label>
    <link:label id="lab_us-gaap_GrossProfit_A33E1EF8C0F16BE59AF4FEEBF0A0A02E_label_en-US" xlink:label="lab_us-gaap_GrossProfit_A33E1EF8C0F16BE59AF4FEEBF0A0A02E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross Profit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit_A33E1EF8C0F16BE59AF4FEEBF0A0A02E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit_A33E1EF8C0F16BE59AF4FEEBF0A0A02E" xlink:to="lab_us-gaap_GrossProfit_A33E1EF8C0F16BE59AF4FEEBF0A0A02E" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_CF91A6772775E1C399A5FEEBF0A09EFA_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract_CF91A6772775E1C399A5FEEBF0A09EFA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_CF91A6772775E1C399A5FEEBF0A09EFA_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract_CF91A6772775E1C399A5FEEBF0A09EFA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_CF91A6772775E1C399A5FEEBF0A09EFA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract_CF91A6772775E1C399A5FEEBF0A09EFA" xlink:to="lab_us-gaap_OperatingExpensesAbstract_CF91A6772775E1C399A5FEEBF0A09EFA" xlink:type="arc" />
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_E9C8089DBF3719304875FEEBF0A04B36_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense_E9C8089DBF3719304875FEEBF0A04B36" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_E9C8089DBF3719304875FEEBF0A04B36_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense_E9C8089DBF3719304875FEEBF0A04B36" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_E9C8089DBF3719304875FEEBF0A04B36" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense_E9C8089DBF3719304875FEEBF0A04B36" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense_E9C8089DBF3719304875FEEBF0A04B36" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_8185D39D78D448F72474FEEBF0A0F0BC_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_8185D39D78D448F72474FEEBF0A0F0BC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_8185D39D78D448F72474FEEBF0A0F0BC_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_8185D39D78D448F72474FEEBF0A0F0BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_8185D39D78D448F72474FEEBF0A0F0BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_8185D39D78D448F72474FEEBF0A0F0BC" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense_8185D39D78D448F72474FEEBF0A0F0BC" xlink:type="arc" />
    <link:label id="lab_eols_RevaluationofContingentRoyaltyObligationPayable_2FB5C2AA7A4D0D6E7880FEEBF0A0591C_terseLabel_en-US" xlink:label="lab_eols_RevaluationofContingentRoyaltyObligationPayable_2FB5C2AA7A4D0D6E7880FEEBF0A0591C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revaluation of contingent royalty obligation payable to Evolus Founders</link:label>
    <link:label id="lab_eols_RevaluationofContingentRoyaltyObligationPayable_2FB5C2AA7A4D0D6E7880FEEBF0A0591C_label_en-US" xlink:label="lab_eols_RevaluationofContingentRoyaltyObligationPayable_2FB5C2AA7A4D0D6E7880FEEBF0A0591C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revaluation of Contingent Royalty Obligation Payable</link:label>
    <link:label id="lab_eols_RevaluationofContingentRoyaltyObligationPayable_2FB5C2AA7A4D0D6E7880FEEBF0A0591C_documentation_en-US" xlink:label="lab_eols_RevaluationofContingentRoyaltyObligationPayable_2FB5C2AA7A4D0D6E7880FEEBF0A0591C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revaluation of Contingent Royalty Obligation Payable</link:label>
    <link:loc xlink:href="eols-20190930.xsd#eols_RevaluationofContingentRoyaltyObligationPayable" xlink:label="loc_eols_RevaluationofContingentRoyaltyObligationPayable_2FB5C2AA7A4D0D6E7880FEEBF0A0591C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_RevaluationofContingentRoyaltyObligationPayable_2FB5C2AA7A4D0D6E7880FEEBF0A0591C" xlink:to="lab_eols_RevaluationofContingentRoyaltyObligationPayable_2FB5C2AA7A4D0D6E7880FEEBF0A0591C" xlink:type="arc" />
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_2D55A73320FF79917C0CFF13749C42E8_verboseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization_2D55A73320FF79917C0CFF13749C42E8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_2D55A73320FF79917C0CFF13749C42E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization_2D55A73320FF79917C0CFF13749C42E8" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization_2D55A73320FF79917C0CFF13749C42E8" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingExpenses_D34A97FE471E0ADFB1CEFEEBF0A16ED3_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses_D34A97FE471E0ADFB1CEFEEBF0A16ED3" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_D34A97FE471E0ADFB1CEFEEBF0A16ED3_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses_D34A97FE471E0ADFB1CEFEEBF0A16ED3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_D34A97FE471E0ADFB1CEFEEBF0A16ED3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses_D34A97FE471E0ADFB1CEFEEBF0A16ED3" xlink:to="lab_us-gaap_OperatingExpenses_D34A97FE471E0ADFB1CEFEEBF0A16ED3" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingIncomeLoss_D8E93FCA3DB87A605C4FFEEBF0A1CA29_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_D8E93FCA3DB87A605C4FFEEBF0A1CA29" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_D8E93FCA3DB87A605C4FFEEBF0A1CA29_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_D8E93FCA3DB87A605C4FFEEBF0A1CA29" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_D8E93FCA3DB87A605C4FFEEBF0A1CA29" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_D8E93FCA3DB87A605C4FFEEBF0A1CA29" xlink:to="lab_us-gaap_OperatingIncomeLoss_D8E93FCA3DB87A605C4FFEEBF0A1CA29" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentIncomeNet_080E9CE7A9B0DF2207A5FEEBF0A13A0E_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNet_080E9CE7A9B0DF2207A5FEEBF0A13A0E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeNet_080E9CE7A9B0DF2207A5FEEBF0A13A0E_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNet_080E9CE7A9B0DF2207A5FEEBF0A13A0E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Income, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeNet" xlink:label="loc_us-gaap_InvestmentIncomeNet_080E9CE7A9B0DF2207A5FEEBF0A13A0E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeNet_080E9CE7A9B0DF2207A5FEEBF0A13A0E" xlink:to="lab_us-gaap_InvestmentIncomeNet_080E9CE7A9B0DF2207A5FEEBF0A13A0E" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract_4F2A2088BB90C5D63E9BFEEBF0A1E2B8_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract_4F2A2088BB90C5D63E9BFEEBF0A1E2B8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense):</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract_4F2A2088BB90C5D63E9BFEEBF0A1E2B8_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract_4F2A2088BB90C5D63E9BFEEBF0A1E2B8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_4F2A2088BB90C5D63E9BFEEBF0A1E2B8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_4F2A2088BB90C5D63E9BFEEBF0A1E2B8" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract_4F2A2088BB90C5D63E9BFEEBF0A1E2B8" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_D51EB7F2D718A232E156FEEBF0A121F1_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_D51EB7F2D718A232E156FEEBF0A121F1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_D51EB7F2D718A232E156FEEBF0A121F1_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_D51EB7F2D718A232E156FEEBF0A121F1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_D51EB7F2D718A232E156FEEBF0A121F1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_D51EB7F2D718A232E156FEEBF0A121F1" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense_D51EB7F2D718A232E156FEEBF0A121F1" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_B041A523EF00815C9D31FEEBF0A2D335_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_B041A523EF00815C9D31FEEBF0A2D335" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss before income taxes:</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_B041A523EF00815C9D31FEEBF0A2D335_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_B041A523EF00815C9D31FEEBF0A2D335" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_B041A523EF00815C9D31FEEBF0A2D335" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_B041A523EF00815C9D31FEEBF0A2D335" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_B041A523EF00815C9D31FEEBF0A2D335" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_5797393046A1E60647FDFEEBF0A2EBBD_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_5797393046A1E60647FDFEEBF0A2EBBD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax (benefit) expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_5797393046A1E60647FDFEEBF0A2EBBD_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_5797393046A1E60647FDFEEBF0A2EBBD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_5797393046A1E60647FDFEEBF0A2EBBD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_5797393046A1E60647FDFEEBF0A2EBBD" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_5797393046A1E60647FDFEEBF0A2EBBD" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_6B60A6F4582739C18692FEEBF0A278C4_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_6B60A6F4582739C18692FEEBF0A278C4" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_6B60A6F4582739C18692FEEBF0A278C4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_6B60A6F4582739C18692FEEBF0A278C4" xlink:to="lab_us-gaap_NetIncomeLoss_6B60A6F4582739C18692FEEBF0A278C4" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_EBE9E7F4D591F120CABCFEEBF0A27988_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_EBE9E7F4D591F120CABCFEEBF0A27988" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive (loss) gain:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_EBE9E7F4D591F120CABCFEEBF0A27988_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_EBE9E7F4D591F120CABCFEEBF0A27988" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_EBE9E7F4D591F120CABCFEEBF0A27988" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_EBE9E7F4D591F120CABCFEEBF0A27988" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_EBE9E7F4D591F120CABCFEEBF0A27988" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_9C4F2768A3DAD1D3C079FEEBF0A2F7BE_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_9C4F2768A3DAD1D3C079FEEBF0A2F7BE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized (loss) gain on available-for-sale securities, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_9C4F2768A3DAD1D3C079FEEBF0A2F7BE_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_9C4F2768A3DAD1D3C079FEEBF0A2F7BE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, after Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_9C4F2768A3DAD1D3C079FEEBF0A2F7BE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_9C4F2768A3DAD1D3C079FEEBF0A2F7BE" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_9C4F2768A3DAD1D3C079FEEBF0A2F7BE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_ADE6BF095483887FE50AFEEBF0A22E07_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_ADE6BF095483887FE50AFEEBF0A22E07" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_ADE6BF095483887FE50AFEEBF0A22E07" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_ADE6BF095483887FE50AFEEBF0A22E07" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax_ADE6BF095483887FE50AFEEBF0A22E07" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_A195BDA2D7C78C705592FEEBF0A3F7C3_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted_A195BDA2D7C78C705592FEEBF0A3F7C3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share, basic and diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_A195BDA2D7C78C705592FEEBF0A3F7C3_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted_A195BDA2D7C78C705592FEEBF0A3F7C3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic and Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_A195BDA2D7C78C705592FEEBF0A3F7C3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted_A195BDA2D7C78C705592FEEBF0A3F7C3" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted_A195BDA2D7C78C705592FEEBF0A3F7C3" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_65AA1E431AB8D5015EE1FEEBF0A32754_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_65AA1E431AB8D5015EE1FEEBF0A32754" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average shares outstanding used to compute basic and diluted net loss per share (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_65AA1E431AB8D5015EE1FEEBF0A32754_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_65AA1E431AB8D5015EE1FEEBF0A32754" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_65AA1E431AB8D5015EE1FEEBF0A32754" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_65AA1E431AB8D5015EE1FEEBF0A32754" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_65AA1E431AB8D5015EE1FEEBF0A32754" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingenciesTable_1E48E21CE8AEE3626CAF0F0251C4915E_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable_1E48E21CE8AEE3626CAF0F0251C4915E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_1E48E21CE8AEE3626CAF0F0251C4915E_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable_1E48E21CE8AEE3626CAF0F0251C4915E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaap_LossContingenciesTable_1E48E21CE8AEE3626CAF0F0251C4915E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable_1E48E21CE8AEE3626CAF0F0251C4915E" xlink:to="lab_us-gaap_LossContingenciesTable_1E48E21CE8AEE3626CAF0F0251C4915E" xlink:type="arc" />
    <link:label id="lab_dei_LegalEntityAxis_670F070667BCF2CCD5FE0F0251C4D29D_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis_670F070667BCF2CCD5FE0F0251C4D29D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_670F070667BCF2CCD5FE0F0251C4D29D_label_en-US" xlink:label="lab_dei_LegalEntityAxis_670F070667BCF2CCD5FE0F0251C4D29D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_670F070667BCF2CCD5FE0F0251C4D29D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis_670F070667BCF2CCD5FE0F0251C4D29D" xlink:to="lab_dei_LegalEntityAxis_670F070667BCF2CCD5FE0F0251C4D29D" xlink:type="arc" />
    <link:label id="lab_dei_EntityDomain_931F9D87EF9E56660C860F0251C5F5D9_terseLabel_en-US" xlink:label="lab_dei_EntityDomain_931F9D87EF9E56660C860F0251C5F5D9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_931F9D87EF9E56660C860F0251C5F5D9_label_en-US" xlink:label="lab_dei_EntityDomain_931F9D87EF9E56660C860F0251C5F5D9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_931F9D87EF9E56660C860F0251C5F5D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain_931F9D87EF9E56660C860F0251C5F5D9" xlink:to="lab_dei_EntityDomain_931F9D87EF9E56660C860F0251C5F5D9" xlink:type="arc" />
    <link:label id="lab_eols_DaewoongMember_05578B193FEBABCE4A580F0251C51666_terseLabel_en-US" xlink:label="lab_eols_DaewoongMember_05578B193FEBABCE4A580F0251C51666" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Daewoong</link:label>
    <link:label id="lab_eols_DaewoongMember_05578B193FEBABCE4A580F0251C51666_label_en-US" xlink:label="lab_eols_DaewoongMember_05578B193FEBABCE4A580F0251C51666" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Daewoong [Member]</link:label>
    <link:label id="lab_eols_DaewoongMember_05578B193FEBABCE4A580F0251C51666_documentation_en-US" xlink:label="lab_eols_DaewoongMember_05578B193FEBABCE4A580F0251C51666" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Daewoong [Member]</link:label>
    <link:loc xlink:href="eols-20190930.xsd#eols_DaewoongMember" xlink:label="loc_eols_DaewoongMember_05578B193FEBABCE4A580F0251C51666" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_DaewoongMember_05578B193FEBABCE4A580F0251C51666" xlink:to="lab_eols_DaewoongMember_05578B193FEBABCE4A580F0251C51666" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingenciesLineItems_464E35EBE56D7DBE11D50F0251C5B8FF_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems_464E35EBE56D7DBE11D50F0251C5B8FF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_464E35EBE56D7DBE11D50F0251C5B8FF_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems_464E35EBE56D7DBE11D50F0251C5B8FF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaap_LossContingenciesLineItems_464E35EBE56D7DBE11D50F0251C5B8FF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems_464E35EBE56D7DBE11D50F0251C5B8FF" xlink:to="lab_us-gaap_LossContingenciesLineItems_464E35EBE56D7DBE11D50F0251C5B8FF" xlink:type="arc" />
    <link:label id="lab_eols_LesseeOperatingLeaseTerminationPeriod_98A9FDDAD479CF2D24CD0F0251C68591_terseLabel_en-US" xlink:label="lab_eols_LesseeOperatingLeaseTerminationPeriod_98A9FDDAD479CF2D24CD0F0251C68591" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Termination period</link:label>
    <link:label id="lab_eols_LesseeOperatingLeaseTerminationPeriod_98A9FDDAD479CF2D24CD0F0251C68591_label_en-US" xlink:label="lab_eols_LesseeOperatingLeaseTerminationPeriod_98A9FDDAD479CF2D24CD0F0251C68591" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Termination Period</link:label>
    <link:label id="lab_eols_LesseeOperatingLeaseTerminationPeriod_98A9FDDAD479CF2D24CD0F0251C68591_documentation_en-US" xlink:label="lab_eols_LesseeOperatingLeaseTerminationPeriod_98A9FDDAD479CF2D24CD0F0251C68591" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Termination Period</link:label>
    <link:loc xlink:href="eols-20190930.xsd#eols_LesseeOperatingLeaseTerminationPeriod" xlink:label="loc_eols_LesseeOperatingLeaseTerminationPeriod_98A9FDDAD479CF2D24CD0F0251C68591" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_LesseeOperatingLeaseTerminationPeriod_98A9FDDAD479CF2D24CD0F0251C68591" xlink:to="lab_eols_LesseeOperatingLeaseTerminationPeriod_98A9FDDAD479CF2D24CD0F0251C68591" xlink:type="arc" />
    <link:label id="lab_eols_LesseeOperatingLeasePeriodOfWrittenNoticePriorToLeaseTerminateDate_0DADB223E557869B42D60F0251C667A5_terseLabel_en-US" xlink:label="lab_eols_LesseeOperatingLeasePeriodOfWrittenNoticePriorToLeaseTerminateDate_0DADB223E557869B42D60F0251C667A5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Period of written notice</link:label>
    <link:label id="lab_eols_LesseeOperatingLeasePeriodOfWrittenNoticePriorToLeaseTerminateDate_0DADB223E557869B42D60F0251C667A5_label_en-US" xlink:label="lab_eols_LesseeOperatingLeasePeriodOfWrittenNoticePriorToLeaseTerminateDate_0DADB223E557869B42D60F0251C667A5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Period Of Written Notice Prior To Lease Terminate Date</link:label>
    <link:label id="lab_eols_LesseeOperatingLeasePeriodOfWrittenNoticePriorToLeaseTerminateDate_0DADB223E557869B42D60F0251C667A5_documentation_en-US" xlink:label="lab_eols_LesseeOperatingLeasePeriodOfWrittenNoticePriorToLeaseTerminateDate_0DADB223E557869B42D60F0251C667A5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Period Of Written Notice Prior To Lease Terminate Date</link:label>
    <link:loc xlink:href="eols-20190930.xsd#eols_LesseeOperatingLeasePeriodOfWrittenNoticePriorToLeaseTerminateDate" xlink:label="loc_eols_LesseeOperatingLeasePeriodOfWrittenNoticePriorToLeaseTerminateDate_0DADB223E557869B42D60F0251C667A5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_LesseeOperatingLeasePeriodOfWrittenNoticePriorToLeaseTerminateDate_0DADB223E557869B42D60F0251C667A5" xlink:to="lab_eols_LesseeOperatingLeasePeriodOfWrittenNoticePriorToLeaseTerminateDate_0DADB223E557869B42D60F0251C667A5" xlink:type="arc" />
    <link:label id="lab_eols_LesseeOperatingLeaseTerminationFeePeriodOfRentEquivalent_D38BD5C3F979DF2D2BF90F0251C69BAC_terseLabel_en-US" xlink:label="lab_eols_LesseeOperatingLeaseTerminationFeePeriodOfRentEquivalent_D38BD5C3F979DF2D2BF90F0251C69BAC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Period of termination fee prior to lease termination date</link:label>
    <link:label id="lab_eols_LesseeOperatingLeaseTerminationFeePeriodOfRentEquivalent_D38BD5C3F979DF2D2BF90F0251C69BAC_label_en-US" xlink:label="lab_eols_LesseeOperatingLeaseTerminationFeePeriodOfRentEquivalent_D38BD5C3F979DF2D2BF90F0251C69BAC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Termination Fee, Period Of Rent Equivalent</link:label>
    <link:label id="lab_eols_LesseeOperatingLeaseTerminationFeePeriodOfRentEquivalent_D38BD5C3F979DF2D2BF90F0251C69BAC_documentation_en-US" xlink:label="lab_eols_LesseeOperatingLeaseTerminationFeePeriodOfRentEquivalent_D38BD5C3F979DF2D2BF90F0251C69BAC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Termination Fee, Period Of Rent Equivalent</link:label>
    <link:loc xlink:href="eols-20190930.xsd#eols_LesseeOperatingLeaseTerminationFeePeriodOfRentEquivalent" xlink:label="loc_eols_LesseeOperatingLeaseTerminationFeePeriodOfRentEquivalent_D38BD5C3F979DF2D2BF90F0251C69BAC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_LesseeOperatingLeaseTerminationFeePeriodOfRentEquivalent_D38BD5C3F979DF2D2BF90F0251C69BAC" xlink:to="lab_eols_LesseeOperatingLeaseTerminationFeePeriodOfRentEquivalent_D38BD5C3F979DF2D2BF90F0251C69BAC" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_D1C8ABB841C0E7CB30C10F0251C68F46_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_D1C8ABB841C0E7CB30C10F0251C68F46" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Renewal term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_D1C8ABB841C0E7CB30C10F0251C68F46_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_D1C8ABB841C0E7CB30C10F0251C68F46" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_D1C8ABB841C0E7CB30C10F0251C68F46" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_D1C8ABB841C0E7CB30C10F0251C68F46" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_D1C8ABB841C0E7CB30C10F0251C68F46" xlink:type="arc" />
    <link:label id="lab_eols_OperatingLeasePercentageOfAnnualRentEscalation_FF211E41B041A0E6AFD30F0251C62CBF_terseLabel_en-US" xlink:label="lab_eols_OperatingLeasePercentageOfAnnualRentEscalation_FF211E41B041A0E6AFD30F0251C62CBF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of annual rent escalation</link:label>
    <link:label id="lab_eols_OperatingLeasePercentageOfAnnualRentEscalation_FF211E41B041A0E6AFD30F0251C62CBF_label_en-US" xlink:label="lab_eols_OperatingLeasePercentageOfAnnualRentEscalation_FF211E41B041A0E6AFD30F0251C62CBF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Percentage Of Annual Rent Escalation</link:label>
    <link:label id="lab_eols_OperatingLeasePercentageOfAnnualRentEscalation_FF211E41B041A0E6AFD30F0251C62CBF_documentation_en-US" xlink:label="lab_eols_OperatingLeasePercentageOfAnnualRentEscalation_FF211E41B041A0E6AFD30F0251C62CBF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Lease, Percentage Of Annual Rent Escalation</link:label>
    <link:loc xlink:href="eols-20190930.xsd#eols_OperatingLeasePercentageOfAnnualRentEscalation" xlink:label="loc_eols_OperatingLeasePercentageOfAnnualRentEscalation_FF211E41B041A0E6AFD30F0251C62CBF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_OperatingLeasePercentageOfAnnualRentEscalation_FF211E41B041A0E6AFD30F0251C62CBF" xlink:to="lab_eols_OperatingLeasePercentageOfAnnualRentEscalation_FF211E41B041A0E6AFD30F0251C62CBF" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseImpairmentLoss_951CCD07F029A493F6840F0251C6B933_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseImpairmentLoss_951CCD07F029A493F6840F0251C6B933" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease, impairment loss</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseImpairmentLoss_951CCD07F029A493F6840F0251C6B933_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseImpairmentLoss_951CCD07F029A493F6840F0251C6B933" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Impairment Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseImpairmentLoss" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss_951CCD07F029A493F6840F0251C6B933" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseImpairmentLoss_951CCD07F029A493F6840F0251C6B933" xlink:to="lab_us-gaap_OperatingLeaseImpairmentLoss_951CCD07F029A493F6840F0251C6B933" xlink:type="arc" />
    <link:label id="lab_us-gaap_PurchaseObligation_C171B27C6335B662D15F0F0251C78BB7_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligation_C171B27C6335B662D15F0F0251C78BB7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase obligation</link:label>
    <link:label id="lab_us-gaap_PurchaseObligation_C171B27C6335B662D15F0F0251C78BB7_label_en-US" xlink:label="lab_us-gaap_PurchaseObligation_C171B27C6335B662D15F0F0251C78BB7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase Obligation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseObligation" xlink:label="loc_us-gaap_PurchaseObligation_C171B27C6335B662D15F0F0251C78BB7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligation_C171B27C6335B662D15F0F0251C78BB7" xlink:to="lab_us-gaap_PurchaseObligation_C171B27C6335B662D15F0F0251C78BB7" xlink:type="arc" />
    <link:label id="lab_eols_MilestonePaymentInConnectionWithLicenseAndSupplyAgreement_E5875EBFE4B24592EA8E0F0251C7BF54_terseLabel_en-US" xlink:label="lab_eols_MilestonePaymentInConnectionWithLicenseAndSupplyAgreement_E5875EBFE4B24592EA8E0F0251C7BF54" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone payment in connection with license and supply agreement</link:label>
    <link:label id="lab_eols_MilestonePaymentInConnectionWithLicenseAndSupplyAgreement_E5875EBFE4B24592EA8E0F0251C7BF54_label_en-US" xlink:label="lab_eols_MilestonePaymentInConnectionWithLicenseAndSupplyAgreement_E5875EBFE4B24592EA8E0F0251C7BF54" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Milestone Payment In Connection With License And Supply Agreement</link:label>
    <link:label id="lab_eols_MilestonePaymentInConnectionWithLicenseAndSupplyAgreement_E5875EBFE4B24592EA8E0F0251C7BF54_documentation_en-US" xlink:label="lab_eols_MilestonePaymentInConnectionWithLicenseAndSupplyAgreement_E5875EBFE4B24592EA8E0F0251C7BF54" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Milestone Payment In Connection With License And Supply Agreement</link:label>
    <link:loc xlink:href="eols-20190930.xsd#eols_MilestonePaymentInConnectionWithLicenseAndSupplyAgreement" xlink:label="loc_eols_MilestonePaymentInConnectionWithLicenseAndSupplyAgreement_E5875EBFE4B24592EA8E0F0251C7BF54" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_MilestonePaymentInConnectionWithLicenseAndSupplyAgreement_E5875EBFE4B24592EA8E0F0251C7BF54" xlink:to="lab_eols_MilestonePaymentInConnectionWithLicenseAndSupplyAgreement_E5875EBFE4B24592EA8E0F0251C7BF54" xlink:type="arc" />
    <link:label id="lab_eols_MilestonePaymentCurrent_357555C5E8440F9A45360F06F9834B36_terseLabel_en-US" xlink:label="lab_eols_MilestonePaymentCurrent_357555C5E8440F9A45360F06F9834B36" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">EU milestone payment to Daewoong</link:label>
    <link:loc xlink:href="eols-20190930.xsd#eols_MilestonePaymentCurrent" xlink:label="loc_eols_MilestonePaymentCurrent_357555C5E8440F9A45360F06F9834B36" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_MilestonePaymentCurrent_357555C5E8440F9A45360F06F9834B36" xlink:to="lab_eols_MilestonePaymentCurrent_357555C5E8440F9A45360F06F9834B36" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_B4D4A370D23E52C3BC240F0251C706DC_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue_B4D4A370D23E52C3BC240F0251C706DC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss contingency accrual</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_B4D4A370D23E52C3BC240F0251C706DC_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue_B4D4A370D23E52C3BC240F0251C706DC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency Accrual</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_B4D4A370D23E52C3BC240F0251C706DC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualAtCarryingValue_B4D4A370D23E52C3BC240F0251C706DC" xlink:to="lab_us-gaap_LossContingencyAccrualAtCarryingValue_B4D4A370D23E52C3BC240F0251C706DC" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_0611C79CBBCC7CB6DAB845374E903122_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_0611C79CBBCC7CB6DAB845374E903122" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholder's Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_0611C79CBBCC7CB6DAB845374E903122_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_0611C79CBBCC7CB6DAB845374E903122" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_0611C79CBBCC7CB6DAB845374E903122" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_0611C79CBBCC7CB6DAB845374E903122" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_0611C79CBBCC7CB6DAB845374E903122" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1AD48FE492B3B1E77DD30F0252B2E15B_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1AD48FE492B3B1E77DD30F0252B2E15B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1AD48FE492B3B1E77DD30F0252B2E15B_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1AD48FE492B3B1E77DD30F0252B2E15B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1AD48FE492B3B1E77DD30F0252B2E15B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1AD48FE492B3B1E77DD30F0252B2E15B" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1AD48FE492B3B1E77DD30F0252B2E15B" xlink:type="arc" />
    <link:label id="lab_srt_CounterpartyNameAxis_E1C19A7D074962993B390F0252B2D072_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis_E1C19A7D074962993B390F0252B2D072" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_E1C19A7D074962993B390F0252B2D072_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis_E1C19A7D074962993B390F0252B2D072" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_E1C19A7D074962993B390F0252B2D072" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis_E1C19A7D074962993B390F0252B2D072" xlink:to="lab_srt_CounterpartyNameAxis_E1C19A7D074962993B390F0252B2D072" xlink:type="arc" />
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_A3D56864C77473B92E340F0252B2BC91_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain_A3D56864C77473B92E340F0252B2BC91" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_A3D56864C77473B92E340F0252B2BC91_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain_A3D56864C77473B92E340F0252B2BC91" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_A3D56864C77473B92E340F0252B2BC91" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_A3D56864C77473B92E340F0252B2BC91" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain_A3D56864C77473B92E340F0252B2BC91" xlink:type="arc" />
    <link:label id="lab_eols_ALPHAEONMember_52428684978D5065727D0F0252B389F1_terseLabel_en-US" xlink:label="lab_eols_ALPHAEONMember_52428684978D5065727D0F0252B389F1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ALPHAEON</link:label>
    <link:label id="lab_eols_ALPHAEONMember_52428684978D5065727D0F0252B389F1_label_en-US" xlink:label="lab_eols_ALPHAEONMember_52428684978D5065727D0F0252B389F1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ALPHAEON [Member]</link:label>
    <link:label id="lab_eols_ALPHAEONMember_52428684978D5065727D0F0252B389F1_documentation_en-US" xlink:label="lab_eols_ALPHAEONMember_52428684978D5065727D0F0252B389F1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">ALPHAEON [Member]</link:label>
    <link:loc xlink:href="eols-20190930.xsd#eols_ALPHAEONMember" xlink:label="loc_eols_ALPHAEONMember_52428684978D5065727D0F0252B389F1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_ALPHAEONMember_52428684978D5065727D0F0252B389F1" xlink:to="lab_eols_ALPHAEONMember_52428684978D5065727D0F0252B389F1" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_373C6744772776ABB7B80F0252B419EC_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis_373C6744772776ABB7B80F0252B419EC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_373C6744772776ABB7B80F0252B419EC_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis_373C6744772776ABB7B80F0252B419EC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_373C6744772776ABB7B80F0252B419EC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_373C6744772776ABB7B80F0252B419EC" xlink:to="lab_us-gaap_BusinessAcquisitionAxis_373C6744772776ABB7B80F0252B419EC" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_318A1F5470D94F6006780F0252B468FA_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain_318A1F5470D94F6006780F0252B468FA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_318A1F5470D94F6006780F0252B468FA_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain_318A1F5470D94F6006780F0252B468FA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_318A1F5470D94F6006780F0252B468FA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_318A1F5470D94F6006780F0252B468FA" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain_318A1F5470D94F6006780F0252B468FA" xlink:type="arc" />
    <link:label id="lab_eols_EvolusIncMember_B9A3738D58044184FEEB0F0252B400CF_terseLabel_en-US" xlink:label="lab_eols_EvolusIncMember_B9A3738D58044184FEEB0F0252B400CF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Evolus, Inc.</link:label>
    <link:label id="lab_eols_EvolusIncMember_B9A3738D58044184FEEB0F0252B400CF_label_en-US" xlink:label="lab_eols_EvolusIncMember_B9A3738D58044184FEEB0F0252B400CF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Evolus, Inc [Member]</link:label>
    <link:label id="lab_eols_EvolusIncMember_B9A3738D58044184FEEB0F0252B400CF_documentation_en-US" xlink:label="lab_eols_EvolusIncMember_B9A3738D58044184FEEB0F0252B400CF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Evolus, Inc [Member]</link:label>
    <link:loc xlink:href="eols-20190930.xsd#eols_EvolusIncMember" xlink:label="loc_eols_EvolusIncMember_B9A3738D58044184FEEB0F0252B400CF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_EvolusIncMember_B9A3738D58044184FEEB0F0252B400CF" xlink:to="lab_eols_EvolusIncMember_B9A3738D58044184FEEB0F0252B400CF" xlink:type="arc" />
    <link:label id="lab_eols_SCHAEONLLCMember_9049CD4CE7EB8E93EBD10F0252B5550C_terseLabel_en-US" xlink:label="lab_eols_SCHAEONLLCMember_9049CD4CE7EB8E93EBD10F0252B5550C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SCH</link:label>
    <link:label id="lab_eols_SCHAEONLLCMember_9049CD4CE7EB8E93EBD10F0252B5550C_label_en-US" xlink:label="lab_eols_SCHAEONLLCMember_9049CD4CE7EB8E93EBD10F0252B5550C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SCH-AEON, LLC [Member]</link:label>
    <link:label id="lab_eols_SCHAEONLLCMember_9049CD4CE7EB8E93EBD10F0252B5550C_documentation_en-US" xlink:label="lab_eols_SCHAEONLLCMember_9049CD4CE7EB8E93EBD10F0252B5550C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">SCH-AEON, LLC [Member]</link:label>
    <link:loc xlink:href="eols-20190930.xsd#eols_SCHAEONLLCMember" xlink:label="loc_eols_SCHAEONLLCMember_9049CD4CE7EB8E93EBD10F0252B5550C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_SCHAEONLLCMember_9049CD4CE7EB8E93EBD10F0252B5550C" xlink:to="lab_eols_SCHAEONLLCMember_9049CD4CE7EB8E93EBD10F0252B5550C" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8EF1C02844AE837E70410F0252B7906C_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8EF1C02844AE837E70410F0252B7906C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8EF1C02844AE837E70410F0252B7906C_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8EF1C02844AE837E70410F0252B7906C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8EF1C02844AE837E70410F0252B7906C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8EF1C02844AE837E70410F0252B7906C" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8EF1C02844AE837E70410F0252B7906C" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyDomain_A595E998A45E0E39FAA60F0252B777C2_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain_A595E998A45E0E39FAA60F0252B777C2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_A595E998A45E0E39FAA60F0252B777C2_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain_A595E998A45E0E39FAA60F0252B777C2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_A595E998A45E0E39FAA60F0252B777C2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain_A595E998A45E0E39FAA60F0252B777C2" xlink:to="lab_us-gaap_RelatedPartyDomain_A595E998A45E0E39FAA60F0252B777C2" xlink:type="arc" />
    <link:label id="lab_eols_ChiefMedicalOfficerMember_533AA1A4DC93837A59F50F0252B854A8_terseLabel_en-US" xlink:label="lab_eols_ChiefMedicalOfficerMember_533AA1A4DC93837A59F50F0252B854A8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Chief Medical Officer</link:label>
    <link:label id="lab_eols_ChiefMedicalOfficerMember_533AA1A4DC93837A59F50F0252B854A8_label_en-US" xlink:label="lab_eols_ChiefMedicalOfficerMember_533AA1A4DC93837A59F50F0252B854A8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Chief Medical Officer [Member]</link:label>
    <link:label id="lab_eols_ChiefMedicalOfficerMember_533AA1A4DC93837A59F50F0252B854A8_documentation_en-US" xlink:label="lab_eols_ChiefMedicalOfficerMember_533AA1A4DC93837A59F50F0252B854A8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Chief Medical Officer [Member]</link:label>
    <link:loc xlink:href="eols-20190930.xsd#eols_ChiefMedicalOfficerMember" xlink:label="loc_eols_ChiefMedicalOfficerMember_533AA1A4DC93837A59F50F0252B854A8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_ChiefMedicalOfficerMember_533AA1A4DC93837A59F50F0252B854A8" xlink:to="lab_eols_ChiefMedicalOfficerMember_533AA1A4DC93837A59F50F0252B854A8" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_278BE927F2AF05412CBC0F0252B8FC6E_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems_278BE927F2AF05412CBC0F0252B8FC6E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_278BE927F2AF05412CBC0F0252B8FC6E_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems_278BE927F2AF05412CBC0F0252B8FC6E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_278BE927F2AF05412CBC0F0252B8FC6E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_278BE927F2AF05412CBC0F0252B8FC6E" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems_278BE927F2AF05412CBC0F0252B8FC6E" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction_B44ACAB55F20680A86F60F0252B89F3E_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction_B44ACAB55F20680A86F60F0252B89F3E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related party transaction amount in period</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction_B44ACAB55F20680A86F60F0252B89F3E_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction_B44ACAB55F20680A86F60F0252B89F3E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction, Amounts of Transaction</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_B44ACAB55F20680A86F60F0252B89F3E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_B44ACAB55F20680A86F60F0252B89F3E" xlink:to="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction_B44ACAB55F20680A86F60F0252B89F3E" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_69F89A223D88169840340F0252B8E638_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_69F89A223D88169840340F0252B8E638" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest rate on debt</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_69F89A223D88169840340F0252B8E638_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_69F89A223D88169840340F0252B8E638" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_69F89A223D88169840340F0252B8E638" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_69F89A223D88169840340F0252B8E638" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_69F89A223D88169840340F0252B8E638" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_2721DD83389B0A2DA3010F0252B95719_negatedLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_2721DD83389B0A2DA3010F0252B95719" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2721DD83389B0A2DA3010F0252B95719" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2721DD83389B0A2DA3010F0252B95719" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_2721DD83389B0A2DA3010F0252B95719" xlink:type="arc" />
    <link:label id="lab_eols_BusinessCombinationUpfrontPaymentUponObtainingFDAApproval_C7A94D3D98651C6CB7500F0252BA2535_terseLabel_en-US" xlink:label="lab_eols_BusinessCombinationUpfrontPaymentUponObtainingFDAApproval_C7A94D3D98651C6CB7500F0252BA2535" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Up-front payment upon obtaining FDA approval</link:label>
    <link:label id="lab_eols_BusinessCombinationUpfrontPaymentUponObtainingFDAApproval_C7A94D3D98651C6CB7500F0252BA2535_label_en-US" xlink:label="lab_eols_BusinessCombinationUpfrontPaymentUponObtainingFDAApproval_C7A94D3D98651C6CB7500F0252BA2535" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Up-front Payment Upon Obtaining FDA Approval</link:label>
    <link:label id="lab_eols_BusinessCombinationUpfrontPaymentUponObtainingFDAApproval_C7A94D3D98651C6CB7500F0252BA2535_documentation_en-US" xlink:label="lab_eols_BusinessCombinationUpfrontPaymentUponObtainingFDAApproval_C7A94D3D98651C6CB7500F0252BA2535" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Up-front Payment Upon Obtaining FDA Approval</link:label>
    <link:loc xlink:href="eols-20190930.xsd#eols_BusinessCombinationUpfrontPaymentUponObtainingFDAApproval" xlink:label="loc_eols_BusinessCombinationUpfrontPaymentUponObtainingFDAApproval_C7A94D3D98651C6CB7500F0252BA2535" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_BusinessCombinationUpfrontPaymentUponObtainingFDAApproval_C7A94D3D98651C6CB7500F0252BA2535" xlink:to="lab_eols_BusinessCombinationUpfrontPaymentUponObtainingFDAApproval_C7A94D3D98651C6CB7500F0252BA2535" xlink:type="arc" />
    <link:label id="lab_eols_RelatedPartyTransactionPeriodOfTerminationOfFirstCommercialSale_B26CB9D437A0613572BE0F0252BAB5F7_terseLabel_en-US" xlink:label="lab_eols_RelatedPartyTransactionPeriodOfTerminationOfFirstCommercialSale_B26CB9D437A0613572BE0F0252BAB5F7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Period of termination of first commercial sale</link:label>
    <link:label id="lab_eols_RelatedPartyTransactionPeriodOfTerminationOfFirstCommercialSale_B26CB9D437A0613572BE0F0252BAB5F7_label_en-US" xlink:label="lab_eols_RelatedPartyTransactionPeriodOfTerminationOfFirstCommercialSale_B26CB9D437A0613572BE0F0252BAB5F7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction, Period Of Termination Of First Commercial Sale</link:label>
    <link:label id="lab_eols_RelatedPartyTransactionPeriodOfTerminationOfFirstCommercialSale_B26CB9D437A0613572BE0F0252BAB5F7_documentation_en-US" xlink:label="lab_eols_RelatedPartyTransactionPeriodOfTerminationOfFirstCommercialSale_B26CB9D437A0613572BE0F0252BAB5F7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related Party Transaction, Period Of Termination Of First Commercial Sale</link:label>
    <link:loc xlink:href="eols-20190930.xsd#eols_RelatedPartyTransactionPeriodOfTerminationOfFirstCommercialSale" xlink:label="loc_eols_RelatedPartyTransactionPeriodOfTerminationOfFirstCommercialSale_B26CB9D437A0613572BE0F0252BAB5F7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_RelatedPartyTransactionPeriodOfTerminationOfFirstCommercialSale_B26CB9D437A0613572BE0F0252BAB5F7" xlink:to="lab_eols_RelatedPartyTransactionPeriodOfTerminationOfFirstCommercialSale_B26CB9D437A0613572BE0F0252BAB5F7" xlink:type="arc" />
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_7E1CEA6D76A8C0EA6A710F0252BAFDD6_terseLabel_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_7E1CEA6D76A8C0EA6A710F0252BAFDD6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Due to related parties</link:label>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_7E1CEA6D76A8C0EA6A710F0252BAFDD6_label_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_7E1CEA6D76A8C0EA6A710F0252BAFDD6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Due to Related Parties</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_7E1CEA6D76A8C0EA6A710F0252BAFDD6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_7E1CEA6D76A8C0EA6A710F0252BAFDD6" xlink:to="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_7E1CEA6D76A8C0EA6A710F0252BAFDD6" xlink:type="arc" />
    <link:label id="lab_eols_StockPurchaseAgreementPeriodAvailabletoCureBreach_B16DCC8A03A79C17832C0F0252BAB482_terseLabel_en-US" xlink:label="lab_eols_StockPurchaseAgreementPeriodAvailabletoCureBreach_B16DCC8A03A79C17832C0F0252BAB482" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Period available to cure breach</link:label>
    <link:label id="lab_eols_StockPurchaseAgreementPeriodAvailabletoCureBreach_B16DCC8A03A79C17832C0F0252BAB482_label_en-US" xlink:label="lab_eols_StockPurchaseAgreementPeriodAvailabletoCureBreach_B16DCC8A03A79C17832C0F0252BAB482" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Purchase Agreement, Period Available to Cure Breach</link:label>
    <link:label id="lab_eols_StockPurchaseAgreementPeriodAvailabletoCureBreach_B16DCC8A03A79C17832C0F0252BAB482_documentation_en-US" xlink:label="lab_eols_StockPurchaseAgreementPeriodAvailabletoCureBreach_B16DCC8A03A79C17832C0F0252BAB482" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Purchase Agreement, Period Available to Cure Breach</link:label>
    <link:loc xlink:href="eols-20190930.xsd#eols_StockPurchaseAgreementPeriodAvailabletoCureBreach" xlink:label="loc_eols_StockPurchaseAgreementPeriodAvailabletoCureBreach_B16DCC8A03A79C17832C0F0252BAB482" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_StockPurchaseAgreementPeriodAvailabletoCureBreach_B16DCC8A03A79C17832C0F0252BAB482" xlink:to="lab_eols_StockPurchaseAgreementPeriodAvailabletoCureBreach_B16DCC8A03A79C17832C0F0252BAB482" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_9940796C556A981B610F0F0252BBE2DD_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_9940796C556A981B610F0F0252BBE2DD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of voting interests acquired (at least)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_9940796C556A981B610F0F0252BBE2DD_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_9940796C556A981B610F0F0252BBE2DD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Percentage of Voting Interests Acquired</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_9940796C556A981B610F0F0252BBE2DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_9940796C556A981B610F0F0252BBE2DD" xlink:to="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_9940796C556A981B610F0F0252BBE2DD" xlink:type="arc" />
    <link:label id="lab_eols_BusinessAcquisitionUnwindingFee_D2342640DC5408ACF0DD0F0252BBAD43_terseLabel_en-US" xlink:label="lab_eols_BusinessAcquisitionUnwindingFee_D2342640DC5408ACF0DD0F0252BBAD43" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unwinding fee</link:label>
    <link:label id="lab_eols_BusinessAcquisitionUnwindingFee_D2342640DC5408ACF0DD0F0252BBAD43_label_en-US" xlink:label="lab_eols_BusinessAcquisitionUnwindingFee_D2342640DC5408ACF0DD0F0252BBAD43" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Unwinding Fee</link:label>
    <link:label id="lab_eols_BusinessAcquisitionUnwindingFee_D2342640DC5408ACF0DD0F0252BBAD43_documentation_en-US" xlink:label="lab_eols_BusinessAcquisitionUnwindingFee_D2342640DC5408ACF0DD0F0252BBAD43" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Acquisition, Unwinding Fee</link:label>
    <link:loc xlink:href="eols-20190930.xsd#eols_BusinessAcquisitionUnwindingFee" xlink:label="loc_eols_BusinessAcquisitionUnwindingFee_D2342640DC5408ACF0DD0F0252BBAD43" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_BusinessAcquisitionUnwindingFee_D2342640DC5408ACF0DD0F0252BBAD43" xlink:to="lab_eols_BusinessAcquisitionUnwindingFee_D2342640DC5408ACF0DD0F0252BBAD43" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_7CA027BE1FD81C4DC71D45374EF3D691_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock_7CA027BE1FD81C4DC71D45374EF3D691" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements and Short-Term Investments</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_7CA027BE1FD81C4DC71D45374EF3D691_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock_7CA027BE1FD81C4DC71D45374EF3D691" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_7CA027BE1FD81C4DC71D45374EF3D691" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock_7CA027BE1FD81C4DC71D45374EF3D691" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock_7CA027BE1FD81C4DC71D45374EF3D691" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_B7914C5D42E281EB902045374EA44933_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock_B7914C5D42E281EB902045374EA44933" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Oxford Term Loans</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_B7914C5D42E281EB902045374EA44933_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock_B7914C5D42E281EB902045374EA44933" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_B7914C5D42E281EB902045374EA44933" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock_B7914C5D42E281EB902045374EA44933" xlink:to="lab_us-gaap_DebtDisclosureTextBlock_B7914C5D42E281EB902045374EA44933" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentTable_1ED429D4C0F1ADF21BA045374E329BF9_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable_1ED429D4C0F1ADF21BA045374E329BF9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_1ED429D4C0F1ADF21BA045374E329BF9_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable_1ED429D4C0F1ADF21BA045374E329BF9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_1ED429D4C0F1ADF21BA045374E329BF9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable_1ED429D4C0F1ADF21BA045374E329BF9" xlink:to="lab_us-gaap_DebtInstrumentTable_1ED429D4C0F1ADF21BA045374E329BF9" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_93C9A8E9D0BF5C30B03D45374E32AFD5_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis_93C9A8E9D0BF5C30B03D45374E32AFD5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_93C9A8E9D0BF5C30B03D45374E32AFD5_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis_93C9A8E9D0BF5C30B03D45374E32AFD5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_93C9A8E9D0BF5C30B03D45374E32AFD5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_93C9A8E9D0BF5C30B03D45374E32AFD5" xlink:to="lab_us-gaap_LongtermDebtTypeAxis_93C9A8E9D0BF5C30B03D45374E32AFD5" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_16615FCCE008C6E8CB0345374E3347AA_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain_16615FCCE008C6E8CB0345374E3347AA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_16615FCCE008C6E8CB0345374E3347AA_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain_16615FCCE008C6E8CB0345374E3347AA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_16615FCCE008C6E8CB0345374E3347AA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_16615FCCE008C6E8CB0345374E3347AA" xlink:to="lab_us-gaap_LongtermDebtTypeDomain_16615FCCE008C6E8CB0345374E3347AA" xlink:type="arc" />
    <link:label id="lab_us-gaap_SecuredDebtMember_E81801399283DCA20B0B45374E33A755_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredDebtMember_E81801399283DCA20B0B45374E33A755" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Secured Debt</link:label>
    <link:label id="lab_us-gaap_SecuredDebtMember_E81801399283DCA20B0B45374E33A755_label_en-US" xlink:label="lab_us-gaap_SecuredDebtMember_E81801399283DCA20B0B45374E33A755" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Secured Debt [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SecuredDebtMember" xlink:label="loc_us-gaap_SecuredDebtMember_E81801399283DCA20B0B45374E33A755" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredDebtMember_E81801399283DCA20B0B45374E33A755" xlink:to="lab_us-gaap_SecuredDebtMember_E81801399283DCA20B0B45374E33A755" xlink:type="arc" />
    <link:label id="lab_eols_TermLoanFacilityTrancheOneMember_5BBA1F6725720632EFED45374E340218_terseLabel_en-US" xlink:label="lab_eols_TermLoanFacilityTrancheOneMember_5BBA1F6725720632EFED45374E340218" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term Loan Facility, Tranche One</link:label>
    <link:label id="lab_eols_TermLoanFacilityTrancheOneMember_5BBA1F6725720632EFED45374E340218_label_en-US" xlink:label="lab_eols_TermLoanFacilityTrancheOneMember_5BBA1F6725720632EFED45374E340218" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Term Loan Facility, Tranche One [Member]</link:label>
    <link:label id="lab_eols_TermLoanFacilityTrancheOneMember_5BBA1F6725720632EFED45374E340218_documentation_en-US" xlink:label="lab_eols_TermLoanFacilityTrancheOneMember_5BBA1F6725720632EFED45374E340218" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Term Loan Facility, Tranche One [Member]</link:label>
    <link:loc xlink:href="eols-20190930.xsd#eols_TermLoanFacilityTrancheOneMember" xlink:label="loc_eols_TermLoanFacilityTrancheOneMember_5BBA1F6725720632EFED45374E340218" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_TermLoanFacilityTrancheOneMember_5BBA1F6725720632EFED45374E340218" xlink:to="lab_eols_TermLoanFacilityTrancheOneMember_5BBA1F6725720632EFED45374E340218" xlink:type="arc" />
    <link:label id="lab_eols_TermLoanFacilityTrancheTwoMember_ED8A8E84CD7D0CBC07CC45374E344D54_terseLabel_en-US" xlink:label="lab_eols_TermLoanFacilityTrancheTwoMember_ED8A8E84CD7D0CBC07CC45374E344D54" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term Loan Facility, Tranche Two</link:label>
    <link:label id="lab_eols_TermLoanFacilityTrancheTwoMember_ED8A8E84CD7D0CBC07CC45374E344D54_label_en-US" xlink:label="lab_eols_TermLoanFacilityTrancheTwoMember_ED8A8E84CD7D0CBC07CC45374E344D54" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Term Loan Facility, Tranche Two [Member]</link:label>
    <link:label id="lab_eols_TermLoanFacilityTrancheTwoMember_ED8A8E84CD7D0CBC07CC45374E344D54_documentation_en-US" xlink:label="lab_eols_TermLoanFacilityTrancheTwoMember_ED8A8E84CD7D0CBC07CC45374E344D54" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Term Loan Facility, Tranche Two [Member]</link:label>
    <link:loc xlink:href="eols-20190930.xsd#eols_TermLoanFacilityTrancheTwoMember" xlink:label="loc_eols_TermLoanFacilityTrancheTwoMember_ED8A8E84CD7D0CBC07CC45374E344D54" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_TermLoanFacilityTrancheTwoMember_ED8A8E84CD7D0CBC07CC45374E344D54" xlink:to="lab_eols_TermLoanFacilityTrancheTwoMember_ED8A8E84CD7D0CBC07CC45374E344D54" xlink:type="arc" />
    <link:label id="lab_eols_TermLoanFacilityMember_88A7F07C7460A0B896A645374E341000_terseLabel_en-US" xlink:label="lab_eols_TermLoanFacilityMember_88A7F07C7460A0B896A645374E341000" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term Loan Facility</link:label>
    <link:label id="lab_eols_TermLoanFacilityMember_88A7F07C7460A0B896A645374E341000_label_en-US" xlink:label="lab_eols_TermLoanFacilityMember_88A7F07C7460A0B896A645374E341000" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Term Loan Facility [Member]</link:label>
    <link:label id="lab_eols_TermLoanFacilityMember_88A7F07C7460A0B896A645374E341000_documentation_en-US" xlink:label="lab_eols_TermLoanFacilityMember_88A7F07C7460A0B896A645374E341000" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Term Loan Facility [Member]</link:label>
    <link:loc xlink:href="eols-20190930.xsd#eols_TermLoanFacilityMember" xlink:label="loc_eols_TermLoanFacilityMember_88A7F07C7460A0B896A645374E341000" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_TermLoanFacilityMember_88A7F07C7460A0B896A645374E341000" xlink:to="lab_eols_TermLoanFacilityMember_88A7F07C7460A0B896A645374E341000" xlink:type="arc" />
    <link:label id="lab_us-gaap_VariableRateAxis_C181B7D0BE95A6D8C89745374E34FCB1_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis_C181B7D0BE95A6D8C89745374E34FCB1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_C181B7D0BE95A6D8C89745374E34FCB1_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis_C181B7D0BE95A6D8C89745374E34FCB1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaap_VariableRateAxis_C181B7D0BE95A6D8C89745374E34FCB1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis_C181B7D0BE95A6D8C89745374E34FCB1" xlink:to="lab_us-gaap_VariableRateAxis_C181B7D0BE95A6D8C89745374E34FCB1" xlink:type="arc" />
    <link:label id="lab_us-gaap_VariableRateDomain_170DE32D32E7B375554945374E340847_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain_170DE32D32E7B375554945374E340847" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_170DE32D32E7B375554945374E340847_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain_170DE32D32E7B375554945374E340847" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_170DE32D32E7B375554945374E340847" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain_170DE32D32E7B375554945374E340847" xlink:to="lab_us-gaap_VariableRateDomain_170DE32D32E7B375554945374E340847" xlink:type="arc" />
    <link:label id="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_364162F36F9613FA939C45374E35D791_terseLabel_en-US" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_364162F36F9613FA939C45374E35D791" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">London Interbank Offered Rate (LIBOR)</link:label>
    <link:label id="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_364162F36F9613FA939C45374E35D791_label_en-US" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_364162F36F9613FA939C45374E35D791" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">London Interbank Offered Rate (LIBOR) [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_364162F36F9613FA939C45374E35D791" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_364162F36F9613FA939C45374E35D791" xlink:to="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_364162F36F9613FA939C45374E35D791" xlink:type="arc" />
    <link:label id="lab_eols_ApplicableRateMember_20B0D79E808B1CE19F4E45374E35DF35_terseLabel_en-US" xlink:label="lab_eols_ApplicableRateMember_20B0D79E808B1CE19F4E45374E35DF35" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Applicable Rate</link:label>
    <link:label id="lab_eols_ApplicableRateMember_20B0D79E808B1CE19F4E45374E35DF35_label_en-US" xlink:label="lab_eols_ApplicableRateMember_20B0D79E808B1CE19F4E45374E35DF35" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Applicable Rate [Member]</link:label>
    <link:label id="lab_eols_ApplicableRateMember_20B0D79E808B1CE19F4E45374E35DF35_documentation_en-US" xlink:label="lab_eols_ApplicableRateMember_20B0D79E808B1CE19F4E45374E35DF35" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Applicable Rate [Member]</link:label>
    <link:loc xlink:href="eols-20190930.xsd#eols_ApplicableRateMember" xlink:label="loc_eols_ApplicableRateMember_20B0D79E808B1CE19F4E45374E35DF35" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_ApplicableRateMember_20B0D79E808B1CE19F4E45374E35DF35" xlink:to="lab_eols_ApplicableRateMember_20B0D79E808B1CE19F4E45374E35DF35" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_7D8DE52E76877D70DE0A45374E351877_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems_7D8DE52E76877D70DE0A45374E351877" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_7D8DE52E76877D70DE0A45374E351877_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems_7D8DE52E76877D70DE0A45374E351877" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_7D8DE52E76877D70DE0A45374E351877" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7D8DE52E76877D70DE0A45374E351877" xlink:to="lab_us-gaap_DebtInstrumentLineItems_7D8DE52E76877D70DE0A45374E351877" xlink:type="arc" />
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_DE873B6485DF1CF60A2A45374E35FD66_verboseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_DE873B6485DF1CF60A2A45374E35FD66" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Maximum borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_DE873B6485DF1CF60A2A45374E35FD66_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_DE873B6485DF1CF60A2A45374E35FD66" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_DE873B6485DF1CF60A2A45374E35FD66" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_DE873B6485DF1CF60A2A45374E35FD66" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_DE873B6485DF1CF60A2A45374E35FD66" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_E02CD5338D0ED6DD633945374E364BE5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_E02CD5338D0ED6DD633945374E364BE5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis spread on variable rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_E02CD5338D0ED6DD633945374E364BE5_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_E02CD5338D0ED6DD633945374E364BE5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_E02CD5338D0ED6DD633945374E364BE5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_E02CD5338D0ED6DD633945374E364BE5" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_E02CD5338D0ED6DD633945374E364BE5" xlink:type="arc" />
    <link:label id="lab_eols_DebtInstrumentPeriodOfInterestOnlyPayments_73605DDFAF0F46136D1145374E36A042_terseLabel_en-US" xlink:label="lab_eols_DebtInstrumentPeriodOfInterestOnlyPayments_73605DDFAF0F46136D1145374E36A042" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Period of interest only payments</link:label>
    <link:label id="lab_eols_DebtInstrumentPeriodOfInterestOnlyPayments_73605DDFAF0F46136D1145374E36A042_label_en-US" xlink:label="lab_eols_DebtInstrumentPeriodOfInterestOnlyPayments_73605DDFAF0F46136D1145374E36A042" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Period Of Interest Only Payments</link:label>
    <link:label id="lab_eols_DebtInstrumentPeriodOfInterestOnlyPayments_73605DDFAF0F46136D1145374E36A042_documentation_en-US" xlink:label="lab_eols_DebtInstrumentPeriodOfInterestOnlyPayments_73605DDFAF0F46136D1145374E36A042" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Period Of Interest Only Payments</link:label>
    <link:loc xlink:href="eols-20190930.xsd#eols_DebtInstrumentPeriodOfInterestOnlyPayments" xlink:label="loc_eols_DebtInstrumentPeriodOfInterestOnlyPayments_73605DDFAF0F46136D1145374E36A042" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_DebtInstrumentPeriodOfInterestOnlyPayments_73605DDFAF0F46136D1145374E36A042" xlink:to="lab_eols_DebtInstrumentPeriodOfInterestOnlyPayments_73605DDFAF0F46136D1145374E36A042" xlink:type="arc" />
    <link:label id="lab_eols_DebtInstrumentAmortizationPeriod_805997E3697DFD3295B745374E366DB4_terseLabel_en-US" xlink:label="lab_eols_DebtInstrumentAmortizationPeriod_805997E3697DFD3295B745374E366DB4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization period</link:label>
    <link:label id="lab_eols_DebtInstrumentAmortizationPeriod_805997E3697DFD3295B745374E366DB4_label_en-US" xlink:label="lab_eols_DebtInstrumentAmortizationPeriod_805997E3697DFD3295B745374E366DB4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Amortization Period</link:label>
    <link:label id="lab_eols_DebtInstrumentAmortizationPeriod_805997E3697DFD3295B745374E366DB4_documentation_en-US" xlink:label="lab_eols_DebtInstrumentAmortizationPeriod_805997E3697DFD3295B745374E366DB4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Amortization Period</link:label>
    <link:loc xlink:href="eols-20190930.xsd#eols_DebtInstrumentAmortizationPeriod" xlink:label="loc_eols_DebtInstrumentAmortizationPeriod_805997E3697DFD3295B745374E366DB4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_DebtInstrumentAmortizationPeriod_805997E3697DFD3295B745374E366DB4" xlink:to="lab_eols_DebtInstrumentAmortizationPeriod_805997E3697DFD3295B745374E366DB4" xlink:type="arc" />
    <link:label id="lab_eols_DebtInstrumentAdditionalPeriodOfAgreementOfInterestPayment_1E63C0661BDE5E299F5F45374E36E5AF_terseLabel_en-US" xlink:label="lab_eols_DebtInstrumentAdditionalPeriodOfAgreementOfInterestPayment_1E63C0661BDE5E299F5F45374E36E5AF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional period of agreement of interest payment</link:label>
    <link:label id="lab_eols_DebtInstrumentAdditionalPeriodOfAgreementOfInterestPayment_1E63C0661BDE5E299F5F45374E36E5AF_label_en-US" xlink:label="lab_eols_DebtInstrumentAdditionalPeriodOfAgreementOfInterestPayment_1E63C0661BDE5E299F5F45374E36E5AF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Additional Period Of Agreement Of Interest Payment</link:label>
    <link:label id="lab_eols_DebtInstrumentAdditionalPeriodOfAgreementOfInterestPayment_1E63C0661BDE5E299F5F45374E36E5AF_documentation_en-US" xlink:label="lab_eols_DebtInstrumentAdditionalPeriodOfAgreementOfInterestPayment_1E63C0661BDE5E299F5F45374E36E5AF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Additional Period Of Agreement Of Interest Payment</link:label>
    <link:loc xlink:href="eols-20190930.xsd#eols_DebtInstrumentAdditionalPeriodOfAgreementOfInterestPayment" xlink:label="loc_eols_DebtInstrumentAdditionalPeriodOfAgreementOfInterestPayment_1E63C0661BDE5E299F5F45374E36E5AF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_DebtInstrumentAdditionalPeriodOfAgreementOfInterestPayment_1E63C0661BDE5E299F5F45374E36E5AF" xlink:to="lab_eols_DebtInstrumentAdditionalPeriodOfAgreementOfInterestPayment_1E63C0661BDE5E299F5F45374E36E5AF" xlink:type="arc" />
    <link:label id="lab_eols_DebtInstrumentTermAggregatePeriod_19B38B01C229318BF88145374E37457F_terseLabel_en-US" xlink:label="lab_eols_DebtInstrumentTermAggregatePeriod_19B38B01C229318BF88145374E37457F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate period</link:label>
    <link:label id="lab_eols_DebtInstrumentTermAggregatePeriod_19B38B01C229318BF88145374E37457F_label_en-US" xlink:label="lab_eols_DebtInstrumentTermAggregatePeriod_19B38B01C229318BF88145374E37457F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Term, Aggregate Period</link:label>
    <link:label id="lab_eols_DebtInstrumentTermAggregatePeriod_19B38B01C229318BF88145374E37457F_documentation_en-US" xlink:label="lab_eols_DebtInstrumentTermAggregatePeriod_19B38B01C229318BF88145374E37457F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Term, Aggregate Period</link:label>
    <link:loc xlink:href="eols-20190930.xsd#eols_DebtInstrumentTermAggregatePeriod" xlink:label="loc_eols_DebtInstrumentTermAggregatePeriod_19B38B01C229318BF88145374E37457F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_DebtInstrumentTermAggregatePeriod_19B38B01C229318BF88145374E37457F" xlink:to="lab_eols_DebtInstrumentTermAggregatePeriod_19B38B01C229318BF88145374E37457F" xlink:type="arc" />
    <link:label id="lab_eols_DebtInstrumentAdditionalAmortizationPeriod_E47C1802E09FB28A664A45374E37C4E3_terseLabel_en-US" xlink:label="lab_eols_DebtInstrumentAdditionalAmortizationPeriod_E47C1802E09FB28A664A45374E37C4E3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional amortization period</link:label>
    <link:label id="lab_eols_DebtInstrumentAdditionalAmortizationPeriod_E47C1802E09FB28A664A45374E37C4E3_label_en-US" xlink:label="lab_eols_DebtInstrumentAdditionalAmortizationPeriod_E47C1802E09FB28A664A45374E37C4E3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Additional Amortization Period</link:label>
    <link:label id="lab_eols_DebtInstrumentAdditionalAmortizationPeriod_E47C1802E09FB28A664A45374E37C4E3_documentation_en-US" xlink:label="lab_eols_DebtInstrumentAdditionalAmortizationPeriod_E47C1802E09FB28A664A45374E37C4E3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Additional Amortization Period</link:label>
    <link:loc xlink:href="eols-20190930.xsd#eols_DebtInstrumentAdditionalAmortizationPeriod" xlink:label="loc_eols_DebtInstrumentAdditionalAmortizationPeriod_E47C1802E09FB28A664A45374E37C4E3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_DebtInstrumentAdditionalAmortizationPeriod_E47C1802E09FB28A664A45374E37C4E3" xlink:to="lab_eols_DebtInstrumentAdditionalAmortizationPeriod_E47C1802E09FB28A664A45374E37C4E3" xlink:type="arc" />
    <link:label id="lab_eols_DebtInstrumentPercentageOfPrincipalAmountBalloonPayment_B37379F9750DA970DAA845374E376AE8_terseLabel_en-US" xlink:label="lab_eols_DebtInstrumentPercentageOfPrincipalAmountBalloonPayment_B37379F9750DA970DAA845374E376AE8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of final payment of full principal amount</link:label>
    <link:label id="lab_eols_DebtInstrumentPercentageOfPrincipalAmountBalloonPayment_B37379F9750DA970DAA845374E376AE8_label_en-US" xlink:label="lab_eols_DebtInstrumentPercentageOfPrincipalAmountBalloonPayment_B37379F9750DA970DAA845374E376AE8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Percentage Of Principal Amount, Balloon Payment</link:label>
    <link:label id="lab_eols_DebtInstrumentPercentageOfPrincipalAmountBalloonPayment_B37379F9750DA970DAA845374E376AE8_documentation_en-US" xlink:label="lab_eols_DebtInstrumentPercentageOfPrincipalAmountBalloonPayment_B37379F9750DA970DAA845374E376AE8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Percentage Of Principal Amount, Balloon Payment</link:label>
    <link:loc xlink:href="eols-20190930.xsd#eols_DebtInstrumentPercentageOfPrincipalAmountBalloonPayment" xlink:label="loc_eols_DebtInstrumentPercentageOfPrincipalAmountBalloonPayment_B37379F9750DA970DAA845374E376AE8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_DebtInstrumentPercentageOfPrincipalAmountBalloonPayment_B37379F9750DA970DAA845374E376AE8" xlink:to="lab_eols_DebtInstrumentPercentageOfPrincipalAmountBalloonPayment_B37379F9750DA970DAA845374E376AE8" xlink:type="arc" />
    <link:label id="lab_eols_DebtInstrumentPrepaymentFeePercentageNextTwelveMonths_05064D151E0B423BA49145374E371858_terseLabel_en-US" xlink:label="lab_eols_DebtInstrumentPrepaymentFeePercentageNextTwelveMonths_05064D151E0B423BA49145374E371858" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepayment fee percentage, next twelve months</link:label>
    <link:label id="lab_eols_DebtInstrumentPrepaymentFeePercentageNextTwelveMonths_05064D151E0B423BA49145374E371858_label_en-US" xlink:label="lab_eols_DebtInstrumentPrepaymentFeePercentageNextTwelveMonths_05064D151E0B423BA49145374E371858" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Prepayment Fee Percentage, Next Twelve Months</link:label>
    <link:label id="lab_eols_DebtInstrumentPrepaymentFeePercentageNextTwelveMonths_05064D151E0B423BA49145374E371858_documentation_en-US" xlink:label="lab_eols_DebtInstrumentPrepaymentFeePercentageNextTwelveMonths_05064D151E0B423BA49145374E371858" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Prepayment Fee Percentage, Next Twelve Months</link:label>
    <link:loc xlink:href="eols-20190930.xsd#eols_DebtInstrumentPrepaymentFeePercentageNextTwelveMonths" xlink:label="loc_eols_DebtInstrumentPrepaymentFeePercentageNextTwelveMonths_05064D151E0B423BA49145374E371858" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_DebtInstrumentPrepaymentFeePercentageNextTwelveMonths_05064D151E0B423BA49145374E371858" xlink:to="lab_eols_DebtInstrumentPrepaymentFeePercentageNextTwelveMonths_05064D151E0B423BA49145374E371858" xlink:type="arc" />
    <link:label id="lab_eols_DebtInstrumentPrepaymentFeePercentageYearTwo_82D15EF1991BE751076D45374E386248_terseLabel_en-US" xlink:label="lab_eols_DebtInstrumentPrepaymentFeePercentageYearTwo_82D15EF1991BE751076D45374E386248" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepayment fee percentage, year two</link:label>
    <link:label id="lab_eols_DebtInstrumentPrepaymentFeePercentageYearTwo_82D15EF1991BE751076D45374E386248_label_en-US" xlink:label="lab_eols_DebtInstrumentPrepaymentFeePercentageYearTwo_82D15EF1991BE751076D45374E386248" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Prepayment Fee Percentage, Year Two</link:label>
    <link:label id="lab_eols_DebtInstrumentPrepaymentFeePercentageYearTwo_82D15EF1991BE751076D45374E386248_documentation_en-US" xlink:label="lab_eols_DebtInstrumentPrepaymentFeePercentageYearTwo_82D15EF1991BE751076D45374E386248" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Prepayment Fee Percentage, Year Two</link:label>
    <link:loc xlink:href="eols-20190930.xsd#eols_DebtInstrumentPrepaymentFeePercentageYearTwo" xlink:label="loc_eols_DebtInstrumentPrepaymentFeePercentageYearTwo_82D15EF1991BE751076D45374E386248" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_DebtInstrumentPrepaymentFeePercentageYearTwo_82D15EF1991BE751076D45374E386248" xlink:to="lab_eols_DebtInstrumentPrepaymentFeePercentageYearTwo_82D15EF1991BE751076D45374E386248" xlink:type="arc" />
    <link:label id="lab_eols_DebtInstrumentPrepaymentFeePercentageThereafter_4F3652043956750B737245374E38E6A7_terseLabel_en-US" xlink:label="lab_eols_DebtInstrumentPrepaymentFeePercentageThereafter_4F3652043956750B737245374E38E6A7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepayment fee percentage, thereafter</link:label>
    <link:label id="lab_eols_DebtInstrumentPrepaymentFeePercentageThereafter_4F3652043956750B737245374E38E6A7_label_en-US" xlink:label="lab_eols_DebtInstrumentPrepaymentFeePercentageThereafter_4F3652043956750B737245374E38E6A7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Prepayment Fee Percentage, Thereafter</link:label>
    <link:label id="lab_eols_DebtInstrumentPrepaymentFeePercentageThereafter_4F3652043956750B737245374E38E6A7_documentation_en-US" xlink:label="lab_eols_DebtInstrumentPrepaymentFeePercentageThereafter_4F3652043956750B737245374E38E6A7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Prepayment Fee Percentage, Thereafter</link:label>
    <link:loc xlink:href="eols-20190930.xsd#eols_DebtInstrumentPrepaymentFeePercentageThereafter" xlink:label="loc_eols_DebtInstrumentPrepaymentFeePercentageThereafter_4F3652043956750B737245374E38E6A7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_DebtInstrumentPrepaymentFeePercentageThereafter_4F3652043956750B737245374E38E6A7" xlink:to="lab_eols_DebtInstrumentPrepaymentFeePercentageThereafter_4F3652043956750B737245374E38E6A7" xlink:type="arc" />
    <link:label id="lab_eols_DebtInstrumentDefaultInterestRate_D3CEEDD6F6C18198FC6245374E38ECA6_terseLabel_en-US" xlink:label="lab_eols_DebtInstrumentDefaultInterestRate_D3CEEDD6F6C18198FC6245374E38ECA6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Default interest rate</link:label>
    <link:label id="lab_eols_DebtInstrumentDefaultInterestRate_D3CEEDD6F6C18198FC6245374E38ECA6_label_en-US" xlink:label="lab_eols_DebtInstrumentDefaultInterestRate_D3CEEDD6F6C18198FC6245374E38ECA6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Default Interest Rate</link:label>
    <link:label id="lab_eols_DebtInstrumentDefaultInterestRate_D3CEEDD6F6C18198FC6245374E38ECA6_documentation_en-US" xlink:label="lab_eols_DebtInstrumentDefaultInterestRate_D3CEEDD6F6C18198FC6245374E38ECA6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Default Interest Rate</link:label>
    <link:loc xlink:href="eols-20190930.xsd#eols_DebtInstrumentDefaultInterestRate" xlink:label="loc_eols_DebtInstrumentDefaultInterestRate_D3CEEDD6F6C18198FC6245374E38ECA6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_DebtInstrumentDefaultInterestRate_D3CEEDD6F6C18198FC6245374E38ECA6" xlink:to="lab_eols_DebtInstrumentDefaultInterestRate_D3CEEDD6F6C18198FC6245374E38ECA6" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_4A797881620D90D2845D45374E38BB2D_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount_4A797881620D90D2845D45374E38BB2D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt discount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_4A797881620D90D2845D45374E38BB2D_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount_4A797881620D90D2845D45374E38BB2D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Unamortized Discount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_4A797881620D90D2845D45374E38BB2D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscount_4A797881620D90D2845D45374E38BB2D" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscount_4A797881620D90D2845D45374E38BB2D" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredFinanceCostsGross_F7909D2767B14A28B55345374E38B180_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross_F7909D2767B14A28B55345374E38B180" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt issuance costs</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsGross_F7909D2767B14A28B55345374E38B180_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross_F7909D2767B14A28B55345374E38B180" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Issuance Costs, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredFinanceCostsGross" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_F7909D2767B14A28B55345374E38B180" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsGross_F7909D2767B14A28B55345374E38B180" xlink:to="lab_us-gaap_DeferredFinanceCostsGross_F7909D2767B14A28B55345374E38B180" xlink:type="arc" />
    <link:label id="lab_eols_AccountingPoliciesTable_6F83B4E2CB3EA830A723371E11BE3357_terseLabel_en-US" xlink:label="lab_eols_AccountingPoliciesTable_6F83B4E2CB3EA830A723371E11BE3357" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Policies [Table]</link:label>
    <link:label id="lab_eols_AccountingPoliciesTable_6F83B4E2CB3EA830A723371E11BE3357_label_en-US" xlink:label="lab_eols_AccountingPoliciesTable_6F83B4E2CB3EA830A723371E11BE3357" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Table]</link:label>
    <link:label id="lab_eols_AccountingPoliciesTable_6F83B4E2CB3EA830A723371E11BE3357_documentation_en-US" xlink:label="lab_eols_AccountingPoliciesTable_6F83B4E2CB3EA830A723371E11BE3357" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accounting Policies [Table]</link:label>
    <link:loc xlink:href="eols-20190930.xsd#eols_AccountingPoliciesTable" xlink:label="loc_eols_AccountingPoliciesTable_6F83B4E2CB3EA830A723371E11BE3357" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_AccountingPoliciesTable_6F83B4E2CB3EA830A723371E11BE3357" xlink:to="lab_eols_AccountingPoliciesTable_6F83B4E2CB3EA830A723371E11BE3357" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_0888B51FE6252D1415A0371E11BE0648_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_0888B51FE6252D1415A0371E11BE0648" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_0888B51FE6252D1415A0371E11BE0648_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_0888B51FE6252D1415A0371E11BE0648" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_0888B51FE6252D1415A0371E11BE0648" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_0888B51FE6252D1415A0371E11BE0648" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_0888B51FE6252D1415A0371E11BE0648" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_3E2CDC4C941D7B4F5C21371E11BEEDA5_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_3E2CDC4C941D7B4F5C21371E11BEEDA5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_3E2CDC4C941D7B4F5C21371E11BEEDA5_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_3E2CDC4C941D7B4F5C21371E11BEEDA5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3E2CDC4C941D7B4F5C21371E11BEEDA5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3E2CDC4C941D7B4F5C21371E11BEEDA5" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain_3E2CDC4C941D7B4F5C21371E11BEEDA5" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_EE5A2093BA5D0663FB5B371E11BE2140_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember_EE5A2093BA5D0663FB5B371E11BE2140" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_EE5A2093BA5D0663FB5B371E11BE2140_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember_EE5A2093BA5D0663FB5B371E11BE2140" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_EE5A2093BA5D0663FB5B371E11BE2140" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember_EE5A2093BA5D0663FB5B371E11BE2140" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember_EE5A2093BA5D0663FB5B371E11BE2140" xlink:type="arc" />
    <link:label id="lab_us-gaap_SoftwareDevelopmentMember_BFA0C5F640B54CE2A8D5371E11BEABE3_terseLabel_en-US" xlink:label="lab_us-gaap_SoftwareDevelopmentMember_BFA0C5F640B54CE2A8D5371E11BEABE3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Internal-use software</link:label>
    <link:label id="lab_us-gaap_SoftwareDevelopmentMember_BFA0C5F640B54CE2A8D5371E11BEABE3_label_en-US" xlink:label="lab_us-gaap_SoftwareDevelopmentMember_BFA0C5F640B54CE2A8D5371E11BEABE3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Software Development [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SoftwareDevelopmentMember" xlink:label="loc_us-gaap_SoftwareDevelopmentMember_BFA0C5F640B54CE2A8D5371E11BEABE3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SoftwareDevelopmentMember_BFA0C5F640B54CE2A8D5371E11BEABE3" xlink:to="lab_us-gaap_SoftwareDevelopmentMember_BFA0C5F640B54CE2A8D5371E11BEABE3" xlink:type="arc" />
    <link:label id="lab_eols_AccountingPoliciesLineItems_2347D9E561310B28597E371E11BEDED2_terseLabel_en-US" xlink:label="lab_eols_AccountingPoliciesLineItems_2347D9E561310B28597E371E11BEDED2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Policies [Line Items]</link:label>
    <link:label id="lab_eols_AccountingPoliciesLineItems_2347D9E561310B28597E371E11BEDED2_label_en-US" xlink:label="lab_eols_AccountingPoliciesLineItems_2347D9E561310B28597E371E11BEDED2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Line Items]</link:label>
    <link:label id="lab_eols_AccountingPoliciesLineItems_2347D9E561310B28597E371E11BEDED2_documentation_en-US" xlink:label="lab_eols_AccountingPoliciesLineItems_2347D9E561310B28597E371E11BEDED2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Line Items] for Accounting Policies [Table]</link:label>
    <link:loc xlink:href="eols-20190930.xsd#eols_AccountingPoliciesLineItems" xlink:label="loc_eols_AccountingPoliciesLineItems_2347D9E561310B28597E371E11BEDED2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_AccountingPoliciesLineItems_2347D9E561310B28597E371E11BEDED2" xlink:to="lab_eols_AccountingPoliciesLineItems_2347D9E561310B28597E371E11BEDED2" xlink:type="arc" />
    <link:label id="lab_us-gaap_NumberOfReportingUnits_343543727BAF8E5B083B371E11BEEC98_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportingUnits_343543727BAF8E5B083B371E11BEEC98" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of reporting units</link:label>
    <link:label id="lab_us-gaap_NumberOfReportingUnits_343543727BAF8E5B083B371E11BEEC98_label_en-US" xlink:label="lab_us-gaap_NumberOfReportingUnits_343543727BAF8E5B083B371E11BEEC98" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Reporting Units</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NumberOfReportingUnits" xlink:label="loc_us-gaap_NumberOfReportingUnits_343543727BAF8E5B083B371E11BEEC98" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportingUnits_343543727BAF8E5B083B371E11BEEC98" xlink:to="lab_us-gaap_NumberOfReportingUnits_343543727BAF8E5B083B371E11BEEC98" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_3E0AD6478C88FB507CB0371E11BE6CBD_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss_3E0AD6478C88FB507CB0371E11BE6CBD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_3E0AD6478C88FB507CB0371E11BE6CBD_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss_3E0AD6478C88FB507CB0371E11BE6CBD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_3E0AD6478C88FB507CB0371E11BE6CBD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss_3E0AD6478C88FB507CB0371E11BE6CBD" xlink:to="lab_us-gaap_GoodwillImpairmentLoss_3E0AD6478C88FB507CB0371E11BE6CBD" xlink:type="arc" />
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_DF5E9AD3001D66209D1B371E11BE2174_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_DF5E9AD3001D66209D1B371E11BE2174" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of intangible assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_DF5E9AD3001D66209D1B371E11BE2174_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_DF5E9AD3001D66209D1B371E11BE2174" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment of Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_DF5E9AD3001D66209D1B371E11BE2174" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_DF5E9AD3001D66209D1B371E11BE2174" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_DF5E9AD3001D66209D1B371E11BE2174" xlink:type="arc" />
    <link:label id="lab_eols_AccruedCouponAndRebateLiabilityCurrent_FCA235A064EDCE2AE9E5371E11BE1CDC_terseLabel_en-US" xlink:label="lab_eols_AccruedCouponAndRebateLiabilityCurrent_FCA235A064EDCE2AE9E5371E11BE1CDC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued volume-based rebate and coupon liability</link:label>
    <link:label id="lab_eols_AccruedCouponAndRebateLiabilityCurrent_FCA235A064EDCE2AE9E5371E11BE1CDC_label_en-US" xlink:label="lab_eols_AccruedCouponAndRebateLiabilityCurrent_FCA235A064EDCE2AE9E5371E11BE1CDC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Coupon And Rebate Liability, Current</link:label>
    <link:label id="lab_eols_AccruedCouponAndRebateLiabilityCurrent_FCA235A064EDCE2AE9E5371E11BE1CDC_documentation_en-US" xlink:label="lab_eols_AccruedCouponAndRebateLiabilityCurrent_FCA235A064EDCE2AE9E5371E11BE1CDC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Coupon And Rebate Liability, Current</link:label>
    <link:loc xlink:href="eols-20190930.xsd#eols_AccruedCouponAndRebateLiabilityCurrent" xlink:label="loc_eols_AccruedCouponAndRebateLiabilityCurrent_FCA235A064EDCE2AE9E5371E11BE1CDC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_AccruedCouponAndRebateLiabilityCurrent_FCA235A064EDCE2AE9E5371E11BE1CDC" xlink:to="lab_eols_AccruedCouponAndRebateLiabilityCurrent_FCA235A064EDCE2AE9E5371E11BE1CDC" xlink:type="arc" />
    <link:label id="lab_eols_ProvisionsForAccruedVolumeBasedRebateAndCouponLiability_F53355FB41C3C46878BD371E11BE851E_terseLabel_en-US" xlink:label="lab_eols_ProvisionsForAccruedVolumeBasedRebateAndCouponLiability_F53355FB41C3C46878BD371E11BE851E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provisions for accrued volume-based rebate and coupon liability</link:label>
    <link:label id="lab_eols_ProvisionsForAccruedVolumeBasedRebateAndCouponLiability_F53355FB41C3C46878BD371E11BE851E_label_en-US" xlink:label="lab_eols_ProvisionsForAccruedVolumeBasedRebateAndCouponLiability_F53355FB41C3C46878BD371E11BE851E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Provisions For Accrued Volume-Based Rebate And Coupon Liability</link:label>
    <link:label id="lab_eols_ProvisionsForAccruedVolumeBasedRebateAndCouponLiability_F53355FB41C3C46878BD371E11BE851E_documentation_en-US" xlink:label="lab_eols_ProvisionsForAccruedVolumeBasedRebateAndCouponLiability_F53355FB41C3C46878BD371E11BE851E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Provisions For Accrued Volume-Based Rebate And Coupon Liability</link:label>
    <link:loc xlink:href="eols-20190930.xsd#eols_ProvisionsForAccruedVolumeBasedRebateAndCouponLiability" xlink:label="loc_eols_ProvisionsForAccruedVolumeBasedRebateAndCouponLiability_F53355FB41C3C46878BD371E11BE851E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_ProvisionsForAccruedVolumeBasedRebateAndCouponLiability_F53355FB41C3C46878BD371E11BE851E" xlink:to="lab_eols_ProvisionsForAccruedVolumeBasedRebateAndCouponLiability_F53355FB41C3C46878BD371E11BE851E" xlink:type="arc" />
    <link:label id="lab_eols_PaymentsForProvisionsForAccruedVolumeBasedRebateAndCouponLiability_C6B3AE839A0D8B6009FF371E11BEC169_terseLabel_en-US" xlink:label="lab_eols_PaymentsForProvisionsForAccruedVolumeBasedRebateAndCouponLiability_C6B3AE839A0D8B6009FF371E11BEC169" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments for Provisions for accrued volume-based rebate and coupon liability</link:label>
    <link:label id="lab_eols_PaymentsForProvisionsForAccruedVolumeBasedRebateAndCouponLiability_C6B3AE839A0D8B6009FF371E11BEC169_label_en-US" xlink:label="lab_eols_PaymentsForProvisionsForAccruedVolumeBasedRebateAndCouponLiability_C6B3AE839A0D8B6009FF371E11BEC169" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments For Provisions For Accrued Volume-Based Rebate And Coupon Liability</link:label>
    <link:label id="lab_eols_PaymentsForProvisionsForAccruedVolumeBasedRebateAndCouponLiability_C6B3AE839A0D8B6009FF371E11BEC169_documentation_en-US" xlink:label="lab_eols_PaymentsForProvisionsForAccruedVolumeBasedRebateAndCouponLiability_C6B3AE839A0D8B6009FF371E11BEC169" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments For Provisions For Accrued Volume-Based Rebate And Coupon Liability</link:label>
    <link:loc xlink:href="eols-20190930.xsd#eols_PaymentsForProvisionsForAccruedVolumeBasedRebateAndCouponLiability" xlink:label="loc_eols_PaymentsForProvisionsForAccruedVolumeBasedRebateAndCouponLiability_C6B3AE839A0D8B6009FF371E11BEC169" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_PaymentsForProvisionsForAccruedVolumeBasedRebateAndCouponLiability_C6B3AE839A0D8B6009FF371E11BEC169" xlink:to="lab_eols_PaymentsForProvisionsForAccruedVolumeBasedRebateAndCouponLiability_C6B3AE839A0D8B6009FF371E11BEC169" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_1192FA22A5764B681BAF371E11BEADF4_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_1192FA22A5764B681BAF371E11BEADF4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Income tax benefit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_1192FA22A5764B681BAF371E11BEADF4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_1192FA22A5764B681BAF371E11BEADF4" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_1192FA22A5764B681BAF371E11BEADF4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_DADCDE0F29F2F4FC4D4B371E11BE9AF6_verboseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_DADCDE0F29F2F4FC4D4B371E11BE9AF6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Valuation allowance recorded against gross deferred tax asset</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_DADCDE0F29F2F4FC4D4B371E11BE9AF6_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_DADCDE0F29F2F4FC4D4B371E11BE9AF6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_DADCDE0F29F2F4FC4D4B371E11BE9AF6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_DADCDE0F29F2F4FC4D4B371E11BE9AF6" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_DADCDE0F29F2F4FC4D4B371E11BE9AF6" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_BDE3DDCB2B96F4CD7C60371E11BE4917_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_BDE3DDCB2B96F4CD7C60371E11BE4917" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Securities excluded from the computation of diluted net loss per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_BDE3DDCB2B96F4CD7C60371E11BE4917_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_BDE3DDCB2B96F4CD7C60371E11BE4917" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_BDE3DDCB2B96F4CD7C60371E11BE4917" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_BDE3DDCB2B96F4CD7C60371E11BE4917" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_BDE3DDCB2B96F4CD7C60371E11BE4917" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_4048F6C98BF5025164F545374E9EC3BF_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_4048F6C98BF5025164F545374E9EC3BF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_4048F6C98BF5025164F545374E9EC3BF_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_4048F6C98BF5025164F545374E9EC3BF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_4048F6C98BF5025164F545374E9EC3BF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_4048F6C98BF5025164F545374E9EC3BF" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_4048F6C98BF5025164F545374E9EC3BF" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_390B18F6C66DAEA3461CFF48E1B800D4_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_390B18F6C66DAEA3461CFF48E1B800D4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payment, Due [Abstract]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_390B18F6C66DAEA3461CFF48E1B800D4_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_390B18F6C66DAEA3461CFF48E1B800D4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payment, Due [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_390B18F6C66DAEA3461CFF48E1B800D4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_390B18F6C66DAEA3461CFF48E1B800D4" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_390B18F6C66DAEA3461CFF48E1B800D4" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_6349BD8BC1D032C638C8FEEBEEE86954_verboseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_6349BD8BC1D032C638C8FEEBEEE86954" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Remainder of 2019</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_6349BD8BC1D032C638C8FEEBEEE86954_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_6349BD8BC1D032C638C8FEEBEEE86954" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_6349BD8BC1D032C638C8FEEBEEE86954" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_6349BD8BC1D032C638C8FEEBEEE86954" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_6349BD8BC1D032C638C8FEEBEEE86954" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_B4F62CE63F5E0CF10F44FEEBEEE83157_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_B4F62CE63F5E0CF10F44FEEBEEE83157" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2020</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_B4F62CE63F5E0CF10F44FEEBEEE83157_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_B4F62CE63F5E0CF10F44FEEBEEE83157" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Two</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_B4F62CE63F5E0CF10F44FEEBEEE83157" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_B4F62CE63F5E0CF10F44FEEBEEE83157" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_B4F62CE63F5E0CF10F44FEEBEEE83157" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_371A2A9C53A80D27C007FEEBEEE890C5_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_371A2A9C53A80D27C007FEEBEEE890C5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_371A2A9C53A80D27C007FEEBEEE890C5_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_371A2A9C53A80D27C007FEEBEEE890C5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Three</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_371A2A9C53A80D27C007FEEBEEE890C5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_371A2A9C53A80D27C007FEEBEEE890C5" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_371A2A9C53A80D27C007FEEBEEE890C5" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_D58D747416B1FAE8B2F1FEEBEEE97B8E_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_D58D747416B1FAE8B2F1FEEBEEE97B8E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_D58D747416B1FAE8B2F1FEEBEEE97B8E_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_D58D747416B1FAE8B2F1FEEBEEE97B8E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Four</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_D58D747416B1FAE8B2F1FEEBEEE97B8E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_D58D747416B1FAE8B2F1FEEBEEE97B8E" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_D58D747416B1FAE8B2F1FEEBEEE97B8E" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_81EF0928C90CC0066B39FEEBEEE9B0A1_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_81EF0928C90CC0066B39FEEBEEE9B0A1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_81EF0928C90CC0066B39FEEBEEE9B0A1_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_81EF0928C90CC0066B39FEEBEEE9B0A1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_81EF0928C90CC0066B39FEEBEEE9B0A1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_81EF0928C90CC0066B39FEEBEEE9B0A1" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_81EF0928C90CC0066B39FEEBEEE9B0A1" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_7BBA9A64CD3751C24A46FEEBEEE9C71F_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_7BBA9A64CD3751C24A46FEEBEEE9C71F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_7BBA9A64CD3751C24A46FEEBEEE9C71F_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_7BBA9A64CD3751C24A46FEEBEEE9C71F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due after Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_7BBA9A64CD3751C24A46FEEBEEE9C71F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_7BBA9A64CD3751C24A46FEEBEEE9C71F" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_7BBA9A64CD3751C24A46FEEBEEE9C71F" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_F0E6045BF4356D812B52FEEBEEE9A8C8_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_F0E6045BF4356D812B52FEEBEEE9A8C8" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_F0E6045BF4356D812B52FEEBEEE9A8C8_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_F0E6045BF4356D812B52FEEBEEE9A8C8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_F0E6045BF4356D812B52FEEBEEE9A8C8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_F0E6045BF4356D812B52FEEBEEE9A8C8" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_F0E6045BF4356D812B52FEEBEEE9A8C8" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_A90D1055DDDE88952DA0FEEBEEE939E5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_A90D1055DDDE88952DA0FEEBEEE939E5" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less: imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_A90D1055DDDE88952DA0FEEBEEE939E5_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_A90D1055DDDE88952DA0FEEBEEE939E5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_A90D1055DDDE88952DA0FEEBEEE939E5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_A90D1055DDDE88952DA0FEEBEEE939E5" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_A90D1055DDDE88952DA0FEEBEEE939E5" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseLiability_BECF3AF7B4B0BD44B93DFEEBEEE9A94D_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability_BECF3AF7B4B0BD44B93DFEEBEEE9A94D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Present value of operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_BECF3AF7B4B0BD44B93DFEEBEEE9A94D_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability_BECF3AF7B4B0BD44B93DFEEBEEE9A94D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_BECF3AF7B4B0BD44B93DFEEBEEE9A94D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability_BECF3AF7B4B0BD44B93DFEEBEEE9A94D" xlink:to="lab_us-gaap_OperatingLeaseLiability_BECF3AF7B4B0BD44B93DFEEBEEE9A94D" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_2569C4CB878DCBF58179FF48772FFAEF_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_2569C4CB878DCBF58179FF48772FFAEF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_2569C4CB878DCBF58179FF48772FFAEF_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_2569C4CB878DCBF58179FF48772FFAEF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_2569C4CB878DCBF58179FF48772FFAEF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_2569C4CB878DCBF58179FF48772FFAEF" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_2569C4CB878DCBF58179FF48772FFAEF" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_8B04F565A5FA080DEE2CFF477A9AE634_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_8B04F565A5FA080DEE2CFF477A9AE634" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2019</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_8B04F565A5FA080DEE2CFF477A9AE634_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_8B04F565A5FA080DEE2CFF477A9AE634" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Remainder of Fiscal Year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_8B04F565A5FA080DEE2CFF477A9AE634" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_8B04F565A5FA080DEE2CFF477A9AE634" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_8B04F565A5FA080DEE2CFF477A9AE634" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_7CD4A20555B37EF28771FF47BB313E63_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_7CD4A20555B37EF28771FF47BB313E63" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2020</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_7CD4A20555B37EF28771FF47BB313E63_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_7CD4A20555B37EF28771FF47BB313E63" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Two Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_7CD4A20555B37EF28771FF47BB313E63" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_7CD4A20555B37EF28771FF47BB313E63" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_7CD4A20555B37EF28771FF47BB313E63" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_09098FB18F34BD029A02FF47EB05C42E_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_09098FB18F34BD029A02FF47EB05C42E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_09098FB18F34BD029A02FF47EB05C42E_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_09098FB18F34BD029A02FF47EB05C42E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Three Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_09098FB18F34BD029A02FF47EB05C42E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_09098FB18F34BD029A02FF47EB05C42E" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_09098FB18F34BD029A02FF47EB05C42E" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_8BED9297693445C93243FF481AAFB840_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_8BED9297693445C93243FF481AAFB840" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_8BED9297693445C93243FF481AAFB840_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_8BED9297693445C93243FF481AAFB840" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments Due</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_8BED9297693445C93243FF481AAFB840" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_8BED9297693445C93243FF481AAFB840" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_8BED9297693445C93243FF481AAFB840" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_F05ADA81F34464FE842F45392061A59F_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_F05ADA81F34464FE842F45392061A59F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_F05ADA81F34464FE842F45392061A59F_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_F05ADA81F34464FE842F45392061A59F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_F05ADA81F34464FE842F45392061A59F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_F05ADA81F34464FE842F45392061A59F" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_F05ADA81F34464FE842F45392061A59F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_330BE366E8B718683E54453920612A23_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_330BE366E8B718683E54453920612A23" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Stock Options, Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_330BE366E8B718683E54453920612A23_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_330BE366E8B718683E54453920612A23" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_330BE366E8B718683E54453920612A23" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_330BE366E8B718683E54453920612A23" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_330BE366E8B718683E54453920612A23" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_3B3080E985CA161ABCA1453920618EA4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_3B3080E985CA161ABCA1453920618EA4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation, Restricted Stock Units Award Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_3B3080E985CA161ABCA1453920618EA4_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_3B3080E985CA161ABCA1453920618EA4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_3B3080E985CA161ABCA1453920618EA4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_3B3080E985CA161ABCA1453920618EA4" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_3B3080E985CA161ABCA1453920618EA4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_70E8211EAF873EB17814453920612B94_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_70E8211EAF873EB17814453920612B94" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock-based Compensation Expense Allocation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_70E8211EAF873EB17814453920612B94_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_70E8211EAF873EB17814453920612B94" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_70E8211EAF873EB17814453920612B94" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_70E8211EAF873EB17814453920612B94" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_70E8211EAF873EB17814453920612B94" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_A645E3BED6F4489CBDD145374E54713F_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_A645E3BED6F4489CBDD145374E54713F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Intangible Assets and Goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_A645E3BED6F4489CBDD145374E54713F_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_A645E3BED6F4489CBDD145374E54713F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Intangible Assets and Goodwill [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_A645E3BED6F4489CBDD145374E54713F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_A645E3BED6F4489CBDD145374E54713F" xlink:to="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_A645E3BED6F4489CBDD145374E54713F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_7D8B5E3843B4BE81DDA145374E54B8DC_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_7D8B5E3843B4BE81DDA145374E54B8DC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_7D8B5E3843B4BE81DDA145374E54B8DC_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_7D8B5E3843B4BE81DDA145374E54B8DC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_7D8B5E3843B4BE81DDA145374E54B8DC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_7D8B5E3843B4BE81DDA145374E54B8DC" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_7D8B5E3843B4BE81DDA145374E54B8DC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_89E13F4BDA88ECCF2B420F0252563B5C_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_89E13F4BDA88ECCF2B420F0252563B5C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_89E13F4BDA88ECCF2B420F0252563B5C_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_89E13F4BDA88ECCF2B420F0252563B5C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_89E13F4BDA88ECCF2B420F0252563B5C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_89E13F4BDA88ECCF2B420F0252563B5C" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_89E13F4BDA88ECCF2B420F0252563B5C" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_7B11ABAFEABF9D7793CD0F0252592B2B_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems_7B11ABAFEABF9D7793CD0F0252592B2B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_7B11ABAFEABF9D7793CD0F0252592B2B_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems_7B11ABAFEABF9D7793CD0F0252592B2B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_7B11ABAFEABF9D7793CD0F0252592B2B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7B11ABAFEABF9D7793CD0F0252592B2B" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems_7B11ABAFEABF9D7793CD0F0252592B2B" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_6704FD075CD5A2115DD60F02525988A3_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod_6704FD075CD5A2115DD60F02525988A3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill acquired</link:label>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_6704FD075CD5A2115DD60F02525988A3_label_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod_6704FD075CD5A2115DD60F02525988A3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Acquired During Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_6704FD075CD5A2115DD60F02525988A3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAcquiredDuringPeriod_6704FD075CD5A2115DD60F02525988A3" xlink:to="lab_us-gaap_GoodwillAcquiredDuringPeriod_6704FD075CD5A2115DD60F02525988A3" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_947EAFAF4A83DF2572B80F02525AD2CE_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_947EAFAF4A83DF2572B80F02525AD2CE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets acquired, indefinite-lived intangible assets (IPR&amp;D)</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_947EAFAF4A83DF2572B80F02525AD2CE_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_947EAFAF4A83DF2572B80F02525AD2CE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_947EAFAF4A83DF2572B80F02525AD2CE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_947EAFAF4A83DF2572B80F02525AD2CE" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_947EAFAF4A83DF2572B80F02525AD2CE" xlink:type="arc" />
    <link:label id="lab_eols_AcquiredFinitelivedIntangibleAssetPeriodOfExtensionOfTermsBasedOnCertainPerformanceRequirements_DA9E0793A77F285DB33F0F02525A6EED_terseLabel_en-US" xlink:label="lab_eols_AcquiredFinitelivedIntangibleAssetPeriodOfExtensionOfTermsBasedOnCertainPerformanceRequirements_DA9E0793A77F285DB33F0F02525A6EED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Extension period</link:label>
    <link:label id="lab_eols_AcquiredFinitelivedIntangibleAssetPeriodOfExtensionOfTermsBasedOnCertainPerformanceRequirements_DA9E0793A77F285DB33F0F02525A6EED_label_en-US" xlink:label="lab_eols_AcquiredFinitelivedIntangibleAssetPeriodOfExtensionOfTermsBasedOnCertainPerformanceRequirements_DA9E0793A77F285DB33F0F02525A6EED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acquired Finite-lived Intangible Asset, Period Of Extension Of Terms Based On Certain Performance Requirements</link:label>
    <link:label id="lab_eols_AcquiredFinitelivedIntangibleAssetPeriodOfExtensionOfTermsBasedOnCertainPerformanceRequirements_DA9E0793A77F285DB33F0F02525A6EED_documentation_en-US" xlink:label="lab_eols_AcquiredFinitelivedIntangibleAssetPeriodOfExtensionOfTermsBasedOnCertainPerformanceRequirements_DA9E0793A77F285DB33F0F02525A6EED" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Acquired Finite-lived Intangible Asset, Period Of Extension Of Terms Based On Certain Performance Requirements</link:label>
    <link:loc xlink:href="eols-20190930.xsd#eols_AcquiredFinitelivedIntangibleAssetPeriodOfExtensionOfTermsBasedOnCertainPerformanceRequirements" xlink:label="loc_eols_AcquiredFinitelivedIntangibleAssetPeriodOfExtensionOfTermsBasedOnCertainPerformanceRequirements_DA9E0793A77F285DB33F0F02525A6EED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_AcquiredFinitelivedIntangibleAssetPeriodOfExtensionOfTermsBasedOnCertainPerformanceRequirements_DA9E0793A77F285DB33F0F02525A6EED" xlink:to="lab_eols_AcquiredFinitelivedIntangibleAssetPeriodOfExtensionOfTermsBasedOnCertainPerformanceRequirements_DA9E0793A77F285DB33F0F02525A6EED" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_5E7A4B640899CAE32A590F02525A0F2A_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_5E7A4B640899CAE32A590F02525A0F2A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration upon successful completion of certain technical and sales milestones</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_5E7A4B640899CAE32A590F02525A0F2A_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_5E7A4B640899CAE32A590F02525A0F2A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_5E7A4B640899CAE32A590F02525A0F2A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_5E7A4B640899CAE32A590F02525A0F2A" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_5E7A4B640899CAE32A590F02525A0F2A" xlink:type="arc" />
    <link:label id="lab_eols_MilestonePaymentsForIntangibleAssets_4F2E736B012193829E440F02525A9EEE_verboseLabel_en-US" xlink:label="lab_eols_MilestonePaymentsForIntangibleAssets_4F2E736B012193829E440F02525A9EEE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Milestone payment for intangible assets</link:label>
    <link:loc xlink:href="eols-20190930.xsd#eols_MilestonePaymentsForIntangibleAssets" xlink:label="loc_eols_MilestonePaymentsForIntangibleAssets_4F2E736B012193829E440F02525A9EEE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_MilestonePaymentsForIntangibleAssets_4F2E736B012193829E440F02525A9EEE" xlink:to="lab_eols_MilestonePaymentsForIntangibleAssets_4F2E736B012193829E440F02525A9EEE" xlink:type="arc" />
    <link:label id="lab_us-gaap_CapitalizedComputerSoftwareAdditions_93385DC9E5964F28A0810F02525ADBB9_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedComputerSoftwareAdditions_93385DC9E5964F28A0810F02525ADBB9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capitalized computer software</link:label>
    <link:label id="lab_us-gaap_CapitalizedComputerSoftwareAdditions_93385DC9E5964F28A0810F02525ADBB9_label_en-US" xlink:label="lab_us-gaap_CapitalizedComputerSoftwareAdditions_93385DC9E5964F28A0810F02525ADBB9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capitalized Computer Software, Additions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalizedComputerSoftwareAdditions" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareAdditions_93385DC9E5964F28A0810F02525ADBB9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedComputerSoftwareAdditions_93385DC9E5964F28A0810F02525ADBB9" xlink:to="lab_us-gaap_CapitalizedComputerSoftwareAdditions_93385DC9E5964F28A0810F02525ADBB9" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_8193A3E2CD2BDA5B04350F02525BCD7B_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_8193A3E2CD2BDA5B04350F02525BCD7B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Amortization period</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_8193A3E2CD2BDA5B04350F02525BCD7B_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_8193A3E2CD2BDA5B04350F02525BCD7B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Remaining Amortization Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_8193A3E2CD2BDA5B04350F02525BCD7B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_8193A3E2CD2BDA5B04350F02525BCD7B" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_8193A3E2CD2BDA5B04350F02525BCD7B" xlink:type="arc" />
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_D21891A11368DA33B9E80F02525BEEF8_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets_D21891A11368DA33B9E80F02525BEEF8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization expense</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_D21891A11368DA33B9E80F02525BEEF8_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets_D21891A11368DA33B9E80F02525BEEF8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_D21891A11368DA33B9E80F02525BEEF8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets_D21891A11368DA33B9E80F02525BEEF8" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets_D21891A11368DA33B9E80F02525BEEF8" xlink:type="arc" />
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_4FF5E2B5278FD125115745374E9A5712_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_4FF5E2B5278FD125115745374E9A5712" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_4FF5E2B5278FD125115745374E9A5712_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_4FF5E2B5278FD125115745374E9A5712" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_4FF5E2B5278FD125115745374E9A5712" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_4FF5E2B5278FD125115745374E9A5712" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_4FF5E2B5278FD125115745374E9A5712" xlink:type="arc" />
    <link:label id="lab_us-gaap_UseOfEstimates_80FA6B5AAC71F1E2392A45374E9AA33B_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates_80FA6B5AAC71F1E2392A45374E9AA33B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_80FA6B5AAC71F1E2392A45374E9AA33B_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates_80FA6B5AAC71F1E2392A45374E9AA33B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_80FA6B5AAC71F1E2392A45374E9AA33B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates_80FA6B5AAC71F1E2392A45374E9AA33B" xlink:to="lab_us-gaap_UseOfEstimates_80FA6B5AAC71F1E2392A45374E9AA33B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_26776B03A7C2405646D645374E9AA248_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk_26776B03A7C2405646D645374E9AA248" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk and Uncertainties</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_26776B03A7C2405646D645374E9AA248_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk_26776B03A7C2405646D645374E9AA248" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_26776B03A7C2405646D645374E9AA248" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk_26776B03A7C2405646D645374E9AA248" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk_26776B03A7C2405646D645374E9AA248" xlink:type="arc" />
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_736ADDF1C214CDBDFA1D45374E9A0C5D_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_736ADDF1C214CDBDFA1D45374E9A0C5D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Reporting</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_736ADDF1C214CDBDFA1D45374E9A0C5D_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_736ADDF1C214CDBDFA1D45374E9A0C5D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_736ADDF1C214CDBDFA1D45374E9A0C5D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_736ADDF1C214CDBDFA1D45374E9A0C5D" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_736ADDF1C214CDBDFA1D45374E9A0C5D" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_3D76DFF18C73EED4867C45374E9B69A9_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_3D76DFF18C73EED4867C45374E9B69A9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_3D76DFF18C73EED4867C45374E9B69A9_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_3D76DFF18C73EED4867C45374E9B69A9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_3D76DFF18C73EED4867C45374E9B69A9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_3D76DFF18C73EED4867C45374E9B69A9" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_3D76DFF18C73EED4867C45374E9B69A9" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_F13EB86AD125EA952D5845374E9B5FF2_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock_F13EB86AD125EA952D5845374E9B5FF2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-Term Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_F13EB86AD125EA952D5845374E9B5FF2_label_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock_F13EB86AD125EA952D5845374E9B5FF2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock_F13EB86AD125EA952D5845374E9B5FF2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentPolicyTextBlock_F13EB86AD125EA952D5845374E9B5FF2" xlink:to="lab_us-gaap_InvestmentPolicyTextBlock_F13EB86AD125EA952D5845374E9B5FF2" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_CE2450482B8D14D994E145374E9B86B7_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock_CE2450482B8D14D994E145374E9B86B7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_CE2450482B8D14D994E145374E9B86B7_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock_CE2450482B8D14D994E145374E9B86B7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_CE2450482B8D14D994E145374E9B86B7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock_CE2450482B8D14D994E145374E9B86B7" xlink:to="lab_us-gaap_InventoryPolicyTextBlock_CE2450482B8D14D994E145374E9B86B7" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_8B9985D9A4A271F0B9B545374E9B063D_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_8B9985D9A4A271F0B9B545374E9B063D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_8B9985D9A4A271F0B9B545374E9B063D_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_8B9985D9A4A271F0B9B545374E9B063D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_8B9985D9A4A271F0B9B545374E9B063D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_8B9985D9A4A271F0B9B545374E9B063D" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_8B9985D9A4A271F0B9B545374E9B063D" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_10DC7BA107418D381ECA45374E9B33EF_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_10DC7BA107418D381ECA45374E9B33EF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_10DC7BA107418D381ECA45374E9B33EF_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_10DC7BA107418D381ECA45374E9B33EF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_10DC7BA107418D381ECA45374E9B33EF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_10DC7BA107418D381ECA45374E9B33EF" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_10DC7BA107418D381ECA45374E9B33EF" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_37E533A688663B0CFBD245374E9B0081_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_37E533A688663B0CFBD245374E9B0081" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_37E533A688663B0CFBD245374E9B0081_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_37E533A688663B0CFBD245374E9B0081" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_37E533A688663B0CFBD245374E9B0081" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_37E533A688663B0CFBD245374E9B0081" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_37E533A688663B0CFBD245374E9B0081" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_3FBF68EF952D572BB5BA45374E9BEA5E_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock_3FBF68EF952D572BB5BA45374E9BEA5E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_3FBF68EF952D572BB5BA45374E9BEA5E_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock_3FBF68EF952D572BB5BA45374E9BEA5E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_3FBF68EF952D572BB5BA45374E9BEA5E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock_3FBF68EF952D572BB5BA45374E9BEA5E" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock_3FBF68EF952D572BB5BA45374E9BEA5E" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_265940C8459102395B3B45374E9C2B77_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_265940C8459102395B3B45374E9C2B77" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent Royalty Obligation Payable to the Evolus Founders</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_265940C8459102395B3B45374E9C2B77_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_265940C8459102395B3B45374E9C2B77" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_265940C8459102395B3B45374E9C2B77" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_265940C8459102395B3B45374E9C2B77" xlink:to="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_265940C8459102395B3B45374E9C2B77" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtPolicyTextBlock_9766889637DB8B29D22245374E9C1A16_terseLabel_en-US" xlink:label="lab_us-gaap_DebtPolicyTextBlock_9766889637DB8B29D22245374E9C1A16" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Term Debt</link:label>
    <link:label id="lab_us-gaap_DebtPolicyTextBlock_9766889637DB8B29D22245374E9C1A16_label_en-US" xlink:label="lab_us-gaap_DebtPolicyTextBlock_9766889637DB8B29D22245374E9C1A16" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="loc_us-gaap_DebtPolicyTextBlock_9766889637DB8B29D22245374E9C1A16" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtPolicyTextBlock_9766889637DB8B29D22245374E9C1A16" xlink:to="lab_us-gaap_DebtPolicyTextBlock_9766889637DB8B29D22245374E9C1A16" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_AFBF295429AC230D6E4045374E9CDB4E_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_AFBF295429AC230D6E4045374E9CDB4E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_AFBF295429AC230D6E4045374E9CDB4E_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_AFBF295429AC230D6E4045374E9CDB4E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_AFBF295429AC230D6E4045374E9CDB4E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_AFBF295429AC230D6E4045374E9CDB4E" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_AFBF295429AC230D6E4045374E9CDB4E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_5109EF9FC53F9D34960445374E9C8546_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_5109EF9FC53F9D34960445374E9C8546" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_5109EF9FC53F9D34960445374E9C8546_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_5109EF9FC53F9D34960445374E9C8546" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_5109EF9FC53F9D34960445374E9C8546" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_5109EF9FC53F9D34960445374E9C8546" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_5109EF9FC53F9D34960445374E9C8546" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_315EABE5698C375772BB45374E9CD884_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock_315EABE5698C375772BB45374E9CD884" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_315EABE5698C375772BB45374E9CD884_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock_315EABE5698C375772BB45374E9CD884" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_315EABE5698C375772BB45374E9CD884" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock_315EABE5698C375772BB45374E9CD884" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock_315EABE5698C375772BB45374E9CD884" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_2DBAC053A391595A6B7045374E9C966E_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock_2DBAC053A391595A6B7045374E9C966E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_2DBAC053A391595A6B7045374E9C966E_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock_2DBAC053A391595A6B7045374E9C966E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_2DBAC053A391595A6B7045374E9C966E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock_2DBAC053A391595A6B7045374E9C966E" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock_2DBAC053A391595A6B7045374E9C966E" xlink:type="arc" />
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_DF16E80D5833AD02933045374E9C0AD4_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_DF16E80D5833AD02933045374E9C0AD4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_DF16E80D5833AD02933045374E9C0AD4_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_DF16E80D5833AD02933045374E9C0AD4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_DF16E80D5833AD02933045374E9C0AD4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_DF16E80D5833AD02933045374E9C0AD4" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_DF16E80D5833AD02933045374E9C0AD4" xlink:type="arc" />
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_27B3440615772490C5220EF6E14F0A7C_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_27B3440615772490C5220EF6E14F0A7C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Table]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_27B3440615772490C5220EF6E14F0A7C_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_27B3440615772490C5220EF6E14F0A7C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_27B3440615772490C5220EF6E14F0A7C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_27B3440615772490C5220EF6E14F0A7C" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_27B3440615772490C5220EF6E14F0A7C" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_B0DD478C69CEB484652C0EF6E150B6D1_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_B0DD478C69CEB484652C0EF6E150B6D1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</link:label>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_B0DD478C69CEB484652C0EF6E150B6D1_label_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_B0DD478C69CEB484652C0EF6E150B6D1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_B0DD478C69CEB484652C0EF6E150B6D1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_B0DD478C69CEB484652C0EF6E150B6D1" xlink:to="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_B0DD478C69CEB484652C0EF6E150B6D1" xlink:type="arc" />
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_06DD188E3BF67D1D09210EF6E1501420_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember_06DD188E3BF67D1D09210EF6E1501420" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Type of Adoption [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_06DD188E3BF67D1D09210EF6E1501420_label_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember_06DD188E3BF67D1D09210EF6E1501420" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Type of Adoption [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_06DD188E3BF67D1D09210EF6E1501420" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfAdoptionMember_06DD188E3BF67D1D09210EF6E1501420" xlink:to="lab_us-gaap_TypeOfAdoptionMember_06DD188E3BF67D1D09210EF6E1501420" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201602Member_6097BFA444F12996F9000EF6E150890F_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201602Member_6097BFA444F12996F9000EF6E150890F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments Due to the Adoption of ASC 842</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201602Member_6097BFA444F12996F9000EF6E150890F_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201602Member_6097BFA444F12996F9000EF6E150890F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Standards Update 2016-02 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_6097BFA444F12996F9000EF6E150890F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201602Member_6097BFA444F12996F9000EF6E150890F" xlink:to="lab_us-gaap_AccountingStandardsUpdate201602Member_6097BFA444F12996F9000EF6E150890F" xlink:type="arc" />
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_34A682CC5743AD04DF470EF6E151EB3E_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_34A682CC5743AD04DF470EF6E151EB3E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_34A682CC5743AD04DF470EF6E151EB3E_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_34A682CC5743AD04DF470EF6E151EB3E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_34A682CC5743AD04DF470EF6E151EB3E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_34A682CC5743AD04DF470EF6E151EB3E" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_34A682CC5743AD04DF470EF6E151EB3E" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_52D3374BC416E99A33B30EF6E151EF71_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset_52D3374BC416E99A33B30EF6E151EF71" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_52D3374BC416E99A33B30EF6E151EF71" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset_52D3374BC416E99A33B30EF6E151EF71" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset_52D3374BC416E99A33B30EF6E151EF71" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_DE02D2877123A1AF3B6B0EF6E1511B9C_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent_DE02D2877123A1AF3B6B0EF6E1511B9C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current portion of operating lease liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_DE02D2877123A1AF3B6B0EF6E1511B9C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent_DE02D2877123A1AF3B6B0EF6E1511B9C" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent_DE02D2877123A1AF3B6B0EF6E1511B9C" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_E855C31495F9093F13180EF6E151619B_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_E855C31495F9093F13180EF6E151619B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_E855C31495F9093F13180EF6E151619B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_E855C31495F9093F13180EF6E151619B" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_E855C31495F9093F13180EF6E151619B" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredRentCreditNoncurrent_99E302C63767313671290EFDCF90944D_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredRentCreditNoncurrent_99E302C63767313671290EFDCF90944D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred rent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="loc_us-gaap_DeferredRentCreditNoncurrent_99E302C63767313671290EFDCF90944D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRentCreditNoncurrent_99E302C63767313671290EFDCF90944D" xlink:to="lab_us-gaap_DeferredRentCreditNoncurrent_99E302C63767313671290EFDCF90944D" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_7113B205FC29734B7374FEEBEEFCFA33_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_7113B205FC29734B7374FEEBEEFCFA33" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_7113B205FC29734B7374FEEBEEFCFA33_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_7113B205FC29734B7374FEEBEEFCFA33" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_7113B205FC29734B7374FEEBEEFCFA33" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_7113B205FC29734B7374FEEBEEFCFA33" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_7113B205FC29734B7374FEEBEEFCFA33" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_437D9A9B3E056309AB1BFEEBEEFCDECD_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_437D9A9B3E056309AB1BFEEBEEFCDECD" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_437D9A9B3E056309AB1BFEEBEEFCDECD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_437D9A9B3E056309AB1BFEEBEEFCDECD" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_437D9A9B3E056309AB1BFEEBEEFCDECD" xlink:type="arc" />
    <link:label id="lab_eols_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityPayments_C1401E2A56C73302922AFEEBEEFD4D6D_negatedTerseLabel_en-US" xlink:label="lab_eols_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityPayments_C1401E2A56C73302922AFEEBEEFD4D6D" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payments</link:label>
    <link:label id="lab_eols_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityPayments_C1401E2A56C73302922AFEEBEEFD4D6D_label_en-US" xlink:label="lab_eols_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityPayments_C1401E2A56C73302922AFEEBEEFD4D6D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Payments</link:label>
    <link:label id="lab_eols_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityPayments_C1401E2A56C73302922AFEEBEEFD4D6D_documentation_en-US" xlink:label="lab_eols_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityPayments_C1401E2A56C73302922AFEEBEEFD4D6D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Payments</link:label>
    <link:loc xlink:href="eols-20190930.xsd#eols_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityPayments" xlink:label="loc_eols_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityPayments_C1401E2A56C73302922AFEEBEEFD4D6D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityPayments_C1401E2A56C73302922AFEEBEEFD4D6D" xlink:to="lab_eols_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityPayments_C1401E2A56C73302922AFEEBEEFD4D6D" xlink:type="arc" />
    <link:label id="lab_eols_RevaluationofContingentRoyaltyObligationPayable_B30980BB4C0A5C8792FEFEEBEEFDC6DE_verboseLabel_en-US" xlink:label="lab_eols_RevaluationofContingentRoyaltyObligationPayable_B30980BB4C0A5C8792FEFEEBEEFDC6DE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value recorded in operating expenses</link:label>
    <link:loc xlink:href="eols-20190930.xsd#eols_RevaluationofContingentRoyaltyObligationPayable" xlink:label="loc_eols_RevaluationofContingentRoyaltyObligationPayable_B30980BB4C0A5C8792FEFEEBEEFDC6DE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_RevaluationofContingentRoyaltyObligationPayable_B30980BB4C0A5C8792FEFEEBEEFDC6DE" xlink:to="lab_eols_RevaluationofContingentRoyaltyObligationPayable_B30980BB4C0A5C8792FEFEEBEEFDC6DE" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_6719326334B49078B804FEEBEEFD651B_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_6719326334B49078B804FEEBEEFD651B" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_6719326334B49078B804FEEBEEFD651B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_6719326334B49078B804FEEBEEFD651B" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_6719326334B49078B804FEEBEEFD651B" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_9EEE5DFC7A6EFFD210DD284202D9C2E1_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent_9EEE5DFC7A6EFFD210DD284202D9C2E1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued professional services</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_9EEE5DFC7A6EFFD210DD284202D9C2E1_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent_9EEE5DFC7A6EFFD210DD284202D9C2E1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_9EEE5DFC7A6EFFD210DD284202D9C2E1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent_9EEE5DFC7A6EFFD210DD284202D9C2E1" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent_9EEE5DFC7A6EFFD210DD284202D9C2E1" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_70BA3AD813F6AB26FC76284202DB4DEB_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_70BA3AD813F6AB26FC76284202DB4DEB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued payroll and related benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_70BA3AD813F6AB26FC76284202DB4DEB_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_70BA3AD813F6AB26FC76284202DB4DEB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_70BA3AD813F6AB26FC76284202DB4DEB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_70BA3AD813F6AB26FC76284202DB4DEB" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_70BA3AD813F6AB26FC76284202DB4DEB" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_4DAA4AF3AE4531245F72284202DB89E6_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent_4DAA4AF3AE4531245F72284202DB89E6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other accrued expenses</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_4DAA4AF3AE4531245F72284202DB89E6_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent_4DAA4AF3AE4531245F72284202DB89E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_4DAA4AF3AE4531245F72284202DB89E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent_4DAA4AF3AE4531245F72284202DB89E6" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent_4DAA4AF3AE4531245F72284202DB89E6" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_0CE996C66EBBCAC96171284202DBB128_totalLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_0CE996C66EBBCAC96171284202DBB128" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued liabilities, current</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_0CE996C66EBBCAC96171284202DBB128_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_0CE996C66EBBCAC96171284202DBB128" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_0CE996C66EBBCAC96171284202DBB128" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_0CE996C66EBBCAC96171284202DBB128" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_0CE996C66EBBCAC96171284202DBB128" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9B31E8796ADBE46220BE45374F587EED_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9B31E8796ADBE46220BE45374F587EED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Stock Unit</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9B31E8796ADBE46220BE45374F587EED_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9B31E8796ADBE46220BE45374F587EED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9B31E8796ADBE46220BE45374F587EED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9B31E8796ADBE46220BE45374F587EED" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9B31E8796ADBE46220BE45374F587EED" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_B2D903DF15D797CA038545374F585C3A_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_B2D903DF15D797CA038545374F585C3A" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_B2D903DF15D797CA038545374F585C3A_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_B2D903DF15D797CA038545374F585C3A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_B2D903DF15D797CA038545374F585C3A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_B2D903DF15D797CA038545374F585C3A" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_B2D903DF15D797CA038545374F585C3A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_A6388630CC1C59A8953045374F5883E5_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_A6388630CC1C59A8953045374F5883E5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_A6388630CC1C59A8953045374F5883E5_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_A6388630CC1C59A8953045374F5883E5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_A6388630CC1C59A8953045374F5883E5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_A6388630CC1C59A8953045374F5883E5" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_A6388630CC1C59A8953045374F5883E5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_C6BC2A82AE84ED10F74545374F58ACE8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_C6BC2A82AE84ED10F74545374F58ACE8" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_C6BC2A82AE84ED10F74545374F58ACE8_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_C6BC2A82AE84ED10F74545374F58ACE8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_C6BC2A82AE84ED10F74545374F58ACE8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_C6BC2A82AE84ED10F74545374F58ACE8" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_C6BC2A82AE84ED10F74545374F58ACE8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_A6C5B9489CDFF441B26145374F59713D_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_A6C5B9489CDFF441B26145374F59713D" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_A6C5B9489CDFF441B26145374F59713D_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_A6C5B9489CDFF441B26145374F59713D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_A6C5B9489CDFF441B26145374F59713D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_A6C5B9489CDFF441B26145374F59713D" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_A6C5B9489CDFF441B26145374F59713D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_E7B47C6761168B4F4CC945374F59698D_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_E7B47C6761168B4F4CC945374F59698D" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_E7B47C6761168B4F4CC945374F59698D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_E7B47C6761168B4F4CC945374F59698D" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_E7B47C6761168B4F4CC945374F59698D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_2C054314F62C9665040045374F5988CD_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_2C054314F62C9665040045374F5988CD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_2C054314F62C9665040045374F5988CD_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_2C054314F62C9665040045374F5988CD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_2C054314F62C9665040045374F5988CD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_2C054314F62C9665040045374F5988CD" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_2C054314F62C9665040045374F5988CD" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_AEBD9D91A2F27678B38445374F59987A_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_AEBD9D91A2F27678B38445374F59987A" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_AEBD9D91A2F27678B38445374F59987A_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_AEBD9D91A2F27678B38445374F59987A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_AEBD9D91A2F27678B38445374F59987A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_AEBD9D91A2F27678B38445374F59987A" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_AEBD9D91A2F27678B38445374F59987A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_E88A7833EB1DDFAF20C445374F593810_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_E88A7833EB1DDFAF20C445374F593810" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_E88A7833EB1DDFAF20C445374F593810_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_E88A7833EB1DDFAF20C445374F593810" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_E88A7833EB1DDFAF20C445374F593810" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_E88A7833EB1DDFAF20C445374F593810" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_E88A7833EB1DDFAF20C445374F593810" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_35C932577D4BA89E6E8C45374F5918D5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_35C932577D4BA89E6E8C45374F5918D5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_35C932577D4BA89E6E8C45374F5918D5_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_35C932577D4BA89E6E8C45374F5918D5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_35C932577D4BA89E6E8C45374F5918D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_35C932577D4BA89E6E8C45374F5918D5" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_35C932577D4BA89E6E8C45374F5918D5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_4E4689D8C5D40BE1DFC345374F5A3E27_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_4E4689D8C5D40BE1DFC345374F5A3E27" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_4E4689D8C5D40BE1DFC345374F5A3E27_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_4E4689D8C5D40BE1DFC345374F5A3E27" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_4E4689D8C5D40BE1DFC345374F5A3E27" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_4E4689D8C5D40BE1DFC345374F5A3E27" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_4E4689D8C5D40BE1DFC345374F5A3E27" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_5D6F83BB046AAC07E41545374F5A38E9_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_5D6F83BB046AAC07E41545374F5A38E9" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in dollars per share)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_5D6F83BB046AAC07E41545374F5A38E9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_5D6F83BB046AAC07E41545374F5A38E9" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_5D6F83BB046AAC07E41545374F5A38E9" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_7C79037918ADCBD54C5B45374F090B14_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_7C79037918ADCBD54C5B45374F090B14" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remaining in 2019</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_7C79037918ADCBD54C5B45374F090B14_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_7C79037918ADCBD54C5B45374F090B14" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Remainder of Fiscal Year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_7C79037918ADCBD54C5B45374F090B14" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_7C79037918ADCBD54C5B45374F090B14" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_7C79037918ADCBD54C5B45374F090B14" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_70624366894F7A1E81C745374F09A8C7_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_70624366894F7A1E81C745374F09A8C7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2020</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_70624366894F7A1E81C745374F09A8C7_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_70624366894F7A1E81C745374F09A8C7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Two</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_70624366894F7A1E81C745374F09A8C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_70624366894F7A1E81C745374F09A8C7" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_70624366894F7A1E81C745374F09A8C7" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_29E9AC60910E00C1D01E45374F0A26B7_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_29E9AC60910E00C1D01E45374F0A26B7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_29E9AC60910E00C1D01E45374F0A26B7_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_29E9AC60910E00C1D01E45374F0A26B7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Three</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_29E9AC60910E00C1D01E45374F0A26B7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_29E9AC60910E00C1D01E45374F0A26B7" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_29E9AC60910E00C1D01E45374F0A26B7" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_C322B1C731412D7AA69B45374F0A569E_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_C322B1C731412D7AA69B45374F0A569E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_C322B1C731412D7AA69B45374F0A569E_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_C322B1C731412D7AA69B45374F0A569E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Four</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_C322B1C731412D7AA69B45374F0A569E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_C322B1C731412D7AA69B45374F0A569E" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_C322B1C731412D7AA69B45374F0A569E" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_C940D565A6E0CC2A6DA545374F0A3FE7_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_C940D565A6E0CC2A6DA545374F0A3FE7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_C940D565A6E0CC2A6DA545374F0A3FE7_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_C940D565A6E0CC2A6DA545374F0A3FE7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_C940D565A6E0CC2A6DA545374F0A3FE7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_C940D565A6E0CC2A6DA545374F0A3FE7" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_C940D565A6E0CC2A6DA545374F0A3FE7" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_CCB2A7976CA9CC052BA145374F0AAF63_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_CCB2A7976CA9CC052BA145374F0AAF63" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_CCB2A7976CA9CC052BA145374F0AAF63_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_CCB2A7976CA9CC052BA145374F0AAF63" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, after Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_CCB2A7976CA9CC052BA145374F0AAF63" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_CCB2A7976CA9CC052BA145374F0AAF63" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_CCB2A7976CA9CC052BA145374F0AAF63" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_B702E0EC757FA580C0831835DA9ADD78_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_B702E0EC757FA580C0831835DA9ADD78" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash used in operations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_B702E0EC757FA580C0831835DA9ADD78" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_B702E0EC757FA580C0831835DA9ADD78" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_B702E0EC757FA580C0831835DA9ADD78" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_85CB5F270A7C1512C5CA1835DA9B6251_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_85CB5F270A7C1512C5CA1835DA9B6251" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents, and short-term investments</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_85CB5F270A7C1512C5CA1835DA9B6251_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_85CB5F270A7C1512C5CA1835DA9B6251" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, and Short-term Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_85CB5F270A7C1512C5CA1835DA9B6251" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_85CB5F270A7C1512C5CA1835DA9B6251" xlink:to="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_85CB5F270A7C1512C5CA1835DA9B6251" xlink:type="arc" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>eols-20190930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.evolus.com/role/AccruedExpenses" xlink:href="eols-20190930.xsd#AccruedExpenses" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/AccruedExpensesDetails" xlink:href="eols-20190930.xsd#AccruedExpensesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/AccruedExpensesTables" xlink:href="eols-20190930.xsd#AccruedExpensesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/CommitmentsAndContingencies" xlink:href="eols-20190930.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/CommitmentsAndContingenciesLeaseCostDetails" xlink:href="eols-20190930.xsd#CommitmentsAndContingenciesLeaseCostDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/CommitmentsAndContingenciesNarrativeDetails" xlink:href="eols-20190930.xsd#CommitmentsAndContingenciesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/CommitmentsAndContingenciesOperatingLeaseMaturityDetails" xlink:href="eols-20190930.xsd#CommitmentsAndContingenciesOperatingLeaseMaturityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/CommitmentsAndContingenciesTables" xlink:href="eols-20190930.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/CondensedBalanceSheets" xlink:href="eols-20190930.xsd#CondensedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/CondensedBalanceSheetsParenthetical" xlink:href="eols-20190930.xsd#CondensedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/CondensedStatementsOfCashFlows" xlink:href="eols-20190930.xsd#CondensedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/CondensedStatementsOfOperationsAndComprehensiveLoss" xlink:href="eols-20190930.xsd#CondensedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/CondensedStatementsOfStockholdersEquity" xlink:href="eols-20190930.xsd#CondensedStatementsOfStockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/DescriptionOfBusinessAndBasisOfPresentation" xlink:href="eols-20190930.xsd#DescriptionOfBusinessAndBasisOfPresentation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/DescriptionOfBusinessAndBasisOfPresentationDetails" xlink:href="eols-20190930.xsd#DescriptionOfBusinessAndBasisOfPresentationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/DocumentAndEntityInformation" xlink:href="eols-20190930.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/FairValueMeasurementsAndShortTermInvestments" xlink:href="eols-20190930.xsd#FairValueMeasurementsAndShortTermInvestments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/FairValueMeasurementsAndShortTermInvestmentsAssetsAndLiabilitiesOnRecurringBasisDetails" xlink:href="eols-20190930.xsd#FairValueMeasurementsAndShortTermInvestmentsAssetsAndLiabilitiesOnRecurringBasisDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/FairValueMeasurementsAndShortTermInvestmentsContingentRoyaltyObligationDetails" xlink:href="eols-20190930.xsd#FairValueMeasurementsAndShortTermInvestmentsContingentRoyaltyObligationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/FairValueMeasurementsAndShortTermInvestmentsNarrativeDetails" xlink:href="eols-20190930.xsd#FairValueMeasurementsAndShortTermInvestmentsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/FairValueMeasurementsAndShortTermInvestmentsScheduleOfShortTermInvestmentsDetails" xlink:href="eols-20190930.xsd#FairValueMeasurementsAndShortTermInvestmentsScheduleOfShortTermInvestmentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/FairValueMeasurementsAndShortTermInvestmentsTables" xlink:href="eols-20190930.xsd#FairValueMeasurementsAndShortTermInvestmentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/GoodwillAndIntangibleAssetNarrativeDetails" xlink:href="eols-20190930.xsd#GoodwillAndIntangibleAssetNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/GoodwillAndIntangibleAssets" xlink:href="eols-20190930.xsd#GoodwillAndIntangibleAssets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/GoodwillAndIntangibleAssetsFutureAmortizationExpenseDetails" xlink:href="eols-20190930.xsd#GoodwillAndIntangibleAssetsFutureAmortizationExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/GoodwillAndIntangibleAssetsScheduleOfDefiniteAndIndefiniteLivedIntangibleAssetsDetails" xlink:href="eols-20190930.xsd#GoodwillAndIntangibleAssetsScheduleOfDefiniteAndIndefiniteLivedIntangibleAssetsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/GoodwillAndIntangibleAssetsTables" xlink:href="eols-20190930.xsd#GoodwillAndIntangibleAssetsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/OxfordTermLoans" xlink:href="eols-20190930.xsd#OxfordTermLoans" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/OxfordTermLoansMaturitiesOfDebtDetails" xlink:href="eols-20190930.xsd#OxfordTermLoansMaturitiesOfDebtDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/OxfordTermLoansNarrativeDetails" xlink:href="eols-20190930.xsd#OxfordTermLoansNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/OxfordTermLoansTables" xlink:href="eols-20190930.xsd#OxfordTermLoansTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/RelatedPartyTransactions" xlink:href="eols-20190930.xsd#RelatedPartyTransactions" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/RelatedPartyTransactionsDetails" xlink:href="eols-20190930.xsd#RelatedPartyTransactionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/StockholdersEquity" xlink:href="eols-20190930.xsd#StockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/StockholdersEquityNarrativeDetails" xlink:href="eols-20190930.xsd#StockholdersEquityNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/StockholdersEquityRestrictedStockUnitDetails" xlink:href="eols-20190930.xsd#StockholdersEquityRestrictedStockUnitDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/StockholdersEquityScheduleOfStockOptionActivityDetails" xlink:href="eols-20190930.xsd#StockholdersEquityScheduleOfStockOptionActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/StockholdersEquityScheduleOfValuationAssumptionsDetails" xlink:href="eols-20190930.xsd#StockholdersEquityScheduleOfValuationAssumptionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/StockholdersEquityStockBasedCompensationExpenseAllocationDetails" xlink:href="eols-20190930.xsd#StockholdersEquityStockBasedCompensationExpenseAllocationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/StockholdersEquityTables" xlink:href="eols-20190930.xsd#StockholdersEquityTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="eols-20190930.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:href="eols-20190930.xsd#SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/SummaryOfSignificantAccountingPoliciesNewAccountingPronouncementsDetails" xlink:href="eols-20190930.xsd#SummaryOfSignificantAccountingPoliciesNewAccountingPronouncementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="eols-20190930.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="eols-20190930.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:presentationLink xlink:role="http://www.evolus.com/role/AccruedExpenses" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_DEC2817484D01838C5561835DA5AB362" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_B6A9299E5F58FE0301D91835DA5A3B7D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_DEC2817484D01838C5561835DA5AB362" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_B6A9299E5F58FE0301D91835DA5A3B7D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/AccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_6E8BCCDAA42FFB371BD8284202D9796E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_9EEE5DFC7A6EFFD210DD284202D9C2E1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_6E8BCCDAA42FFB371BD8284202D9796E" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_9EEE5DFC7A6EFFD210DD284202D9C2E1" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_AccruedCouponAndRebateLiabilityCurrent" xlink:label="loc_eols_AccruedCouponAndRebateLiabilityCurrent_07CBD79C49A1255762E3284202D95F0D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_6E8BCCDAA42FFB371BD8284202D9796E" xlink:to="loc_eols_AccruedCouponAndRebateLiabilityCurrent_07CBD79C49A1255762E3284202D95F0D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_70BA3AD813F6AB26FC76284202DB4DEB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_6E8BCCDAA42FFB371BD8284202D9796E" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_70BA3AD813F6AB26FC76284202DB4DEB" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_MilestonePaymentCurrent" xlink:label="loc_eols_MilestonePaymentCurrent_97995C7E3DF650070A7D284202DBF901" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_6E8BCCDAA42FFB371BD8284202D9796E" xlink:to="loc_eols_MilestonePaymentCurrent_97995C7E3DF650070A7D284202DBF901" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_4DAA4AF3AE4531245F72284202DB89E6" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_6E8BCCDAA42FFB371BD8284202D9796E" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_4DAA4AF3AE4531245F72284202DB89E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_0CE996C66EBBCAC96171284202DBB128" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_6E8BCCDAA42FFB371BD8284202D9796E" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_0CE996C66EBBCAC96171284202DBB128" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/AccruedExpensesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_3F978B3F4E7F7C11233F1835DA58A4B0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_6267B2AABB2ECD062C691835DA583F98" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_3F978B3F4E7F7C11233F1835DA58A4B0" xlink:to="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_6267B2AABB2ECD062C691835DA583F98" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/CommitmentsAndContingencies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5C3893B36A5D78A467CA45374E9E8F12" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_4048F6C98BF5025164F545374E9EC3BF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5C3893B36A5D78A467CA45374E9E8F12" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_4048F6C98BF5025164F545374E9EC3BF" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/CommitmentsAndContingenciesLeaseCostDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_431E0D88C9623AC1A7A0FEEBEEEDDA40" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaap_OperatingLeaseCost_E4DD5742E71AC01E5DEEFEEBEEEDB1A0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_431E0D88C9623AC1A7A0FEEBEEEDDA40" xlink:to="loc_us-gaap_OperatingLeaseCost_E4DD5742E71AC01E5DEEFEEBEEEDB1A0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableLeaseCost" xlink:label="loc_us-gaap_VariableLeaseCost_DE44854FBC7D4A7F7001FEEBEEEE5698" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_431E0D88C9623AC1A7A0FEEBEEEDDA40" xlink:to="loc_us-gaap_VariableLeaseCost_DE44854FBC7D4A7F7001FEEBEEEE5698" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermLeaseCost" xlink:label="loc_us-gaap_ShortTermLeaseCost_C4402B8A5D3B5F26A9F1FEEBEEEE9C4E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_431E0D88C9623AC1A7A0FEEBEEEDDA40" xlink:to="loc_us-gaap_ShortTermLeaseCost_C4402B8A5D3B5F26A9F1FEEBEEEE9C4E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaap_LeaseCost_1596ADD6B3FF42DAA24BFEEBEEEE10EF" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_431E0D88C9623AC1A7A0FEEBEEEDDA40" xlink:to="loc_us-gaap_LeaseCost_1596ADD6B3FF42DAA24BFEEBEEEE10EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_6BBC37A099DA03C2D5FCFEEBEEEEFAE1" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_431E0D88C9623AC1A7A0FEEBEEEDDA40" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_6BBC37A099DA03C2D5FCFEEBEEEEFAE1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_7832705C22F9198ADDAFFEEBEEEE9DE3" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_431E0D88C9623AC1A7A0FEEBEEEDDA40" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_7832705C22F9198ADDAFFEEBEEEE9DE3" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/CommitmentsAndContingenciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_D8D8E2FAC4A4E43F9DDA0F0251C403B9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaap_LossContingenciesTable_1E48E21CE8AEE3626CAF0F0251C4915E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_D8D8E2FAC4A4E43F9DDA0F0251C403B9" xlink:to="loc_us-gaap_LossContingenciesTable_1E48E21CE8AEE3626CAF0F0251C4915E" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_670F070667BCF2CCD5FE0F0251C4D29D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_1E48E21CE8AEE3626CAF0F0251C4915E" xlink:to="loc_dei_LegalEntityAxis_670F070667BCF2CCD5FE0F0251C4D29D" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_931F9D87EF9E56660C860F0251C5F5D9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_670F070667BCF2CCD5FE0F0251C4D29D" xlink:to="loc_dei_EntityDomain_931F9D87EF9E56660C860F0251C5F5D9" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_DaewoongMember" xlink:label="loc_eols_DaewoongMember_05578B193FEBABCE4A580F0251C51666" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_931F9D87EF9E56660C860F0251C5F5D9" xlink:to="loc_eols_DaewoongMember_05578B193FEBABCE4A580F0251C51666" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaap_LossContingenciesLineItems_464E35EBE56D7DBE11D50F0251C5B8FF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_1E48E21CE8AEE3626CAF0F0251C4915E" xlink:to="loc_us-gaap_LossContingenciesLineItems_464E35EBE56D7DBE11D50F0251C5B8FF" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_LesseeOperatingLeaseTerminationPeriod" xlink:label="loc_eols_LesseeOperatingLeaseTerminationPeriod_98A9FDDAD479CF2D24CD0F0251C68591" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_464E35EBE56D7DBE11D50F0251C5B8FF" xlink:to="loc_eols_LesseeOperatingLeaseTerminationPeriod_98A9FDDAD479CF2D24CD0F0251C68591" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_LesseeOperatingLeasePeriodOfWrittenNoticePriorToLeaseTerminateDate" xlink:label="loc_eols_LesseeOperatingLeasePeriodOfWrittenNoticePriorToLeaseTerminateDate_0DADB223E557869B42D60F0251C667A5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_464E35EBE56D7DBE11D50F0251C5B8FF" xlink:to="loc_eols_LesseeOperatingLeasePeriodOfWrittenNoticePriorToLeaseTerminateDate_0DADB223E557869B42D60F0251C667A5" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_LesseeOperatingLeaseTerminationFeePeriodOfRentEquivalent" xlink:label="loc_eols_LesseeOperatingLeaseTerminationFeePeriodOfRentEquivalent_D38BD5C3F979DF2D2BF90F0251C69BAC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_464E35EBE56D7DBE11D50F0251C5B8FF" xlink:to="loc_eols_LesseeOperatingLeaseTerminationFeePeriodOfRentEquivalent_D38BD5C3F979DF2D2BF90F0251C69BAC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_D1C8ABB841C0E7CB30C10F0251C68F46" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_464E35EBE56D7DBE11D50F0251C5B8FF" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_D1C8ABB841C0E7CB30C10F0251C68F46" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_OperatingLeasePercentageOfAnnualRentEscalation" xlink:label="loc_eols_OperatingLeasePercentageOfAnnualRentEscalation_FF211E41B041A0E6AFD30F0251C62CBF" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_464E35EBE56D7DBE11D50F0251C5B8FF" xlink:to="loc_eols_OperatingLeasePercentageOfAnnualRentEscalation_FF211E41B041A0E6AFD30F0251C62CBF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseImpairmentLoss" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss_951CCD07F029A493F6840F0251C6B933" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_464E35EBE56D7DBE11D50F0251C5B8FF" xlink:to="loc_us-gaap_OperatingLeaseImpairmentLoss_951CCD07F029A493F6840F0251C6B933" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseObligation" xlink:label="loc_us-gaap_PurchaseObligation_C171B27C6335B662D15F0F0251C78BB7" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_464E35EBE56D7DBE11D50F0251C5B8FF" xlink:to="loc_us-gaap_PurchaseObligation_C171B27C6335B662D15F0F0251C78BB7" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_MilestonePaymentInConnectionWithLicenseAndSupplyAgreement" xlink:label="loc_eols_MilestonePaymentInConnectionWithLicenseAndSupplyAgreement_E5875EBFE4B24592EA8E0F0251C7BF54" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_464E35EBE56D7DBE11D50F0251C5B8FF" xlink:to="loc_eols_MilestonePaymentInConnectionWithLicenseAndSupplyAgreement_E5875EBFE4B24592EA8E0F0251C7BF54" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_MilestonePaymentCurrent" xlink:label="loc_eols_MilestonePaymentCurrent_357555C5E8440F9A45360F06F9834B36" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_464E35EBE56D7DBE11D50F0251C5B8FF" xlink:to="loc_eols_MilestonePaymentCurrent_357555C5E8440F9A45360F06F9834B36" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_B4D4A370D23E52C3BC240F0251C706DC" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_464E35EBE56D7DBE11D50F0251C5B8FF" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_B4D4A370D23E52C3BC240F0251C706DC" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/CommitmentsAndContingenciesOperatingLeaseMaturityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_177830CB97206A6E3AB8FEEBEEE8D15A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_390B18F6C66DAEA3461CFF48E1B800D4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_177830CB97206A6E3AB8FEEBEEE8D15A" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_390B18F6C66DAEA3461CFF48E1B800D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_6349BD8BC1D032C638C8FEEBEEE86954" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_390B18F6C66DAEA3461CFF48E1B800D4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_6349BD8BC1D032C638C8FEEBEEE86954" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_B4F62CE63F5E0CF10F44FEEBEEE83157" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_390B18F6C66DAEA3461CFF48E1B800D4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_B4F62CE63F5E0CF10F44FEEBEEE83157" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_371A2A9C53A80D27C007FEEBEEE890C5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_390B18F6C66DAEA3461CFF48E1B800D4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_371A2A9C53A80D27C007FEEBEEE890C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_D58D747416B1FAE8B2F1FEEBEEE97B8E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_390B18F6C66DAEA3461CFF48E1B800D4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_D58D747416B1FAE8B2F1FEEBEEE97B8E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_81EF0928C90CC0066B39FEEBEEE9B0A1" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_390B18F6C66DAEA3461CFF48E1B800D4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_81EF0928C90CC0066B39FEEBEEE9B0A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_7BBA9A64CD3751C24A46FEEBEEE9C71F" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_390B18F6C66DAEA3461CFF48E1B800D4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_7BBA9A64CD3751C24A46FEEBEEE9C71F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_F0E6045BF4356D812B52FEEBEEE9A8C8" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_390B18F6C66DAEA3461CFF48E1B800D4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_F0E6045BF4356D812B52FEEBEEE9A8C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_A90D1055DDDE88952DA0FEEBEEE939E5" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_390B18F6C66DAEA3461CFF48E1B800D4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_A90D1055DDDE88952DA0FEEBEEE939E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_BECF3AF7B4B0BD44B93DFEEBEEE9A94D" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_390B18F6C66DAEA3461CFF48E1B800D4" xlink:to="loc_us-gaap_OperatingLeaseLiability_BECF3AF7B4B0BD44B93DFEEBEEE9A94D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_2569C4CB878DCBF58179FF48772FFAEF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_177830CB97206A6E3AB8FEEBEEE8D15A" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_2569C4CB878DCBF58179FF48772FFAEF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_8B04F565A5FA080DEE2CFF477A9AE634" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_2569C4CB878DCBF58179FF48772FFAEF" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_8B04F565A5FA080DEE2CFF477A9AE634" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_7CD4A20555B37EF28771FF47BB313E63" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_2569C4CB878DCBF58179FF48772FFAEF" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_7CD4A20555B37EF28771FF47BB313E63" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_09098FB18F34BD029A02FF47EB05C42E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_2569C4CB878DCBF58179FF48772FFAEF" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_09098FB18F34BD029A02FF47EB05C42E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_8BED9297693445C93243FF481AAFB840" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_2569C4CB878DCBF58179FF48772FFAEF" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_8BED9297693445C93243FF481AAFB840" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/CommitmentsAndContingenciesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_18AB80FCA5895D164ECAFEEBEEF7FF5C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_ED493476090E8F4DA371FEEBEEF84D99" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_18AB80FCA5895D164ECAFEEBEEF7FF5C" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_ED493476090E8F4DA371FEEBEEF84D99" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_B01BC7AFBCCB0AAB7A3FFEEBEEF8EB38" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_18AB80FCA5895D164ECAFEEBEEF7FF5C" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_B01BC7AFBCCB0AAB7A3FFEEBEEF8EB38" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_8E75F682F4D0A27F0435FF469D05720D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_18AB80FCA5895D164ECAFEEBEEF7FF5C" xlink:to="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_8E75F682F4D0A27F0435FF469D05720D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/CondensedBalanceSheets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_B8F13031E625839398690EF6E21B74C3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_2F458A811A44FB73EE670EF6E21BD614" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_B8F13031E625839398690EF6E21B74C3" xlink:to="loc_us-gaap_AssetsAbstract_2F458A811A44FB73EE670EF6E21BD614" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_278C98CFCF331B6C7C450EF6E21B531C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_2F458A811A44FB73EE670EF6E21BD614" xlink:to="loc_us-gaap_AssetsCurrentAbstract_278C98CFCF331B6C7C450EF6E21B531C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2CD7A35344706DA74ED30EF6E21B338C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_278C98CFCF331B6C7C450EF6E21B531C" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2CD7A35344706DA74ED30EF6E21B338C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_D7869C8C8A381588CE000EF6E21B498C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_278C98CFCF331B6C7C450EF6E21B531C" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_D7869C8C8A381588CE000EF6E21B498C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_4BFC79BF13792AE223130EF6E21B1D98" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_278C98CFCF331B6C7C450EF6E21B531C" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_4BFC79BF13792AE223130EF6E21B1D98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_1833D8D70CDCE4A652640EF6E21B2A74" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_278C98CFCF331B6C7C450EF6E21B531C" xlink:to="loc_us-gaap_InventoryNet_1833D8D70CDCE4A652640EF6E21B2A74" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_50EABAF176BBE27F13470EF6E21B2277" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_278C98CFCF331B6C7C450EF6E21B531C" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_50EABAF176BBE27F13470EF6E21B2277" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_CF8F5603A36ACC706C400EF6E21B88E4" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_278C98CFCF331B6C7C450EF6E21B531C" xlink:to="loc_us-gaap_AssetsCurrent_CF8F5603A36ACC706C400EF6E21B88E4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_516C2645603A80DF13280EF6E21B0BAF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_2F458A811A44FB73EE670EF6E21BD614" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_516C2645603A80DF13280EF6E21B0BAF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_5F6AA08ED91C77C2F3960EF6E21BDA76" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_2F458A811A44FB73EE670EF6E21BD614" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_5F6AA08ED91C77C2F3960EF6E21BDA76" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_C6BBFCAD021B9EC1D0E90EF6E21BC28C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_2F458A811A44FB73EE670EF6E21BD614" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_C6BBFCAD021B9EC1D0E90EF6E21BC28C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_B559EB2EF8841E1105210EF6E21BBBE4" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_2F458A811A44FB73EE670EF6E21BD614" xlink:to="loc_us-gaap_Goodwill_B559EB2EF8841E1105210EF6E21BBBE4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_A1679CB1109C8E9BAF8D0EF6E21B4406" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_2F458A811A44FB73EE670EF6E21BD614" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_A1679CB1109C8E9BAF8D0EF6E21B4406" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_49276E681F476394FC340EF6E21BF3EB" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_2F458A811A44FB73EE670EF6E21BD614" xlink:to="loc_us-gaap_Assets_49276E681F476394FC340EF6E21BF3EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_589FA61E08D0C276B07D0EF6E21B1560" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_B8F13031E625839398690EF6E21B74C3" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_589FA61E08D0C276B07D0EF6E21B1560" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_26084C3ED497004483E10EF6E21BE26F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_589FA61E08D0C276B07D0EF6E21B1560" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_26084C3ED497004483E10EF6E21BE26F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_334DFD8DC5C3062AB4D10EF6E21B1663" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_26084C3ED497004483E10EF6E21BE26F" xlink:to="loc_us-gaap_AccountsPayableCurrent_334DFD8DC5C3062AB4D10EF6E21B1663" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_C79317B9E64C8C62EAED0EF6E21BD8EC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_26084C3ED497004483E10EF6E21BE26F" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_C79317B9E64C8C62EAED0EF6E21BD8EC" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_ContingentRoyaltyObligationPayabletoRelatedPartyCurrent" xlink:label="loc_eols_ContingentRoyaltyObligationPayabletoRelatedPartyCurrent_E58F10EC8C711CFE0CD70EF6E21B6A08" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_26084C3ED497004483E10EF6E21BE26F" xlink:to="loc_eols_ContingentRoyaltyObligationPayabletoRelatedPartyCurrent_E58F10EC8C711CFE0CD70EF6E21B6A08" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_73A01B71DFCC4FA614F40EF6E21B50ED" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_26084C3ED497004483E10EF6E21BE26F" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_73A01B71DFCC4FA614F40EF6E21B50ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_A098A96CE3AA4437A4E30EF6E21B4612" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_26084C3ED497004483E10EF6E21BE26F" xlink:to="loc_us-gaap_LiabilitiesCurrent_A098A96CE3AA4437A4E30EF6E21B4612" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_F23CFC40F34CD4CF6AC80EF6E21BBD11" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_589FA61E08D0C276B07D0EF6E21B1560" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_F23CFC40F34CD4CF6AC80EF6E21BBD11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="loc_us-gaap_DeferredRentCreditNoncurrent_A16F1CB1390002DAD6D80EFE5E0D80D3" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_589FA61E08D0C276B07D0EF6E21B1560" xlink:to="loc_us-gaap_DeferredRentCreditNoncurrent_A16F1CB1390002DAD6D80EFE5E0D80D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractualObligation" xlink:label="loc_us-gaap_ContractualObligation_C3D8FC9B8D3BD0F895500EF6E21BE83B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_589FA61E08D0C276B07D0EF6E21B1560" xlink:to="loc_us-gaap_ContractualObligation_C3D8FC9B8D3BD0F895500EF6E21BE83B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaap_LongTermNotesPayable_0B1885296A39FABD51240EF6E21B2DEA" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_589FA61E08D0C276B07D0EF6E21B1560" xlink:to="loc_us-gaap_LongTermNotesPayable_0B1885296A39FABD51240EF6E21B2DEA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_83115134960350A15AF00EF6E21BF584" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_589FA61E08D0C276B07D0EF6E21B1560" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_83115134960350A15AF00EF6E21BF584" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_AA2B3B44365FAE8F0E5B0EF6E21B1612" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_589FA61E08D0C276B07D0EF6E21B1560" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_AA2B3B44365FAE8F0E5B0EF6E21B1612" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_1654196692E5FD6A4EB30EF6E21B4992" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_589FA61E08D0C276B07D0EF6E21B1560" xlink:to="loc_us-gaap_Liabilities_1654196692E5FD6A4EB30EF6E21B4992" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_4A032372AE4D426E185E0EF6E21B0F6B" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_589FA61E08D0C276B07D0EF6E21B1560" xlink:to="loc_us-gaap_CommitmentsAndContingencies_4A032372AE4D426E185E0EF6E21B0F6B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_8FEE722206AC9FF88ABC0EF6E21B696F" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_589FA61E08D0C276B07D0EF6E21B1560" xlink:to="loc_us-gaap_StockholdersEquityAbstract_8FEE722206AC9FF88ABC0EF6E21B696F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_82C0DC3416A462D6D43B0EF6E21B6004" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_8FEE722206AC9FF88ABC0EF6E21B696F" xlink:to="loc_us-gaap_PreferredStockValue_82C0DC3416A462D6D43B0EF6E21B6004" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_7F660A100D52443421AD0EF6E225B212" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_8FEE722206AC9FF88ABC0EF6E21B696F" xlink:to="loc_us-gaap_CommonStockValue_7F660A100D52443421AD0EF6E225B212" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_BD04AA2D1F3DD24AE3360EF6E225186F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_8FEE722206AC9FF88ABC0EF6E21B696F" xlink:to="loc_us-gaap_AdditionalPaidInCapital_BD04AA2D1F3DD24AE3360EF6E225186F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_6A220BA3538552EC54C20EF6E225032F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_8FEE722206AC9FF88ABC0EF6E21B696F" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_6A220BA3538552EC54C20EF6E225032F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_1F0C09A6842E632F9AC80EF6E225F41F" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_8FEE722206AC9FF88ABC0EF6E21B696F" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_1F0C09A6842E632F9AC80EF6E225F41F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_D186A1A8C7FC0655D8410EF6E225DD74" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_8FEE722206AC9FF88ABC0EF6E21B696F" xlink:to="loc_us-gaap_StockholdersEquity_D186A1A8C7FC0655D8410EF6E225DD74" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_CF10D0AF24A8AB7091180EF6E2253B54" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_589FA61E08D0C276B07D0EF6E21B1560" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_CF10D0AF24A8AB7091180EF6E2253B54" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/CondensedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_2DED38E7FF6CCD04D5D2FEEBF0A72824" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_4F97A585AA2704AEF62AFEEBF0A7F663" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2DED38E7FF6CCD04D5D2FEEBF0A72824" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_4F97A585AA2704AEF62AFEEBF0A7F663" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_519A1CF7F094DBAE38FAFEEBF0A7988F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2DED38E7FF6CCD04D5D2FEEBF0A72824" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_519A1CF7F094DBAE38FAFEEBF0A7988F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_3CA4D55E4B64C74B2FBBFEEBF0A8D804" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2DED38E7FF6CCD04D5D2FEEBF0A72824" xlink:to="loc_us-gaap_PreferredStockSharesIssued_3CA4D55E4B64C74B2FBBFEEBF0A8D804" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_5B24A38D504B47C03460FEEBF0A87D72" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2DED38E7FF6CCD04D5D2FEEBF0A72824" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_5B24A38D504B47C03460FEEBF0A87D72" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_75EE8536336A58128650FEEBF0A8EB20" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2DED38E7FF6CCD04D5D2FEEBF0A72824" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_75EE8536336A58128650FEEBF0A8EB20" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_A3DDD6F83D5DF7C1BAB7FEEBF0A8EE69" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2DED38E7FF6CCD04D5D2FEEBF0A72824" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_A3DDD6F83D5DF7C1BAB7FEEBF0A8EE69" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_39B48CB88DC06006EF18FEEBF0A8EEAA" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2DED38E7FF6CCD04D5D2FEEBF0A72824" xlink:to="loc_us-gaap_CommonStockSharesIssued_39B48CB88DC06006EF18FEEBF0A8EEAA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_3037379F8795BF0C3362FEEBF0A89C44" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2DED38E7FF6CCD04D5D2FEEBF0A72824" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_3037379F8795BF0C3362FEEBF0A89C44" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/CondensedStatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_423A457965AC71AE0B451835DAD53408" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9A51797BE59EC65E43DF1835DAD6B114" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_423A457965AC71AE0B451835DAD53408" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9A51797BE59EC65E43DF1835DAD6B114" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_27DFB00E9F3B143687BD1835DAD682E0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9A51797BE59EC65E43DF1835DAD6B114" xlink:to="loc_us-gaap_NetIncomeLoss_27DFB00E9F3B143687BD1835DAD682E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_D863E70D4A8C84F93F4B1835DAD6FDB6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9A51797BE59EC65E43DF1835DAD6B114" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_D863E70D4A8C84F93F4B1835DAD6FDB6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_6AE64675CB8B77A87BAC1835DAD66407" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_D863E70D4A8C84F93F4B1835DAD6FDB6" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_6AE64675CB8B77A87BAC1835DAD66407" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_8A15F9ADDDB9984174B71835DAD74C23" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_D863E70D4A8C84F93F4B1835DAD6FDB6" xlink:to="loc_us-gaap_ShareBasedCompensation_8A15F9ADDDB9984174B71835DAD74C23" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_ProvisionsForRebateAndCouponPrograms" xlink:label="loc_eols_ProvisionsForRebateAndCouponPrograms_223672EE4B953B57F2351835DAD76907" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_D863E70D4A8C84F93F4B1835DAD6FDB6" xlink:to="loc_eols_ProvisionsForRebateAndCouponPrograms_223672EE4B953B57F2351835DAD76907" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_AmortizationOfDiscountOnShorttermInvestments" xlink:label="loc_eols_AmortizationOfDiscountOnShorttermInvestments_B2425D67354B13F9BCF61835DAD7C45B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_D863E70D4A8C84F93F4B1835DAD6FDB6" xlink:to="loc_eols_AmortizationOfDiscountOnShorttermInvestments_B2425D67354B13F9BCF61835DAD7C45B" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_OperatingLeaseRightofUseAssetAmortization" xlink:label="loc_eols_OperatingLeaseRightofUseAssetAmortization_2B47AEDF4B92277224A01835DAD73A15" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_D863E70D4A8C84F93F4B1835DAD6FDB6" xlink:to="loc_eols_OperatingLeaseRightofUseAssetAmortization_2B47AEDF4B92277224A01835DAD73A15" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_7668AA262C90F16018CD1835DAD73CAA" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_D863E70D4A8C84F93F4B1835DAD6FDB6" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_7668AA262C90F16018CD1835DAD73CAA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_2DFAF2B1812E996A1A3B1835DAD7CBB5" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_D863E70D4A8C84F93F4B1835DAD6FDB6" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_2DFAF2B1812E996A1A3B1835DAD7CBB5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_E5942EE24C455CF07CD51835DAD87FAB" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_D863E70D4A8C84F93F4B1835DAD6FDB6" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_E5942EE24C455CF07CD51835DAD87FAB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_45DCBEC19FC1BE03BF051835DAD8429D" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_D863E70D4A8C84F93F4B1835DAD6FDB6" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_45DCBEC19FC1BE03BF051835DAD8429D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_080BBC8D0212AEA5DA4C1835DAD8CD30" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_45DCBEC19FC1BE03BF051835DAD8429D" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_080BBC8D0212AEA5DA4C1835DAD8CD30" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_461072F78F2005BDAC921835DAD8C69B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_45DCBEC19FC1BE03BF051835DAD8429D" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_461072F78F2005BDAC921835DAD8C69B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_C6DD5D962B647CE919161835DAD826BF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_45DCBEC19FC1BE03BF051835DAD8429D" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_C6DD5D962B647CE919161835DAD826BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_CDEB8F695CD24DC6AFDF1835DAD87A6C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_45DCBEC19FC1BE03BF051835DAD8429D" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_CDEB8F695CD24DC6AFDF1835DAD87A6C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_6ABD2080661EDA2BF8D91835DAD8D96E" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_45DCBEC19FC1BE03BF051835DAD8429D" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_6ABD2080661EDA2BF8D91835DAD8D96E" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_IncreasedecreaseInOperatingLeaseLiabilities" xlink:label="loc_eols_IncreasedecreaseInOperatingLeaseLiabilities_F1E1CF29DBB69BF31A321835DAD91762" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_45DCBEC19FC1BE03BF051835DAD8429D" xlink:to="loc_eols_IncreasedecreaseInOperatingLeaseLiabilities_F1E1CF29DBB69BF31A321835DAD91762" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredLiabilities_B9F7DBCD269B076A34401835DAD9F181" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_45DCBEC19FC1BE03BF051835DAD8429D" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredLiabilities_B9F7DBCD269B076A34401835DAD9F181" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5066AEB44A67D04B3D081835DAD9100E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9A51797BE59EC65E43DF1835DAD6B114" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5066AEB44A67D04B3D081835DAD9100E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6A00B59BC07F63884B6C1835DAD921AC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_423A457965AC71AE0B451835DAD53408" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6A00B59BC07F63884B6C1835DAD921AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_ED9F50C0919047EED8FB1835DAD93452" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6A00B59BC07F63884B6C1835DAD921AC" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_ED9F50C0919047EED8FB1835DAD93452" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForSoftware" xlink:label="loc_us-gaap_PaymentsForSoftware_2BF2DF6E23AADAED8EC51835DADAF7D1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6A00B59BC07F63884B6C1835DAD921AC" xlink:to="loc_us-gaap_PaymentsForSoftware_2BF2DF6E23AADAED8EC51835DADAF7D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_F29824A98FD8A94B10561835DADACEEF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6A00B59BC07F63884B6C1835DAD921AC" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_F29824A98FD8A94B10561835DADACEEF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_E60BFB6215A5E187AD581835DADA346D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6A00B59BC07F63884B6C1835DAD921AC" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_E60BFB6215A5E187AD581835DADA346D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_41A9FC93FA516AF1D5E41835DADA2811" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6A00B59BC07F63884B6C1835DAD921AC" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_41A9FC93FA516AF1D5E41835DADA2811" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_FB418C8BC986B29DC5521835DADAB6F5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_423A457965AC71AE0B451835DAD53408" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_FB418C8BC986B29DC5521835DADAB6F5" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_PaymentsOfContingentRoyaltyObligation" xlink:label="loc_eols_PaymentsOfContingentRoyaltyObligation_E9CECED7BBFA18B38E871835DADA8066" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_FB418C8BC986B29DC5521835DADAB6F5" xlink:to="loc_eols_PaymentsOfContingentRoyaltyObligation_E9CECED7BBFA18B38E871835DADA8066" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_MilestonePaymentsForIntangibleAssets" xlink:label="loc_eols_MilestonePaymentsForIntangibleAssets_C2306104C7DC5160ED871835DADBB330" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_FB418C8BC986B29DC5521835DADAB6F5" xlink:to="loc_eols_MilestonePaymentsForIntangibleAssets_C2306104C7DC5160ED871835DADBB330" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_14C55FFB7DBE971BB40F1835DADB1E30" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_FB418C8BC986B29DC5521835DADAB6F5" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_14C55FFB7DBE971BB40F1835DADB1E30" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_4C8C14BA38AAA8BFDCBC1835DADB4CCA" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_FB418C8BC986B29DC5521835DADAB6F5" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_4C8C14BA38AAA8BFDCBC1835DADB4CCA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_F77A68FF2EB4F4BFB0861835DADBF48F" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_FB418C8BC986B29DC5521835DADAB6F5" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_F77A68FF2EB4F4BFB0861835DADBF48F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_0CBF55DB802BF422EEC51835DADBF576" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_FB418C8BC986B29DC5521835DADAB6F5" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_0CBF55DB802BF422EEC51835DADBF576" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_72FCC68DA4E6CBFD494F1835DADCFAAD" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_FB418C8BC986B29DC5521835DADAB6F5" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_72FCC68DA4E6CBFD494F1835DADCFAAD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_6F9E297487F449EA616E1835DADCD1CB" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_FB418C8BC986B29DC5521835DADAB6F5" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_6F9E297487F449EA616E1835DADCD1CB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaap_ProceedsFromRelatedPartyDebt_30A0DB6834860B144E9C1835DADCB8D6" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_FB418C8BC986B29DC5521835DADAB6F5" xlink:to="loc_us-gaap_ProceedsFromRelatedPartyDebt_30A0DB6834860B144E9C1835DADCB8D6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaap_RepaymentsOfRelatedPartyDebt_B2E9BD6EF8A6813C5AF91835DADC15E8" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_FB418C8BC986B29DC5521835DADAB6F5" xlink:to="loc_us-gaap_RepaymentsOfRelatedPartyDebt_B2E9BD6EF8A6813C5AF91835DADC15E8" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_ProceedsFromPaymentsForIssuanceOfCommonStockInConnectionWithEquityIncentivePlan" xlink:label="loc_eols_ProceedsFromPaymentsForIssuanceOfCommonStockInConnectionWithEquityIncentivePlan_96F974B38CED97FF13681835DADCDEE9" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_FB418C8BC986B29DC5521835DADAB6F5" xlink:to="loc_eols_ProceedsFromPaymentsForIssuanceOfCommonStockInConnectionWithEquityIncentivePlan_96F974B38CED97FF13681835DADCDEE9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2FB7ADBDF41FA83369381835DADC0229" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_FB418C8BC986B29DC5521835DADAB6F5" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2FB7ADBDF41FA83369381835DADC0229" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_A9402C48E033B24527831835DADC938D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_423A457965AC71AE0B451835DAD53408" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_A9402C48E033B24527831835DADC938D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9B385291230204FCFF031835DADDA2CF" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_423A457965AC71AE0B451835DAD53408" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9B385291230204FCFF031835DADDA2CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_29904181EE5907EF37FB1835DADD6224" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_423A457965AC71AE0B451835DAD53408" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_29904181EE5907EF37FB1835DADD6224" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_3902C55A9BDEA6CC2B8F1835DADDC8ED" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_423A457965AC71AE0B451835DAD53408" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_3902C55A9BDEA6CC2B8F1835DADDC8ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet_A6AF02D5AE0EF83966FB1835DADDC8CB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_3902C55A9BDEA6CC2B8F1835DADDC8ED" xlink:to="loc_us-gaap_InterestPaidNet_A6AF02D5AE0EF83966FB1835DADDC8CB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments_59AD2B65108EB324D6EA1835DADD491D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_3902C55A9BDEA6CC2B8F1835DADDC8ED" xlink:to="loc_us-gaap_OperatingLeasePayments_59AD2B65108EB324D6EA1835DADD491D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_8DD2C208C8AFA45511AF1835DADD88F6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_3902C55A9BDEA6CC2B8F1835DADDC8ED" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_8DD2C208C8AFA45511AF1835DADD88F6" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_NonCashRelatedPartyReceivable" xlink:label="loc_eols_NonCashRelatedPartyReceivable_0455832BB58119A9265C1835DADE6160" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_8DD2C208C8AFA45511AF1835DADD88F6" xlink:to="loc_eols_NonCashRelatedPartyReceivable_0455832BB58119A9265C1835DADE6160" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_NonCashRelatedPartyBorrowings" xlink:label="loc_eols_NonCashRelatedPartyBorrowings_8FC041DB7B50A3AD49E51835DADE0079" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_8DD2C208C8AFA45511AF1835DADD88F6" xlink:to="loc_eols_NonCashRelatedPartyBorrowings_8FC041DB7B50A3AD49E51835DADE0079" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_NonCashNoteObligation" xlink:label="loc_eols_NonCashNoteObligation_A9DD994C46C46CF7B1FF1835DADE5ECE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_8DD2C208C8AFA45511AF1835DADD88F6" xlink:to="loc_eols_NonCashNoteObligation_A9DD994C46C46CF7B1FF1835DADE5ECE" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_ContingentRoyaltyObligation" xlink:label="loc_eols_ContingentRoyaltyObligation_E2B566F7B10F590FAAD11835DADEDB61" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_8DD2C208C8AFA45511AF1835DADD88F6" xlink:to="loc_eols_ContingentRoyaltyObligation_E2B566F7B10F590FAAD11835DADEDB61" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_ContingentPromissoryNote" xlink:label="loc_eols_ContingentPromissoryNote_DA7FD6D33324E93DC2CB1835DADEFD4C" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_8DD2C208C8AFA45511AF1835DADD88F6" xlink:to="loc_eols_ContingentPromissoryNote_DA7FD6D33324E93DC2CB1835DADEFD4C" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_CapitalContributionConvertibleNoteWriteOff" xlink:label="loc_eols_CapitalContributionConvertibleNoteWriteOff_4656FC3F7C06D99149BB1835DADFCEE8" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_8DD2C208C8AFA45511AF1835DADD88F6" xlink:to="loc_eols_CapitalContributionConvertibleNoteWriteOff_4656FC3F7C06D99149BB1835DADFCEE8" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_CapitalContributionForgivenessofRelatedPartyBorrowings" xlink:label="loc_eols_CapitalContributionForgivenessofRelatedPartyBorrowings_DD9BBAFF5692518917AA1835DADF1E98" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_8DD2C208C8AFA45511AF1835DADD88F6" xlink:to="loc_eols_CapitalContributionForgivenessofRelatedPartyBorrowings_DD9BBAFF5692518917AA1835DADF1E98" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_NonCashDeferredOfferingCosts" xlink:label="loc_eols_NonCashDeferredOfferingCosts_E078A9E163E968267D3B1835DADF0D6C" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_8DD2C208C8AFA45511AF1835DADD88F6" xlink:to="loc_eols_NonCashDeferredOfferingCosts_E078A9E163E968267D3B1835DADF0D6C" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_AccountsPayablePaidbyParent" xlink:label="loc_eols_AccountsPayablePaidbyParent_29D38C92B8E7C12988FB1835DADF811E" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_8DD2C208C8AFA45511AF1835DADD88F6" xlink:to="loc_eols_AccountsPayablePaidbyParent_29D38C92B8E7C12988FB1835DADF811E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_E9191E8EF7FBF0B9F95C1835DADF777E" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_8DD2C208C8AFA45511AF1835DADD88F6" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_E9191E8EF7FBF0B9F95C1835DADF777E" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_NonCashLandlordPaidTenantImprovement" xlink:label="loc_eols_NonCashLandlordPaidTenantImprovement_A10D33423EEB5190924F18454908B732" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_8DD2C208C8AFA45511AF1835DADD88F6" xlink:to="loc_eols_NonCashLandlordPaidTenantImprovement_A10D33423EEB5190924F18454908B732" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_NonCashFinanceAndInsurancePayment" xlink:label="loc_eols_NonCashFinanceAndInsurancePayment_65440467FF01AF9F9B261844B1196698" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_8DD2C208C8AFA45511AF1835DADD88F6" xlink:to="loc_eols_NonCashFinanceAndInsurancePayment_65440467FF01AF9F9B261844B1196698" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_CFAD7D816414A240E8011835DADFBA34" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_8DD2C208C8AFA45511AF1835DADD88F6" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_CFAD7D816414A240E8011835DADFBA34" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_MilestonePaymentCurrent" xlink:label="loc_eols_MilestonePaymentCurrent_B90F00620092219BAB881843C067D832" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_8DD2C208C8AFA45511AF1835DADD88F6" xlink:to="loc_eols_MilestonePaymentCurrent_B90F00620092219BAB881843C067D832" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/CondensedStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_206ED27E48806F0E7EB0FEEBF09F9220" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2684A2F5FB1E60A25EB6FEEBF09F3DF2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_206ED27E48806F0E7EB0FEEBF09F9220" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2684A2F5FB1E60A25EB6FEEBF09F3DF2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_AE6E0E6CF0C6A68DFEEFFEEBF09F2AC0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_206ED27E48806F0E7EB0FEEBF09F9220" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_AE6E0E6CF0C6A68DFEEFFEEBF09F2AC0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit_A33E1EF8C0F16BE59AF4FEEBF0A0A02E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_206ED27E48806F0E7EB0FEEBF09F9220" xlink:to="loc_us-gaap_GrossProfit_A33E1EF8C0F16BE59AF4FEEBF0A0A02E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_CF91A6772775E1C399A5FEEBF0A09EFA" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_206ED27E48806F0E7EB0FEEBF09F9220" xlink:to="loc_us-gaap_OperatingExpensesAbstract_CF91A6772775E1C399A5FEEBF0A09EFA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_E9C8089DBF3719304875FEEBF0A04B36" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_CF91A6772775E1C399A5FEEBF0A09EFA" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_E9C8089DBF3719304875FEEBF0A04B36" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_8185D39D78D448F72474FEEBF0A0F0BC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_CF91A6772775E1C399A5FEEBF0A09EFA" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_8185D39D78D448F72474FEEBF0A0F0BC" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_RevaluationofContingentRoyaltyObligationPayable" xlink:label="loc_eols_RevaluationofContingentRoyaltyObligationPayable_2FB5C2AA7A4D0D6E7880FEEBF0A0591C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_CF91A6772775E1C399A5FEEBF0A09EFA" xlink:to="loc_eols_RevaluationofContingentRoyaltyObligationPayable_2FB5C2AA7A4D0D6E7880FEEBF0A0591C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_2D55A73320FF79917C0CFF13749C42E8" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_CF91A6772775E1C399A5FEEBF0A09EFA" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_2D55A73320FF79917C0CFF13749C42E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_D34A97FE471E0ADFB1CEFEEBF0A16ED3" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_CF91A6772775E1C399A5FEEBF0A09EFA" xlink:to="loc_us-gaap_OperatingExpenses_D34A97FE471E0ADFB1CEFEEBF0A16ED3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_D8E93FCA3DB87A605C4FFEEBF0A1CA29" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_206ED27E48806F0E7EB0FEEBF09F9220" xlink:to="loc_us-gaap_OperatingIncomeLoss_D8E93FCA3DB87A605C4FFEEBF0A1CA29" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeNet" xlink:label="loc_us-gaap_InvestmentIncomeNet_080E9CE7A9B0DF2207A5FEEBF0A13A0E" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_206ED27E48806F0E7EB0FEEBF09F9220" xlink:to="loc_us-gaap_InvestmentIncomeNet_080E9CE7A9B0DF2207A5FEEBF0A13A0E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_4F2A2088BB90C5D63E9BFEEBF0A1E2B8" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_206ED27E48806F0E7EB0FEEBF09F9220" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_4F2A2088BB90C5D63E9BFEEBF0A1E2B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_D51EB7F2D718A232E156FEEBF0A121F1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_4F2A2088BB90C5D63E9BFEEBF0A1E2B8" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_D51EB7F2D718A232E156FEEBF0A121F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_B041A523EF00815C9D31FEEBF0A2D335" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_206ED27E48806F0E7EB0FEEBF09F9220" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_B041A523EF00815C9D31FEEBF0A2D335" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_5797393046A1E60647FDFEEBF0A2EBBD" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_206ED27E48806F0E7EB0FEEBF09F9220" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_5797393046A1E60647FDFEEBF0A2EBBD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_6B60A6F4582739C18692FEEBF0A278C4" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_206ED27E48806F0E7EB0FEEBF09F9220" xlink:to="loc_us-gaap_NetIncomeLoss_6B60A6F4582739C18692FEEBF0A278C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_EBE9E7F4D591F120CABCFEEBF0A27988" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_206ED27E48806F0E7EB0FEEBF09F9220" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_EBE9E7F4D591F120CABCFEEBF0A27988" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_9C4F2768A3DAD1D3C079FEEBF0A2F7BE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_EBE9E7F4D591F120CABCFEEBF0A27988" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_9C4F2768A3DAD1D3C079FEEBF0A2F7BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_ADE6BF095483887FE50AFEEBF0A22E07" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_EBE9E7F4D591F120CABCFEEBF0A27988" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_ADE6BF095483887FE50AFEEBF0A22E07" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_A195BDA2D7C78C705592FEEBF0A3F7C3" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_206ED27E48806F0E7EB0FEEBF09F9220" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_A195BDA2D7C78C705592FEEBF0A3F7C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_65AA1E431AB8D5015EE1FEEBF0A32754" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_206ED27E48806F0E7EB0FEEBF09F9220" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_65AA1E431AB8D5015EE1FEEBF0A32754" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/CondensedStatementsOfStockholdersEquity" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_2A718766F326E06A9B361E20339AB158" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_DAA36AEA17C4524777BD1E20339B00A7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_2A718766F326E06A9B361E20339AB158" xlink:to="loc_us-gaap_StatementTable_DAA36AEA17C4524777BD1E20339B00A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_CAA5F0E4A6393AD62FF91E20339BD3CB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_DAA36AEA17C4524777BD1E20339B00A7" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_CAA5F0E4A6393AD62FF91E20339BD3CB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_A7072A595A2AC29EBF371E20339B17F5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_CAA5F0E4A6393AD62FF91E20339BD3CB" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_A7072A595A2AC29EBF371E20339B17F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_0059C702302448EF94AB1E20339C6150" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_A7072A595A2AC29EBF371E20339B17F5" xlink:to="loc_us-gaap_IPOMember_0059C702302448EF94AB1E20339C6150" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_0E95FC2A3A6C0F4825961E20339C8880" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_DAA36AEA17C4524777BD1E20339B00A7" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_0E95FC2A3A6C0F4825961E20339C8880" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_F05F420169BD2F6A09C71E20339C63D0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_0E95FC2A3A6C0F4825961E20339C8880" xlink:to="loc_us-gaap_EquityComponentDomain_F05F420169BD2F6A09C71E20339C63D0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_BB144F88EC266DE68CF41E20339C8582" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_F05F420169BD2F6A09C71E20339C63D0" xlink:to="loc_us-gaap_PreferredStockMember_BB144F88EC266DE68CF41E20339C8582" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_EA19271852CC70B6EB5A1E20339CFDF6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_F05F420169BD2F6A09C71E20339C63D0" xlink:to="loc_us-gaap_CommonStockMember_EA19271852CC70B6EB5A1E20339CFDF6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_B0910A213D430EFF1B7E1E20339D3244" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_F05F420169BD2F6A09C71E20339C63D0" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_B0910A213D430EFF1B7E1E20339D3244" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_26BDD9039C8476153C381E20339DA7C1" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_F05F420169BD2F6A09C71E20339C63D0" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_26BDD9039C8476153C381E20339DA7C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_0809E414A42511BCFF231E20339DBD4A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_F05F420169BD2F6A09C71E20339C63D0" xlink:to="loc_us-gaap_RetainedEarningsMember_0809E414A42511BCFF231E20339DBD4A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_C4AAC72D1631D5EE6F0B1E20339D0ADB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_DAA36AEA17C4524777BD1E20339B00A7" xlink:to="loc_us-gaap_StatementClassOfStockAxis_C4AAC72D1631D5EE6F0B1E20339D0ADB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_8E59374AF305BA13BEB41E20339D8691" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_C4AAC72D1631D5EE6F0B1E20339D0ADB" xlink:to="loc_us-gaap_ClassOfStockDomain_8E59374AF305BA13BEB41E20339D8691" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_01B99BEF9596C37E55E61E20339D5A06" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_8E59374AF305BA13BEB41E20339D8691" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_01B99BEF9596C37E55E61E20339D5A06" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_10AD680306A7621BD9B01E20339E87AC" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_DAA36AEA17C4524777BD1E20339B00A7" xlink:to="loc_us-gaap_StatementLineItems_10AD680306A7621BD9B01E20339E87AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_0B0D804A596A6926FC831E20339E9C15" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_10AD680306A7621BD9B01E20339E87AC" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_0B0D804A596A6926FC831E20339E9C15" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_642A7DAFD8538002FA6B1E20339EB702" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_10AD680306A7621BD9B01E20339E87AC" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_642A7DAFD8538002FA6B1E20339EB702" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_5F4D4CA6B073104DD10E1E20339E0F1C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_642A7DAFD8538002FA6B1E20339EB702" xlink:to="loc_us-gaap_SharesIssued_5F4D4CA6B073104DD10E1E20339E0F1C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_72DE7DFD7B7C714C64931E20339F8A92" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_642A7DAFD8538002FA6B1E20339EB702" xlink:to="loc_us-gaap_StockholdersEquity_72DE7DFD7B7C714C64931E20339F8A92" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_DeemedContributionFromParentIncreaseOfRelatedPartyReceivable" xlink:label="loc_eols_DeemedContributionFromParentIncreaseOfRelatedPartyReceivable_15673E7BAAF838400DB81E20339FABDF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_642A7DAFD8538002FA6B1E20339EB702" xlink:to="loc_eols_DeemedContributionFromParentIncreaseOfRelatedPartyReceivable_15673E7BAAF838400DB81E20339FABDF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Dividends" xlink:label="loc_us-gaap_Dividends_9771A66945D1C182761E1E20339F9F79" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_642A7DAFD8538002FA6B1E20339EB702" xlink:to="loc_us-gaap_Dividends_9771A66945D1C182761E1E20339F9F79" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_C8861EB44ED0B870EE201E20339F4EBE" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_642A7DAFD8538002FA6B1E20339EB702" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_C8861EB44ED0B870EE201E20339F4EBE" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_CapitalContributionFromParentForgivenessOfRelatedPartyBorrowings" xlink:label="loc_eols_CapitalContributionFromParentForgivenessOfRelatedPartyBorrowings_E5622A933517C718095D1E20339F59DB" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_642A7DAFD8538002FA6B1E20339EB702" xlink:to="loc_eols_CapitalContributionFromParentForgivenessOfRelatedPartyBorrowings_E5622A933517C718095D1E20339F59DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_87E80F2381B11F85CED41E20339F3736" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_642A7DAFD8538002FA6B1E20339EB702" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_87E80F2381B11F85CED41E20339F3736" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_D5AC9BE8AE97214217181E2033A0A250" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_642A7DAFD8538002FA6B1E20339EB702" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_D5AC9BE8AE97214217181E2033A0A250" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_B03EBD87602E126FBDE01E2033A0C801" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_642A7DAFD8538002FA6B1E20339EB702" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_B03EBD87602E126FBDE01E2033A0C801" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan" xlink:label="loc_eols_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan_45C06B2BB774CAC11F951E2033A0F663" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_642A7DAFD8538002FA6B1E20339EB702" xlink:to="loc_eols_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan_45C06B2BB774CAC11F951E2033A0F663" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan" xlink:label="loc_eols_StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan_32743583593F49C6ED531E2033A07918" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_642A7DAFD8538002FA6B1E20339EB702" xlink:to="loc_eols_StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan_32743583593F49C6ED531E2033A07918" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_77A6732ED232E91746351E2033A0AE03" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_642A7DAFD8538002FA6B1E20339EB702" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_77A6732ED232E91746351E2033A0AE03" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_9EB42640B319FA0905421E2033A024A2" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_642A7DAFD8538002FA6B1E20339EB702" xlink:to="loc_us-gaap_NetIncomeLoss_9EB42640B319FA0905421E2033A024A2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_F30FAB31BA237AD751D91E2033A02622" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_642A7DAFD8538002FA6B1E20339EB702" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_F30FAB31BA237AD751D91E2033A02622" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_C3EC881E2AC6231859DF1E2033A1F1B8" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_642A7DAFD8538002FA6B1E20339EB702" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_C3EC881E2AC6231859DF1E2033A1F1B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_B29141A6B28A12C5D1431E2033A16D0D" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_642A7DAFD8538002FA6B1E20339EB702" xlink:to="loc_us-gaap_SharesIssued_B29141A6B28A12C5D1431E2033A16D0D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_54CDA1473F2BE72C63771E2033A1DCE5" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_642A7DAFD8538002FA6B1E20339EB702" xlink:to="loc_us-gaap_StockholdersEquity_54CDA1473F2BE72C63771E2033A1DCE5" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/DescriptionOfBusinessAndBasisOfPresentation" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4FE31DB613082886E3501835DA9DDFD6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_7C41BB4611FC737B70041835DA9D6D5A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4FE31DB613082886E3501835DA9DDFD6" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_7C41BB4611FC737B70041835DA9D6D5A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/DescriptionOfBusinessAndBasisOfPresentationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2F377B24AEADDE8BF9AA1835DA9A192D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_E9A3AD0772F824D770DB1835DA9A6906" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2F377B24AEADDE8BF9AA1835DA9A192D" xlink:to="loc_us-gaap_NetIncomeLoss_E9A3AD0772F824D770DB1835DA9A6906" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_B702E0EC757FA580C0831835DA9ADD78" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2F377B24AEADDE8BF9AA1835DA9A192D" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_B702E0EC757FA580C0831835DA9ADD78" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_85CB5F270A7C1512C5CA1835DA9B6251" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2F377B24AEADDE8BF9AA1835DA9A192D" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_85CB5F270A7C1512C5CA1835DA9B6251" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_96949C960D47958800821835DA9B7110" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2F377B24AEADDE8BF9AA1835DA9A192D" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_96949C960D47958800821835DA9B7110" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/DocumentAndEntityInformation" xlink:type="extended">
    <link:loc xlink:href="eols-20190930.xsd#eols_DocumentAndEntityInformationAbstract" xlink:label="loc_eols_DocumentAndEntityInformationAbstract_12FA04BA27FCC306294C45374EE9B4FE" xlink:type="locator" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_9468B7E1DEDB174997DA45374EE9001B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_DocumentAndEntityInformationAbstract_12FA04BA27FCC306294C45374EE9B4FE" xlink:to="loc_dei_DocumentType_9468B7E1DEDB174997DA45374EE9001B" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_A2021231754DB63972BB45374EE90E98" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_DocumentAndEntityInformationAbstract_12FA04BA27FCC306294C45374EE9B4FE" xlink:to="loc_dei_AmendmentFlag_A2021231754DB63972BB45374EE90E98" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_E191FBA8865B055B421B45374EE9DC43" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_DocumentAndEntityInformationAbstract_12FA04BA27FCC306294C45374EE9B4FE" xlink:to="loc_dei_DocumentPeriodEndDate_E191FBA8865B055B421B45374EE9DC43" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_9804748F59B19C71B9A445374EE94E70" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_DocumentAndEntityInformationAbstract_12FA04BA27FCC306294C45374EE9B4FE" xlink:to="loc_dei_DocumentFiscalYearFocus_9804748F59B19C71B9A445374EE94E70" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_538B071CD546F70916A745374EE96957" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_DocumentAndEntityInformationAbstract_12FA04BA27FCC306294C45374EE9B4FE" xlink:to="loc_dei_DocumentFiscalPeriodFocus_538B071CD546F70916A745374EE96957" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_4CB8D2D00966413B7A3E45374EEA0CB4" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_DocumentAndEntityInformationAbstract_12FA04BA27FCC306294C45374EE9B4FE" xlink:to="loc_dei_EntityRegistrantName_4CB8D2D00966413B7A3E45374EEA0CB4" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_659D796DBA6EB95F0D5345374EEAC3A0" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_DocumentAndEntityInformationAbstract_12FA04BA27FCC306294C45374EE9B4FE" xlink:to="loc_dei_EntityCentralIndexKey_659D796DBA6EB95F0D5345374EEAC3A0" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_2A52BD65445A549F2E4345374EEA015D" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_DocumentAndEntityInformationAbstract_12FA04BA27FCC306294C45374EE9B4FE" xlink:to="loc_dei_CurrentFiscalYearEndDate_2A52BD65445A549F2E4345374EEA015D" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_10F6C745C66EE81221EE45374EEAD290" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_DocumentAndEntityInformationAbstract_12FA04BA27FCC306294C45374EE9B4FE" xlink:to="loc_dei_EntityFilerCategory_10F6C745C66EE81221EE45374EEAD290" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_A0D13F27A4C4DBE3CD0D45374EEAD100" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_DocumentAndEntityInformationAbstract_12FA04BA27FCC306294C45374EE9B4FE" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_A0D13F27A4C4DBE3CD0D45374EEAD100" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_9FB73C8A9828EF0803E945374EEA99D8" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_DocumentAndEntityInformationAbstract_12FA04BA27FCC306294C45374EE9B4FE" xlink:to="loc_dei_EntityEmergingGrowthCompany_9FB73C8A9828EF0803E945374EEA99D8" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_CF12D45CAFB9D09D645545374EEB032E" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_DocumentAndEntityInformationAbstract_12FA04BA27FCC306294C45374EE9B4FE" xlink:to="loc_dei_EntitySmallBusiness_CF12D45CAFB9D09D645545374EEB032E" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod_E0B9EDFEC5253A0FE34B45374EEB06E8" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_DocumentAndEntityInformationAbstract_12FA04BA27FCC306294C45374EE9B4FE" xlink:to="loc_dei_EntityExTransitionPeriod_E0B9EDFEC5253A0FE34B45374EEB06E8" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_65CF788687A50F8D22C145374EEB3674" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_DocumentAndEntityInformationAbstract_12FA04BA27FCC306294C45374EE9B4FE" xlink:to="loc_dei_EntityCurrentReportingStatus_65CF788687A50F8D22C145374EEB3674" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_C99FA02A648B4EAB0E2945374EEB6DA9" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_DocumentAndEntityInformationAbstract_12FA04BA27FCC306294C45374EE9B4FE" xlink:to="loc_dei_EntityShellCompany_C99FA02A648B4EAB0E2945374EEB6DA9" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/FairValueMeasurementsAndShortTermInvestments" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_DF57EFC03C548370BF4545374EF390A0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_7CA027BE1FD81C4DC71D45374EF3D691" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_DF57EFC03C548370BF4545374EF390A0" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_7CA027BE1FD81C4DC71D45374EF3D691" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/FairValueMeasurementsAndShortTermInvestmentsAssetsAndLiabilitiesOnRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_7A33B58BE518A2E8F9ACFEEBEF15B16A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_B461F57BE487DDB9D8BDFEEBEF151D25" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_7A33B58BE518A2E8F9ACFEEBEF15B16A" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_B461F57BE487DDB9D8BDFEEBEF151D25" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_994A01A8E38BDA26D14DFEEBEF1533A4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_B461F57BE487DDB9D8BDFEEBEF151D25" xlink:to="loc_us-gaap_FinancialInstrumentAxis_994A01A8E38BDA26D14DFEEBEF1533A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_773138481A4B5667F3DEFEEBEF16095F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_994A01A8E38BDA26D14DFEEBEF1533A4" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_773138481A4B5667F3DEFEEBEF16095F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_B1EC52D65C8639DC56E2FEEBEF16F0F6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_773138481A4B5667F3DEFEEBEF16095F" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_B1EC52D65C8639DC56E2FEEBEF16F0F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_2DBA83E08D24CF1025C2FEEBEF1654A3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_773138481A4B5667F3DEFEEBEF16095F" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_2DBA83E08D24CF1025C2FEEBEF1654A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_40EFBF892FEA7C855F33FEEBEF175B6B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_B461F57BE487DDB9D8BDFEEBEF151D25" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_40EFBF892FEA7C855F33FEEBEF175B6B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_10F5E386F6159F14B358FEEBEF17EC3C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_40EFBF892FEA7C855F33FEEBEF175B6B" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_10F5E386F6159F14B358FEEBEF17EC3C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_4B47C5931F9C69B301BCFEEBEF17909D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_10F5E386F6159F14B358FEEBEF17EC3C" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_4B47C5931F9C69B301BCFEEBEF17909D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_2187AE9D0A373C350FB3FEEBEF17351F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_10F5E386F6159F14B358FEEBEF17EC3C" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_2187AE9D0A373C350FB3FEEBEF17351F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_824006330E63FB66CBA3FEEBEF17775F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_10F5E386F6159F14B358FEEBEF17EC3C" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_824006330E63FB66CBA3FEEBEF17775F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_EEDDAC65994FBF269A22FEEBEF18CF38" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_B461F57BE487DDB9D8BDFEEBEF151D25" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_EEDDAC65994FBF269A22FEEBEF18CF38" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_9985BC9B5B88058B8CBDFEEBEF1876EF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_EEDDAC65994FBF269A22FEEBEF18CF38" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_9985BC9B5B88058B8CBDFEEBEF1876EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_9E07431CCB87C00CF366FEEBEF1853CE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_EEDDAC65994FBF269A22FEEBEF18CF38" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_9E07431CCB87C00CF366FEEBEF1853CE" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/FairValueMeasurementsAndShortTermInvestmentsContingentRoyaltyObligationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_83C52825BDA31ACBB586FEEBEEFC5C0C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_7113B205FC29734B7374FEEBEEFCFA33" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_83C52825BDA31ACBB586FEEBEEFC5C0C" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_7113B205FC29734B7374FEEBEEFCFA33" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_437D9A9B3E056309AB1BFEEBEEFCDECD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_7113B205FC29734B7374FEEBEEFCFA33" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_437D9A9B3E056309AB1BFEEBEEFCDECD" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityPayments" xlink:label="loc_eols_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityPayments_C1401E2A56C73302922AFEEBEEFD4D6D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_7113B205FC29734B7374FEEBEEFCFA33" xlink:to="loc_eols_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityPayments_C1401E2A56C73302922AFEEBEEFD4D6D" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_RevaluationofContingentRoyaltyObligationPayable" xlink:label="loc_eols_RevaluationofContingentRoyaltyObligationPayable_B30980BB4C0A5C8792FEFEEBEEFDC6DE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_7113B205FC29734B7374FEEBEEFCFA33" xlink:to="loc_eols_RevaluationofContingentRoyaltyObligationPayable_B30980BB4C0A5C8792FEFEEBEEFDC6DE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_6719326334B49078B804FEEBEEFD651B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_7113B205FC29734B7374FEEBEEFCFA33" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_6719326334B49078B804FEEBEEFD651B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/FairValueMeasurementsAndShortTermInvestmentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_454418951403AD5782E1FEEBEF018A54" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_E540B8C49CD8B221B6DAFEEBEF01E381" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_454418951403AD5782E1FEEBEF018A54" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_E540B8C49CD8B221B6DAFEEBEF01E381" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_070F3E651C49E123C300FEEBEF02AFDB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_E540B8C49CD8B221B6DAFEEBEF01E381" xlink:to="loc_us-gaap_DebtInstrumentAxis_070F3E651C49E123C300FEEBEF02AFDB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_6ED9D41B4FF1F9776678FEEBEF027EB8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_070F3E651C49E123C300FEEBEF02AFDB" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_6ED9D41B4FF1F9776678FEEBEF027EB8" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_OxfordTermLoansMember" xlink:label="loc_eols_OxfordTermLoansMember_8B193CBD594B49E006ECFEEBEF021C23" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_6ED9D41B4FF1F9776678FEEBEF027EB8" xlink:to="loc_eols_OxfordTermLoansMember_8B193CBD594B49E006ECFEEBEF021C23" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_CE756E96EE84D3E81464FEEBEF029C88" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_E540B8C49CD8B221B6DAFEEBEF01E381" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_CE756E96EE84D3E81464FEEBEF029C88" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_2C172F29F4B4EB921902FEEBEF02A737" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_CE756E96EE84D3E81464FEEBEF029C88" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_2C172F29F4B4EB921902FEEBEF02A737" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_3F81A530ABAAEF208FD1FEEBEF03A001" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_2C172F29F4B4EB921902FEEBEF02A737" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_3F81A530ABAAEF208FD1FEEBEF03A001" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_22CABA68359D3C7D91D5FEEBEF03AA6A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_2C172F29F4B4EB921902FEEBEF02A737" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_22CABA68359D3C7D91D5FEEBEF03AA6A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_D36D1D7EA913398A7C6EFEEBEF031D0A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_E540B8C49CD8B221B6DAFEEBEF01E381" xlink:to="loc_us-gaap_FinancialInstrumentAxis_D36D1D7EA913398A7C6EFEEBEF031D0A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3CE7614028C31BFE3D26FEEBEF037714" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_D36D1D7EA913398A7C6EFEEBEF031D0A" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3CE7614028C31BFE3D26FEEBEF037714" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_ContingentRoyaltyObligationMember" xlink:label="loc_eols_ContingentRoyaltyObligationMember_78C18887C48031B8C99DFEEBEF04D3B9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3CE7614028C31BFE3D26FEEBEF037714" xlink:to="loc_eols_ContingentRoyaltyObligationMember_78C18887C48031B8C99DFEEBEF04D3B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_2505B847A84004010E09FEEBEF046156" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_E540B8C49CD8B221B6DAFEEBEF01E381" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_2505B847A84004010E09FEEBEF046156" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_4304D949E47D18E67F48FEEBEF043F23" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_2505B847A84004010E09FEEBEF046156" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_4304D949E47D18E67F48FEEBEF043F23" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_2057FA256B875C5AA88BFEEBEF04DBAA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_4304D949E47D18E67F48FEEBEF043F23" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_2057FA256B875C5AA88BFEEBEF04DBAA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_51E1AB92B3AC6B99BE38FEEBEF055775" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_4304D949E47D18E67F48FEEBEF043F23" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_51E1AB92B3AC6B99BE38FEEBEF055775" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_453F87F9761B0E1AF937FEEBEF058947" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_E540B8C49CD8B221B6DAFEEBEF01E381" xlink:to="loc_srt_RangeAxis_453F87F9761B0E1AF937FEEBEF058947" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_4A97477283E41C1DCDD9FEEBEF05EAC2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_453F87F9761B0E1AF937FEEBEF058947" xlink:to="loc_srt_RangeMember_4A97477283E41C1DCDD9FEEBEF05EAC2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_8B7B32C75C182DEFCE28FEEBEF05BDC9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_4A97477283E41C1DCDD9FEEBEF05EAC2" xlink:to="loc_srt_MinimumMember_8B7B32C75C182DEFCE28FEEBEF05BDC9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_ADA58D01B6E11945D2B0FEEBEF055059" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_4A97477283E41C1DCDD9FEEBEF05EAC2" xlink:to="loc_srt_MaximumMember_ADA58D01B6E11945D2B0FEEBEF055059" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_C285D6B8E715028F6AADFEEBEF06AA0D" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_E540B8C49CD8B221B6DAFEEBEF01E381" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_C285D6B8E715028F6AADFEEBEF06AA0D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AlternativeInvestmentMeasurementInput" xlink:label="loc_us-gaap_AlternativeInvestmentMeasurementInput_5256F0A5B671ED36B8C9FEEBEF066627" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_C285D6B8E715028F6AADFEEBEF06AA0D" xlink:to="loc_us-gaap_AlternativeInvestmentMeasurementInput_5256F0A5B671ED36B8C9FEEBEF066627" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure_61F681322F21F33EAEDEFEEBEF06DA1A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_C285D6B8E715028F6AADFEEBEF06AA0D" xlink:to="loc_us-gaap_NotesPayableFairValueDisclosure_61F681322F21F33EAEDEFEEBEF06DA1A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_BA508AE0314C0E6F67F7FF40D323AC88" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_C285D6B8E715028F6AADFEEBEF06AA0D" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_BA508AE0314C0E6F67F7FF40D323AC88" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/FairValueMeasurementsAndShortTermInvestmentsScheduleOfShortTermInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_3556F7AEAE6960D7079F45374E4F9806" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_D91795B44DE1DF2D763F45374E4F2269" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_3556F7AEAE6960D7079F45374E4F9806" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_D91795B44DE1DF2D763F45374E4F2269" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_694BA90308CAE9E2255A45374E4F73C3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_D91795B44DE1DF2D763F45374E4F2269" xlink:to="loc_us-gaap_FinancialInstrumentAxis_694BA90308CAE9E2255A45374E4F73C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0D28E54022D2421BD20945374E50A67C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_694BA90308CAE9E2255A45374E4F73C3" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0D28E54022D2421BD20945374E50A67C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_A3822B052EA571CA986145374E506A61" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0D28E54022D2421BD20945374E50A67C" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_A3822B052EA571CA986145374E506A61" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_DA068C5BB97FC9D67A9645374E501A66" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_D91795B44DE1DF2D763F45374E4F2269" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_DA068C5BB97FC9D67A9645374E501A66" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_1E22D68F6056C6CFF5B145374E50C8AD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_DA068C5BB97FC9D67A9645374E501A66" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_1E22D68F6056C6CFF5B145374E50C8AD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTaxAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTaxAbstract_7D4D0878D655723E38E645374E51A6D1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_DA068C5BB97FC9D67A9645374E501A66" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTaxAbstract_7D4D0878D655723E38E645374E51A6D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_CC3AE7B95DB9E32667C545374E51808F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTaxAbstract_7D4D0878D655723E38E645374E51A6D1" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_CC3AE7B95DB9E32667C545374E51808F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_32CF58437C3534D1EC4045374E51BA76" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTaxAbstract_7D4D0878D655723E38E645374E51A6D1" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_32CF58437C3534D1EC4045374E51BA76" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_17DF5DF4D7E4FAFED76545374E516E9B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_DA068C5BB97FC9D67A9645374E501A66" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_17DF5DF4D7E4FAFED76545374E516E9B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/FairValueMeasurementsAndShortTermInvestmentsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_02C5256EC43E6782F2AA453920A04BD9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_DF934ECD03F99BBB3397453920A0D55F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_02C5256EC43E6782F2AA453920A04BD9" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_DF934ECD03F99BBB3397453920A0D55F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_7449E0EA470E97945D1D453920A07D31" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_02C5256EC43E6782F2AA453920A04BD9" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_7449E0EA470E97945D1D453920A07D31" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_325728DEE88D729DD550453920A0D5C0" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_02C5256EC43E6782F2AA453920A04BD9" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_325728DEE88D729DD550453920A0D5C0" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/GoodwillAndIntangibleAssetNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_CDC38D051AF557ABBF1B0F0252566D30" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_89E13F4BDA88ECCF2B420F0252563B5C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_CDC38D051AF557ABBF1B0F0252566D30" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_89E13F4BDA88ECCF2B420F0252563B5C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0C745DA3298F2BF837C90F0252570506" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_89E13F4BDA88ECCF2B420F0252563B5C" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0C745DA3298F2BF837C90F0252570506" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_83348E9E98BF42E1A6BA0F025257F3CF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0C745DA3298F2BF837C90F0252570506" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_83348E9E98BF42E1A6BA0F025257F3CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DistributionRightsMember" xlink:label="loc_us-gaap_DistributionRightsMember_E1F2E840506CC381B56C0F02525798AE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_83348E9E98BF42E1A6BA0F025257F3CF" xlink:to="loc_us-gaap_DistributionRightsMember_E1F2E840506CC381B56C0F02525798AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_7615190F17ABB8E9D5700F02525849C1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_83348E9E98BF42E1A6BA0F025257F3CF" xlink:to="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_7615190F17ABB8E9D5700F02525849C1" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_0C169964A8B6EF104F9A0F0252584451" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_89E13F4BDA88ECCF2B420F0252563B5C" xlink:to="loc_dei_LegalEntityAxis_0C169964A8B6EF104F9A0F0252584451" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_397F0968AC9ED9F1CB500F025258DA35" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_0C169964A8B6EF104F9A0F0252584451" xlink:to="loc_dei_EntityDomain_397F0968AC9ED9F1CB500F025258DA35" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_SCHAEONLLCMember" xlink:label="loc_eols_SCHAEONLLCMember_667367216AB44B7622CF0F0252582E11" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_397F0968AC9ED9F1CB500F025258DA35" xlink:to="loc_eols_SCHAEONLLCMember_667367216AB44B7622CF0F0252582E11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1249E4F89749F22085F20F0252589D44" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_89E13F4BDA88ECCF2B420F0252563B5C" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1249E4F89749F22085F20F0252589D44" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9C76E67B17F45CB7BA650F02525981E4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1249E4F89749F22085F20F0252589D44" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9C76E67B17F45CB7BA650F02525981E4" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_EvolusIncMember" xlink:label="loc_eols_EvolusIncMember_F97D123DCB74BA495A200F025259C2B2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9C76E67B17F45CB7BA650F02525981E4" xlink:to="loc_eols_EvolusIncMember_F97D123DCB74BA495A200F025259C2B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_7B11ABAFEABF9D7793CD0F0252592B2B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_89E13F4BDA88ECCF2B420F0252563B5C" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_7B11ABAFEABF9D7793CD0F0252592B2B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_6704FD075CD5A2115DD60F02525988A3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7B11ABAFEABF9D7793CD0F0252592B2B" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_6704FD075CD5A2115DD60F02525988A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_947EAFAF4A83DF2572B80F02525AD2CE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7B11ABAFEABF9D7793CD0F0252592B2B" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_947EAFAF4A83DF2572B80F02525AD2CE" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_AcquiredFinitelivedIntangibleAssetPeriodOfExtensionOfTermsBasedOnCertainPerformanceRequirements" xlink:label="loc_eols_AcquiredFinitelivedIntangibleAssetPeriodOfExtensionOfTermsBasedOnCertainPerformanceRequirements_DA9E0793A77F285DB33F0F02525A6EED" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7B11ABAFEABF9D7793CD0F0252592B2B" xlink:to="loc_eols_AcquiredFinitelivedIntangibleAssetPeriodOfExtensionOfTermsBasedOnCertainPerformanceRequirements_DA9E0793A77F285DB33F0F02525A6EED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_5E7A4B640899CAE32A590F02525A0F2A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7B11ABAFEABF9D7793CD0F0252592B2B" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_5E7A4B640899CAE32A590F02525A0F2A" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_MilestonePaymentsForIntangibleAssets" xlink:label="loc_eols_MilestonePaymentsForIntangibleAssets_4F2E736B012193829E440F02525A9EEE" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7B11ABAFEABF9D7793CD0F0252592B2B" xlink:to="loc_eols_MilestonePaymentsForIntangibleAssets_4F2E736B012193829E440F02525A9EEE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_EFC9BC4E2D4EFF7BD7BA0F02525A7E9D" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7B11ABAFEABF9D7793CD0F0252592B2B" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_EFC9BC4E2D4EFF7BD7BA0F02525A7E9D" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_MilestonePaymentCurrent" xlink:label="loc_eols_MilestonePaymentCurrent_6AD30C339A844981D4250F06F8092ABE" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7B11ABAFEABF9D7793CD0F0252592B2B" xlink:to="loc_eols_MilestonePaymentCurrent_6AD30C339A844981D4250F06F8092ABE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalizedComputerSoftwareAdditions" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareAdditions_93385DC9E5964F28A0810F02525ADBB9" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7B11ABAFEABF9D7793CD0F0252592B2B" xlink:to="loc_us-gaap_CapitalizedComputerSoftwareAdditions_93385DC9E5964F28A0810F02525ADBB9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_8193A3E2CD2BDA5B04350F02525BCD7B" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7B11ABAFEABF9D7793CD0F0252592B2B" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_8193A3E2CD2BDA5B04350F02525BCD7B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_D21891A11368DA33B9E80F02525BEEF8" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7B11ABAFEABF9D7793CD0F0252592B2B" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_D21891A11368DA33B9E80F02525BEEF8" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/GoodwillAndIntangibleAssets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_7C7B6AE29D516F07642045374F524514" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_D208B93E08CA60E4AF4E45374F528357" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_7C7B6AE29D516F07642045374F524514" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_D208B93E08CA60E4AF4E45374F528357" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/GoodwillAndIntangibleAssetsFutureAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_151FEAFB2BB676FFA46745374F099647" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_7C79037918ADCBD54C5B45374F090B14" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_151FEAFB2BB676FFA46745374F099647" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_7C79037918ADCBD54C5B45374F090B14" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_70624366894F7A1E81C745374F09A8C7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_151FEAFB2BB676FFA46745374F099647" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_70624366894F7A1E81C745374F09A8C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_29E9AC60910E00C1D01E45374F0A26B7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_151FEAFB2BB676FFA46745374F099647" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_29E9AC60910E00C1D01E45374F0A26B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_C322B1C731412D7AA69B45374F0A569E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_151FEAFB2BB676FFA46745374F099647" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_C322B1C731412D7AA69B45374F0A569E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_C940D565A6E0CC2A6DA545374F0A3FE7" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_151FEAFB2BB676FFA46745374F099647" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_C940D565A6E0CC2A6DA545374F0A3FE7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_CCB2A7976CA9CC052BA145374F0AAF63" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_151FEAFB2BB676FFA46745374F099647" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_CCB2A7976CA9CC052BA145374F0AAF63" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_7C427CEED56F3717447845374F0A6657" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_151FEAFB2BB676FFA46745374F099647" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_7C427CEED56F3717447845374F0A6657" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/GoodwillAndIntangibleAssetsScheduleOfDefiniteAndIndefiniteLivedIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_C07AF3517DBD92BEC8CB45374F0043E1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_03B082C06081D7B8C12A45374F00407F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_C07AF3517DBD92BEC8CB45374F0043E1" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_03B082C06081D7B8C12A45374F00407F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_A1794D6EDF1E050F359D45374F009988" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_03B082C06081D7B8C12A45374F00407F" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_A1794D6EDF1E050F359D45374F009988" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_C97441DA954FFEE9E8EB45374F019ADF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_A1794D6EDF1E050F359D45374F009988" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_C97441DA954FFEE9E8EB45374F019ADF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_53FD0DF6698B6199DEAC45374F01A169" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_C97441DA954FFEE9E8EB45374F019ADF" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_53FD0DF6698B6199DEAC45374F01A169" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_07AB8EF3D1BD5068A6AE45374F01E140" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_03B082C06081D7B8C12A45374F00407F" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_07AB8EF3D1BD5068A6AE45374F01E140" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_E1E598BC322150F9BABB45374F01F15F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_07AB8EF3D1BD5068A6AE45374F01E140" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_E1E598BC322150F9BABB45374F01F15F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DistributionRightsMember" xlink:label="loc_us-gaap_DistributionRightsMember_CC8A9C1EA67D49CC900445374F02B63F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_E1E598BC322150F9BABB45374F01F15F" xlink:to="loc_us-gaap_DistributionRightsMember_CC8A9C1EA67D49CC900445374F02B63F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_22F9A5E7024B1C73BED845374F02C9B1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_E1E598BC322150F9BABB45374F01F15F" xlink:to="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_22F9A5E7024B1C73BED845374F02C9B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_263B4790F344A157BF2345374F02EAED" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_03B082C06081D7B8C12A45374F00407F" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_263B4790F344A157BF2345374F02EAED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_A18E6305F69760D915C745374F02990E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_263B4790F344A157BF2345374F02EAED" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_A18E6305F69760D915C745374F02990E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_9082F04AA5B2FF178FF345374F03FCD8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_A18E6305F69760D915C745374F02990E" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_9082F04AA5B2FF178FF345374F03FCD8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_7084DFBD9D709FDB7D9645374F03C8FB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_A18E6305F69760D915C745374F02990E" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_7084DFBD9D709FDB7D9645374F03C8FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_CDE43F0DDB641CFC6C5545374F033E3B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_A18E6305F69760D915C745374F02990E" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_CDE43F0DDB641CFC6C5545374F033E3B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_586ED507059C00A3BB6B45374F03B056" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_A18E6305F69760D915C745374F02990E" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_586ED507059C00A3BB6B45374F03B056" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_DEB7C65514C5D1E1703945374F0414BB" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_A18E6305F69760D915C745374F02990E" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_DEB7C65514C5D1E1703945374F0414BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_EA175C97796BF38294DF45374F041B62" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_263B4790F344A157BF2345374F02EAED" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_EA175C97796BF38294DF45374F041B62" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_DAA37CFFBDF5D44BE31C45374F04D4FD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_EA175C97796BF38294DF45374F041B62" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_DAA37CFFBDF5D44BE31C45374F04D4FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_0EDBE648D581F15C484B45374F041560" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_EA175C97796BF38294DF45374F041B62" xlink:to="loc_us-gaap_Goodwill_0EDBE648D581F15C484B45374F041560" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_IntangibleAssetsGrossIncludingGoodwill" xlink:label="loc_eols_IntangibleAssetsGrossIncludingGoodwill_A72DD75CA14273CAD14A45374F045518" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_263B4790F344A157BF2345374F02EAED" xlink:to="loc_eols_IntangibleAssetsGrossIncludingGoodwill_A72DD75CA14273CAD14A45374F045518" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_B1A7E9B3218DF0EAD00445374F054119" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_263B4790F344A157BF2345374F02EAED" xlink:to="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_B1A7E9B3218DF0EAD00445374F054119" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/GoodwillAndIntangibleAssetsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_F4FC55F0AB4191C5E9AA45374E544F39" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_A645E3BED6F4489CBDD145374E54713F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_F4FC55F0AB4191C5E9AA45374E544F39" xlink:to="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_A645E3BED6F4489CBDD145374E54713F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_7D8B5E3843B4BE81DDA145374E54B8DC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_F4FC55F0AB4191C5E9AA45374E544F39" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_7D8B5E3843B4BE81DDA145374E54B8DC" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/OxfordTermLoans" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_3A84F9A83B33872C09CD45374EA48EC5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_B7914C5D42E281EB902045374EA44933" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_3A84F9A83B33872C09CD45374EA48EC5" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_B7914C5D42E281EB902045374EA44933" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/OxfordTermLoansMaturitiesOfDebtDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_11129F66D3DCEDEEAE5145374E3F8D43" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtByMaturityAbstract" xlink:label="loc_us-gaap_LongTermDebtByMaturityAbstract_7F638FCB6C2F3BC3FF7345374E3F6452" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_11129F66D3DCEDEEAE5145374E3F8D43" xlink:to="loc_us-gaap_LongTermDebtByMaturityAbstract_7F638FCB6C2F3BC3FF7345374E3F6452" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_LongtermDebtMaturitiesPrincipalPaymentExcludingFinalPaymentDueInYearThree" xlink:label="loc_eols_LongtermDebtMaturitiesPrincipalPaymentExcludingFinalPaymentDueInYearThree_5C5635B19A765A77B33D45374E3F22C0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_7F638FCB6C2F3BC3FF7345374E3F6452" xlink:to="loc_eols_LongtermDebtMaturitiesPrincipalPaymentExcludingFinalPaymentDueInYearThree_5C5635B19A765A77B33D45374E3F22C0" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_LongtermDebtMaturitiesPrincipalPaymentExcludingFinalPaymentDueInYearFour" xlink:label="loc_eols_LongtermDebtMaturitiesPrincipalPaymentExcludingFinalPaymentDueInYearFour_D7D944D07A0EBA7C426345374E4091F1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_7F638FCB6C2F3BC3FF7345374E3F6452" xlink:to="loc_eols_LongtermDebtMaturitiesPrincipalPaymentExcludingFinalPaymentDueInYearFour_D7D944D07A0EBA7C426345374E4091F1" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_LongtermDebtMaturitiesPrincipalPaymentExcludingFinalPaymentDueInYearFive" xlink:label="loc_eols_LongtermDebtMaturitiesPrincipalPaymentExcludingFinalPaymentDueInYearFive_3BA320E87ADCC9059A1B45374E406F8E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_7F638FCB6C2F3BC3FF7345374E3F6452" xlink:to="loc_eols_LongtermDebtMaturitiesPrincipalPaymentExcludingFinalPaymentDueInYearFive_3BA320E87ADCC9059A1B45374E406F8E" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_LongtermDebtMaturitiesPrincipalPaymentExcludingFinalPayment" xlink:label="loc_eols_LongtermDebtMaturitiesPrincipalPaymentExcludingFinalPayment_96BC57975C31BAF492C445374E406684" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_7F638FCB6C2F3BC3FF7345374E3F6452" xlink:to="loc_eols_LongtermDebtMaturitiesPrincipalPaymentExcludingFinalPayment_96BC57975C31BAF492C445374E406684" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_LongTermDebtFinalPaymentAbstract" xlink:label="loc_eols_LongTermDebtFinalPaymentAbstract_4AB254A98E610BEDF05145374E405FE6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_11129F66D3DCEDEEAE5145374E3F8D43" xlink:to="loc_eols_LongTermDebtFinalPaymentAbstract_4AB254A98E610BEDF05145374E405FE6" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_LongtermDebtMaturitiesFinalPaymentsInYearThree" xlink:label="loc_eols_LongtermDebtMaturitiesFinalPaymentsInYearThree_63D28D92DCAA4FA2832845374E4032AC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_LongTermDebtFinalPaymentAbstract_4AB254A98E610BEDF05145374E405FE6" xlink:to="loc_eols_LongtermDebtMaturitiesFinalPaymentsInYearThree_63D28D92DCAA4FA2832845374E4032AC" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_LongtermDebtMaturitiesFinalPaymentsInYearFour" xlink:label="loc_eols_LongtermDebtMaturitiesFinalPaymentsInYearFour_7C655A1D8B7CE68232CF45374E417873" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_LongTermDebtFinalPaymentAbstract_4AB254A98E610BEDF05145374E405FE6" xlink:to="loc_eols_LongtermDebtMaturitiesFinalPaymentsInYearFour_7C655A1D8B7CE68232CF45374E417873" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_LongtermDebtMaturitiesFinalPaymentsInYearFive" xlink:label="loc_eols_LongtermDebtMaturitiesFinalPaymentsInYearFive_EB2AB42838314B03E5F845374E41713C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_LongTermDebtFinalPaymentAbstract_4AB254A98E610BEDF05145374E405FE6" xlink:to="loc_eols_LongtermDebtMaturitiesFinalPaymentsInYearFive_EB2AB42838314B03E5F845374E41713C" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_LongtermDebtMaturitiesFinalPayments" xlink:label="loc_eols_LongtermDebtMaturitiesFinalPayments_2587A0F31226DF3954B845374E41D2EA" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_LongTermDebtFinalPaymentAbstract_4AB254A98E610BEDF05145374E405FE6" xlink:to="loc_eols_LongtermDebtMaturitiesFinalPayments_2587A0F31226DF3954B845374E41D2EA" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_LongTermDebtByMaturityTotalAbstract" xlink:label="loc_eols_LongTermDebtByMaturityTotalAbstract_1702B91F574D83EC41D445374E415D06" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_11129F66D3DCEDEEAE5145374E3F8D43" xlink:to="loc_eols_LongTermDebtByMaturityTotalAbstract_1702B91F574D83EC41D445374E415D06" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_C73E1915A51513149D5A45374E41FA9B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_LongTermDebtByMaturityTotalAbstract_1702B91F574D83EC41D445374E415D06" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_C73E1915A51513149D5A45374E41FA9B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_F98F19D1524DB87F646B45374E42D4E8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_LongTermDebtByMaturityTotalAbstract_1702B91F574D83EC41D445374E415D06" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_F98F19D1524DB87F646B45374E42D4E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_110F9467719664BE133245374E42D6F3" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_LongTermDebtByMaturityTotalAbstract_1702B91F574D83EC41D445374E415D06" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_110F9467719664BE133245374E42D6F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_8FCC8D5280255A259A6C45374E4231FC" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_LongTermDebtByMaturityTotalAbstract_1702B91F574D83EC41D445374E415D06" xlink:to="loc_us-gaap_LongTermDebt_8FCC8D5280255A259A6C45374E4231FC" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/OxfordTermLoansNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_B054F5E29C50CEB7F1A045374E32318A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_1ED429D4C0F1ADF21BA045374E329BF9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_B054F5E29C50CEB7F1A045374E32318A" xlink:to="loc_us-gaap_DebtInstrumentTable_1ED429D4C0F1ADF21BA045374E329BF9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_93C9A8E9D0BF5C30B03D45374E32AFD5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1ED429D4C0F1ADF21BA045374E329BF9" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_93C9A8E9D0BF5C30B03D45374E32AFD5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_16615FCCE008C6E8CB0345374E3347AA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_93C9A8E9D0BF5C30B03D45374E32AFD5" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_16615FCCE008C6E8CB0345374E3347AA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SecuredDebtMember" xlink:label="loc_us-gaap_SecuredDebtMember_E81801399283DCA20B0B45374E33A755" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_16615FCCE008C6E8CB0345374E3347AA" xlink:to="loc_us-gaap_SecuredDebtMember_E81801399283DCA20B0B45374E33A755" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_7650F7B84559E95A6A0A45374E330E44" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1ED429D4C0F1ADF21BA045374E329BF9" xlink:to="loc_us-gaap_DebtInstrumentAxis_7650F7B84559E95A6A0A45374E330E44" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_ECBA6DAD5C882B35D9BB45374E33C47F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_7650F7B84559E95A6A0A45374E330E44" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_ECBA6DAD5C882B35D9BB45374E33C47F" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_TermLoanFacilityTrancheOneMember" xlink:label="loc_eols_TermLoanFacilityTrancheOneMember_5BBA1F6725720632EFED45374E340218" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_ECBA6DAD5C882B35D9BB45374E33C47F" xlink:to="loc_eols_TermLoanFacilityTrancheOneMember_5BBA1F6725720632EFED45374E340218" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_TermLoanFacilityTrancheTwoMember" xlink:label="loc_eols_TermLoanFacilityTrancheTwoMember_ED8A8E84CD7D0CBC07CC45374E344D54" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_ECBA6DAD5C882B35D9BB45374E33C47F" xlink:to="loc_eols_TermLoanFacilityTrancheTwoMember_ED8A8E84CD7D0CBC07CC45374E344D54" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_TermLoanFacilityMember" xlink:label="loc_eols_TermLoanFacilityMember_88A7F07C7460A0B896A645374E341000" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_ECBA6DAD5C882B35D9BB45374E33C47F" xlink:to="loc_eols_TermLoanFacilityMember_88A7F07C7460A0B896A645374E341000" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaap_VariableRateAxis_C181B7D0BE95A6D8C89745374E34FCB1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1ED429D4C0F1ADF21BA045374E329BF9" xlink:to="loc_us-gaap_VariableRateAxis_C181B7D0BE95A6D8C89745374E34FCB1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_170DE32D32E7B375554945374E340847" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_C181B7D0BE95A6D8C89745374E34FCB1" xlink:to="loc_us-gaap_VariableRateDomain_170DE32D32E7B375554945374E340847" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_364162F36F9613FA939C45374E35D791" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_170DE32D32E7B375554945374E340847" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_364162F36F9613FA939C45374E35D791" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_ApplicableRateMember" xlink:label="loc_eols_ApplicableRateMember_20B0D79E808B1CE19F4E45374E35DF35" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_170DE32D32E7B375554945374E340847" xlink:to="loc_eols_ApplicableRateMember_20B0D79E808B1CE19F4E45374E35DF35" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_7D8DE52E76877D70DE0A45374E351877" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1ED429D4C0F1ADF21BA045374E329BF9" xlink:to="loc_us-gaap_DebtInstrumentLineItems_7D8DE52E76877D70DE0A45374E351877" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_DE873B6485DF1CF60A2A45374E35FD66" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7D8DE52E76877D70DE0A45374E351877" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_DE873B6485DF1CF60A2A45374E35FD66" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_12BA82887AAC9D64A6CF45374E36D073" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7D8DE52E76877D70DE0A45374E351877" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_12BA82887AAC9D64A6CF45374E36D073" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_E02CD5338D0ED6DD633945374E364BE5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7D8DE52E76877D70DE0A45374E351877" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_E02CD5338D0ED6DD633945374E364BE5" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_DebtInstrumentPeriodOfInterestOnlyPayments" xlink:label="loc_eols_DebtInstrumentPeriodOfInterestOnlyPayments_73605DDFAF0F46136D1145374E36A042" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7D8DE52E76877D70DE0A45374E351877" xlink:to="loc_eols_DebtInstrumentPeriodOfInterestOnlyPayments_73605DDFAF0F46136D1145374E36A042" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_DebtInstrumentAmortizationPeriod" xlink:label="loc_eols_DebtInstrumentAmortizationPeriod_805997E3697DFD3295B745374E366DB4" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7D8DE52E76877D70DE0A45374E351877" xlink:to="loc_eols_DebtInstrumentAmortizationPeriod_805997E3697DFD3295B745374E366DB4" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_DebtInstrumentAdditionalPeriodOfAgreementOfInterestPayment" xlink:label="loc_eols_DebtInstrumentAdditionalPeriodOfAgreementOfInterestPayment_1E63C0661BDE5E299F5F45374E36E5AF" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7D8DE52E76877D70DE0A45374E351877" xlink:to="loc_eols_DebtInstrumentAdditionalPeriodOfAgreementOfInterestPayment_1E63C0661BDE5E299F5F45374E36E5AF" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_DebtInstrumentTermAggregatePeriod" xlink:label="loc_eols_DebtInstrumentTermAggregatePeriod_19B38B01C229318BF88145374E37457F" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7D8DE52E76877D70DE0A45374E351877" xlink:to="loc_eols_DebtInstrumentTermAggregatePeriod_19B38B01C229318BF88145374E37457F" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_DebtInstrumentAdditionalAmortizationPeriod" xlink:label="loc_eols_DebtInstrumentAdditionalAmortizationPeriod_E47C1802E09FB28A664A45374E37C4E3" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7D8DE52E76877D70DE0A45374E351877" xlink:to="loc_eols_DebtInstrumentAdditionalAmortizationPeriod_E47C1802E09FB28A664A45374E37C4E3" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_DebtInstrumentPercentageOfPrincipalAmountBalloonPayment" xlink:label="loc_eols_DebtInstrumentPercentageOfPrincipalAmountBalloonPayment_B37379F9750DA970DAA845374E376AE8" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7D8DE52E76877D70DE0A45374E351877" xlink:to="loc_eols_DebtInstrumentPercentageOfPrincipalAmountBalloonPayment_B37379F9750DA970DAA845374E376AE8" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_DebtInstrumentPrepaymentFeePercentageNextTwelveMonths" xlink:label="loc_eols_DebtInstrumentPrepaymentFeePercentageNextTwelveMonths_05064D151E0B423BA49145374E371858" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7D8DE52E76877D70DE0A45374E351877" xlink:to="loc_eols_DebtInstrumentPrepaymentFeePercentageNextTwelveMonths_05064D151E0B423BA49145374E371858" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_DebtInstrumentPrepaymentFeePercentageYearTwo" xlink:label="loc_eols_DebtInstrumentPrepaymentFeePercentageYearTwo_82D15EF1991BE751076D45374E386248" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7D8DE52E76877D70DE0A45374E351877" xlink:to="loc_eols_DebtInstrumentPrepaymentFeePercentageYearTwo_82D15EF1991BE751076D45374E386248" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_DebtInstrumentPrepaymentFeePercentageThereafter" xlink:label="loc_eols_DebtInstrumentPrepaymentFeePercentageThereafter_4F3652043956750B737245374E38E6A7" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7D8DE52E76877D70DE0A45374E351877" xlink:to="loc_eols_DebtInstrumentPrepaymentFeePercentageThereafter_4F3652043956750B737245374E38E6A7" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_DebtInstrumentDefaultInterestRate" xlink:label="loc_eols_DebtInstrumentDefaultInterestRate_D3CEEDD6F6C18198FC6245374E38ECA6" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7D8DE52E76877D70DE0A45374E351877" xlink:to="loc_eols_DebtInstrumentDefaultInterestRate_D3CEEDD6F6C18198FC6245374E38ECA6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_4A797881620D90D2845D45374E38BB2D" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7D8DE52E76877D70DE0A45374E351877" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_4A797881620D90D2845D45374E38BB2D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredFinanceCostsGross" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_F7909D2767B14A28B55345374E38B180" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_7D8DE52E76877D70DE0A45374E351877" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_F7909D2767B14A28B55345374E38B180" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/OxfordTermLoansTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_A4E46DE7963B746CB9C045374F5054F2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_36D0EC98228A4366BA5845374F5005B6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_A4E46DE7963B746CB9C045374F5054F2" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_36D0EC98228A4366BA5845374F5005B6" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/RelatedPartyTransactions" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_8B2596815FD25E33877545374EA030A2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_299671A51C42D297CF4C45374EA0ED11" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_8B2596815FD25E33877545374EA030A2" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_299671A51C42D297CF4C45374EA0ED11" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_34FE44EC3AF4D794D2950F0252B19257" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1AD48FE492B3B1E77DD30F0252B2E15B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_34FE44EC3AF4D794D2950F0252B19257" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1AD48FE492B3B1E77DD30F0252B2E15B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_E1C19A7D074962993B390F0252B2D072" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1AD48FE492B3B1E77DD30F0252B2E15B" xlink:to="loc_srt_CounterpartyNameAxis_E1C19A7D074962993B390F0252B2D072" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_A3D56864C77473B92E340F0252B2BC91" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_E1C19A7D074962993B390F0252B2D072" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_A3D56864C77473B92E340F0252B2BC91" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_ALPHAEONMember" xlink:label="loc_eols_ALPHAEONMember_52428684978D5065727D0F0252B389F1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_A3D56864C77473B92E340F0252B2BC91" xlink:to="loc_eols_ALPHAEONMember_52428684978D5065727D0F0252B389F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_5681CDB3BE239F32B88E0F0252B30308" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1AD48FE492B3B1E77DD30F0252B2E15B" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_5681CDB3BE239F32B88E0F0252B30308" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_F45C8ABB457BAE1063920F0252B343C4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_5681CDB3BE239F32B88E0F0252B30308" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_F45C8ABB457BAE1063920F0252B343C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_7308DB2E8E3B7C0E67ED0F0252B375B1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_F45C8ABB457BAE1063920F0252B343C4" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_7308DB2E8E3B7C0E67ED0F0252B375B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_373C6744772776ABB7B80F0252B419EC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1AD48FE492B3B1E77DD30F0252B2E15B" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_373C6744772776ABB7B80F0252B419EC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_318A1F5470D94F6006780F0252B468FA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_373C6744772776ABB7B80F0252B419EC" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_318A1F5470D94F6006780F0252B468FA" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_EvolusIncMember" xlink:label="loc_eols_EvolusIncMember_B9A3738D58044184FEEB0F0252B400CF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_318A1F5470D94F6006780F0252B468FA" xlink:to="loc_eols_EvolusIncMember_B9A3738D58044184FEEB0F0252B400CF" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_AE1CD3FD743E96DBF5950F0252B44A6F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1AD48FE492B3B1E77DD30F0252B2E15B" xlink:to="loc_dei_LegalEntityAxis_AE1CD3FD743E96DBF5950F0252B44A6F" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1287C4A90595A70DD1580F0252B421E1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_AE1CD3FD743E96DBF5950F0252B44A6F" xlink:to="loc_dei_EntityDomain_1287C4A90595A70DD1580F0252B421E1" xlink:type="arc" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1287C4A90595A70DD1580F0252B421E1" xlink:to="loc_eols_ALPHAEONMember_52428684978D5065727D0F0252B389F1" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_SCHAEONLLCMember" xlink:label="loc_eols_SCHAEONLLCMember_9049CD4CE7EB8E93EBD10F0252B5550C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1287C4A90595A70DD1580F0252B421E1" xlink:to="loc_eols_SCHAEONLLCMember_9049CD4CE7EB8E93EBD10F0252B5550C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8EF1C02844AE837E70410F0252B7906C" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1AD48FE492B3B1E77DD30F0252B2E15B" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8EF1C02844AE837E70410F0252B7906C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_A595E998A45E0E39FAA60F0252B777C2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8EF1C02844AE837E70410F0252B7906C" xlink:to="loc_us-gaap_RelatedPartyDomain_A595E998A45E0E39FAA60F0252B777C2" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_ChiefMedicalOfficerMember" xlink:label="loc_eols_ChiefMedicalOfficerMember_533AA1A4DC93837A59F50F0252B854A8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_A595E998A45E0E39FAA60F0252B777C2" xlink:to="loc_eols_ChiefMedicalOfficerMember_533AA1A4DC93837A59F50F0252B854A8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_278BE927F2AF05412CBC0F0252B8FC6E" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1AD48FE492B3B1E77DD30F0252B2E15B" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_278BE927F2AF05412CBC0F0252B8FC6E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_B44ACAB55F20680A86F60F0252B89F3E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_278BE927F2AF05412CBC0F0252B8FC6E" xlink:to="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_B44ACAB55F20680A86F60F0252B89F3E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_69F89A223D88169840340F0252B8E638" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_278BE927F2AF05412CBC0F0252B8FC6E" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_69F89A223D88169840340F0252B8E638" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2721DD83389B0A2DA3010F0252B95719" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_278BE927F2AF05412CBC0F0252B8FC6E" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2721DD83389B0A2DA3010F0252B95719" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_NonCashRelatedPartyReceivable" xlink:label="loc_eols_NonCashRelatedPartyReceivable_EB6CDEA3901A71B2BEA60F0252B984CF" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_278BE927F2AF05412CBC0F0252B8FC6E" xlink:to="loc_eols_NonCashRelatedPartyReceivable_EB6CDEA3901A71B2BEA60F0252B984CF" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_BusinessCombinationUpfrontPaymentUponObtainingFDAApproval" xlink:label="loc_eols_BusinessCombinationUpfrontPaymentUponObtainingFDAApproval_C7A94D3D98651C6CB7500F0252BA2535" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_278BE927F2AF05412CBC0F0252B8FC6E" xlink:to="loc_eols_BusinessCombinationUpfrontPaymentUponObtainingFDAApproval_C7A94D3D98651C6CB7500F0252BA2535" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_RelatedPartyTransactionPeriodOfTerminationOfFirstCommercialSale" xlink:label="loc_eols_RelatedPartyTransactionPeriodOfTerminationOfFirstCommercialSale_B26CB9D437A0613572BE0F0252BAB5F7" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_278BE927F2AF05412CBC0F0252B8FC6E" xlink:to="loc_eols_RelatedPartyTransactionPeriodOfTerminationOfFirstCommercialSale_B26CB9D437A0613572BE0F0252BAB5F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractualObligation" xlink:label="loc_us-gaap_ContractualObligation_5E046A959D59AFDDD3040F0252BA78C6" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_278BE927F2AF05412CBC0F0252B8FC6E" xlink:to="loc_us-gaap_ContractualObligation_5E046A959D59AFDDD3040F0252BA78C6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaap_LongTermNotesPayable_9781711748BC5ED016F10F0252BA78D3" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_278BE927F2AF05412CBC0F0252B8FC6E" xlink:to="loc_us-gaap_LongTermNotesPayable_9781711748BC5ED016F10F0252BA78D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_7E1CEA6D76A8C0EA6A710F0252BAFDD6" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_278BE927F2AF05412CBC0F0252B8FC6E" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_7E1CEA6D76A8C0EA6A710F0252BAFDD6" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_StockPurchaseAgreementPeriodAvailabletoCureBreach" xlink:label="loc_eols_StockPurchaseAgreementPeriodAvailabletoCureBreach_B16DCC8A03A79C17832C0F0252BAB482" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_278BE927F2AF05412CBC0F0252B8FC6E" xlink:to="loc_eols_StockPurchaseAgreementPeriodAvailabletoCureBreach_B16DCC8A03A79C17832C0F0252BAB482" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_9940796C556A981B610F0F0252BBE2DD" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_278BE927F2AF05412CBC0F0252B8FC6E" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_9940796C556A981B610F0F0252BBE2DD" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_BusinessAcquisitionUnwindingFee" xlink:label="loc_eols_BusinessAcquisitionUnwindingFee_D2342640DC5408ACF0DD0F0252BBAD43" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_278BE927F2AF05412CBC0F0252B8FC6E" xlink:to="loc_eols_BusinessAcquisitionUnwindingFee_D2342640DC5408ACF0DD0F0252BBAD43" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3EE8519F0B88C834541945374E90145F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_0611C79CBBCC7CB6DAB845374E903122" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3EE8519F0B88C834541945374E90145F" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_0611C79CBBCC7CB6DAB845374E903122" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1E17F6F97A04DCEB4815FEEBEED68FAE" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_D3CC8BFAB2736AE8D141FEEBEED66509" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1E17F6F97A04DCEB4815FEEBEED68FAE" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_D3CC8BFAB2736AE8D141FEEBEED66509" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_3F04C68BE701A4485E45FEEBEED792C9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_D3CC8BFAB2736AE8D141FEEBEED66509" xlink:to="loc_srt_RangeAxis_3F04C68BE701A4485E45FEEBEED792C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_8F1D378B2D7D3AB06A07FEEBEED7EF86" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_3F04C68BE701A4485E45FEEBEED792C9" xlink:to="loc_srt_RangeMember_8F1D378B2D7D3AB06A07FEEBEED7EF86" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_81A8B03387CB4184E4E5FEEBEED7F7D9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_8F1D378B2D7D3AB06A07FEEBEED7EF86" xlink:to="loc_srt_MinimumMember_81A8B03387CB4184E4E5FEEBEED7F7D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_01EDF2BE51666E37843AFEEBEED73C8A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_8F1D378B2D7D3AB06A07FEEBEED7EF86" xlink:to="loc_srt_MaximumMember_01EDF2BE51666E37843AFEEBEED73C8A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_1122475C92242EF6B057FEEBEED869B3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_D3CC8BFAB2736AE8D141FEEBEED66509" xlink:to="loc_us-gaap_ClassOfStockLineItems_1122475C92242EF6B057FEEBEED869B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_60EE219685BE2EBD9DE6FEEBEED8D0BF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1122475C92242EF6B057FEEBEED869B3" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_60EE219685BE2EBD9DE6FEEBEED8D0BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_E77EE55D9382868F26F9FEEBEED8CAA6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1122475C92242EF6B057FEEBEED869B3" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_E77EE55D9382868F26F9FEEBEED8CAA6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_7C4972E741E51DDBFBECFEEBEED87801" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1122475C92242EF6B057FEEBEED869B3" xlink:to="loc_us-gaap_PreferredStockSharesIssued_7C4972E741E51DDBFBECFEEBEED87801" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_9ACDBE30A4BFEAA9D1A6FEEBEED81E50" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1122475C92242EF6B057FEEBEED869B3" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_9ACDBE30A4BFEAA9D1A6FEEBEED81E50" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_F50CDD8F8221412D449CFEEBEED89CDA" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1122475C92242EF6B057FEEBEED869B3" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_F50CDD8F8221412D449CFEEBEED89CDA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_7DCE433BE2879F15C250FEEBEED99FA1" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1122475C92242EF6B057FEEBEED869B3" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_7DCE433BE2879F15C250FEEBEED99FA1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_CEB026B401A62E75B2CAFEEBEED9FF50" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1122475C92242EF6B057FEEBEED869B3" xlink:to="loc_us-gaap_CommonStockSharesIssued_CEB026B401A62E75B2CAFEEBEED9FF50" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_310B77970C854072A350FEEBEED97B2F" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1122475C92242EF6B057FEEBEED869B3" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_310B77970C854072A350FEEBEED97B2F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_1D213A73D0279F1B44D8FEEBEED99FEA" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1122475C92242EF6B057FEEBEED869B3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_1D213A73D0279F1B44D8FEEBEED99FEA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_CAE150B2A87562E13C55FEEBEED9EA25" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1122475C92242EF6B057FEEBEED869B3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_CAE150B2A87562E13C55FEEBEED9EA25" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_CommonStockAdditionalCapitalSharesReservedforFutureIssuance" xlink:label="loc_eols_CommonStockAdditionalCapitalSharesReservedforFutureIssuance_E7B221C075894214B4ABFEEBEED9C9FF" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1122475C92242EF6B057FEEBEED869B3" xlink:to="loc_eols_CommonStockAdditionalCapitalSharesReservedforFutureIssuance_E7B221C075894214B4ABFEEBEED9C9FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_E59B5034CD149CC296CBFEEBEED9344B" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1122475C92242EF6B057FEEBEED869B3" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_E59B5034CD149CC296CBFEEBEED9344B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_B5703FC7C639ABA52044FEEBEEDA5722" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1122475C92242EF6B057FEEBEED869B3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_B5703FC7C639ABA52044FEEBEEDA5722" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_EE558FFF06519B1F5333FEEBEEDA0871" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1122475C92242EF6B057FEEBEED869B3" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_EE558FFF06519B1F5333FEEBEEDA0871" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_AllocatedShareBasedCompensationExpenseCapitalized" xlink:label="loc_eols_AllocatedShareBasedCompensationExpenseCapitalized_B7AF77EA6E9EC4A5D31AFEEBEEDA515F" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1122475C92242EF6B057FEEBEED869B3" xlink:to="loc_eols_AllocatedShareBasedCompensationExpenseCapitalized_B7AF77EA6E9EC4A5D31AFEEBEEDA515F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/StockholdersEquityRestrictedStockUnitDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_174C6AADE0129847AE3E45374F561C98" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6F645C7441520ECA36C845374F56097D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_174C6AADE0129847AE3E45374F561C98" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6F645C7441520ECA36C845374F56097D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_D965A7AF5B2C5F2C513D45374F57A870" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6F645C7441520ECA36C845374F56097D" xlink:to="loc_us-gaap_AwardTypeAxis_D965A7AF5B2C5F2C513D45374F57A870" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_53B722ECBF8313EB9DEB45374F57F9C0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_D965A7AF5B2C5F2C513D45374F57A870" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_53B722ECBF8313EB9DEB45374F57F9C0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_6BAEE73E9A8273B5079F45374F57B57B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_53B722ECBF8313EB9DEB45374F57F9C0" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_6BAEE73E9A8273B5079F45374F57B57B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_688D4BAFBE3CFDE0C73945374F57C636" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6F645C7441520ECA36C845374F56097D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_688D4BAFBE3CFDE0C73945374F57C636" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9B31E8796ADBE46220BE45374F587EED" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_688D4BAFBE3CFDE0C73945374F57C636" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9B31E8796ADBE46220BE45374F587EED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_B2D903DF15D797CA038545374F585C3A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9B31E8796ADBE46220BE45374F587EED" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_B2D903DF15D797CA038545374F585C3A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_A6388630CC1C59A8953045374F5883E5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9B31E8796ADBE46220BE45374F587EED" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_A6388630CC1C59A8953045374F5883E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_C6BC2A82AE84ED10F74545374F58ACE8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9B31E8796ADBE46220BE45374F587EED" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_C6BC2A82AE84ED10F74545374F58ACE8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_A6C5B9489CDFF441B26145374F59713D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9B31E8796ADBE46220BE45374F587EED" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_A6C5B9489CDFF441B26145374F59713D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_E7B47C6761168B4F4CC945374F59698D" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9B31E8796ADBE46220BE45374F587EED" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_E7B47C6761168B4F4CC945374F59698D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_2C054314F62C9665040045374F5988CD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_688D4BAFBE3CFDE0C73945374F57C636" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_2C054314F62C9665040045374F5988CD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_AEBD9D91A2F27678B38445374F59987A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_2C054314F62C9665040045374F5988CD" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_AEBD9D91A2F27678B38445374F59987A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_E88A7833EB1DDFAF20C445374F593810" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_2C054314F62C9665040045374F5988CD" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_E88A7833EB1DDFAF20C445374F593810" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_35C932577D4BA89E6E8C45374F5918D5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_2C054314F62C9665040045374F5988CD" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_35C932577D4BA89E6E8C45374F5918D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_4E4689D8C5D40BE1DFC345374F5A3E27" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_2C054314F62C9665040045374F5988CD" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_4E4689D8C5D40BE1DFC345374F5A3E27" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_5D6F83BB046AAC07E41545374F5A38E9" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_2C054314F62C9665040045374F5988CD" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_5D6F83BB046AAC07E41545374F5A38E9" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/StockholdersEquityScheduleOfStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_814724E5A4CC9AC6043A0F02518B6F21" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_CA58A9F1B8B90CBEDF460F02518B71E2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_814724E5A4CC9AC6043A0F02518B6F21" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_CA58A9F1B8B90CBEDF460F02518B71E2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_AB9407685687C9CAF9FE0F02518CEEE1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_CA58A9F1B8B90CBEDF460F02518B71E2" xlink:to="loc_us-gaap_AwardTypeAxis_AB9407685687C9CAF9FE0F02518CEEE1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_AB684578DA55D82231040F02518C4E42" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_AB9407685687C9CAF9FE0F02518CEEE1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_AB684578DA55D82231040F02518C4E42" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_87F2C175C9F0553D54250F02518CC6B1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_AB684578DA55D82231040F02518C4E42" xlink:to="loc_us-gaap_EmployeeStockOptionMember_87F2C175C9F0553D54250F02518CC6B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_602243EF8520793568D50F02518C2130" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_CA58A9F1B8B90CBEDF460F02518B71E2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_602243EF8520793568D50F02518C2130" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_655828E1E22E3DE61DDC0F02518DE0C5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_602243EF8520793568D50F02518C2130" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_655828E1E22E3DE61DDC0F02518DE0C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_C30ECCB9C8C08EC4DEBD0F02518D1FAD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_655828E1E22E3DE61DDC0F02518DE0C5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_C30ECCB9C8C08EC4DEBD0F02518D1FAD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_4591A2B656151298D7A30F02518DDE59" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_655828E1E22E3DE61DDC0F02518DE0C5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_4591A2B656151298D7A30F02518DDE59" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_099D486CF5F1BDCEE9DB0F02518DF70E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_655828E1E22E3DE61DDC0F02518DE0C5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_099D486CF5F1BDCEE9DB0F02518DF70E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_44B74CF9ED4BAABB3B800F02518D8642" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_655828E1E22E3DE61DDC0F02518DE0C5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_44B74CF9ED4BAABB3B800F02518D8642" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_E514AE89E5A7054E56830F02518E6F27" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_655828E1E22E3DE61DDC0F02518DE0C5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_E514AE89E5A7054E56830F02518E6F27" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_93C3945072BF3045A7020F02518EBF1B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_602243EF8520793568D50F02518C2130" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_93C3945072BF3045A7020F02518EBF1B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8B128698F1217E304DA50F02518EDC82" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_602243EF8520793568D50F02518C2130" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8B128698F1217E304DA50F02518EDC82" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3CA4FBBF12A925ECCE6A0F02518E5CD6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8B128698F1217E304DA50F02518EDC82" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3CA4FBBF12A925ECCE6A0F02518E5CD6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_46ED59FA076786C991120F02518E2158" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8B128698F1217E304DA50F02518EDC82" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_46ED59FA076786C991120F02518E2158" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_50CD54E2914DA251FA6D0F02518F5FD1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8B128698F1217E304DA50F02518EDC82" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_50CD54E2914DA251FA6D0F02518F5FD1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_9E085A64773A11D678420F02518F9354" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8B128698F1217E304DA50F02518EDC82" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_9E085A64773A11D678420F02518F9354" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_F21FEA337BD62004D3CE0F02518F30A5" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8B128698F1217E304DA50F02518EDC82" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_F21FEA337BD62004D3CE0F02518F30A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_EEF1DFD749A9B7A4A6A10F02518F5D4C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_602243EF8520793568D50F02518C2130" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_EEF1DFD749A9B7A4A6A10F02518F5D4C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_CAE44C5B0DB8EDECB5300F02518F123B" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_602243EF8520793568D50F02518C2130" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_CAE44C5B0DB8EDECB5300F02518F123B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_575873D8A98EEDFD4A700F02518F36BF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_CAE44C5B0DB8EDECB5300F02518F123B" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_575873D8A98EEDFD4A700F02518F36BF" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermExercisable" xlink:label="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermExercisable_4457B1367B7773875B180F025190A5E7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_CAE44C5B0DB8EDECB5300F02518F123B" xlink:to="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermExercisable_4457B1367B7773875B180F025190A5E7" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:label="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract_BD837264AA149B4B60F80F02519031BF" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_602243EF8520793568D50F02518C2130" xlink:to="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract_BD837264AA149B4B60F80F02519031BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_E779FE025FBD223EB4A60F025190C7F3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract_BD837264AA149B4B60F80F02519031BF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_E779FE025FBD223EB4A60F025190C7F3" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsGrantedinPeriodIntrinsicValue" xlink:label="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsGrantedinPeriodIntrinsicValue_94FFCBB0F29500110FBF0F0251906C88" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract_BD837264AA149B4B60F80F02519031BF" xlink:to="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsGrantedinPeriodIntrinsicValue_94FFCBB0F29500110FBF0F0251906C88" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_12B8FC49B8B0E03DB4740F025191EC25" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract_BD837264AA149B4B60F80F02519031BF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_12B8FC49B8B0E03DB4740F025191EC25" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsForfeitedinPeriodIntrinsicValue" xlink:label="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsForfeitedinPeriodIntrinsicValue_BB2D25C2B13A179B198F0F025191FB5B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract_BD837264AA149B4B60F80F02519031BF" xlink:to="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsForfeitedinPeriodIntrinsicValue_BB2D25C2B13A179B198F0F025191FB5B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_0CCDC68D2D651784E0C10F0251911220" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract_BD837264AA149B4B60F80F02519031BF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_0CCDC68D2D651784E0C10F0251911220" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_3AEB9B13A0F805BFCD240F0251910ECE" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_602243EF8520793568D50F02518C2130" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_3AEB9B13A0F805BFCD240F0251910ECE" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/StockholdersEquityScheduleOfValuationAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_D1CB91CD3EC30A8D9437B5DED549A6D1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_72E34AFA742ABAC9EC62B5DED549C5D7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_D1CB91CD3EC30A8D9437B5DED549A6D1" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_72E34AFA742ABAC9EC62B5DED549C5D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_9B606042FA8F6D4CC593B5DED5491520" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_72E34AFA742ABAC9EC62B5DED549C5D7" xlink:to="loc_us-gaap_AwardTypeAxis_9B606042FA8F6D4CC593B5DED5491520" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_D4D99CFD3C7E7AAA3CAEB5DED54AD756" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_9B606042FA8F6D4CC593B5DED5491520" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_D4D99CFD3C7E7AAA3CAEB5DED54AD756" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_98747E28619CE232388CB5DED54A7689" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_D4D99CFD3C7E7AAA3CAEB5DED54AD756" xlink:to="loc_us-gaap_EmployeeStockOptionMember_98747E28619CE232388CB5DED54A7689" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_B9EFD77387BAC2E5792EB5DED54A3E1B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_72E34AFA742ABAC9EC62B5DED549C5D7" xlink:to="loc_us-gaap_ClassOfStockLineItems_B9EFD77387BAC2E5792EB5DED54A3E1B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_AD0496E3F2E5C0BFEE5FB5DED54ADD74" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_B9EFD77387BAC2E5792EB5DED54A3E1B" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_AD0496E3F2E5C0BFEE5FB5DED54ADD74" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_9402ED79E4B21E88DE7FB5DED54B9DB9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_B9EFD77387BAC2E5792EB5DED54A3E1B" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_9402ED79E4B21E88DE7FB5DED54B9DB9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_887A84DC4E5403AC73CDB5DED54B6A63" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_B9EFD77387BAC2E5792EB5DED54A3E1B" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_887A84DC4E5403AC73CDB5DED54B6A63" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_FE0A37335F52F0089B07B5DED54B5A25" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_B9EFD77387BAC2E5792EB5DED54A3E1B" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_FE0A37335F52F0089B07B5DED54B5A25" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/StockholdersEquityStockBasedCompensationExpenseAllocationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9C93F80CCDC9FC3D5CC645374EE3805F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_89D21E0A1C381BC0418445374EE3F484" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9C93F80CCDC9FC3D5CC645374EE3805F" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_89D21E0A1C381BC0418445374EE3F484" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_5EE2DACEF8620B01F4F145374EE3270B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_89D21E0A1C381BC0418445374EE3F484" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_5EE2DACEF8620B01F4F145374EE3270B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_F8B892BB46E558DA224A45374EE4D731" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_5EE2DACEF8620B01F4F145374EE3270B" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_F8B892BB46E558DA224A45374EE4D731" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_77702E1679F4EC7B5D5445374EE475E1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_F8B892BB46E558DA224A45374EE4D731" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_77702E1679F4EC7B5D5445374EE475E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_8899F1A62635826AA05845374EE49F7C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_F8B892BB46E558DA224A45374EE4D731" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_8899F1A62635826AA05845374EE49F7C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0248B13CE9C5A7182DEB45374EE43D37" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_89D21E0A1C381BC0418445374EE3F484" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0248B13CE9C5A7182DEB45374EE43D37" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_D803503548C41E338F9045374EE5A2BE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0248B13CE9C5A7182DEB45374EE43D37" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_D803503548C41E338F9045374EE5A2BE" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/StockholdersEquityTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_13400A60BD15CC6B11AA45392061FF17" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_F05ADA81F34464FE842F45392061A59F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_13400A60BD15CC6B11AA45392061FF17" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_F05ADA81F34464FE842F45392061A59F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_330BE366E8B718683E54453920612A23" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_13400A60BD15CC6B11AA45392061FF17" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_330BE366E8B718683E54453920612A23" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_3B3080E985CA161ABCA1453920618EA4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_13400A60BD15CC6B11AA45392061FF17" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_3B3080E985CA161ABCA1453920618EA4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_70E8211EAF873EB17814453920612B94" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_13400A60BD15CC6B11AA45392061FF17" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_70E8211EAF873EB17814453920612B94" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_58B8A6BD46E6E92DA41E45374E763EEF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_7638844F5C24A87F46F945374E7673F7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_58B8A6BD46E6E92DA41E45374E763EEF" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_7638844F5C24A87F46F945374E7673F7" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_DB13D6D1F8B17ADF7F4F371E11BE61D7" xlink:type="locator" />
    <link:loc xlink:href="eols-20190930.xsd#eols_AccountingPoliciesTable" xlink:label="loc_eols_AccountingPoliciesTable_6F83B4E2CB3EA830A723371E11BE3357" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_DB13D6D1F8B17ADF7F4F371E11BE61D7" xlink:to="loc_eols_AccountingPoliciesTable_6F83B4E2CB3EA830A723371E11BE3357" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_0888B51FE6252D1415A0371E11BE0648" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_AccountingPoliciesTable_6F83B4E2CB3EA830A723371E11BE3357" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_0888B51FE6252D1415A0371E11BE0648" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3E2CDC4C941D7B4F5C21371E11BEEDA5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_0888B51FE6252D1415A0371E11BE0648" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3E2CDC4C941D7B4F5C21371E11BEEDA5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_774A8105865E14189018371E11BE429F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3E2CDC4C941D7B4F5C21371E11BEEDA5" xlink:to="loc_us-gaap_EmployeeStockOptionMember_774A8105865E14189018371E11BE429F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_EE5A2093BA5D0663FB5B371E11BE2140" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3E2CDC4C941D7B4F5C21371E11BEEDA5" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_EE5A2093BA5D0663FB5B371E11BE2140" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_D9F48F31CAC5B2F6AC83371E11BE318F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_AccountingPoliciesTable_6F83B4E2CB3EA830A723371E11BE3357" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_D9F48F31CAC5B2F6AC83371E11BE318F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6135F075CD7AC0C3C8B0371E11BE668B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_D9F48F31CAC5B2F6AC83371E11BE318F" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6135F075CD7AC0C3C8B0371E11BE668B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DistributionRightsMember" xlink:label="loc_us-gaap_DistributionRightsMember_75557EC4E660F3FA94BD371E11BE006F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6135F075CD7AC0C3C8B0371E11BE668B" xlink:to="loc_us-gaap_DistributionRightsMember_75557EC4E660F3FA94BD371E11BE006F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SoftwareDevelopmentMember" xlink:label="loc_us-gaap_SoftwareDevelopmentMember_BFA0C5F640B54CE2A8D5371E11BEABE3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6135F075CD7AC0C3C8B0371E11BE668B" xlink:to="loc_us-gaap_SoftwareDevelopmentMember_BFA0C5F640B54CE2A8D5371E11BEABE3" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_AccountingPoliciesLineItems" xlink:label="loc_eols_AccountingPoliciesLineItems_2347D9E561310B28597E371E11BEDED2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_AccountingPoliciesTable_6F83B4E2CB3EA830A723371E11BE3357" xlink:to="loc_eols_AccountingPoliciesLineItems_2347D9E561310B28597E371E11BEDED2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NumberOfReportingUnits" xlink:label="loc_us-gaap_NumberOfReportingUnits_343543727BAF8E5B083B371E11BEEC98" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_AccountingPoliciesLineItems_2347D9E561310B28597E371E11BEDED2" xlink:to="loc_us-gaap_NumberOfReportingUnits_343543727BAF8E5B083B371E11BEEC98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_3E0AD6478C88FB507CB0371E11BE6CBD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_AccountingPoliciesLineItems_2347D9E561310B28597E371E11BEDED2" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_3E0AD6478C88FB507CB0371E11BE6CBD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_E3C0F9A4AF9F37BC58C8371E11BE9BB7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_AccountingPoliciesLineItems_2347D9E561310B28597E371E11BEDED2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_E3C0F9A4AF9F37BC58C8371E11BE9BB7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_DF5E9AD3001D66209D1B371E11BE2174" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_AccountingPoliciesLineItems_2347D9E561310B28597E371E11BEDED2" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_DF5E9AD3001D66209D1B371E11BE2174" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_AccruedCouponAndRebateLiabilityCurrent" xlink:label="loc_eols_AccruedCouponAndRebateLiabilityCurrent_FCA235A064EDCE2AE9E5371E11BE1CDC" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_AccountingPoliciesLineItems_2347D9E561310B28597E371E11BEDED2" xlink:to="loc_eols_AccruedCouponAndRebateLiabilityCurrent_FCA235A064EDCE2AE9E5371E11BE1CDC" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_ProvisionsForAccruedVolumeBasedRebateAndCouponLiability" xlink:label="loc_eols_ProvisionsForAccruedVolumeBasedRebateAndCouponLiability_F53355FB41C3C46878BD371E11BE851E" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_AccountingPoliciesLineItems_2347D9E561310B28597E371E11BEDED2" xlink:to="loc_eols_ProvisionsForAccruedVolumeBasedRebateAndCouponLiability_F53355FB41C3C46878BD371E11BE851E" xlink:type="arc" />
    <link:loc xlink:href="eols-20190930.xsd#eols_PaymentsForProvisionsForAccruedVolumeBasedRebateAndCouponLiability" xlink:label="loc_eols_PaymentsForProvisionsForAccruedVolumeBasedRebateAndCouponLiability_C6B3AE839A0D8B6009FF371E11BEC169" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_AccountingPoliciesLineItems_2347D9E561310B28597E371E11BEDED2" xlink:to="loc_eols_PaymentsForProvisionsForAccruedVolumeBasedRebateAndCouponLiability_C6B3AE839A0D8B6009FF371E11BEC169" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_1192FA22A5764B681BAF371E11BEADF4" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_AccountingPoliciesLineItems_2347D9E561310B28597E371E11BEDED2" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_1192FA22A5764B681BAF371E11BEADF4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_DADCDE0F29F2F4FC4D4B371E11BE9AF6" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_AccountingPoliciesLineItems_2347D9E561310B28597E371E11BEDED2" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_DADCDE0F29F2F4FC4D4B371E11BE9AF6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_BDE3DDCB2B96F4CD7C60371E11BE4917" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_AccountingPoliciesLineItems_2347D9E561310B28597E371E11BEDED2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_BDE3DDCB2B96F4CD7C60371E11BE4917" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/SummaryOfSignificantAccountingPoliciesNewAccountingPronouncementsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_32C0AA8E640ACA26A1380EF6E14F4159" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_27B3440615772490C5220EF6E14F0A7C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_32C0AA8E640ACA26A1380EF6E14F4159" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_27B3440615772490C5220EF6E14F0A7C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_B0DD478C69CEB484652C0EF6E150B6D1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_27B3440615772490C5220EF6E14F0A7C" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_B0DD478C69CEB484652C0EF6E150B6D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_06DD188E3BF67D1D09210EF6E1501420" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_B0DD478C69CEB484652C0EF6E150B6D1" xlink:to="loc_us-gaap_TypeOfAdoptionMember_06DD188E3BF67D1D09210EF6E1501420" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_6097BFA444F12996F9000EF6E150890F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_06DD188E3BF67D1D09210EF6E1501420" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_6097BFA444F12996F9000EF6E150890F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_34A682CC5743AD04DF470EF6E151EB3E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_27B3440615772490C5220EF6E14F0A7C" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_34A682CC5743AD04DF470EF6E151EB3E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_52D3374BC416E99A33B30EF6E151EF71" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_34A682CC5743AD04DF470EF6E151EB3E" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_52D3374BC416E99A33B30EF6E151EF71" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_DE02D2877123A1AF3B6B0EF6E1511B9C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_34A682CC5743AD04DF470EF6E151EB3E" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_DE02D2877123A1AF3B6B0EF6E1511B9C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_E855C31495F9093F13180EF6E151619B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_34A682CC5743AD04DF470EF6E151EB3E" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_E855C31495F9093F13180EF6E151619B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="loc_us-gaap_DeferredRentCreditNoncurrent_99E302C63767313671290EFDCF90944D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_34A682CC5743AD04DF470EF6E151EB3E" xlink:to="loc_us-gaap_DeferredRentCreditNoncurrent_99E302C63767313671290EFDCF90944D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_AA58E02F2CB4EA358FBA45374E9A7614" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_4FF5E2B5278FD125115745374E9A5712" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_AA58E02F2CB4EA358FBA45374E9A7614" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_4FF5E2B5278FD125115745374E9A5712" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_80FA6B5AAC71F1E2392A45374E9AA33B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_AA58E02F2CB4EA358FBA45374E9A7614" xlink:to="loc_us-gaap_UseOfEstimates_80FA6B5AAC71F1E2392A45374E9AA33B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_26776B03A7C2405646D645374E9AA248" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_AA58E02F2CB4EA358FBA45374E9A7614" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_26776B03A7C2405646D645374E9AA248" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_736ADDF1C214CDBDFA1D45374E9A0C5D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_AA58E02F2CB4EA358FBA45374E9A7614" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_736ADDF1C214CDBDFA1D45374E9A0C5D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_3D76DFF18C73EED4867C45374E9B69A9" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_AA58E02F2CB4EA358FBA45374E9A7614" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_3D76DFF18C73EED4867C45374E9B69A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock_F13EB86AD125EA952D5845374E9B5FF2" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_AA58E02F2CB4EA358FBA45374E9A7614" xlink:to="loc_us-gaap_InvestmentPolicyTextBlock_F13EB86AD125EA952D5845374E9B5FF2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_CE2450482B8D14D994E145374E9B86B7" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_AA58E02F2CB4EA358FBA45374E9A7614" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_CE2450482B8D14D994E145374E9B86B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_8B9985D9A4A271F0B9B545374E9B063D" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_AA58E02F2CB4EA358FBA45374E9A7614" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_8B9985D9A4A271F0B9B545374E9B063D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_10DC7BA107418D381ECA45374E9B33EF" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_AA58E02F2CB4EA358FBA45374E9A7614" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_10DC7BA107418D381ECA45374E9B33EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_37E533A688663B0CFBD245374E9B0081" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_AA58E02F2CB4EA358FBA45374E9A7614" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_37E533A688663B0CFBD245374E9B0081" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_3FBF68EF952D572BB5BA45374E9BEA5E" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_AA58E02F2CB4EA358FBA45374E9A7614" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_3FBF68EF952D572BB5BA45374E9BEA5E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_265940C8459102395B3B45374E9C2B77" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_AA58E02F2CB4EA358FBA45374E9A7614" xlink:to="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_265940C8459102395B3B45374E9C2B77" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="loc_us-gaap_DebtPolicyTextBlock_9766889637DB8B29D22245374E9C1A16" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_AA58E02F2CB4EA358FBA45374E9A7614" xlink:to="loc_us-gaap_DebtPolicyTextBlock_9766889637DB8B29D22245374E9C1A16" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_AFBF295429AC230D6E4045374E9CDB4E" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_AA58E02F2CB4EA358FBA45374E9A7614" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_AFBF295429AC230D6E4045374E9CDB4E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_5109EF9FC53F9D34960445374E9C8546" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_AA58E02F2CB4EA358FBA45374E9A7614" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_5109EF9FC53F9D34960445374E9C8546" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_315EABE5698C375772BB45374E9CD884" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_AA58E02F2CB4EA358FBA45374E9A7614" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_315EABE5698C375772BB45374E9CD884" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_2DBAC053A391595A6B7045374E9C966E" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_AA58E02F2CB4EA358FBA45374E9A7614" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_2DBAC053A391595A6B7045374E9C966E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_DF16E80D5833AD02933045374E9C0AD4" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_AA58E02F2CB4EA358FBA45374E9A7614" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_DF16E80D5833AD02933045374E9C0AD4" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_55CAC78ED6567AB83BDB45374E925587" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:label="loc_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_5AE8E20E006D26F843F845374E923B30" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_55CAC78ED6567AB83BDB45374E925587" xlink:to="loc_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_5AE8E20E006D26F843F845374E923B30" xlink:type="arc" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6801265728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholder's Equity - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 21, 2017</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Nov. 21, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares, issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,425,230<span></span>
</td>
<td class="nump">27,425,230<span></span>
</td>
<td class="nump">27,274,991<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares, outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,425,230<span></span>
</td>
<td class="nump">27,425,230<span></span>
</td>
<td class="nump">27,274,991<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Maximum number of shares authorized under the plan (in shares)</a></td>
<td class="nump">4,361,291<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Annual increase percentage of maximum shares outstanding (equal to)</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_CommonStockAdditionalCapitalSharesReservedforFutureIssuance', window );">Additional capital shares reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,091,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Capital shares reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">971,684<span></span>
</td>
<td class="nump">971,684<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Contractual term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_AllocatedShareBasedCompensationExpenseCapitalized', window );">Capitalized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30<span></span>
</td>
<td class="nump">$ 76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_AllocatedShareBasedCompensationExpenseCapitalized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Allocated Share-Based Compensation Expense Capitalized</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_AllocatedShareBasedCompensationExpenseCapitalized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_CommonStockAdditionalCapitalSharesReservedforFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Additional Capital Shares Reserved for Future Issuance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_CommonStockAdditionalCapitalSharesReservedforFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6658248224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Summary of Significant Accounting Policies</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">There have been no material changes in the Company&#8217;s significant accounting policies during the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">nine months ended September 30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> as compared with those disclosed in the Annual Report other than the adoption of the new lease and revenue recognition accounting standards described below. </font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The preparation of financial statements in conformity with GAAP requires management to make estimates, judgments, and assumptions that affect the amounts reported in the financial statements and disclosures made in the accompanying notes. Actual results could materially differ from those estimates, judgments, and assumptions. Management considers many factors in selecting appropriate financial accounting policies and controls and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes, and management must select an amount that falls within that range of reasonable estimates.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On an ongoing basis, the Company evaluates the most significant estimates, including those related to net revenues, allowance for doubtful accounts, fair value measurements, goodwill and long-lived asset valuations and impairment assessments, inventory valuations, income tax valuations and stock-based compensation expense, among others. Although the Company bases estimates on historical experience, knowledge of current events and actions it may undertake in the future, and on various other assumptions that are believed to be reasonable, this process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Risk and Uncertainties</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In 2013, Evolus and Daewoong Pharmaceuticals Co., Ltd. (&#8220;Daewoong&#8221;) entered into an agreement (the &#8220;Daewoong Agreement&#8221;), pursuant to which, the Company has an exclusive distribution license to Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> from Daewoong for aesthetic indications in the United States, European Union, Canada, Australia, Russia, Commonwealth of Independent States, and South Africa, as well as co-exclusive distribution rights with Daewoong in Japan. Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> is manufactured by Daewoong in a facility in South Korea. The Company also has the option to negotiate first with Daewoong to secure a distribution license for any product that Daewoong directly or indirectly develops or commercializes that is classified as an injectable botulinum toxin (other than Jeuveau&#174;) in a territory covered by the Daewoong Agreement. The Company relies on Daewoong, its exclusive and sole supplier, to manufacture Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. Any termination or loss of significant rights, including exclusivity, under the Daewoong Agreement would materially and adversely affect the Company&#8217;s commercialization of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. The Daewoong Agreement, and Daewoong&#8217;s rights relating to Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, are subject to litigation. See </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Note 8</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Commitments and Contingencies</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> for additional information regarding such litigation.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company commercially launched Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> in the United States in May 2019 and, as such, has a limited history of sales. Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> also requires regulatory approval from certain regulatory authorities prior to commercial sales in the related jurisdictions. If any previously granted approval is retracted or the Company is denied approval or approval is delayed by any other regulators, it may have a material adverse impact on the Company&#8217;s business and its financial statements.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company is subject to risks common to early stage companies in the pharmaceutical industry including, but not limited to, dependency on the clinical and commercial success of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and any future product candidates, ability to obtain and maintain regulatory approval of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and any future product candidates in the jurisdictions where approval is sought, the need for additional financing to achieve its goals, uncertainty of broad adoption of its approved products, if any, by physicians and patients, significant competition and untested manufacturing capabilities.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Segment Reporting</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company has determined that it operates in a single </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">operating and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">reportable segment. The Company&#8217;s chief operating decision maker is its Chief Executive Officer who manages operations and reviews the financial information as a single operating segment for purposes of allocating resources and evaluating its financial performance.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Cash and Cash Equivalents</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Cash and cash equivalents consist of cash and highly liquid investments with remaining maturities at purchase of three months or less that can be liquidated without prior notice or penalty. Cash and cash equivalents may include deposits, money market funds and debt securities. &#160;Amounts receivable from credit card issuers are typically converted to cash within two to four days of the original sales transaction and are considered to be cash equivalents. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company places its cash and cash equivalents with high credit quality financial institutions.&#160;At times, such investments may be in excess of the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;) limit. Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash deposits.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Short-Term Investments</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Short-term investments as of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">September&#160;30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> consisted of available-for-sale U.S. Treasury securities with original maturities greater than three months and remaining maturities of less than twelve months. These investments are recorded at fair value based on quoted prices in active markets, with unrealized gains and losses reported in other comprehensive (loss) gain in the Company&#8217;s condensed statements of operations and comprehensive loss. Purchase premiums and discounts are recognized in interest expense using the effective interest method over the terms of the securities. Realized gains and losses and declines in fair value that are deemed to be other than temporary are reflected in the condensed statements of operations and comprehensive loss using the specific-identification method. The Company periodically reviews all available-for-sale securities for other than temporary declines in fair value below the cost basis whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company also evaluates whether it has plans or is required to sell short-term investments before recovery of their amortized cost bases. To date, the Company has not identified any other than temporary declines in fair value of its short-term investments. </font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Inventories</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Inventories consist of finished goods held for sale and distribution. Cost is determined using the first&#8209;in, first&#8209;out method. However, the Company ships products with the earliest expiration dates.&#160;Inventory valuation reserves are established based on a number of factors including, but not limited to, finished goods not meeting product specifications, product excess and obsolescence, or application of the lower of cost or net realizable value concepts. The determination of events requiring the establishment of inventory valuation reserves, together with the calculation of the amount of such reserves may require judgment. No material inventory valuation reserves have been recorded for the periods presented. Adverse changes in assumptions utilized in the Company&#8217;s inventory reserve calculations could result in an increase to its inventory valuation reserves.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Fair Value of Financial Instruments</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Fair value is defined as the exchange price that would be received for an asset or an exit price paid to transfer a liability in an orderly transaction between market participants in a principal market on the measurement date.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The fair value hierarchy defines a three-tiered valuation hierarchy for disclosure of fair value measurement is classified and disclosed by the Company in one of the three categories as follows:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Level 1&#8212;Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Level 2&#8212;Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities in active markets; quoted prices in markets that are not active; or other inputs that are observable, either directly or indirectly, or can be corroborated by observable market data for substantially the full term of the asset or liability; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Level 3&#8212;Prices or valuation techniques that require inputs that are unobservable that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Goodwill</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Goodwill represents the excess of the purchase price over the fair value of the net tangible and intangible assets acquired in a business combination. The Company reviews goodwill for impairment annually and whenever events or changes in circumstances indicate the carrying amount of goodwill may not be recoverable. The Company performs an annual qualitative assessment of its goodwill in the fourth quarter of each calendar year to determine if any events or circumstances exist, such as an adverse change in business climate or a decline in the overall industry demand, that would indicate that it would more likely than not reduce the fair value of a reporting unit below its carrying amount, including goodwill. If events or circumstances do not indicate that the fair value of a reporting unit is below its carrying amount, then goodwill is not considered to be impaired and no further testing is required. If further testing is required, the Company performs a two-step process. The first step involves comparing the fair value of the Company&#8217;s reporting unit to its carrying value, including goodwill. If the carrying value of the reporting unit exceeds its fair value, the second step of the test is performed by comparing the carrying value of the goodwill in the reporting unit to its implied fair value. An impairment charge is recognized for the excess of the carrying value of goodwill over its implied fair value. For the purpose of impairment testing, the Company has determined that it has </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">one</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> reporting unit. There was </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">no</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> impairment of goodwill for any of the periods presented.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Intangible Assets</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Upon FDA approval of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> in February 2019, in process research and development (&#8220;IPR&amp;D&#8221;) related to Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> was evaluated as completed and reclassified to a definite-lived distribution right intangible asset, which is amortized over the period the asset is expected to contribute to the future cash flows of the Company. The Company determined the pattern of this intangible asset&#8217;s future cash flows could not be readily determined with a high level of precision. As a result, the distribution right intangible asset is being amortized on a straight-line basis over the estimated useful life of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">20</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> years.  </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company capitalizes certain internal-use software costs associated with the development of its mobile and web-based customer platforms. These costs include personnel expenses and external costs that are directly associated with the software projects. These costs are included as intangible assets in the accompanying condensed balance sheets. The capitalized internal-use software costs are amortized on a straight-line basis over the estimated useful life of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">two years</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> upon being placed in service. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company reviews long-term and identifiable definite-lived intangible assets or asset groups for impairment when events or changes in circumstances indicate that the carrying amount of an asset or asset group may not be recoverable. If the sum of the expected future undiscounted cash flows is less than the carrying amount of the asset or an asset group, further impairment analysis is performed. An impairment loss is measured as the amount by which the carrying amount of the asset or asset groups exceeds the fair value for assets to be held and used or fair value less cost to sell for assets to be disposed of. The Company also reviews the useful lives of its assets periodically to determine whether events and circumstances warrant a revision to the remaining useful life. Changes in the useful life are adjusted prospectively by revising the remaining period over which the asset is amortized. There was </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">no</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> material impairment of long-lived assets for any periods presented.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Leases</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In accordance with Accounting Standards Update (&#8220;ASU&#8221;) No. 2016-02 as adopted on January 1, 2019, at the inception of a contractual arrangement, the Company determines whether the contract contains a lease by assessing whether there is an identified asset and whether the contract conveys the right to control the use of the identified asset in exchange for consideration over a period of time. If both criteria are met, upon lease commencement, the Company records a lease liability which represents the Company&#8217;s obligation to make lease payments arising from the lease, and a corresponding right-of-use (&#8220;ROU&#8221;) asset which represents the Company&#8217;s right to use an underlying asset during the lease term. Operating lease assets and liabilities are included in ROU assets, current portion of operating lease liabilities and noncurrent operating lease liabilities in the accompanying condensed balance sheets. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Operating lease ROU assets and lease liabilities are initially recognized based on the present value of the future minimum lease payments over the lease term at commencement date calculated using the Company&#8217;s incremental borrowing rate applicable to the underlying asset unless the implicit rate is readily determinable. Operating lease ROU assets also include any lease payments made at or before lease commencement and exclude any lease incentives received, if any. The Company determines the lease term as the noncancellable period of the lease and may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise such options. The Company&#8217;s leases do not contain any residual value guarantees. Leases with a term of 12 months or less are not recognized on the condensed balance sheets. For operating leases, the Company recognized rent expense on a straight-line basis over the lease term. There were no significant finance leases as of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">September&#160;30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Contingent Royalty Obligation Payable to the Evolus Founders</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company determines the fair value of the contingent royalty obligation payable at each reporting period end based on Level 3 inputs using a discounted cash flows method. Changes in the fair value of the contingent royalty obligation payable are determined at each reporting period end and recorded in operating expenses in the accompanying statements of operations and comprehensive loss and as a liability in the condensed balance sheets.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Contingent Promissory Note Payable to Evolus Founders</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On February 12, 2018, the Company recognized a contingent promissory note payable at present value using a discount rate for similar rated debt securities based on an estimated date that the Company believed the contingent promissory note will mature. Discount amortization related to the contingent promissory note is recorded in interest expense in the condensed statements of operations and comprehensive loss with a corresponding increase to the non-current liabilities in the condensed balance sheets. </font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Long-Term Debt</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company recorded borrowings classified as long-term debt in the accompanying condensed balance sheets. Debt issuance costs represent legal, lender and consulting costs or fees associated with debt financing. Debt&#160;discounts and issuance costs are allocated pro rata between the funded and unfunded portions of the debt and are amortized into interest expense over the term of the debt.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Revenue Recognition</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company applies Accounting Standards Codification 606, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Revenue from Contracts with Customers</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> (&#8220;ASC 606&#8221;), to account for revenue generated since the commercial launch of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> in May 2019. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">General</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company currently generates all of its revenue from the sale of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> in the United States.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company recognizes revenue when control of the promised goods under a contract is transferred to a customer, in an amount that reflects the consideration the Company expects to receive in exchange for those goods as specified in the customer contract. The transfer of control occurs upon receipt of the goods by the customer since that is when the customer has obtained control of the goods&#8217; economic benefits. The Company does not provide any service-type warranties and does not accept product returns except under limited circumstances such as damages in transit or ineffective product. The Company also excludes any amounts related to taxes assessed by governmental authorities from revenue measurement. Shipping and handling costs associated with outbound product freight are accounted for as fulfillment costs and are included in selling, general and marketing expenses in the accompanying condensed statements of operations and comprehensive loss.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Disaggregation of Revenue</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company&#8217;s disaggregation of revenue is consistent with its operating segment as disclosed above, and all of the Company&#8217;s net sales are considered revenue from contracts with customers.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Gross-to-Net Revenue Adjustments</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company provides customers with trade and volume discounts and prompt pay discounts that are directly reflected in the invoice price. Revenues are recorded net of sales-related adjustments, wherever applicable, for rebates and coupon programs. Accrued rebate and coupon balances are recorded in accrued expenses on the accompanying condensed balance sheets.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Volume-based Rebates - </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Volume-based rebates are contractually offered to certain customers. The rebates payable to each customer are determined based on the contract and quarterly purchase volumes. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Coupons - </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company implemented a program by which customers receive coupons redeemable into gift cards funded by the Company for the benefit of patients. The coupons are accounted for as variable consideration. The Company estimates the coupon redemption rates based on historical data. The coupons are accrued based on estimated redemption rates and the volume of products purchased and are recorded as a reduction to revenues on product delivery. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">September&#160;30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, accrued volume-based rebate and coupon liability was </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$3,932</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.  During the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">three and nine months ended September 30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, provisions for accrued volume-based rebate and coupon liability were </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$5,740</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$6,671</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, respectively, which were offset by related payments of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$2,739</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> in the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">three and nine months ended September 30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> .</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Contract balances</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">A contract with a customer states the terms of the sale, including the description, quantity and price of each product purchased. Amounts are recorded as accounts receivable when the Company&#8217;s right to consideration becomes unconditional. As payment terms are short-term, the Company does not have any significant financing components in customer contracts given the expected time between transfer of the promised products and the payment of the associated consideration is less than one year. As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">September&#160;30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, all amounts included in accounts receivable, net on the accompanying condensed balance sheets are related to contracts with customers.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company did not have any contract assets nor unbilled receivables as of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">September&#160;30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. Sales commissions are included in selling, general and administrative expenses when incurred.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Contract liabilities reflect estimated amounts that the Company is obligated to pay to customers or patients under the rebate and coupon programs. The Company&#8217;s contract liabilities are included in accounts payable and accrued expenses in the condensed balance sheets.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">During the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">three and nine months ended September 30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the Company did not recognize any revenue related to changes in transaction prices regarding its contracts with customers and did not recognize any material changes in revenue related to amounts included in contract liabilities at the beginning of the period.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Collectability</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Accounts receivable are recorded at the invoiced amount and do not bear interest. At the time of contract inception or new customer account set-up, the Company performs a collectability assessment of the customer&#8217;s creditworthiness. The Company assesses the probability that the Company will collect the entitled consideration in exchange for the goods sold, by considering the customer&#8217;s ability and intention to pay when consideration is due. On a recurring basis, the Company estimates the amount of receivables considered uncollectable to reflect an allowance for doubtful accounts.&#160;There was no significant provision for allowance or write-off of doubtful accounts during the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">nine months ended September 30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Practical Expedients</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company expenses sales commissions when incurred as the amortization period is one year or less. These costs are recorded within selling, general and administrative expenses in the accompanying condensed statements of operations and comprehensive loss. The Company does not adjust the amount of promised consideration for the effects of the time value of money for contracts in which the anticipated period between when the Company transfers the goods or services to the customer and when the customer pays within one year.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Stock-Based Compensation</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company recognizes stock-based compensation expense for employees, consultants and members of the Board of Directors based on the fair value at the date of grant. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company uses the Black-Scholes option pricing model to value stock option grants. The Black-Scholes option pricing model requires the input of subjective assumptions, including the expected volatility of the Company&#8217;s common stock, expected risk-free interest rate and the option&#8217;s expected life. The fair value of the Company&#8217;s restricted stock units (&#8220;RSUs&#8221;) is based on the fair value on the grant date of the Company&#8217;s common stock. The Company also evaluates the impact of modifications made to the original terms of equity awards when they occur.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The fair value of equity awards that are expected to vest is amortized on a straight-line basis over the requisite service period. Stock-based compensation expense is recognized net of actual forfeitures when they occur, as an increase to additional paid-in capital in the condensed balance sheets and in the selling, general and administrative or research and development expenses in the condensed statements of operations and comprehensive loss. </font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Income Taxes</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company applies an estimated annual effective tax rate (&#8220;ETR&#8221;) approach for calculating a tax provision or benefit for interim periods, as required under GAAP.&#160; The Company recorded a benefit for income taxes of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$149</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$14,899</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">three and nine months ended September 30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, respectively, and did not record a significant tax provision or benefit for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">three and nine months ended September 30, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.&#160;The Company&#8217;s ETR differs from the U.S. federal statutory tax rate of 21% primarily as a result of the impact of a valuation allowance on its deferred tax assets.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company accounts for income taxes using the asset and liability method. Under this method, deferred tax assets and liabilities are determined on the basis of differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">A valuation allowance is recorded against deferred tax assets to reduce the net carrying value when it is more likely than not that some portion or all of a deferred tax asset will not be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, and ongoing prudent and feasible tax planning strategies in assessing the amount of the valuation allowance. When the Company establishes or reduces the valuation allowance against its deferred tax assets, its provision for income taxes will increase or decrease, respectively, in the period such determination is made.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As of each reporting date, the Company considers evidence, both positive and negative, that could affect its view of the future realization of deferred tax assets.&#160;As of December 31, 2018, the deferred tax assets were primarily the result of U.S. net operating loss and tax credit carryforwards, and a valuation allowance of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$34,500</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> was recorded against the gross deferred tax asset balance.&#160;Upon FDA approval of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> in February 2019, the Company&#8217;s IPR&amp;D intangible asset was reclassified to a definite-lived distribution right intangible asset. As a result, management determined that it was more likely than not that certain deferred tax assets became realizable due to the future reversals of the deferred tax liability associated with such intangible asset.&#160;Accordingly, the Company released </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$14,402</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> of its valuation allowance as a discrete item upon FDA approval in February 2019. For the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">three and nine months ended September 30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the Company released an additional </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$149</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$497</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, respectively, from its valuation allowance.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Additionally, the Company recognizes the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities based on the technical merits of the position. The tax benefit recognized in the financial statements for a particular tax position is based on the largest benefit that is more likely than not to be realized upon settlement. Accordingly, the Company establishes reserves for uncertain tax positions. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In accordance with SEC Staff Accounting Bulletin No. 118, the Company&#8217;s accounting for the elements of the Tax Cuts and Jobs Act was complete as of December 31, 2018 and no adjustments were made to the original provisional estimate recorded in 2017.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Net Loss Per Share</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Basic net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock outstanding during the period including contingently issuable shares. Diluted earnings per share is based on the treasury stock method and includes the effect from potential issuance of ordinary shares, such as shares issuable pursuant to the exercise of stock options and the vesting of restricted stock units. Because the impact of the options and non-vested RSUs are anti-dilutive during periods of net loss, there was no difference between the weighted-average number of shares used to calculate basic and diluted net loss per common share for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">three and nine months ended September 30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. Excluded from the dilutive net loss per share computation were </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">4,052,161</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> stock options and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">182,758</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> non-vested RSUs for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">three and nine months ended September 30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> because their inclusion would have been anti-dilutive. Although these securities were anti-dilutive for these periods, they could be dilutive in future periods.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Recently Adopted Accounting Pronouncements</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In August 2018, the SEC adopted the final rule under SEC Release No. 33-10532,&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Disclosure Update and Simplification</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, amending certain disclosure requirements that were redundant, duplicative, overlapping, outdated or superseded. In addition, the amendments expanded the disclosure requirements on the analysis of stockholders&#8217; equity for interim financial statements. Under the amendments, an analysis of changes in each caption of stockholders&#8217; equity presented in the balance sheet must be provided in a note or separate statement. The analysis should present a reconciliation of the beginning balance to the ending balance of each period for which a statement of comprehensive income is required to be filed. This final rule was effective on November 5, 2018 and it did not have a material impact on the Company&#8217;s financial statements upon adoption on January 1, 2019.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In July 2018, the Financial Accounting Standards Board (the &#8220;FASB&#8221;) issued&#160;ASU No. 2018-09,&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Codification Improvements</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, which clarifies certain amendments to guidance that may have been incorrectly or inconsistently applied by certain entities and includes Amendments to Subtopic 718-740, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Compensation - Stock Compensation - Income Taxes</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. The guidance in paragraph 718-740-35-2, as amended by the amendments in&#160;ASU 2016-09, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, is unclear on whether an entity should recognize excess tax benefits (or tax deficiencies) for compensation expense that is taken on the entity&#8217;s tax return. The amendment to paragraph 718-740-35-2 in this update clarifies that an entity should recognize excess tax benefits in the period in which the amount of deduction is determined. The Company adopted the guidance on January 1, 2019, and such adoption did not have a material impact on its financial statements.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In June 2018, the FASB issued ASU No. 2018-07,&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Compensation&#8212;Stock Compensation (Topic 718): Improvements to Nonemployee Share-based Payment Accounting,</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> which amends the financial reporting for stock-based payments issued to nonemployees and also expands the scope of ASC 718,&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Compensation - Stock Compensation</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">,&#160;to also include stock-based payments issued to nonemployees for goods and services. The amendment substantially aligns accounting for stock-based payments to employees and nonemployees. The Company early adopted the guidance in the quarter ended December 31, 2018. The adoption did not have a material impact on the Company&#8217;s financial statements.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In February 2016, the FASB issued ASU No. 2016-02 and its related amendments which introduced </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Leases (Topic 842, or </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8220;ASC 842&#8221;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">)</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, a new comprehensive lease accounting model that supersedes the current lease guidance under&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Leases (Topic 840)</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. The new accounting standard requires lessees to recognize ROU assets and corresponding lease liabilities for all leases with lease terms of greater than 12 months. It also changes the definition of a lease and expands the disclosure requirements of lease arrangements. In July 2018, the FASB added a transition option for implementation that allows companies to continue to use the legacy guidance in ASC 840, Leases, including its disclosure requirements, in the comparative periods presented in the year of adoption. The Company adopted the guidance effective January 1, 2019. The Company elected the transition package of three practical expedients and elected the optional transition method that allows for a cumulative-effect adjustment in the period of adoption without a restatement of prior periods. Further, the Company elected a short-term lease exception policy, permitting the Company to not apply the recognition requirements of this standard to short-term leases (i.e. leases with terms of 12 months or less) and an accounting policy to account for lease and non-lease components as a single component for certain classes of assets. As a result of the adoption, the Company adjusted its beginning balance of 2019 by recording operating lease ROU assets and liabilities through a cumulative-effect adjustment. The adoption impacted the accompanying condensed balance sheet, but did not have an impact on the condensed statements of operations and comprehensive loss. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The impact of the adoption of ASC 842 on the accompanying condensed balance sheet as of January 1, 2019 was as follows:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.8015873015873%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:44%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">December 31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Adjustments Due to the Adoption of ASC 842</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">January 1, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Operating lease right-of-use assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,029</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,029</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Current portion of operating lease liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">916</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">916</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Operating lease liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">138</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">138</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Deferred rent</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">25</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(25</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Times New Roman;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Recent Accounting Pronouncements</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In November 2018, the FASB issued ASU No. 2018-18,&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Clarifying the Interaction between Topic 808 and Topic 606</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, which requires transactions in collaborative arrangements to be accounted for under ASC 606,&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Revenue from Contracts with Customers</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">,&#160;if the counter-party is a customer for a good or service that is a distinct unit of account. The amendments also preclude entities from presenting consideration from transactions with a collaborator that is not a customer together with revenue recognized from contracts with customers. The guidance is effective for interim and annual reporting periods during the year ending December 31, 2020. Early adoption is permitted, including in any interim period.&#160;The Company is currently evaluating the impact that the adoption of this guidance will have on its financial statements and related disclosures.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In August 2018, the FASB issued&#160;ASU No. 2018-15,&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Intangibles-Goodwill and Other-Internal-Use Software: Customer&#8217;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement that is a Service Contract</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.&#160;ASU 2018-15&#160;requires implementation costs incurred by customers in cloud computing arrangements (i.e., hosting arrangements) to be capitalized under the same premises of authoritative guidance for internal-use software, and deferred over the noncancellable term of the cloud computing arrangements plus any option renewal periods that are reasonably certain to be exercised by the customer or for which the exercise is controlled by the service provider. The guidance is effective for interim and annual reporting periods during the year ending December 31, 2020. Early adoption is permitted. The Company is in the process of determining the effects the adoption will have on its financial statements as well as whether to early adopt the new guidance.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In August 2018, the FASB issued&#160;ASU No. 2018-13,&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Fair Value Measurement (Topic 820): Disclosure Framework &#8212; Changes to the Disclosure Requirements for Fair Value Measurement</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.&#160;The update&#160;is part of the disclosure framework project and eliminates certain disclosure requirements for fair value measurements, requires entities to disclose new information, and modifies existing disclosure requirements. Under the new guidance,&#160;entities will no longer be required to disclose the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy, or valuation processes for Level 3 fair value measurements. However, public companies will be required to disclose the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and related changes in unrealized gains and losses included in other comprehensive income. The guidance is effective for interim and annual reporting periods during the year ending December 31, 2020. Early adoption is permitted. The Company is currently evaluating the impact this change will have on its financial statements as well as whether to early adopt the new guidance.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In January 2017, the FASB issued ASU No. 2017-04,&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Intangibles&#8212;Goodwill and Other (Topic 350):&#160;Simplifying the Test for Goodwill Impairment</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. The update simplifies the accounting for goodwill impairment by removing step two of the goodwill impairment test, which requires a hypothetical purchase price allocation. A goodwill impairment will be the amount by which a reporting unit&#8217;s carrying amount, including goodwill, exceeds its fair value. The impairment charge will be limited to the amount of goodwill allocated to that reporting unit. The update is effective for the Company beginning January&#160;1, 2020. The standard requires prospective application. Early adoption is permitted. The Company is evaluating the effect of this standard on its financial statements and related disclosures as well as whether to early adopt the new guidance.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In June 2016, the FASB issued ASU No. 2016-13,&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, which modifies the measurement and recognition of credit losses for most financial assets and certain other instruments. The new standard requires the use of forward-looking expected credit loss models based on historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount, which may result in earlier recognition of credit losses under the new standard. The new guidance also modifies the impairment models for available-for-sale debt securities and for purchased financial assets with credit deterioration since their origination. Subsequent to the issuance of ASU 2016-13, the FASB issued ASU 2018-19,&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Codification Improvements to Topic 326, Financial Instruments - Credit Losses</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. This ASU does not change the core principle of the guidance in ASU 2016-13, instead these amendments are intended to clarify and improve operability of certain topics included within the credit losses standard.&#160;The FASB also subsequently issued ASU 2019-04 which did not change the core principle of the guidance in ASU 2016-13 but clarified that expected recoveries of amounts previously written off and expected to be written off should be included in the valuation account and should not exceed amounts previously written off and expected to be written off. The guidance is effective for interim and annual reporting periods beginning after December 15, 2019 and interim periods within those periods, and early adoption is permitted. The guidance will be effective for the Company during the first quarter of 2020. The Company is in the process of determining the effects the adoption will have on its financial statements and reviewing credit loss models to assess the impact of the adoption of the standard on the financial statements. Based on initial assessments, the Company believes that while adoption will modify the way it analyzes financial instruments, it does not expect adoption of this guidance will have a material impact to its financial statements.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Other recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the American Institute of Certified Public Accountants, and the SEC did not, or are not believed by management to, have a material impact on the Company&#8217;s present or future financial position, results of operations or cash flows.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6775619744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholder's Equity - Stock-based Compensation Expense Allocation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated stock-based compensation expense</a></td>
<td class="nump">$ 2,526<span></span>
</td>
<td class="nump">$ 1,482<span></span>
</td>
<td class="nump">$ 6,981<span></span>
</td>
<td class="nump">$ 5,111<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated stock-based compensation expense</a></td>
<td class="nump">2,417<span></span>
</td>
<td class="nump">1,160<span></span>
</td>
<td class="nump">6,443<span></span>
</td>
<td class="nump">4,083<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated stock-based compensation expense</a></td>
<td class="nump">$ 109<span></span>
</td>
<td class="nump">$ 322<span></span>
</td>
<td class="nump">$ 538<span></span>
</td>
<td class="nump">$ 1,028<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6801775344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenues</a></td>
<td class="nump">$ 13,167<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 15,478<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales (excludes amortization of intangible assets)</a></td>
<td class="nump">3,718<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,378<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">9,449<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">11,100<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">30,897<span></span>
</td>
<td class="nump">7,209<span></span>
</td>
<td class="nump">83,308<span></span>
</td>
<td class="nump">16,924<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">693<span></span>
</td>
<td class="nump">1,977<span></span>
</td>
<td class="nump">3,555<span></span>
</td>
<td class="nump">5,303<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_RevaluationofContingentRoyaltyObligationPayable', window );">Revaluation of contingent royalty obligation payable to Evolus Founders</a></td>
<td class="nump">1,795<span></span>
</td>
<td class="nump">2,300<span></span>
</td>
<td class="nump">7,977<span></span>
</td>
<td class="nump">11,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">1,202<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">2,664<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">34,587<span></span>
</td>
<td class="nump">11,489<span></span>
</td>
<td class="nump">97,504<span></span>
</td>
<td class="nump">33,634<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(25,138)<span></span>
</td>
<td class="num">(11,489)<span></span>
</td>
<td class="num">(86,404)<span></span>
</td>
<td class="num">(33,634)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNet', window );">Interest income</a></td>
<td class="nump">460<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,464<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Interest expense</a></td>
<td class="num">(2,455)<span></span>
</td>
<td class="num">(322)<span></span>
</td>
<td class="num">(5,485)<span></span>
</td>
<td class="num">(750)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes:</a></td>
<td class="num">(27,133)<span></span>
</td>
<td class="num">(11,811)<span></span>
</td>
<td class="num">(90,425)<span></span>
</td>
<td class="num">(34,384)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax (benefit) expense</a></td>
<td class="num">(149)<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="num">(14,899)<span></span>
</td>
<td class="nump">41<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(26,984)<span></span>
</td>
<td class="num">(11,830)<span></span>
</td>
<td class="num">(75,526)<span></span>
</td>
<td class="num">(34,425)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive (loss) gain:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized (loss) gain on available-for-sale securities, net of tax</a></td>
<td class="num">(24)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (27,008)<span></span>
</td>
<td class="num">$ (11,830)<span></span>
</td>
<td class="num">$ (75,507)<span></span>
</td>
<td class="num">$ (34,425)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share, basic and diluted (in dollars per share)</a></td>
<td class="num">$ (0.98)<span></span>
</td>
<td class="num">$ (0.48)<span></span>
</td>
<td class="num">$ (2.76)<span></span>
</td>
<td class="num">$ (1.47)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average shares outstanding used to compute basic and diluted net loss per share (in shares)</a></td>
<td class="nump">27,470,558<span></span>
</td>
<td class="nump">24,768,581<span></span>
</td>
<td class="nump">27,403,683<span></span>
</td>
<td class="nump">23,417,417<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_RevaluationofContingentRoyaltyObligationPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revaluation of Contingent Royalty Obligation Payable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_RevaluationofContingentRoyaltyObligationPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e557-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(a),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=68048583&amp;loc=d3e3636-108311<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6804805840">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional services</a></td>
<td class="nump">$ 4,488<span></span>
</td>
<td class="nump">$ 931<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_AccruedCouponAndRebateLiabilityCurrent', window );">Accrued volume-based rebate and coupon liability</a></td>
<td class="nump">3,932<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued payroll and related benefits</a></td>
<td class="nump">3,453<span></span>
</td>
<td class="nump">2,577<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_MilestonePaymentCurrent', window );">EU milestone payment to Daewoong</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued expenses</a></td>
<td class="nump">1,505<span></span>
</td>
<td class="nump">210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued liabilities, current</a></td>
<td class="nump">$ 14,378<span></span>
</td>
<td class="nump">$ 3,718<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_AccruedCouponAndRebateLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Coupon And Rebate Liability, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_AccruedCouponAndRebateLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_MilestonePaymentCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone Payment, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_MilestonePaymentCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6789084192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business and Basis of Presentation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="6">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">$ (26,984)<span></span>
</td>
<td class="num">$ (37,567)<span></span>
</td>
<td class="num">$ (10,975)<span></span>
</td>
<td class="num">$ (11,830)<span></span>
</td>
<td class="num">$ (16,433)<span></span>
</td>
<td class="num">$ (6,162)<span></span>
</td>
<td class="num">$ (75,526)<span></span>
</td>
<td class="num">$ (34,425)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Cash used in operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(77,461)<span></span>
</td>
<td class="num">$ (13,661)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents, and short-term investments</a></td>
<td class="nump">74,029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74,029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">$ 198,551<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 198,551<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 123,025<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6591712928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Oxford Term Loans (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of Maturities of Long-term Debt</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">September&#160;30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the principal amounts of long-term debt maturities during each of the next five fiscal years, and the Final Payment in 2024 which is amortized into interest expense over the life of the Term Loans are as follows:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:88.4920634920635%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:56%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Fiscal year</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Principal</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Final Payment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2022</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">26,087</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">26,087</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2023</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">39,130</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">39,130</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">2024</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">9,783</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">4,125</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">13,908</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">75,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">4,125</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">79,125</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the combined aggregate amount of maturities and sinking fund requirements for all long-term borrowings for each of the five years following the date of the latest balance sheet date presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6800876560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Basis of Presentation</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">T</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">he accompanying unaudited condensed financial statements have been prepared </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">on a consistent basis with the annual financial statements and</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) and the requirements of the Securities and Exchange Commission (&#8220;SEC&#8221;) for interim reporting</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. Pursuant to these SEC rules and regulations, the Company has condensed or omitted certain financial information and disclosures normally included in annual financial statements prepared in accordance with GAAP. In the opinion of management, the interim financial statements reflect all adjustments, which include normal recurring adjustments, considered necessary for a fair statement of the interim periods. The interim results presented herein are not necessarily indicative of the results of operations to be expected for the full year ending </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> or for any other interim period.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The accompanying unaudited condensed financial statements and related disclosures should be read in conjunction with the financial statements and notes included in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2018, as filed with the SEC on March 20, 2019.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The preparation of financial statements in conformity with GAAP requires management to make estimates, judgments, and assumptions that affect the amounts reported in the financial statements and disclosures made in the accompanying notes. Actual results could materially differ from those estimates, judgments, and assumptions. Management considers many factors in selecting appropriate financial accounting policies and controls and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes, and management must select an amount that falls within that range of reasonable estimates.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On an ongoing basis, the Company evaluates the most significant estimates, including those related to net revenues, allowance for doubtful accounts, fair value measurements, goodwill and long-lived asset valuations and impairment assessments, inventory valuations, income tax valuations and stock-based compensation expense, among others. Although the Company bases estimates on historical experience, knowledge of current events and actions it may undertake in the future, and on various other assumptions that are believed to be reasonable, this process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Risk and Uncertainties</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Risk and Uncertainties</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In 2013, Evolus and Daewoong Pharmaceuticals Co., Ltd. (&#8220;Daewoong&#8221;) entered into an agreement (the &#8220;Daewoong Agreement&#8221;), pursuant to which, the Company has an exclusive distribution license to Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> from Daewoong for aesthetic indications in the United States, European Union, Canada, Australia, Russia, Commonwealth of Independent States, and South Africa, as well as co-exclusive distribution rights with Daewoong in Japan. Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> is manufactured by Daewoong in a facility in South Korea. The Company also has the option to negotiate first with Daewoong to secure a distribution license for any product that Daewoong directly or indirectly develops or commercializes that is classified as an injectable botulinum toxin (other than Jeuveau&#174;) in a territory covered by the Daewoong Agreement. The Company relies on Daewoong, its exclusive and sole supplier, to manufacture Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. Any termination or loss of significant rights, including exclusivity, under the Daewoong Agreement would materially and adversely affect the Company&#8217;s commercialization of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. The Daewoong Agreement, and Daewoong&#8217;s rights relating to Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, are subject to litigation. See </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Note 8</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Commitments and Contingencies</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> for additional information regarding such litigation.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company commercially launched Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> in the United States in May 2019 and, as such, has a limited history of sales. Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> also requires regulatory approval from certain regulatory authorities prior to commercial sales in the related jurisdictions. If any previously granted approval is retracted or the Company is denied approval or approval is delayed by any other regulators, it may have a material adverse impact on the Company&#8217;s business and its financial statements.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company is subject to risks common to early stage companies in the pharmaceutical industry including, but not limited to, dependency on the clinical and commercial success of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and any future product candidates, ability to obtain and maintain regulatory approval of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and any future product candidates in the jurisdictions where approval is sought, the need for additional financing to achieve its goals, uncertainty of broad adoption of its approved products, if any, by physicians and patients, significant competition and untested manufacturing capabilities.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"></font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Segment Reporting</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company has determined that it operates in a single </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">operating and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">reportable segment. The Company&#8217;s chief operating decision maker is its Chief Executive Officer who manages operations and reviews the financial information as a single operating segment for purposes of allocating resources and evaluating its financial performance.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Cash and Cash Equivalents</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Cash and cash equivalents consist of cash and highly liquid investments with remaining maturities at purchase of three months or less that can be liquidated without prior notice or penalty. Cash and cash equivalents may include deposits, money market funds and debt securities. &#160;Amounts receivable from credit card issuers are typically converted to cash within two to four days of the original sales transaction and are considered to be cash equivalents. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company places its cash and cash equivalents with high credit quality financial institutions.&#160;At times, such investments may be in excess of the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;) limit. Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash deposits.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Short-Term Investments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Short-Term Investments</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Short-term investments as of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">September&#160;30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> consisted of available-for-sale U.S. Treasury securities with original maturities greater than three months and remaining maturities of less than twelve months. These investments are recorded at fair value based on quoted prices in active markets, with unrealized gains and losses reported in other comprehensive (loss) gain in the Company&#8217;s condensed statements of operations and comprehensive loss. Purchase premiums and discounts are recognized in interest expense using the effective interest method over the terms of the securities. Realized gains and losses and declines in fair value that are deemed to be other than temporary are reflected in the condensed statements of operations and comprehensive loss using the specific-identification method. The Company periodically reviews all available-for-sale securities for other than temporary declines in fair value below the cost basis whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company also evaluates whether it has plans or is required to sell short-term investments before recovery of their amortized cost bases. To date, the Company has not identified any other than temporary declines in fair value of its short-term investments. </font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Inventories</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Inventories consist of finished goods held for sale and distribution. Cost is determined using the first&#8209;in, first&#8209;out method. However, the Company ships products with the earliest expiration dates.&#160;Inventory valuation reserves are established based on a number of factors including, but not limited to, finished goods not meeting product specifications, product excess and obsolescence, or application of the lower of cost or net realizable value concepts. The determination of events requiring the establishment of inventory valuation reserves, together with the calculation of the amount of such reserves may require judgment. No material inventory valuation reserves have been recorded for the periods presented. Adverse changes in assumptions utilized in the Company&#8217;s inventory reserve calculations could result in an increase to its inventory valuation reserves.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Fair Value of Financial Instruments</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Fair value is defined as the exchange price that would be received for an asset or an exit price paid to transfer a liability in an orderly transaction between market participants in a principal market on the measurement date.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The fair value hierarchy defines a three-tiered valuation hierarchy for disclosure of fair value measurement is classified and disclosed by the Company in one of the three categories as follows:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Level 1&#8212;Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Level 2&#8212;Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities in active markets; quoted prices in markets that are not active; or other inputs that are observable, either directly or indirectly, or can be corroborated by observable market data for substantially the full term of the asset or liability; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Level 3&#8212;Prices or valuation techniques that require inputs that are unobservable that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Goodwill</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Goodwill represents the excess of the purchase price over the fair value of the net tangible and intangible assets acquired in a business combination. The Company reviews goodwill for impairment annually and whenever events or changes in circumstances indicate the carrying amount of goodwill may not be recoverable. The Company performs an annual qualitative assessment of its goodwill in the fourth quarter of each calendar year to determine if any events or circumstances exist, such as an adverse change in business climate or a decline in the overall industry demand, that would indicate that it would more likely than not reduce the fair value of a reporting unit below its carrying amount, including goodwill. If events or circumstances do not indicate that the fair value of a reporting unit is below its carrying amount, then goodwill is not considered to be impaired and no further testing is required. If further testing is required, the Company performs a two-step process. The first step involves comparing the fair value of the Company&#8217;s reporting unit to its carrying value, including goodwill. If the carrying value of the reporting unit exceeds its fair value, the second step of the test is performed by comparing the carrying value of the goodwill in the reporting unit to its implied fair value. An impairment charge is recognized for the excess of the carrying value of goodwill over its implied fair value. For the purpose of impairment testing, the Company has determined that it has </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">one</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> reporting unit.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy', window );">Intangible Assets</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Intangible Assets</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Upon FDA approval of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> in February 2019, in process research and development (&#8220;IPR&amp;D&#8221;) related to Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> was evaluated as completed and reclassified to a definite-lived distribution right intangible asset, which is amortized over the period the asset is expected to contribute to the future cash flows of the Company. The Company determined the pattern of this intangible asset&#8217;s future cash flows could not be readily determined with a high level of precision. As a result, the distribution right intangible asset is being amortized on a straight-line basis over the estimated useful life of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">20</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> years.  </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company capitalizes certain internal-use software costs associated with the development of its mobile and web-based customer platforms. These costs include personnel expenses and external costs that are directly associated with the software projects. These costs are included as intangible assets in the accompanying condensed balance sheets. The capitalized internal-use software costs are amortized on a straight-line basis over the estimated useful life of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">two years</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> upon being placed in service. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company reviews long-term and identifiable definite-lived intangible assets or asset groups for impairment when events or changes in circumstances indicate that the carrying amount of an asset or asset group may not be recoverable. If the sum of the expected future undiscounted cash flows is less than the carrying amount of the asset or an asset group, further impairment analysis is performed. An impairment loss is measured as the amount by which the carrying amount of the asset or asset groups exceeds the fair value for assets to be held and used or fair value less cost to sell for assets to be disposed of. The Company also reviews the useful lives of its assets periodically to determine whether events and circumstances warrant a revision to the remaining useful life. Changes in the useful life are adjusted prospectively by revising the remaining period over which the asset is amortized. There was </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">no</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> material impairment of long-lived assets for any periods presented.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Leases</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In accordance with Accounting Standards Update (&#8220;ASU&#8221;) No. 2016-02 as adopted on January 1, 2019, at the inception of a contractual arrangement, the Company determines whether the contract contains a lease by assessing whether there is an identified asset and whether the contract conveys the right to control the use of the identified asset in exchange for consideration over a period of time. If both criteria are met, upon lease commencement, the Company records a lease liability which represents the Company&#8217;s obligation to make lease payments arising from the lease, and a corresponding right-of-use (&#8220;ROU&#8221;) asset which represents the Company&#8217;s right to use an underlying asset during the lease term. Operating lease assets and liabilities are included in ROU assets, current portion of operating lease liabilities and noncurrent operating lease liabilities in the accompanying condensed balance sheets. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Operating lease ROU assets and lease liabilities are initially recognized based on the present value of the future minimum lease payments over the lease term at commencement date calculated using the Company&#8217;s incremental borrowing rate applicable to the underlying asset unless the implicit rate is readily determinable. Operating lease ROU assets also include any lease payments made at or before lease commencement and exclude any lease incentives received, if any. The Company determines the lease term as the noncancellable period of the lease and may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise such options. The Company&#8217;s leases do not contain any residual value guarantees. Leases with a term of 12 months or less are not recognized on the condensed balance sheets. For operating leases, the Company recognized rent expense on a straight-line basis over the lease term. There were no significant finance leases as of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">September&#160;30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock', window );">Contingent Royalty Obligation Payable to the Evolus Founders</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Contingent Royalty Obligation Payable to the Evolus Founders</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company determines the fair value of the contingent royalty obligation payable at each reporting period end based on Level 3 inputs using a discounted cash flows method. Changes in the fair value of the contingent royalty obligation payable are determined at each reporting period end and recorded in operating expenses in the accompanying statements of operations and comprehensive loss and as a liability in the condensed balance sheets.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Contingent Promissory Note Payable to Evolus Founders</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On February 12, 2018, the Company recognized a contingent promissory note payable at present value using a discount rate for similar rated debt securities based on an estimated date that the Company believed the contingent promissory note will mature. Discount amortization related to the contingent promissory note is recorded in interest expense in the condensed statements of operations and comprehensive loss with a corresponding increase to the non-current liabilities in the condensed balance sheets. </font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtPolicyTextBlock', window );">Long-Term Debt</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Long-Term Debt</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company recorded borrowings classified as long-term debt in the accompanying condensed balance sheets. Debt issuance costs represent legal, lender and consulting costs or fees associated with debt financing. Debt&#160;discounts and issuance costs are allocated pro rata between the funded and unfunded portions of the debt and are amortized into interest expense over the term of the debt.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Revenue Recognition</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company applies Accounting Standards Codification 606, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Revenue from Contracts with Customers</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> (&#8220;ASC 606&#8221;), to account for revenue generated since the commercial launch of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> in May 2019. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">General</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company currently generates all of its revenue from the sale of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> in the United States.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company recognizes revenue when control of the promised goods under a contract is transferred to a customer, in an amount that reflects the consideration the Company expects to receive in exchange for those goods as specified in the customer contract. The transfer of control occurs upon receipt of the goods by the customer since that is when the customer has obtained control of the goods&#8217; economic benefits. The Company does not provide any service-type warranties and does not accept product returns except under limited circumstances such as damages in transit or ineffective product. The Company also excludes any amounts related to taxes assessed by governmental authorities from revenue measurement. Shipping and handling costs associated with outbound product freight are accounted for as fulfillment costs and are included in selling, general and marketing expenses in the accompanying condensed statements of operations and comprehensive loss.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Disaggregation of Revenue</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company&#8217;s disaggregation of revenue is consistent with its operating segment as disclosed above, and all of the Company&#8217;s net sales are considered revenue from contracts with customers.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Gross-to-Net Revenue Adjustments</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company provides customers with trade and volume discounts and prompt pay discounts that are directly reflected in the invoice price. Revenues are recorded net of sales-related adjustments, wherever applicable, for rebates and coupon programs. Accrued rebate and coupon balances are recorded in accrued expenses on the accompanying condensed balance sheets.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Volume-based Rebates - </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Volume-based rebates are contractually offered to certain customers. The rebates payable to each customer are determined based on the contract and quarterly purchase volumes. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Coupons - </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company implemented a program by which customers receive coupons redeemable into gift cards funded by the Company for the benefit of patients. The coupons are accounted for as variable consideration. The Company estimates the coupon redemption rates based on historical data. The coupons are accrued based on estimated redemption rates and the volume of products purchased and are recorded as a reduction to revenues on product delivery. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">September&#160;30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, accrued volume-based rebate and coupon liability was </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$3,932</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.  During the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">three and nine months ended September 30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, provisions for accrued volume-based rebate and coupon liability were </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$5,740</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$6,671</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, respectively, which were offset by related payments of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$2,739</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> in the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">three and nine months ended September 30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> .</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Contract balances</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">A contract with a customer states the terms of the sale, including the description, quantity and price of each product purchased. Amounts are recorded as accounts receivable when the Company&#8217;s right to consideration becomes unconditional. As payment terms are short-term, the Company does not have any significant financing components in customer contracts given the expected time between transfer of the promised products and the payment of the associated consideration is less than one year. As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">September&#160;30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, all amounts included in accounts receivable, net on the accompanying condensed balance sheets are related to contracts with customers.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company did not have any contract assets nor unbilled receivables as of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">September&#160;30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. Sales commissions are included in selling, general and administrative expenses when incurred.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Contract liabilities reflect estimated amounts that the Company is obligated to pay to customers or patients under the rebate and coupon programs. The Company&#8217;s contract liabilities are included in accounts payable and accrued expenses in the condensed balance sheets.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">During the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">three and nine months ended September 30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the Company did not recognize any revenue related to changes in transaction prices regarding its contracts with customers and did not recognize any material changes in revenue related to amounts included in contract liabilities at the beginning of the period.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Collectability</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Accounts receivable are recorded at the invoiced amount and do not bear interest. At the time of contract inception or new customer account set-up, the Company performs a collectability assessment of the customer&#8217;s creditworthiness. The Company assesses the probability that the Company will collect the entitled consideration in exchange for the goods sold, by considering the customer&#8217;s ability and intention to pay when consideration is due. On a recurring basis, the Company estimates the amount of receivables considered uncollectable to reflect an allowance for doubtful accounts.&#160;There was no significant provision for allowance or write-off of doubtful accounts during the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">nine months ended September 30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Practical Expedients</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company expenses sales commissions when incurred as the amortization period is one year or less. These costs are recorded within selling, general and administrative expenses in the accompanying condensed statements of operations and comprehensive loss. The Company does not adjust the amount of promised consideration for the effects of the time value of money for contracts in which the anticipated period between when the Company transfers the goods or services to the customer and when the customer pays within one year.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Stock-Based Compensation</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company recognizes stock-based compensation expense for employees, consultants and members of the Board of Directors based on the fair value at the date of grant. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company uses the Black-Scholes option pricing model to value stock option grants. The Black-Scholes option pricing model requires the input of subjective assumptions, including the expected volatility of the Company&#8217;s common stock, expected risk-free interest rate and the option&#8217;s expected life. The fair value of the Company&#8217;s restricted stock units (&#8220;RSUs&#8221;) is based on the fair value on the grant date of the Company&#8217;s common stock. The Company also evaluates the impact of modifications made to the original terms of equity awards when they occur.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The fair value of equity awards that are expected to vest is amortized on a straight-line basis over the requisite service period. Stock-based compensation expense is recognized net of actual forfeitures when they occur, as an increase to additional paid-in capital in the condensed balance sheets and in the selling, general and administrative or research and development expenses in the condensed statements of operations and comprehensive loss. </font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"></font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Income Taxes</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company applies an estimated annual effective tax rate (&#8220;ETR&#8221;) approach for calculating a tax provision or benefit for interim periods, as required under GAAP.&#160; The Company recorded a benefit for income taxes of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$149</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$14,899</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">three and nine months ended September 30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, respectively, and did not record a significant tax provision or benefit for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">three and nine months ended September 30, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.&#160;The Company&#8217;s ETR differs from the U.S. federal statutory tax rate of 21% primarily as a result of the impact of a valuation allowance on its deferred tax assets.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company accounts for income taxes using the asset and liability method. Under this method, deferred tax assets and liabilities are determined on the basis of differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">A valuation allowance is recorded against deferred tax assets to reduce the net carrying value when it is more likely than not that some portion or all of a deferred tax asset will not be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, and ongoing prudent and feasible tax planning strategies in assessing the amount of the valuation allowance. When the Company establishes or reduces the valuation allowance against its deferred tax assets, its provision for income taxes will increase or decrease, respectively, in the period such determination is made.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As of each reporting date, the Company considers evidence, both positive and negative, that could affect its view of the future realization of deferred tax assets.&#160;As of December 31, 2018, the deferred tax assets were primarily the result of U.S. net operating loss and tax credit carryforwards, and a valuation allowance of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$34,500</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> was recorded against the gross deferred tax asset balance.&#160;Upon FDA approval of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> in February 2019, the Company&#8217;s IPR&amp;D intangible asset was reclassified to a definite-lived distribution right intangible asset. As a result, management determined that it was more likely than not that certain deferred tax assets became realizable due to the future reversals of the deferred tax liability associated with such intangible asset.&#160;Accordingly, the Company released </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$14,402</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> of its valuation allowance as a discrete item upon FDA approval in February 2019. For the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">three and nine months ended September 30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the Company released an additional </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$149</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$497</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, respectively, from its valuation allowance.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Additionally, the Company recognizes the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities based on the technical merits of the position. The tax benefit recognized in the financial statements for a particular tax position is based on the largest benefit that is more likely than not to be realized upon settlement. Accordingly, the Company establishes reserves for uncertain tax positions. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In accordance with SEC Staff Accounting Bulletin No. 118, the Company&#8217;s accounting for the elements of the Tax Cuts and Jobs Act was complete as of December 31, 2018 and no adjustments were made to the original provisional estimate recorded in 2017.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Net Loss Per Share</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Basic net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock outstanding during the period including contingently issuable shares. Diluted earnings per share is based on the treasury stock method and includes the effect from potential issuance of ordinary shares, such as shares issuable pursuant to the exercise of stock options and the vesting of restricted stock units. Because the impact of the options and non-vested RSUs are anti-dilutive during periods of net loss, there was no difference between the weighted-average number of shares used to calculate basic and diluted net loss per common share for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">three and nine months ended September 30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. </font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Recently Adopted Accounting Pronouncements</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In August 2018, the SEC adopted the final rule under SEC Release No. 33-10532,&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Disclosure Update and Simplification</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, amending certain disclosure requirements that were redundant, duplicative, overlapping, outdated or superseded. In addition, the amendments expanded the disclosure requirements on the analysis of stockholders&#8217; equity for interim financial statements. Under the amendments, an analysis of changes in each caption of stockholders&#8217; equity presented in the balance sheet must be provided in a note or separate statement. The analysis should present a reconciliation of the beginning balance to the ending balance of each period for which a statement of comprehensive income is required to be filed. This final rule was effective on November 5, 2018 and it did not have a material impact on the Company&#8217;s financial statements upon adoption on January 1, 2019.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In July 2018, the Financial Accounting Standards Board (the &#8220;FASB&#8221;) issued&#160;ASU No. 2018-09,&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Codification Improvements</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, which clarifies certain amendments to guidance that may have been incorrectly or inconsistently applied by certain entities and includes Amendments to Subtopic 718-740, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Compensation - Stock Compensation - Income Taxes</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. The guidance in paragraph 718-740-35-2, as amended by the amendments in&#160;ASU 2016-09, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, is unclear on whether an entity should recognize excess tax benefits (or tax deficiencies) for compensation expense that is taken on the entity&#8217;s tax return. The amendment to paragraph 718-740-35-2 in this update clarifies that an entity should recognize excess tax benefits in the period in which the amount of deduction is determined. The Company adopted the guidance on January 1, 2019, and such adoption did not have a material impact on its financial statements.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In June 2018, the FASB issued ASU No. 2018-07,&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Compensation&#8212;Stock Compensation (Topic 718): Improvements to Nonemployee Share-based Payment Accounting,</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> which amends the financial reporting for stock-based payments issued to nonemployees and also expands the scope of ASC 718,&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Compensation - Stock Compensation</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">,&#160;to also include stock-based payments issued to nonemployees for goods and services. The amendment substantially aligns accounting for stock-based payments to employees and nonemployees. The Company early adopted the guidance in the quarter ended December 31, 2018. The adoption did not have a material impact on the Company&#8217;s financial statements.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In February 2016, the FASB issued ASU No. 2016-02 and its related amendments which introduced </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Leases (Topic 842, or </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8220;ASC 842&#8221;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">)</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, a new comprehensive lease accounting model that supersedes the current lease guidance under&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Leases (Topic 840)</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. The new accounting standard requires lessees to recognize ROU assets and corresponding lease liabilities for all leases with lease terms of greater than 12 months. It also changes the definition of a lease and expands the disclosure requirements of lease arrangements. In July 2018, the FASB added a transition option for implementation that allows companies to continue to use the legacy guidance in ASC 840, Leases, including its disclosure requirements, in the comparative periods presented in the year of adoption. The Company adopted the guidance effective January 1, 2019. The Company elected the transition package of three practical expedients and elected the optional transition method that allows for a cumulative-effect adjustment in the period of adoption without a restatement of prior periods. Further, the Company elected a short-term lease exception policy, permitting the Company to not apply the recognition requirements of this standard to short-term leases (i.e. leases with terms of 12 months or less) and an accounting policy to account for lease and non-lease components as a single component for certain classes of assets. As a result of the adoption, the Company adjusted its beginning balance of 2019 by recording operating lease ROU assets and liabilities through a cumulative-effect adjustment. The adoption impacted the accompanying condensed balance sheet, but did not have an impact on the condensed statements of operations and comprehensive loss. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The impact of the adoption of ASC 842 on the accompanying condensed balance sheet as of January 1, 2019 was as follows:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.8015873015873%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:44%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">December 31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Adjustments Due to the Adoption of ASC 842</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">January 1, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Operating lease right-of-use assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,029</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,029</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Current portion of operating lease liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">916</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">916</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Operating lease liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">138</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">138</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Deferred rent</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">25</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(25</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Times New Roman;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Recent Accounting Pronouncements</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In November 2018, the FASB issued ASU No. 2018-18,&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Clarifying the Interaction between Topic 808 and Topic 606</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, which requires transactions in collaborative arrangements to be accounted for under ASC 606,&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Revenue from Contracts with Customers</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">,&#160;if the counter-party is a customer for a good or service that is a distinct unit of account. The amendments also preclude entities from presenting consideration from transactions with a collaborator that is not a customer together with revenue recognized from contracts with customers. The guidance is effective for interim and annual reporting periods during the year ending December 31, 2020. Early adoption is permitted, including in any interim period.&#160;The Company is currently evaluating the impact that the adoption of this guidance will have on its financial statements and related disclosures.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In August 2018, the FASB issued&#160;ASU No. 2018-15,&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Intangibles-Goodwill and Other-Internal-Use Software: Customer&#8217;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement that is a Service Contract</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.&#160;ASU 2018-15&#160;requires implementation costs incurred by customers in cloud computing arrangements (i.e., hosting arrangements) to be capitalized under the same premises of authoritative guidance for internal-use software, and deferred over the noncancellable term of the cloud computing arrangements plus any option renewal periods that are reasonably certain to be exercised by the customer or for which the exercise is controlled by the service provider. The guidance is effective for interim and annual reporting periods during the year ending December 31, 2020. Early adoption is permitted. The Company is in the process of determining the effects the adoption will have on its financial statements as well as whether to early adopt the new guidance.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In August 2018, the FASB issued&#160;ASU No. 2018-13,&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Fair Value Measurement (Topic 820): Disclosure Framework &#8212; Changes to the Disclosure Requirements for Fair Value Measurement</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.&#160;The update&#160;is part of the disclosure framework project and eliminates certain disclosure requirements for fair value measurements, requires entities to disclose new information, and modifies existing disclosure requirements. Under the new guidance,&#160;entities will no longer be required to disclose the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy, or valuation processes for Level 3 fair value measurements. However, public companies will be required to disclose the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and related changes in unrealized gains and losses included in other comprehensive income. The guidance is effective for interim and annual reporting periods during the year ending December 31, 2020. Early adoption is permitted. The Company is currently evaluating the impact this change will have on its financial statements as well as whether to early adopt the new guidance.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In January 2017, the FASB issued ASU No. 2017-04,&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Intangibles&#8212;Goodwill and Other (Topic 350):&#160;Simplifying the Test for Goodwill Impairment</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. The update simplifies the accounting for goodwill impairment by removing step two of the goodwill impairment test, which requires a hypothetical purchase price allocation. A goodwill impairment will be the amount by which a reporting unit&#8217;s carrying amount, including goodwill, exceeds its fair value. The impairment charge will be limited to the amount of goodwill allocated to that reporting unit. The update is effective for the Company beginning January&#160;1, 2020. The standard requires prospective application. Early adoption is permitted. The Company is evaluating the effect of this standard on its financial statements and related disclosures as well as whether to early adopt the new guidance.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In June 2016, the FASB issued ASU No. 2016-13,&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, which modifies the measurement and recognition of credit losses for most financial assets and certain other instruments. The new standard requires the use of forward-looking expected credit loss models based on historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount, which may result in earlier recognition of credit losses under the new standard. The new guidance also modifies the impairment models for available-for-sale debt securities and for purchased financial assets with credit deterioration since their origination. Subsequent to the issuance of ASU 2016-13, the FASB issued ASU 2018-19,&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Codification Improvements to Topic 326, Financial Instruments - Credit Losses</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. This ASU does not change the core principle of the guidance in ASU 2016-13, instead these amendments are intended to clarify and improve operability of certain topics included within the credit losses standard.&#160;The FASB also subsequently issued ASU 2019-04 which did not change the core principle of the guidance in ASU 2016-13 but clarified that expected recoveries of amounts previously written off and expected to be written off should be included in the valuation account and should not exceed amounts previously written off and expected to be written off. The guidance is effective for interim and annual reporting periods beginning after December 15, 2019 and interim periods within those periods, and early adoption is permitted. The guidance will be effective for the Company during the first quarter of 2020. The Company is in the process of determining the effects the adoption will have on its financial statements and reviewing credit loss models to assess the impact of the adoption of the standard on the financial statements. Based on initial assessments, the Company believes that while adoption will modify the way it analyzes financial instruments, it does not expect adoption of this guidance will have a material impact to its financial statements.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Other recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the American Institute of Certified Public Accountants, and the SEC did not, or are not believed by management to, have a material impact on the Company&#8217;s present or future financial position, results of operations or cash flows.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 450<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6491354&amp;loc=d3e6052-115624<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 450<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491354&amp;loc=d3e6049-115624<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=68068213&amp;loc=d3e12565-110249<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108315417&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13279-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e32247-109318<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e32280-109318<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65884525&amp;loc=d3e40913-109327<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116846552&amp;loc=d3e543-108305<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6593870016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Oxford Term Loans<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Oxford Term Loans</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Oxford Term Loans</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On March 15, 2019, the Company entered into a credit facility of up to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$100,000</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> with Oxford Finance (&#8220;Oxford&#8221;). Pursuant to the terms of the credit facility, the lender extended term loans (the &#8220;Term Loans&#8221;), available in two advances, to the Company. The first tranche of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$75,000</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> was funded on the closing date. The second tranche of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$25,000</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> may be drawn, at the request of the Company, no later than September 30, 2020, upon achieving specified minimum net sales milestones based on a trailing six-month basis and no event of default. As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">September&#160;30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the Company had not yet met the net sales milestone to draw the second tranche. The credit facility bears an annual interest rate equal to the greater of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">9.5%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, or the 30-day U.S. Dollar LIBOR rate plus </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">7.0%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. The Company agreed to pay interest-only on each tranche funded for the first </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">36</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> months until May 2022, which is followed by a </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">23</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">-month amortization period. Notwithstanding the foregoing, if the Company maintains compliance with the specified minimum net sales covenant and meets other conditions during the initial interest-only period, upon the Company&#8217;s request, the interest-only period may be extended by an additional </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">12</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> months to a total of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">48</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> months followed by an </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">11</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">-month amortization period.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Upon the earliest to occur of the maturity date, the acceleration of the term loans, or the prepayment of the term loans, the Company is required to pay to Oxford a final payment of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">5.5%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> of the full principal amount of the term loans funded (&#8220;Final Payment&#8221;). The Company may elect to prepay all amounts owed prior to the maturity date, provided that a prepayment fee is also paid, which shall be equal to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">3.0%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> of the amount prepaid if the prepayment occurs on or prior to March 15, 2020, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2.0%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> of the amount prepaid if the prepayment occurs after March 15, 2020 and on or prior to March 15, 2021, or </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">1.0%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> of the amount prepaid if the prepayment occurs thereafter (&#8220;Prepayment Fee&#8221;).  If the Term Loans are accelerated following the occurrence of an event of default, the Company is required to immediately pay to Oxford an amount equal to the sum of all outstanding principal of the term loans plus accrued and unpaid interest thereon through the prepayment date, the Final Payment, the Prepayment Fee and all other obligations that are due and payable, including payment of Oxford&#8217;s expenses and interest at the default rate with respect to any past due amounts.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The credit facility is secured by substantially all of the Company&#8217;s assets. The credit facility includes affirmative and negative covenants applicable to the Company and any subsidiaries it may create in the future. The affirmative covenants include, among others, covenants requiring the Company to maintain its legal corporate existence and governmental approvals, deliver certain financial reports, maintain insurance coverage and satisfy certain requirements regarding deposit accounts. The negative covenants include, among others, restrictions on us transferring collateral, incurring additional indebtedness, engaging in mergers or acquisitions, paying dividends or making other distributions, making investments, creating liens, selling assets and suffering a change in control, in each case subject to certain exceptions.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The credit facility also includes events of default, the occurrence and continuation of which could cause interest to be charged at a default interest rate equal to the applicable rate plus </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">5.0%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and Oxford, as collateral agent, with the right to exercise remedies against the Company and the collateral securing the credit facility, including foreclosure against the property securing the credit facility, including the Company&#8217;s cash. These events of default include, among other things, any failure by the Company to pay principal or interest due under the credit facility, a breach of certain covenants under the credit facility, the Company&#8217;s insolvency, a material adverse change, the occurrence of any default under certain other indebtedness and one or more judgments against the Company, the institution of certain temporary or permanent relief in connection with pending litigation, or the breach, termination or other adverse events under the Daewoong Agreement. As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">September&#160;30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the Company was in compliance with its debt covenants.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">At the closing date, the Company incurred </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$1,094</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$2,205</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> in debt discounts and issuance costs related to the Term Loans, respectively. Debt&#160;discounts and issuance costs related to the entire Term Loans have been allocated pro rata between the funded and unfunded portions. Debt&#160;discounts and issuance costs allocated to the first tranche of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$75,000</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> have been presented as a deduction to the debt balance and are amortized into interest expense using the effective interest method. As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">September&#160;30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the borrowings outstanding under the Term Loans were classified as long-term debt in the accompanying condensed balance sheets. Debt discounts and issuance costs associated with the unfunded tranche are deferred as assets until the tranche is drawn and are amortized into interest expense using the straight-line method over the term of the debt. The overall effective interest rate was approximately </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">11.6%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> as of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">September&#160;30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">September&#160;30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the principal amounts of long-term debt maturities during each of the next five fiscal years, and the Final Payment in 2024 which is amortized into interest expense over the life of the Term Loans are as follows:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:88.4920634920635%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:56%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Fiscal year</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Principal</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Final Payment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2022</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">26,087</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">26,087</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2023</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">39,130</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">39,130</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">2024</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">9,783</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">4,125</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">13,908</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">75,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">4,125</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">79,125</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6801158768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Asset - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 01, 2019</div></th>
<th class="th"><div>Oct. 31, 2013</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_MilestonePaymentsForIntangibleAssets', window );">Milestone payment for intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_MilestonePaymentCurrent', window );">EU milestone payment to Daewoong</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedComputerSoftwareAdditions', window );">Capitalized computer software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">761<span></span>
</td>
<td class="nump">3,303<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,115<span></span>
</td>
<td class="nump">$ 2,522<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=eols_SCHAEONLLCMember', window );">SCH | Evolus, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">Assets acquired, indefinite-lived intangible assets (IPR&amp;D)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56,076<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_AcquiredFinitelivedIntangibleAssetPeriodOfExtensionOfTermsBasedOnCertainPerformanceRequirements', window );">Extension period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration upon successful completion of certain technical and sales milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_MilestonePaymentsForIntangibleAssets', window );">Milestone payment for intangible assets</a></td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DistributionRightsMember', window );">Distribution right</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember', window );">Capitalized software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Amortization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_AcquiredFinitelivedIntangibleAssetPeriodOfExtensionOfTermsBasedOnCertainPerformanceRequirements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Acquired Finite-lived Intangible Asset, Period Of Extension Of Terms Based On Certain Performance Requirements</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_AcquiredFinitelivedIntangibleAssetPeriodOfExtensionOfTermsBasedOnCertainPerformanceRequirements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_MilestonePaymentCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone Payment, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_MilestonePaymentCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_MilestonePaymentsForIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone Payments For Intangible Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_MilestonePaymentsForIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedComputerSoftwareAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additions made to capitalized computer software costs during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedComputerSoftwareAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=eols_SCHAEONLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=eols_SCHAEONLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=eols_EvolusIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=eols_EvolusIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DistributionRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DistributionRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6802526816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements and Short-Term Investments - Assets and Liabilities on a Recurring Basis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Contingent royalty obligation payable to Evolus Founders</a></td>
<td class="nump">$ 48,895<span></span>
</td>
<td class="nump">$ 47,169<span></span>
</td>
<td class="nump">$ 50,200<span></span>
</td>
<td class="nump">$ 51,100<span></span>
</td>
<td class="nump">$ 48,800<span></span>
</td>
<td class="nump">$ 39,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Available-for-sale debt securities</a></td>
<td class="nump">34,913<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S treasury securities | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Available-for-sale debt securities</a></td>
<td class="nump">34,913<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S treasury securities | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Available-for-sale debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S treasury securities | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Available-for-sale debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Notes Payable, Other Payables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Contingent royalty obligation payable to Evolus Founders</a></td>
<td class="nump">48,895<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Notes Payable, Other Payables | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Contingent royalty obligation payable to Evolus Founders</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Notes Payable, Other Payables | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Contingent royalty obligation payable to Evolus Founders</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Notes Payable, Other Payables | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Contingent royalty obligation payable to Evolus Founders</a></td>
<td class="nump">$ 48,895<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_NotesPayableOtherPayablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_NotesPayableOtherPayablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6789984320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Lease Cost (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Fixed operating lease expense</a></td>
<td class="nump">$ 297<span></span>
</td>
<td class="nump">$ 798<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable operating lease expense</a></td>
<td class="nump">31<span></span>
</td>
<td class="nump">92<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term operating lease expense</a></td>
<td class="nump">24<span></span>
</td>
<td class="nump">73<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Lease, cost</a></td>
<td class="nump">$ 352<span></span>
</td>
<td class="nump">$ 963<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term (years)</a></td>
<td class="text">5 years 88 days<span></span>
</td>
<td class="text">5 years 88 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="nump">9.40%<span></span>
</td>
<td class="nump">9.40%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>24
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M_>%W$W;>V(/]Q\970=G"K[N07U!+ P04    " "J@&1/F5R<(Q &  "<)P
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M,TV+FEV5F:[U7 R-P[!0O!N;(C1U9L4?4$L#!!0    ( *J 9$_VHP9H1@0
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MJIB5" ^!6T%J!5@GMLAM1KT(,J<R%_$CHQ&0^]'4#[*.$%"QL?D_V;T?&;7
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MS%G%/*M89!5WV7"3\^+P>7&'3FQR7ASNP>,>/#BSY#*8>CZ)RFMR3C*B)):
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MCTWWMIOZW?'G)\</3?W<_[1F<OI]S^W_4$L#!!0    ( *J 9$\%L5)#,P8
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MSW8<L]'PIIM^$)N_<?X.4$L#!!0    ( *J 9$^>EN[^M $  -(#   9
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MN'"\\6<SC=ED.-W//X@LW[C\ %!+ P04    " "J@&1/X^2&HM,!  "<!
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M1TO H-)VFIBYG&[E%&C1SP\.7EZ]_ ]02P,$%     @ JH!D3\Y\%T2^ @
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MT[:3:">,U*I)<KI.;?D?4$L#!!0    ( *J 9$\#(&354P,  )$.   9
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M ZX_.+[=+8$+!@$*!K&.&?8&]U% <&@ ES< ^Z+@#4Z #4[(  6\<PCYQ-#
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M,[0,*#E+W<U5GT^7\320;)C?&; \=M5?4$L#!!0    ( *J 9$_EM.''$@,
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M%]E>MXIS!=HQ>- UU_H]G0,&E3+31,_%^*J,@>+]]&"B^=4N_P%02P,$%
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M+'*^D_HU4>]U=W_M%E)4YFX>7/X@S/\"4$L#!!0    ( *J 9$\QD @Q"@,
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M"$&!T B$=P*+2:$ #/9@DP@TB>8"B3<Q 3 X@$UBT"0&3/#$!,+XL$D"FB2
M0# Q@3 A;)*")BD@$$U,YIA@D< F"]!D 9C$$Y,>$QM,8S"II_Y@&^S!.]$#
MC&9;L0=%(Z<XCO!CKP>['L^K$DV_ 0L:>VFCL5>_?2UPG/X$LOL0<A\QV$36
MV >JDTXC]F<1SV+U/QT(W$AP  3RH!5AN)7@\//-",.- @-=()UV"@L:YXIQ
MY %?)AH=%S7E%W,4"^?(KHVY!XQ6A^-^[9OCYAW>WQ5^$'XI&^$<F%2'ECE:
MSHQ)J@+RGE1 A;J>#).*GJ4>)FK,^S.ZGTC6VOL'&BY!^7]02P,$%     @
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M0>IMJO:\FTG=0;*F'[?>,//SOU!+ P04    " "J@&1/:FF9KEP#  !O#@
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MRA$B>^-RA^@#H9RS'"<B,=Y,,4*5V=T4NUR0YEGFJ4;B:5R"<'&;BSA<+$Z
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M:.>P_CRT2!T[N(SDZRI44+\=_9WTD\OH)8_B108N2FC K'N,/\$DZ2UD.X?
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MHF&CA"Y)SX.K^K;:P#@5:GNU"/QQ3;A'WD8KI,0LZM6J:("5PO;2IWOZ3&^
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M3QQF\@3WL+?%>J=U"T8Z.H(V,@L:V+G9>H;4S]]R#"E1\,X]<G0[L-0+#-;
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M[4,+MF@A2NT6[C^KPY[MDGK;5>8U!3T-M(MRX7@Z^>9!4"N\"GD4VXZA[$V
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M]R/;90RM9L,,B;$PV %K.52?@*'X\@_1\LQ;R 65!*T;?#"4N=BCBP@,Z$=
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M!U+ 7_GJB2-.T<>J+7)I%S 8ZX>RE*K7NU57J'MA361JN_9#C>4RX!^OR;&
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M6^"N.-^7@R=(R0ORC0^Y?XZS'T!X8")5;$@%IY-E,1W=<8%J=!0Q7@*6<K3
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MX@E5>EM7&#D"K<#K5Y>3_.+EV1A!D*W!T4VSG6.*.!;V\0.QCVN\!6BJ,W0
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M7&/K%-;YF>)JNHET99BG. V)4X#L(W:3Z ;%&LT:FU5O5P]6&255A32&;*X
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MPFK8D!^ZD\S,NS)48Z$^R(0)PX*5MP\M&+"%:,);N/]2+]JQ7=*)N\K\>8B
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M@A275Q25Q=WGE?TD%J$%?GUG'CZ'3-"[/7-*@G8,SKB'.4(O2]B:1!B.E&1
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M7P*JQKEG<L("I6+ 84L-;V_73W@"0)K3&,:B>7-1"I1.7S^D&]!M3M&!&>5
M?KB.?2Y38R!^645F5_*I !+W7ED_/,!#8]6HY +D]6VY'C/5EKG3[==CVX,+
MUZ?VIHQJURBQHG M+4DM</+3E@W?(0C4_,9I[KQ>)X,>,LZJA#?S%1]IQ3&H
MBH3:\L.$E/WOIH0! >C0MVH?0\UMHB?>(H-,>FS8E^XQ'QOP2-7\EH]@AQ8
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M'<Q?TBIR(FBPTSK&.@]<[Q1O[/G!A0D4;TC C\%$S!;J^!4K27GOAP*9P<I
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M03-ZD R!C$-^$L*:K[4 KH7OM0"PA2^V +*%;[8 M(6OM@"VA>^V +B%+[<
MNH5OMP"\A:^W KV5K[<"O?4!S]KH89NOMP*]E:^W KV5K[<"O96OMP*]E:^W
M KV5K[<"O96OMP*]E:^W ;V-K[<!O8VOMP&][0%G)>BPA*^W ;V-K[<!O8VO
MMP&]C:^W ;V-K[<!O8VOMP&]C:^W!WI[OMX>Z.WY>GN@M^?K[8'>_@%GW>BP
MFZ^W!WI[OMZ^HW<L\B:L/E*S+3?QWB47PV_6=.".Z;0/]\\X3[VYOZ-T:K<$
M=_Z\^RU^GOH;X2Y>UKW^ %!+ P04    " "J@&1/-QE]R+@!  #;&P  $P
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MM5X>YK/N/[W9-U!+ 0(4 Q0    ( *J 9$\?(\\#P    !,"   +
M      "  0    !?<F5L<R\N<F5L<U!+ 0(4 Q0    ( *J 9$\GZ(<.@@
M +$    0              "  >D   !D;V-0<F]P<R]A<' N>&UL4$L! A0#
M%     @ JH!D3_,"-HWN    *P(  !$              ( !F0$  &1O8U!R
M;W!S+V-O<F4N>&UL4$L! A0#%     @ JH!D3YE<G",0!@  G"<  !,
M         ( !M@(  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " "J
M@&1/F"-Q984"  "E"0  &               @ 'W"   >&PO=V]R:W-H965T
M<R]S:&5E=#$N>&UL4$L! A0#%     @ JH!D3_:C!FA&!   7Q4  !@
M         ( !L@L  'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0
M   ( *J 9$^Y@ZOE.P(  +0'   8              "  2X0  !X;"]W;W)K
M<VAE971S+W-H965T,RYX;6Q02P$"% ,4    " "J@&1/YU/VIFH$  #,%
M&               @ &?$@  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L!
M A0#%     @ JH!D3\MIG31'"   ZS,  !@              ( !/Q<  'AL
M+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    ( *J 9$\%L5)#,P8
M )8B   8              "  ;P?  !X;"]W;W)K<VAE971S+W-H965T-BYX
M;6Q02P$"% ,4    " "J@&1/A<#K]; !  #2 P  &               @ $E
M)@  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ JH!D3VL>
MW[FT 0  T@,  !@              ( !"R@  'AL+W=O<FMS:&5E=',O<VAE
M970X+GAM;%!+ 0(4 Q0    ( *J 9$\XD/R1M0$  -(#   8
M  "  ?4I  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4    " "J
M@&1/7TW4\+,!  #2 P  &0              @ '@*P  >&PO=V]R:W-H965T
M<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( *J 9$^GM<=!M $  -(#   9
M          "  <HM  !X;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#
M%     @ JH!D3\C.\^2U 0  T@,  !D              ( !M2\  'AL+W=O
M<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4    " "J@&1/GI;N_K0!  #2
M P  &0              @ &A,0  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM
M;%!+ 0(4 Q0    ( *J 9$]%G_V9M $  -(#   9              "  8PS
M  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%     @ JH!D3Z [
M]G.W 0  T@,  !D              ( !=S4  'AL+W=O<FMS:&5E=',O<VAE
M970Q-2YX;6Q02P$"% ,4    " "J@&1/S;SD$YT"  "J"@  &0
M    @ %E-P  >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    (
M *J 9$\U+V0'N $  -(#   9              "  3DZ  !X;"]W;W)K<VAE
M971S+W-H965T,3<N>&UL4$L! A0#%     @ JH!D3X[<MRNW 0  T@,  !D
M             ( !*#P  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"
M% ,4    " "J@&1/PE6Q,L0!   W!   &0              @ $6/@  >&PO
M=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( *J 9$\3X)TQM@$
M -(#   9              "  1%   !X;"]W;W)K<VAE971S+W-H965T,C N
M>&UL4$L! A0#%     @ JH!D3^/DAJ+3 0  G 0  !D              ( !
M_D$  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4    " "J@&1/
MDR7(?],!  "<!   &0              @ $(1   >&PO=V]R:W-H965T<R]S
M:&5E=#(R+GAM;%!+ 0(4 Q0    ( *J 9$\]BX]$X $   $%   9
M      "  1)&  !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%
M  @ JH!D3\Y\%T2^ @  M0D  !D              ( !*4@  'AL+W=O<FMS
M:&5E=',O<VAE970R-"YX;6Q02P$"% ,4    " "J@&1/ R!DU5,#  "1#@
M&0              @ $>2P  >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+
M 0(4 Q0    ( *J 9$\_3CBI80(  &0(   9              "  :A.  !X
M;"]W;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @ JH!D3^U_A"PV
M P  ^ T  !D              ( !0%$  'AL+W=O<FMS:&5E=',O<VAE970R
M-RYX;6Q02P$"% ,4    " "J@&1/*5!U<#<"  #X!@  &0
M@ &M5   >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( *J
M9$_EM.''$@,  ) ,   9              "  1M7  !X;"]W;W)K<VAE971S
M+W-H965T,CDN>&UL4$L! A0#%     @ JH!D3S7!GR\! @  P04  !D
M         ( !9%H  'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"% ,4
M    " "J@&1/BU5?6^4"   L#   &0              @ &<7   >&PO=V]R
M:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    ( *J 9$\QD @Q"@,  .L-
M   9              "  ;A?  !X;"]W;W)K<VAE971S+W-H965T,S(N>&UL
M4$L! A0#%     @ JH!D3S[]YBE2 @  50@  !D              ( !^6(
M 'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"% ,4    " "J@&1/:Y;%
M5-4!  #+!   &0              @ &"90  >&PO=V]R:W-H965T<R]S:&5E
M=#,T+GAM;%!+ 0(4 Q0    ( *J 9$_97AYF] (  +$-   9
M  "  8YG  !X;"]W;W)K<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @
MJH!D3[[7WLO# @  % L  !D              ( !N6H  'AL+W=O<FMS:&5E
M=',O<VAE970S-BYX;6Q02P$"% ,4    " "J@&1/L@ND)F\"   2"   &0
M            @ &S;0  >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4
M Q0    ( *J 9$_\$WZ6B0(  ! )   9              "  5EP  !X;"]W
M;W)K<VAE971S+W-H965T,S@N>&UL4$L! A0#%     @ JH!D3P,H$PM  @
M&0<  !D              ( !&7,  'AL+W=O<FMS:&5E=',O<VAE970S.2YX
M;6Q02P$"% ,4    " "J@&1/BV#52'$"  #%"   &0              @ &0
M=0  >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    ( *J 9$\;
MTB&;*0,  (L.   9              "  3AX  !X;"]W;W)K<VAE971S+W-H
M965T-#$N>&UL4$L! A0#%     @ JH!D3YNTOK9- @  _P<  !D
M     ( !F'L  'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6Q02P$"% ,4
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M2P$"% ,4    " "J@&1/PCVU3DT"  !F"P  #0              @ %:'P$
M>&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( *J 9$^/02K3\ ,  )<>   /
M          "  =(A 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " "J@&1/
M9VT:EL !  "\&P  &@              @ 'O)0$ >&PO7W)E;',O=V]R:V)O
M;VLN>&UL+G)E;'-02P$"% ,4    " "J@&1/-QE]R+@!  #;&P  $P
M        @ 'G)P$ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     -@ V *P.
(  #0*0$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>25
<FILENAME>0001570562-19-000143-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001570562-19-000143-xbrl.zip
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MZR>.AKT&O;U\6#/MIM=@KL*#NN$W#4$^>% S?-H409S6AA"G#>;-M,ZVF39
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MZ\./)F+_/(O8LX@]HHCM>!?JJ"+VU;J(?8Z"\Y')L^WKKROQ=)3H;N%R/O+
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M4N<![9H']Z8.L&O.4N>129W[MG5NQ\,%!]W.!F^SZ?NKWC1;7^?!\ NLS3H
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MU(9PV/N4-UQ="JU-D)>93(WP<K!U@(S2.="Q/D1-;(P1M \2.EI>(>X:O'O
M<F?0@=J-H L)PAP+3#7'B$=D/ BT''0:L UQ&W2J*=E@C&X(_/?M<)H-(GB?
M\VP$ON?@U1BTU.<AK):9S;*EN7%Q&;[-%Z[NQ66J%#6SO5DVN!B[;#KO#9/4
MO)Q,KWOC?O8NRU^93(;-K9G8C/[!+OKSYONZ[]U_F'#QYO5KMW5MO=B*.< +
M2;V:%;Y,1K<S\+R7H8(U0P?V%@\*^>#!WE%@ J-06+Y18Q!];^F?)>E.2HL5
MS4>C%!3(!KE=D,]-0@[>F$<*ELZ_Z]T,Y[W1\'^R>IWW1\MNY4HY$2)L6.5
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MZ59[P1M]_Q/!_R#T:?/CK:+@)4EK+)&.!ND$*D-2GO#&G(IG0Y\=I]B4!16
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MQ04R>!DL;QZ%SB]_-:=BK&[.%U^SW\L?_V.835-IW^^O4V'?#9U?CEE D _
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MN))TV@#4BKTN+K=EZZ*C,FR0>H&U3U\=YK'T6@=.* D<@^&WNDT6=%L282?
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M,$A=+,?SR?00^D=LC>!"66]2FR[GHBA%4G15H=H*^1H@=X!X!ZV-B\9[)74
M!F$IOL%6UA=3%=]&D)W;=V^XWTXS\*D'Q0H560SC1<.(NO;7>RR!4WFI'AI3
MTU;%=+1%]4]8 J8KYH2D%5OB #!/@>@N!1ZMX9CAX(R W8XM4V7'9O!0JZUC
MV$[UT1W3U@;<.^(UVY=Z=KRM,=B?X)[TLUG>%2[E-*>Z/M6,O293.8(2QM)1
M34R,E*?[^&41250-"55;FG>EPB8%*V<J^U&MV9P.-.KH<(A:6TG!9]1EW5Y/
M0O4Z> T^NV&Z.PZMA_@>F0!2%.0G!^!H"M05H0-B5+7)1^5P\P@XE#TE#UL'
M3+W35"MP#3&H7@'N+5TKG52)VDI)*C&CW3#='8?VY% FD BID')$&D<E:%G*
M)E!7D:4*([&M'3KCD <:4LW(RA'J7M:HT0Q'846J80] >U+:<<%4KZ9M@KK^
MZ4Y0[;+TL>&$ 6#$@9\ED0+E5$#EM:N6T:)5,C;#MM"VWSM7^+;(LZ ($"H
M)!& DJ6QR$UL.^58_^C^P+2>)E*/H@C>.R^"\!Q)5<96$*'5*!!";#M8V S3
MHJQRV9BH>P,TH27'7&//=*H@3;@J^_E@5:V;OP76UN</@:[5Z@2514#02Z5,
M]%Z ."_[83OP $X,W8Y8E&:,.HYM!(,8?'0?A"SC.\'@ZB43L>U9'07$UA"4
MI-8HR2/B&NQ?I50LZT YL'>KII38%M6M,+Y.YE7JE="9>)8:;+'BVJ0^K6#R
M,;LZL/*^+@MQ [#RR_N#TRI>G6-$("\U!\N"$NE#Z2THYBMNLA9T'W! -63+
MZ/3X<SZFO!#TMO<]KWGNNUZ_3462+?"8))JIH)!6OEQ3D+D5NRZ55-Z"=3^P
M#D'E#DGE3D=JM4 1%)H02E'-RENI/K)JNQ*V958<!.,A2!Z&GTP=KE.B/#6$
M6 7<KDO;#\7MDJNI C3>9OENX!V,6N?4Z<B(8X8K FL'FPB,*5>RI-3;39=3
MI72N#D=M*VFZR]P#TJ4QB2IU^@;CEAF5)+TI3_MTK+K=>+NS3&?X#D:N:XHT
MTR1R9*C#BC 44K' \M"<V6K2+*"&#T=M,SEZKZE'N+"!F$=@-&.BD? 6@=H1
M98T>3FN2)ND!PG+G-8W6MWP<#Y;]E%)D(OG[YKJQ252S-0(RQ&C0HSH0BJD&
M#5;:F2%6#PVZB<\F&'<A^2X;9U][H]3-J0&=57 4>1\\%8HJ 8MEI%C>2T@]
M48,D+WY[*]#O[?"N?6X#LJ:8[2Y/(C K67#*>NF<=(H+0PNB4E\M=:'DMI'7
M$)UMA:A5BQA*.29$6<6C%I;%6-:]5J+FBEDJLTL[@I3Z!J;>RU>3$3#U;-$R
MH!OEJ*$$1&5TT3K*9?1.EBU,-%C*=>5]&&N"LQ:@NP'?VFC)8!I!O'NA0(]%
M\&QE&3I#J)JK /)3"'$,X ^JQ V ^>@YB^#F(MA"GA3^+O%15/O<<B(;@:VI
M7GW76MO KQ@KT)W #Q@;&G4H-Y%&U4@\X5HV<D(M?./LXG+1I*=L%]?[-KR^
MO;:3Z73R%:2#Z]W DP8^.'K[11U)RJ:R47).(CCTKBBP@@+(MTI8)&\9L87Q
M_C@=A1;;+1CW)47J$-&_RB[&V58B\K%Z.)+@'?-2@,/%4^5=JHK 5YZ_^@QI
M"9;2B6CI&$X6'Y#0&633E2G/5[&HZLD*>7RT/!8IP" $\T^RW-Y+YTN&ZM)E
M ?E9$Y8[&BT A0]+%#H;[,1J3@(&HR3$U!>LK*ZL<*RXR%+CK4/-]6\WP?1[
M;[ZLAOTNNUE:N!>7;Z?#<7]XDTJU''AIW# L!#&<*XY"H!:OTJ$\]U6+ %9&
M-0*_-Y!WP[*S*TS K1!@K8*3F'+\ B-K;3VHJ<:U%@7"[X3EMD/<]04'>,4.
MG">3.J)Q$,Z1,1-0V5L67*Q*)@,1:*N?U6%0-N%Y:'=*V-8!O& AP-QCU!IO
M65G++G#2=E10__E# &RU]QG'6@2GJ8T$I4ZKJP ]M[PBIR3-&Y@?!.=ZM:6.
M33Y]4$1CZ;&E8+XYS%!I,',CJ[$M\/!8+93K,'2'L95E$1'<IX[8$1QDI@2E
M93Y7C+RRU%ANWPB_,XP+,N*8?<+-12@Q8M%Y,.D=)A)\.FMT:3PJCBL&#Q:(
MD8YPSF:+[.G/V;C_/<_GZHW,W/6FT^_PR_VJD&^9%DB!02&I!2_.@])QE*YR
M_F+5+]T =P]PC@#_%G-LP>^<$*"0@(M!3J?TY\+EHS1U[#LF_&\R>#:[>CN=
MI/9W _O]XRQE5RR+H8T_F_Y\^.6P/+EH-0M6:,X<"B@UKU5EK0YAJDD?X)@I
MNJEE]X?N6#CM3&$$E]9(L%@%"T%&&GS92I3S:H%T4#5;$8^CHK0X$KO;,@D0
M0L!HP2"F%0@@YWB9XD0#K5XAT?O@4P/9L?#9L4211Z&"8Z!$4\-$Y84I4\8%
MKDEUIR!:]V*[PW JHX)W6",?A0P>ISH:X"F!BV!CF?*H:*RN$:9"X'UPJH'N
M6#CM; :+ M;1L*B]=0[&J[+S8DI)JN D)3L63JO;.TW-2IMS.;&S2LE(2.KF
M#.I1R?+6!QB>E9/VEP*6;1OJU?<[ W;:+JJ<46:P -4>042#RR"**Z>,2EGM
MWWU,[$CKI4I-G/,1>1Q3Y2?F-$:E3M>AY@*+8+0B>>\ V6GI#E8?!B>-&4Z4
M%N##J%!N!D]=Y<S_J.BU)D<XDKH34!FT$* @?#2!E+><?-7/3[=9M[S(NT%V
MXK;!5C@&U@D8B5YSQ120/H;@!; UL%C-):YCHM>JEU/!2PLV$Q7:$NXPM66
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ME'$HSLV MC75G!LV=FUF_YX ME?9 %,!; 4E2:0*]DS@Y9&9UU6.E+IAH?<
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M9NAG\7:>(K<PX?KVNO4Z>IMP0X(R:SR.@E@,WA0XM 904-A8ZRSKNND:H3H
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MB$BIT1+,-8$U!K!YV:HWUN0#:*45J66+SF"_G28I/?_^=M0;S\UXD/S"O,5
M9Z+C8$0$B8'3-E0>6Q'+)A66X(H<UNT(- )V+'1VB1<E8(,J[GW*<Y D64H%
M.LA6#\TH$\= :+KL4Y'OEK>]Z<4T=]D'>=([F(SOKRI::&>!!D&8!!FIE"5*
M #L)2ERI@^QVL]7B(_GI&?RSEMJ^'W3'P*>U8(,QL!X6%+ZC#*E4&S^N\M $
M(_>&3_YX9F[G5Y-I,OV[%L[@DDF6^A PA1RS)N R ="8C?KPL_Q+JUI433AL
M0W07V-O70/T_]KYLN7'D2O1YYBL0=>T;[0E*QKY4VX[ ZBG?MJNFJ]H3?IJ
MR*0(-PC06*32?/T])Q,  8*D2 F@2"K+[BJ)Q))Y\NRKJWB*[CN&I_N6"V1B
MKS,%-$D_P=I1EAP-<TWV?</R1$7#$<RN[HBBW]23RXJX9=W/+)@MXZ6+W0MD
M7;4MV7!!I14-#:PWVUBKMH'4F7LRZ&(_ET6.>0:@NA\)7E]T+=^T+!^4<< /
MP_2UIH.-K+P$O*VUO&K9>P%M.(%C2PJ.5P)&+YFR;#?E[M@G8:1E']9MIZM
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M"E'?D8#QR\ M5</Q+:FIFG7ZB13&%J[TTBVL^TA2SL9L+V!K;AC'Z'P G;+
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M(&L&U*-G&?X_>TF^M*6*NB@%E@3G KLP?$UN@DJNZ>T7G$<O;XS=[4](E:S
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M?T]C> S&:,?F[)V(E&\ZOJ8[KN;KIN8XLNHW96V6Y&]O@*Y98T.^"XQS@/U
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M0!H'.D.=NJEY@:X[IJ]8DNCXMNWKC<-:]WUE6^Q;T551,3?=U2_8EWPAIQ[
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MC3>Y5QON#E53?='T'-<37=W190]HW:Z)6S/<<SN]S8F"S\[Y54U/=DU5T?W
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M (8Z$7XN\QS_10Z8)H\$5,$%,O!/@.A8#8=843^.MB%)2[C GF?P:II1^TA
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M0-X-&<^:=J!+UGMX&RAI71,<)2NRZZ J0]]-#GL'AA4-*%7-FIN$%IJP VC
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M_(F7"'S8.DB+:1F'!<'S %3#]<VJ<^N@78T?]/CF*2MV[9'?<)A?+#)"&+B
M=@5X=['(!4(K=9OZ1>$$98MT#2,^'Y;?[[XXW.-O^VO?+PJ?$6EMZ8=),#0'
M9MW?(#^J^MCP12,P'%\W/5US)%_3+";[1-\V->?=R+X]Z47"7REG)+1TF.+B
M5UI53)L9?%I7%0\F"<]._E=UN/0E(^_]3+6 =C^'680"I! 6P-H%_&![D7G#
MHG$"=\4V/3*MN*9$N:9Y*]C766H^P?X/^RKSVY!:A#,0Z,LP0K8G+,.BL@*$
MF.2H=H2)(,F5 +H5>"> U[^5=P+@G0"NNBKZO&[G>[_0Q5_4WB\DO_WLG/]G
MEO+'.P%<'V;Q3@"\$P!G9*=!,-X)X-S0[5W7*?). !SI>"< CG7O .MX)P".
M=KP3P,54J_6#?LP1P#L!7&;.Z7ME?AQ_./YP_.'XP_'G=/#AG0!X)P!>E\([
M 9QW70HOB3LC]> LL(VSGI="A7<"X&R'LQW.=G@G ,Y_./_A_.>=\!_>"6#X
M3@"OD@<O6> 55*!=;9U8DO9JP>ZPBCI*A+ J;R_3,A?*)F.T*HE.\P@KNFF=
MW3+-R$:AV*0I&]\LW&,#F6GI7HJUW#=XXPUL?I5F6$6&=>-1QI;#JN/S=@CT
MF7K>JZGTM/.<5 6O/T7A712SFKRJ&A;@5PBM(MD4C^MG!!(MG,>V">^J*G3)
MP,+@E1$<99T+4Q "(2!R-44;.R4D>9&552DQG;E=PSANP1A .T?0/JQ!FS6@
MQ38!=1EDZZ)YA:CM-SS25U35DCDO^N-%?U== '5>M_.]7^CB+VKO%Y+*=G9V
M_GJY&J_-:FH J9%QC"5PV0F6YXN5/.%WT(1?CGH<]88I<2 /)!8DCG<<[]X
M[V2.=QSOW@#O#HY_7(C>=S:%-3-R5_#JFHN(X[Y7]L?QA^,/QQ^./QQ_3@<?
M7EW#JVMXKA?/]3KO7"^>9GI&ZL%98!MG/9SU<-;#60]G/1?$>GB%#><_G/]P
M_L/YS^7P'QYGVQ-G:U4K<(?D^;+M*Q-K''\X_G#\X?C#\><,X7.<OK2$)<?D
MW074W+2>)0T+>PKCXDE([^"5(2VS785/M-RN2 7_(8W+7 @0-"3C$3=N^[T4
M*JHY,2V-FWW<[71Y^L-98!MG/=SMQ/D/YS^<_W#^<QX8P?D/YS^<_YP__^&F
MU_"-[7@_)=Y/:1?=7&!OF?.ZG>_]0A=_47N_D,R*LU,O>3^EG?V4/#+=;*<D
MT79*Y@N4#XZ4+T%*WN.!MU/BJ'=^J,?;*7&\X^V4.-Z]+[SC[91XFO>YTO&9
MH=;9P8?C#\<?CC\<?SC^G"%\>-^D@V;8*/0/3_KFF0=[@#)>YH$F3F11'!TT
MUY)YP).>SDB;. MLXZR')UUR_L/Y#^<_G/^<!T9P_L/Y#^<_Y\]_N.G%IYEW
MZ?[M)R?78[F++$SR.<GH8.YJ,'*:=>8B+UNSIY\9D"S<D>(1YXC'&'+-A5E)
MORL69 \C'6Z#"1Q,-8A<( #9V7JJHG""L>JW[PJ!2$&R)6PDI^/>>T.QJRGR
MS_DX 6W@F."#*D@O1,FJ!!PL<T2<$/ TGP*O*^"B:9@O!!3TB)+%(IVQ<=PY
M0"B: Y^$%Y5)>I>3[($^FCX)<;I<KO"=N%! 8;BP?4_\)$P7(:QS<QM1,HW+
M&1%^B'XG%-$2EP,[R\A]&8=%F@&UK%99"M?2=-._D/*!A.6(V(5/R\O5#N$
M\O#''EJM'VJLBK8^8Z@,/>%Y6QG?<*N> /P @ "I?Y(IGB).75^#,R& '7#R
M24G:W +1 X>I"RN0,NEL(CPNHNE"8!@7%G!ME-#K_E6&&7Q:#5NO[QYQ/U)?
MC@_W\)LGD$@ H22"T\U#P+&*EN91E@/FILLER>A$>SK'BJ/=SE77^/%+$B'2
M?2T0:2@N(C7#%S5?$3+XAB+E#]$#^VJ-G146YK>"MT;-$5==+#+"%O/&DHRN
M8<3G;TW#'Y+I%"U)51:@R?PO@+!SYFM=94QNH=^*O[WD<]+&7?\$F/\\!L&
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MRV494[4G7 *[K(D6H9D D[Q+TU_KF<E/P#G_256H!LI,TZD]*%-Z[W##\#:
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MI448XWB,="Y\):N"+.]()BCB1, FW]R<YWZ0"P4<'RW+1\N>3@";RD0S!XO
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M'Z';'AH-8!=ZJT \OU&[2NJ@Z@'MP"/B9X=UX787N%T>1KK,MANW,AM#JZ8
M//DD)ADO6&"_06[8B:]>TA@=O.6[Q]Q\PYO-65HF\1DXIM]*A!Z$CA_""4;(
M)<W947I!^3D7K'XAE^5=DLJ\0'&DC+=?0/WUG0Y=R7]W%8@-D-QYH'E'L[M'
M:M@M549LZLK<2O8UYOM[FV!YZOPM?(!+HI:S2J> V$9C8-K=4WLB^4*K9%\"
MMIN%1\ENNC%P%II<%*#!$4Z1[Y/0\@*04#$V&N9'X@K#U7,K;>7T5F.461H
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M?"@WPX?Z]1Y3=XV#]]R;P3DL$*#L<]P%4@IE[C^66?7()C"T[%,."\6_(A!
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MYRK5 4UA.654*TG*"3*3*P1^(L22Z)$2Q6Z]!4XKQ8B'G&=0S'-8+T5<@3E
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MK2F$ZS-LLOA>F3M<=VS)!S-5)X,T0'>='%M.">"J<(MWA^^/J8,@?LZ7@NA
M'N>28M@OFTJ>#4^G"%$8J+;[:W'/&*R#>[D#/<&46TN)Y ''+ILQT5S05VO1
MNL.LJCJ3??>S$%M^^U[L^%C43X7IL#;JZ*^&)1VB]HCS;R5*Y8;SEHU$(H?S
M#HY=B:0Z<GJ,L94UTUD-^-*TD?G!J"\'SAP&Z@/%S2>E3H$_EET8#PX)3YT;
MBLK-]/3L>+MP]:8A;L3V:'X:V,@'CUM:!BMMGZN#>;QUYGI01$[!IZ<*URG'
M/S1<.%@5*STN1L[WNK61!9 VQ7YG94LM'K7F/&;SZ+7XDJ=]R"\(*1W J1^=
M!9R4L%"="N9P8AA'J$V!0UE761H0UP2PDH5$<NM&I)-AGL$FX22'V9>]4?4Q
M,]]3LHHR^5I."HET==YZ06#,4CK\D>4;[0L?V9CT8ASP_MFX*%'A\VI^8B8'
MZ/HKSITC_)SBC PUW _45MDEVF/?<I;\&& F'>7?1*#5/1@!.YE2#YK(2;K*
MDQV@(7;.I5XVN8.1R7"F@JT>F.?_U$/P <L>J756(?F.,^IBI<E/U=/71!:5
MQLDEL'6 !I2_KLRO95ZJO,@X].<T T[=H)AIZ;KU-@,J;\>W9?5P*ODT;T3,
M4T$#V]!/CXH(/M^HUBN//63U=*;:9V0JH5$F <_15B7G,5D5^T:2"*0Y8V$Z
M31:IK\6I4?XLJ^G<F(KI#,M,>QG9R:@?"!\>(B_!WD74 F/MX>;(I!JE@&WL
M^M8,^#.R"XIU78'F-?>.+>U+ZYOQFHF2LS(<5U-PE'C_EM-/2&R3@BT="4A)
MOF)\L5#YN2:/EQU)=S)XJDW2+4_BYKRR IO2_I8\_U.\EK.MM2>,Q) >+0!T
M+#B\FVE>N39[Z!7#[IKD$&=0*K]/T;&E'4&QP>.Q(29GF^N)CYF8PP+KM>QW
M8.>Q.@#M^WDZ>%I2A[I+0:E9BGHSNQ/SU!>?%DH1^,P6T"28RY2\7S)E\2O^
MLDMAZE6O<]F_NIAT1J-QY^RRU[NXUH6IUQ?=P9L7IC:4_"=%4],<,OE37<QO
M1NUSMH'KLR R7RTGKYCUOYVVF92S4VK4#H!=NA$8,;Q(-TU"]05YG?D;SH4:
MCT_;[>&X=S;@?__P\Q09872"FHZ[BL5/ZH\U9"G/M-+I.Z-<6L_NB5*\OK/A
M'W9-U<K=WWGE[?WW??TQ;7ZWQ#DFY$+"6Z'6WOPL"=_\BHFANTTRH,$ L-AH
M :KY3W?>'(A^9Y;H!:#_>QL2U;21L&W.D$EQO1_>'%8E\-F>J[Y0:-#'M68&
M.5-D!^A9[++8]3QVF;UTM@6>Y6<U8YS45)1*M_KN4$MO1^F3!XV1I<X6R^8L
MTM6,=*-:V=_4G?U^&V&U]8FT#6<S(1:+=T#1F@L+<L;N*@H7@AQ;V(1+>DW>
MD[HWGH-$?[)DUW"_:>#]/U6!\%FT? J4-4",,+H6D/5;_='6)/YBL#4&BYZ4
M(W#?-')FOG"C/_\0A('XX8\:"&^!5$<LCBU#LPRM&I"->^ME!9:=O8"=[8DY
M^Y9JV[;U/R^Q0[HUN%MVL"KJ(\CR^K07DN2A$%?SZ*AQ*L'A4X9.>NI6AC>'
M0A_6F;"#,\%]C$*?4U94&JQJ$5@'O54*YD808J_5'_1JUQH/A3;WB SW5Z@=
M'I%U6X/AT!*9M;YV0!QYMCWZCY]V]<V!.T6<8,:@KI$-]?ABJV$:]W=:[?9Z
MFX@CURV;1T7[*Z;VEC*L[65MKU>@SR>:V%LLDZU%$7PF_^#P%,5.:] >5*8H
MOA1\AT+->T2X^RL&#X\(NYW*],:#)[$]L=4:1UX[,.X>,&XL@_7%JQ+O&A.X
MW=WNK2X58%O 'D)*0 D@._U6;UA=RM-ST&P,REF3VC([R^R.C-GU6L/M,[@M
MKWM5U^ZR0G7S[ZQH_36EY^4E[%?+E1\^"G'#N>0W=VXDSC%-"2OV11!3HX")
M#P^@OSXMOJC.2O//5.M_@:T1=JEOO^Q==<<75^?7P_/+B^%Y?SRX;%-]>_?J
M^F(T.;/U[5E[BT6(O5T\[-A"]=]QNERZD8<S%>,$P"TSRF;&62F?D@/7Q7BG
MG@9*$[B<S[X;U%T=_V+H'6[Y_&ATVLV*Y]O#477U\YVS2@KH^^/WK2%O[W4%
MO-V\W?P>;-YZG%[IT!V^0]5G0VL\OU+3T7^$U.;M"MN\;=*0;<L%BY5OA96_
M8N_!VI#2\L^#J)K?WM_0',1N7A^'RKPV%ET/$ETK\Q]:!FHQTC)0BZ['AJZV
MA4Z%B4DWSW=J?D_NT(ADI[UI+=&DZ"E3:ZO?L45*;X8:1ZP)6LYC.4\^ZQT0
MR'(>RWDLY[&<YTTYSUFKW[?=#RSGL9S'<IZW;C[:'EG.4ZMWZ."<0"5)SE]$
M#""=W?%D1G$O_'"%;2%>XN@\Q(+WLB*8=F4^]$,AK^914N/D][%12:]K&U=:
M*K%4\C25#'J590A8*K%4<J!4TFFUNY9.JC!IK(>E457&C6^2W^3RXZ.8RU "
MX6YKT#U[?R@W!D>MQ]KR4\M/+3]]N7;9'U7FJ[#\U/)3RT\M/SUB?GK6&H^J
MFR-F^:GEIY:?6GYZO/QTT.IT+#]]<Z?JZQN45=Q8K+Q[V;7K1?]T_51,XE@D
M\20PVY_]0[AQ&HGYIP >G4814 4LP"NT1=NB8]EHV.]T)F>=P=5D>'E^==8;
M=\ZI8UFO>WG>G5S:CF5&QS(X$><>C\0)%]AV+!:.%\1)E&)B3>P\N+$#_\>-
MS>*Z&Y%M >QGX;9??<;&X].S=J\S[,M_.XWK,S;HO6O#I7?N<F;W;O=^X'O?
MDW33QIEDV7('MIV3JH*?Q*A'Z%Y-&6![[9:S2T<'BY4'T<FAH6B*AHA#EDA5
MMJI%/8MZ6Z'>+UBWX%3F([%X9_%N![RK+'9L\<[BW0YXMW7UWY[H?37'+O@C
MWO:3E\!K9E*[OG<]'UU6)XLP.HE=7SAS,847H,.4G*AUH._;H&?CR+MA&-<X
M^%C\L?AC\<?BC\6?!L*GSH*;]@$H6'3_M],;)XDH[/SX,AVJ<KQK1',+V^CD
MI5#I]5OCCNUT\F:X<<3BS[(>RWHLZ[&LQ[(>RWK>F?4P$HVZG6[]Y&?YC^4_
MEO]8_F/YCVTR65N<S:A*L [)YK+M Q-K%G\L_EC\L?AC\:>!\-E-7UK"DGUQ
M= &U"_@.5BC@"5'XZ/K)HQ-.X954,NJLW$<JMTM"Y^H^]-/8N4;0B,A&W*SM
M]U*H]$>MT7A@S3[K=MH__:$1V&99CW4[6?YC^8_E/Y;_- ,C+/^Q_,?RG^;S
M'VMZU=NNR_93LOV4]KRW3+-NMWO?T\7OU=[W)+.B<>JE[:>TL9_2I9@5VREU
MJ)W2UH.F+%+:'@^VG9)%O8-#/=M.R>*=;:=D\>ZX\,ZV4[)IWDVEXX:A5N/@
M8_''XH_%'XL_%G\:"!_;-VGGD4\VZ=MF'KQQYL&@W>JVV[6#YE R#VS24X.T
MB49@FV4]-NG2\A_+?RS_L?RG&1AA^8_E/Y;_-)__6-/K_68T5S ^><-<YC2!
M6__A!=XR77X10>+ZG]U'F@!\'4:?5B)RT<7S"[Q"[#Z/^>JJ?3;LGG=[E^?G
MW<N+T?C\ZO+ZNG\VONR.+\>79W8>LYGKMX99U;U@AS3"ZE[:<MP@2%W?61"2
M.4O&,G0,\HAI\@;BZ&DG5(CF^(AICGL;"2'G4'O)G0/D=S)S@YGPV:4HHF7L
MP#5N0@]P P?HTWD$4G5<>-/[SZVN#HKK:'&X-1R#\6FO.^B-ST;RW^IJ./J5
ME' ,WSF9WN:S;Z$%K*V@'B+M]CJ+;GM37JP7 V2((^V@,=D W78*5>4!NL-'
M4WK:+F.8-T(6 '2PYE\)S%YO#"+ #L42+ '0:&R-PEIYV)&RJNXN:*7WT]TD
M.5_*MG;(!GXKBNOT7L_%)6X=-6%9Y:! <;L4TVQ'<1LS]N6;*SV"!I)J'4&;
MEX+TJ&G=!G2VIM(>H-0\3-$7])K"&OE0<C.M5>H<A<Z_+53?&(AOIJ:TVMW*
M%)5G@=D8=-N?H-++8S_EP:2/\(C@UH,+=9CJKV$X?_!\?^?047LX[HP[W<ON
M\'QXU9Y,!IW!67_0&[:[5]?CP:!K0T?\M*]WPF&__52 L''B.T!TBJFP3U+,
M3UR@*/=6.+ZW$"TG!/+W M>',XB3EN/.9NDR]5VXT'&7(9#>OSE]VPWF3B 2
M9QJ&OSOW&'MTIH_.TOTMC!Q/'[3CXDD#0L/_>@L@6[SWO8(NAQL8Z;3;%;:S
MJB86TFN_,A@QVN?.0IW7[GZ?;^_N]>I?>WO7!N'VUMIYOT8"VVN=;]E4X'^4
MDC"12L(OH"0X'_X7]-/XQZJ@;;'1MKC8"AL_*=WT G13BWT6^]ZVXYYA"DT,
M4\@BHD7$-T7$7\&B/D>S>Z?&>H<6 JL#U'1;KA/0I5AX@9>($]^[![HO>C8J
MJU5O$* ;QQ4LX&IGIV\(Q'T 7&. 93'.8IS%.(MQC4B6S@/J$)H6L8KGQ4GD
M35,*:]$R]]>BJ]TBD:E@^PNA9M%A'?!I&GU55BZ]9[GP=/]@W&H/SZJ"P*'D
MJ5BV8-G"4;.%#YW6N%^Y%,U0?P_QP883+?.PS&,KG6+8ZO2L3E&%27M$#7KI
M_@MW1=&-?PL 3+A('MRHLLE,#?)2O9$9?("0:YPH>[Z.;,N0\$&5DM']O5:O
MO?6\E]>FO!U\V9@E4DND=5AZ@U%U<N*UT+,&HJ5D2\DO5?=:PYTJX*VXK=Q<
MR^%.[^Q0K+*/Q:RR%I;667]8<_UA!P:?K;G^WC+OLVZK-[1M<2QI6-)8LU"Z
MK4&W\GG%UM2P!'0D!#08MT:#H94M%2CX#3+-WZ?>Y&,P?[KBQ#I!;#)V8P%G
MD[$MQEF,VPO -098%N.. >-LP4EVOVIZM[]&YMODU_S7_@*H6<1795QO;ZWT
M;J?5;:_/LZHI?G<H5KPE+>O@JJ-+N:4/2Q\'0Q_5BI9#(0WK 'X><[Z&B>OC
M/,IPX=R(54)3.)U>FX9O5M<<O3E ;1QWLH"K!7"U3(S8=!J-Z>W_MM/#GQUY
M\(JA<GLS6(+N'_5:@U%E$=B7 [8QB&@+)2S3M$S3,LVWR_MZ/6!WRAC;*^RU
ME2N6M386.2UKK4$?[;3:9X/W!VQC$+%10\^,?=D)4\<\86J\UW.&[(2I?5W]
M:V]_V]?;"5-VPE1E&>]VPM1[1V'M:)4GL-%.F++8]W[89R=,641L!"+:"5,-
MJOBS,Z;>75FW@+/E,!;C&@(XBW$6XRS&-1]PMN3/Z/#V^0L!$/__\K_VN+#-
M5O[M&_.JM^2B ;1UW+,@SNQ\*<L6+%NP;,%6;%K>8'F#Y0U696A<M>K!F+%5
M=ZYID--ISPS;!D&N<>*KLEXW!SC#XDV;X!S\$ M+I6]!I0='A3589Y;4+*E9
M4JM=X!TZE>U)KO];M^:Y%#/9F:=#G7DJ0RC+G"Q\JM/ JZIK;DK5:+/*E]\)
M<O7)QN&PU1WUWPQ^C4$K&UVP#,TRM -D:'78U9:K6:YFN9KE:E9-.R2&5FO/
M&-WMQ=A\CL"+[6#Z(_BB8M21_BEU;O@T!_[[_S?\]R3@=MC\:_<^>MW61YMW
M[OP7_/_:I&WGP4ON'$_7X#E8@Q<[=^X]7!'0#XF(EEY #7A<V:/ ]Q;B]-U
M=M9^ Y#]UW\YN:1UQXN=521BC(W/T2VFE*UN^^>UBD6>7ZXNZ/P,<'22._AU
M-@N7P#$>86_ /7 [,3QMZOIN,!-.?"?@YJ<!J_[^TQ_3^.36=5<_W<SNQ#SU
MQ:=%=KH36L8DF*N,A:]X?E\!B.=^./O]+__Y'W]:O_T?;I("P_%$_&GQ2QC<
M?H6#OQ33)'\OKAM/XXM8_/F'ZTOLT_W?O?_]>OF#X\WA"W>6G'3[U]>CX>3R
MJMOI75P/+Z\ZO:O^H#=L]]I7[?;@^H>_%%!D9T5W1X[4W17%VF_"D";D7%T[
M[NI>H%NJ9RK=QM[JU;VU1;B^BKQ@YJW0A[P,TR"AO?HA:B: 5\X<$,M9:HQS
MYO '$(5P9W=X(3XA@ -Q%L"/X)\8!+GSB$U16L"7YO3[-76J^.P^+N'(D,2Z
M[6[?>;CSX!% K2YW$."*XA#_$4"_B2.^KY#L'%2AZ3G(S=0[$>>=7T(W@/LC
M)&=G$?J@9\<_5<7N;$LUV5)M-#KMC[OMLQ[_.ZBPOUJWDOYJ@[/W;7/5W>LF
M77;S^[)Y&_3<W GD.I,\.UB@MLO*-K#]K#0$ZX:KS UG,6\[JC8T1XM]%OO>
M%/LHL^8%GKHC%LZ<R]:N;ER#K>+:\RJN[EFK7=W(HT/QZS>/,31.1EFV<,AL
MP19^6]Y@>8/E#59EJ-7 :%"UT1M9'KV7F,''5V_4&[<ZO795-';P]49[1&>-
M$]9'3&6V@-:2FB4U*]":1V7676TD1?7H/ZU"[I+#O#7%[2-AE8!GW!J.=E&Q
MC\(T:Q[=[*]D.A ZZ;<ZW<H&ZUHZL71R"'1"]W=ZK7%UG4X.A33VW;O7.$+:
M(:VEJCK'QD\WWUV,O5TYY+.X? AUDB40'@Y:L,KW!W-CD-3ZEBQ#M0S5,M1&
M6%Z6GUI^:OFIY:='S$^'8\M0F]OOXZDV ]OU"2CO,0 8,IG-L!X<4/ES% ;P
MYTQ@&0YV*[BX<X-;$7\,S&NH2,P7\2X=",ZOKMN]T5GGHG=VV>U<=2_.!UWN
M0-#K74[: ]N!0):BW G'6ZX 9*H WIV'J\0+ _P\N;EP1OVN$V[?O4(VC/V[
M&Z1N].APN]BQ\P!?VUKZG4]LZUKZ\?ATU.X,1L,>_]NX6OI^_WTKJM^YE-]N
M_D@VOR?Y#XVS6FSE:/Y^^KA6.6K[L%L,?%\,G,Q_2^.$]'7G,A5.$I)J.%G7
M&BUJ6M1\4]0LV!PO,(WMX,/M7#>?5B)RT3AW?.'&PJ%UGX2+DS16'1#?D_H;
MD63[MDV!7^%#;)*;T!8WV(#)FTM7RW\L_\DE$K;:W:VU!\MY+.>QG,=R'LMY
M]B.U^?#L,[K_(HTB;(*]PI;7[(8)"T::[[E3SZ>P[7NRJ*9![J@[HMAN2=8M
MV2#UQ?*&!O&&<>?,\@3+$RQ/L#S!\H2*K9 C"A^5!HP:8HLTPD2V[I(&62^-
MP CKKCT2W:81V&;YSXO=M;W*\N\:@0F6[UB^8_F.Y3N'Q'=LD"B[_U(L1!2)
MN1.]\]2KI@'FJ'TZMIV<=?.^OTIB64*#6,*'ZGC".M[O(3+\:#F'Y1R6<]B$
MDL:TX*BBC49Y@XZ;.S<2YVXLYA?A<B6"V,6$LB\B3B)OEHCY30*W?@L\>-&#
M&\TGL\2[]Y+'?.^/+3IT=*XO1YWVZ/KZ_/JBW;EHC^$OZM#1O;J^Z@TFMD.'
M++ATXG2YQ+JV<.%\N?GFN!+B#ACM(J+JR\^^&SB+D#^LX6-U:PD ALX2+KN+
M'0%OGSLW8I7(BN3VAK*[ZE[?<KS8644BQJ+"N3,5*->>)#_;2F3W5B+#]FF[
M-SX;=0?RW^IZB0PK:24R&+VNHP,>_A[WLWCE[:\$GFV'\29:LEYN'>W:=Z_H
M;AQ\+/YLB3_/=0QX&_QYIXX _T-?B/D+5'3+K2RWLMS*<JM:N%6^I48Y[YH
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M/T9JSKP+N,B9NV),\ZJ,RC4X#&!KM&R-EJW1LC5:V]9H'0C;NW!C3K^F/Z[
M& '((+T?.OO3&Y_A'R+;.&=:Q91#/U,7W<'^T'G@P75S2FF(I:N'@AN1[L4+
M:)I*RPP8!N#B[,Z-904'5J/(+%!T2J,R3&P%Y#(F O##=681,E<V[D#GQG(
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M.BE3G(O<8C()FKSN!?&XCK"A# 0Z.%QW%1<]8#3AI_),\_Q+-SK!I(4?ISJ
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MK(]2+(%QJ%47/5Q$@6$+DZZ4RLO$Y"*F^IX%^.9%J89^D((>M-[(2MZ$MP0
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MC$U/5*J6T<9093W(8KXL$V:]6PAD(IE['_"GTOL2R&_>^R2=B)]8%4[@!QA
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M>$I@@PFFRK"X(8Y!(5.)M3(@J*)?:NB)_^ 5,)-MRN+'-H6@U"1+,GSUQKW
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MB4$0R>2;%^"XBXU" _U:40N%^%O<,$QEYF5I0&\Y#:[A^7 5?:K-^^I$_I"
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M+G"5] CIIW<>2(&'IL52Q#) D"!/?,=_"P]^)_'*69HL".0E.(<-A7!?V@9
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MAN5XX2M2DJ&*.G2$[R4S_Y@SV\)<7/_I0 JV ZHIPO*1/"N/9%3VCX8K_8#
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M=R7CMG[<5M<3N<=J_)*#=::P[&-]T$ZK,IC/Y,X?SW](&<^GXG> 0_I[9[%
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MXC7=RI[):;O*;G# 4D;<.=R<0S,+EFU<JWLK1&SW>&+?X?B28V3.8YZJR-C
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MV3M[BDX[),': W8 E!N$T_G?SVG:GI ZZ#0\D GXTTW %>#<9PO>SV)Z4;S
M0E'/K4"*"@(BCR7DF#4H&:FM#XHXL]<.T-HD^2L87:=3.Y0N# L\2>.06US-
ME7 ^G(?E\M0MC][AP1\<:W_P)GT 65?2= MB9WU\/?9D#?EQ#Q%3CG,,(E$*
MZ9&3E",LM49.^20U<<GHP29CZXL*#< :F';N3/(<2$?W[YWI.G3G_'L"2N1X
MH8\3.^[O10^9EK/?R<T.[5'Z.!E_S8W+;=D@QQX_5EB:B#$>UG08*O0P0U#@
M,#TE8\X+3K&L=W%Y]SUZ0/OB/JUU/D93CGUY;4<?QG4V=_>KL C,.$>@?4F9
MA"R1%!E#<XNQ9M$$R=W@<TCM/^R3 V&X=W*@W,+9BQ;>MVJ9M_K>U9'O"K_[
M\/T\;F92NR\H</+12 >:PD6/8E(*N1#PG8[%3-$&F[?],ZLK0DP&@G[+G'S<
MMNG>Q%M72R%I3-([BH0/&GD%9HE-.M[W+TC7SAG:5\^N%B'N:TFS,W!;PE/V
MJJ]0C#)MF$):6A@"0B62^;BR5UA20X2(;O"G20ZG.O>$\*":<PV-6JV_2!JF
M%LFW@+&<1,XZC4S 8CGML+<N\5>G-W=G0]MJ<T_LN]>:NY-N324%25+I9& 5
M'T- RE&'@E9W.0JY$($UL/4'JC.[8%9[  ]78VZ.;=JKOL+"'**2)R2PL\AR
MYY ,E*+HM72"<@.:9NB!Q ?4F/M!>%B-N9I&K=9?))FXISS?AD(]8@%6/21Y
M<B>UL<.V05;CH6K,G=G0NL;<#_L>-.;.I%M326%(4I9RBJS5%O$$ZR ;);_/
MZDL8:9#]:Z@:LP-FM0=PE_1I0)I".ND3C1Q,1Q=1"MPA&_+FTJ(G!+ZT@W5W
M==/) [L>#K8'.0P@6S-(#V%L#0G'08BI6IJY T.K$,%%2X)$Q,-BF#B;;R<G
M=P!3AW$:[/Y0OYT?KA]_8)+P)\"^-6?0P(3GSP!]TU5%1U$@]2(D3J#R9U<V
M##Q,XH@9)A4_DL>4"7)&Q;$XSC#S4RZ.J#*=Q5'\'/IO*SP_LX+L@1 MB8<N
MQF&H*\FM7>UVJ7F C<>^*=<YWGUKH_X2>3U[<=<!D!=Q$2+ZR5:S'U\J>*'U
MBX3U_;^Q<V3[3"/^\EW],>CENR_B=%:5?I;3JL-W?XS++0&GG;3B4<KD_-WY
M(K_Y$0S^#7QYT/;\_>XFNJ,IB-?K0]%Q\<FQG>;\CE?Y8/V3,_:CA8[I(SOW
MRY9U+84^9Z56_0!FE%_'92J]'<^.O)_,%RG*/TU&I2\/__X>IW"]]L1OCSZL
M)F/XU<<:"<A[:^%01FXK?Y=61/[A8 +^]4__'U!+ P04    " "J@&1/W$L8
M_75    6)P, %0   &5O;',M,C Q.3 Y,S!?9&5F+GAM;.U]6Y/;.)+N^_Z*
M/GV>>XS[96-G-W"==42URU'NGMGSQ* E5ID[*K&6DGS97W] 251=7)(HDJ H
M=T=TV[)$@,@O/P")1"+Q;__Q]7[VT^>L7.3%_*\_P[^ GW_*YI-BFL_O_OKS
M[Q]^41_,V[<__\>__\N__9]??ODO?7/UDRTFJ_MLOOS)E%FZS*8_?<F7GW[Z
MQS1;_/.GV[*X_^D?1?G/_'/ZRR^;0C^M/\SR^3__M?KC8[K(?OJZR/]U,?F4
MW:=7Q21=KM_]:;E\^-<W;[Y\^?*7KQ_+V5^*\NX- @"_V97:^T3UKU_JQWZI
MOOH%HE\P_,O7Q?3GGX*$\\7ZW0U>4C]>_3I=[@H\?9B^V?RX>_2[JK_@];-0
M2OEF_>ONT47^VH.A4OCFOWZ]^K"&Y)=\OEBF\TGV\[__RT\_;9 KBUEVD]W^
M5/W]^\W;9Y5DGXO9:O&727'_IOKYC9I,RE4V=5\?LODB6X1WKZOX5&:W?_TY
M*V:+@!"40&)0X?-_]SR^_/:0_?7G17[_, N@O.FE*39;IOGLU!:]*!6C8;^E
M'V<G(_6\4"_-,L7]?;ZL>M="S:>FF"]#/PS],3_>N 9%8S?Q*@L=R!2+94,]
MMZ@JM@COTK(,X]'GK+L(^ZJ*+<+U0U:]=WZWQO#7=+DJ\^6W[O(TJC>V<,TZ
M:N,*>FKN?%H-"%.=SJIA^\.G+%LV:..A4A$;]CXM S"?LF4^26?M6OEJ%?TV
M^<,RV!9K#5[?FG3QR<^*+\TQ/5@Z7D.W7:28;VAW_U!FG\)#80RX*A;M6M^L
MRG@B?5@6DW]^*F;38"*Z_UF%'M]*C/W5]-)TFRTF9?Y0X71]JU>+?)XM*L!T
MNLC#V]^7V2*T8XWCL>:WJ&IH$1J.Y>UK[$>@[3HAO-&% 7CY[>W\MBCOFRFA
M0=E>&NG3O/Q[.EMEOX9);55F]9SQX5-1+G_+RONW\\_98C.5'&MTF[H&%T(M
M%MGZQZL\_9C/\F4UL\]OLLFJ+,,DN>9&0WY%?NW@T.SLA.5-\2V=+;]=?YSE
M=Z?TN#AO&QR(4XW@/NH>7,AJK3U=S;(P-[WR:P3)3WKAX' T,ZS;U]B+0'\K
MBNF7?#8+;WP;9J[Y71Y>L1Y:3J7LZ35%%J!#BP=KHE^%-5^F[H.N\_]=CU1;
M5TAGT!M7'5O$QTYJL]M\GB^S]4/3[3^N B^^*]-=^A[>&AN89N-#XPIZ:>[U
MUV 43JMAYZI(YT<;M^?Q&$W9>D<J(R>H]&-3A]AIM<1H^*GC:,/B,9K:C)$'
M"_72K)ML5FV#O$_+Y;??RO".=+)>KQ]KV;%R41O74+T-B_?2U-,]#9&="M]7
M?VKO:%Y#I ;?!&.LS"?+RAD3?OL]S":MFWZ\KDA"/#&<J]^NUQX-%8CXN;E?
MNUNMT06K;.JUU1/FRM7]PRE=M&.UL42KO@FK^FSMLPR&W%.;3LUFVUW?]C*V
MJC^2L,UFHF/E^FG<ZOX^+;\%4N=W\_PVGZ3SI9I,BM7:V?"^F.5-]A)/JV7
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MX09H[QSU.TU:WCX /1JA>UY0C [CB^3V3;[XIR^SRBF2E=EB.22S7WMW(@E
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M"+P9+K^]7L&Q -YX;TV $$)3Z!U#%%E((%6@5@Y@I/UIV$ANH'Z8]G)2&PW
M@QE:KS:X49CEL:()#@JPAAA)H.6:>%H=MME*[*RBX_8%C8(+C?C9&?(_ ME&
MZ53Z(3GV(T3N<DZ4@&$IS*@+T D)H*AE)$B.,.];?VIK'(5[&D@#NI>695Y%
M.JQ;_'M0P>+FP^]-'$O[RR7KY6I8(VA%+6 ,5R>2:UD1).U/2T5S*44C1)]
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MHEQ5H3ZKAP#K?'J3?4PK8J<?UR?8S:HLUWOP>^,D&I1.O%$(4P48<;:RC%Q
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MRTP*EGV6&U%88=QV$GB4J%:!G]$H#8,D"Z(@Q![)0K?'AF 2KYY=M&E-AN2
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MNJEG0)6:S8)RX#+XF&+V4R-2PAFQOS_JZB9;UU_HKOQVO%0Z] ,81@F((Y:
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MG&T'U>'7$7&P;SA:ISC"E5 VL]P+9(_9:)><F3V!Z5S=.#U0YVKO?#R2?KD
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M/)/NI@O+O%EQ0C_+J1N\Y/MPQ==BF^^W]0HDB0?CN'FD(O-2/XF]?H1  4W
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M<\MS<24 7CA?!,3FEH\&I/,+3^:;<KO-]F=_J'@'[&C2Y2JT*?E6*[0Z9*(
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MW#%IU)>55*9U_85L,P/_ZF,!?*R*G;CH9?V/8U$5]5H0OC_[KL:S@@GC.2_
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MF3[M:D5N_HS[%_X1A^K][D.=858H A!&P"7$(V&"8!*V#QAQ^!"P4.UJC,7
MMKZGML;#M76!V54UPG,G5XNA76IN;5P66Z\;IW^6U/HPE+-D5LW6]+,G5EU:
M)LNKH^(V?UK]:UT3]/!)A(F/H(\8#!CUW#0.^JH $0853K(N#KN4 (\^W=J
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M0N@%+!.[4M#H_6!1O"MFPP-'2$=.%;C B -J$/(22A&_6>6WJMPZW&FL_T>
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M3&_&T4Q?,R$"W7T;3I:C2,9O93GZ.IY,]MK$AX<'$[=@;Y0%D5+I4C$/MPW
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MN$X,:>A2S)[)HHD!@*92&\ ]PT(0S:KH4O3WU84ULNWR4DQS7.^LC,7@?A.
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M5P_FXV'*'QA/EHMB7_[J@9%!04FUC3X7-]%.XH#2K>&4ZE_D''?U\1I8TR9
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MTG*FA 'QI^AF5O1')4HQ20/LP]G>AD(K[+X\JV UO_WSX^OBH<T:K)XF^;3
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M.H-&TK)\2.HT8/'VML[L;A?L=J4Y\=F@-;*(&A0#.@6YU%"*RBQ!KVG*YO2
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M#$8L_<*_5N> 4T,#C@*PAAA)HJG0Y8(,*XJ=3;I=;4! '!1V:N'Y8A%=9W\
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M_;!)Q-Q,+LYR,]W=+ _AY\+7!4]C2$*])C#&K(0)+IYW+@2%*<61 [KFNAU
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MVR&NSJ]K<JN_.@FSVN\($%C#M8* $R@L%M"9BL,:XWHW'C15=7&54&N+U0.
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M@F!?G;JCHH3LS601UX;6P?O=>Y!'#3NS_8OB/\7%]O_[7_\/4$L! A0#%
M  @ JH!D3_J/953Z8 $ ;M 0 !$              ( !     &5O;',M,C Q
M.3 Y,S N>&UL4$L! A0#%     @ JH!D3ZLLGS^*$   V[,  !$
M     ( !*6$! &5O;',M,C Q.3 Y,S N>'-D4$L! A0#%     @ JH!D3YOO
MZ)4F(@  &G,! !4              ( !XG$! &5O;',M,C Q.3 Y,S!?8V%L
M+GAM;%!+ 0(4 Q0    ( *J 9$_<2QC]=4   !8G P 5              "
M 3N4 0!E;VQS+3(P,3DP.3,P7V1E9BYX;6Q02P$"% ,4    " "J@&1/+N0$
MV$:^  "*40H %0              @ 'CU $ 96]L<RTR,#$Y,#DS,%]L86(N
M>&UL4$L! A0#%     @ JH!D3Z0*U1Y?<@  Y<<% !4              ( !
M7)," &5O;',M,C Q.3 Y,S!?<')E+GAM;%!+!08     !@ & (H!  #N!0,
"   !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6790957504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock', window );">Schedule of New Accounting Pronouncements and Changes in Accounting Principles</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The impact of the adoption of ASC 842 on the accompanying condensed balance sheet as of January 1, 2019 was as follows:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.8015873015873%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:44%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">December 31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Adjustments Due to the Adoption of ASC 842</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">January 1, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Operating lease right-of-use assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,029</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,029</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Current portion of operating lease liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">916</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">916</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Operating lease liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">138</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">138</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Deferred rent</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">25</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(25</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=116846552&amp;loc=d3e765-108305<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.10-01.(b)(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=27015980&amp;loc=d3e46468-122699<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=116846552&amp;loc=d3e725-108305<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6601249536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements and Short-Term Investments<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements and Short-Term Investments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Fair Value Measurements and Short-Term Investments</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;">Short-Term Investments</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company did not have any short-term investments for the year ended December 31, 2018. As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">September&#160;30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, all of the Company&#8217;s investments had remaining maturities less than 12 months. The following is a summary of the Company&#8217;s short-term investments, considered available-for-sale, as of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">September&#160;30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.60317460317461%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Amortized</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Gross Unrealized</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Estimated</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;">Available-for-sale securities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">U.S treasury securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">34,894</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">19</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">34,913</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Times New Roman;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">September&#160;30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, no investments had been in a continuous unrealized loss position for more than 12 months, and the Company did not record any other-than-temporary impairments on these securities. </font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;">Assets and Liabilities Measured at Fair Value on a Recurring Basis</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company measures and reports certain financial instruments as assets and liabilities at fair value on a recurring basis. The fair value of these instruments was as follows:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.60317460317461%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">As of September&#160;30, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Level 3</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;">Available-for-sale debt securities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">U.S treasury securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">34,913</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">34,913</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;">Liabilities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Contingent royalty obligation payable to Evolus Founders</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">48,895</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">48,895</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.60317460317461%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">As of December&#160;31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Level 3</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;">Liabilities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Contingent royalty obligation payable to Evolus Founders</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">50,200</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">50,200</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Times New Roman;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company did not transfer any assets or liabilities measured at fair value on a recurring basis between levels during the&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">nine months ended September 30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company determines the fair value of the contingent royalty obligation payable based on Level 3 inputs using a discounted cash flows method. The significant unobservable input assumptions that can significantly change the fair value include (i) timing of regulatory approvals of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, (ii) projected and timing of net revenues during the payment period, which terminates in the quarter following the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">10</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">-year anniversary of the first commercial sale of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> in the United States, (iii) the discount rate and (iv) the timing of payments. During the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">three and nine months ended September 30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the Company utilized discount rates between </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">16.0%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">25.0%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, reflecting changes in the Company&#8217;s risk profile. Net revenue projections are also updated to reflect changes in the timing of regulatory approval and expected sales. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The following table shows a reconciliation of the beginning and ending fair value measurements of the contingent royalty obligation payable:</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:center;padding-left:48px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:92.85714285714286%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Three Months Ended<br clear="none"/>September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Nine Months Ended<br clear="none"/>September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Fair value, beginning of period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">47,169</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">48,800</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">50,200</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">39,700</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Payments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(69</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(9,282</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Change in fair value recorded in operating expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,795</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2,300</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">7,977</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">11,400</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Fair value, end of period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">48,895</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">51,100</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">48,895</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">51,100</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Times New Roman;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;">Other Financial Assets and Liabilities</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company&#8217;s financial instruments consist primarily of cash and cash equivalents, short-term available-for-sale debt securities, accounts receivable, accounts payable, accrued expenses, lease liabilities, and long-term debt. The carrying amount of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses approximates their fair value because of the short-term maturity of such instruments. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company estimates the fair value of contingent promissory note payable to the Evolus Founders, long-term debt and operating lease liabilities using the discounted cash flow analysis based on the interest rates for similar rated debt securities (Level 2). As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">September&#160;30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the fair value of contingent promissory note and long-term debt was estimated to be </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$16,072</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$74,947</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, respectively. The fair value of operating lease liabilities&#160;at </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">September&#160;30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> approximated their carrying value. As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the fair value of contingent promissory note was </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$17,181</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6801631216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_LesseeOperatingLeaseTerminationPeriod', window );">Termination period</a></td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_LesseeOperatingLeasePeriodOfWrittenNoticePriorToLeaseTerminateDate', window );">Period of written notice</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_LesseeOperatingLeaseTerminationFeePeriodOfRentEquivalent', window );">Period of termination fee prior to lease termination date</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Renewal term</a></td>
<td class="text">60 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_OperatingLeasePercentageOfAnnualRentEscalation', window );">Percentage of annual rent escalation</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseImpairmentLoss', window );">Operating lease, impairment loss</a></td>
<td class="nump">$ 80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseObligation', window );">Purchase obligation</a></td>
<td class="nump">6,651,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_MilestonePaymentCurrent', window );">EU milestone payment to Daewoong</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Loss contingency accrual</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=eols_DaewoongMember', window );">Daewoong</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_MilestonePaymentInConnectionWithLicenseAndSupplyAgreement', window );">Milestone payment in connection with license and supply agreement</a></td>
<td class="nump">$ 11,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_LesseeOperatingLeasePeriodOfWrittenNoticePriorToLeaseTerminateDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Period Of Written Notice Prior To Lease Terminate Date</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_LesseeOperatingLeasePeriodOfWrittenNoticePriorToLeaseTerminateDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_LesseeOperatingLeaseTerminationFeePeriodOfRentEquivalent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Termination Fee, Period Of Rent Equivalent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_LesseeOperatingLeaseTerminationFeePeriodOfRentEquivalent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_LesseeOperatingLeaseTerminationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Termination Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_LesseeOperatingLeaseTerminationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_MilestonePaymentCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone Payment, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_MilestonePaymentCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_MilestonePaymentInConnectionWithLicenseAndSupplyAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone Payment In Connection With License And Supply Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_MilestonePaymentInConnectionWithLicenseAndSupplyAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_OperatingLeasePercentageOfAnnualRentEscalation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Percentage Of Annual Rent Escalation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_OperatingLeasePercentageOfAnnualRentEscalation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from impairment of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 25<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888369&amp;loc=SL77918431-209957<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=eols_DaewoongMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=eols_DaewoongMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6790935552">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Future Amortization Expense (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">Remaining in 2019</a></td>
<td class="nump">$ 1,168<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2020</a></td>
<td class="nump">4,674<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2021</a></td>
<td class="nump">3,528<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2022</a></td>
<td class="nump">2,955<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2023</a></td>
<td class="nump">2,955<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">Thereafter</a></td>
<td class="nump">44,577<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Book Value</a></td>
<td class="nump">$ 59,857<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the remainder of the fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6659495776">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements and Short-Term Investments - Schedule of Short-term Investments (Details) - U.S treasury securities<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 34,894<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTaxAbstract', window );"><strong>Gross Unrealized</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gains</a></td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Losses</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">$ 34,913<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26610-111562<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6798224816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Nov. 01, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_DocumentAndEntityInformationAbstract', window );"><strong>Document And Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">EVOLUS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001570562<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,425,230<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Smaller Reporting Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Transition Period</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Document and Entity Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6804732432">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Statements of Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th">
<div>Preferred Stock </div>
<div>Series A Preferred Stock</div>
</th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid In Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive (Loss) Gain</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>IPO</div></th>
<th class="th">
<div>IPO </div>
<div>Common Stock</div>
</th>
<th class="th">
<div>IPO </div>
<div>Additional Paid In Capital</div>
</th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250,000<span></span>
</td>
<td class="nump">16,527,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2017</a></td>
<td class="num">$ (75,543)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (75,543)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_DeemedContributionFromParentIncreaseOfRelatedPartyReceivable', window );">Deemed contribution from Parent, increase of related-party receivable</a></td>
<td class="nump">1,051<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,051<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Dividends', window );">Deemed distribution to Parent, increase of convertible note obligation</a></td>
<td class="num">(2,002)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,387)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(615)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt', window );">Capital contribution from Parent, convertible note write-off</a></td>
<td class="nump">66,998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_CapitalContributionFromParentForgivenessOfRelatedPartyBorrowings', window );">Capital contribution from Parent, forgiveness of related party borrowings</a></td>
<td class="nump">13,188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Preferred stock conversion upon initial public offering (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,250,000)<span></span>
</td>
<td class="num">(2,065,875)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock upon initial public offering, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,047,514<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock upon initial public offering, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 53,446<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 53,445<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">1,006<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,006<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(6,162)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,162)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Mar. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">23,640,389<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2018</a></td>
<td class="nump">51,982<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">134,301<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(82,320)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250,000<span></span>
</td>
<td class="nump">16,527,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2017</a></td>
<td class="num">(75,543)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(75,543)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(34,425)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Other comprehensive loss</a></td>
<td class="num">(34,425)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Sep. 30, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">27,274,991<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2018</a></td>
<td class="nump">94,966<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">205,548<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(110,583)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Mar. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">23,640,389<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2018</a></td>
<td class="nump">51,982<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">134,301<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(82,320)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan', window );">Issuance of common stock in connection with the incentive equity plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,602<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan', window );">Issuance of common stock in connection with the incentive equity plan</a></td>
<td class="num">(238)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(238)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">2,623<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,623<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(16,433)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16,433)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Jun. 30, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">23,674,991<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2018</a></td>
<td class="nump">37,934<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">136,686<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(98,753)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock upon initial public offering, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock upon initial public offering, net of issuance costs</a></td>
<td class="nump">67,380<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67,380<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">1,482<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,482<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(11,830)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,830)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Other comprehensive loss</a></td>
<td class="num">(11,830)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Sep. 30, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">27,274,991<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2018</a></td>
<td class="nump">$ 94,966<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">205,548<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(110,583)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares, outstanding (in shares)</a></td>
<td class="nump">27,274,991<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">27,274,991<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2018</a></td>
<td class="nump">$ 84,384<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">207,408<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(123,025)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan', window );">Issuance of common stock in connection with the incentive equity plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,372<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan', window );">Issuance of common stock in connection with the incentive equity plan</a></td>
<td class="num">(58)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(58)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">2,015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(10,975)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,975)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Other comprehensive loss</a></td>
<td class="num">(9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Mar. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">27,285,363<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2019</a></td>
<td class="nump">75,357<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">209,365<span></span>
</td>
<td class="num">(9)<span></span>
</td>
<td class="num">(134,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">27,274,991<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2018</a></td>
<td class="nump">84,384<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">207,408<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(123,025)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(75,526)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Other comprehensive loss</a></td>
<td class="num">(75,507)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Sep. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2019</a></td>
<td class="nump">17,043<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">215,574<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="num">(198,551)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Mar. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">27,285,363<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2019</a></td>
<td class="nump">75,357<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">209,365<span></span>
</td>
<td class="num">(9)<span></span>
</td>
<td class="num">(134,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan', window );">Issuance of common stock in connection with the incentive equity plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107,641<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan', window );">Issuance of common stock in connection with the incentive equity plan</a></td>
<td class="nump">853<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">853<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">2,486<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,486<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(37,567)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(37,567)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="nump">52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Jun. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">27,393,004<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2019</a></td>
<td class="nump">41,181<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">212,704<span></span>
</td>
<td class="nump">43<span></span>
</td>
<td class="num">(171,567)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan', window );">Issuance of common stock in connection with the incentive equity plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,226<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan', window );">Issuance of common stock in connection with the incentive equity plan</a></td>
<td class="nump">314<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">314<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">2,556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(26,984)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(26,984)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Other comprehensive loss</a></td>
<td class="num">(27,008)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="num">(24)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(24)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Sep. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2019</a></td>
<td class="nump">$ 17,043<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 215,574<span></span>
</td>
<td class="nump">$ 19<span></span>
</td>
<td class="num">$ (198,551)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares, outstanding (in shares)</a></td>
<td class="nump">27,425,230<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_CapitalContributionFromParentForgivenessOfRelatedPartyBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Capital Contribution From Parent, Forgiveness Of Related-Party Borrowings</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_CapitalContributionFromParentForgivenessOfRelatedPartyBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_DeemedContributionFromParentIncreaseOfRelatedPartyReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deemed Contribution From Parent, Increase Of Related-Party Receivable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_DeemedContributionFromParentIncreaseOfRelatedPartyReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Issuance Of Common Stock In Connection With Incentive Equity Plan</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, Issuance Of Common Stock In Connection With Incentive Equity Plan</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustment to additional paid in capital resulting from the recognition of convertible debt instruments as two separate components - a debt component and an equity component. This bifurcation may result in a basis difference associated with the liability component that represents a temporary difference for purposes of applying accounting for income taxes. The initial recognition of deferred taxes for the tax effect of that temporary difference is as an adjustment to additional paid in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=51819886&amp;loc=SL6014347-161799<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118258462&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=118258462&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116855982&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e557-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Dividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Dividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities. Excludes amounts related to other than temporary impairment (OTTI) loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6783732160">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Operating Lease Maturity (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Lessee, Operating Lease, Liability, Payment, Due [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">Remainder of 2019</a></td>
<td class="nump">$ 239<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2020</a></td>
<td class="nump">1,201<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2021</a></td>
<td class="nump">1,205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2022</a></td>
<td class="nump">1,258<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2023</a></td>
<td class="nump">1,312<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">1,484<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total operating lease payments</a></td>
<td class="nump">6,699<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(1,484)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of operating lease liabilities</a></td>
<td class="nump">$ 5,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract', window );"><strong>Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear', window );">2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 890<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">139<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,029<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease having an initial or remaining lease term in excess of one year due in remainder of fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the remainder of the fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6632680752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Related Party Transactions</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"> </font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Services with ALPHAEON</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Prior to the Company&#8217;s initial public offering (&#8220;IPO&#8221;) in February 2018, the Company had funded its operations primarily through contributions and related party borrowings from ALPHAEON Corporation (&#8220;ALPHAEON&#8221;). For the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">three and nine months ended September 30, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$0</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$383</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, respectively, were included in Evolus&#8217; selling, general and administrative expenses that were generated by transactions with ALPHAEON. After completion of the Company&#8217;s IPO on February 12, 2018, ALPHAEON did not incur any administrative or research and development expenses on the Company&#8217;s behalf. As of December 31, 2018 and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">September&#160;30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, there were no related party accounts receivable, payable, or debt with ALPHAEON, respectively. </font><font style="font-family:Times New Roman;font-size:10pt;font-style:normal;font-weight:normal;">  </font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Evolus Founders</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Certain of the Evolus Founders from whom SCH-AEON, LLC (&#8220;SCH&#8221;) purchased its equity interests include individuals who were previously employed by the Company in operational roles, including the Company&#8217;s former Chief Operating Officer. </font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Payment Obligations Related to the Acquisition by ALPHAEON</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company was acquired by SCH in 2013 and subsequently by its subsidiary, ALPHAEON Corporation, by means of a stock purchase agreement (&#8220;Stock Purchase Agreement&#8221;) pursuant to which ALPHAEON assumed certain payment obligations related to the acquisition. On December 14, 2017, the Stock Purchase Agreement was amended (&#8220;Amended Stock Purchase Agreement&#8221;), and, as a result, effective upon the closing of the Company&#8217;s IPO, the Company assumed all of ALPHAEON&#8217;s payment obligations under the Amended Stock Purchase Agreement. Refer to the notes to the financial statements in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2018 for details of the acquisition of the Company.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Under the Amended Stock Purchase Agreement, the payment obligations consisted of (i) a </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$9,200</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> up-front payment upon obtaining FDA approval for Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> for the treatment of glabellar lines which was paid in full during the first quarter of 2019, (ii) quarterly royalty payments of a low single digit percentage of net sales of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, and (iii) a </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$20,000</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> promissory note that matures in November 2021. The payment obligations set forth in (ii) above terminates in the quarter following the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">10</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">-year anniversary of the first commercial sale of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> in the United States. Under the Amended Stock Purchase Agreement, the Company recorded the fair value of all revised payment obligations and the promissory note owed to the Evolus Founders of </font><font style="font-family:Times New Roman;font-size:10pt;">$55,742</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> (comprised of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$39,700</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> related to the contingent royalty obligation payable and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$16,042</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> related to the contingent promissory note) as of February 12, 2018. See </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Note 7</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Fair</font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;"> Value Measurements</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;"> </font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;">and Short-Term Investments</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;"> for more information about the Company&#8217;s accounting thereof. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In addition, the outstanding related party borrowings from ALPHAEON as of February 12, 2018 were offset and reduced, on a dollar-for-dollar basis, taking into account the then-fair value of all payment obligations the Company assumed from ALPHAEON, the fair value of which, as of February 12, 2018, was </font><font style="font-family:Times New Roman;font-size:10pt;">$55,742</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.  </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Under the Amended Stock Purchase Agreement, Evolus paid one-time bonuses of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$1,575</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> to certain current and former employees upon FDA approval of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> in February 2019, including a one-time bonus of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$700</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> paid to the Company&#8217;s Chief Medical Officer and Head of Research &amp; Development. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The payment is included in research and development expenses in the accompanying condensed statements of operations and comprehensive loss for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">three and nine months ended September 30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company has the right to prepay the promissory note, in whole or in part, at any time and from time to time without penalty. Upon an event of default under the promissory note, all unpaid principal becomes immediately due and payable at the option of the holder. An event of default occurs under the terms of the promissory note upon any of the following events: (i) Evolus fails to meet the obligations to make the required payments thereunder, (ii) Evolus makes an assignment for the benefit of creditors, (iii) Evolus commences any bankruptcy proceeding, or (iv) Evolus materially breaches the Amended Stock Purchase Agreement or Tax Indemnity Agreement (which is defined below) and such breach is not cured within </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">30</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> days. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In addition, upon a change-of-control of Evolus, all unpaid principal becomes immediately due and payable. Under the terms of the promissory note, a change-of-control is defined as (i) the sale of all or substantially all of Evolus&#8217; assets, (ii) the exclusive license of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> or the business related to Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> to a third-party (other than a sublicense under the Daewoong Agreement), or (iii) any merger, consolidation, or acquisition of Evolus, except a merger, consolidation, or acquisition of Evolus in which the holders of capital stock of Evolus immediately prior to such merger, consolidation, or acquisition hold at least </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">50%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> of the voting power of the capital stock of Evolus or the surviving entity. Notwithstanding the foregoing, the promissory note expressly provides that neither the IPO or any merger with or acquisition by ALPHAEON or any of its subsidiaries or affiliates constitutes a change-of-control. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In connection with the Amended Stock Purchase Agreement, the Company entered into a tax indemnity agreement with the Evolus Founders (&#8220;Tax Indemnity Agreement&#8221;). Pursuant to the Tax Indemnity Agreement, the Company is obligated to indemnify the Evolus Founders for any tax liability resulting from the Company&#8217;s assumption of the revised payment obligations under the Amended Stock Purchase Agreement from ALPHAEON. Such assumption of the revised payment obligations occurred upon the completion of the IPO. Under the Amended Stock Purchase Agreement, the payment obligations are contingent and thus eligible for installment sale reporting under Section 453 of the Internal Revenue Code of 1986, as amended. Under the Tax Indemnity Agreement, the Company was obligated to indemnify the Evolus Founders for any taxes or penalties required to be paid by the Evolus Founders in the event the U.S. Internal Revenue Service or other taxing authority were to determine that Company&#8217;s assumption of the revised payment obligations under the Amended Stock Purchase Agreement rendered continued installment sale reporting unavailable to the Evolus Founders. Any taxes or penalties paid by us on behalf of the Evolus Founders under the Tax Indemnity Agreement will be offset dollar-for-dollar against the promissory note and future royalties that will be payable to the Evolus Founders under the Amended Stock Purchase Agreement. </font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Exclusive Distribution and Supply Agreement with Clarion Medical Technologies Inc.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On November 30, 2017, the Company entered into an exclusive distribution and supply agreement (the &#8220;Distribution Agreement&#8221;), with Clarion Medical Technologies Inc. (&#8220;Clarion&#8221;). The Distribution Agreement provides terms pursuant to which the Company will exclusively supply </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> to Clarion in Canada.&#160; Clarion was previously a wholly-owned subsidiary of ALPHAEON. However, pursuant to previous agreements among ALPHAEON, Clarion, and previous equity holders of Clarion, the previous equity holders of Clarion had the option, and exercised such option, to unwind ALPHAEON&#8217;s acquisition of Clarion. As a result, ALPHAEON owes the equity holders of Clarion an unwinding fee of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$9,550</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> (the &#8220;Unwinding Fee&#8221;). The Distribution Agreement sets forth that a portion of the proceeds received by the Company from each unit of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> purchased by Clarion shall be paid directly to the previous equity holders of Clarion, and will reduce, on a dollar-for-dollar basis, the amount of the Unwinding Fee ALPHAEON owes. In addition, ALPHAEON and SCH have agreed with Clarion to pay the unpaid amount of the Unwinding Fee on December 31, 2022, if demanded by the previous equity holders of Clarion. There were no sales of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174; </sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">in Canada under the Distribution Agreement in any of the periods presented in these financial statements.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6801120656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity - Restricted Stock Unit (Details) - Restricted stock units<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2019 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Restricted Stock Unit</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning balance (in shares) | shares</a></td>
<td class="nump">271,404<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">3,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares) | shares</a></td>
<td class="num">(22,125)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares) | shares</a></td>
<td class="num">(19,409)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending balance (in shares) | shares</a></td>
<td class="nump">232,870<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 16.53<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">18.33<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share) | $ / shares</a></td>
<td class="nump">25.69<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">13.71<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 15.92<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6805341760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Feb. 28, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($) </div>
<div>unit </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportingUnits', window );">Number of reporting units | unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment of goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_AccruedCouponAndRebateLiabilityCurrent', window );">Accrued volume-based rebate and coupon liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,932,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,932,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_ProvisionsForAccruedVolumeBasedRebateAndCouponLiability', window );">Provisions for accrued volume-based rebate and coupon liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,740,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,671,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_PaymentsForProvisionsForAccruedVolumeBasedRebateAndCouponLiability', window );">Payments for Provisions for accrued volume-based rebate and coupon liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,739,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,739,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(149,000)<span></span>
</td>
<td class="nump">$ 19,000<span></span>
</td>
<td class="num">(14,899,000)<span></span>
</td>
<td class="nump">$ 41,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Valuation allowance recorded against gross deferred tax asset</a></td>
<td class="num">$ (14,402,000)<span></span>
</td>
<td class="num">$ (149,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (497,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DistributionRightsMember', window );">Distribution right</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_SoftwareDevelopmentMember', window );">Internal-use software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Common stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Securities excluded from the computation of diluted net loss per share (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,052,161.000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,052,161<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Securities excluded from the computation of diluted net loss per share (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">182,758<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">182,758<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_AccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>[Line Items] for Accounting Policies [Table]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_AccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_AccruedCouponAndRebateLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Coupon And Rebate Liability, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_AccruedCouponAndRebateLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_PaymentsForProvisionsForAccruedVolumeBasedRebateAndCouponLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments For Provisions For Accrued Volume-Based Rebate And Coupon Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_PaymentsForProvisionsForAccruedVolumeBasedRebateAndCouponLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_ProvisionsForAccruedVolumeBasedRebateAndCouponLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Provisions For Accrued Volume-Based Rebate And Coupon Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_ProvisionsForAccruedVolumeBasedRebateAndCouponLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportingUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportingUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e32123-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DistributionRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DistributionRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_SoftwareDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_SoftwareDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6659382288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements and Short-Term Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Debt Securities, Available-for-sale</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The following is a summary of the Company&#8217;s short-term investments, considered available-for-sale, as of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">September&#160;30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.60317460317461%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Amortized</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Gross Unrealized</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Estimated</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;">Available-for-sale securities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">U.S treasury securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">34,894</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">19</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">34,913</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The fair value of these instruments was as follows:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.60317460317461%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">As of September&#160;30, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Level 3</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;">Available-for-sale debt securities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">U.S treasury securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">34,913</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">34,913</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;">Liabilities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Contingent royalty obligation payable to Evolus Founders</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">48,895</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">48,895</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.60317460317461%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">As of December&#160;31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Level 3</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;">Liabilities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Contingent royalty obligation payable to Evolus Founders</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">50,200</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">50,200</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of Financial Instruments Recorded at Fair Value on a Recurring Basis</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The following table shows a reconciliation of the beginning and ending fair value measurements of the contingent royalty obligation payable:</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:center;padding-left:48px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:92.85714285714286%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Three Months Ended<br clear="none"/>September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Nine Months Ended<br clear="none"/>September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Fair value, beginning of period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">47,169</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">48,800</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">50,200</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">39,700</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Payments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(69</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(9,282</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Change in fair value recorded in operating expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,795</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2,300</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">7,977</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">11,400</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Fair value, end of period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">48,895</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">51,100</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">48,895</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">51,100</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6801608016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Schedule of Definite and Indefinite-Lived Intangible Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Definite-lived intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Original Cost</a></td>
<td class="nump">$ 62,379<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(2,522)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Book Value</a></td>
<td class="nump">59,857<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">59,857<span></span>
</td>
<td class="nump">$ 56,076<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Indefinite-lived intangible asset</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">21,208<span></span>
</td>
<td class="nump">21,208<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_IntangibleAssetsGrossIncludingGoodwill', window );">Intangible assets, gross (including goodwill)</a></td>
<td class="nump">83,587<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetIncludingGoodwill', window );">Total net book value</a></td>
<td class="nump">81,065<span></span>
</td>
<td class="nump">77,284<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DistributionRightsMember', window );">Distribution right</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Definite-lived intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Original Cost</a></td>
<td class="nump">59,076<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(1,940)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Book Value</a></td>
<td class="nump">$ 57,136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life</a></td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember', window );">Capitalized software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Definite-lived intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Original Cost</a></td>
<td class="nump">$ 3,303<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(582)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Book Value</a></td>
<td class="nump">$ 2,721<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">IPR&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Indefinite-lived intangible asset</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Indefinite-lived intangible assets (IPR&amp;D)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56,076<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_IntangibleAssetsGrossIncludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intangible Assets, Gross (Including Goodwill)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_IntangibleAssetsGrossIncludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetIncludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of finite-lived intangible assets, indefinite-lived intangible assets and goodwill. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Intangible assets are assets, not including financial assets, lacking physical substance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetIncludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DistributionRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DistributionRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6802162544">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Oxford Term Loans - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 15, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=eols_TermLoanFacilityMember', window );">Term Loan Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.60%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_DebtInstrumentPercentageOfPrincipalAmountBalloonPayment', window );">Percentage of final payment of full principal amount</a></td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_DebtInstrumentPrepaymentFeePercentageNextTwelveMonths', window );">Prepayment fee percentage, next twelve months</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_DebtInstrumentPrepaymentFeePercentageYearTwo', window );">Prepayment fee percentage, year two</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_DebtInstrumentPrepaymentFeePercentageThereafter', window );">Prepayment fee percentage, thereafter</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,094,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,205,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=eols_TermLoanFacilityMember', window );">Term Loan Facility | Applicable Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_DebtInstrumentDefaultInterestRate', window );">Default interest rate</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on debt</a></td>
<td class="nump">9.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_DebtInstrumentPeriodOfInterestOnlyPayments', window );">Period of interest only payments</a></td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_DebtInstrumentAmortizationPeriod', window );">Amortization period</a></td>
<td class="text">23 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_DebtInstrumentAdditionalPeriodOfAgreementOfInterestPayment', window );">Additional period of agreement of interest payment</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_DebtInstrumentTermAggregatePeriod', window );">Aggregate period</a></td>
<td class="text">48 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_DebtInstrumentAdditionalAmortizationPeriod', window );">Additional amortization period</a></td>
<td class="text">11 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Secured Debt | London Interbank Offered Rate (LIBOR)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Secured Debt | Term Loan Facility, Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="nump">$ 75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Secured Debt | Term Loan Facility, Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_DebtInstrumentAdditionalAmortizationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Additional Amortization Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_DebtInstrumentAdditionalAmortizationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_DebtInstrumentAdditionalPeriodOfAgreementOfInterestPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Additional Period Of Agreement Of Interest Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_DebtInstrumentAdditionalPeriodOfAgreementOfInterestPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_DebtInstrumentAmortizationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Amortization Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_DebtInstrumentAmortizationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_DebtInstrumentDefaultInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Default Interest Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_DebtInstrumentDefaultInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_DebtInstrumentPercentageOfPrincipalAmountBalloonPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Percentage Of Principal Amount, Balloon Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_DebtInstrumentPercentageOfPrincipalAmountBalloonPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_DebtInstrumentPeriodOfInterestOnlyPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Period Of Interest Only Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_DebtInstrumentPeriodOfInterestOnlyPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_DebtInstrumentPrepaymentFeePercentageNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Prepayment Fee Percentage, Next Twelve Months</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_DebtInstrumentPrepaymentFeePercentageNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_DebtInstrumentPrepaymentFeePercentageThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Prepayment Fee Percentage, Thereafter</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_DebtInstrumentPrepaymentFeePercentageThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_DebtInstrumentPrepaymentFeePercentageYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Prepayment Fee Percentage, Year Two</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_DebtInstrumentPrepaymentFeePercentageYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_DebtInstrumentTermAggregatePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Term, Aggregate Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_DebtInstrumentTermAggregatePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=eols_TermLoanFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=eols_TermLoanFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=eols_ApplicableRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=eols_ApplicableRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=eols_TermLoanFacilityTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=eols_TermLoanFacilityTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=eols_TermLoanFacilityTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=eols_TermLoanFacilityTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6789624400">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements and Short-Term Investments - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($) </div>
<div>year</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Contingent royalty obligation payable to Evolus Founders</a></td>
<td class="nump">$ 48,895<span></span>
</td>
<td class="nump">$ 47,169<span></span>
</td>
<td class="nump">$ 50,200<span></span>
</td>
<td class="nump">$ 51,100<span></span>
</td>
<td class="nump">$ 48,800<span></span>
</td>
<td class="nump">$ 39,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=eols_ContingentRoyaltyObligationMember', window );">Contingent Royalty Obligation | Measurement Input, Expected Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AlternativeInvestmentMeasurementInput', window );">Measurement input | year</a></td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=eols_ContingentRoyaltyObligationMember', window );">Contingent Royalty Obligation | Measurement Input, Discount Rate | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AlternativeInvestmentMeasurementInput', window );">Measurement input</a></td>
<td class="nump">0.160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=eols_ContingentRoyaltyObligationMember', window );">Contingent Royalty Obligation | Measurement Input, Discount Rate | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AlternativeInvestmentMeasurementInput', window );">Measurement input</a></td>
<td class="nump">0.250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value Measurement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Contingent promissory note payable</a></td>
<td class="nump">$ 16,072<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Contingent royalty obligation payable to Evolus Founders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=eols_OxfordTermLoansMember', window );">Oxford Term Loans | Estimate of Fair Value Measurement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Contingent promissory note payable</a></td>
<td class="nump">$ 74,947<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AlternativeInvestmentMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure alternative investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AlternativeInvestmentMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of notes payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20,22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=eols_ContingentRoyaltyObligationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=eols_ContingentRoyaltyObligationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=eols_OxfordTermLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=eols_OxfordTermLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6791050544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock', window );">Schedule of Intangible Assets and Goodwill</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The table below shows the weighted-average life, original cost, accumulated amortization and net book value by major intangible asset classification:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14" rowspan="1"></td></tr><tr><td style="width:30%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:21%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Weighted-Average Life (Years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Original Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Accumulated Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Net Book Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;">Definite-lived intangible assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Distribution right</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">20</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">59,076</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(1,940</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">57,136</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Capitalized software</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">3,303</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(582</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2,721</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Intangible assets, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">62,379</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(2,522</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">59,857</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;">Indefinite-lived intangible asset</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Goodwill</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">21,208</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">21,208</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Total as of September 30, 2019</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">83,587</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(2,522</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">81,065</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14" rowspan="1"></td></tr><tr><td style="width:30%;" rowspan="1" colspan="1"></td><td style="width:19%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:21%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Weighted-Average Life (Years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Original Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Accumulated Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Net Book Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;">Indefinite-lived intangible assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">IPR&amp;D**</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">56,076</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">56,076</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Goodwill</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">*</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">21,208</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">21,208</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Total as of December 31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">77,284</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">77,284</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">    ________________________</font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:48px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#000000;">     *   Intangible assets with indefinite lives have an indeterminable average life.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:60px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#000000;">** IPR&amp;D is presented as &#8220;intangible assets, net&#8221; in the accompanying condensed balance sheets.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The following table outlines the estimated future amortization expense related to intangible assets held as of&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">September&#160;30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> that are subject to amortization:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:57.14285714285714%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:57%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Fiscal year</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Remaining in 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,168</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">4,674</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">3,528</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2022</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2,955</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">2023</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">2,955</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">44,577</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">59,857</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6791043632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholder's Equity</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Stockholders&#8217; Equity</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Preferred Stock</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company has </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">10,000,000</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> authorized shares of preferred stock with a par value of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$0.00001</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> per share. As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">September&#160;30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">none</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> were issued and outstanding. </font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Common Stock</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company has </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">100,000,000</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> authorized shares of common stock with a par value of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$0.00001</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> per share. As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">September&#160;30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">27,425,230</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> shares were issued and outstanding. </font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">2017 Omnibus Incentive Plan and Stock-based Compensation Allocation</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company&#8217;s 2017 Omnibus Incentive Plan (the &#8220;Plan&#8221;) provides for the grant of incentive options to employees of the Company, and for the grant of nonstatutory options, restricted stock awards, restricted stock unit awards, stock appreciation rights, performance stock awards and other forms of stock compensation to the Company&#8217;s employees, including officers, directors, consultants and employees of the Company. The maximum number of shares of common stock that may be issued under the Plan is </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">4,361,291</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> shares, plus an annual increase on each anniversary of November 21 equal to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">4%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> of the total issued and outstanding shares of the Company&#8217;s common stock as of such anniversary (or such lesser number of shares as may be determined by the Company&#8217;s board of directors). On November 21, 2018, an additional </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">1,091,000</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> were reserved under the evergreen provision of the Plan. As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">September&#160;30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the Company has available an aggregate of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">971,684</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> shares of common stock for future issuance under the Plan.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Stock-Based Award Activity and Balances</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Options are granted at exercise prices based on the Company&#8217;s common stock price on the date of grant. The options and RSU grants generally vest over a </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">one</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">- to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">four</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">-year period. There have been no awards granted with performance conditions or market conditions for the periods presented. The options have a contractual term of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">10</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> years. The fair value of options is estimated using the Black&#8209;Scholes option pricing model, which has various inputs, including the grant date common share price, exercise price, risk&#8209;free interest rate, volatility, expected life and dividend yield. The change of any of these inputs could significantly impact the determination of the fair value of the Company&#8217;s options as well as significantly impact its results of operations. The fair value of RSU grants is determined at the grant date based on the common share price. The Company records stock&#8209;based compensation expense net of actual forfeitures when they occur.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The weighted-averages for key assumptions used in determining the fair value of stock options granted were as follows:    </font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.28571428571429%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Three Months Ended<br clear="none"/>September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Nine Months Ended<br clear="none"/>September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Volatility</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">59.5%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">59.0%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">59.3%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">57.7%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">1.75%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">2.87%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">2.49%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">2.64%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Expected life (years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">5.96</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">6.25</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">6.16</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">6.23</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Dividend yield rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">&#8212;%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">&#8212;%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">&#8212;%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">&#8212;%</font></div></td></tr></table></div><font style="font-family:Times New Roman;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">A summary of stock option activity under the Plan for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">nine months ended September 30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, is presented below:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:86.90476190476191%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:43%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Weighted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Weighted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Average</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Average</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Remaining</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Aggregate</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Exercise</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Contractual</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Intrinsic</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Per Share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Terms (Years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Outstanding, December 31, 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">3,257,801</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">11.99</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">9.26</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">7,119</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">1,202,981</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">19.16</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">(138,849</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">9.98</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Canceled/forfeited</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">(269,772</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">14.07</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Outstanding, September&#160;30, 2019</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">4,052,161</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">14.05</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">8.53</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">14,830</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Exercisable, September&#160;30, 2019</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">833,730</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">11.83</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">7.30</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">4,301</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Times New Roman;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The intrinsic values of outstanding and exercisable options were determined by multiplying the number of shares by the difference in exercise price of the options and the fair value of the common stock as of&#160;December&#160;31, 2018 and the first trading day preceding </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">September&#160;30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">A summary of RSU activity under the Plan for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">nine months ended September 30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, is presented below:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:70.03968253968253%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:58%;" rowspan="1" colspan="1"></td><td style="width:20%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Weighted</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Average</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Restricted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Grant Date</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Units</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Per Share</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Outstanding, December 31, 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">271,404</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">16.53</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">3,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">18.33</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Vested</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">(22,125</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">25.69</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Forfeited</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">(19,409</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">13.71</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Outstanding, September&#160;30, 2019</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">232,870</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">15.92</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Times New Roman;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The following table summarizes stock-based compensation expense arising from the above Plan:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:88.29365079365078%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Three Months Ended<br clear="none"/>September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Nine Months Ended<br clear="none"/>September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Selling, general and administrative</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2,417</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,160</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">6,443</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">4,083</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Research and development</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">109</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">322</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">538</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">1,028</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">2,526</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">1,482</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">6,981</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">5,111</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Times New Roman;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In addition, during the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">three and nine months ended September 30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the Company capitalized </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$30</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$76</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, respectively, of stock-based compensation expense in capitalized software. Capitalized software is a component of intangible assets and is presented in the accompanying condensed balance sheets. See </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Note 5</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Goodwill and Intangible Assets</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> for capitalized  software information.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6630771328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Goodwill and Intangible Assets</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Goodwill and Intangible Assets</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The table below shows the weighted-average life, original cost, accumulated amortization and net book value by major intangible asset classification:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14" rowspan="1"></td></tr><tr><td style="width:30%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:21%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Weighted-Average Life (Years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Original Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Accumulated Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Net Book Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;">Definite-lived intangible assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Distribution right</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">20</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">59,076</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(1,940</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">57,136</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Capitalized software</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">3,303</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(582</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2,721</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Intangible assets, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">62,379</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(2,522</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">59,857</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;">Indefinite-lived intangible asset</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Goodwill</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">21,208</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">21,208</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Total as of September 30, 2019</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">83,587</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(2,522</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">81,065</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14" rowspan="1"></td></tr><tr><td style="width:30%;" rowspan="1" colspan="1"></td><td style="width:19%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:21%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Weighted-Average Life (Years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Original Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Accumulated Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Net Book Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;">Indefinite-lived intangible assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">IPR&amp;D**</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">56,076</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">56,076</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Goodwill</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">*</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">21,208</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">21,208</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Total as of December 31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">77,284</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">77,284</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">    ________________________</font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:48px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#000000;">     *   Intangible assets with indefinite lives have an indeterminable average life.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:60px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#000000;">** IPR&amp;D is presented as &#8220;intangible assets, net&#8221; in the accompanying condensed balance sheets.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The following table outlines the estimated future amortization expense related to intangible assets held as of&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">September&#160;30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> that are subject to amortization:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:57.14285714285714%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:57%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Fiscal year</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Remaining in 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,168</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">4,674</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">3,528</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2022</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2,955</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">2023</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">2,955</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">44,577</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">59,857</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Times New Roman;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In connection with the acquisition of the Company by SCH in 2013, the Company recorded goodwill of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$21,208</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and IPR&amp;D of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$56,076</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. The IPR&amp;D recognized represents the license and associated distribution right to develop Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the initial term of which expires in September 2023 and is automatically extended for unlimited additional </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">three</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">-year terms provided that the Company meets certain performance requirements. Additionally, pursuant to the Daewoong Agreement, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$13,500</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> in additional cash consideration is due to Daewoong based upon the Company&#8217;s successful completion of certain technical and sales milestones. Upon FDA approval of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> on February 1, 2019, the Company paid Daewoong a </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$2,000</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> milestone payment which increased the cost basis of the IPR&amp;D, and the IPR&amp;D project was completed and reclassified as a definite-lived distribution right intangible asset, which is amortized on a straight-line basis over the estimated useful life of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">20</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> years. Upon EU approval of the product on September 27, 2019, the Company accrued a </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$1,000</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> milestone payment to Daewoong which also increased the cost basis of the IPR&amp;D. During the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">three and nine months ended September 30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the Company capitalized </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$761</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$3,303</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, respectively, related to costs of computer software developed for internal use. The software is amortized over a </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">two</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">-year period using the straight-line method. During the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">three and nine months ended September 30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, total intangible assets amortization expense of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$1,115</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$2,522</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> was recorded within depreciation and amortization on the accompanying condensed statements of operations and comprehensive loss, respectively.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6798340544">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares, issued (in shares)</a></td>
<td class="nump">27,425,230<span></span>
</td>
<td class="nump">27,274,991<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares, outstanding (in shares)</a></td>
<td class="nump">27,425,230<span></span>
</td>
<td class="nump">27,274,991<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6631887216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Description of Business and Basis of Presentation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Description of Business and Basis of Presentation</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Description of Business</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Evolus, Inc., (&#8220;Evolus&#8221; or the &#8220;Company&#8221;) is a performance beauty company focused on delivering products in the self-pay aesthetic market. The Company received the approval of its first product Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> (prabotulinumtoxinA-xvfs) from the U.S. Food and Drug Administration (the &#8220;FDA&#8221;) in February 2019.  The product was approved by Health Canada in August 2018 and the European Commission (&#8220;EC&#8221;) in 31 countries in September 2019. Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> is a proprietary 900 kDa purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as &#8220;frown lines,&#8221; in adults. In May 2019, the Company commercially launched Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> in the United States and launched in Canada through a distributor in October 2019. The Company is headquartered in Newport Beach, California.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Liquidity and Financial Condition </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The accompanying unaudited condensed financial statements&#160;have been prepared&#160;on a basis that&#160;assumes that&#160;the Company will continue as a going concern. Since inception</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the Company has incurred recurring net operating losses. T</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">he Company has recorded net losses</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$26,984</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$75,526</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">three and nine months ended September 30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, respectively. Additionally, the Company used cash of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$77,461</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> in operations during the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">nine months ended September 30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">September&#160;30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the Company had </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$74,029</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> in </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">cash and cash equivalents and short-term investments, and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">an accumulated deficit of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$198,551</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company&#8217;s ability to execute on its business strategy, meet its future liquidity requirements, and achieve profitable operations, is dependent on a number of factors, including its ability to gain market acceptance of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and achieve a level of revenues adequate to support its cost structure, and operate its business without infringing third party intellectual property rights.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company believes that its current capital resources, which consist of cash, cash equivalents, and short-term investments, are sufficient to fund operations through at least the next twelve months from the date the accompanying financial statements are issued based on the expected cash burn rate. The Company may be required to raise additional capital to fund future operations through the sale of its equity securities, the incurrence of debt </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">to the extent allowed under existing debt arrangements</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the entry into licensing or collaboration agreements with partners, or other sources of financing. Sufficient funds may not be available to the Company at all or on attractive terms when needed from equity or debt financings. If the Company is unable to obtain additional funding from these or other sources when needed, or to the extent needed, it may be necessary to significantly reduce its controllable and variable expenditures and current rate of spending through reductions in staff and delaying, scaling back, or suspending certain research and development, sales and marketing programs and other operational goals.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Basis of Presentation</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">T</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">he accompanying unaudited condensed financial statements have been prepared </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">on a consistent basis with the annual financial statements and</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) and the requirements of the Securities and Exchange Commission (&#8220;SEC&#8221;) for interim reporting</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. Pursuant to these SEC rules and regulations, the Company has condensed or omitted certain financial information and disclosures normally included in annual financial statements prepared in accordance with GAAP. In the opinion of management, the interim financial statements reflect all adjustments, which include normal recurring adjustments, considered necessary for a fair statement of the interim periods. The interim results presented herein are not necessarily indicative of the results of operations to be expected for the full year ending </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> or for any other interim period.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The accompanying unaudited condensed financial statements and related disclosures should be read in conjunction with the financial statements and notes included in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2018, as filed with the SEC on March 20, 2019.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6633244624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity - Schedule of Valuation Assumptions (Details) - Common stock options<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">59.50%<span></span>
</td>
<td class="nump">59.00%<span></span>
</td>
<td class="nump">59.30%<span></span>
</td>
<td class="nump">57.70%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.75%<span></span>
</td>
<td class="nump">2.87%<span></span>
</td>
<td class="nump">2.49%<span></span>
</td>
<td class="nump">2.64%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (years)</a></td>
<td class="text">5 years 351 days<span></span>
</td>
<td class="text">6 years 90 days<span></span>
</td>
<td class="text">6 years 60 days<span></span>
</td>
<td class="text">6 years 84 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6788562880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 12, 2018</div></th>
<th class="th"><div>Dec. 14, 2017</div></th>
<th class="th"><div>Nov. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 198,551<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 123,025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_NonCashRelatedPartyReceivable', window );">Related party receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 73,690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Contingent royalty obligation payable to Evolus Founders</a></td>
<td class="nump">$ 39,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,572<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Contingent promissory note payable to Evolus Founders</a></td>
<td class="nump">16,042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,674<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,904<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=eols_ALPHAEONMember', window );">ALPHAEON</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_StockPurchaseAgreementPeriodAvailabletoCureBreach', window );">Period available to cure breach</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_BusinessAcquisitionUnwindingFee', window );">Unwinding fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=eols_EvolusIncMember', window );">Evolus, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent', window );">Due to related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,575<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Percentage of voting interests acquired (at least)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=eols_EvolusIncMember', window );">Evolus, Inc. | Chief Medical Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent', window );">Due to related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=eols_EvolusIncMember', window );">Evolus, Inc. | SCH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Related party transaction amount in period</a></td>
<td class="nump">$ 55,742<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_BusinessCombinationUpfrontPaymentUponObtainingFDAApproval', window );">Up-front payment upon obtaining FDA approval</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_RelatedPartyTransactionPeriodOfTerminationOfFirstCommercialSale', window );">Period of termination of first commercial sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative | ALPHAEON</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Related party transaction amount in period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 383<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_BusinessAcquisitionUnwindingFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Acquisition, Unwinding Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_BusinessAcquisitionUnwindingFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_BusinessCombinationUpfrontPaymentUponObtainingFDAApproval">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Up-front Payment Upon Obtaining FDA Approval</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_BusinessCombinationUpfrontPaymentUponObtainingFDAApproval</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_NonCashRelatedPartyReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non Cash Related Party Receivable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_NonCashRelatedPartyReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_RelatedPartyTransactionPeriodOfTerminationOfFirstCommercialSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Related Party Transaction, Period Of Termination Of First Commercial Sale</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_RelatedPartyTransactionPeriodOfTerminationOfFirstCommercialSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_StockPurchaseAgreementPeriodAvailabletoCureBreach">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Purchase Agreement, Period Available to Cure Breach</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_StockPurchaseAgreementPeriodAvailabletoCureBreach</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting equity interests acquired at the acquisition date in the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(3),(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transactions with related party during the financial reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-107864<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAmountsOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=eols_ALPHAEONMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=eols_ALPHAEONMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=eols_EvolusIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=eols_EvolusIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=eols_ChiefMedicalOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=eols_ChiefMedicalOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=eols_SCHAEONLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=eols_SCHAEONLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6659210688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholder's Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The weighted-averages for key assumptions used in determining the fair value of stock options granted were as follows:    </font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.28571428571429%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Three Months Ended<br clear="none"/>September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Nine Months Ended<br clear="none"/>September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Volatility</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">59.5%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">59.0%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">59.3%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">57.7%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">1.75%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">2.87%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">2.49%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">2.64%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Expected life (years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">5.96</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">6.25</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">6.16</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">6.23</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Dividend yield rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">&#8212;%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">&#8212;%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">&#8212;%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">&#8212;%</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Share-based Compensation, Stock Options, Activity</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">A summary of stock option activity under the Plan for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">nine months ended September 30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, is presented below:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:86.90476190476191%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:43%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Weighted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Weighted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Average</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Average</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Remaining</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Aggregate</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Exercise</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Contractual</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Intrinsic</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Per Share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Terms (Years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Outstanding, December 31, 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">3,257,801</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">11.99</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">9.26</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">7,119</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">1,202,981</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">19.16</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">(138,849</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">9.98</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Canceled/forfeited</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">(269,772</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">14.07</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Outstanding, September&#160;30, 2019</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">4,052,161</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">14.05</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">8.53</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">14,830</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Exercisable, September&#160;30, 2019</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">833,730</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">11.83</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">7.30</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">4,301</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Schedule of Share-based Compensation, Restricted Stock Units Award Activity</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">A summary of RSU activity under the Plan for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">nine months ended September 30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, is presented below:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:70.03968253968253%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:58%;" rowspan="1" colspan="1"></td><td style="width:20%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Weighted</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Average</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Restricted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Grant Date</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Units</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Per Share</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Outstanding, December 31, 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">271,404</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">16.53</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">3,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">18.33</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Vested</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">(22,125</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">25.69</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Forfeited</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">(19,409</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">13.71</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Outstanding, September&#160;30, 2019</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">232,870</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">15.92</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-based Compensation Expense Allocation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The following table summarizes stock-based compensation expense arising from the above Plan:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:88.29365079365078%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Three Months Ended<br clear="none"/>September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Nine Months Ended<br clear="none"/>September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Selling, general and administrative</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2,417</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,160</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">6,443</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">4,083</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Research and development</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">109</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">322</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">538</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">1,028</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">2,526</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">1,482</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">6,981</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">5,111</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.19.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>162</ContextCount>
  <ElementCount>400</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>41</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="eols-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="eols-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001000 - Statement - Condensed Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/CondensedBalanceSheets</Role>
      <ShortName>Condensed Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="eols-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1001001 - Statement - Condensed Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/CondensedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="eols-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1002000 - Statement - Condensed Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/CondensedStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Condensed Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="eols-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1003000 - Statement - Condensed Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/CondensedStatementsOfStockholdersEquity</Role>
      <ShortName>Condensed Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="eols-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1004000 - Statement - Condensed Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/CondensedStatementsOfCashFlows</Role>
      <ShortName>Condensed Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="eols-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2101100 - Disclosure - Description of Business and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/DescriptionOfBusinessAndBasisOfPresentation</Role>
      <ShortName>Description of Business and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="eols-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2102100 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="eols-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2103100 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="eols-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2104100 - Disclosure - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/AccruedExpenses</Role>
      <ShortName>Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="eols-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2104100 - Disclosure - Goodwill and Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/GoodwillAndIntangibleAssets</Role>
      <ShortName>Goodwill and Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="eols-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2105100 - Disclosure - Oxford Term Loans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/OxfordTermLoans</Role>
      <ShortName>Oxford Term Loans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="eols-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2106100 - Disclosure - Fair Value Measurements and Short-Term Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/FairValueMeasurementsAndShortTermInvestments</Role>
      <ShortName>Fair Value Measurements and Short-Term Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="eols-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2107100 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="eols-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2108100 - Disclosure - Stockholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders??? Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="eols-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.evolus.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="eols-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2302302 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolus.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="eols-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2304301 - Disclosure - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/AccruedExpensesTables</Role>
      <ShortName>Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolus.com/role/AccruedExpenses</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="eols-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2304301 - Disclosure - Goodwill and Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/GoodwillAndIntangibleAssetsTables</Role>
      <ShortName>Goodwill and Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolus.com/role/GoodwillAndIntangibleAssets</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="eols-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Oxford Term Loans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/OxfordTermLoansTables</Role>
      <ShortName>Oxford Term Loans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolus.com/role/OxfordTermLoans</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="eols-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2306301 - Disclosure - Fair Value Measurements and Short-Term Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/FairValueMeasurementsAndShortTermInvestmentsTables</Role>
      <ShortName>Fair Value Measurements and Short-Term Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolus.com/role/FairValueMeasurementsAndShortTermInvestments</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="eols-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2307301 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/CommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolus.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="eols-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2308301 - Disclosure - Stockholder's Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholder's Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="eols-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2401401 - Disclosure - Description of Business and Basis of Presentation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/DescriptionOfBusinessAndBasisOfPresentationDetails</Role>
      <ShortName>Description of Business and Basis of Presentation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.evolus.com/role/DescriptionOfBusinessAndBasisOfPresentation</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="eols-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2402403 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="eols-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2402404 - Disclosure - Summary of Significant Accounting Policies - New Accounting Pronouncements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/SummaryOfSignificantAccountingPoliciesNewAccountingPronouncementsDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - New Accounting Pronouncements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="eols-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2403401 - Disclosure - Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/RelatedPartyTransactionsDetails</Role>
      <ShortName>Related Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.evolus.com/role/RelatedPartyTransactions</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="eols-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2404402 - Disclosure - Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/AccruedExpensesDetails</Role>
      <ShortName>Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.evolus.com/role/AccruedExpensesTables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="eols-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2404402 - Disclosure - Goodwill and Intangible Assets - Schedule of Definite and Indefinite-Lived Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/GoodwillAndIntangibleAssetsScheduleOfDefiniteAndIndefiniteLivedIntangibleAssetsDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Schedule of Definite and Indefinite-Lived Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="eols-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2404403 - Disclosure - Goodwill and Intangible Assets - Future Amortization Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/GoodwillAndIntangibleAssetsFutureAmortizationExpenseDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Future Amortization Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="eols-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2404404 - Disclosure - Goodwill and Intangible Asset - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/GoodwillAndIntangibleAssetNarrativeDetails</Role>
      <ShortName>Goodwill and Intangible Asset - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="eols-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2405402 - Disclosure - Oxford Term Loans - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/OxfordTermLoansNarrativeDetails</Role>
      <ShortName>Oxford Term Loans - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="eols-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2405403 - Disclosure - Oxford Term Loans - Maturities of Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/OxfordTermLoansMaturitiesOfDebtDetails</Role>
      <ShortName>Oxford Term Loans - Maturities of Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="eols-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Fair Value Measurements and Short-Term Investments - Schedule of Short-term Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/FairValueMeasurementsAndShortTermInvestmentsScheduleOfShortTermInvestmentsDetails</Role>
      <ShortName>Fair Value Measurements and Short-Term Investments - Schedule of Short-term Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="eols-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2406403 - Disclosure - Fair Value Measurements and Short-Term Investments - Assets and Liabilities on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/FairValueMeasurementsAndShortTermInvestmentsAssetsAndLiabilitiesOnRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements and Short-Term Investments - Assets and Liabilities on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="eols-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2406404 - Disclosure - Fair Value Measurements and Short-Term Investments - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/FairValueMeasurementsAndShortTermInvestmentsNarrativeDetails</Role>
      <ShortName>Fair Value Measurements and Short-Term Investments - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.evolus.com/role/FairValueMeasurementsAndShortTermInvestmentsTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="eols-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2406405 - Disclosure - Fair Value Measurements and Short-Term Investments - Contingent Royalty Obligation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/FairValueMeasurementsAndShortTermInvestmentsContingentRoyaltyObligationDetails</Role>
      <ShortName>Fair Value Measurements and Short-Term Investments - Contingent Royalty Obligation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="eols-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2407402 - Disclosure - Commitments and Contingencies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/CommitmentsAndContingenciesNarrativeDetails</Role>
      <ShortName>Commitments and Contingencies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="eols-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Commitments and Contingencies - Lease Cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/CommitmentsAndContingenciesLeaseCostDetails</Role>
      <ShortName>Commitments and Contingencies - Lease Cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="eols-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2407404 - Disclosure - Commitments and Contingencies - Operating Lease Maturity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/CommitmentsAndContingenciesOperatingLeaseMaturityDetails</Role>
      <ShortName>Commitments and Contingencies - Operating Lease Maturity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="eols-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2408402 - Disclosure - Stockholder's Equity - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/StockholdersEquityNarrativeDetails</Role>
      <ShortName>Stockholder's Equity - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="eols-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2408403 - Disclosure - Stockholders??? Equity - Schedule of Valuation Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/StockholdersEquityScheduleOfValuationAssumptionsDetails</Role>
      <ShortName>Stockholders??? Equity - Schedule of Valuation Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="eols-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2408404 - Disclosure - Stockholders??? Equity - Schedule of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/StockholdersEquityScheduleOfStockOptionActivityDetails</Role>
      <ShortName>Stockholders??? Equity - Schedule of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="eols-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2408405 - Disclosure - Stockholders??? Equity - Restricted Stock Unit (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/StockholdersEquityRestrictedStockUnitDetails</Role>
      <ShortName>Stockholders??? Equity - Restricted Stock Unit (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="eols-20190930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2408406 - Disclosure - Stockholder's Equity - Stock-based Compensation Expense Allocation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/StockholdersEquityStockBasedCompensationExpenseAllocationDetails</Role>
      <ShortName>Stockholder's Equity - Stock-based Compensation Expense Allocation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>eols-20190930.xml</File>
    <File>eols-20190930.xsd</File>
    <File>eols-20190930_cal.xml</File>
    <File>eols-20190930_def.xml</File>
    <File>eols-20190930_lab.xml</File>
    <File>eols-20190930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/srt/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6800992368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity - Schedule of Stock Option Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted Average Contractual Term</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Contractual term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Common stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Stock Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning balance (in shares)</a></td>
<td class="nump">3,257,801<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">1,202,981<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(138,849)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Cancelled/forfeited (in shares)</a></td>
<td class="num">(269,772)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending balance (in shares)</a></td>
<td class="nump">4,052,161<span></span>
</td>
<td class="nump">3,257,801<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable (in shares)</a></td>
<td class="nump">833,730<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning balance (in dollars per share)</a></td>
<td class="nump">$ 11.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">19.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="nump">9.98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Cancelled/forfeited (in dollars per share)</a></td>
<td class="nump">14.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending balance (in dollars per share)</a></td>
<td class="nump">14.05<span></span>
</td>
<td class="nump">$ 11.99<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable (in dollars per share)</a></td>
<td class="nump">$ 11.83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted Average Contractual Term</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Contractual term</a></td>
<td class="text">8 years 6 months 10 days<span></span>
</td>
<td class="text">9 years 3 months 4 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermExercisable', window );">Exercisable</a></td>
<td class="text">7 years 110 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Beginning balance</a></td>
<td class="nump">$ 7,119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsGrantedinPeriodIntrinsicValue', window );">Granted</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsForfeitedinPeriodIntrinsicValue', window );">Canceled/forfeited</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Ending balance</a></td>
<td class="nump">14,830<span></span>
</td>
<td class="nump">$ 7,119<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable</a></td>
<td class="nump">$ 4,301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsForfeitedinPeriodIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeited in Period, Intrinsic Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsForfeitedinPeriodIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsGrantedinPeriodIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Granted in Period, Intrinsic Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsGrantedinPeriodIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Intrinsic Value [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Exercisable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6800778272">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 39,116<span></span>
</td>
<td class="nump">$ 93,162<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">34,913<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">7,206<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">10,043<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">3,906<span></span>
</td>
<td class="nump">1,177<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">95,184<span></span>
</td>
<td class="nump">94,339<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">984<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">4,238<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">59,857<span></span>
</td>
<td class="nump">56,076<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">21,208<span></span>
</td>
<td class="nump">21,208<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">1,195<span></span>
</td>
<td class="nump">221<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">182,666<span></span>
</td>
<td class="nump">171,844<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">6,125<span></span>
</td>
<td class="nump">1,558<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">14,378<span></span>
</td>
<td class="nump">3,718<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_ContingentRoyaltyObligationPayabletoRelatedPartyCurrent', window );">Contingent royalty obligation payable to Evolus Founders</a></td>
<td class="nump">4,323<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">1,148<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">25,974<span></span>
</td>
<td class="nump">5,276<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities</a></td>
<td class="nump">4,067<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditNoncurrent', window );">Deferred rent</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Contingent royalty obligation payable to Evolus Founders</a></td>
<td class="nump">44,572<span></span>
</td>
<td class="nump">50,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Contingent promissory note payable to Evolus Founders</a></td>
<td class="nump">17,674<span></span>
</td>
<td class="nump">16,904<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, net of discounts and issuance costs</a></td>
<td class="nump">73,180<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liability</a></td>
<td class="nump">156<span></span>
</td>
<td class="nump">15,055<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">165,623<span></span>
</td>
<td class="nump">87,460<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 8)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.00001 par value; 10,000,000 shares authorized; no shares issued and outstanding at September 30, 2019 and December 31, 2018, respectively</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.00001 par value; 100,000,000 shares authorized; 27,425,230 and 27,274,991 shares issued and outstanding at September 30, 2019 and December 31, 2018, respectively</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">215,574<span></span>
</td>
<td class="nump">207,408<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive gain</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(198,551)<span></span>
</td>
<td class="num">(123,025)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">17,043<span></span>
</td>
<td class="nump">84,384<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 182,666<span></span>
</td>
<td class="nump">$ 171,844<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_ContingentRoyaltyObligationPayabletoRelatedPartyCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent Royalty Obligation Payable to Related Party, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_ContingentRoyaltyObligationPayabletoRelatedPartyCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118952595&amp;loc=d3e4428-111522<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=118952595&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669686-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6801-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e31931-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For a classified balance sheet, the cumulative difference between the rental income or payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, more than one year after the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.26(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902458&amp;loc=d3e39927-112707<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCreditNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116846819&amp;loc=d3e3927-108312<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6802559024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (75,526)<span></span>
</td>
<td class="num">$ (34,425)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">2,664<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">6,981<span></span>
</td>
<td class="nump">5,111<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_ProvisionsForRebateAndCouponPrograms', window );">Provisions for rebate and coupon programs</a></td>
<td class="nump">6,671<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_AmortizationOfDiscountOnShorttermInvestments', window );">Accretion of discount on short-term investments</a></td>
<td class="num">(912)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_OperatingLeaseRightofUseAssetAmortization', window );">Amortization of operating lease right-of-use assets</a></td>
<td class="nump">702<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt discount and issuance costs</a></td>
<td class="nump">1,513<span></span>
</td>
<td class="nump">749<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="num">(14,899)<span></span>
</td>
<td class="nump">41<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Revaluation of contingent royalty obligation payable to Evolus Founders</a></td>
<td class="nump">7,977<span></span>
</td>
<td class="nump">11,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="num">(6,225)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable, net</a></td>
<td class="num">(7,206)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(1,406)<span></span>
</td>
<td class="num">(739)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">3,825<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">736<span></span>
</td>
<td class="nump">378<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_IncreasedecreaseInOperatingLeaseLiabilities', window );">Operating lease liabilities</a></td>
<td class="num">(531)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredLiabilities', window );">Deferred rent</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(77,461)<span></span>
</td>
<td class="num">(13,661)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(346)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForSoftware', window );">Additions to capitalized software</a></td>
<td class="num">(3,080)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Purchases of short-term investments</a></td>
<td class="num">(98,982)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments', window );">Maturities of short-term investments</a></td>
<td class="nump">65,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(37,408)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_PaymentsOfContingentRoyaltyObligation', window );">Payment of contingent royalty obligation to Evolus Founders</a></td>
<td class="num">(9,282)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_MilestonePaymentsForIntangibleAssets', window );">Milestone payment for intangible assets</a></td>
<td class="num">(2,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from issuance of long-term debt, net of discounts</a></td>
<td class="nump">73,906<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Payment for debt obligation</a></td>
<td class="num">(705)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payments for debt issuance costs</a></td>
<td class="num">(2,205)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from initial public offering, net of underwriters fees</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">56,330<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from follow-on offering, net of underwriters fees</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">67,680<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments for offering costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,060)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Related party borrowings</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,127<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfRelatedPartyDebt', window );">Payments on related party borrowings</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(5,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_ProceedsFromPaymentsForIssuanceOfCommonStockInConnectionWithEquityIncentivePlan', window );">Issuance of common stock in connection with incentive equity plan</a></td>
<td class="nump">1,109<span></span>
</td>
<td class="num">(239)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">60,823<span></span>
</td>
<td class="nump">118,838<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Change in cash and cash equivalents</a></td>
<td class="num">(54,046)<span></span>
</td>
<td class="nump">105,168<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, beginning of period</a></td>
<td class="nump">93,162<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, end of period</a></td>
<td class="nump">39,116<span></span>
</td>
<td class="nump">105,168<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">3,365<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for operating leases</a></td>
<td class="nump">716<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Non-cash investing and financing information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_NonCashRelatedPartyReceivable', window );">Related party receivable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">73,690<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_NonCashRelatedPartyBorrowings', window );">Related party borrowings</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(68,767)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_NonCashNoteObligation', window );">Note obligation</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(140,688)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_ContingentRoyaltyObligation', window );">Contingent royalty obligation payable to Evolus Founders</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">39,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_ContingentPromissoryNote', window );">Contingent promissory note payable to Evolus Founders</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">16,042<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_CapitalContributionConvertibleNoteWriteOff', window );">Capital contribution from Parent, convertible note write-off</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">66,998<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_CapitalContributionForgivenessofRelatedPartyBorrowings', window );">Capital contribution from Parent, forgiveness of related party borrowings</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">13,188<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_NonCashDeferredOfferingCosts', window );">Deferred offering costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,885)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_AccountsPayablePaidbyParent', window );">Accounts payable, paid by Parent</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(163)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating lease right-of-use assets obtained in exchange for operating lease liabilities</a></td>
<td class="nump">5,565<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_NonCashLandlordPaidTenantImprovement', window );">Landlord paid tenant improvements</a></td>
<td class="nump">781<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_NonCashFinanceAndInsurancePayment', window );">Financed D &amp; O insurance payment</a></td>
<td class="nump">1,561<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Capitalized software recorded in accounts payable and accrued expenses</a></td>
<td class="nump">147<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_MilestonePaymentCurrent', window );">Accrued milestone payment for intangible assets</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_AccountsPayablePaidbyParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accounts Payable, Paid by Parent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_AccountsPayablePaidbyParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_AmortizationOfDiscountOnShorttermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortization Of Discount On Short-term Investments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_AmortizationOfDiscountOnShorttermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_CapitalContributionConvertibleNoteWriteOff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Capital Contribution, Convertible Note Write-Off</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_CapitalContributionConvertibleNoteWriteOff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_CapitalContributionForgivenessofRelatedPartyBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Capital Contribution, Forgiveness of Related Party Borrowings</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_CapitalContributionForgivenessofRelatedPartyBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_ContingentPromissoryNote">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent Promissory Note</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_ContingentPromissoryNote</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_ContingentRoyaltyObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent Royalty Obligation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_ContingentRoyaltyObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_IncreasedecreaseInOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) In Operating Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_IncreasedecreaseInOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_MilestonePaymentCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone Payment, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_MilestonePaymentCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_MilestonePaymentsForIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone Payments For Intangible Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_MilestonePaymentsForIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_NonCashDeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-Cash Deferred Offering Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_NonCashDeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_NonCashFinanceAndInsurancePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-Cash Finance And Insurance Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_NonCashFinanceAndInsurancePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_NonCashLandlordPaidTenantImprovement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-Cash Landlord Paid Tenant Improvement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_NonCashLandlordPaidTenantImprovement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_NonCashNoteObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-Cash Note Obligation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_NonCashNoteObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_NonCashRelatedPartyBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-Cash Related Party Borrowings</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_NonCashRelatedPartyBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_NonCashRelatedPartyReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non Cash Related Party Receivable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_NonCashRelatedPartyReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_OperatingLeaseRightofUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Right-of-Use Asset, Amortization</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_OperatingLeaseRightofUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_PaymentsOfContingentRoyaltyObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments Of Contingent Royalty Obligation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_PaymentsOfContingentRoyaltyObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_ProceedsFromPaymentsForIssuanceOfCommonStockInConnectionWithEquityIncentivePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From (Payments For) Issuance Of Common Stock In Connection With Equity Incentive Plan</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_ProceedsFromPaymentsForIssuanceOfCommonStockInConnectionWithEquityIncentivePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_ProvisionsForRebateAndCouponPrograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Provisions For Rebate And Coupon Programs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_ProvisionsForRebateAndCouponPrograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change during the period in carrying value for all deferred liabilities due within one year or operating cycle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForSoftware">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the development, modification or acquisition of software programs or applications for internal use (that is, not to be sold, leased or otherwise marketed to others) that qualify for capitalization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForSoftware</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6789095408">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - New Accounting Pronouncements (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jan. 01, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 4,238<span></span>
</td>
<td class="nump">$ 1,029<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liabilities</a></td>
<td class="nump">1,148<span></span>
</td>
<td class="nump">916<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities</a></td>
<td class="nump">4,067<span></span>
</td>
<td class="nump">138<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditNoncurrent', window );">Deferred rent</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member', window );">Adjustments Due to the Adoption of ASC 842</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">916<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditNoncurrent', window );">Deferred rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (25)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For a classified balance sheet, the cumulative difference between the rental income or payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, more than one year after the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.26(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902458&amp;loc=d3e39927-112707<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCreditNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6783645504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Lease, Cost</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">For the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">three and nine months ended September 30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the components of operating lease expense and other quantitative information were as follows:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:93.25396825396825%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:63%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Three Months Ended<br clear="none"/>September 30, 2019</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Nine Months Ended<br clear="none"/>September 30, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Fixed operating lease expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">297</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">798</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Variable operating lease expense</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">31</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">92</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Short-term operating lease expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">24</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">73</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">352</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">963</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">As of September 30, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Weighted-average remaining lease term (years)</font></div></td><td colspan="7" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">5.2</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Weighted-average discount rate</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">9.4%</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Lessee, Operating Lease, Liability, Maturity</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The following table presents the maturity of the Company&#8217;s operating lease liabilities as of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">September&#160;30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, future minimum payments under the operating lease agreements with non-cancelable terms as follows:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;padding-left:9px;text-indent:26px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:58.333333333333336%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:78%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:20%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Fiscal year</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">Remainder of 2019</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">$</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">239</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">2020</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">1,201</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">2021</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">1,205</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">2022</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">1,258</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">2023</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">1,312</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">Thereafter</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">1,484</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">Total operating lease payments</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">6,699</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">Less: imputed interest</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">(1,484</font></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">Present value of operating lease liabilities</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">$</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">5,215</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Schedule of Future Minimum Rental Payments for Operating Leases</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, annual future minimum payments under the operating lease agreements with non-cancelable terms greater than one year are as follows:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> </font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:59.32539682539682%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:79%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:19%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;font-weight:bold;">Fiscal year</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">2019</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">$</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">890</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">2020</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">139</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">2021</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #231f20;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #231f20;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">$</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">1,029</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6775580304">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Oxford Term Loans - Maturities of Debt (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtByMaturityAbstract', window );"><strong>Principal</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_LongtermDebtMaturitiesPrincipalPaymentExcludingFinalPaymentDueInYearThree', window );">2022</a></td>
<td class="nump">$ 26,087<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_LongtermDebtMaturitiesPrincipalPaymentExcludingFinalPaymentDueInYearFour', window );">2023</a></td>
<td class="nump">39,130<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_LongtermDebtMaturitiesPrincipalPaymentExcludingFinalPaymentDueInYearFive', window );">2024</a></td>
<td class="nump">9,783<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_LongtermDebtMaturitiesPrincipalPaymentExcludingFinalPayment', window );">Principal payment excluding final payment</a></td>
<td class="nump">75,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_LongTermDebtFinalPaymentAbstract', window );"><strong>Final Payment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_LongtermDebtMaturitiesFinalPaymentsInYearThree', window );">2022</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_LongtermDebtMaturitiesFinalPaymentsInYearFour', window );">2023</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_LongtermDebtMaturitiesFinalPaymentsInYearFive', window );">2024</a></td>
<td class="nump">4,125<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_LongtermDebtMaturitiesFinalPayments', window );">Final payments</a></td>
<td class="nump">4,125<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_LongTermDebtByMaturityTotalAbstract', window );"><strong>Total</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2022</a></td>
<td class="nump">26,087<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2023</a></td>
<td class="nump">39,130<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive', window );">2024</a></td>
<td class="nump">13,908<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt</a></td>
<td class="nump">$ 79,125<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_LongTermDebtByMaturityTotalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long Term Debt By Maturity Total [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_LongTermDebtByMaturityTotalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_LongTermDebtFinalPaymentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>LongTerm Debt Final Payment [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_LongTermDebtFinalPaymentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_LongtermDebtMaturitiesFinalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long-term Debt, Maturities, Final Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_LongtermDebtMaturitiesFinalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_LongtermDebtMaturitiesFinalPaymentsInYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long-term Debt, Maturities, Final Payments In Year Five</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_LongtermDebtMaturitiesFinalPaymentsInYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_LongtermDebtMaturitiesFinalPaymentsInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long-term Debt, Maturities, Final Payments In Year Four</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_LongtermDebtMaturitiesFinalPaymentsInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_LongtermDebtMaturitiesFinalPaymentsInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long-term Debt, Maturities, Final Payments In Year Three</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_LongtermDebtMaturitiesFinalPaymentsInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_LongtermDebtMaturitiesPrincipalPaymentExcludingFinalPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long-term Debt, Maturities, Principal Payment Excluding Final Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_LongtermDebtMaturitiesPrincipalPaymentExcludingFinalPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_LongtermDebtMaturitiesPrincipalPaymentExcludingFinalPaymentDueInYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long-term Debt, Maturities, Principal Payment Excluding Final Payment Due In Year Five</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_LongtermDebtMaturitiesPrincipalPaymentExcludingFinalPaymentDueInYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_LongtermDebtMaturitiesPrincipalPaymentExcludingFinalPaymentDueInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long-term Debt, Maturities, Principal Payment Excluding Final Payment Due In Year Four</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_LongtermDebtMaturitiesPrincipalPaymentExcludingFinalPaymentDueInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_LongtermDebtMaturitiesPrincipalPaymentExcludingFinalPaymentDueInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long-term Debt, Maturities, Principal Payment Excluding Final Payment Due In Year Three</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_LongtermDebtMaturitiesPrincipalPaymentExcludingFinalPaymentDueInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtByMaturityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtByMaturityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6783689120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements and Short-Term Investments - Contingent Royalty Obligation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balance</a></td>
<td class="nump">$ 47,169<span></span>
</td>
<td class="nump">$ 48,800<span></span>
</td>
<td class="nump">$ 50,200<span></span>
</td>
<td class="nump">$ 39,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityPayments', window );">Payments</a></td>
<td class="num">(69)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(9,282)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_RevaluationofContingentRoyaltyObligationPayable', window );">Change in fair value recorded in operating expenses</a></td>
<td class="nump">1,795<span></span>
</td>
<td class="nump">2,300<span></span>
</td>
<td class="nump">7,977<span></span>
</td>
<td class="nump">11,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending balance</a></td>
<td class="nump">$ 48,895<span></span>
</td>
<td class="nump">$ 51,100<span></span>
</td>
<td class="nump">$ 48,895<span></span>
</td>
<td class="nump">$ 51,100<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_RevaluationofContingentRoyaltyObligationPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revaluation of Contingent Royalty Obligation Payable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_RevaluationofContingentRoyaltyObligationPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6642788736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Commitments and Contingencies</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"> </font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Operating Leases</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company leases office facilities under various operating lease agreements. The Company&#8217;s corporate headquarters is located in Newport Beach, California, in a facility that it subleases under a non-cancelable operating lease for a fixed amount each month. The sublease for this facility expires on January 20, 2020. On May 15, 2019, the Company entered into a non-cancelable operating lease for the same office facility with the original lessor. This non-cancelable operating lease will commence on February 1, 2020 and expire on January 31, 2025. Lease payments increase based on an annual rent escalation clause that occurs each year on February 1. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company may, under certain circumstances, terminate the lease on the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">36</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> month anniversary of the lease commencement date by providing a written notice </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">12 months</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> prior to such anniversary and paying a termination fee&#160;equal to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">six months</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> basic rent plus certain other expenses. The Company has an option to extend the term of the lease for an additional </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">60 months</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, which is not recognized as part of its ROU assets and lease liabilities. The lease with the original lessor is a modification of the existing sublease that is not accounted for as a separate contract.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company also leases an office facility in Santa Barbara, California, under a non-cancelable operating lease, the payments of which include a </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">three</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> percent</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> annual rent escalation clause that occurs on each June 1 anniversary</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. The lease for this facility expires on May 31, 2020 and the Company has an option to extend the term of the lease for an additional </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">60 months</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. In June 2019, the Company subleased the Santa Barbara, California facility to a third-party for a term starting on June 1, 2019 and expiring on May 31, 2020. The </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">sublease</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> income was not significant. Upon signing the sublease, the Company recorded an impairment charge of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$80</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> to the right-of-use asset related to the original lease.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company&#8217;s lease agreements do not contain any residual value guarantees or material restrictive covenants. The payments associated with the renewal will only be included in the measurement of the lease liability and ROU assets if the exercise of the renewal option is determined to be reasonably certain. The Company considers the timing of the renewal period and other economic factors such as the financial implications of a decision to extend or not to extend a lease&#160;in&#160;determining&#160;if the renewal option is reasonably certain to be exercised.&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">For the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">three and nine months ended September 30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the components of operating lease expense and other quantitative information were as follows:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:93.25396825396825%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:63%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Three Months Ended<br clear="none"/>September 30, 2019</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Nine Months Ended<br clear="none"/>September 30, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Fixed operating lease expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">297</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">798</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Variable operating lease expense</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">31</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">92</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Short-term operating lease expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">24</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">73</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">352</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">963</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">As of September 30, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Weighted-average remaining lease term (years)</font></div></td><td colspan="7" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">5.2</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Weighted-average discount rate</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">9.4%</font></div></td></tr></table></div><font style="font-family:Times New Roman;font-size:8pt;color:#000000;"> </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Operating lease&#160;expenses were included in the selling, general and administration expenses in the accompanying condensed statements of operations and comprehensive loss. Operating lease right-of-use assets and related current and noncurrent operating lease liabilities are presented in the accompanying condensed balance sheets. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The following table presents the maturity of the Company&#8217;s operating lease liabilities as of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">September&#160;30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, future minimum payments under the operating lease agreements with non-cancelable terms as follows:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;padding-left:9px;text-indent:26px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:58.333333333333336%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:78%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:20%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Fiscal year</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">Remainder of 2019</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">$</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">239</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">2020</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">1,201</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">2021</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">1,205</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">2022</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">1,258</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">2023</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">1,312</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">Thereafter</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">1,484</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">Total operating lease payments</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">6,699</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">Less: imputed interest</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">(1,484</font></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">Present value of operating lease liabilities</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">$</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">5,215</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Times New Roman;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As required by the new lease accounting standard, legacy disclosures are provided for periods prior to adoption.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, annual future minimum payments under the operating lease agreements with non-cancelable terms greater than one year are as follows:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> </font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:59.32539682539682%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:79%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:19%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;font-weight:bold;">Fiscal year</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">2019</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">$</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">890</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">2020</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">139</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">2021</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #231f20;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #231f20;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">$</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">1,029</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Times New Roman;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Purchase Commitments</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">September&#160;30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the Company has entered into commitments to purchase services and products for an aggregate amount of approximately </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$6,651</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. Certain minimum purchase commitments related to the purchase of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> are described below.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;">License and Supply Agreement</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In connection with the Daewoong Agreement, the Company is obligated to make future milestone payments to Daewoong for certain confidential development and commercial milestones associated with </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">September&#160;30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, Daewoong is eligible to receive contingent milestone payments of up to approximately </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$11,500</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, including the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$1,000</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> milestone payment accrued upon EC approval of the product in September 2019. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Daewoong Agreement also includes certain minimum annual purchases the Company is required to make in order to maintain the exclusivity of the license.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> The Company may, however, meet these minimum purchase obligations by achieving certain market share in its covered territories. These potential minimum purchase obligations were contingent upon the occurrence of future events, including receipt of governmental approvals and the Company&#8217;s future market share in various jurisdictions. </font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Legal Proceedings</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications. The Company&#8217;s exposure under these agreements is unknown because they involve claims that may be made against the Company in the future, but have not yet been made. The Company accrues a liability for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">No</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> amounts were accrued as of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">September&#160;30, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;">Medytox Litigation</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company, Daewoong and other individuals and entities are defendants to a lawsuit brought by Medytox, Inc. (&#8220;Medytox&#8221;) originally instituted </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">in the Superior Court of the State of California in June 2017. With specific regard to the Company, Medytox alleges that (i) the Company has violated California Uniform Trade Secrets Act, Cal. Civ. Code &#167; 3426 because Daewoong&#8217;s alleged knowledge of the misappropriation of certain trade secrets of Medytox is imputed to the Company as a result of the Company&#8217;s relationship with Daewoong, (ii) the Company has stolen the botulinum toxin bacterial strain of Medytox through our possession of and refusal to return the botulinum toxin bacterial strain, (iii) the Company has engaged in unlawful, unfair and fraudulent business acts and practices in violation of California Bus. &amp; Prof. Code &#167; 17200, including conversion of the botulinum toxin bacterial strain and misrepresentations to the public regarding the source of the botulinum toxin bacterial strain used to manufacture Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, and (iv) the Daewoong Agreement is invalid and in violation of Medytox&#8217;s rights</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> (the &#8220;Medytox Litigation&#8221;). </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Medytox seeks, among other things, (i) actual, consequential and punitive damages, (ii) a reasonable royalty, as appropriate, (iii) a declaration that the Daewoong Agreement is void and unenforceable and that Medytox is entitled to disgorgement of all property wrongfully and unjustly retained or acquired by the defendants, including unlawfully gained profits, (iv) injunctive relief prohibiting the Company from using the license under the Daewoong Agreement and distributing Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, and (v) attorneys&#8217; fees and costs.  </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company believes it has meritorious defenses and intends to vigorously defend Medytox&#8217;s claims. Given the early stage in the Medytox Litigation, the Company is unable to determine the likelihood of success of Medytox&#8217;s claims against the Company, and an estimate of the possible loss or range of loss cannot be made. While the Company is entitled to indemnity under the Daewoong Agreement, the indemnity may not be sufficient. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">An adverse ruling by the Superior Court against either us or Daewoong could materially adversely affect the Company&#8217;s ability to carry out its business and which would have a material adverse effect on the Company&#8217;s business, financial position, results of operations, or cash flows and could also result in reputational harm.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;">ITC Case</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On January 30, 2019, Allergan, plc and Allergan, Inc. (collectively, &#8220;Allergan&#8221;) and Medytox filed a complaint against us and Daewoong in the U.S. International Trade Commission (the &#8220;ITC&#8221;), containing substantially similar allegations to the Medytox Litigation, specifically that Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> is manufactured based on misappropriated trade secrets of Medytox and therefore the importation of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> is an unfair act. The ITC matter is entitled </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">In the Matter of Certain Botulinum Toxin Products</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> (the &#8220;ITC Complaint&#8221;).  The ITC instituted an investigation as ITC Inv. No. 337-TA-1145. The ITC complaint seeks (i) an investigation by the ITC pursuant to Section 337 of the Tariff Act of 1930, (ii) a hearing with the ITC on permanent relief, (iii) issuance of a limited exclusion order forbidding entry of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> into the United States, (iv) a cease and desist order prohibiting Daewoong and us from engaging in the importations, sale for importation, marketing, distribution, offering for sale, the sale after the importation of, or otherwise transferring Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> within the United States, (v) a bond issued during the presidential review period, (vi) the return of Medytox&#8217;s trade secrets and other confidential information including the alleged stolen botulinum toxin bacterial strain, and (vii) exclusion and cease and desist orders. The Company intends to defend itself vigorously in the proceedings. The ITC has set a target date for final determination of this matter for October 2020. An adverse ruling by the ITC against either us or Daewoong could result in the imposition of an exclusion order which would bar imports of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> into the United States and a cease and desist order which would bar sales and marketing of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> within the United Sates either of which would materially adversely affect the Company&#8217;s ability to carry out its business and which would have a material adverse effect on the Company&#8217;s business, financial position, results of operations, or cash flows and could also result in reputational harm.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Other Legal Matters</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company, from time to time, is involved in various litigation matters or regulatory encounters arising in the ordinary course of business that could result in unasserted or asserted claims or litigation. These other matters may raise difficult and complex legal issues and are subject to many uncertainties, including, but not limited to, the facts and circumstances of each particular case or claim, the jurisdiction in which each suit or regulatory encounter is brought, and differences in applicable laws and regulations. Except as set forth above, the Company does not believe that these other matters would have a material adverse effect on its accompanying financial position, results of operations or cash flows. However, the resolution of one or more of the other matters in any reporting period could have a material adverse impact on the Company&#8217;s financial results for that period.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6642766848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Expenses</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Accrued Expenses</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Accrued expenses consisted of:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.0079365079365%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Accrued professional services</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">4,488</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">931</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Accrued volume-based rebate and coupon liability</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">3,932</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Accrued payroll and related benefits</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">3,453</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2,577</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">EU milestone payment to Daewoong</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Other accrued expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,505</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">210</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">14,378</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">3,718</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6637899408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of Accounts Payable and Accrued Expenses</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Accrued expenses consisted of:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.0079365079365%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Accrued professional services</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">4,488</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">931</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Accrued volume-based rebate and coupon liability</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">3,932</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Accrued payroll and related benefits</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">3,453</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2,577</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">EU milestone payment to Daewoong</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Other accrued expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,505</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">210</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">14,378</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">3,718</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
